<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7981louxgp7 st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" tabindex="0" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="1001_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf">1001_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">7.4MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 1001_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>which develop resistance rapidly. However, staphylococci including methicillin resistant Staph. aureus are well inhibited. They have high activity against streptococci including Strept. pneumoniae.</p>
<p>Intracellular pathogens such as legionella, brucella, chlamydia and mycoplasma pneumoniae are inhibited to variable degrees.</p>
<p>They are also effective against Mycobacterium tuberculosis and M. avium complex. They are not effective against anaerobes.</p>
<p>Bacteria, including pseudomonas and staphylococci, can develop resistance to fluoroquinolones, generally by genetic mutation and cross resistance amongst various groups is common. In fact, fluroquinolone resistance is already a major problem mainly because of their indiscriminate use. The activity of fluoroquinolones diminishes in acid urine.</p>
<p>Absorption, fate and excretion: The oral bioavailability of fluoroquinolones is excellent; and the plasma levels after oral administration are similar to those after IV administration. Hence, their IV administration is rarely indicated. The simultaneous administration of compounds of aluminium, magnesium (antacids), zinc, iron and calcium leads to formation of complexes in the GI tract, and reduce their bioavailability. Food delays their absorption. They are widely distributed in various tissues. They are concentrated in urine, kidney, prostatic tissue, and achieve therapeutic levels in lungs and bones. There is substantial excretion and reabsorption in the colon. They are concentrated within macrophages and polymorphonuclear neutrophils.</p>
<p>Metabolism of the fluoroquinolones varies considerably. Thus, levofloxacin, ofloxacin and lomefloxacin are entirely eliminated by the kidneys, and a dose adjustment is a must even with minor reductions in renal function. On the other hand, pefloxacin, gemifloxacin and sparfloxacin are mostly eliminated by the liver. Ciprofloxacin is eliminated by both liver and kidneys.</p>
<p>Quinolones such as ciprofloxacin are potent liver enzyme inhibitors and can reduce the metabolism of warfarin, theophylline and sulfonyluereas.</p>
<p>Due to differences in the pharmacokinetic properties, norfloxacin is effective in infections of the urinary and GI tracts; its serum levels are relatively low and therefore, it is not recommended for systemic infections.</p>
<p>Preparations and dosage: See Table 45.6.
Nadifloxacin is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream for topical application to the skin.
Adverse reactions: In general, these drugs are well tolerated.</p>
<ul>
<li>GI toxicity: Anorexia, nausea, vomiting, abdominal discomfort and diarrhoea are the commonest side effects. Trovafloxacin can cause severe hepatotoxicity.</li>
<li>CNS toxicity: They cause mild headache, dizziness, nervousness and insomnia. Confusion, agitation, hallucinations and rarely seizures are seen especially in patients receiving INH, theophylline and NSAIDs.</li>
<li>Tendon and cartilage damage: Rupture of shoulder, hand and Achilles tendons have been reported with these drugs especially in the elderly, those on glucocorticoids and those with renal insufficiency. Treatment should be discontinued if the patient experiences pain, inflammation and rupture of a tendon. Because of the cartilage damage in weight bearing joints of young animals, they should be avoided in pregnant and nursing mothers and in young children.</li>
<li>Cardiac toxicity: Lomefloxacin, sparfloxacin and moxifloxacin can prolong QTc interval in</li>
</ul>
<p>patients on class III or class IA antiarrhythmic drugs (Chapter 28).</p>
<ul>
<li>Miscellaneous: Allergic reactions such as skin rash, arthralgia and photosensitivity have been reported. Rarely, leucopenia and renal damage with acute renal failure can occur. Gatifloxacin has been reported to cause both hyperglycemia and hypoglycemia and hence withdrawn from the market. Only topical formulations are now available.
Therapeutic uses: Because of their pharmacokinetic properties (superior bioavailability, tissue distribution and penetration) broad spectrum, and bactericidal activity against most aerobic Gram negative and many aerobic Gram positive bacteria, fluoroquinolones are useful in treating a wide variety of infections, in many anatomical sites. Table 45.7 lists the conditions for which the fluoroquinolones are preferred.</li>
</ul>
<p>Table 45.7
Conditions in which fluoroquinolones are preferred</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Complicated urinary tract infections
</span>(Chapter 52), especially those caused by Psaeruginosa or other drug resistant Gram negative pathogens.
- Bacterial gastroenteritis in patients ill enough to merit empiric therapy, especially salmonella gastroenteritis.
- Typhoid fever resistant to chloramphenicol, and of the fecal carrier state of S.typhi (for which they are the drugs of choice).
- Invasive otitis media by Psaeruginosa.
- Gram negative osteomyelitis and soft tissue infection.
- Respiratory infections including acute pneumonias and acute exacerbations in chronic bronchitis.
- Multidrug resistant tuberculosis
- Atypical mycobacterial (M. avium complex) infection.
- Leprosy
- Anthrax prophylaxis and treatment
- Meningococcal carriers for eradication.
- Neutropenics for infection prophylaxis
- Empiric treatment of septicemia in emergency.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Complicated urinary tract infections
(Chapter 52), especially those caused by Psaeruginosa or other drug resistant Gram negative pathogens.
- Bacterial gastroenteritis in patients ill enough to merit empiric therapy, especially salmonella gastroenteritis.
- Typhoid fever resistant to chloramphenicol, and of the fecal carrier state of S.typhi (for which they are the drugs of choice).
- Invasive otitis media by Psaeruginosa.
- Gram negative osteomyelitis and soft tissue infection.
- Respiratory infections including acute pneumonias and acute exacerbations in chronic bronchitis.
- Multidrug resistant tuberculosis
- Atypical mycobacterial (M. avium complex) infection.
- Leprosy
- Anthrax prophylaxis and treatment
- Meningococcal carriers for eradication.
- Neutropenics for infection prophylaxis
- Empiric treatment of septicemia in emergency." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Because of their complete GI absorption, they are routinely prescribed orally. However, they can be administered by IV infusion (Table 45.6) in serious conditions such as pneumonia, peritonitis due to bowel leak, HACEK endocarditis, febrile neutropenia, acute severe/complicated pyelonephritis and intra-abdominal infections. Alternatively, these conditions may be treated with IV cephalosporins.</p>
<p>Although they may be highly effective in gonorrhoea and chancroid, the need to exclude syphilis diminishes their value as primary agents in STD. Ofloxacin and sparfloxacin are effective against acid fast bacilli and are used to treat tuberculosis and leprosy (See Chapters 54 and 55). The third generation of fluoroquinolones are recommended for atypical pneumonia (chlamydia, mycoplasma and legionella).</p>
<p>Though effective, fluoroquinolones should not be used for the routine treatment of uncomplicated UTI, mild to moderate GI infections, skin infections and other sundry infections, where a cheaper and equally effective drug such as cotrimoxazole is available. Their extensive misuse has already resulted into the development of drug resistance.</p>
<p>46</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="penicillins-and-other-antibiotics-effective-mainly-against-gram-positive-organisms">Penicillins and Other Antibiotics Effective Mainly Against Gram Positive Organisms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#penicillins-and-other-antibiotics-effective-mainly-against-gram-positive-organisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PENICILLIN, the most important of the antibiotics, was first extracted from the mould Penicillium notatum. Subsequently, a mutant of a related mould, P. chrysogenum, was found to give the highest yield of penicillin and is employed for its commercial production. It belongs to a group of antibiotics called beta-lactam antibiotics; the other members include cephalosporins, cephamycins, monobactams and carbapenems.</p>
<p>The basic structure of the penicillins consists of a thiazolidine ring fused with a beta lactam ring which is essential for antibacterial activity. The two rings constitute the fundamental nucleus of all the penicillins, namely, 6-amino-penicillanic acid (6-APA). A variety of semi-synthetic penicillins are produced by altering the composition of the side chain attached to 6-APA nucleus (Fig. 46.1). Both the 6-APA nucleus and the side chain are essential for the antibacterial activity. In addition, the side chain determines the stability of the penicillin against degradation by gastric acid and by the enzyme beta lactamase (penicillinase) produced by certain micro-organisms such as Staphylococcus aureus, Pseudomonas, Enterobacter and some strains of H. influenzae and N. gonorrhoea.
<img src="assets/images/image-20251214-0e751d0d.jpeg" alt="img-0.jpeg"></p>
<p>Mechanism of action: Penicillins are bactericidal. The effect continues for a period of 3 to 8 hours after withdrawing penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>G</mi></mrow><annotation encoding="application/x-tex">G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">G</span></span></span></span></span> and a bacteriological cure is assured if adequate penicillin is present in patient's plasma for a total period of 6 hours per day. The best effect is achieved by a concentration 5-20 times greater than the minimum concentration which inhibits growth.</p>
<p>The action of penicillins requires the presence of a cell wall that contains peptidoglycans. Peptidoglycan is a major structural component of the bacterial cell wall that is cross-linked into a net like structure that surrounds the bacterial cell and provides strength and rigidity to it. Penicillin binds and inhibits the penicillin binding proteins (PBP) located on the cell membrane, inside the cell wall. One of them is transpeptidase, which is involved in the biosynthesis of peptidoglycan. Its inactivation inhibits the peptidoglycan biosynthesis. This weakens the bacterial cell wall and makes the organisms vulnerable to rupture by solutes in the surrounding medium (viz. plasma). As cell wall synthesis occurs during the growth phase, the antibiotic is most effective against actively multiplying organisms.</p>
<p>Human cells have cell membranes, they lack a cell wall.
In addition, penicillin exerts nonlytic activity. Cell membrane associated holin-like proteins are responsible for maintaining membrane potential. Penicillin interacts with them to block their effects.</p>
<p>The cell walls of Gram-negative bacilli are chemically more complex. Further, these cell walls contain beta lactamases that are enough to inactivate penicillin.</p>
<p>Bacterial resistance: Bacterial resistance to penicillin can be:</p>
<ul>
<li>Natural or</li>
<li>Acquired</li>
</ul>
<p>Fortunately, bacteria do not acquire resistance to penicillin easily and sensitivity of many of the susceptible pathogens has so far remained unchanged. The resistance develops stepwise. Staphylococci resistant to penicillin are common. Streptococcus viridans also develops resistance but to a lesser extent. Partially resistant strains of gonococci, meningococci and pneumococci are also encountered.</p>
<p>The important mechanism of bacterial resistance to the beta-lactams is bacterial production of beta-lactamases, that hydrolyse the beta-lactam ring and render the drug inactive. Penicillinresistant strains of staphylococci elaborate a beta-lactamase (penicillinase). Staphylococci that do not produce beta-lactamase may, however, also develop resistance to penicillin in vitro.Other microorganisms such as E. coli, M. tuberculosis, B. anthracis and A. aerogenes also produce beta-lactamases. Presence of beta-lactamase elaborating bacteria in a mixed infection may cause rapid destruction of penicillin with a consequent reduction in its therapeutic efficacy. Thus, penicillin may not be effective in the treatment of Strep. pyogenes pharyngitis if beta-lactamase elaborating staphylococci are also present in the throat.</p>
<p>BENZYLPENICILLIN: Benzylpenicillin is available in the form of its water soluble sodium and potassium salts. These salts in a dry state are stable at room temperature for years; the aqueous solution, however, requires refrigeration and deteriorates considerably within 72 hours.</p>
<p>The Oxford international unit for benzylpenicillin is equivalent to the activity contained in 0.6 micrograms of sodium salt of benzylpenicillin. One mg of sodium salt is thus equivalent to 1667 units of penicillin. A mega unit of penicillin is 1 million units.</p>
<p>Antibacterial activity: It is one of the most potent antimicrobial agents and inhibits the bacteria act growth of susceptible organisms in vitro in a concentration as low as 1 in 50 million.</p>
<p>It is effective mainly against Gram-positive cocci and bacilli and some Gram-negative cocci. Thus, majority of Streptococci with the exception of D strains (enterococci) are highly susceptible. Staphylococci, initially highly sensitive to penicillin, have acquired resistance on a large scale. Gonococci, Pneumococci and Meningococci are sensitive to penicillin. Bacillus anthracis, Corynebacterium diphtheriae and most anaerobic microorganisms, including the Clostridium species, are highly sensitive; Bacteroides fragilis, however, needs very high concentration to inhibit its growth.</p>
<p>Among the spirochaetes, Treponema pallidum is extremely sensitive to penicillin while leptospira infection responds moderately. Although penicillin is effective in actinomycosis, it is not useful against other fungi.</p>
<p>Absorption, fate and excretion: Given orally, benzylpenicillin is largely inactivated by the gastric acid. The drug is mainly absorbed from the duodenum. Only a small proportion of</p>
<p>the oral dose is detected in feces as a large amount is inactivated by the intestinal bacterial flora. Because of inadequate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) and irregular absorption, the oral dose of benzylpenicillin required to achieve an effective therapeutic plasma level is 4 to 5 times larger than the equivalent IM dose. Food interferes with its absorption and hence it should be given at least 30 minutes before or 2 to 3 hours after a meal. As gastric acidity is low in infants, higher blood levels can be achieved on oral administration.</p>
<p>Benzylpenicillin in aqueous solution is rapidly absorbed after SC or IM administration. Peak plasma level is reached within 15 to 30 minutes and the drug disappears from the plasma within 3 to 6 hours. Absorption of penicillin from mucous membranes is erratic and variable. Moreover, a high risk of sensitisation accompanies the use of penicillin in such forms as lozenges and troches which are, therefore, not recommended.</p>
<p>Penicillin is widely distributed in the body after absorption. Very high concentrations are detected in the kidneys, but its concentrations in ocular, pericardial, pleural and peritoneal fluids is low. However, in the presence of inflammation, its concentration in these fluids is higher. The drug does not readily cross the BBB, but therapeutically adequate CSF concentration is achieved in the presence of meningeal inflammation. It crosses the placental barrier. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of plasma penicillin is bound to albumin; the remainder is present in the free form.</p>
<p>Nearly 30% a single parenteral dose is metabolised. Small amounts appear in bile, milk and saliva. The major portion is eliminated by the kidneys by tubular secretion and only 10 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> by glomerular filtration. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the drug elimination in urine occurs within the first hour, resulting in a rapid decline in the plasma level. The elimination half-time is about 30 minutes. It is important to note that doubling the dose does not double the duration of effect, and that for continuous effect, large and frequent doses are essential. Neonates and infants in whom renal function is not adequately developed, and individuals with renal insufficiency show prolonged and higher plasma levels. In anuria the plasma half life of penicillin is increased to about 10 hours. Thus, in an adult with anuria an adequate dose for the treatment of a highly sensitive infection would be only 2000 units per dose.</p>
<p>Rapid urinary elimination of benzylpenicillin necessitates its parenteral administration at 4 or 6 hourly intervals. Repository preparations are relatively insoluble and release benzylpenicillin slowly when injected. They thus produce relatively low but prolonged plasma concentration. These agents, however, are not useful for treating severe infections where an immediate, high plasma concentration of benzylpenicillin is desirable. In contrast to adults, neonates and infants excrete penicillin slowly and require 12 hourly administration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Benzylpenicillin (Penicillin G) (sodium and potassium salts) injection 500,000 units per ml .
(ii) Benzylpenicillin tablet contains 50,000 to 500,000 units of benzylpenicillin. Dose: 200,000 to 400,000 units 4 hourly. Peak plasma level of 0.2 to 0.3 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> is reached within 1 to 2 hours after oral ingestion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-repository-preparations">The repository preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-repository-preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Procaine benzylpenicillin available in powder form, to be suspended in distilled water, prior to injection. Dose: 600,000 to 1,200,000 units daily by IM injection. After a single dose, the peak plasma level of 0.3 units per ml is reached within 1 to 3 hours. This level is 25</p>
<p>times lower than that attained by parenteral aqueous benzylpenicillin. The drug, however, remains in blood for 8 to 12 hours, and in some patients for 24 hours. Aqueous solutions are stable for many months at temperatures below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">25^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>.
(ii) Fortified benzylpenicillin injection contains a mixture of 300,000 units of procaine benzylpenicillin and 100,000 units of benzylpenicillin per ml. Such a preparation achieves a quick and high serum penicillin concentration and the effective concentration persists for 12 to 24 hours.
(iii) Benzathine penicillin is a dibenzylethyl-enediamine salt of benzylpenicillin. It has a very poor water solubility and is administered IM in the dose of 600,000 to 2,400,000 units. With the dose of 600,000 units, blood levels of 0.03 to 0.1 units per ml persist for 10 days and the drug is detected in the plasma for 2 weeks. A dose of 1.2 million units produces detectable blood levels for 3 weeks.</p>
<p>Benzathine penicillin should be used only in conditions where the infecting microorganism is exquisitely sensitive to low concentrations of penicillin viz.
(a) for treatment and prophylaxis of pharyngitis due to group A beta-hemolytic streptococci;
(b) for treatment of pyoderma due to group A beta-hemolytic streptococci; and
(c) for treatment of syphilis not involving the CNS.</p>
<p>Probenecid, a uricosuric agent, competes with penicillin for tubular transport and delays its excretion. Administered orally in the dose of 2 g per day, in divided doses, along with penicillin, it raises its plasma level twofold to fourfold which is maintained for approximately twice as long as without probenecid. Hence it is sometimes used for this purpose. It is not recommended in children below two years (Chapter 75).</p>
<p>Adverse reactions: Penicillin is a remarkably safe drug. The only important reaction to be feared in practice is anaphylaxis.</p>
<ul>
<li>Minor reactions: Oral use of penicillin may rarely produce nausea, vomiting and diarrhoea. Benzathine penicillin IM may cause local pain erythema and induration; occasionally pyrexia may develop.
Benzylpenicillin, even in large doses, is almost devoid of toxic manifestations provided kidney function is normal. However, when given by intrathecal route, the drug may cause arachnoiditis, convulsions and encephalopathy. Large doses may also cause neurotoxicity.
Prolonged administration of IV benzylpenicillin may lead to thrombophlebitis; accidental IV administration of procaine benzylpenicillin can cause anxiety, mental disturbances, paraesthesiae and seizures, due to procaine.</li>
<li>Allergy and anaphylaxis: The risk of allergic reactions is 5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> with benzathine penicillin, 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> with procaine penicillin and 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> following benzylpenicillin. The mortality in severe reactions has been assessed at 9 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">13 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13%</span></span></span></span></span>. As a generalisation, the incidence of these reactions is considerably greater when benzylpenicillin is used either topically or in an aerosol form, and is least when it is taken orally. However, fatalities have occurred following ingestion.
Some individuals are so sensitive that the mere handling of penicillin tablet or even a skin test dose may precipitate immediate severe reaction. Further, severe reactions have been recorded following first dose of penicillin, in persons who had never received the drug before. This is probably because many of us are exposed and slightly sensitised to</li>
</ul>
<p>various common air-borne moulds that readily grow on and elaborate penicillin and penicillin-like substances in foodstuffs such as bread, fruit, and oil, with or without decay. Penicillin sensitisation can also occur from the presence of the drug in the environment of patients using penicillin aerosols, and by ingesting milk containing penicillin.
Metabolites of penicillin form covalent bonds with serum and tissue proteins and are highly immunogenic. Penicilloic acid either alone or linked to a plasma protein is probably responsible for allergic reactions. A person known to be allergic to one penicillin will also be allergic to other penicillins. Partial cross allergy is seen between penicillin and cephalosporins. Carbapenams and the monobactam, however, carry much less risk. The important allergic reactions are:</p>
<ul>
<li>Skin rashes of various types associated with pruritus are the most common reactions.</li>
<li>A serum sickness like syndrome, characterised by rash, fever, eosinophilia lymphadenopathy, angioneurotic edema, bronchospasm and arthralgia.</li>
<li>Renal disturbances like hematuria and albuminuria.</li>
<li>Hemopoietic disturbances like hemolytic anemia and neutropenia, very rarely.</li>
<li>Anaphylaxis is the most serious reaction but occurs in fewer than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.01</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.01 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.01%</span></span></span></span></span> of patients. The symptoms of anaphylaxis usually begin within a few minutes after penicillin administration. It is characterised by an acute cardiovascular collapse, bronchospasm, and angioedema, particularly edema of the larynx. For details, see Chapters 2 and 23.
Tests for detection of penicillin allergy: A reliable method of detecting penicillin allergy is not available. History of allergy or even a positive skin test is not in itself a complete evidence of allergy, nor does a negative history or negative skin test indicate the safety of penicillin administration. Estimation of IgE antibodies in the serum may be helpful.</li>
</ul>
<p>Skin tests: One method of skin testing is to scratch the skin through a drop of solution containing 10,000 units of benzylpenicillin per ml . If a central wheal due to local edema (not diffuse erythema) occurs after 15 minutes, it is considered a positive reaction. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> positive skin reaction is a relatively reliable indicator of potentially serious penicillin allergy. Unfortunately, fatal anaphylactic reactions can occur though rarely even in persons with negative skin response, whereas some patients with a positive reaction have accepted penicillin without serious reactions. Furthermore, even the small amount of penicillin used for the test may itself rarely produce severe reaction.</p>
<p>Another skin test involves the administration of 0.05 ml of penicilloyl-polylysine intradermally and subsequent observation of the inflammatory response. This test is often combined with benzylpenicillin scratch test. Combination of these two tests will predict virtually all reactions to all the types of penicillin. Scratch test should precede the intradermal test to avoid any dangerous reaction following the latter. Such elaborate testing, however, may not be feasible in clinical practice.</p>
<p>If a person with a positive skin test has to be administered penicillin for a lifethreatening infection, penicillin desensitisation should be carried out under cover of glucocorticoids and antihistaminics in a closely monitored setting. Benzylpenicillin should be administered in doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>5</mn><mo separator="true">,</mo><mn>10.100</mn></mrow><annotation encoding="application/x-tex">1,5,10.100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">10.100</span></span></span></span></span> and 1000 units ID at 60 minute intervals. If that is well tolerated, then progressively larger doses such as 10000 units and 50000 units and so on may be given SC. Desensitisation can also be done with oral administration of penicillin. When full doses are reached, penicillin must not be discontinued and then</p>
<p>restarted because an immediate allergic reaction may occur. The above procedure is dangerous and its efficacy is unproven. Further, corticosteroids may have to be administered in very large doses ( 50 to 100 mg of prednisolone per day) to prevent the development of anaphylaxis. Such large doses may affect the host resistance, which must be weighed against the beneficial antiallergic effect desired. Antihistaminics do not decrease the incidence of penicillin anaphylaxis; however, they are valuable in controlling common minor allergic reactions.</p>
<p>Even in patients in whom the skin test is negative, most physicians administer a test dose of 1000-2000 units of penicillin and proceed to higher doses if no reaction occurs.</p>
<ul>
<li>Jarisch-Herxheimer reaction is a rare reaction reported in patients with syphilis treated with penicillin (Chapter 53).</li>
<li>Superinfection: Long term use of penicillin may suppress the sensitive coccal members of the bacterial flora, and encourage superinfection in the form of bacteremia, urinary infection or pneumonia owing to overgrowth of such resistant microorganisms as Klebsiella, Aerobacter, Pseudomonas and Candida.
Stomatitis, glossitis and a black hairy tongue are known to develop after local use of penicillin troches and lozenges.</li>
<li>Hyperkalemia: Each 15 million units of potassium benzylpenicillin supplies 975 mg (25 mEq ) of ionic potassium, and the drug administered repeatedly in such doses to patients with impaired renal function may cause hyperkalemia.</li>
<li>Acute non-allergic reactions: Intramuscular aqueous procaine penicillin sometimes produces acute non-allergic reaction, which could be serious. It is characterised by transient palpitation, hypertension, twitchings, auditory and visual disturbances, headache, and dizziness. In addition, psychiatric symptoms like fear of imminent death and acute depersonalisation may occur.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The various penicillin regimens can be summarised for practical purposes as shown in Table 46.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-46-1">Table 46.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-46-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="penicillin-regimens">Penicillin regimens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#penicillin-regimens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Regimen 1 (oral): Penicillin V 250-500 mg or benzylpenicillin 400,000-800,000 units orally every six hours.</li>
<li>Regimen 2 (IM small dose, repository penicillin): Fortified benzyl penicillin (procaine benzylpenicillin 600,000 units + benzylpenicillin 200,000 units) IM once a day.</li>
<li>Regimen 3 (IM, large dose benzyl penicillin): Benzylpenicillin 1-2 mea aunts IM every 4-6 hours (4-12 mea aunts per day).</li>
<li>Regimen 4 (IV, large dose benzylpenicillin): Benzylpenicillin 2 mea aunts IV every 2 hours ( 24 mea aunts per day).</li>
</ul>
<p>Regimens 1 or 2 is used in mild infection such as streptococcal pharyngitis. Regimens 3 and 4 are needed in severe infections such as severe pneumonia, empyema, meningitis and bacterial endocarditis. The choice of the regimen in each individual infection is indicated in Table 46.2</p>
<p>Table 46.2
Choice of penicillin regimen in the common infections</p>
<table><thead><tr><th style="text-align: center;">Organisms</th><th style="text-align: center;">Regimens 1 and 2</th><th style="text-align: center;">Regimens 3 and 4</th></tr></thead><tbody><tr><td style="text-align: center;">S. pneumoniae</td><td style="text-align: center;">Pneumonia (mild-moderate), until afebrile for 4 days</td><td style="text-align: center;">Empyema, pericarditis, osteomyelitis, arthritis* (2-4 weeks), meningitis ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">10-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> days)</td></tr><tr><td style="text-align: center;">S. pyogenes, S. viridans, Group A beta hemolytic streptococci</td><td style="text-align: center;">Pharyngitis", erysipelas, pyoderma (7-10 days), otitis media ( 2 weeks)</td><td style="text-align: center;">Mastoiditis (2 weeks) osteomyelitis, arthritis* (2-4 weeks), meningitis (10-14 days), SBE (4-6 weks)</td></tr><tr><td style="text-align: center;">Type D streptococci (enterococci)</td><td style="text-align: center;">-</td><td style="text-align: center;">Meningitis (14-21 days with gentamicin)</td></tr><tr><td style="text-align: center;">Staphylococcus</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Meningitis (14-21 days with gentamicin)</td></tr><tr><td style="text-align: center;">N. gonorrhoeae</td><td style="text-align: center;">Gonorrhoea (uncomplicated) single injection; complicated (14 days)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Treponema pallidum</td><td style="text-align: center;">Syphilis (single dose or weekly for 3 weeks)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Actinomyces isosoli</td><td style="text-align: center;">Actinomycosis ( 2 weeks with sulfadiazine 4 g )</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Nocardia brasiliensis</td><td style="text-align: center;">Nocardiasis</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Corynebactrium diphtheriae</td><td style="text-align: center;">Diphtheria (10-12 days)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Clostridium tetani</td><td style="text-align: center;">Tetanus (10-12 days)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Clostridium species</td><td style="text-align: center;"></td><td style="text-align: center;">Gas gangrene (1-2 weeks)</td></tr><tr><td style="text-align: center;">Fusospirochetal infection</td><td style="text-align: center;">Gingivostomatitis (trench fever) and pharyngitis (Vincents angina)</td><td style="text-align: center;">Lung abscess</td></tr><tr><td style="text-align: center;">Pasturella multocida</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">2-4 weeks</td></tr><tr><td style="text-align: center;">Listeria monocytogenes</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Listeriasis ( 2 weeks)</td></tr><tr><td style="text-align: center;">Streptobacilli: actinobacillus muris and Spirilum minus</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Rat-bite fever (7-10 days)</td></tr></tbody></table>
<p>SBE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Subacute bacterial endocarditis.
*Intracavitary local injection
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Single injection of 1.2 megaunits, benzathine penicillin</p>
<ul>
<li>Pneumococcal infections: Most strains of pneumococci are extremely susceptible to benzylpenicillin and hence, it continues to be the drug of choice for these infections. Pneumococcal pneumonia: The therapeutic response to penicillin becomes apparent within 48 to 72 hours. In milder cases and in patients known to be allergic to penicillin, an oral macrolide such as erythomycin or azithromycin may be used. Unfortunately, 15-30% of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. pneumoniae show resistance to penicillin. Some of them are multi-drug resistant. Hence, in hospitalised patients who are seriously ill, cefotaxime or ceftriaxone is to be preferred. Pneumococcal empyema and pericarditis: In addition to regimen 4, half to one mega unit of benzylpenicillin in 50-100 ml of isotonic saline should be instilled intrapleurally daily for several days. If the pleural fluid is thick and viscous, the proteolytic enzymes streptokinase and streptodornase may be injected intrapleurally along with penicillin, in the dose of 200,000 to 400,000 units and 50,000 to 100,000 units respectively. Several injections may be necessary, particularly when the empyema becomes loculated. By the use of these enzymes combined with daily aspiration and the local injection of penicillin, cure of empyema can be obtained. When these measures fail, surgical intervention is indicated.
Pneumococcal meningitis: Chapter 48.</li>
<li>Streptococcal infections: Infections due to Strep. pyogenes that respond satisfactorily to penicillin, are listed in Table 46.2.
In suppurative arthritis 50,000 to 100,000 units of penicillin may be instilled into the joint cavity.
Streptococcal subacute bacterial endocarditis (SBE): The alpha-hemolytic streptococci (Strep. viridans) account for the majority of cases of subacute bacterial endocarditis. In a few cases the enterococci (Strep. fecalis) and coagulase negative staphylococci may be the causative organisms.
Therapeutic response in bacterial endocarditis depends upon the proper selection of</li>
</ul>
<p>antibiotics, the stage at which treatment is begun and its thoroughness. If the diagnosis and consequently the treatment are delayed, irreversible cardiac damage occurs. In principle high doses of bactericidal drugs are given initially IM/IV to achieve high peak concentration. In all cases therapy is continued for a minimum period of 4-6 weeks and monthly blood cultures are done for at least 3 months to detect a recurrence.</p>
<p>Before institution of therapy, isolation and identification of the causative organism are necessary. During the therapy, its efficacy is determined by determining the sensitivity of causative organisms using minimum inhibitory concentration (MIC) test. Alternatively, a simple serum bactericidal test can be done using the serum of the patient receiving the antibiotic and his own organisms, isolated before starting the antibiotic. If the serum exhibits a bactericidal activity in 1:8 dilution, good correlation between therapy and cure is usually assured.</p>
<p>Regimens for the treatment of the common forms of bacterial endocarditis are given in Table 45.3. The choice of the antibiotic(s) and duration of therapy depend upon the type of organism and the nature of underlying lesion (whether rheumatic valve disease or prosthetic valve).</p>
<p>If cephalosporin and vancomycin (Table 46.3) are not available, a regimen comprising erythromycin plus gentamicin may besubstituted in patients allergic to pencillin. If the diagnosis is well established on clinical grounds and blood cultures are negative, the patient may be treated with the same regimen as for Strep. fecalis (ampicillin + gentamicin for 4-6 weeks).</p>
<p>Table 46.3
Antibiotic regimens for the treatment of bacterial endocarditis</p>
<table><thead><tr><th style="text-align: center;">Organism</th><th style="text-align: center;">Antibiotic regimen</th></tr></thead><tbody><tr><td style="text-align: center;">Strepto. viridans &lt;br&gt; (Alpha-hemolytic)</td><td style="text-align: center;">Penicillin G 10-20 million units/day IV, in six equal doses, plus gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV or IM 8 hourly. &lt;br&gt; Avoid gentamicin in patients over 65 years and in presence of renal failure or eighth nerve damage. Penicillin alone may be used for 4 weeks or combination for two weeks &lt;br&gt; In patients allergic to penicillin: Ceftriaxone 2 g IV or IM once daily or Vancomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (not to exceed 1 g ) IV 12 hourly. &lt;br&gt; Duration: 4 weeks.</td></tr><tr><td style="text-align: center;">Strepto. pyogenes &lt;br&gt; (Beta-hemolytic, &lt;br&gt; Group A)</td><td style="text-align: center;">Pencillin G 2 million units IV 6 hourly. OR Cefazolin 2 g IV 8 hourly Duration: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> weeks.</td></tr><tr><td style="text-align: center;">Strepto. fecalis &lt;br&gt; (Entero. fecalis) &lt;br&gt; (Beta-hemolytic, &lt;br&gt; Group D)</td><td style="text-align: center;">Penicillin G 4 million units/Ampicillin 2 g IV 4 hourly plus gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV 8 hourly for 4-6 weeks. OR Vancomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (not to exceed 1 g ) IV 12 hourly plus gentamicin as above. &lt;br&gt; Duration: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> weeks.</td></tr><tr><td style="text-align: center;">Staph. aureus</td><td style="text-align: center;">Nafcillin 2 g IV 4 hourly, for 4-6 weeks. &lt;br&gt; In complicated cases, nafcillin as above plus gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV 8 hourly for the first <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">3-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> days. &lt;br&gt; In patients allergic to penicillin, cefazolin 2 g IV &lt;br&gt; 4 hourly OR vancomycin as above for 4-6 weeks.</td></tr><tr><td style="text-align: center;">HACEK organisms</td><td style="text-align: center;">Fluoroquinolone OR Cephalosporin IV</td></tr></tbody></table>
<ul>
<li>Staphylococcal infections: A major therapeutic problem is the development of penicillin resistant staphylococci. It has been estimated that 70-90% of staphylococcal infections due to hospital strains and 15 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of those acquired in the community are resistant to penicillin. Table 46.4 lists the drugs recommended in community-acquired staphylococcal infections.</li>
</ul>
<p>Table 46.4
Drugs for community-acquired staphylococcal infections</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Antistaphylococcal penicillins
</span>- Cephalosporins
- Co-trimoxazole
- Minocycline
- Gentamicin; and
- Fluoroquinolones</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Antistaphylococcal penicillins
- Cephalosporins
- Co-trimoxazole
- Minocycline
- Gentamicin; and
- Fluoroquinolones" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>As penicillin penetrates poorly into abscesses, surgical treatment is necessary. For serious systemic staphylococcal infections, see Table 46.2. For infections caused by staphylococci producing beta lactamase, one of the semisynthetic penicillins or a cephalosporin is employed.</p>
<ul>
<li>Meningococcal meningitis: See Chapter 48. Penicillin is the drug of choice in meningococcal meningitis (Table 46.2). But, penicillin and its derivatives do not effectively eradicate this organism from the nasopharynx with short courses, and hence they are not recommended for prophylaxis in close contacts of patients with meningococcal infections.</li>
<li>Sexually transmitted diseases (STD): Penicillin is the drug of choice in the treatment of gonorrhoea and syphilis (Chapter 53).</li>
<li>Actinomycosis: Penicillin is the agent of choice in this condition (Table 46.2). Other antimicrobial agents employed include amoxicillin, tetracyclines, clindamycin and erythromycin</li>
<li>Anthrax: Although Benzylpenicillin is useful, ciprofloxacin 500 mg bid or doxycycline, 100 mg bid for 60 days is currently preferred. In case of severe infection, IV doses are given with clindamycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> rifampicin.</li>
<li>Diphtheria, tetanus and gas gangrene: (Table 46.2) Diphtheria and tetanus in addition to penicillin, require the administration of the specific antiserum. This helps to eliminate the bacilli from the lesions (Chapter 73).</li>
<li>Miscellaneous infections: These are shown in Table 46.2. Erysipeloid, caused by the Gram positive bacillus, Erysipelothrix insidiosa responds to a single injection of 1 to 2 million units of benzathine penicillin. The organism may also cause endocarditis, which is treated in a similar fashion as viridans endocarditis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="penicillin-prophylaxis">- Penicillin prophylaxis:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#penicillin-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Rheumatic fever: Antibiotics neither modify the course of rheumatic fever nor influence the subsequent development of carditis. Yet, it is customary to give antibiotics to eradicate rheumatogenic group A streptococci in the tonsils and the pharynx, in order to prevent the spread of the organism to close contacts. The preferred regimens are (a) Inj. benzathine penicillin 1.2 mega units I.M., single dose; or (b) erythromycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, orally, in divided doses, for 10 days. It is important to prevent recurrence of rheumatic fever by penicillin prophylaxis. Benzathine penicillin IM 1.2 million units every 3 weeks provides the best protection. Oral penicillin V may also be used in the dose of 125 mg 12 hourly in cooperative patients. In patients allergic to penicillin, erythromycin 250 mg twice daily may be used. The prophylactic therapy is continued for 5 years in children without evidence of carditis. In those who develop carditis, it is continued till the</p>
<p>age of 20 years. In patients with valvular disease, it should preferably be life long.
(b) Streptococcal infections: Oral benzylpenicillin in the dose of 200,000 units twice daily for 5 days or a single injection of 1.2 mega units of benzathine penicillin affords satisfactory protection from repeated infections due to Strep. pyogenes.
(c) Bacterial endocarditis: Prophylactic penicillin is indicated in individuals with rheumatic or congenital heart disease, who have to undergo surgical procedures like tooth extraction, dental scaling, surgery involving the gums, and procedures involving the lower genitourinary tract. Recommended drug for this is oral amoxicillin 2 g in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children given 1 hour before the procedure. The alternatives are: (i) azithromycin or clarithromycin 500 mg in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children; or (ii) clindamycin 600 mg in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children; and (iii) cephalexin 2 g in adults or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children, given similarly. In each case, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> the dose is repeated once, 6 hours after the procedure.
When parenteral administration is indicated, give IM or IV ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour before the procedure): (i) ampicillin 2 g in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children; or (ii) clindamycin 600 mg in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children; or (iii) cefazolin 1 g in adults and 25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children. In MDR cases and those allergic to penicillin, a combination of vancomycin and gentamicin is used. These regimens should be used even in patients on rheumatic fever prophylaxis with penicillin.
Daily oral penicillin for rheumatic fever prophylaxis may favour the growth of viridans streptococci relatively resistant to penicillin; in such patients, azithromycin is recommended.
(d) Gonorrhoea and syphilis: Chapter 53.
(e) Recurrent lymphangitis: Benzathine benzylpenicillin, 600,000 units, administered IM once a month is effective in preventing recurrent lymphangitis and consequent lymphedema in patients who have congenital abnormalities of the lymphatic system and in filariasis. Other drug used is doxycycline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="semisynthetic-penicillins">Semisynthetic Penicillins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#semisynthetic-penicillins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major drawbacks of benzylpenicillin are:</p>
<ul>
<li>Inactivation by the gastric acid.</li>
<li>Short duration of action.</li>
<li>Poor penetration into the CSE</li>
<li>Narrow spectrum of activity.</li>
<li>Development of resistant organisms, especially staphylococci; and</li>
<li>Possibility of anaphylaxis.</li>
</ul>
<p>Attempts, therefore, have been made to synthesise penicillins free from such drawbacks.
P. chrysogenum which produces the natural penicillins produces 6-APA nucleus before the attachment of the side chains. This process of attachment of the naturally occurring side chains can be inhibited, and instead, various organic radicals can be substituted to produce a variety of semisynthetic penicillins (Table 46.5). These synthetic penicillins, however, are capable of producing allergic reactions similar to those caused by penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>G</mi></mrow><annotation encoding="application/x-tex">G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">G</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-46-5">Table 46.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-46-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-penicillins">Classification of penicillins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-penicillins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Penicillin G (Benzyl penicillin)
Procaine penicillin G
Benzathine penicillin G
II Acid resistant penicillins:
Phenoxymethlypenicillin (penicillin V)
Phenoxyethylpenicillin (phenethicillin)
III Penicillinase-resistant penicillins*
(a) Acid labile: Methicillin, Nafcillin Cloxacillin, Dicloxacillin
(b) Acid resistant: Flucloxacillin</p>
<p>IV Penicillins effective against Gram-positive and some
Gram-negative organisms:
Ampicillin, Amoxicillin
Talampicillin, Pivampicillin
V Extended spectrum penicillins:
(1) Antipseudomonal penicillins
(a) Carboxypenicillins Carbenicillin, Ticarcillin
(b) Ureidopenicillins</p>
<p>Piperacillin, Mezlocillin, Azlocillin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-amidinopenicillins-mecillinam-pivmecillinam-br-vi-penicillins-with-betalactamase-inhibitors-br-amoxicillin-clavulanic-acid-br-ticarcillin-clavulanic-acid">(2) Amidinopenicillins Mecillinam, Pivmecillinam &lt;br&gt; VI Penicillins with betalactamase inhibitors: &lt;br&gt; Amoxicillin-clavulanic acid &lt;br&gt; Ticarcillin-clavulanic acid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-amidinopenicillins-mecillinam-pivmecillinam-br-vi-penicillins-with-betalactamase-inhibitors-br-amoxicillin-clavulanic-acid-br-ticarcillin-clavulanic-acid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th style="text-align: center;">I Penicillin G and its esters</th></tr></thead><tbody><tr><td style="text-align: center;">Penicillin G (Benzyl penicillin)</td></tr><tr><td style="text-align: center;">Procaine penicillin G</td></tr><tr><td style="text-align: center;">Benzathine penicillin G</td></tr><tr><td style="text-align: center;">II Acid resistant penicillins:</td></tr><tr><td style="text-align: center;">Phenoxymethlypenicillin (penicillin V)</td></tr><tr><td style="text-align: center;">Phenoxyethylpenicillin (phenethicillin)</td></tr><tr><td style="text-align: center;">III Penicillinase-resistant penicillins</td></tr><tr><td style="text-align: center;">(a) Acid labile: Methicillin, Nalclilin Cloxacillin, Dicloxacillin</td></tr><tr><td style="text-align: center;">(b) Acid resistant: Flucioxacillin</td></tr><tr><td style="text-align: center;">IV Penicillins effective against Gram-positive and some Gram-negative organisms:</td></tr><tr><td style="text-align: center;">Ampicillin, Amoxicillin</td></tr><tr><td style="text-align: center;">Talampicillin, Pivampicillin</td></tr><tr><td style="text-align: center;">V Extended spectrum penicillins:</td></tr><tr><td style="text-align: center;">(1) Antipseudomonal penicillins</td></tr><tr><td style="text-align: center;">(a) Carboxypenicillins Carbenicillin, Ticarcillin</td></tr><tr><td style="text-align: center;">(b) Ureidopenicillins</td></tr><tr><td style="text-align: center;">Piperacillin, Mezlocillin, Azlocillin</td></tr><tr><td style="text-align: center;">(2) Amidinopenicillins Mecillinam, Pivmecillinam</td></tr><tr><td style="text-align: center;">VI Penicillins with betalactamase inhibitors:</td></tr><tr><td style="text-align: center;">Amoxicillin-clavulanic acid</td></tr><tr><td style="text-align: center;">Ticarcillin-clavulanic acid</td></tr></tbody></table>
<p>Groups other than Ill are not resistant to penicillinase (beta lactamase) and not effective against Staph. aureus.
*Antistaphylococcal penicillins, not effective against MRSA.
I Acid resistant penicillins: These penicillins are relatively resistant to inactivation by gastric acid and hence, can be given orally.</p>
<p>POTASSIUM PHENOXYMETHYLPENICILLIN (Penicillin V): Its antibacterial spectrum is like that of benzylpenicillin. On an equivalent oral dose basis, the plasma levels achieved by this compound are 4 to 5 times higher than those with benzylpenicillin. Approximately 50 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the drug is bound to the plasma proteins and nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> is eliminated in the urine.</p>
<p>Potassium phenoxymethylpenicillin is freely soluble in water. It is available as 65 and 125 mg tablets. The drug is usually administered in the dose of 250 to 500 mg at 4 to 8 hourly intervals, at least 30 minutes before food.</p>
<p>Therapeutic Uses: Penicillin V may be employed in less serious infections due to pneumococci and streptococci, in conditions that have been brought under control by parenteral therapy, and in infections which require a prolonged treatment. It is much less active than benzylpenicillin against gonococci; hence it is not used to treat gonorrhoea. It may be used prophylactically for similar purposes as benzylpenicillin.</p>
<p>A dose of 250 mg of penicillin V 4 times daily for 4 days, with sulfafurazole 26 to 30 mg</p>
<p>per kg upto 2 g maximum per day for 3 days, has been used for prophylaxis against meningococcal infection in contacts and in school children during an epidemic. However, oral rifampicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per day for three days, is preferred.</p>
<p>Penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> has no place in the management of severe infections and should not be used for the treatment of meningitis, syphilis or actinomycosis.</p>
<p>Potassium phenoxyethyl penicillin and Azidocillin: have actions similar to penicillin V. II Beta-lactamase (Penicillinase) resistant penicillins: These resist the action of betalactamase and are effective in the treatment of infections due to beta-lactamase producing organisms. These are:</p>
<p>METHICILLIN: As several strains of staphylococci have developed resistance to methicillin, it is now rarely used except for laboratory testing for MRSA. The term methicillin resistant Staphylococcus aureus (MRSA) is used to refer to beta-lactam-antibioticresistant (i.e., penicillinase producing) staphylococci. Most of MRSA strains are resistant to cloxacillin, flucloxacillin and all beta-lactam antibiotics (penicillins, cephalosporins and imipenam) and often to other classes of antimicrobial agents.</p>
<p>CLOXACILLIN: This drug has a weaker antibacterial activity than benzylpenicillin but is 5 to 10 times more active than methicillin against resistant staphylococci. It is also acid resistant. Food interferes with its absorption.</p>
<p>After a single oral dose, peak plasma levels are attained within an hour and persist for 4 to 6 hours. The drug is distributed throughout the body, with the highest concentrations in the kidney and liver. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of a single dose is excreted in the urine; over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of the 24 hour urinary excretion occurs within the first 6 hours. Significant amounts are excreted in the bile.</p>
<p>The initial oral dose of cloxacillin varies from 0.5 to 1 g 6 hourly, and the maintenance dose is 250 mg given at the same intervals. In children, the dose varies from 50 to 100 mg per kg daily (according to severity of infection) divided into 4-6 portions. The drug should be administered 1 hour before or 2 hours after a meal to ensure adequate absorption. It can also be given IM and by slow IV bolus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg} 4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hourly.</p>
<p>DICLOXACILLIN: This derivative of cloxacillin is absorbed better (60%) and gives blood levels twice those of cloxacillin on oral administration. It is, however, highly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> ) protein bound and is excreted slowly.</p>
<p>FLUCLOXACILLIN is similar to dicloxacillin but is relatively less protein bound, and hence may be preferred to dicloxacillin. It sometimes causes cholestatic jaundice.</p>
<p>NAFCILLIN: Its GI absorption is slow, irregular and incomplete. IM injection yields quicker and higher plasma levels. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>87</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">87 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">87%</span></span></span></span></span> of the drug is protein bound. It is predominantly excreted by the liver in bile and may be preferred in patients with renal damage. The oral doses are similar to those of cloxacillin. The IM dose is 0.5 to 1 g 4 to 6 hourly and 25 mg per kg twice daily, respectively, in adults and in children. It can be given IV.</p>
<p>Initial treatment of a severe staphylococcal infection should always be with one of the betalactamase resistant penicillins or a cephalosporin. Staphylococci resistant to the above penicillinase-resistant penicillins have been reported. This resistance is based on the chromosomally mediated production of a new penicillin-binding protein with decreased affinity for these penicillins.
III Penicillins effective against Gram-positive and Gram-negative organisms:</p>
<p>AMPICILLIN: Ampicillin is water soluble and acid resistant. Its antibacterial activity is generally similar to that of benzylpenicillin; in addition, it is highly effective against various Gram-negative bacteria. The Gram-positive cocci are less sensitive to ampicillin than to benzylpenicillin. The drug is effective against H. influenzae, Strep. viridans, Proteus mirabilis, Neisseria gonorrhoea, Salmonella typhi, many strains of E. coli and several strains of Shigella. It is moderately effective against Klebsiella, certain strains of Aerobacter and Enterococci. Pseudomonas and indole positive proteus, however, are resistant.</p>
<p>Ampicillin is inactivated by beta lactamase and, therefore, is ineffective against staphylococci resistant to benzylpenicillin. Bacteria can develop resistance to ampicillin, and many strains of salmonella, shigella, E. coli and proteus resistant to this drug have been isolated.</p>
<p>Absorption, fate and excretion: It is readily but incompletely absorbed on oral administration. Food interferes with its absorption. The portion not absorbed is inactivated by beta lactamase of the colonic bacterial flora and hence, the drug rarely produces superinfection in contrast to tetracyclines.</p>
<p>Peak plasma levels are reached within 2 hours and 1 hour respectively after administration of a single oral or IM dose. The levels are considerably higher and more prolonged on IM administration. The drug persists in the plasma for 6-8 hours, and only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> is bound to plasma proteins. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the dose is excreted unchanged in urine and high concentrations are present in the bile. In premature and very young infants, excretion of ampicillin is delayed. The drug crosses the placental barrier and achieves therapeutic concentrations in the amniotic fluid.</p>
<p>Adverse reactions: These are similar to those of penicillin G; however, skin rashes are more common. Ampicillin rash is usually maculopapular and not urticarial like that caused by benzylpenicillin. The onset is delayed. Diarrhoea is common with oral ampicillin and its derivatives. It is sometimes associated with Clostridium difficile infection. Interstitial nephritis is an uncommon adverse effect.</p>
<p>Preparations and dosage: The ampicillin capsule contains ampicillin hydrate equivalent to 250 mg of the base. The usual adult dose by all routes is 250 to 500 mg 6 hourly; doses as large as 1 g 6 hourly may be required for more refractory Gram-negative infections. In children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>13</mn></mrow><annotation encoding="application/x-tex">&lt;13</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">13</span></span></span></span></span> years, the daily oral dose is 50 to 200 mg per kg . Parenterally 25 to 50 mg per kg may be given per day in divided doses. Higher doses are used in the treatment of meningitis and bacterial endocarditis. Ampicillin 500 mg in 5 to 10 ml normal saline may be injected intrapleurally or intra-articularly.</p>
<p>Stability of sodium ampicillin in solution decreases markedly and storing of solutions even at refrigeration temperature results in deterioration of activity; the presence of dextrose and lactate accelerates the loss of potency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Urinary tract infections caused by E. coli, P. Mirabilis, non-hemolytic streptococci and enterococci. It is also useful for prophylaxis against recurrent UTI (Chapter 52).</li>
<li>Respiratory tract infections: It is preferred particularly in mixed infections with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae and P. pneumoniae.</li>
<li>Meningitis and subacute bacterial endocarditis: See Chapter 48 and Table 46.3.</li>
<li>Biliary tract and intestinal infections: Ampicillin can be used against intestinal infections due to E. coli, enterococci, salmonella and shigella. Although it is effective in typhoid fever,</li>
</ul>
<p>ciprofloxacin appears to be superior (see Chapter 49).</p>
<ul>
<li>Miscellaneous: Ampicillin is preferred to tetracyclines in pregnant women and in infants to avoid tetracycline deposition in bones and teeth. It can also be used as an alternative to tetracyclines in the management of intestinal malabsorption and is preferred in the treatment of whooping cough. The other drugs useful in whooping cough are azithromycin (the drug of choice), erythromycin and co-trimoxazole.</li>
</ul>
<p>Because of increasing resistance by bacteria, ampicillin has lost its status as a drug of choice for the empiric treatment of childhood meningitis, salmonellosis, shigellosis and gonococcal infections.
TALAMPICILLIN: This carboxylic ester of ampicillin is a prodrug. It is rapidly absorbed from the gut and is hydrolysed by tissue esterases in the intestinal wall to release ampicillin into the circulation. It has no intrinsic antibacterial activity and hence, is not likely to have direct effect on the bacterial flora of the gut. Dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day.
Pivampicillin has properties similar to those of talampicillin.
AMOXICILLIN: This structural analogue of ampicillin (amino- p-hydroxy-benzylpenicillin) has properties and uses similar to those of ampicillin. However, it has certain advantages:
(a) It is almost completely absorbed and the blood levels on oral administration are twice as high as those after similar dose of ampicillin.
(b) Its absorption is not influenced by food.
(c) It is less protein bound and the urinary excretion is higher than that of ampicillin.
(d) The incidence of diarrhoea is less.</p>
<p>It is, however, much more expensive. It is available as 250 mg capsules. The usual oral dose in adults is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>8</mn></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg} 8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">8</span></span></span></span></span> hourly. In severe or recurrent purulent, respiratory infections doses as large as 3 g 12 hourly are recommended. It can also be given IM or IV but offers no advantage over parenteral ampicillin. It is preferred for preventing the carrier state in typhoid fever.
IV Extended Spectrum Penicillins, also known as antipseudomonal penicillins:
(1) The carboxypenicillins and the ureido penicillins (Table 46.5), are considered extended spectrum penicillins, because they inhibit a wide variety of aerobic Gram negative bacilli, including P. aeruginosa. They have the following properties:</p>
<ul>
<li>They are acid labile and susceptible to beta lactamase.</li>
<li>They are highly active against anaerobes.</li>
<li>They are most useful in infections caused by P. aeruginosa and other Gram negative rods.</li>
<li>They are much less active than penicillin G against Gram positive organisms and are not reliable for treating staphylococcal infections.</li>
<li>The CNS penetration of the carboxy-and the ureido-penicillins is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of their serum levels, and hence they are not recommended for the treatment of meningeal infections.</li>
<li>They act synergistically with aminoglycoside antibiotics, particularly against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa and the Enterobacteriaceae.</li>
<li>They may inactivate the aminoglycoside antibiotics in vitro when mixed together in the same bottle.
P. aeruginosa may develop resistance to these drugs, which is prevented by concurrent administration of an aminoglycoside.</li>
</ul>
<p>CARBENICILLIN: This penicillin has a similar spectrum as but weaker antibacterial activity than ampicillin. Its important advantage over ampicillin is that it is effective against all strains of Proteus and P. aeruginosa.</p>
<p>Carbenicillin is administered IM or IV. When given IM, the peak plasma levels are reached within 2 hours and the drug is eliminated in urine within 6 hours. Indanyl ester of carbenicillin is used orally to treat UTI.</p>
<p>The drug can cause CHF because of its large sodium content, and bleeding due to abnormal platelet aggregation. It is</p>
<p>now replaced by more active analogue, ticarcillin.
TICARCILLIN: This thienyl analogue of carbenicillin is twice as active against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa. Some anaerobes, including many forms of Bacteroides fragilis, are also sensitive to it. It is, however, much less active than ampicillin against streptococci, pneumococci and penicillin sensitive staphylococci.</p>
<p>It diffuses well into the CSF, pleural fluid and sputum and is excreted by the kidneys. The dose recommended in severe infections is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15-20 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day, given as 5 g diluted in 20 ml and injected IV over 3-4 minutes every 6-8 hours. In less severe infections, it can be given IM ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mn>6</mn></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} 6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">6</span></span></span></span></span> hourly). It can be used in the treatment of severe UTI. It is usually combined with clavulanic acid to increase effective blood levels. It can be combined with amino glycosides. Because of its high sodium content, it may cause sodium overload in patients with cardiac or renal damage.</p>
<p>PIPERACILLIN: This ureido-penicillin has a broad spectrum activity against Gram negative bacilli, particularly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa (against which it is three times as active as ticarcillin). It is regarded as one of the most broadly active of the currently available penicillins with regard to other bacterial species especially Proteus, Klebsiella, Bacteroides fragilis, H. influenzae and Gonococci.</p>
<p>Piperacillin is given parenterally. It is mainly eliminated in the urine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) and adjustment of its dose is needed in the presence of renal damage. Piperacillin crosses the BBB and may be useful in neonatal meningitis. Adverse effects are similar to those of other penicillins. However, it is less likely to cause sodium overload.</p>
<p>Although it is useful in a variety of infections, its use should be reserved for serious infections, especially those due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa.</p>
<p>The dosage regimen is identical to that of ticarcillin. The recommended pediatric dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100-300 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in two divided doses for infants under 2 months of age and in 4 divided doses for older infants and children.</p>
<p>Azlocillin and mezlocillin have similar indications as piperacillin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-amidinopenicillins">(2) Amidinopenicillins:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-amidinopenicillins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MECILLINAM: Mecillinam has no therapeutic activity against Gram positive organisms but is highly effective against Gram negative organisma such as E. coli, (including those resistant to ampicillin), Klebsiella species, Shigellae and Salmonellae. Proteus is less susceptible; it has no action on pseudomonas. It is poorly absorbed orally and is given IM. Its ester pivmecillinam is better absorbed orally and is hydrolysed to mecillinam. These compounds have been used in UTI and in typhoid fever, but do not appear to be superior to the other commonly used drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-lactamase-inhibitors">Beta lactamase Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-lactamase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CLAVULANIC ACID: This penicillin analogue produced by Streptomyces clavuligerus has the following properties:</p>
<ul>
<li>It is well absorbed on oral administration but has only a weak antibacterial activity.</li>
<li>It is a potent and irreversible inhibitor of many beta lactamases and protects beta lactam antibiotics from inactivation, when combined with them.</li>
<li>Combined with amoxicillin, it widens the antibacterial spectrum of the latter to include beta lactamase producing strains of Staph. aureus, H. influenzae, N. gonorrhoea, E. coli, Proteus, Klebsiella, M. catarrhalis and Bacteroides species.
It is used in combination with amoxicillin or ticarcillin.
SULBACTAM is another beta lactamase inhibitor penicillin analogue similar in action to clavulanic acid, and it is combined with ampicillin. Tazobactam is a penicillanic-acidsulfone, beta lactamase inhibitor. It is combined with piperacillin.</li>
</ul>
<p>However, these combinations are expensive and are not cost-effective for routine infections wherein the antimicrobial agents alone are adequate. They should be reserved for infections due to beta lactamase producing organisms.</p>
<p>The beta lactamases produced by Ps. aeruginosa and by Enterobacter species are resistant to clavulanic acid and sulbactam. Further, MRSA are not susceptible to antimicrobials containing clavulanic acid or sulbactam.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="macrolides">Macrolides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#macrolides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Erythromycin, oleandomycin, triacetyloleandomycin and spiramycin constitute the macrolide group of antibiotics, so named because of the presence of a large lactone ring in their chemical structure. They have similar antibacterial spectra, erythromycin being the most effective of all.</p>
<p>Mechanism of action: Macrolides act by inhibiting the protein synthesis by binding to the 50s ribosomal subunits. Depending upon its concentration, the antibiotic can be bacteriostatic or bactericidal. Bacteria can develop resistance to macrolides by mutation.</p>
<p>ERYTHROMYCIN is derived from the fungus Streptomyces erythreus. Its antibacterial spectrum resembles that of penicillin. It is mainly effective against the Gram-positive cocci including the streptococci, staphylococci and pneumococci. Neisseria, some strains of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae, C. diphtheriae, Campylobacter jejuni, Listeria, P. multocida, Mycoplasma pneumoniae, Rickettsiae and Treponemas are also inhibited by low concentration. The drug is effective against penicillin resistant staphylococci. However, staphylococci and hemolytic streptococci can develop resistance to it.</p>
<p>Absorption, fate and excretion: Erythromycin is mainly absorbed from the small intestine. The drug is partially destroyed by the gastric juice and, therefore, is administered in the form of enteric coated tablets. The ester form, erythromycin estolate, is more resistant to inactivation by the gastric acid and is absorbed better than the base.</p>
<p>Peak plasma levels are reached within 2 to 4 hours after a single oral dose and the levels decline within 6 to 8 hours; hence, it is given 6 hourly.</p>
<p>Erythromycin readily diffuses into the body fluids but the penetration into the CSF is poor. It is concentrated in the liver, and the levels of the active form in bile are significantly high. Most of the drug ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> ) is metabolised in the liver. It can pass into the foetal circulation.</p>
<p>Adverse reactions: Serious adverse effects are uncommon. Allergic reactions include fever, eosinophilia, urticaria, dermatitis and lymphadenopathy. Nausea, vomiting, epigastric pain and diarrhoea are common. Hepatic dysfunction, particularly cholestatic hepatitis and jaundice, has been described following of erythromycin estolate. It is probably an allergic manifestation though a direct hepatotoxic action cannot be ruled out. It usually clears up within a few days after discontinuation of therapy. Hepatic dysfunction is a relative contraindication for erythromycin therapy. Superinfection with Gram-negative organisms and Candida may develop.</p>
<p>Drug interactions: Erythromycin is a potent inhibitor of hepatic microsomal CYP3A4, thereby interfering with the metabolic degradation of number of drugs such as cisapride, ketoconazole and cimetidine. Important interactions between erythromycin and other drugs are shown in Table 46.6. Some of them have been documented for other macrolide antibiotics as well.</p>
<p>Table 46.6
Drug interactions with erythromycin</p>
<ul>
<li>Reduction in plasma clearance with increased plasma levels and increased toxicity of: Ketoconazole, Theophylline, Carbamazepine, Cyclosporine, Digoxin, Warfarin, Disopyramide, Methylprednisolone.</li>
<li>Interference with the action of chloramphenicol and clindamycin as these drugs compete for the same bacterial binding sites.</li>
<li>Physical/chemical incompatibility (in solution) between parenteral forms of Erythromycin and Vitamin B complex, Ascorbic acid, Tetracycline, Colistin, Chloramphenicol, Heparin, Metaraminol and Phenytoin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Enteric coated tablets contain 250 mg of erythromycin base. Dose: 1 to 2 g per day in divided portions, administered 6 hourly. Food should not be given immediately after its administration. The dose in children is 5 mg per kg 6 hourly in children below 1 year, 10 mg per kg 6 hourly in children upto 8 years and 15 mg per kg in children between 8 and 12 years.
(ii) Erythromycin estolate tablets contain the equivalent of 125 and 250 mg of erythromycin base.</p>
<p>It is administered in similar dosage. It is tasteless and resistant to gastric acid. Food does not interfere with its absorption. Because of its hepatotoxicity, it is used only for short periods.
(iii) Erythromycin stearate filmtabs, contain 100 and 250 mg of the base; cherry flavoured granules for syrup containing 100 mg per 5 ml for children. Dose in children: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per day in divided doses.
(iv) Erythromycin ethylsuccinate for IM injection 2 ml containing 100 mg of the base.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>As a substitute for penicillin: Erythromycin is valuable in patients allergic to penicillins and in those in whom organisms have developed resistance to it. Its antibacterial activity, however, is weaker than that of benzylpenicillin. As erythromycin (bacteriostatic) may interfere with the action of penicillin (bactericidal), the combination of these two drugs should be used only when it has been documented to be beneficial. For subacute bacterial endocarditis due to Strep. viridans, in a penicillin allergic individual, 1 g of the drug is administered at 4 to 6 hourly intervals for 4 to 6 weeks, along with gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mn>8</mn></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg} 8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">8</span></span></span></span></span> hourly. The drug eradicates the diphtheria carrier state in the dose of 250 and 500 mg every 6 hours for 10-12 days in children and adults respectively. The drug can be used for prophylaxis against streptococcal infection and rheumatic fever.</li>
<li>Mycoplasma and chlamydial infection: It is the drug of choice in the treatment of mycoplasma pneumoniae. It should be used in chlamydial pneumonia in infancy and in urogenital infections, particularly during pregnancy.</li>
<li>Whooping Cough: Erythromycin is the drug of choice in the treatment of whooping cough (B. pertussis). It is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in four divided doses for 14 days. Alternatively azithromycin or co-trimoxazole may be used. Although these drugs are useful in clearing B. pertussis, no drug has been shown to alter the course of the illness, once frank paroxysms have supervened.</li>
<li>Diarrhoea due to Campylobacter jejuni. It is the drug of choice (Chapter 41).</li>
<li>Legionnaires disease is caused by legionella, an intracellular pathogen. Erythromycin</li>
</ul>
<p>and tetracycline achieve high intracellular concentration and are highly effective in its treatment; newer macrolide azithromycin may be preferred. Fluoroquinolones are also highly effective.</p>
<ul>
<li>STD: See Chapter 53.</li>
<li>Acne: See Chapter 71. Oleondomycin, triacetyloleandomycin and spiramycin have much weaker actions than those of erythromycin. Spiramycin is used to treat toxoplasmosis (Chapter 58).
Azalides, the other macrolides have a similar spectrum of activity as erythromycin. However,</li>
<li>They are resistant to acid hydrolysis.</li>
<li>They are absorbed better and give higher tissue levels; and</li>
<li>They have longer duration of action and can be given once daily.</li>
</ul>
<p>Examples are roxithromycin, azithromycin and clarithromycin. The latter two are also active against H. influenzae, M. catarrhalis, T. gondii and M. avium complex.</p>
<p>ROXITHROMYCIN: This substituted erythromycin has antibacterial spectrum and therapeutic uses similar to those of erythromycin. It is rapidly absorbed from the gut with a bioavailability of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>; food interferes with its absorption. Most of the drug is excreted in the feces, either unchanged or as metabolites. Its adverse effects are similar to those of erythromycin. The adult dose is either 150 mg bid or 300 mg OD, taken before meals, for 10 days. It is used in ear, throat, respiratory tract and non-gonococcal genitourinary infections.</p>
<p>AZITHROMYCIN: This azalide antibiotic differs chemically from the macrolide group in that the lactone ring contains a nitrogen atom. It has similar activity and toxicity as erythromycin. In addition it:
(a) Acts against certain Gram negative bacilli including H. influenzae and C. trachomatis. It also shows activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. avium complex.
(b) Penetrates the tissues better, concentrates in polymorphs.
(c) Has a longer half life (68-72 hours) and is given OD and
(d) Is largely not metabolised and excreted in bile and faeces.
(e) Should not be administered with food. It is given 1 hr before food or 2 hrs after food.
(f) Should be used cautionsly in patients with CVS risk factors, as it can cause QT prolongation and cadiac arrhythmia.</p>
<p>Its uses are similar to erythromycin. A loading doses of 500 mg , followed by 250 mg 12 hrly for 2-5 days is usually recommended for pharyngitis, pneumonia and skin and soft tissue infections. In NGU (Chapter 53) it is given in a single 1 g dose. In trachoma, three oral doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> each, given at weekly intervals, are highly effective. It is used for prophylaxis and to treat avian complex in AIDS patients. It is also used to treat respiratiory infections, atypical pneumonia, whooping cough, genital infections such as chlamydia and toxoplasmosis.</p>
<p>CLARITHROMYCIN: This azalide differs from erythromycin only in methylation of the hydroxyl group in 6th position. It has good activity against H. influenzae, N. gonorrhoea, L. pnеuтophiliae and chlamydia. It is better than azithromycin against MAC (Chapter 54) and H. pylori. The drug is absorbed rapidly and almost completely from the gut but undergoes first pass metabolism, has a short half-life (3-7 hours) and has better tissue penetrability than erythromycin. Food does not interfere it absorption. It is metabolised to 14-hydroxy-</p>
<p>clarithromycin, which is active, and is excreted by renal and extrarenal mechanisms. Clarithromycin is administered orally in the dose of 500 mg bid.</p>
<p>Among the newer macrolide antibiotics, clarithromycin and azithromycin have much better activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. catarrhalis and hence may be preferred for the treatment of community acquired pneumonia. Clarithromycin is the macrolide of choice for the treatment of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori while azithromycin is preferred for the treatment of Chlamydia trachomatis infections.</p>
<p>TELITHROMYCIN: This first ketolide antibiotic is related to erythromycin with similar antibacterial spectrum. However, it is also effective against macrolide resistant pneumococci. It is given 800 mg OD for 5-10 days. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 10 hrs . Dose adjustment is necessary in the presence of severe renal damage. The drug is a potent inhibitor of CYP3A4. Adverse reactions include diarrhoea, blurred vision, diplopia and QTc prolongation. It can cause exacerbation of myasthenia gravis. Hepatotoxicity limits its use.</p>
<p>FIDAXOMICIN is the narrow spectrum macrolide which is minimally absorbed on oral administration. It inhibits the bacterial RNA polymerase and is bactericidal.</p>
<p>Its oral toxicity is similar to vancomycin. Vomiting is the primary ADR. Given in the dose of 200 mg bid orally for 10 days for Clostridium difficile associated diarrhoea, it selectively eradicates Clostridium difficile without affecting the other bacterial species in the intestine, thus opposing Clostridial growth and reducing the recurrence of infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lincosamide-antibiotics">Lincosamide Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lincosamide-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LINCOMYCIN: Lincomycin, elaborated by Streptomyces lincolenesis, acts by binding to ribosome and interfering with protein synthesis. It is mainly bacteriostatic with spectrum similar to that of penicillin and erythromycin. It inhibits the growth of many Grampositive organisms, especially Staphylococci (including those producing beta lactamase), Pneumococci, certain Streptococci and C. diphtheriae. It also has activity against anaerobes such as B. fragilis. B. anthracis is moderately sensitive.</p>
<p>Enterococci, meningococci, hemophillus and gonococci, however, are little affected. Many clostridia are also resistant. Development of resistance by staphylococci has been reported. Cross resistance with macrolide antibiotics may occur.</p>
<p>Absorption, fate and excretion: On oral administration, approximately 20 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> of lincomycin is absorbed. Food interferes with its absorption. Injection of 600 mg IM produces within 30 to 60 minutes peak plasma levels which are twice as high as those obtained on oral administration. It can also be given IV.</p>
<p>The drug is distributed throughout the body and is concentrated in the liver, spleen, kidneys, lung and bone. Most of the drug is metabolised in the liver and small amount is excreted in urine unchanged. As with erythromycin, high concentration occurs in bile. CSF and brain concentrations are low.</p>
<p>Adverse reactions: The drug is free from serious adverse effects. Nausea, vomiting, abdominal pain and diarrhoea may occur. Pseudomembranous colitis is a rare but serious ADR. A few patients may experience dizziness, headache, rash, bodyache, pruritus, proctitis and vaginitis. A few instances of jaundice or leucopenia neutropenia have been reported. Monilial superinfection may occur.</p>
<p>Preparations and dosage: The oral adult dose of lincomycin hydrochloride monohydrate is 500 mg 3 to 4 times daily. Children are given 30 to 60 mg per kg daily in 3-4 divided doses. The IM and the IV doses are 600 mg given at 12 and 8 to 12 hourly intervals respectively. The comparative doses in children are 10 mg per kg and 10 to 20 mg per kg respectively.</p>
<p>Therapeutic uses: Lincomycin has been employed clinically in staphylococcal, pneumococcal and streptococcal infections resistant to penicillin or erythromycin and in individuals allergic to these antibiotics. It is claimed to be more effective in the treatment of acute and chronic osteomyelitis probably because of its better penetration into bones.</p>
<p>CLINDAMYCIN: This is 7-chloro-7-deoxylincomycin, a semisynthetic derivative of lincomycin. It is bacteriostatic at low concentrations and bactericidal at slightly higher ones. It has antibacterial spectrum similar to that of lincomycin. However, it is
(i) Much better absorbed orally and undergoes entero-hepatic circulation.
(ii) Absorbed adequately in presence of food.
(iii) Highly protein bound; and
(iv) Mostly metabolised in the liver ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 3 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span> ). Like lincomycin, it also achieves high levels in bone and bile.</p>
<p>Adverse reactions: The toxicity is similar to that of lincomycin, including the diarrhoea due to pseudomembraneous colitis. The latter is due to superinfection with Cl . sordellii and Cl . difficile which secrete exotoxins with a necrotizing effect on the colonic mucosa. The organisms are sensitive to vancomycin. However, metronidizole 250 mg tid for 10-14 days is</p>
<p>equally effective.
Therapeutic uses: They are
(1) Like lincomycin, it is used to treat Gram +ve organisms resistant to penicillin or cephalosporins.
(2) It is also useful in the treatment of anaerobic infections, particularly in combination with an aminoglycoside, in the treatment of peritonitis due to mixed infection.
(3) It is preferred for staphylococcal bone and joint infections, and can be used to treat actinomycosis, anthrax and diptheria.
(4) The drug has also been used in combination to treat malaria, toxoplasmosis (Chapter 56,58 ) and locally for acne (Chapter 71). In the treatment of toxoplasmosis, sulfadiazine can be substituted by clindamycin.</p>
<p>Its usual dose varies between 150 and 450 mg four times daily. In children and infants, it is given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily in 3 to 4 divided doses. Intramuscularly or by IV infusion, dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">600 \mathrm{mg} 8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hourly.</p>
<p>For severe infections in adults, doses upto 4.8 g by IV infusion have been used.
There is a partial cross resistance between lincosamides and macrolides.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glycopeptide-antibiotics">Glycopeptide Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glycopeptide-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>VANCOMYCIN: Vancomycin, obtained from the fungus Streptomyces orientalis, is highly effective against Gram positive cocci, MRSA and Enterococcus fecalis. The drug is bactericidal. It acts by interfering with trans glycosylase reaction in the cell wall synthesis.</p>
<p>Vancomycin is not absorbed orally and IM administration is very painful. It is given IV. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the drug is eliminated in urine within 24 hours. Bacteria (enterococci and staphylococci) can develop resistance to vancomycin.</p>
<p>Adverse reactions: These include local thrombophlebitis, generalised cutaneous reactions (Red Man Syndrome) due to massive histamine release and renal/auditory damage. As the drug is mainly eliminated by the kidney, it should be used with caution in patients with renal damage.</p>
<p>Therapeutic uses: Vancomycin is given IV in the dose of 500 mg over 60 minutes every 6 hours or 1 g every 12 hours. It is mainly used to treat multiresistant staphylococcal and E. fecalis infections. It may also be used in penicillin and cephalosporin resistant infections.</p>
<p>Oral dose of 125 mg 6 hourly adequately controls acute staphylococcal enterocolitis, and pseudo-membranous colitis caused by the toxins of Cl. difficile. However, metronidazole is equally effective and cheaper.</p>
<p>Teicoplanin: It is produced by Actinoplanes teicomyetius and is structurally related to vancomycin and has similar properties. Staphylococci can develop resistance to this drug. Unlike vancomycin, it can be given safely by IM injection. It is highly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) protein bound with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 50 hours.</p>
<p>It is used in preference to vancomycin in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">6-30 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day to treat MDR infections caused by staphylococci, streptococci and enterococci. However, it is not as efficacious as antistaphylococcal penicillins for treating severe infections caused by methicillin-susceptible organisms.</p>
<p>Dalbavancin is a semisynthetic lipoglyco-peptide derived from teicoplanin and shares the same mechanism of action. It has activity against Gram positive bacteria including MRSA and VRSA. The drugs has a long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (or approx 14 days) and therefore is administered once weekly IV infusion. The common ADR include nausea, diarrhoea and headache. Red-man syndrome can also occur.</p>
<p>Telavancin, a semisynthetic lipoglycopep-tide derived from vancomycin, acts similar to vancomycin. Given IV once daily, it acts against Gram positive bacteria including vancomycin resistant strains. However, its use is limited because of ADR like taste disturbances, nausea and vomiting, nephrotoxicity, and QT prolongation..</p>
<p>Bacteria can develop resistance to all the glycopeptide.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-antibiotics">Miscellaneous Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DAPTOMYCIN: This bactericidal antibiotic produced by Streptomyces roseosprous belongs to a new class called cyclic lipopeptides.</p>
<p>Mechanism of action: It binds to the bacterial plasma membrane. causing membrane depolarisation and release of intracellular ions. This causes cell damage.</p>
<p>Its spectrum is similar to that of vancomycin and includes. Gram positive bacteria including MRSA and VRSA, penicillin resistant S. pneumoniae, VRE faecalis. It has plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of nine hours. It is largely excreted by the kidney.</p>
<p>Adverse reactions: include GI disturbances, rash, headache and dose related muscle pain/weakness. Hence CPK monitoring is advisable.</p>
<p>The drug appears to be similar to vancomycin in efficacy against vancomycin sensitive organisms, but is also useful to treat vancomycin resistant skin and soft tissue infections. It is usually administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV/OD.</p>
<p>SODIUM FUSIDATE: Fucidin, the sodium salt of fucidic acid, is obtained from the parasitic fungus Fusidium coccineum. It has a steroidal structure. The drug is effective mainly against Gram-positive organisms and is used against beta lactamase-producing staphylococci. It is bacteriostatic. However staphylococci rapidly develop resistance to this antibiotic by mutation. The antibiotic exerts a synergistic effect when combined with flucloxacillin and erythromycin.</p>
<p>After an oral dose of 500 mg , peak plasma levels are obtained at 2 hours, and antibacterial activity can be detected in the plasma upto 24 hours ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>5</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">5</span></span></span></span></span> hours). Milk considerably retards its absorption. It is mostly metabolised in the liver. Significant amounts are present in bile. CSF concentration is low.</p>
<p>Adverse reactions: These include skin reactions, nausea, vomiting, epigastric pain, diarrhoea and hepatic dysfunction.</p>
<p>Therapeutic uses: In resistant staphylococcal infections, sodium fusidate may be administered orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>8</mn></mrow><annotation encoding="application/x-tex">500-1000 \mathrm{mg} 8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">8</span></span></span></span></span> hourly. It can also be given by IV infusion as diethanolamine fusidate in the dose of 580 mg 8 hourly. It is employed locally as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> sodium fusidate in a neutral ointment base to treat staphylococcal skin lesions.</p>
<p>BACITRACIN: Bacitracin is a polypeptide antibiotic obtained from Bacillus subtilis. It resembles penicillin in antibacterial activity and is effective against Gram-positive organisms like streptococci, staphylococci, pneumococci and enterococci. Corynebacterium, gonococci, meningococci, Cl. tetani, Cl. difficile, treponema and H. influenzae are highly sensitive. Microorganisms do not readily develop resistance to bacitracin. It probably acts by inhibiting the bacterial cell wall synthesis.</p>
<p>Bacitracin is not much absorbed orally. Parenterally, it is nephrotoxic. Acute tubular necrosis and anuria may occur. It is used only topically as an antiseptic in combination.</p>
<p>MUPIROCIN: This antibiotic is obtained from the cultures of Pseudomonas fluorescens. It is bactericidal. It is most active against Gram-positive bacteria but also has activity against Gram-negative aerobic organisms. It is used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> ointment to treat localised superficial skin infections caused by staphylococci and streptococci, and for eradication of nasal colonisation by Staph. aureus. Its application to large areas should be avoided because the PEG in the ointment may get absorbed and cause toxicity (Chapter 6).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="streptogramins">Streptogramins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#streptogramins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>QUINUPRISTIN (Q)/DALFOPRISTIN (D) is a combination of streptogramin B with streptogramin A in the ratio of 30:70. They are semisynthetic derivatives of pristinamycin which had been in use in France for 30 years. They act synergistically on the bacterial ribosome to disrupt protein synthesis. The combination is bactericidal. It is active against E. faecium, S, aureus, S. epidermidis, S. pneumoniae, N. meningitidis, Moraxella catarrhalis, Legionella, Mycoplasma pneumoniae and Cl. perfringens. It has no activity against Enterococcus faecalisn The combination is administered by IV infusion in 5% dextrose (not in saline). Both have elimination half life of about one hour. They are metabolised in the liver. Bacteria can develop resistance to these drugs.</p>
<p>Adverse reactions: Locally, the combination causes inflammation, pain and thrombophlebitis. Other ADR reported are arthralgia and myalgia. Both the drugs are potent inhibitors of the liver cytochrome enzymes CYP3A4 and hence may increase the blood levels of drugs such as nifedipine, midazolam, and cyclosporine during coadministration.</p>
<p>Therapeutic uses: The combination is used to treat the Vancomycin resistant Enterococcus faecium (VREF) and complicated skin infections caused by MDR Staph. aureus and Strep. pyogenes, nosocomial pneumonia with S. pneumoniae. Because of high incidence of ADR, drug interactions and very high cost, their routine use is to be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oxazolidinones">Oxazolidinones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oxazolidinones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LINEZOLID: This antibacterial drug belongs to a new chemical class called oxazolidinones. It is bacteriostatic against staphycocci and enterococci and bactericidal against streptococci and pneumococci. Its main advantage is that it is active against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span>. faecium, MRSA and VRSA. It also acts against penicillin-resistant pneumococci and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. tuberculosis. However, it has no action against Gram-ve organisms.</p>
<p>Mechanism of action : It acts by preventing initiation of protein synthesis. Because of its unique binding site (on 50 S subunit), there is no cross-resistance with other drug classes. Bacteria can develop resistance to this drug by mutation.</p>
<p>Given orally, the drug is rapidly and completely absorbed. It undergoes nonenzymatic oxidation in the liver and excreted in urine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> being in an active form. It has a half life of about 5 hours. It can also be given IV. The drug gets decomposed by light. As linezolid and its metabolites are eliminated by dialysis, the drug should be administered following dialysis. No dose adjustment is recommended in chronic renal failure.</p>
<p>Adverse reactions: These include diarrhoea, nausea, vomiting, headache, rash, thrombocytopenia, leukopenia and rarely bone marrow suppression and neuropathy. The drug is an MAO inhibitor.</p>
<p>Therapeutic Uses: It should be reserved for the treatment of well documented serious VREF and VRSA infections, MDR respiratory infection and chronic osteomyelitis. It is now advocated in the treatment of MDR TB (Chapter 54). It is given in the dose of 400-600 mg 12 hourly. It is expensive.</p>
<p>Tedizolid, a new oxazolidinone, is an active moiety of a prodrug tedizolid phosphate. The action, and antibacterial spectrum, therapeutic uses and ADR are similar to linezolid.</p>
<p>47</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aminoglycosides-and-other-antibiotics-effective-mainly-against-gram-negative-organisms">Aminoglycosides and Other Antibiotics Effective Mainly Against Gram Negative Organisms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aminoglycosides-and-other-antibiotics-effective-mainly-against-gram-negative-organisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aminoglycosides form an important group of antibiotics, useful mainly against aerobic Gram-negative bacteria (Table 47.1). They are protein-synthesis inhibitors, interfering with ribosomal function. Compounds derived from Streptomyces are called 'mycins' (e.g., streptomycin) whereas those derived from Micromonospora are called 'micins' (e.g., gentamicin). The aminoglycosides have certain features in common:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-47-1">Table 47.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-47-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Aminoglycosides in therapeutic use</p>
<p>For topical use in the eye and on the skin: Neomycin, Framycetin, Gentamicin. For GI infections and gut sterilisation: Neomycin, Panomomycin. For systemic use: Streptomycin, Gentamicin, Kanamycin, Amikacin, Tobramycin, Netilmicin.</p>
<ul>
<li>Chemically, they are polycations containing aminosugars in glycoside linkage.</li>
<li>They are bactericidal and their activity is maximum in an alkaline medium.</li>
<li>They have similar spectrum of activity. They are highly effective in infections caused by Gram negative microorganisms, and are not effective in infections due to anaerobes.</li>
<li>They are highly polar (water soluble) and are not absorbed orally. Their distribution is essentially extracellular, and penetration into the CSF (except in the neonate) and into the eye is poor on systemic administration.</li>
<li>They are excreted unchanged relatively rapidly by the kidneys by glomerular filtration and dosage adjustment is a must in patients with renal impairment and in old people.</li>
<li>Bacteria develop resistance to them fairly rapidly and may even exhibit cross resistance among different aminoglycosides.</li>
<li>They exhibit synergism when combined with a beta lactam antibiotic such as a penicillin or a cephalosporin; however, they should not be added to an infusion containing these drugs, as aminoglycosides tend to be inactivated by them.</li>
<li>High concentrations are found in the renal cortex and in the endolymph and the perilymph of the inner ear. This perhaps contributes to their nephrotoxicity and ototoxicity (eighth cranial nerve damage) and may be avoided in pregnancy.</li>
<li>They are also toxic to the neuro-muscular junction.</li>
</ul>
<p>Mechanism of action: Aminoglycosides diffuse through the outer cytoplasmic membrane and are transported to ribosomes. Ribosomes manufacture enzymes as per the directions from messenger RNA (mRNA). Aminoglycosides bind mainly to 30s ribosomes and interfere with initiation of protein synthesis, block the translation of mRNA and prematurely terminate the synthesis. Incorrect amino acids get incorporated in the protein chain, leading to production of abnormal proteins. These proteins on insertion into the cell membrane, cause its disruption. They exhibit concentration-dependent killing and also have a post-antibiotic effect, depending on concentration. Hence the present trend is to</p>
<p>administer these antibiotics in a single daily high dose which probably reduces the incidence of oto-and renal toxicity.</p>
<p>Aminoglycoside resistance: The microorganisms readily develop resistance to aminoglycosides. Some important examples are S. pneumoniae, M. tuberculosis, Proteus, E. coli, Aerobacter, H. influenzae, Brucella, Staph. aureus and Strep. fecalis.</p>
<p>Resistance to aminoglycosides arises from several different mechanisms.</p>
<ul>
<li>Low level resistance is due to decreased cell permeability to the antibiotic. Thus, the bacterial cell becomes impermeable, preventing the drug reaching the drug sensitive ribosomes.</li>
<li>High level resistance results from a single step mutation which affects the ribosomal proteins. This is relatively uncommon and is specific for streptomycin.</li>
<li>'R' factor mediated resistance (see Chapter 51) is clinically significant. The genetic material transferred during conjugation confers on the recipient cell the capacity to synthesise specific enzymes which destroy the aminoglycoside. There is cross resistance among various aminoglycosides.
STREPTOMYCIN: This antibiotic, obtained from Streptomyces griseus, is an organic base. It is stable in dry state at room temperature. The aqueous solution of the salt retains its activity at pH 3 to 7 for 3 months, if kept at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>28</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">28^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">2</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> or below.</li>
</ul>
<p>Antibacterial activity: The organisms usually sensitive to streptomycin are: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. tuberculosis, Shigella species, E. Coli, Proteus, Pseudomonas aeruginosa, Aerobacter aerogenes, H. influenzae, H. ducreyii, Y. pestis, F. tularensis, Brucella, Actinobacillus mallei, Listeria and Nocardia.</p>
<p>The moderately sensitive organisms include Staphylococci, Strep. pyogens, Strep. faecalis, Strep. viridans, S. pneumoniae, Vibrio comma and the Salmonella organisms. The Gonococci and Meningococci exhibit a variable response.</p>
<p>Streptomycin is bacteriostatic in low and bactericidal in high concentrations. Its bactericidal action increases progressively with rise in concentration.</p>
<p>Absorption, fate and excretion: Given IM, peak plasma level is reached within 30 to 60 minutes and the activity persists for 6 to 8 hours. The drug is well absorbed when instilled intrapleurally. About 30 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> of the drug is bound to plasma proteins. It diffuses into the synovial, pericardial and peritoneal fluids but repeated systemic administration is necessary to produce a high concentration in the pleural fluid. It does not readily cross the BBB; however, in the presence of meningeal inflammation, higher CSF concentrations are usually achieved. It is concentrated mainly in kidneys, liver and skeletal muscles. It crosses the placental barrier and the cord blood concentration is similar to that of the maternal blood.</p>
<p>Streptomycin is excreted unchanged by glomerular filtration. Approximately 50 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of the drug is eliminated in urine in an active form within 24 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Local irritation: Pain at the site of injection is common.</li>
<li>Allergy: The manifestations include various skin rashes, eosinophilia, drug fever and lymphadenopathy. Serious manifestations like angioedema, pericarditis, exfoliative dermatitis and blood dyscrasias are rare.</li>
<li>Eighth cranial nerve damage: This is the most serious adverse effect of streptomycin. Streptomycin is more prone to impair the vestibular function; however, the symptoms of</li>
</ul>
<p>vestibular damage are usually reversible. The incidence of this complication is dependent on the dose and duration of therapy. The likelihood of ototoxicity is greater in infants, elderly patients and in those with impaired renal function.
The labyrinthine dysfunction presents itself with a moderately severe headache which precedes the acute illness in which nausea, vomiting, giddiness, ataxia and nystagmus develop. These persist for 8 to 15 days. The acute stage is usually followed by chronic labyrinthitis and ataxia. With stoppage of the drug, recovery usually occurs within 12 to 18 months.</p>
<p>Streptomycin causes deafness. It is usually preceded by tinnitus. A few cases of congenital loss of hearing have been reported following its administration during pregnancy.</p>
<p>Other rare toxic effects include optic neuritis and peripheral neuritis. As chloramphenicol is also capable of producing optic neuritis, the two drugs should generally not be combined.</p>
<ul>
<li>Neuromuscular blockade: All aminoglycosides have a potential curarimimetic action, producing neuromuscular block and respiratory arrest on intrapleural or intraperitoneal instillation. It probably acts by inhibition of ACh release at the neuromuscular junction through competition with calcium ions. The blockade can be antagonised by calcium salts and by neostigmine.</li>
<li>Nephrotoxicity: Mild albuminuria, cylindruria or acute tubular necrosis may occur in patients receiving streptomycin, but azotemia is rare. Hence, dosage adjustment must be made in patients with renal insufficiency.</li>
<li>Superinfection: Superinfection with Staph. aureus and Candida has been reported.</li>
</ul>
<p>Preparations and dosage: Streptomycin sulfate injection: Dose: 0.5 to 1 g of the base daily by deep intramuscular injection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Tuberculosis: Chapter 54.</p>
</li>
<li>
<p>Plague: Streptomycin is highly specific and the drug of choice in the treatment of plague. The drug therapy must be instituted within first 15 hours of overt illness, particularly in plague pneumonia, to ensure a favourable response. It is administered in the dose of 30 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day IM in 2 divided doses for 10 days. Streptomycin may be used in pregnant women, old people and children with pneumonic plague. For optimum results, tetracycline is combined with streptomycin, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, preferably IV (or orally), in four divided doses per day, for 5 days. In meningitic plague, chloramphenicol-streptomycin is the preferred regimen; chloramphenicol is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40-50 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day IV in four divided doses, for 10 days. Supportive care includes the use of IV fluids, oxygen and vasopressor drugs to combat hypotension.
Contacts of a case of pneumonic plague should be treated with either tetracycline (250 mg qid orally) or cotrimoxazole ( 250 mg qid orally) for 5-10 days.
Doxycycline, amoxicillin, fluoroquinolones beta-lactams and newer aminoglycosides are effective in vitro and in experimental plague in animals; but, the clinical experience is limited.</p>
</li>
<li>
<p>Tularemia: This infection is highly sensitive to streptomycin and most cases respond to IM dose of 1 to 2 g daily for 7-10 days.</p>
</li>
<li>
<p>Brucellosis: Brucellosis is transmitted to humans from the cattle and camel through contaminated dairy products, especially fresh cheeses. In several Eastern Mediterranean countries, serious outbreaks of B. mellitensis infection in the sheep cause epidemics in people. Streptomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.75</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.75-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> IM daily for 3 weeks plus doxycycline 100 mg bid for 6 weeks is recommended as the treatment of choice; it causes rapid clinical improvement with only few relapses. In case of complicated brucellosis or in non-compliant patients, rifampicin 600 mg once daily for 6 weeks is added. Doxycycline plus rifampicin 3-6 weeks can be used as prophylaxis. WHO recommends the latter regimen for treatment also but it has higher relapse rate. Cotrimoxazole in high doses can also be used if doxycycline is contraindicated.</p>
</li>
<li>
<p>Enterococcal infections: Streptomycin is sometimes used in serious infections with susceptible enterococci. It exhibits synergistic effect with penicillin G.
KANAMYCIN: This aminoglycoside is derived from Streptomyces kanamyceticus. Its antibacterial spectrum, pharmacokinetics and toxicity are similar to those of streptomycin. However, it is much more toxic and is now rarely used.</p>
</li>
</ul>
<p>GENTAMICIN: This aminoglycoside antibiotic is produced by Micromonospora purpura.
Antibacterial activity: Gentamicin is highly effective against Pseudomonas, E. coli, Proteus, A. aerogenes, K. pneumoniae, salmonellae and Group A beta hemolytic streptococci. Staphylococci are also highly sensitive including those resistant to penicillin. It is 5-10 times more effective than kanamycin against Pseudomonas aeruginosa. M. tuberculosis and Mycoplasma pneumoniae are also highly sensitive. Resistance develops slowly. It exerts synergistic action with beta-lactams and metronidazole.</p>
<p>Absorption, fate and excretion: Gentamicin is not significantly absorbed on oral administration. Given IM, the peak plasma levels are reached within 60-90 minutes and therapeutically effective concentration persists for 6-8 hours. Approximately 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the drug is bound to plasma proteins. It is excreted largely unchanged by glomerular filtration and its urinary concentration ranges from 50 to 100 times that in the plasma.</p>
<p>Adverse reactions: It is much less toxic than kanamycin and streptomycin. Allergic skin reactions and possibly photosensitivity reactions have occurred following topical gentamicin. Parenteral therapy, particularly in the presence of renal impairment, may produce vestibular damage and ototoxicity. Dizziness is the main presenting symptom. A transient rise in blood urea nitrogen has also been reported in some patients.</p>
<p>Preparations and dosage: It is available as sulfate. The IM or slow IV dose of the drug is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-5 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses, for patients with normal renal function. The dose should be reduced in the presence of renal damage.</p>
<p>Administration of entire dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">60</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> ) once daily appears to be less toxic and is as effective. High concentration achieved by the single dose accounts for higher efficacy and may be cost effective. It is preferred in clinical practice except in pregnancy, neonates and low dose combination therapy of bacterial endocarditis. The single dose regimen is also avoided if creatinine clearance is less than 20-25 ml per min.</p>
<p>A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span></span></span></span></span> cream, ointment or eye drops is used for topical application.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Topical use: Gentamicin has been employed in a variety of skin infections in cases of burns infected with pseudomonas, bed sores, the nasal carriers of staphylococci, and ocular infections.</p>
</li>
<li>
<p>Urinary tract infections: Chapter 52.</p>
</li>
<li>
<p>Systemic infections: Although several Gram-positive bacteria are susceptible to gentamicin, safer and equally or more effective agents are available for treating infections caused by these bacteria. However, gentamicin is a valuable adjunct to penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>G</mi></mrow><annotation encoding="application/x-tex">G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">G</span></span></span></span></span> and ampicillin in the treatment of bacterial endocarditis caused by Streptococcus viridans and Streptococcus fecalis, respectively.
In combination with a carbenicillin or a cephalosporin, it is valuable in treating serious Gram negative bacillary infections especially those caused by P. aeruginosa, enterobacter, Klebsiella and Serratia and by other species resistant to other antibiotics. The infections so treated include urinary tract infections, peritonitis, meningitis, osteomyelitis, septic burns, otitis, pneumonia and septicemia.</p>
</li>
</ul>
<p>In pseudomonas infections, the gentamicin plus carbenicillin or piperacillin combination has been shown to be particularly effective. Tetracyclines and chloramphenicol should not be used together with gentamicin as they reduce its therapeutic efficacy. However, the effect of ampicillin is additive and it can be combind with gentamicin.</p>
<p>Netilmicin (Netromycin) has activity similar to gentamicin but is effective against some Gram negative bacilli resistant to gentamicin and tobramycin. It is less active than gentamicin against pseudomonas. It is available as sulphate for IM and IV use.</p>
<p>TOBRAMYCIN: This aminoglycoside antibiotic, belonging to the family of nebramycins, is derived from the actinomycetes Streptomyces tenebrarius. Its antibacterial spectrum, pharmacodynamic properties and toxicity are similar to those of gentamicin. However, clinically, it is four times as active as gentamicin against Pseudomonas and is relatively less toxic. It is active against a number of bacterial strains with acquired resistance to gentamicin. It is, however, less active against proteus. It is administered IM or IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3-5 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in 3-4 equal doses. Inhalatational tobramycin is used to treat infections in patients with cystic fibrosis.</p>
<p>AMIKACIN is a semisynthetic derivative of kanamycin A with pharmacokinetic properties similar to those of kanamycin. It has the broadest spectrum antibacterial activity among the aminoglycosides. Its uses and adverse effects are similar to those of gentamicin. It is not much affected by most of the enzymes that degrade gentamicin and tobramycin. Hence, it is active against gentamicin-resistant organisms such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa, Klebsiella, E. Coli and Proteus.</p>
<p>It is much more expensive than gentamicin and is usually reserved for hospital-acquired Gram-negative infections and in MDR tuberculosis. It is given IM or by slow IV drip in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in two divided doses.</p>
<p>From among gentamicin, amikacin and tobramycin, gentamicin is the most active against all gentamicin sensitive bacilli except Ps. aeruginosa which is more sensitive to tobramycin.</p>
<p>NEOMYCIN: This antibiotic obtained from Streptomyces fradiae, is a polybasic, water soluble substance relatively stable to heat and changes in pH . It is used as a sulfate complex.</p>
<p>Antibacterial activity: Neomycin is effective against a wide variety of Gram-positive and Gram-negative organisms including Enterococci, Streptococci, Staphylococci, B. anthracis, C. diptheriae, H. Influenzae, H. pertussis, Proteus, Pasteurella, Vibrio comma, Salmonella and Shigella. Resistance to the antibiotic is known and the resistant organisms show cross</p>
<p>resistance to kanamycin and streptomycin.
Neomycin is poorly absorbed orally. It is used mainly as an intestinal antiseptic. It is administered orally in the dose of 1g 4-6 hourly. It is also used locally for skin, eye and ear infections.</p>
<p>Adverse reactions: Its toxicity on parenteral administration is qualitatively similar to but more severe than that of streptomycin. Hence, it is not used systemically.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>For topical application to the skin and eye, it is usually combined with other antibiotics like bacitracin or polymyxin to prevent the emergence of resistant strains and to widen the spectrum;</li>
<li>As an intestinal antiseptic prior to colonic surgery and for suppression of intestinal flora in hepatic failure.
FRAMYCETIN: This antibiotic, produced by Streptomyces decaris, is used as the water soluble sulfate salt. Its antimicrobial spectrum, uses and toxicity are similar to neomycin.</li>
</ul>
<p>Framycetin sulfate, as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> ointment, cream or solution is used for staphylococcal skin infections and in the treatment of nasal carriers of staphylococci.</p>
<p>PAROMOMYCIN: This antibiotic, obtained from a strain of Streptomyces rimosus, has a similar spectrum of activity and toxicity as neomycin. It also shows considerable activity against E. histolytica. The drug is not absorbed orally. Adverse effects of oral therapy include headache, emesis, diarrhoea and skin rashes; superinfection with Candida may occur after prolonged oral therapy. The drug was used in amoebic dysentery, for sterilisation of the bowel before surgery and in hepatic coma. Given IM, it has been claimed to be effective in treating leishmaniasis (Chapter 58).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="non-aminoglycoside-agents">Non-aminoglycoside Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-aminoglycoside-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>COLISTIN (Polymyxin E) : This polypeptide antibiotic is obtained from the bacterium Aerobacillus colistinus. It acts by causing disruption of the phospholipids of the cell membrane because of its detergent property.</p>
<p>Antibacterial activity: Colistin is bactericidal to many Gram-negative organisms, e.g., <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pertussis, Pseudomonas, E. coli, A. aerogenes, K. pneumoniae, H. influenzae and Shigella. Most strains of Proteus, Gram-negative cocci, Gram-positive organisms and fungi are resistant to it. Resistance to the antibiotic appears slowly. There is a complete cross-susceptibility as well as cross resistance between colistin and polymyxin B.</p>
<p>Absorption, fate and excretion: Colistin is not significantly absorbed orally. It is given parenterally for systemic infections. It is largely excreted unchanged by the kidneys.</p>
<p>Adverse reactions: These occur in a large proportion of patients and include local pain, circumoral and lingual paraesthesiae, nausea, skin rash, pruritus, vertigo, ataxia, nystagmus (neurotoxicity) and renal damage. Other serious toxic effects include partial deafness, neutropenia, hepatotoxicity and transient disturbances of vision and speech. The drug has a curariform effect. Because of its toxicity, its use is restricted to topical purposes and sometimes for bowel sterilisation.</p>
<p>POLYMYXIN B: Polymyxin is the generic name for a group of closely related polypeptide antibiotics elaborated by various strains of Bacillus polymyxa. Polymyxin B, initially thought to be the least toxic of these antibiotics, is used as a sulfate. The antibacterial spectrum, absorption, metabolism and toxicity of polymyxin are similar to those of colistin. It is prescribed as spray, cream or powder for local application, for skin, ear and eye infections.</p>
<p>TYROTHRICIN: This antibiotic, obtained from Bacillus brevis, is in fact a 80:20 mixture of two antibiotics, Tyrocidine and Gramicidine, respectively. Tyrothricin is bacteriostatic. It is particularly effective against Pneumococci, Streptococci, Staphylococci and C. diptheriae. In addition, it exhibits a mild antibacterial action against certain Gram-negative organisms. Tyrothricin is ineffective orally and is too toxic parenterally. It is employed only topically.</p>
<p>CYCLOSERINE: This antibiotic, obtained from Streptomyces orchidaceus is mainly used as a second line drug in the treatment of tuberculosis (Chapter 54) and in UTI due to resistant E. coli (Chapter 52).</p>
<p>SPECTINOMYCIN: This antibiotic derived from Streptomyces spectabillis has moderate in vitro activity against many Gram-positive and Gram-negative bacteria. Although it is not an aminoglycoside, like streptomycin it contains a cyclic amino polyol (aminocyclitol) group. Resistance tends to develop rapidly by certain microorganisms, particularly the staphylococci. It is bactericidal for both penicillin sensitive and penicillin resistant strains of gonococci. Hence, it is mainly used to treat uncomplicated gonorrhoea, as an alternative to penicillin. It is usually administered in the dose of 2-4 g deep IM as a single dose. Adverse effects reported include nausea, insomnia and allergic reactions.</p>
<p>FOSFOMYCIN: This antibiotic has bactericidal action against many urinary pathogens: E. coli, E. fecalis, Klebsiella, P. aeruginosa, enterobacter, enterococci including VREF, and staphylococci. Its combination with beta lactam antibiotics, aminoglycosides or fluoroquinolones is synergistic against Gram positive and Gram negative organisms.</p>
<p>Mechanism of Action: As a phosphonic acid derivative, fosfomycin inhibits bacterial cell</p>
<p>wall synthesis (bactericidal) by inactivating the enzyme, pyruvyl transferase, which is critical in the synthesis of cell walls by bacteria.</p>
<p>Absorption, fate and excretion: It is well absorbed orally and high concentrations are achieved in the urine. Antacids or calcium salts may decrease its absorption. Protein binding is minimal. Half life is 4-8 hours. It is excreted unchanged in the urine; high urinary levels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mcg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) persist for more than 48 hours.</p>
<p>Adverse reactions: These are headache, rash, diarrhea, nausea, vomiting, abdominal discomfort, anorexia, dizziness, drowsiness, fatigue, pruritus. No dosage adjustment is required in hepatic impairment.</p>
<p>Therapeutic uses: It is administered as single dose of 3 g in 100 ml of water. It is currently used in the therapy of uncomplicated UTI in women. Multiple doses, 3 g every 3 days for 3-7 doses, are used in complicated UTI.</p>
<p>For extended spectrum penicillins effective against Gram negative organisms, see Chapter 46.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="monobactams">Monobactams<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monobactams" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>AZTREONAM: This synthetic antibiotic belongs to the class of beta lactam antibiotics, referred to as monobactams. The monobactams are naturally occurring and, unlike penicillins and cephalosporins, are not produced by moulds or fungi but by bacteria in the soil. The word monobactam is derived from mono (a single ring), bact (produced by bacteria) and am (a beta lactam). Aztreonam is produced in nature by Chromobacterium violaceum. Like other beta lactam antibiotics, it acts on the bacterial cell wall and is bactericidal. It has activity only against aerobic Gram negative species; E. coli, Klebsiella, H. influenzae and Proteus are highly sensitive. Higher concentrations are effective against Pseudomonas. It has negligible activity against anaerobes. Its advantage is lack of cross allergenicity with penicillins and cephalosporins, except for ceftazidime. It also lacks the ototoxicity and the nephrotoxicity of aminoglycosides.</p>
<p>Absorption, fate and excretion: It is not absorbed orally. It is resistant to hydrolysis by most beta-lactamases. It is largely excreted unchanged by glomerular filtration.</p>
<p>It is administered IM or by IV infusion in the dose of 1-2 g every 8-12 hours. Higher doses are used in systemic Ps.aeruginosa infection and in lung infection in patients with cystic fibrosis.</p>
<p>Adverse reactions: Toxicity reported so far is mild and includes skin rashes, GI upset, neutropenia and rarely hepatotoxicity.</p>
<p>Therapeutic uses:</p>
<ul>
<li>As an alternative to aminoglycosides in severe infections caused by susceptible Gram negative organisms e.g. complicated UTI (Chapter 52).</li>
<li>In neonatal Gram negative infections, in conjunction with ampicillin; and,</li>
<li>In patients who are allergic to penicillin and cephalosporins.</li>
</ul>
<p>48</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antibiotics-effective-against-both-gram-positive-and-gram-negative-organisms">Antibiotics Effective Against Both Gram Positive and Gram Negative Organisms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antibiotics-effective-against-both-gram-positive-and-gram-negative-organisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antibiotics which are effective in both Gram-positive and Gram-negative infections are: semisynthetic penicillins, e.g., ampicillin, and carbenicillin; rifamycins (see later); cephalosporins; carbapenam; tetracyclines and chloramphenicol. The last two are also effective against certain protozoa and rickettsiae and hence are called 'broad spectrum antibiotics'. They are discussed in Chapter 49.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cephalosporins">Cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The discovery of cephalosporins is as fascinating as that of penicillin. In 1945, Professor G. Brotzu of Sardinia made cultures from sea water at a sewage outfall on the assumption that this might contain organisms antagonistic to intestinal pathogens. He succeeded in isolating a fungus, identified as Cephalosporium acremonium. The crude extract prepared from its culture was demonstrated to be active in humans against certain pathogens. He published the original findings of this brilliant work in a local Sardinian journal. But for Dr. Blyth Brook, a public health officer in Sardinia who wrote to Florey about Dr. Brotzu's work, it might have remained unknown to the rest of the world. The culture was received by Florey in 1948, and in 1955 he described the amazing initial findings that the fungus produced not one but seven antibiotics.</p>
<p>Cephalosporins have 7-amino cephalosporanic acid nucleus (Fig. 48.1), which bears close resemblance to the 6-APA nucleus of penicillins. Structurally, they contain beta lactam and dihydrothiazine rings. They are water soluble and stable to changes in pH and temperature. The various cephalosporins, however, differ in their antibacterial spectrum and their resistance to betalactamases.
<img src="assets/images/image-20251214-27fefc65.jpeg" alt="img-1.jpeg"></p>
<p>Cephamycins are similar to cephalosporins but they are derived from an actinomycete. Examples are cefoxitin and cefotetan.</p>
<p>Antibacterial activity: Cephalosporins possess a wide range of activity against Grampositive and Gram-negative bacteria. They are effective against pneumococci, C. diphtheriae and Group <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> and beta hemolytic streptococci. The older cephalosporins (cephaloridine and cephalothin) are active against staphylococci. Although cefotaxime is active against Bacteroides fragilis, its activity against this species is not superior to metronidazole.</p>
<p>The Gram negative organisms susceptible to these antibiotics include E.coli, Proteus mirabilis, K. pneumoniae, N. gonorrhoea and Paracolobacterium species. Cephaloridine shows good activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. typhi and paratyphi, and is also effective against some strains of Shigella. The newer derivatives are effective against Pseudomonas aeruginosa, Enterobacter, indole positive Proteus and Bacteroides, and against many strains of E. coli and Klebsiellae resistant to the older cephalosporins. They have activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae.</p>
<p>Mechanism of action: Cephalosporins act by inhibiting bacterial cell wall synthesis in a manner similar to penicillins, and are bactericidal. Resistance to cephalosporins develops slowly and is mediated either by bacterial beta-lactamases or by lack of bacterial permeability to the drug. Cross resistance for other betalactam agents also occurs. Therefore, their use should be restricted to selective indications.</p>
<p>Some of the newer cephalosporins are much more resistant than the older ones to the</p>
<p>action of betalactamases, and consequently have a broader anti-bacterial spectrum.
Absorption, fate and excretion: As with penicillins, cephalosporins are administered either orally or IV; IM administration is painful. Their body distribution is similar to that of penicillin. There are significant differences among the various cephalosporins regarding their pharmacokinetics.</p>
<p>Cephalosporins are eliminated mainly by renal tubular secretion and high concentrations are achieved in the urinary tract. Renal tubular blocking with probenecid increases the plasma levels significantly. The renal excretion is markedly reduced in renal insufficiency. Therefore their dose should be appropriately reduced in case of renal impairment. Concentration in the bile is similar to that in the plasma. Unlike other cephalosporins, cefotaxime is partly metabolised by the liver before excretion by the kidneys.</p>
<p>Adverse reactions: In general, cephalosporins are well tolerated.</p>
<ul>
<li>Local reactions: IM injections are painful and IV injections can cause thrombophlebitis.</li>
<li>Allergy: Skin rash, fever, serum sickness, anaphylactoid reaction (rare), eosinophilia, neutropenia, transient splenomegaly and increased SGOT levels.</li>
<li>Drug fever: Cephalosporins are among the common causes of drug fever.</li>
<li>Superinfection: Superinfection with resistant organisms can occur during therapy, generally with broad spectrum third generation agents.</li>
<li>Diarrhoea: is more common with cefoperazone, which undergoes biliary excretion.</li>
<li>Nephrotoxicity: Large doses can cause nephrotoxicity. It is probably dose related and is potentially reversible on drug withdrawal; it is enhanced by loop diuretics such as furosemide.</li>
<li>CNS toxicity: Signs of cerebral irritation, nystagmus and hallucinations may occur following intrathecal administration.</li>
<li>Hematological toxicity: Impairment of normal hemostasis may result from hypo-prothrombinaemia and abnormalities in platelet aggregation. Parenteral vitamin K therapy will correct the abnormality and is recommended prophylactically when moxalactam, cefaperazone, cefotetan and cefamandole (with methyltetrazole moiety) are used for prolonged periods. A false positive Coomb's test may occur in as many as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of patients on cephalothin therapy. Thrombocytopenia, neutropenia and hemolytic anemia may rarely occur.</li>
<li>Disulfuram like reaction: Cefoperazone, cefamandole and cefotetan cause disulfiramlike effect when ingested with alcohol.
In patients with skin-test reactivity to antigen of penicillin metabolite, cephalosporins should be avoided. In patients with a history of severe allergy to penicillin, cross-reaction to cephalosporin is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>. In those with less than severe reactions, the risk of crossreaction is reported to be very low.</li>
</ul>
<p>Preparations and dosage: Table 48.1 shows various available cephalosporins.</p>
<p>Table 48.1
Cephalosporins - bacterial sensitivity, pharmacokinetics and doses</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Staph. &lt;br&gt; aureus</th><th style="text-align: center;">H.influenzae Enterobacter</th><th style="text-align: center;">Psaeruginosa B.fragilis</th><th style="text-align: center;"></th><th style="text-align: center;">Protein &lt;br&gt; binding %</th><th style="text-align: center;">Plasma half &lt;br&gt; life (hr)</th><th style="text-align: center;">Disposal</th><th style="text-align: center;">Urinary &lt;br&gt; excretion &lt;br&gt; %</th><th style="text-align: center;"></th><th style="text-align: center;">Dose</th></tr></thead><tbody><tr><td style="text-align: center;">I Generation</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefalexin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0</mn><mi mathvariant="normal">/</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">0 /+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0/</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">18-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span></td><td style="text-align: center;">0.9</td><td style="text-align: center;">R</td><td style="text-align: center;">88</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>6</mn><mo>−</mo><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-1.0 \mathrm{~g} \mathrm{q} 6-8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cefadroxil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0</mn><mi mathvariant="normal">/</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">0 /+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0/</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">18-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span></td><td style="text-align: center;">1.6</td><td style="text-align: center;">R</td><td style="text-align: center;">88</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{~g} \mathrm{q} 12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Parenteral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefazolin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">80</td><td style="text-align: center;">1.8</td><td style="text-align: center;">R</td><td style="text-align: center;">90</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>6</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 6-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">6</span><span class="mord">−</span></span></span></span></span> &lt;br&gt; 8 h</td></tr><tr><td style="text-align: center;">II Generation</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefaclor</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td><td style="text-align: center;">40</td><td style="text-align: center;">0.6</td><td style="text-align: center;">R</td><td style="text-align: center;">60</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.5 \mathrm{~g} \mathrm{q} 8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cefuroxime asetil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">40</td><td style="text-align: center;">1.3</td><td style="text-align: center;">R</td><td style="text-align: center;">50</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.5 \mathrm{~g} \mathrm{q} 12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Parenteral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefamandole</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">70</td><td style="text-align: center;">0.8</td><td style="text-align: center;">R</td><td style="text-align: center;">75</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>4</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">0.5-2.0 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 4-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">4</span><span class="mord">−</span></span></span></span></span> &lt;br&gt; 8 h</td></tr><tr><td style="text-align: center;">Cefoxitin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">75</td><td style="text-align: center;">0.7</td><td style="text-align: center;">R</td><td style="text-align: center;">90</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>6</mn><mo>−</mo><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 6-8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cefuroxime</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">35</td><td style="text-align: center;">1.4</td><td style="text-align: center;">R</td><td style="text-align: center;">80</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.75</mn><mo>−</mo><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">0.75-1.5 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">III Generation</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefixime</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">67</td><td style="text-align: center;">3.5</td><td style="text-align: center;">H/R</td><td style="text-align: center;">18</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in 1- &lt;br&gt; 2 div. doses</td></tr><tr><td style="text-align: center;">Cefpodoxime Proxetil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">25</td><td style="text-align: center;">2.2</td><td style="text-align: center;">H/R</td><td style="text-align: center;">30</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg} \mathrm{q} 12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Parenteral</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefotaxime*</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">40</td><td style="text-align: center;">0.9</td><td style="text-align: center;">H/R</td><td style="text-align: center;">90</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ceftriaxone*</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">95</td><td style="text-align: center;">8.5</td><td style="text-align: center;">H/R</td><td style="text-align: center;">60</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mo>−</mo><mn>24</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 12-24 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">24</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Cefaperazone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">90</td><td style="text-align: center;">1.7</td><td style="text-align: center;">H/R</td><td style="text-align: center;">25</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mo>−</mo><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 8-12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ceftazidime*</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">17</td><td style="text-align: center;">1.8</td><td style="text-align: center;">R</td><td style="text-align: center;">85</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mo>−</mo><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 8-12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ceftizoxime*</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">30</td><td style="text-align: center;">1.6</td><td style="text-align: center;">R</td><td style="text-align: center;">80</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">q</mi><mn>8</mn><mo>−</mo><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g} \mathrm{IM} / \mathrm{IV} \mathrm{q} 8-12 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ceftibuten</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td><td style="text-align: center;">0</td><td style="text-align: center;">65</td><td style="text-align: center;">2.4</td><td style="text-align: center;">H/R</td><td style="text-align: center;">56</td><td style="text-align: center;">400 mg OD</td></tr><tr><td style="text-align: center;">Ceftolozane (with &lt;br&gt; tazobactam)</td><td style="text-align: center;">0</td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">20</td><td style="text-align: center;">3</td><td style="text-align: center;">R</td><td style="text-align: center;">95</td><td style="text-align: center;">1.5 g IV infusion 8 h</td></tr><tr><td style="text-align: center;">IV Generation</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cefepime*</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">17</td><td style="text-align: center;">2.0</td><td style="text-align: center;">R</td><td style="text-align: center;">80</td><td style="text-align: center;">2 g IV q 8-12 h</td></tr></tbody></table>
<p>q 6-8 h = every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hours. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">R</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{R}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Renal. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Hepatic.
*Good CNS penetration. Penetration of others is not enough to treat meningitis.
Therapeutic uses: The cephalosporins have added substantially to the therapeutic armamentarium of the physicians, but the physicians find their multiplicity confusing. For the generalist, it is enough to remember a few guiding principles about using cephalosporins, and to learn in detail how to use a few selected ones. The guiding principles are shown in Table 48.2.</p>
<p>Table 48.2
Guiding principles for the use of cephalosporins</p>
<ul>
<li>Cephalosporins are expensive and should not be used where an equally effective, alternative antibiotic is available.</li>
<li>None of them is effective against infection by enterococci (Strep. fecalis).</li>
<li>None of them is the agent of choice against anaerobic infections.</li>
<li>Except for cefotaxime, ceftriaxone, ceftazidime, ceftizoxime and cefepime, the CNS penetration of cephalosporins is poor. However, these five are the drugs of choice in Gram negative bacillary meningitis (see Tables 48.1 and 48.3).</li>
<li>First generation cephalosporins predominantly act against Gram positive organisms such as staphylococci, pneumococci, streptococci, but also against (though less effectively) the common Gram negative pathogens such as E. coli, Klebsiella and Proteus. However, they are not effective against salmonella, shigella, B. fragilis and pseudomonas. Further their efficacy against beta lactamase producing organisms is poor. Cefalexin and cefadroxil have been useful in treating community acquired, respiratory and urinary tract infections, and in surgical prophylaxis. However, they are not considered the agents of choice for any serious systemic infections.
Cefazolin is considered the agent of choice for antimicrobial prophylaxis in most surgical procedures because of its activity against most pathogens that cause infection of wounds. It is given IM/IV.</li>
<li>Second generation cephalosporins offer a wider coverage against Gram negative bacilli than the first generation cephalosporin. They are also more resistant than the first generation drugs to beta lactamases. Their main use would appear to be in the Gram negative infections, especially those caused by beta lactamase producing organisms, including <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae. They have less activity than the first generation drugs against the Gram positive cocci and are inactive against anaerobes and P. aeruginosa. Only cefoxitin, cefotetan and loracarbef are active against B. fragilis.</li>
<li>Third generation cephalosporins are more active against the Gram negative bacilli than the first and second generation cephalosporins. In addition, they possess anti-pseudomonal activity. They have poor activity against the Gram positive cocci. The CNS penetration of these drugs is better than that of the first two generation drugs. Ceftriaxone has sufficiently long half life to permit once a day administration in some infections. These agents are not indicated for routine surgical prophylaxis.
The indications for these drugs include aminoglycoside resistant or multi-resistant Gram negative bacillary systemic infections. They have almost replaced the second generation cephalosporins for this purpose.
In serious Gram negative infections, a third generation cephalosporin is combined with gentamicin or amikacin.</li>
<li>Fourth generation cephalosporins: Cefepime has properties like those of the third generation cephalosporins, but it is more resistant to some beta-lactamases. It is active against streptococci and methicillin-sensitive staphylococci, but not against MRSA. Its main use is in serious Gram negative infections (especially enterobacter, citrobacter and serratia groups of organisms), including infections of the CNS into which it has excellent penetration. It has a half life of about 2 hours. It is administered in the dose of 2 gm IV every 12 hours.
Cefpirome also has similar properties and uses. It gives higher CSF concentration. Ceftaroline is a new addition to this group, which is effective against MRSA.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="carbapenems">Carbapenems<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbapenems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This group of betalactam antibiotics are obtained by modification of a parent antibiotic thienamycin, derived from Streptomyces cattleya. Thienamycin itself is chemically unstable. Like penicillin, carbapenems act by inhibiting cell wall synthesis. They are bactericidal and have a wider antibacterial spectrum than cephalosporins. They are active against enterococci except Enterococcus fecium. They are active against MRSA and non-beta lactamase producing penicillin resistant strains.</p>
<p>IMIPENEM: This carbapenem is highly active against Gram negative aerobes including Ps. aeruginosa, Gram positive aerobes and many anaerobes. It is not easily hydrolysed by bacterial beta lactamase. It is not active against chlamydia and mycoplasma species.</p>
<p>Absorption, fate and excretion: It is not absorbed orally and must be administered parenterally. It does not penetrate intracellularly and therefore is inactive against intracellular organisms. It is hydrolysed by a dehydropeptidase in the kidney and therefore the concentration of the active drug in the kidney is less than that in the plasma. It is commonly combined with cilastatin, an inhibitor of the renal dehydropeptidase. Cilastatin has no antimicrobial activity but prevents inactivation and toxicity of imipenem.</p>
<p>Adverse reactions: Imipenem has most of the adverse effects of other beta lactam antibiotics. They include nausea, vomiting, allergic reactions and transient elevation of liver enzymes in the blood. It can cause pseudomembranous colitis. In high doses, it can cause convulsions. Leucopenia and granulocytopenia have been reported. Cross allergy with penicillin can occur.</p>
<p>Therapeutic uses: Its use should be restricted to the treatment of:
(a) Seriously ill and/or hospitalised patients with mixed bacterial infections, and
(b) Multi-drug resistant Gram negative infections including those due to pseudomonas.</p>
<p>Imipenem + cilastatin combination is highly effective in infections such as UTI, lower respiratory tract infection, abdominal and pelvic infections, musculoskeletal and joint infections due to Gram positive and Gram negative aerobes and anaerobes (including all subspecies of B. fragilis). It should be avoided in meningitis because of its epileptogenic properties.</p>
<p>It is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>750</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">500-750 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> (in terms of imipenem) by deep IM injection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hourly; it can also be administered by IV infusion in the dose of 1-2 g daily, in 3-4 divided doses. Bacteria can develop resistance to this drug.</p>
<p>Meropenem is a dimethyl-carbamoyl derivative of thienamycin. It is not susceptible to renal dipeptidase and does not require co-administration with cilastatin. Its antibacterial spectrum is similar to that of imipenam, but it is effective against imipenam-resistant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa.</p>
<p>Ertapenem is once daily IV carbapenem, not active against pseudomonas and acinobacter species. It has longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>. Its spectrum includes Gram've organisms, enterobacter and anaerobes, which allows its use in intraabdominal and pelvic infections.</p>
<p>Doripenem is a parenteral carbopenem with properties and uses similar to those of meropenem.</p>
<p>Feropenem: This carbapenem unlike earlier ones is effective orally in a dose of 150 mg tid.</p>
<p>A carbapenem is the reasonable first choice for empiric monotherapy of serious,</p>
<p>complicated, intra-abdominal infections. Other alternatives are: piperacillin + tazobactam; a fluoroquinolone + metronidozole; or tigecycline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rifamycins">Rifamycins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rifamycins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are a group of antibiotics derived from a strain of Streptomyces mediterranei. Rifampicin (Rifampin) is a semisynthetic derivative of rifamycin B while rifabutin is a derivative of rifamycin S. Both these drugs act by inhibiting RNA polymerase and have action against certain Gram positive and Gram negative bacteria and mycobacteria. They are mainly used in the treatment of tuberculosis, leprosy and infections with Staph. aureus (Chapters 54 and 55).</p>
<p>Rifaximin is an oral, non-absorbable rifampin derivative, used to treat infective diarrhoeas (Chapter 41).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-bacterial-meningitis">Drug Therapy of Bacterial Meningitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-bacterial-meningitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute bacterial meningitis is a medical emergency. In adults the commonest organisms are Strep. pneumoniae and N.meningitidis, with Gram negative bacilli, staphylococci and streptococci following suit. In the neonates, the vast majority of infections are due to Gram negative bacilli like E.coli and streptococci, commonly non-haemolytic. Listeria infections are also common. In children under the age of 15 , the majority of cases are due to Strep. pneumoniae, N. meningitidis, and H. influenzae. Staphylococci and Gram negative meningitis (especially due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa) should be thought of in the setting of head injury, neurosurgical procedures, diabetes mellitus, cirrhosis of the liver and renal failure. To be effective, the appropriate antibiotic treatment (Table 48.3) must be started immediately, before the full identification of the causative pathogen is available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-48-3">Table 48.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-48-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drug therapy of specific forms of bacterial meningitis (adult doses)
IV, q 4 h for 7 days."
After the patient becomes afebrile, Ampicillin (2g q 4h).
b) Amoxicillin/Ampicillin 2 g q 4 h .</p>
<p>Cefotaxime 2 g IV q 6h/Ceftriaxone 2 g IV q 12 h with or without
Ampicillin. In patients allergic to penicillin,
Chloramphenicol 4-6 g IV q 6 h for 7 days.
Penicillin resistant Cefotaxime/Ceftriaxone. Cefepime 2g q 8h/Meropenem1g IV q 8 h/Chloramphenicol. Cephalosporin resistant Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 \mathrm{~g} \mathrm{q} 12 \mathrm{~h}+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Pneumococci Penicillin sensitive and resistant Same as Meningococcal meningitis Cephalosporin resistant Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9324em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins for 10-14 days. If highly resistant, Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9324em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins + Rifampicin 600 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Moxifloxacin in non-responders. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> H. influenzae Beta-lactamase negative Ampicillin + Sulbactam 4 g q 8 h for 7 days. Cefotaxime/Ceftriaxone/Cefepime/Chloramphenicol/Aztreonam 50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>
IM q 8 h for 10-14 days.
Beta-lactamase positive Cefotaxime/Ceftriaxone.
Cefepime/Chloramphenicol/Aztreonam. Beta-lactamase negative and ampicillin resistant Meropenem 1g IV q 8 h. Fluoroquinolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span></p>
<p>Enterococci Penicillin G as above + Gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV q 8 h for 14-21 days. Vancomycin + Gentamicin. If resistant, Quinpristin/Dalfopristin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV over 1 hr , q 8 h or Tigecycline 100 mg IV infusion followed by 50 mg IV infusion q 12 h. - Staphylococcus aureus Methicillin sensitive Nafcillin or Oxacillin 2g IV q 4 h for 14 days. Vancomycin/Linezolid 600mg IV q <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{~h} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span><span class="mord">/</span></span></span></span></span> Daptomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV infusion q 24 h . Methicillin resistant Vancomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> Rifampicin.
Cotrimoxazole/Linezolid/Daptomycin. - Gram negative bacilli other than P. aeruginosa Cefotaxime/Ceftriaxone for 21 days. Cotrimoxazole <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV q <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{~h} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span><span class="mord">/</span></span></span></span></span> (Ampicillin + Sulbactam)/Meropenem/Aztreonam. - P. aeruginosa Ceftazidime 2g IV q 8h/Cefepime for 21 days. Aztreonam/Meropenem <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Bacterioides fragilis and Fusobacterium spp Metronidazole 0.5 g q 6 h for 7 days. - Listeria monocytogenes Amoxicillin/Ampicillin for 3 weeks In critically ill, add Gentamicin. In patients allergic to penicillin, Cotrimoxazole 6 hrly. --&gt;</p>
<table><thead><tr><th style="text-align: center;">Organism</th><th style="text-align: center;">Preferred regimen</th><th style="text-align: center;">Other regimens</th></tr></thead><tbody><tr><td style="text-align: center;">- Meningococci</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Penicillin sensitive</td><td style="text-align: center;">a) Penicillin G 4 million units &lt;br&gt; IV, q 4 h for 7 days. &lt;br&gt; After the patient becomes afebrile, Ampicillin (2g q 4h). &lt;br&gt; b) Amoxicillin/Ampicillin 2g q 4h.</td><td style="text-align: center;">Cefotaxime <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi><mi mathvariant="normal">q</mi><mn>6</mn><mi mathvariant="normal">h</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2 \mathrm{~g} \mathrm{IVq6h} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord"><span class="mord mathrm">IVq6h</span></span><span class="mord">/</span></span></span></span></span> Ceftriaxone 2 g IV q 12 h with or without Ampicillin. In patients allergic to penicillin, &lt;br&gt; Chloramphenicol 4-6 g IV q 6 h for 7 days.</td></tr><tr><td style="text-align: center;">Penicillin resistant</td><td style="text-align: center;">Cefotaxime/Ceftriaxone.</td><td style="text-align: center;">Cefepime 2g q 8h/Meropenemlg IV q 8 h/Chloramphenicol.</td></tr><tr><td style="text-align: center;">Cephalosporin resistant</td><td style="text-align: center;">Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">q</mi><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 \mathrm{~g} \mathrm{q} 12 \mathrm{~h}+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord mathrm">q</span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation</td><td style="text-align: center;">Cephalosporins.</td></tr><tr><td style="text-align: center;">- Pneumococci</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Penicillin sensitive and resistant</td><td style="text-align: center;">Same as Meningococcal meningitis</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cephalosporin resistant</td><td style="text-align: center;">Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9324em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins for 10-14 days.</td><td style="text-align: center;">If highly resistant, Vanomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">+3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9324em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins + Rifampicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">600 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Moxifloxacin in non-responders.</td></tr><tr><td style="text-align: center;">- H. influenzae</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Beta-lactamase negative</td><td style="text-align: center;">Ampicillin + Sulbactam 4 g q 8 h for 7 days.</td><td style="text-align: center;">Cefotaxime/Ceftriaxone/Cefepime/Chloramphenicol/Aztreonam <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IM q 8 h for 10-14 days.</td></tr><tr><td style="text-align: center;">Beta-lactamase positive</td><td style="text-align: center;">Cefotaxime/Ceftriaxone.</td><td style="text-align: center;">Cefepime/Chloramphenicol/Aztreonam.</td></tr><tr><td style="text-align: center;">Beta-lactamase negative and ampicillin resistant</td><td style="text-align: center;">Meropenem 1 g IV q 8 h .</td><td style="text-align: center;">Fluoroquinolone</td></tr><tr><td style="text-align: center;">- Enterococci</td><td style="text-align: center;">Penicillin G as above + Gentamicin 1 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV q 8 h for 14-21 days.</td><td style="text-align: center;">Vancomycin + Gentamicin. If resistant, Quinpristin/Dalfopristin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">q</mi><mn>8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{hr}, \mathrm{q} 8 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">hr</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">q</span><span class="mord">8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span> or Tigecycline 100 mg IV infusion followed by 50 mg IV infusion q 12 h .</td></tr><tr><td style="text-align: center;">- Staphylococcus aureus</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Methicillin sensistive</td><td style="text-align: center;">Nalciilin or Oxacillin 2 g IV q 4 h for 14 days.</td><td style="text-align: center;">Vancomycin/Linezolid 600mg IV q 12 h/Daptomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV infusion q 24 h .</td></tr><tr><td style="text-align: center;">Methicillin resistant</td><td style="text-align: center;">Vancomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> Rifampicin.</td><td style="text-align: center;">Cotrimoxazole/Linezolid/Daptomycin.</td></tr><tr><td style="text-align: center;">- Gram negative bacilli other than P. aeruginosa</td><td style="text-align: center;">Cefotaxime/Ceftriaxone for 21 days.</td><td style="text-align: center;">Cotrimoxazole <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV q <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow><mi mathvariant="normal">/</mi><mo stretchy="false">(</mo></mrow><annotation encoding="application/x-tex">12 \mathrm{~h} /(</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span><span class="mord">/</span><span class="mopen">(</span></span></span></span></span> Ampicillin + Sulbactam)/Meropenem/Aztreonam.</td></tr><tr><td style="text-align: center;">- P. aeruginosa</td><td style="text-align: center;">Ceftazidime 2 g IV q 8h/Cefepime for 21 days.</td><td style="text-align: center;">Aztreonam/Meropenem</td></tr><tr><td style="text-align: center;">- Bacterioides fragilis and Fusobacterium spp</td><td style="text-align: center;">Metronidazole 0.5 g q 6 h for 7 days.</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Listeria monocytogenes</td><td style="text-align: center;">Amoxicillin/Ampicillin for 3 weeks In critically ill, add Gentamicin.</td><td style="text-align: center;">In patients allergic to penicillin, Cotrimoxazole 6 hry.</td></tr></tbody></table>
<p>'Close contacts and family members should receive prophylaxis with rifampicin 600 mg orally bid for 2 days; alternatively, ceftriaxone 250 mg single IM dose or ofloxacin 400 mg single oral dose may be used. These drugs, in short courses, achieve long term (3-4 weeks) eradication of meningococci from the pharynx. The index case should also be treated with rifampicin before discharge.
"2 g IV q 4 h = 2 g intravenously every 4 hours. Penicillin should not be injected intrathecally.
The initial treatment before identification of the pathogen or when the CSF culture is negative (although the diagnosis of bacterial meningitis appears to be reasonably certain) is based on the probability of the offending pathogen. The antibiotics which penetrate the CSF adequately are penicillin G, ampicillin, chloramphenicol, vancomycin and the third generation cephalosporins. These drugs should be administered parenterally in high doses. The recommended empirical therapy of severe meningitis is a combination of third or fourth generation cephalosporin (ceftriaxone/cefotaxime/cefepime) + vancomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> ampicillin (all given IV). These cephalosporins are effective against resistant S. pneumoniae and other organisms like meningococci, group B streptococci and H. influenzae. Cefepime is useful if enterobacter or P. aeruginosa is suspected. Vancomycin is effective against staphylococci. Amoxicillin or ampicillin may be added to provide coverage against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>L</mi></mrow><annotation encoding="application/x-tex">L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">L</span></span></span></span></span>. monocytogenes especially in neonates, elderly, pregnant and immunosuppressed individuals. In patients with otitis, sinusitis and mastoditis, Gram negative anaerobes should be suspected and metronidazole is added to the above-mentioned empirical</p>
<p>regimen.
In the neonate, the preferred initial regimen is cefotaxime + ampicillin with or without gentamicin. In children the initial treatment should be with a third generation cephalosporin with vancomycin or with ampicillin + chloramphenicol.</p>
<p>If nosocomial infection is suspected or neutropenia is present, ceftriaxone or cefotaxime in the empirical therapy should be replaced by ceftazidime/cefepime/meropenem. The latter three have good activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. aeruginosa. Thus, a triple regime consisting of ceftazidime/cefepime/meropenem + vancomycin + ampicillin is preferred.</p>
<p>Dexamethasone, 10 mg IV is used as adjunctive therapy 20 min before, or at least concurrently with the first dose of antibiotics and then repeated every 6 h for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">4-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> days. It inhibits the production of TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and IL-1 by macrophages and microglia, and thereby decreases inflammation and neurological morbidity. However, dexamethasone is of no use once these cells are induced by endotoxins released from ruptured cell walls of bacteria. Dexamethasone may not be helpful for patients presenting late with advanced disease, malnourishment, HIV co-infection and those pretreated with antibiotic.</p>
<p>49</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tetracyclines-and-chloramphenicol">Tetracyclines and Chloramphenicol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tetracyclines-and-chloramphenicol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Systematic screening of a multitude of soil microorganisms for potential antibiotic activity by the American Pharmaceutical Industry resulted in the discovery of tetracyclines. The first member chlortetracycline, isolated from Streptomyces aureofaciens, was introduced in 1948, followed by oxytetracycline derived from Streptomyces rimosus in 1950 and tetracycline prepared by catalytic hydrogenation of chlortetracycline in 1953. Since then other semi-synthetic tetracyclines have been introduced.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tetracyclines">Tetracyclines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tetracyclines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The tetracyclines are naphthacene derivatives, made up by fusion of four partially unsaturated cyclohexane radicals and hence the name tetracyclines (Fig. 49.1). The crystalline bases of these compounds are pale yellow, slightly bitter and sparingly soluble in water. However, they form water soluble sodium salts. Tetracyclines are more stable at acid pH .
<img src="assets/images/image-20251214-4c8411ac.jpeg" alt="img-2.jpeg"></p>
<p>FIG. 49.1 Basic structure of tetracyclines</p>
<p>Antibacterial activity: Various tetracyclines have similar antibacterial spectrum. They are bacteriostatic and along with chloramphenicol are termed broad spectrum antibiotics, as in addition to their antibacterial activity against a number of Gram-positive and Gramnegative organisms, they also inhibit the growth of certain actinomyces, rickettsiae and chlamydia organisms. Gram-positive organisms in general respond better than Gramnegative organisms.</p>
<p>The Gram-positive and Gram-negative organisms inhibited by tetracyclines include Pneumococci, Gonococci, some strains of alpha and beta hemolytic Streptococci, Clostridia, H. influenzae, B. pertussis, H. ducreyi, Brucella, K. pneumoniae, Vibrio cholerae and Donovania granulomatis. The moderately sensitive organisms include E. coli, Aerobacter, Salmonella, Shigella, B. anthracis, F. tularensis, Y. pestis, Fusobacterium, Listeria monocytogenes and M. tuberculosis. Pseudomonas is relatively resistant. Other organisms which respond satisfactorily are Borrelia recurrentis, Mycoplasma pneumoniae, Leptospira icterohaemorrhagiae and T. pallidum. Actinomyces and Nocardia also respond but less than to penicillin. Amongst the protozoa, it has action against E. histolytica and plasmodia. Tetracyclines are highly effective against rickettsial organisms and chlamydia.</p>
<p>Mechanism of action: The susceptible bacteria accumulate the antibiotic by an active transport system which is absent in the mammalian cells. Tetracyclines bind to 30S ribosomes. They block the attachment of aminoacyl transfer RNA to the acceptor site on the mRNA-ribosome complex and interfere with protein synthesis by preventing addition of amino acids to the growing peptide chain. Tetracyclines also chelate calcium and magnesium ions, which may contribute to its action.</p>
<p>Tetracycline resistance: This has been demonstrated by many organisms including Staphylococci, Group A Steptococci, H. influenzae, Pneumococci, and E. coli. Resistance may</p>
<p>occur through several mechanisms and can be passed from one organism to another by transfer of plasmids called R-factors that contain genetic information for the development of resistance. In resistant organisms, accumulation of the drug is absent. Gram-negative organisms resistant to tetracyclines are usually resistant to chloramphenicol as well, but the tetracycline resistant Gram-positive organisms are usually susceptible to chloramphenicol.</p>
<p>Absorption, fate and excretion: The absorption of oral tetracyclines is variable but adequate (Table 49.1). The tetracyclines form insoluble complexes by chelation with calcium, magnesium and aluminium and hence, substances like milk that contain calcium, and antacids reduce their absorption. Ingestion of food and iron interferes with their absorption.</p>
<p>Table 49.1
Properties of commonly used tetracyclines</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">Tetracycline</th><th style="text-align: center;">Oxytetracycline</th><th style="text-align: center;">Doxycycline</th><th style="text-align: center;">Minocycline</th></tr></thead><tbody><tr><td style="text-align: left;">Stability</td><td style="text-align: center;">Less</td><td style="text-align: center;">Less</td><td style="text-align: center;">More</td><td style="text-align: center;">More</td></tr><tr><td style="text-align: left;">Absorption</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>77</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">77 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">77%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>58</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">58 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">58%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Plasma protein binding</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>76</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">76 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">76%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Urinary recovery</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">CSF level</td><td style="text-align: center;">+</td><td style="text-align: center;">+</td><td style="text-align: center;">++</td><td style="text-align: center;">+++</td></tr><tr><td style="text-align: left;">Half-life (hours)</td><td style="text-align: center;">8</td><td style="text-align: center;">9</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>18</mn></mrow><annotation encoding="application/x-tex">16-18</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span></span></span></span></span></td><td style="text-align: center;">16</td></tr><tr><td style="text-align: left;">Effect on bone</td><td style="text-align: center;">+++</td><td style="text-align: center;">+++</td><td style="text-align: center;">++</td><td style="text-align: center;">+</td></tr><tr><td style="text-align: left;">Relative in vitro activity</td><td style="text-align: center;">100</td><td style="text-align: center;">80</td><td style="text-align: center;">110</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>200</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">200^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">20</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Usual oral dose</td><td style="text-align: center;">250 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">500 \mathrm{mg} 6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hourly</td><td style="text-align: center;">200 mg loading 100 mg daily</td><td style="text-align: center;">100 mg b.i.d.</td><td style="text-align: center;"></td></tr></tbody></table>
<p>'Against S. aureus.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> Active against organisms resistant to other tetracyclines.
The tetracyclines are mainly absorbed from the duodenum and the upper small intestine. With larger doses, proportionately more of the drug escapes absorption and may cause gastrointestinal disturbances.</p>
<p>After oral administration of a single therapeutic dose of tetracycline and oxytetracycline, peak plasma level is reached within 3 to 4 hours. They are usually administered at 6 hourly intervals in order to maintain their therapeutic plasma concentration. Oxytetracycline and tetracycline, given IM produce peak plasma levels within 1 hour and adequate levels are maintained for 12 hours.</p>
<p>The tetracyclines are widely distributed in the body and their diffusion into various body fluids and glandular secretions is very much like that of penicillin. Concentrations in the bile are 5-20 times those in the plasma as they undergo enterohepatic circulation. The compounds are concentrated in liver, bone marrow, enamel of unerupted teeth and lungs. They cross the placental barrier and are also secreted in milk. Their concentration in the ocular fluids, however, is poor.</p>
<p>The tetracyclines are metabolised in the liver and metabolites excreted mainly in the urine by glomerular filtration. In anuria, the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mn>1</mn></msup><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1} 1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span></span></span></span></span><span class="mord">1/2</span></span></span></span></span> of tetracycline is 4 to 5 days and that of oxytetracycline 2 to 3 days. Doxycycline and minocycline are eliminated by non-renal</p>
<p>route.
Adverse reactions: Tetracyclines, in general, have an acceptable toxicity. The adverse effects are:</p>
<ul>
<li>Allergy: Skin rashes may develop mainly on topical application of these agents. Severe allergic reactions, however, are rare.
Photosensitivity is manifested by marked erythema and even vesicular exanthema. A brown-black discolouration of nails accompanied by marked loosening may also occur.</li>
<li>GI tract: Nausea, vomiting, epigastric distress and loose stools are relatively common. Nausea and vomiting may be prevented by taking these drugs after meals. Mild diarrhoea appears to be dose-dependent and is more common following daily doses over 2 g .
Diarrhoea secondary to irritation is not accompanied by RBCs or pus cells in feces, and can thus be differentiated from serious diarrhoea secondary to GI superinfection.</li>
<li>Superinfection: Suppression of the normal intestinal flora with resultant superinfection is liable to occur after prolonged tetracycline therapy, particularly in patients with diabetes mellitus, leukemia or leucopenia and in those on steroid therapy.
Infection with Candida albicans is especially common and may cause diarrhoea or soft, bulky, odourless stools, soreness and redness of the mouth (thrush), glossitis, black hairy tongue and inflammatory lesions of the vulva, vagina and perianal region causing pruritus. Nystatin is effective locally in oropharyngeal, vaginal and perineal lesions. Most of the yeast infections are generally limited to the duration of therapy and routine prophylaxis with antifungal agents is unnecessary.
Superinfection with resistant S. aureus occurs more frequently in hospitalised patients. Serious staphylococcal enteritis is heralded by sudden loss of appetite, abdominal discomfort, distension and a profuse watery diarrhoea; the stools show the presence of blood. It carries a mortality rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>. Immediate stoppage of tetracyclines, institution of appropriate antibiotic therapy and correction of dehydration and electrolyte imbalance are recommended.
Pseudomembranous colitis characterised by profuse diarrhoea and fever may occur due to superinfection with Clostridium difficile. The stools contain shreds of mucous membrane and blood (also see Chapter 46).</li>
<li>Teeth and bones: Tetracyclines chelate calcium, forming a tetracycline-orthophosphate complex and are deposited in areas of calcification in bones and teeth. Administration of these antibiotics to pregnant women may lead to yellow staining of the teeth of the infant; defective formation of enamel and hypoplasia of the teeth may also occur. Pigmentation of permanent teeth and increased risk of caries may occur in children. Even a short course given after the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>14</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">14^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> week of pregnancy can be damaging. Tetracyclines administered during pregnancy are deposited in foetal bones and may reduce their linear growth. They should also be avoided in infants and in children upto the age of 12 years. They are also deposited in nails, which may cause nails to fluoresce.</li>
<li>Antianabolic effect: Since tetracyclines inhibit protein synthesis, their prolonged use produces an antianabolic effect and weight loss.</li>
<li>Liver: Fatal hepatic dysfunction with pancreatitis may occur in patients receiving large doses of tetracyclines over short periods, particularly by IV route. Such patients develop jaundice, azotemia and coma. Pregnancy, hepatic damage, renal impairment and</li>
</ul>
<p>concurrent use of other hepatotoxic drugs may enhance the hepatotoxic action. Tetracyclines should be avoided in pregnancy in the interest of both mother and foetus.</p>
<ul>
<li>Kidney: In patients with significant renal impairment, tetracyclines may cause an aggravation of azotemia and exaggerated antianabolic effect.
A reversible 'Fanconi-like' syndrome, characterised by nausea, vomiting, proteinuria, glycosuria, acidosis and aminoaciduria may develop after ingestion of outdated tetracycline capsules. It is attributed to a degradation product, epianhydrotetracycline. The formation of this toxic product is promoted by warmth, moisture and an acidic pH , with change of colour from yellow to brown.</li>
<li>Benign intracranial hypertension: Some patients may develop increased intracranial pressure. This causes bulging of the anterior fontanelle in infants and headache, photophobia and papilloedema in adults.</li>
<li>Miscellaneous: IV tetracyclines may cause local thrombosis. They may interfere with blood coagulation. This effect is probably secondary to chelation of calcium.
Jarish-Herxheimer reaction has been reported very rarely following IV tetracycline. It is characterised by sudden rise of temperature, rigors, hypertension, hyperventilation and tachycardia, followed by hypotension.</li>
</ul>
<p>Uremic patients may develop peptic ulcers. Tetracyclines have been observed to inhibit urease of gastric mucosa which breaks down urea into ammonia. Ammonia serves to reduce gastric acidity and hence, lowering of ammonia concentration by tetracyclines may lead to hyperacidity with ulceration.</p>
<p>Steatorrhea and deficiency of vitamin K may occur after prolonged tetracycline therapy.
Drug interactions: See Table 49.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-49-2">Table 49.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-49-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interactions-of-tetracyclines">Drug interactions of tetracyclines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-of-tetracyclines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Decreased bioavailability of tetracyclines: Divalent or trivalent cations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">g</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">e</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">Z</mi><mi mathvariant="normal">n</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{Ca}^{-}, \mathrm{Mg}^{-}, \mathrm{Fe}^{-}, \mathrm{Zn}^{-}, \mathrm{Al}^{-}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2057em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Fe</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Zn</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Al</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>; milk and milk products; antacids, vitamin or mineral products and cathartics containing divalent or trivalent cations; bismuth subsalicylate.</li>
<li>Decreased half life of tetracyclines: Carbamazepine; Phenytoin; Barbiturates; Chronic ethanol ingestion.</li>
<li>Interference with the bactericidal action of penicillin.</li>
<li>Potentiation of the anticoagulant action of coumarin drugs, eg. warfarin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) For oral administration: Oxytetracycline hydrochloride, Tetracycline hydrochloride capsules or tablets 250 mg , as paediatric syrup <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">125 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> and paediatric drops 100 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. The adult dose varies between 1 and 2 g per day in 3-4 divided doses; for children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight, daily, in divided doses.
(ii) For parenteral administration: Oxytetracycline and tetracycline are available for IM and IV administration. The usual IM dose is 100 mg at 8 hourly intervals. Because of irregular absorption, IM administration is generally not satisfactory. The total daily IV dose of oxytetracycline and tetracycline for most acute infections in adults is 1-2 g in two equal doses at 12 hourly intervals. The tetracyclines are never administered intrathecally. (iii) Ophthalmic ointments and eye drops containing tetracyclines ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> ).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="semisynthetic-tetracyclines">Semisynthetic Tetracyclines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#semisynthetic-tetracyclines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These compounds have better absorption, longer duration of action or greater facility of parenteral administration than the older tetracyclines. Whereas tetracycline and oxytetracycline are short acting, demeclocycline and methacycline are intermediate acting, and doxycycline and minocycline are long acting.</p>
<p>Demethylchlortetracycline (Demeclocycline): Given orally, it is well absorbed (66%), is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> protein bound and has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 12 hours. The concentration in the CSF is poor. As the drug is slowly excreted by kidneys the therapeutic blood levels are maintained for at least 24 hours after cessation of treatment.</p>
<p>Demethylchlortetracycline shares all the adverse effects of the tetracyclines.
It is available as 150 mg and 300 mg capsules and as a syrup. The usual adult dose is 600 mg daily in 2 or 3 divided doses. It is now used for SIADH (See later).</p>
<p>Methacycline shows almost identical in vitro activity as demethyl-chlortetracycline. It gives higher and more sustained blood levels than the older tetracyclines. Lymecycline is a tetracycline made soluble by combining it with the amino acid lysine. It is claimed to be almost completely absorbed on oral administration.</p>
<p>DOXYCYCLINE: It is well absorbed from the gut and is more slowly excreted than other tetracyclines (Table 49.1). With a single dose of 500 mg serum level of 1 mcg per ml has been reported to be present upto 4 days. It is metabolised in the liver and excreted in feces as an inactive conjugate. Its plasma half life is not significantly affected by renal insufficiency and the drug does not aggravate azotemia.</p>
<p>Doxycycline has similar toxicity as the conventional tetracyclines. However it has many advantages. These are:</p>
<ul>
<li>Better GI absorption and hence smaller doses.</li>
<li>Longer half life, ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>16</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 16</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">16</span></span></span></span></span> hours), permitting less frequent dosing schedule.</li>
<li>Higher lipid solubility, leading to higher tissue concentrations.</li>
<li>Elimination independent of renal function; hence it can be used in patients with impaired renal function; and</li>
<li>Less propensity to cause diarrhoea.</li>
</ul>
<p>Preparations and dosage:
The drug is available in 100 mg capsules. The recommended dose in adults is 200 mg (single dose) on day one and then 100 mg once a day. In severe infections a dose of 100 mg every 12 hours is recommended. For children, a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per kg daily is given initially in 2 divided doses. In severe infections a larger dose may be given. Subsequently, a maintenance dose of 1-2 mg per kg is administered either as a single dose or divided into 2 doses. Doxycycline can also be given IV by infusion.</p>
<p>MINOCYCLINE: This tetracycline is absorbed completely from the GI tract and exhibits greater antibacterial activity than older tetracyclines. It is retained in fat; hence it is long acting with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 16 hours. It is excreted in bile and faeces. The drug has better tissue penetration. It is effective against tetracycline resistant Staph. aureus, Strep. pyogenes, enterococci, meningococci and E. coli and exhibits a significant activity against nocardia, asteroides and acid fast bacilli. Minocycline achieves satisfactory levels in the CNS and is preferred in prophylaxis of meningococcal meningitis. Unlike other tetracyclines, it causes reversible vestibular toxicity such as vertigo, dizziness, ataxia, nausea and vomiting. The</p>
<p>dose is 100 mg bid.
TIGECYCLINE is a glycylcycline, a derivative of minocycline with a broad spectrum. Its mechanism of action is similar to that of other tetracyclines. It is highly effective against methicillin-resistant staphylococci (MRSA), vancomycin-resistant staphylococci (VRSA) and enterococci (VRE), penicillin resistant staphylococci, Streptococcus pneumoniae and many Gram negative bacilli resistant to older tetracyclines. It is also effective against Gram positive and negative anaerobes, and rapidly growing mycobacteria.</p>
<p>Absorption, fate and excretion: Given IV, it has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 42 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> is excreted unchanged via the biliary route into the feces and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> in urine. Dose adjustment is needed in hepatic failure. The IV dose is 100 mg loading dose, followed by 50 mg every 12 hours.</p>
<p>It is generally well tolerated but may cause nausea and vomiting. Cl. difficile associated diarrhoea and pancreatitis have been reported. It should not be used in children and pregnant women. Its use should be restricted to life-threatening skin, soft tissue and intraabdominal infections as well as community acquired pneumonia.</p>
<p>Therapeutic uses of tetracyclines: Although tetracyclines are effective against a wide range of organisms, they are not to be preferred routinely against the organisms that are highly sensitive to other equally safe and bactericidal agents like penicillin and cotrimoxazole. Tetracyclines are indicated in:</p>
<ul>
<li>Rickettsial infections: They are very effective in rickettsial infections like murine, epidemic and scrub typhus, Q fever and Rocky mountain spotted fever. Relapses are rare. The dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> during the first 24 hours, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> daily till the temperature subsides.</li>
<li>Primary atypical pneumonia: This condition, caused by Mycoplasma pneumoniae, responds satisfactorily to tetracyclines. However macrolides and fluoroquinolones are preferred.</li>
<li>Cholera: Cholera is caused by strains of Gram negative Vibrio cholerae and is characterised by severe diarrhoea, leading to rapid and massive loss of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{HCO}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.039em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and water, and shock. Hence, rapid rehydration is the mainstay of treatment, for which WHO ORS formulation is preferred (Chapter 37). Patients in shock will need IV fluids initially, given rapidly; acidosis can be corrected by giving IV Ringer lactate and oral potassium supplements.
The organisms respond to a single oral dose of doxycycline 200 mg or ciprofloxacin 20-30 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> as a single dose. For children, erythromycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in 3-4 divided doses, for 3 days is useful; cotrimoxazole may also be used (Chapter 45). In patients with multi-drug-resistant cholera, azithromycin 1 g as a single dose is reported to be highly effective.</li>
<li>Chlamydia infections: Chlamydia trachomatis causes trachoma, non gonococcal urethritis (NGU), cervicitis, epidydimitis, inclusion conjunctivitis, lymphogranuloma venereum and infant pneumonia (Chapter 53). Like the viruses, these organisms are obligate intracellular parasites of very small size but unlike viruses and like bacteria they multiply by binary fission. Their cell walls resemble those of Gram-negative bacteria. Table 49.3 lists the drugs used in chlamydial infections.</li>
</ul>
<p>Table 49.3
Drugs used in chlamydial infections</p>
<ul>
<li>Doxycycline/Tetracycline.</li>
<li>Erythromycin, Azithromycin.</li>
<li>Ofloxacin; and</li>
<li>Sulfonamides.</li>
</ul>
<p>In psittacosis caused by C. psittaci a dosage schedule of 2 g daily for two weeks is usually recommended. Use of tetracyclines in lymphogranuloma venereum and NGU is discussed in Chapter 53.</p>
<p>In trachoma, doxycycline 100 mg bid for 7 days can be used. However, azithromycin 1 g single oral dose is preferred. Adequate drug therapy early in the disease can lead to complete healing without any sequelae. In endemic areas, where adequate therapy is not possible, the antibiotic ointment may be applied twice daily on every alternate day for 6 months.</p>
<p>In children, azithromycin given as single dose is preferred to tetracycline.
Inclusion conjunctivitis responds to topical application of tetracycline ointment 4 times daily for a period of 2 to 3 weeks.
H. pylori infection in patients with peptic ulcer: (Chapter 43).</p>
<ul>
<li>Granuloma inguinale: See Chapter 53.</li>
<li>Bacillary infections: Tetracyclines can be used in the treatment of traveller's diarrhoea, caused by enterotoxigenic E.coli. Although tetracyclines are effective in tularemia, streptomycin is usually preferred. They can also be used in infections due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae but either ampicillin or chloramphenicol is preferred.</li>
<li>Brucellosis: See Chapter 47.</li>
<li>Sexually transmitted diseases: They are now less preferred (Chapter 53).</li>
<li>Urinary tract infections: They are particularly useful in non-gonoccocal urethritis caused by chlamydia trachomatis. Doxycycline is often preferred for the empiric treatment of the acute urethral syndrome (Chapter 52).</li>
<li>Plague: See Chapter 47.</li>
<li>Acne vulgaris: See Chapter 71.</li>
<li>Drug resistant malaria (see Chapter 56).</li>
<li>Leptospirosis: is caused by spirochetes, L. interrgous sansulato. Mild cases respond to doxycycline 100 mg bid or ampicillin 500-750 mg qid. Severe cases need IV penicillin G 1.5 million units qid or IV ampicillin 1 g qid or Ceftriaxone 1 g OD. Doxycycline 200 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> week appears to be adequate for prophylaxis.</li>
<li>Amoebic dysentery: (See Chapter 57). Balantidium coli, a protozoon, causes a disease similar to amoebic dysentery in children. Tetracycline in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">8-10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> thrice daily for 10 days is highly effective.</li>
<li>SIADH: Demeclocycline is useful in the treatment of chronic hyponatremia due to Secretion of Inappropriate Anti-diuretic Hormone (SIADH). The drug produces unresponsiveness to ADH. Its action is dose-dependent and reversible.</li>
<li>Miscellaneous: Other infections which respond to tetracyclines include anthrax, actinomycosis, yaws, relapsing fever and lyme disease. In these conditions, penicillin is preferred. Tetracyclines have also been used in the treatment of tropical sprue and blind</li>
</ul>
<p>loop syndrome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chloramphenicol">Chloramphenicol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chloramphenicol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chloramphenicol is a broad spectrum antibiotic derived originally from Streptomyces venezuelae. The commercial preparation however, is entirely synthetic. It is a derivative of dichloroacetic acid, containing a nitrobenzene moiety (Fig. 49.2). The antibiotic is stable over the pH range of 2 to 9 .
<img src="assets/images/image-20251214-fdb0eecd.jpeg" alt="img-3.jpeg"></p>
<p>FIG. 49.2 Chloramphenicol
Antibacterial activity: The antibacterial spectrum of chloramphenicol is similar to that of tetracyclines. Thus, it is effective against rickettsia, the chlamydia of the psittacosis-lymphogranuloma group, Mycoplasma pneumoniae, and against a variety of Gram- negative and Gram-positive organisms. Salm. typhi, H. influenzae and B. pertussis are more susceptible to chloramphenicol than tetracycline. The bacteroides, some staphylococci resistant to penicillin and a few strains of streptococci are also inhibited. Essentially it is a bacteriostatic but can be bactericidal against common meningeal pathogens-H. influenzae, N. meningitidis and Strep. pneumoniae.</p>
<p>Mechanism of action: Chloramphenicol readily penetrates into the bacterial cell and acts by interfering with the synthesis of bacterial proteins by binding to 50 S ribosomes and preventing transpeptidation. Resistance develops slowly to this antibiotic in vivo. However, resistant strains of E. coli, salmonella, shigella and other Gram negative bacteria have been reported; it is due to the presence of a specific resistance (R) factor.</p>
<p>Absorption, fate and excretion: Unlike tetracyclines, chloramphenicol is completely absorbed from the gut and is better diffusible into the various tissues including brain. The CNS concentrations are equal to those in serum. Blood levels of chloramphenicol after oral administration are superior to those after IM administration because of the hydrolysis of its salt in the gut. Being poorly water soluble, its absorption depends to a great extent on particle size.</p>
<p>Given orally, peak plasma levels are reached within 2 hours; it has a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>2</mn><mo>−</mo><msup><mn>3</mn><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">1^{1 / 2} 2-3^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of plasma chloramphenicol is bound to protein. The binding is reduced in cirrhotic patients and in neonates, giving high concentrations of the free drug.</p>
<p>Chloramphenicol palmitate, the pediatric oral preparation, is inactive in vitro, but in vivo, it is slowly hydrolysed by pancreatic lipases in the duodenum, which release free chloramphenicol for absorption. Hence, blood levels achieved are lower than those after chloramphenicol itself.</p>
<p>Chloramphenicol is largely inactivated by hepatic conjugation to glucuronide. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> is excreted as the inactive form by the kidney. Hence, chloramphenicol can be relatively safely administered in patients with renal impairment but not in those with hepatic insufficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Allergy: This is relatively uncommon. However, skin rashes, drug fever, angioneurotic edema, exfoliative dermatitis, atrophic glossitis have been reported.</p>
</li>
<li>
<p>Bone marrow toxicity: Aplastic anemia, reported in all age groups, is an idiosyncratic reaction; its incidence is between 1:10,000 and 1:100,000. Prolonged treatment and repeated courses appear to be more likely to cause this complication, although it can occur even on ingestion of a few grams of the drug. The clinical manifestations may be delayed for 2 to 6 months after treatment. Thus, menorrhagia or GI hemorrhage occurring several months after therapy may be the first indication of aplastic anemia. Many patients may develop less pronounced hemopoietic changes which are dose dependent and reversible. Weekly blood smear, may detect early dose-dependent changes.
It must be noted that the risk of this complication should not prevent the use of chloramphenicol in life-threatening situations.</p>
</li>
<li>
<p>Gray baby syndrome: This complication with high mortality is observed in neonates and infants. The initial manifestations are vomiting, lethargy, anorexia, abdominal distension and shallow irregular respiration. Later, the condition worsens, leading to hypothermia, flaccidity, peripheral vascular collapse, gray cyanosis, shock and finally death. The factors incriminated are
(a) Deficient conjugation of chloramphenicol in the liver due to a low level of hepatic glucoronyl transferase enzyme activity in the first 2 or 3 weeks of life; and
(b) Immaturity of the renal tubules leading to impairment of excretion of the free form.</p>
</li>
<li>
<p>Liver toxicity: Liver damage with chloramphenicol is rare.</p>
</li>
<li>
<p>CNS toxicity: It may cause headache, peripheral neuritis, internal ophthalmoplegia, mental confusion, depression and delirium. Optic neuritis, probably secondary to drug induced pyridoxine deficiency, may occur rarely. The drug may also affect the cochlear function if used locally, for ear infections.</p>
</li>
<li>
<p>Miscellaneous: A 'typhoid shock' syndrome may develop in patients having typhoid fever, on administration of a large loading dose. It is attributed to excessive release of endotoxin from the micro-organisms.</p>
</li>
<li>
<p>Superinfection is uncommon as the drug is almost completely absorbed.</p>
</li>
</ul>
<p>Drug interactions: Pre-treatment with phenobarbitone results in lower chloramphenicol blood levels, whereas chloramphenicol may increase the toxicity of phenytoin in epilepsy, and may cause hypoglycemia in diabetics on tolbutamide, by inhibiting the hepatic microsomal enzymes that metabolise these drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Chloramphenicol 250 mg capsules. Dose: adults, 1 to 3 g daily in divided doses. For children, 25 to 50 mg per kg daily in divided doses.
(ii) Chloramphenicol palmitate oral suspension: 125 mg of chloramphenicol base in each 4 ml . The preparation is tasteless and, therefore, is preferred in children.
(iii) Chloramphenicol monostearoylglycolate used in the form of a dry syrup.
(iv) Chloramphenicol sodium succinate has a high aqueous solubility and is, therefore, the agent of choice for parenteral therapy. It can be given SC, IM or IV slow infusion. The doses are similar to those given orally. Absorption from SC and IM sites is unreliable.
(v) Chloramphenicol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> ophthalmic ointment, as applicaps and as eye drops <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span>.</p>
<p>Therapeutic uses: Compared to tetracyclines, chloramphenicol is better diffusible in tissues, causes less GI disturbances and can be used for similar indications; but because of</p>
<p>its bone marrow toxicity, it is not employed primarily as a broad spectrum antibiotic. The major indications are:</p>
<ul>
<li>Typhoid fever is caused by S. typhi. After invading the intestinal mucosa (mainly terminal ileum) the organisms invade the regional lymph nodes and other tissues. Drugs effective in treating typhoid fever are listed in Table 49.4.</li>
</ul>
<p>Table 49.4
Drugs effective in typhoid fever</p>
<ul>
<li>Ciprofloxacin</li>
<li>Chloramphenicol.</li>
<li>Ampicillin</li>
<li>Cotrimoxazole</li>
</ul>
<p>Against multi-drug resistant organisms:</p>
<ul>
<li>Ceftriaxone</li>
<li>Azithromycin</li>
</ul>
<p>Empirical treament:</p>
<ul>
<li>Ceftriaxone</li>
<li>Azithromycin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></li>
</ul>
<table><thead><tr><th style="text-align: left;">Against sensitive organisms:</th></tr></thead><tbody><tr><td style="text-align: left;">- Ciprofloxacin</td></tr><tr><td style="text-align: left;">- Chloramphenicol.</td></tr><tr><td style="text-align: left;">- Ampicillin</td></tr><tr><td style="text-align: left;">- Cotrimoxazole</td></tr><tr><td style="text-align: left;">Against multi-drug resistant organisms:</td></tr><tr><td style="text-align: left;">- Ceftriaxone</td></tr><tr><td style="text-align: left;">- Azithromycin</td></tr><tr><td style="text-align: left;">Empirical treament:</td></tr><tr><td style="text-align: left;">- Ceftriaxone</td></tr><tr><td style="text-align: left;">- Azithromycin</td></tr></tbody></table>
<p>Chloramphenicol is highly effective if the organisms are sensitive. It is given orally in the dose of 50 mg per kg daily (about 2 g in adults) in 4 divided doses at 6 hourly intervals until the temperature is normal. The dose is then reduced to 30 mg per kg per day. It should be continued for a total period of 14 days. It can also be administered IM or IV. The clinical improvement is seen within 48 to 72 hours. Temperature returns to normal within 3 to 5 days. Clinical cure is thus achieved before the GI ulcerations have healed and hemorrhage and perforation can occur during therapy even in an afebrile patient. It is desirable, therefore, to advise bed rest for a period of 2 to 3 weeks to allow sufficient time for healing of the ulcerated bowel. Relapses can occur but are amenable to similar treatment.</p>
<p>Resistance to chloramphenicol is well documented from many countries including India. Hence, a fluoroquinolone such as ciprofloxacin or ofloxacin with high cure rate is now preferred. It is given twice a day for 5-7 days. Since they are bactericidal, relapse rate is lower and the</p>
<p>occurrence of fecal carrier state is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>. Cotrimoxazole in the dose of 2 tablets bid, continued for 5-7 days after defervescence, is also effective, but to a lesser magnitude.</p>
<p>Amoxycillin ( 1 g tid) has also been used to treat typhoid fever. The therapeutic response, however, is slower in onset and often inadequate.</p>
<p>Unfortunately, multi-drug-resistant (MDR) S. typhi have been frequently encountered in endemic areas. In such cases, a third generation cephalosporin such as ceftriaxone (1-2 g IM/IV for 10-14 days) is recommended. Azithromycin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day for 5 days) is also effective. Patients with severe typhoid fever (diarrhoea, persistent vomiting, delirium, obtundation, stupor, coma or shock) may need parenteral therapy for 7-10 days, and total therapy for 14 days.</p>
<p>Empirical therapy cosists of ceftriaxone or azithromycin.
A glucocorticoid may be added to antibiotic therapy in severe typhoid fever and in those with shock-like syndrome. Prednisolone is given in the dose of 40 mg in 4 divided doses on the first day, 30 mg on the 2 nd day and 20 mg day subsequently. Treatment should be given for a total period of 5-6 days and tapered off gradually. Their routine use in all cases is, however, not recommended.</p>
<p>The incidence of relapse following fluoroquinolones ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.5%</span></span></span></span></span> ) and broad spectrum cephalosporins ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> ) is lower than that following chloramphenicol, cotrimoxazole and ampicillin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ). Supportive therapy includes maintenance of adequate nutrition and antipyretics. Either ibuprofen or paracetamol 6 hourly may be given till 36 hours after defervescence. Irritant purgatives are contraindicated for fear of causing hemorrhage or perforation.</p>
<p>In addition to S. typhi, campylobacter and yersinia infections can progress to 'enteric fever' by penetrating the intestinal cells and causing systemic infection. Thus, typhoid is an enteric fever but all enteric fevers are not typhoid.</p>
<p>Treatment of carriers: Carriers are defined as patients who continue to excrete the organisms in the stool for more than 3 months after recovery. Chloramphenicol does not prevent or eliminate the carrier state. The treatment of choice is ciprofloxacin 750 mg twice daily for 28 days. The other drugs effective are ampicillin or amoxycillin ( 2 g qid for 4 weeks) and cotrimoxazole ( 2 tablets bid for 4 weeks), which are secreted in bile. Patients with cholecystitis may need cholecystectomy.</p>
<p>Paratyphoid fever, though usually a milder disease, is treated similarly.</p>
<ul>
<li>Ophthalmic infections: Because of its satisfactory penetration into the intraocular fluid on local and systemic administration, chloramphenicol is widely employed in the treatment of ocular infections.</li>
<li>H. influenzae or meningococcal meningitis: Chapter 48.</li>
<li>Anaerobic infections and Ricketssial infections: B. fragilis are effectively treated with chloramphenicol; however it is not preferred in ricketssial infections.</li>
<li>Plague: Chapter 47.</li>
<li>Miscellaneous: It is also used in chronic otorrhea, particularly due to Gram negative organisms. Though effective in brucellosis, rifampicin is preferred.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-bacillary-dysentery">Pharmacotherapy of Bacillary Dysentery<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-bacillary-dysentery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute bacillary dysentery or shigellosis is usually a self-limited illness characterised by diarrhoea with blood and mucus in the feces, tenesmus, fever, intestinal colic and tenderness. Nausea and vomiting may occur. In many patients, the illness is characteristically short, for 12-24 hours, followed by constipation, and needs to be treated only with Oral Rehydration Therapy (ORT) (Chapter 41). The infection is usually localised to the GI tract but pneumonitis is not infrequent in children and bacteremia may occur rarely. Shigella shiga infection is often more severe than that due to other strains.
I Specific treatment: Cotrimoxazole or ampicillin is preferred for general use. Amoxycillin should not be substituted for ampicillin because it is not so useful against shigellosis. In cases of suspected MDR shigellosis, norfloxacin or ciprofloxacin, given twice daily, for 5-7 days, is now preferred, particularly in cases where the drug susceptibility is unknown (Chapter 41). Neonates with shigellosis should be treated with parenteral antibiotics. The other drugs found useful are pivamipcillinam, azithromycin and ceftriaxone.</p>
<p>It must be emphasised that spontaneous clearance of stools is known to occur irrespective of whether or not the patient has received antibacterial treatment. Hence mild cases could be treated with ORS alone. Nonabsorbable drugs such as neomycin, kanamycin and colistin are clinically ineffective despite in-vitro activity.
II Adjuvant treatment:</p>
<ul>
<li>Correction of fluid and electrolyte imbalance is very important and is often life saving (Chapter 41); and</li>
<li>Symptomatic treatment of diarrhoea: The role of antimotility agents in shigellosis is controversial; they may control the diarrhoea but delay the excretion of the infecting organisms and delay the recovery (Chapter 41).
In the post-diarrhoeal phase, the patient's constipation should not be interfered with because it represents the body's effort to splint the bowel and it usually clears up within 3 days.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-chronic-bronchitis">Pharmacotherapy of Chronic Bronchitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-chronic-bronchitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The etiology of chronic bronchitis is not known. There is no obvious cause such as acute inflammatory or neoplastic disease of the lung or bronchiectasis. Chronic bronchitis with airflow obstruction leads to COPD, characterized by irreversible air flow resistance. In many elderly patients, it is progressive and incurable, terminating eventually in right heart failure.</p>
<p>Patients with chronic bronchitis should receive a prophylactic dose of pneumococcal vaccine (Chapter 73).</p>
<p>Pharmacotherapy of chronic bronchitis is directed primarily towards the inflammation and infection which are controllable. The pathological changes associated with emphysema, however, are irreversible.</p>
<p>The treatment can be divided into
I Treatment of exacerbations and
II Management of the chronic state.
I Treatment of exacerbations:
Antimicrobial therapy: Patients with chronic bronchitis are extremely susceptible to acute attacks which usually develop during the monsoon months in India and during the winter in the Western countries. During such attacks, the sputum becomes purulent, more viscous or merely more profuse. The commonest pathogens involved are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. pneumoniae and Moraxella catarrhalis although Staph. aureus or K. pneumoniae are not infrequent.</p>
<p>Acute exacerbations of chronic bronchitis should be treated promptly with an antibiotic. Ideally, microscopic examination and culture of the sputum should be carried out if the patient has a chill, fever, purulent sputum or chest pain. The antibiotic regimens recommended in the absence of pneumonia are (i) tetracycline 250 mg qid; (ii) doxycycline 150 mg once daily; (iii) ampicillin/amoxicillin 250 mg qid; and (iv) cotrimoxazole, 2 tablets bid. All these regimens are equally effective and any one may be selected. Some patients may need erythromycin, azithromycin, a respiratory fluoroquinolone (Chapter 45) or a cephalosporin, depending upon the causative organism.</p>
<p>Antimicrobial therapy should be continued for at least 7-10 days. If the patient fails to respond satisfactorily, bacteriological examination of the sputum is indicated and an appropriate change in the antibiotic therapy should be made. Prompt institution of antibacterial treatment at the beginning of illness minimises further bronchopulmonary damage.</p>
<p>Patients with pneumonia need amoxicillin (with or without clavulinic acid), a fluoroquinolone, a third generation cephalosporin, or cotrimoxazole depending on the nature of the infecting organism.</p>
<p>Control of symptoms: Bronchodilators counter the respiratory distress due to bronchospasm. If the asthmatic element is prominent, glucocorticoid may have to be employed. For liquefaction of thick and sticky secretions, mucolytic agents may be useful. Steam, inhalation and expectorants facilitate the expulsion of secretions. If the patient is expectorating large quantities of sputum, postural coughing is highly beneficial (Chapter 26).</p>
<p>In severe respiratory distress with resting hypoxemia and signs of pulmonary hypertension or right heart failure, oxygen has to be given continuously (Chapter 77). Such</p>
<p>oxygen therapy has been shown to decrease mortality.
II Management of chronic state: Usefulness of routine antimicrobial prophylaxis is questionable. Hence, a short course of therapy, started at the first sign of an exacerbation, is recommended. Presence of pulmonary inefficiency and persistent purulent (yellow) sputum need long-term treatment; amoxicillin or trimethoprim may be preferred. it is important to avoid all irritants to the respiratory tract, especially smoke, dust, chemicals and environmental pollutants. Breathing exercises postural drainage and bronchodilators are beneficial. For details of management of COPD, see Chapter 27.</p>
<p>50</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antifungal-agents">Antifungal Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antifungal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Fungal infections are common, both as primary diseases, and secondary to oral antibiotics therapy. Individuals suffering from malignancy, diabetes mellitus, those on corticosteroids and immunocompromised subjects are more prone to fungal infections.</p>
<p>Fungi occur as either rounded budding forms (yeast-like) or hyphi (moulds). The common fungi are listed in Table 50.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-50-1">Table 50.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-50-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="types-of-fungi-infecting-the-humans">Types of fungi infecting the humans<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-of-fungi-infecting-the-humans" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="surface-malassezia-furfur-tinea-versicolor-or-pityriasis-versicolor-br-cutaneous-dermatophyte-species-dermatophytosis-or-ringworm-infection">Surface: Malassezia furfur (tinea versicolor or pityriasis versicolor) &lt;br&gt; Cutaneous: Dermatophyte species (dermatophytosis or ringworm infection)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surface-malassezia-furfur-tinea-versicolor-or-pityriasis-versicolor-br-cutaneous-dermatophyte-species-dermatophytosis-or-ringworm-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-responsible-for-invasive-fungal-infection">II Responsible for invasive fungal infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-responsible-for-invasive-fungal-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-opportunistic">(a) Opportunistic:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-opportunistic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Yeasts: Candida sp. (candidiasis) and Cryptococcus sp. (cryptococcosis)</li>
</ul>
<p>Mycelial or Filamentous Fungi:
(a) Zygomycetes- Mucor sp, Rhizopus sp, Conididiobolus, Basidiobolus (zygomycosis),
(b) Pseudallescheria boydii (mycetoma and maduromycosis) and
(c) Aspergillus spp. (aspergillosis)</p>
<ul>
<li>Protozoan-like fungi: Pneumocystis jiroveci (pneumonia)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-true-pathogenic">(b) True pathogenic:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-true-pathogenic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Common: Histoplasma capsulatum (histoplasmosis), Blastomyces dermatitidis (blastomycosis), Coccidioides immitis (coccidioidomycosis)</li>
<li>Rare: Paracoccidiodies brasiliensis (paracoccidioidomycosis), Cladophialophora carrionii, (chromomycosis chromoblastomycosis), Sporothrix schenckii (sporotrichosis), Trichosporon sp (trichosporonosis)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo></mrow><annotation encoding="application/x-tex">--</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span></span></span></span></span></li>
</ul>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-antifungal-agents">Classification of antifungal agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-antifungal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Those employed topically: These include many synthetic drugs such as Azoles, Tolnaftate, Undecyclenic acid, Terbinafine and Ciclopirox. (Chapter 71). Only Nystatin, an antibiotic, is discussed here.
II Those used systemically:</p>
<ul>
<li>Antibiotics: Griseofulvin and Amphotericin B.</li>
<li>Antimetabolites: Flucytosine.</li>
<li>Azole derivatives: eg. Clotrimazole, Ketoconazole, Itraconazole and Fluconazole.</li>
<li>Allylamine: Terbinafine</li>
<li>Echinocandins: Caspofungin</li>
</ul>
<p>I Agents employed topically:
NYSTATIN: This antibiotic, obtained from
Streptomyces noursei, contains many double bonds in its chemical structure and hence, is called a polyene antibiotic. It is stable for several months in dry state at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>4</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">4^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>; it rapidly loses its activity in the presence of water or plasma.</p>
<p>Antifungal activity: Nystatin shows inhibitory activity against several fungi in vitro; Candida, Histoplasma, Blastomycoses, Trichophyton and Microsporum audouini are sensitive. It binds to ergosterol present in the cell membrane of the yeast and creates pores/channels, thus increasing the membrane permeability. Depending upon concentration, it can act either as a fungistatic or a fungicidal.</p>
<p>It is not absorbed from the gut, the skin or the mucous membranes. On parenteral administration, it produces a variety of toxic effects including serious nephrotoxicity; its activity is reduced in the presence of plasma. Hence, it is not used for systemic infections. Resistance does not readily develop to this antibiotic in vivo.</p>
<p>Adverse reactions: Adverse effects encountered with nystatin used locally are usually mild. Oral administration may cause nausea, vomiting and diarrhoea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Nystatin tablet 500,000 units. Dose: 500,000 units 8 hourly in adults and in children over 6; 200,000 units 8 hourly in younger children; and 100,000 units 8 hourly below the age of 1 year.
(ii) Nystatin suspension 100,000 units per ml. for oral topical application.
(iii) Nystatin pessary or vaginal tablet 100,000 units twice or thrice daily.
(iv) Nystatin ointment 100,000 units per gram. Therapeutic uses: Nystatin is effective in the treatment of localised candidiasis of vagina, mouth, skin and the gut. Nail involvement due to candida does not respond to it.</p>
<p>Monilial/candidial infection of the vagina responds to the insertion of 100,000 units twice daily for a minimum period of 2 weeks. Treatment of monilial vaginitis in pregnant patients reduces the possibility of thrush in the newborn. For the latter, a suspension containing 100,000 units of the antibiotic is dropped into the infant's mouth 4 times daily. The treatment should be continued for a prolonged period after all clinical lesions have subsided. For intestinal candidiasis, 500,000 units 6 hourly is the adult dose.
II Agents employed systemically:
GRISEOFULVIN: Griseofulvin, isolated from Penicillium griseofulvium is the first oral compound to cure effectively infections due to the superficial dermatophytes (ringworm).</p>
<p>Antifungal activity: In vitro, the antibiotic inhibits the growth of various species of</p>
<p>Trichophyton, Microsporum and Epidermophyton. It is not effective against bacteria, C. albicans, or any of the deep fungi. The antibiotic is mainly fungistatic.</p>
<p>Mechanism of action: The antibiotic exhibits mild cytotoxic properties similar to those of colchicine, and damages the microtubular protein, thus preventing mitosis. It acts mainly on the growing fungal cells and inhibits hyphal cell-wall synthesis. Dermatophytes specifically attack the keratinous tissue. Griseofulvin binds to the keratinocyte precursor cells and gets incorporated into keratin of the skin, hair and nails, making the new keratin resistant to fungal invasion. The already established fungus is not affected. Hence, the treatment takes a long time to ensure cure. It also has a weak anti-inflammatory action.</p>
<p>Absorption, fate and excretion: Small particles are better absorbed than large particles; divided oral doses achieve higher level than a single dose; and a diet rich in fat enhances its absorption. It is metabolised in the liver; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> get excreted in the urine as metabolites.</p>
<p>Adverse reactions: These are:</p>
<ul>
<li>Mild reactions such as headache, epigastric distress, nausea, vomiting and diarrhoea.</li>
<li>Allergic and photosensitivity reactions. Cross allerginicity with penicillin, as griseofulvin is derived from a penicillium.</li>
<li>Nervous system disturbances such as peripheral neuritis, vertigo, psychomotor incoordination, lethargy and blurred vision.</li>
<li>Superinfection with Candida albicans.</li>
<li>Rarely, hepatotoxicity transient leucopenia, proteinuria, gynecomastia, pigmentation of the genitalia are reported.
Drug interactions: Concurrent administration of griseofulvin and phenobarbitone may retard the absorption of the former from the GI tract. It is a hepatic microsomal enzyme inducer and hence it depresses the blood levels of drugs like warfarin and oral contraceptives. It can cause antabuse like reaction with alcohol.</li>
</ul>
<p>Preparations and dosage: The adult dose is 500 mg daily in 2 or 4 divided doses. In certain infections like Tinea capitis, a larger dose of 1.5 g daily may be necessary. Children are given 10 mg per kg daily, administered as a single dose or in divided doses.</p>
<p>Therapeutic uses: Griseofulvin has made clinical control of some chronic resistant ringworm infections possible. Nevertheless, the narrow spectrum and the high cost of griseofulvin demand that it should not be used unless the cheaper and well established topical therapy fails or the lesion is known to be resistant to such topical therapy. The indications are:</p>
<ul>
<li>Tinea capitis - ringworm of the scalp, where clinical cure usually occurs within 4 to 6 weeks of therapy.</li>
<li>Tinea barbae - fungus infection of the beard caused by T. faviforme, T. mentagrophytes and M. canis.</li>
<li>Tinea cruris and tinea corporis - ringworm of the groin and the body.</li>
<li>Tinea pedis and tinea manus - ringworm of the feet and hands. Griseofulvin is more effective in chronic fungal infections at these sites than in the acutely inflamed forms. In all above conditions, the treatment is continued for some weeks after both clinical and microscopic evidence of infection has disappeared. Usually, this takes 4-8 weeks.</li>
<li>Onychomycosis: It is more useful for fungal infection of fingernails than toenails which may respond minimally or not at all. Treatment for infection of the fingernails is given for 4 to 6 months, while an infection of the toenails is treated for 8 to 12 months. Since</li>
</ul>
<p>chronic fungal infections tend to cause hyperkeratosis, concomitant topical keratolytic therapy with salicylic acid is beneficial. It is not useful for superficial candidiasis and T. versicolor (Chapter 71).
AMPHOTERICIN B: This polyene antibiotic, obtained from Streptomyces nodosus, is a yellowish powder, relatively insoluble in water but is amphiphilic and hence the name. Its mechanism of action is similar to that of nystatin. In addition, it also causes oxidative damage to fungi cells.</p>
<p>Antifungal activity: Amphotericin B has a wide antifungal activity. It inhibits the growth of Histoplasma capsulatum, Cryptococcus neoformans, Sporothrix schenkii, Coccidioides immitis, Paracoccidiodies brasiliensis and Blastomycosis dermatitidis in low concentrations. Candida responds to a slightly higher concentration. Depending upon the concentration, it can be fungistatic or fungicidal. Candida may develop resistance to this antibiotic in vivo.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="absorption-fate-and-excretion">Absorption, fate and excretion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absorption-fate-and-excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amphotericin B is poorly absorbed from the gut and after topical application. The IM administration is painful. The drug, therefore, is given by IV infusion. Following a therapeutic dose, only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of the drug is found in urine within 24 hours. It is concentrated in liver, spleen, kidney and lungs and remains in the body for several weeks. The CSF concentration is poor. Its metabolic fate is unknown.</p>
<p>Adverse reactions: Infusion-related reactions include phlebitis at the site of injection, nausea, anorexia, vomiting and profound generalised malaise. Chills, fever, flushing, headache, skin rash, diplopia, vertigo, convulsions, myalgia and peripheral neuritis are also seen.</p>
<p>Amphotericin B is nephrotoxic. Many patients develop impairment of renal function, hypokalemia, appearance of urinary casts and sometimes microscopic hematuria. Irreversible renal damage may occur. Varying degrees of anaemia may result.</p>
<p>The drug can cause hemorrhagic gastroenteritis, thrombocytopenia and hepatic failure. Hypotension, ventricular failure and cardiac arrest may develop rarely.</p>
<p>Intrathecal administration of the drug may result in seizures and arachnoiditis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Amphotericin B lotion 3%.
(ii) Amphotericin B deoxycholate (IV): A concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{ml} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">%</span></span></span></span></span> in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose should be used. Therapy is initiated with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.25 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, infused over 6-12 hours. If the drug is tolerated, the dose is gradually increased to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. The maximum dose is 1.5 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day on alternate days. It is recommended that one litre of normal saline should be infused on the day of amphoterian therapy, to reduce the risk of nephrotoxicity.
(iii) Other lipid formulations available are amphotericin B lipid complex, amphotericin B colloidal dispersion and liposomal amphotericin B (AmBisome). The drug is released slowly from these formulations and hence causes less toxicity. They are very expensive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Topically, the antibiotic is useful in the treatment of candida lesions and as eyedrops to treat fungal corneal ulcers and keratitis.</li>
<li>For systemic therapy, the patient should be hospitalised. A course of treatment should not be embarked upon unless the diagnosis is certain. Though toxic, it could be life saving. Its toxicity could be reduced by using (a) smaller doses in combination with other systemic antifungal agents or (b) lipid formulations (liposomes).</li>
</ul>
<p>Amphotericin IV is the treatment of choice in the primary, cutaneous and disseminated forms of blastomycosis, histoplasmosis, cryptococcosis, candidiasis, sporotrichosis, aspergillosis, chromoblastomycosis and occasionally in phycomycosis and maduramycosis. It may be administered intrathecally in fungal meningitis that does not respond to IV therapy. It is used to treat mucormycosis in diabetics.</p>
<p>It is also used in treatment of leishmaniasis (Chapter 58).
FLUCYTOSINE: This prodrug is a synthetic fluorinated pyrimidine. It is taken up by fungal cells and converted to 5-fluorouracil. The antifungal activity is due to 5-fluorouracil, an antimetabolite, which inhibits, DNA and RNA synthesis. Human cells do not convert the drug to active metabolites. Given orally, it is well absorbed and reaches adequate concentrations in the blood and CSF. It is mostly excreted unchanged by glomerular filtration.</p>
<p>Adverse reactions include GI disturbances, liver damage, neutropenia, thrombocytopenia and colitis. It is less toxic than amphotericin B.</p>
<p>Therapeutic uses: The drug is useful in cryptococcal meningitis and systemic candidiasis, including UTI. Used alone, it can lead to rapid emergence of drug resistance. Hence, it is usually combined with amphotericin B or itraconazole. It is administered daily, in the oral dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in four divided doses. It can also be given by IV infusion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azole-derivatives">Azole Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azole-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Therapeutically, drugs belonging to 'azole' group are classified as:
I Antibacterial and antiprotozoal agents e.g. Metronidazole and Tinidazole. (Chapter 57)
II Anthelminitic agents e.g. Mebendazole, Albendazole (Chapter 60) and
III Antifungal azole agents
Azoles possess a five member azole ring that is attached by a carbon-nitrogen bond to other aromatic rings as their basic structural unit (Fig. 50.1). Antifungal azoles are classified into:
<img src="assets/images/image-20251214-3b9b96ab.jpeg" alt="img-4.jpeg"></p>
<p>FIG. 50.1 Azole nucleus
I Imidazoles indicating two nitrogen atoms in the azole ring, e.g., Clotrimazole, Miconazole Ketoconazole, Econazole and Sulconazole.</p>
<p>Imidazoles are generally used topically to treat superficial mycoses, and cutaneous and vaginal candidiasis; and
II Triazoles with three nitrogens in the azole ring e.g. Terconazole, Itraconazole, Fluconazole.</p>
<p>Triazoles in general, have greater volume of distribution, slower rate of metabolism, greater selectivity and better CNS penetrability than imidazoles. They are also considered to be less toxic as they have less effect on human sterol synthesis and cause less endocrinal disturbances.</p>
<p>Antifungal activity: Azoles act by inhibiting synthesis of ergosterol, an important constituent of the fungal cell membrane. They interfere with fungal cytochrome P450 enzymes ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi>α</mi></mrow><annotation encoding="application/x-tex">14 \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> sterol de-methylase) and disturb the membrane. They also cause accumulation of hydrogen peroxide with lethal effect. They have a broad spectrum antifungal and antibacterial activity and are effective against Dermatophytes, Microsporum, Cryptococcus, Blastomyces, Coccidioides, Madurella, Nocardia, and Candida.</p>
<p>Imidazoles are less selective and can interact with human cytochrome P450 causing more drug interactions and ADR. All azoles are potentially embryotoxic and teratogenic, and should be avoided during pregnancy and lactation. The azoles used systemically are potent inhibitors of hepatic microsomal enzymes and can increase the blood levels and toxicity of several drugs.</p>
<p>CLOTRIMAZOLE: It is used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream or 100 mg tablets in vaginal candidiasis and locally to treat dermatophytosis and other fungal infections (Chapter 71). This drug is not used for systemic infections because of its toxicity.</p>
<p>Butoconazole, oxiconazole, sertaconazole, econazole, sulconazole, isconazole and fenticonazole have similar actions and uses as clotrimazole.</p>
<p>MICONAZOLE: This imidazole has a broad spectrum antifungal and Gram positive antibacterial activity. High concentrations are trichomonicidal. It is useful locally in mixed skin infections as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> cream.</p>
<p>The drug is metabolised in the liver. For systemic fungal infections, it is given IV and sometimes intrathecally. Good results are reported in infections caused by Candida, Cryptococcus and Aspergillus. The drug may cause fever, chills, nausea and allergic reactions and rarely, leucopenia and thrombocytopenia.</p>
<p>Efinaconazole topical solution ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ) is available for toenail onychomycosis.
KETOCONAZOLE: This imidazole has spectrum similar to that of miconazole but it is claimed to be more active against Coccidioides. It is water soluble and well absorbed from the gut.</p>
<p>In large doses, ketoconazole inhibits several biosynthetic steps in the synthesis of adrenal and gonadal steroids. It can thus reduce the plasma levels of cortisol and testosterone.</p>
<p>Adverse reactions: The drug can cause headache, gastric irritation, allergic reactions, gynecomastia (due to impairment of testosterone synthesis) and acute hepatic necrosis. It is a CYP3A4 inhibitor and inhibits the metabolism of many drugs such as warfarin, phenytoin and combination OC pills.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>As a topical antifungal agent (Chapter 71).</li>
<li>Familial testotoxicosis (gonadotropin independent activation of Leydig cells)</li>
<li>Cushing's syndrome; and</li>
<li>Prostatic cancer</li>
</ul>
<p>Because of its poor efficacy and toxicity, it has now been largely replaced by itraconazole and fluconazole. It is relatively much cheaper.</p>
<p>ITRACONAZOLE: This broad spectrum antifungal drug, related to ketoconazole, exerts both topical and systemic activity. It is given orally or IV. However, its bioavailability is variable. It is metabolised mostly in the liver ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>30</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 30-40 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span> ) to its active metabolite. It is both a substrate for and a potent inhibitor of CYP3A4. It does not appear in the urine or the CSF and unlike ketaconozole it does not inhibit the production of steroids.</p>
<p>Itraconazole is well tolerated except for GI disturbances at 200 mg daily. Serious toxicity like cardiac arrhythmias may result from drug interactions. Other ADR include hepatotoxicity, skin rash, hypokalemia and with IV use, CHF in patients with impaired ventricular function.</p>
<p>It is administered in the dose of 200 mg OD for oropharyngeal and esophageal candidiasis and also for subungual onychomycosis. It is the drug of choice for indolent, nonmeningeal invasive aspergillosis and mild to moderate true pathogenic fungal infections. Larger doses for longer periods (6-12 months) are required to treat these deep fungal infections.</p>
<p>FLUCONAZOLE: This triazole derivative undergoes complete absorption and is effective both, orally and by IV infusion. It has plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">25-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> hours and is given once daily. Its bioavailability is not affected by food or gastric pH . It penetrates readily into the CSF. Unlike itraconazole, almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the drug is eliminated in the urine unchanged. It inhibits CYP3A4, CYP2C9 and CYP2C19. However, drug interactions are uncommon unless patient is on high dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily) or has elevated fluconazole levels due to azotemia.</p>
<p>Because of fewer hepatic enzyme interactions and GI disturbances, it is preferred to itraconazole in the treatment of severe/widespread dermatophytosis, local and systemic candidiasis and cryptococcal infections including meningitis. It is not active against aspergillosis, mucormycosis and other true pathogenic fungi. It is less effective against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>. glabrata and C. krusei. It is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once daily orally or by IV infusion. A loading dose is needed on the first day of therapy. In dermatophytosis, 150 mg once or twice a week needs to be given for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">4-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> weeks.</p>
<p>The drug may cause headache, nausea, GI disturbances, abnormalities of liver enzymes and at high doses, alopecia, muscle weakness and skin rash.</p>
<p>POSACONAZOLE, an oral triazole, is related chemically to itraconazole. It is particularly useful in prevention and treatment of invasive fungal infections, including aspergillosis, and oropharyngeal candidiasis refractory to fluconazole. It is preferred to amphotericin-B for the treatment of zygomycete infection. It is available as suspension and its bioavailability is increased by food. It has a long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo stretchy="false">(</mo><mn>25</mn><mo>−</mo><mn>31</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}(25-31 \mathrm{hrs})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.138em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">31</span><span class="mord"><span class="mord mathrm">hrs</span></span><span class="mclose">)</span></span></span></span></span>, a large volume of distribution and high protein binding. It undergoes glucuronidation Majority of administered drug undergoes faecal excretion.</p>
<p>It is well tolerated. Like itraconazole, it inhibits CYP3A4. It is used in the dose of 200 mg qid initially, followed by 400 mg bid for 25 days.</p>
<p>VORICONAZOLE: It has structural similarity to fluconazole but has an expanded spectrum. It is active against fluconazole resistant candida (including C. glabrata and C. krusei) and is a drug of choice in invasive aspergillosis. Both oral and IV formulations are available. Oral drug is given either 1 hour before or 1 hour after meals as high-fat meals reduces its bioavailability. Given orally, voriconazole undergoes extensive tissue distribution and crosses CSF barrier. It is metabolised by CYP2C19, CYP2C9, and CYP3A4; the metabolites are excreted in urine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 6 hrs ). The drug and its major metabolite inhibit these enzymes and interact with many drugs which get metabolised by these CYPs. Voriconazole exhibits nonlinear metabolism and dose should be reduced in patients with liver failure.</p>
<p>Voriconazole is generally well tolerated but can cause hepatotoxicity, skin rashes (including photosensitivity) and prolongation of QTc interval. With IV infusion, transient visual or auditory hallucinations and anaphylactoid reactions may occur. Omeprazole and voriconazole increase each other's concentrations in plasma and hence omeprazole dose needs to be reduced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> when initiating voriconazole therapy.</p>
<p>It is given as IV infusion, as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 12 hours for two doses, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 12 hours. Oral dose is 200 mg every 12 hours. It is an expensive drug.</p>
<p>Isavuconazole, a produção, releases active triazole. It is under evaluation for deeply invasive candidiasis and aspergillosis.</p>
<p>TERBINAFINE: This synthetic allyl-amine is kertophillic like griseofulvin but is fungicidal. It acts by inhibiting the enzyme squalene epoxidase and blocking ergosterol biosynthesis. The accumulated squalene is cytotoxic. It is effective orally and topically. It is extensively metabolised in the liver. Oral treatment with 250 mg daily has been reported to cure onychomycosis in about 12 weeks as against 18 months required by griseofulvin. Topically, it is used to treat dermatophyte infections of the skin. It is available as nail lacquer for onychomycosis! It is generally well tolerated. Adverse effects include GI distress, headache and rash.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="echinocandins">Echinocandins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#echinocandins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CASPOFUNGIN: This agent belongs to a group of new antifungals called echinocandins. Unlike the azoles, it acts on the fungal cell wall to block the synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">\beta 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord">1</span></span></span></span></span> (1-3) glucans. It is fungicidal and is effective in infections with C. albicans and Aspergillus fumigatus. It is not absorbed orally. Given IV, it is highly bound ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">97%</span></span></span></span></span> ) to albumin and is metabolised by the liver. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 10 hours. It is given once daily. The drug is well tolerated. The adverse reactions reported are local phlebitis, headache, nausea, fever and rash. It may cause hypercalcemia and is embryotoxic. Currently, it is used in the treatment of serious, invasive candidiasis and aspergillosis, and appears to be as effective as amphotericin B. It is very expensive.</p>
<p>Micafugin and anidulafugin are other echinocandins.
Table 50.2 outlines the choice of antifungal agents in superficial fungal infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-50-2">Table 50.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-50-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="choice-of-anti-fungal-agents">Choice of anti-fungal agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-anti-fungal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Type of infection</th><th style="text-align: left;">Drug/s preferred</th></tr></thead><tbody><tr><td style="text-align: left;">Tinea pedis/cruris</td><td style="text-align: left;">Topical azoles</td></tr><tr><td style="text-align: left;">Tinea corporis</td><td style="text-align: left;">Oral azole/Terbinafine</td></tr><tr><td style="text-align: left;">Onychomycosis</td><td style="text-align: left;">Terbinafine/topical etinaconazole/oral azole; Griseofulvin</td></tr><tr><td style="text-align: left;">Cutaneous candidiasis</td><td style="text-align: left;">Topical azoles/nystatin</td></tr><tr><td style="text-align: left;">Vulovaginal candidiasis</td><td style="text-align: left;">Topical azoles/nystatin; Fluconazole (oral single dose); if required 7 days course</td></tr><tr><td style="text-align: left;">Oral candidiasis</td><td style="text-align: left;">Topical nystatin or amphotericin B; Systemic fluconazole (in immunocompromised patients)</td></tr><tr><td style="text-align: left;">Oesophageal candidiasis</td><td style="text-align: left;">Systemic fluconazole; Echinocandin; newer triazoles if indicated</td></tr></tbody></table>
<p>For invasive fungal infection, see text</p>
<p>51</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-principles-of-chemotherapy-of-infections">General Principles of Chemotherapy of Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-principles-of-chemotherapy-of-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Infections still remain a major problem in medical practice; and their rational treatment with drugs is of prime importance. Since many therapeutically effective antimicrobials are now available and more are being added, it is necessary to lay down certain guiding principles for tailoring a rational therapeutic regimen for an individual patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="selection-of-antimicrobial-agent">Selection of Antimicrobial Agent<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#selection-of-antimicrobial-agent" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The choice of an antimicrobial agent is decided by:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-host-related-factors">I Host-related factors:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-host-related-factors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Age of the patient: Certain drugs like chloramphenicol may cause serious toxic effects in infants in whom liver enzymes/renal function are not fully developed.</li>
<li>Pregnancy and neonatal period: Most antimicrobial agents cross the placenta and can reach therapeutic concentrations in fetal tissues. Hence, they should be used during pregnancy only when it is a must. Penicillins, cephalosporins, erythromycin, (except estolate which is hepatotoxic), lincomycin, clindamycin, azithromycin, INH, ethambutol and probably sulfonamides (for short term) can be safely used in pregnancy. As serious Gram-negative infections are common in the neonatal period, a bactericidal drug (a third generation cephalosporin) or a drug combination (gentamicin plus ampicillin) effective in Gram-negative infections is recommended for use during this period of life.</li>
<li>Immunocompetency status of the patient. Bactericidal agents are always to be preferred in immunocompromised patients.</li>
<li>Severity of the infection and general condition of the patient. Thus, a mild case of bacillary dysentery in an otherwise healthy individual will usually respond satisfactorily to ORT, while in severe cases, cotrimoxazole or a fluoroquinolone is necessary, in addition. A combination of bactericidal agents effective against a wide variety of organisms (Gram-positive and Gram-negative organisms as well as the anaerobes) is commonly used in patients with neutropenia. More aggressive treatment is needed in the presence of diabetes mellitus and in those taking corticosteroids.</li>
<li>History of previous allergic reaction or intolerance to the antimicrobial agent.</li>
<li>Hepatic and renal status: People over 80 have reduced hepatic and renal function (See later).
II Pathogen-related factors:</li>
<li>The probable causative organism and the expected clinical course of the infection:</li>
</ul>
<p>One must decide whether the given illness is likely to be due to a microorganism susceptible to one of the available antimicrobials. Antibiotics are not nonspecific antipyretics and their use in all cases of fever is to be deprecated. It should also be appreciated that many cases of fever such as due to common cold are due to viruses that are not susceptible to antibiotics. Routine use of antibiotics in such cases is not justified.</p>
<p>The choice of the antibiotic based on expectation of a particular micro-organism has been illustrated by reference to meningitis. (Chapter 48).</p>
<ul>
<li>Identification of the causative micro-organism and its sensitivity to antimicrobial drugs:</li>
</ul>
<p>Though ideal, this may not always be possible owing to lack of facilities. Light microscopy and subsequent culturing of the organism is useful. In certain cases e.g tuberculosis and viral infections, polymerase chain reaction (PCR) studies using tissue material e.g. pleural fluid, CSF etc. are valuable for detecting specific microbes.</p>
<ul>
<li>Possibility of drug resistance e.g. if the infection is due to drug resistant TB, malaria or Staphylococci, where alternative therapy with another antibiotic will have to be used.
III Drug-related factors:</li>
<li>Nature of the drug, (Table 51.1). Bactericidal drugs are always preferred to bacteriostatic agents. Carriers should be treated only with bactericidal drugs since bacteriostatic</li>
</ul>
<p>agents are not so effective in the absence of inflammation.</p>
<p>Table 51.1
Commonly used bactericidal and bacteriostatic drugs</p>
<table><thead><tr><th style="text-align: left;">Bactericidal</th><th style="text-align: left;">Bacteriostatic</th></tr></thead><tbody><tr><td style="text-align: left;">Penicillin</td><td style="text-align: left;">Sulfonamides</td></tr><tr><td style="text-align: left;">Aminoglycosides</td><td style="text-align: left;">Nitrofurans</td></tr><tr><td style="text-align: left;">Rifampicin</td><td style="text-align: left;">Erythromycin</td></tr><tr><td style="text-align: left;">Cephalosporins</td><td style="text-align: left;">Tetracyclines</td></tr><tr><td style="text-align: left;">Metronidazole</td><td style="text-align: left;">Chloramphenicol</td></tr><tr><td style="text-align: left;">Cotrimoxazole</td><td style="text-align: left;">Lincomycin</td></tr><tr><td style="text-align: left;">Fluoroquinolones</td><td style="text-align: left;">Trimethoprim</td></tr></tbody></table>
<ul>
<li>Risk of drug toxicity, particularly in the presence of cardiac, liver or kidney damage. The risk involved in using a more toxic drug in preference to less effective but less toxic agent is justified only if the infection is severe.</li>
<li>Pharmacokinetic properties of the drug e.g., oral/parenteral; tissue penetration; metabolism; duration of action; and its elimination.</li>
<li>The cost of therapy: This is particularly important where many equally effective drugs are available for a given infection. An antibiotic should not be selected simply because it is 'the latest'. Newer drugs are always costly and not necessarily better than established ones; and</li>
<li>Drug compliance by the patient (Chapter 4).</li>
</ul>
<p>Although bacterial sensitivity tests give important information, they are neither necessary nor practicable in daily practice. Sometimes, they can even be misleading and hence, the physician should use his clinical judgement in selecting the antibiotic and not depend blindly on the results of such tests. It must be realised that the organisms isolated by the bacteriologist may not be the prime cause of the disease under treatment. This is particularly so in case of organisms cultured from sputum and feces. Similarly, the sensitivity data obtained from in vitro studies do not necessarily hold true in vivo. Bacterial sensitivity tests, however, are useful in selecting a proper regimen in chronic diseases like respiratory or urinary tract infections, resistant Staphylococcal infections, endocarditis, chronic osteomyelitis, and resistant TB.</p>
<p>Many drugs are metabolised by the liver to inactive products and although these metabolites accumulate in the presence of renal failure, they are not so harmful (Table 51.2). In contrast to this, other antimicrobial drugs (Table 51.3) are removed almost entirely by the kidney and accumulate in the blood in the active form in patients with impaired renal function. Many of these agents e.g. aminoglycosides are highly effective against Gram negative organisms but are also capable of producing nephrotoxicity and neurotoxicity. If these drugs are to be used in the presence of renal damage, they should be used in reduced doses, as guided by the plasma creatinine level. In such patients therapeutic drug monitoring (TDM) may be useful.</p>
<p>Table 51.2
Antimicrobials cleared by non-renal mechanisms</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Erythromycin
</span>    - Chloramphenicol
    - Doxycycline
    - Rifampicin
    - Cefaperazone and
    - Ceftriaxone</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Erythromycin
    - Chloramphenicol
    - Doxycycline
    - Rifampicin
    - Cefaperazone and
    - Ceftriaxone" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Table 51.3
Antimicrobials eliminated by renal excretion</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Penicillins
</span>    - Aminoglycosides
    - Most cephalosporins
    - Fluoroquinolones
    - Polymyxins
    - Colistin
    - Amphotericin B; and
    - Amantadine</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Penicillins
    - Aminoglycosides
    - Most cephalosporins
    - Fluoroquinolones
    - Polymyxins
    - Colistin
    - Amphotericin B; and
    - Amantadine" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>In patients with impaired renal function, the maintenance dose of drugs, which are eliminated almost completely ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) by kidney can be calculated as follows:</p>
<p>The renal clearance of drugs like penicillins, aminoglycosides, most of the cephalosporins and tetracycline is reduced by the same proportion as the reduction from 100 ml per minute in the measured or calculated creatinine clearance. Creatinine clearance in adults can be estimated from serum creatinine by the Cockroft and Gault formula:</p>
<p>Creatinine clearance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{ml} / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span> in males <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span></p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mo stretchy="false">(</mo><mn>140</mn><mo>−</mo><mtext>&nbsp;Age&nbsp;</mtext><mo>−</mo><mtext>&nbsp;in&nbsp;year&nbsp;</mtext><mo stretchy="false">)</mo><mo>×</mo><mtext>&nbsp;Weight&nbsp;</mtext><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><mrow><mn>72</mn><mo>×</mo><mtext>&nbsp;Serum&nbsp;creatinine&nbsp;</mtext><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow></mfrac></mrow><annotation encoding="application/x-tex">\frac{(140-\text { Age }- \text { in year }) \times \text { Weight }(\mathrm{kg})}{72 \times \text { Serum creatinine }(\mathrm{mg} / \mathrm{dl})}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.363em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">72</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">&nbsp;Serum&nbsp;creatinine&nbsp;</span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mopen">(</span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">&nbsp;Age&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">&nbsp;in&nbsp;year&nbsp;</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">&nbsp;Weight&nbsp;</span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>In females, multiply the figure obtained, by 0.85 . Creatinine clearance is corrected to 1.73 square meter body surface area (BSA). Thus, if the serum creatinine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> in a 50 year old male who weighs 60 kg , then his calculated creatinine clearance is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. It should be corrected to BSA of 1.73 square meter. The maintenance dose of the above drugs then equals: corrected creatinine clearance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mn>100</mn><mi mathvariant="normal">x</mi></mrow><annotation encoding="application/x-tex">/ 100 \mathrm{x}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/100</span><span class="mord mathrm">x</span></span></span></span></span> the usual daily maintenance dose.</p>
<p>However, the first dose in such patients should be the same as the initial dose used in a patient with normal renal function (loading dose). In the case of penicillin G, no adjustment is required if the daily dose is 1.2 mega units or less; it is required in case massive doses are being used. It is beyond the scope of this book to give detailed instructions about dose adjustment for each antimicrobial drug in renal impairment. The manufacturer's instructions should be consulted for this purpose. However, the following generalisations can be made:</p>
<ul>
<li>Antibiotics like ampicillin, cloxacillin, carbenicillin and other</li>
</ul>
<p>penicillins can be used safely but need substantial reduction in dosage, in patients with chronic kidney disease.</p>
<ul>
<li>The tetracyclines increase protein catabolism. Further, accumulation of protein metabolites in the uraemic patient would make the condition worse. The disturbance in protein metabolism may result in liver failure. It is advisable, therefore, to avoid tetracyclines (except doxycycline) in chronic kidney disease.</li>
<li>Fluoroquinolones can accumulate in the presence of renal damage and need dose adjustment.</li>
<li>The renal excretory mechanisms in neonates and in premature infants are not well developed. Hence, antimicrobials which are essentially excreted by the kidney tend to accumulate in such cases, leading to toxic effects. The doses of these drugs for newborns and premature infants should therefore be reduced and spacing between doses increased compared to those advocated for adults (See also Chapter 80).</li>
<li>The elderly have diminished renal function, and antimicrobials which are disposed of largely by the kidneys should be administered in reduced doses.</li>
<li>It takes longer to reach a steady state if the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is prolonged due to renal damage e.g. amoxicillin and gentamicin.
Antimicrobials of choice in various infections are given in Table 51.4.</li>
</ul>
<p>Table 51.4</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-drugs-of-choice">Antimicrobial drugs of choice<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-drugs-of-choice" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th style="text-align: center;">Organism</th><th style="text-align: center;">Antimic</th><th style="text-align: center;">Agents</th></tr></thead><tbody><tr><td style="text-align: center;">First choice</td><td style="text-align: center;"></td><td style="text-align: center;">Other effective drugs</td></tr><tr><td style="text-align: center;">Actinomyces lwoeli thovisi</td><td style="text-align: center;">Penicillin-G, Amoxicillin</td><td style="text-align: center;">Tetracycline, Erythromycin, Clindamycin</td></tr><tr><td style="text-align: center;">Anaerobes tather than Clostridial</td><td style="text-align: center;">Metronidazole, Penicillin-G, Cefoxitin, Carbapenems, Ampicillin + Sulbactam, Piperacillin + Tacobactam</td><td style="text-align: center;">Chloramphenicol, Clindamycin</td></tr><tr><td style="text-align: center;">Bacillus anthracis</td><td style="text-align: center;">Ciprofloxacin, Doxycycline</td><td style="text-align: center;">Clindamycin + Rifampicin, Penicillin G</td></tr><tr><td style="text-align: center;">Bordetella pertussis</td><td style="text-align: center;">Azithromycin</td><td style="text-align: center;">Cotrimoxazole, Erythromycin, Clarithromycin</td></tr><tr><td style="text-align: center;">Brucella</td><td style="text-align: center;">Doxycycline + Streptomycin/Gentamicin</td><td style="text-align: center;">Doxycycline + Rifampicin Cotrimoxazole + Rifampicin Ciprofloxacin + Rifampicin</td></tr><tr><td style="text-align: center;">Candida albicans</td><td style="text-align: center;">Fluconazole, Voriconazole</td><td style="text-align: center;">Echinocandine, Nystatin</td></tr><tr><td style="text-align: center;">Chlamydia trachomatis</td><td style="text-align: center;">Azithromycin</td><td style="text-align: center;">Ofloxacin, Doxycycline Erythromycin</td></tr><tr><td style="text-align: center;">Clostridium difficile</td><td style="text-align: center;">Metronidazole, Vancomycin</td><td style="text-align: center;">Nitazoxanide, Bacitracin, Panidic acid, Rifasimin</td></tr><tr><td style="text-align: center;">Clostridia tetani</td><td style="text-align: center;">Penicillin-G, Metronidazole</td><td style="text-align: center;">Clindamycin</td></tr><tr><td style="text-align: center;">Corynebacterium diphtheriae</td><td style="text-align: center;">Procaine Penicillin, Erythromycin</td><td style="text-align: center;">Rifampicin, Clindamycin</td></tr><tr><td style="text-align: center;">Donoram bodies of granuloma inguinale</td><td style="text-align: center;">Azithromycin, Doxycycline</td><td style="text-align: center;">Erythromycin, Cotrimoxazole, Chloramphenicol, Norfloxacin</td></tr><tr><td style="text-align: center;">Enterococcus, Streptococcus faecalis</td><td style="text-align: center;">Penicillin-G/Vancomycin + Gentamicin</td><td style="text-align: center;">(Ampicillin + Sulbactam) + Imipenem, (Ampicillin + Sulbactam) + Ceftriaxone Linezolid, Daptomycin</td></tr><tr><td style="text-align: center;">Escherichia coli</td><td style="text-align: center;">Fluoroquinolones</td><td style="text-align: center;">Amoxicillin + Clavulanic acid, Amikacin, Cephalosporin, Tigecycline, Polymyxin B</td></tr><tr><td style="text-align: center;">Fusaspinuchotes</td><td style="text-align: center;">Penicillin-G</td><td style="text-align: center;">Erythromycin, Clindamycin, Metronidazole</td></tr><tr><td style="text-align: center;">Gardenella vaginalis</td><td style="text-align: center;">Metronidazole</td><td style="text-align: center;">Clindamycin</td></tr><tr><td style="text-align: center;">Haemophilus ducreyi</td><td style="text-align: center;">Azithromycin</td><td style="text-align: center;">Fluoroquinolone, Erythromycin, Ceftriaxone</td></tr><tr><td style="text-align: center;">Haemophilus influenzae</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporin</td><td style="text-align: center;">Fluoroquinolones, Chloramphenicol, Amoxicillin + Clavulanic acid, Azithromycin</td></tr><tr><td style="text-align: center;">Klebsiella pneumoniae in serinonly ill patients</td><td style="text-align: center;">Imipenem, Amikacin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporin, Cotrimoxazole</td></tr><tr><td style="text-align: center;">Legionella pneumoniae</td><td style="text-align: center;">Azithromycin/Clarithromycin Fluoroquinolones</td><td style="text-align: center;">Doxycycline, Cotrimoxazole</td></tr><tr><td style="text-align: center;">Mycoplasma pneumoniae</td><td style="text-align: center;">Azithromycin/Clarithromycin Fluoroquinolones</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporin Doxycycline</td></tr><tr><td style="text-align: center;">Micrococcus catarrhalis</td><td style="text-align: center;">Cotrimoxazole</td><td style="text-align: center;">Amoxicillin, Erythromycin, Tetracycline, Cephalosporin</td></tr><tr><td style="text-align: center;">Neisseria gonorrhoeae</td><td style="text-align: center;">Ceftriaxone, Cefixime, Doxycycline/Azithromycin</td><td style="text-align: center;">Cephalosporin (Cefotaxime, Ceftizoxime, Cefotetan) + Probenecid Spectinomycin</td></tr><tr><td style="text-align: center;">Neisseria meningitidis (intracellularix)</td><td style="text-align: center;">Penicillin-G, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporin</td><td style="text-align: center;">Carbapenem, Chloramphenicol</td></tr><tr><td style="text-align: center;">Yersenia pestis</td><td style="text-align: center;">Streptomycin, Doxycycline</td><td style="text-align: center;">Cotrimoxazole, Chloramphenicol Gentamicin, Ciprofloxacin</td></tr><tr><td style="text-align: center;">Francisella tularensis</td><td style="text-align: center;">Gentamicin, Chloramphenicol</td><td style="text-align: center;">Ciprofloxacin, Doxycyline, Levofloxacin</td></tr><tr><td style="text-align: center;">Pneumocystis jiroveci</td><td style="text-align: center;">Cotrimoxazole</td><td style="text-align: center;">Trimethoprim + Dapsone, Atovaquone, Clindamycin + Primaquine, Pentamidine, Trimethopir + Leucovorin</td></tr><tr><td style="text-align: center;">Proteus mirabilis and Proteus vulgaris</td><td style="text-align: center;">Amikacin, Cotrimoxazole, Imipenem</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporin</td></tr><tr><td style="text-align: center;">Pseudomonas aeruginosa</td><td style="text-align: center;">Ceftazidime, Cefepime Amikacin + (Carbenicillin &lt;br&gt; Carbapenem/Piperacillin)</td><td style="text-align: center;">Fluoroquinolones</td></tr><tr><td style="text-align: center;">Rickettsiae</td><td style="text-align: center;">Doxycycline</td><td style="text-align: center;">Chloramphenicol, Erythromycin</td></tr><tr><td style="text-align: center;">Salmonella typhi</td><td style="text-align: center;">Fluoroquinolones, Chloramphenicol</td><td style="text-align: center;">Cefoperazone, Ceftriaxone, Cotrimoxazole, Amoxicillin, Azithromycin</td></tr><tr><td style="text-align: center;">Shigella</td><td style="text-align: center;">Ciprofloxacin</td><td style="text-align: center;">Azithromycin, Ceftriaxone, Premecilinum</td></tr><tr><td style="text-align: center;">Spirillum minus</td><td style="text-align: center;">Penicillin-G</td><td style="text-align: center;">Streptomycin, a Tetracycline</td></tr><tr><td style="text-align: center;">Staphylococcus aureus</td><td style="text-align: center;">Semiline to penelilin &lt;br&gt; Penicillin-G &lt;br&gt; Semiline to methicillin &lt;br&gt; Methicillin &lt;br&gt; MRSA: Vancomycin &lt;br&gt; VRSA: Linezolid, Tigecycline</td><td style="text-align: center;">Semiline to methicillin Nalcilin, Oxacillin &lt;br&gt; MRSA: Daptomycin, Quetipristin + Daltepristin</td></tr><tr><td style="text-align: center;">Streptococcus pneumoniae</td><td style="text-align: center;">Penicillin-G, Amoxicillin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation Cephalosporins, Fluoroquinolones, Azithromycin, Doxycycline</td></tr><tr><td style="text-align: center;">Streptococcus pyogenes</td><td style="text-align: center;">Penicillin-G or V</td><td style="text-align: center;">Cephalosporin, Erythromycin Azithromycin, Clindamycin</td></tr><tr><td style="text-align: center;">Streptococcus viridans</td><td style="text-align: center;">Penicillin G alone or with (Gentamicin or streptomycin)</td><td style="text-align: center;">Cephalosporin, Vancomycin</td></tr><tr><td style="text-align: center;">Toxoplasma gondii</td><td style="text-align: center;">Sulfadiazine + Pyrimethamine, Clindamycin</td><td style="text-align: center;">Atovaquone + Pyrimethamine Spiramycin, Cotrimoxazole</td></tr><tr><td style="text-align: center;">Treponema pallidum</td><td style="text-align: center;">Penicillin-G</td><td style="text-align: center;">Doxycycline, Ceftriaxone, Azithromycin</td></tr><tr><td style="text-align: center;">Vibrio cholerae</td><td style="text-align: center;">Doxycline, Tetracycline</td><td style="text-align: center;">Cotrimoxazole, Chloramphenicol, Fluoroquinolone, Azithromycin</td></tr></tbody></table>
<p>The selected drug should be given in adequate doses for a sufficient period depending upon the type of case. In majority of the uncomplicated acute infections and even in certain chronic conditions, orally effective, relatively nontoxic and inexpensive drugs should be preferred. Drugs such as chloramphenicol, rifampicin and co-trimoxazole have such reliable oral absorption that parenteral therapy is seldom indicated. Parenteral therapy is inconvenient to the patient, is more expensive, and needs medical supervision.</p>
<p>It should be reserved for:</p>
<ul>
<li>Emergency and serious cases with bacteremia/shock.</li>
<li>Patients who cannot take oral therapy or in whom the drugs are not likely to be absorbed orally; and</li>
<li>Those in whom the organisms have developed resistance to orally used drugs.
In the management of obstructive lesions, necrotic and pyogenic infections such as abscesses, empyema, surgical drainage may be necessary for effecting a complete cure.</li>
</ul>
<p>Drugs used commonly to treat infections with common Gram negative anaerobes are listed in Table 51.5.</p>
<p>Table 51.5
Drugs used to treat infections with common Gram negative anaerobes</p>
<table><thead><tr><th style="text-align: left;">- Metronidazole</th></tr></thead><tbody><tr><td style="text-align: left;">- Fluoroquinolones</td></tr><tr><td style="text-align: left;">- Ticarcillin-clavulanic acid</td></tr><tr><td style="text-align: left;">- Piperacillin-tazobactam</td></tr><tr><td style="text-align: left;">- Imipenem</td></tr><tr><td style="text-align: left;">- Monobactams</td></tr><tr><td style="text-align: left;">- Ampicillin-sulbactam</td></tr></tbody></table>
<p>Community associated MRSA is now frequently found, which is a cause of skin and soft tissue infections. These organisms are resistant to fluoroquinolones. Oral agents preferred in these conditions are clindamycin, doxycycline/minocycline, linezolid and cotrimoxazole, which are to be given for 5-10 days. Rifampicin is used only in combination with other agents. In patients with severe systemic illness, parenteral agents like vancomycin, daptomycin, ceftaronil fosamil, telavancin and tigecycline are used.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-combinations">Antimicrobial Combinations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-combinations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Simultaneous use of two or more antimicrobial agents is not routinely recommended. These drugs may, however, be combined under certain circumstances for the following reasons:</p>
<ul>
<li>To achieve an additive or synergistic effect against a single organism: True antibiotic synergism is rare and the enhanced therapeutic activity observed following certain combinations is usually an additive effect. Penicillin is combined with streptomycin in bacterial endocarditis due to streptococci. Brucellosis responds better to rifampicin + tetracycline combination than to tetracycline alone. A combination of gentamicin with carbenicillin acts synergistically against pseudomonas infection. It should be noted, however, that for a given antibiotic combination the dose of the individual antibiotic needed to accomplish synergism varies according to the type of organism.</li>
<li>In mixed infections with bacteria sensitive to different drugs: Penicillin or metronidazole is combined with an aminoglycoside in peritonitis to control certain aerobes as well as anaerobes.</li>
<li>To delay the development of or to overcome the drug resistance as in chronic infections like tuberculosis and malaria (see Chapters 54, 56).</li>
<li>To decrease the adverse reactions to an individual drug, another agent may be added so that the doses of each drug can be reduced and possible dose-dependent toxicity avoided. e.g. flucytosine + amphotericin B.</li>
<li>When etiological diagnosis is not known, the infection is severe and the body defence is poor (as in malnourished patients, chronic alcoholics, patients with chronic renal failure, immunosuppressed patients and in neutropenic patients), empirical combined antimicrobial therapy may be given in order to cover a range of organisms. However, in such cases, the appropriate regimen should be instituted as soon as the organisms are identified.</li>
<li>For reducing the chances of superinfection: Long term tetracycline therapy is sometimes combined with antifungal agents to prevent the superinfection due to fungi such as monilia. Unfortunately, not all fungi are eliminated and even when the fungal population is decreased, diarrhoea may persist.
It is not possible to predict which combination will have a synergistic effect and which will be antagonistic. The laboratory data are not always applicable to the disease processes in humans.</li>
</ul>
<p>The bactericidal drugs more effectively attack the multiplying bacteria and hence, if a bacteriostatic drug is used along with a bactericidal agent, inhibition of bacterial multiplication may reduce the efficacy of the bactericidal agent. Combination of penicillin with chlortetracycline has been shown to produce antagonistic effect in pneumococcal meningitis. Significant antagonism occurs if patients are exposed to a broad spectrum bacteriostatic antibiotic before the institution of penicillin therapy. The presence of leucopenia may further compound the development of antagonism. Such antagonism between a bactericidal and a bacteriostatic drug is not always seen e.g., the action of penicillin is not antagonised but may be actually enhanced by addition of sulfonamides.</p>
<p>Combination of bacteriostatic drug with a bactericidal agent can cause:
(a) Drug antagonism: If the bacteria are highly sensitive to the bactericidal drug; or</p>
<p>(b) Additive effect: If the bacteria are relatively resistant to the bactericidal drug.</p>
<p>Combining bacteriostatic drugs usually leads to an additive effect; but the effect may sometimes be synergistic as with the combination of sulfamethoxazole and trimethoprim.</p>
<p>Combination of bactericidal drugs among themselves may cause synergistic effect particularly with the drugs with different mechanisms of action. Thus, streptomycin or gentamicin added to penicillin has a synergistic effect in the treatment of enterococcal endocarditis. Further, a combination of either ampicillin or carbenicillin with an aminoglycoside has been shown to act synergistically against susceptible E. coli, Klebsiella, Proteus, Providencia and Pseudomonas. This is because penicillin promotes the entry of the aminoglycoside through the microbial cell wall. A combination of ampicillin and clavulanic acid acts synergistically since the latter drug inhibits beta-lactamase production by the organisms and thus protects ampicillin.</p>
<p>Combined antibiotic therapy involves certain risks. These are:</p>
<ul>
<li>Emergence of organisms resistant to the multiple drugs used,</li>
<li>Increased risk of adverse reactions,</li>
<li>Increased risk of superinfection by resistant organisms,</li>
<li>Sense of false security which may lead to incomplete evaluation and inadequate therapy of the patient; and</li>
<li>Increase in the cost of therapy.</li>
</ul>
<p>As a rule, antimicrobials should not be combined for purpose of synergy unless therapeutic results with one of the drugs is known to be unsatisfactory or proven to be so in a given patient. When indicated, the best known combination should be selected. Readymade combinations should not be used routinely, as they do not allow adequate doses of the major drugs and it is difficult to make dose adjustment of individual drugs. Furthermore, one should be critical of the combinations recommended on the basis of laboratory evaluation or inadequately conducted clinical trials.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-prophylaxis">Antimicrobial Prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Use of antimicrobials in prophylaxis of certain diseases is well established. It must be remembered, however, that a drug which can cure a disease does not necessarily prevent it. Antimicrobials are not likely to be useful in chemoprophylaxis, if they are given as a blanket cover to prevent colonisation by various organisms in the internal and external environments of a patient. They are, however, useful when used as single specific agents to prevent or destroy the infection due to specific organisms. Further, short term prophylaxis is more likely to be successful than prolonged prophylaxis because resistant organisms are likely to emerge during prolonged prophylaxis. Circumstances where such chemoprophylaxis may be useful are:</p>
<ul>
<li>For preventing meningococcal infection in healthy children during an epidemic; for prevention of diseases like syphilis, gonorrhea, malaria, filariasis and bacillary dysentery. Syphilis in newborn can be prevented by treating the mother during pregnancy. Immunocompromised patients with neutropenia as in AIDS benefit from chemoprophylaxis.</li>
<li>For preventing endocarditis following minor surgical procedures like tonsillectomy or tooth extraction in patients with cardiac lesions, for preventing repeated attacks of streptococcal infection particularly in patients with history of rheumatic fever, and for preventing recurrent UTI.</li>
<li>For preventing invasion of blood stream by pathogens during certain surgical manipulations, e.g., catheterisation in patients with UTI, colonic surgery. Routine prophylaxis in all ordinary operative procedures is unnecessary. Such prophylaxis is, however, useful in surgery of the GI tract, biliary tract, uterus, and vagina; in joint replacement; and in open heart surgery. Prophylaxis should be started not more than 2 hours before surgery and should not be continued for more than 48 hours after surgery in majority of cases.</li>
<li>In patients with compound musculo-skeletal injury, penetrating wounds and skull injuries with rhinorrhea and otorrhea.</li>
<li>For those puncture wounds that are at high risk for infection, e.g., contaminated wounds, deep wounds, wounds to the forefoot and wounds in individuals with diabetes mellitus or peripheral vascular disease.</li>
<li>Animal and human bites, as they are at high risk for infection by the oral flora.</li>
<li>To prevent microbial complications like bronchopneumonia, e.g., in severe cases of measles and tetanus.</li>
<li>Given orally for preventing the development or worsening of coma in hepatic failure, where they act by inhibiting the intestinal organisms which produce ammonia.</li>
<li>In comatose or paralytic states to prevent aspiration bronchopneumonia, e.g., in poisoning cases. However, routine use of prophylactic antibiotics in all unconscious patients is of no benefit and may cause adverse effects.
Routine prophylactic antimicrobial therapy to prevent secondary infection in conditions like mild viral upper respiratory infections in children, in congestive heart failure and in the newborn delivered after prolonged labour, is not of any benefit. The indiscriminate prophylactic use of antibacterial agents may cause adverse and allergic reactions, produce resistant organisms and cause superinfection due to other nonsusceptible pathogens. As</li>
</ul>
<p>pointed out in an editorial in the Lancet "the unwarranted use of antibiotics and particularly broad-spectrum antibiotics in a mistaken prophylactic attempt is a sin and it would be wise to 'avoid not only the sin but also the occasions of sin' by better understanding of the epidemiology of Gram negative bacteria and the application of aseptic and other methods designed to prevent these bacteria colonising or infecting patients."</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="microbial-drug-resistance">Microbial Drug Resistance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#microbial-drug-resistance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug resistance is not a characteristic of all bacteria and many strains responsible for common infections have largely remained susceptible to antibiotics e.g. pneumococci, Streptococcus pyogenes, meningococci, and Treponema pallidum. The host defense, environmental factors and the properties of the drug used influence the development of bacterial resistance to a drug.</p>
<p>Bacterial resistance is often quantitative and not qualitative. Thus, an antibacterial agent which is not effective in small doses may inhibit the bacteria in vitro in large concentrations. This, however, may not be of much clinical significance as such high levels can rarely be achieved in vivo owing to possible toxicity. High concentrations may, however, sometimes be used for treating resistant local infections.</p>
<p>Bacterial resistance can be:
(1) Natural; or
(2) Acquired</p>
<p>In organisms which are naturally resistant, (1) the drug sensitive enzyme reactions may be absent. (2) The drug may fail to reach the target due to permeability barrier or absence of transport mechanisms or presence of efflux pumps. (3) Some naturally resistant organisms may elaborate a substance which destroys the antibiotic e.g. E. coli produce beta lactamase which destroys penicillin. Following the use of an antimicrobial agent which destroys the sensitive strain, these naturally resistant variants multiply and become dominant.</p>
<p>The development of acquired microbial resistance can be demonstrated in vitro by serially culturing the organism in increasing concentrations of an antimicrobial drug. Organisms thus made resistant in vitro usually again become susceptible to the drug following their serial subculture in the drug free medium. On the other hand, the organisms which are naturally resistant or those which develop resistance after exposure to the drug in vivo usually retain this property.</p>
<p>Microbes acquire resistance after a change in their DNA. Such change may occur by:</p>
<ul>
<li>Genetic mutation i.e. by alteration in the structure of their own DNA; or more commonly,</li>
<li>Genetic exchange i.e. by acquisition of extra-chromosomal DNA from other bacteria.</li>
</ul>
<p>In genetic mutation, the resistance is of a low level, to a single drug, and involves nonenzymatic mechanisms such as decreased permeability to the antibiotic e.g. methicillin resistance of Staph. aureus. Such resistance is not transferable to other bacteria. In some cases, the mutant bacteria even possess the capacity to multiply in the presence of higher concentrations of the drug concerned e.g. streptomycin-resistant mutants.</p>
<p>Genetic exchange is the most important cause of serious clinical drug resistance because it can produce epidemic resistance to multiple drugs. In genetic exchange, the resistance genes are transferred from one bacterial species to another by means of discrete, movable, extrachromosomal DNA elements called plasmids. The plasmids that encode for resistance to anti-microbial drugs are called R-plasmids or R-factors. A plasmid can reproduce itself and in the case of plasmid transfer, the replicating plasmid donates one copy to the new recipient cell while the donor plasmid retains its own copy. Transfer of R-plasmids between bacteria can occur by</p>
<ul>
<li>Conjugation, i.e., direct physical mating between bacteria;</li>
<li>Transduction, i.e., through the agency of bacteriophages;</li>
<li>Transformation where resistance genes from chromosomes may be transferred directly through a sex pilus without the mediation of a vector (plasmid or phage). Examples of microbes where such transfer is seen are streptococci, pneumococci, and some species of hemophilus, clostridia and bacteroids; and</li>
<li>Transposition occurs independent of R-plasmids. Resistance determinants (transposons) have the ability to 'hop' from one plasmid to another plasmid, or to a chromosome, or to a bacteriophage. After entry into the host cell, the plasmid and the phage may be lost, leaving the transposons permanently in the plasmids or the chromosomes of the host cell. Since transposons may carry multiple resistances, the recipient bacteria can acquire resistance to multiple drugs.
Plasmid (R-factor) and/or transposon mediated resistance results in:</li>
<li>Decreased bacterial cell wall permeability to the antibiotic, e.g., resistance to penicillin and chloramphenicol.</li>
<li>Active extrusion of the antibiotic from the bacterial cell, e.g., resistance to tetracycline.</li>
<li>Extracellular inactivation of the antibiotic, e.g., enzymatic degradation or modification of penicillin, cephalosporins, aminoglycosides and chloramphenicol by resistant strains.</li>
<li>Intracellular inactivation of a small amount of the antibiotic; this inactivated part then binds to the bacterial ribosomes and prevents them from taking up the active drug e.g., resistance to aminoglycosides.</li>
<li>Change in the bacterial ribosomes which are no longer susceptible to the action of the antibiotic e.g., resistance to macrolides.</li>
<li>Synthesis of a drug-resistant enzyme in place of the drug-sensitive enzyme in the biosynthetic pathway of the bacterial cell e.g., resistance to sulfonamides and trimethoprim.
Fortunately, in the absence of further exposure to the drug involved, the R-factor mediated resistance is often spontaneously lost within weeks or months of its acquisition. In contrast, the resistance due to genetic mutation is liable to be permanent.</li>
</ul>
<p>R factors are found in intestinal bacteria, especially in E. coli, Enterobacter aerogenes, K. pneumoniae, Salmonella, Shigella, Proteus, and Pseudomonas. Since R factors can be transferred from one bacterial species to another, regardless of pathogenicity, they can be transferred from resistant E. coli to Salmonella or Shigella within the human bowel. In the case of some bacteria the R-factor may carry up to 8-10 different R-determinants, each responsible for resistance to a different drug.</p>
<p>Clinically, resistant Gram negative bacteria carrying R factors present a serious problem because their resistance to multiple drugs can spread in epidemic proportions.
Widespread outbreaks of bacillary dysentery caused by multiple drug-resistant (MDR) Shigellae have been reported from Japan, Bangladesh and South America; many of these Shigella strains carried R factors. In Mexico, MDR Salmonella typhi produced the worst epidemic of typhoid fever in modern history; and MDR resistant S. typhi strains have been isolated from India. Transferable drug resistance is frequent in Gram negative bacilli causing urinary infections.</p>
<p>The other examples of microbes where plasmid mediated transfer is known to occur are pneumococci, penicillin resistant H.influenzae and N. gonorrhoeae.</p>
<p>Organisms that become resistant to one drug may exhibit cross resistance to other related compounds, e.g., cross resistance is seen between kanamycin and neomycin, between erythromycin and triacetyloleandomycin.</p>
<p>It is known that resistance genes and plasmids were present in bacteria even before the advent of antibiotics. They would appear to be one of the mechanisms of natural selection and survival of the bacteria. It is likely that in their struggle for survival in nature, the bacteria (those nonpathogenic to humans and even those which are naturally present in animals) may develop resistance genes. Unfortunately, these genes can then be transferred to the human pathogens with disastrous results. Further, the excessive and indiscriminate use of antimicrobials in humans in the hospitals and in the community and in animals, has encouraged the development of resistance and has now posed a major problem. Thus, many hospital strains of staphylococci, certain strains of E. coli and pseudomonas have become resistant to multiple commonly used antimicrobial agents.</p>
<p>Table 51.6 lists the various ways of avoiding the development of antimicrobial resistance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-51-6">Table 51.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-51-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="how-to-avoid-development-of-antimicrobial-resistance">How to avoid development of antimicrobial resistance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#how-to-avoid-development-of-antimicrobial-resistance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Use antibioticsonly when necessary.</li>
<li>Select the appropriate antibiotic and use it for an adequate period of time.</li>
<li>Use a drug combination when it is known to delay the development of drug resistance (e.g., treatment of tuberculosis). However, remember that incidence of bacterial resistance parallels the number of antibiotics used in a given patient.</li>
<li>Regular monitoring of drug resistance pattern in hospitals and the community, and recommending changes in prescribing to avoid the spread of resistant organisms.</li>
<li>Establishing hospital committee for prescription audit and suggesting guidelines for antimicrobial usage.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dangers-of-antimicrobial-therapy">Dangers of Antimicrobial Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dangers-of-antimicrobial-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antimicrobials are the most useful life-saving agents in therapeutics. But, they are potentially harmful. The harmful effects are:</p>
<ul>
<li>Development of allergic and anaphylactic reactions. Hence, antibiotics such as penicillin which are very useful for systemic infections must not be used locally.</li>
<li>Selective toxicity such as aplastic anemia or nephrotoxicity, the toxicity being more serious than the disease being treated.</li>
<li>Development of superinfection</li>
<li>Development of multi-drug-resistant (MDR) organisms</li>
<li>Deficiency of certain vitamins, e.g., vitamins K and folic acid because of the destruction of nonpathogenic bacteria in the intestine which synthesise these vitamins.</li>
<li>Fetal damage by transplacental passage of certain antimicrobials.</li>
<li>A false sense of security in the patient as well as the physician, leading to the neglect of the need to establish the exact diagnosis. Similarly, strict asepsis may be neglected by a surgeon who relies too much on antimicrobials.
Superinfections are defined as new infections that occur during chemotherapy of primary infection. They are manifested by new clinical symptomatology usually related to intestinal, renal and respiratory tracts or to blood stream. The organisms most commonly encountered are Staphylococci, C. albicans, E. coli, Proteus and Pseudomonas. Some of the superinfections can be dangerous and may cause fatal results, e.g., resistant Staphylococcal enterocolitis and systemic fungal infections. The mechanisms are given in Table 51.7.</li>
</ul>
<p>Table 51.7
Mechanisms of development of superinfection</p>
<ul>
<li>Eradication of susceptible organisms in a patient with a mixed infection leaving the resistant strains to multiply.</li>
<li>Destruction of normal nonpathogenic bacterial flora, thus creating a bacterial vaccum leading to overgrowth of resistant organisms, and</li>
<li>Colonisation of the lesion with resistant exogenous organisms from the environment.</li>
</ul>
<p>Superinfections are usually related to the dose and duration of antimicrobial therapy. Further, they occur more frequently when large doses of two or more drugs are given simultaneously. Infants, patients with pulmonary diseases, diabetics and immunocompromised patients (such as with AIDS) are more prone to get superinfections.</p>
<p>Failure to respond to antimicrobial therapy: When a patient does not respond to antibiotic therapy, the case should be reviewed with a view to answer the questions listed in Table 51.8.</p>
<p>Table 51.8
Failure of antimicrobial therapy - why?</p>
<ul>
<li>Was an antibiotic really necessary?</li>
<li>Is the right antibiotic being used?</li>
<li>Is the bacterial strain isolated really responsible for the illness? Or, is a previously unsuspected infection present?</li>
<li>Is the antibiotic being given in adequate doses and by proper route?</li>
<li>Is the antibiotic reaching the site of infection?</li>
<li>Is drainage necessary?</li>
<li>Does the patient have resistant organisms or a superinfection?</li>
<li>Is the fever due to the underlying disease, a drug reaction or an iatrogenic complication such as phlebitis?</li>
<li>Is diabetes mellitus or AIDS present?</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="misuse-of-antimicrobial-agents">Misuse of Antimicrobial agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#misuse-of-antimicrobial-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The present total consumption of antimicrobials in relation to the known incidence of infections is very much in excess, indicating that antimicrobials are often misused. This obviously would create many problems as discussed above.</p>
<p>The various conflicting advertised claims of superiority of one antibiotic over the older established drugs used for similar purpose should be critically evaluated before accepting the change in established prescribing practice. Thus, cotrimoxazole may work out to be as effective and safe as and cheaper than a cephalosporin or a fluoroquinolone in the treatment of uncomplicated UTI or bacillary dysentry.</p>
<p>From the many antimicrobials now available, one needs to know only the important representatives of each class. It is suggested that the family physician familiarises himself/herself thoroughly with the use of the following drugs for day-to-day practice: cotrimoxazole, penicillin, ampicillin/amoxicillin, erythromycin, doxycycline, gentamicin/amikacin, ciprofloxacin and metronidazole.</p>
<p>Once started, the drug must not be changed without valid reasons. Too large or too low a dosage should be avoided as it may either produce toxicity or cause bacterial resistance. If any adverse effect is observed during the therapy, the drug should preferably be withdrawn instead of using another compound to suppress toxicity. Antibiotics are not antipyretics and they should not be used routinely in all fever cases without understanding their nature, simply with the hope of attacking the targets which we do not see to give 'quick benefits' of chemotherapy</p>
<p>52</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-urinary-tract-infections">Chemotherapy of Urinary Tract Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-urinary-tract-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Urinary Tract Infection (UTI) is a common disorder at all ages and in both sexes. A healthy and normal urinary tract is generally resistant to infection. However, for anatomical reasons, the female lower urinary tract is more susceptible to infection. In every patient with recurrent UTI, it is essential to look for a predisposing cause, especially diabetes mellitus, congenital anomalies and obstructive lesions. In at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of patients with UTI, a predisposing cause cannot be demonstrated inspite of adequate investigations.</p>
<p>UTI may present itself in acute or chronic form.
Acute infection: Infection localised to the urethra and bladder (cysto-urethritis, lower UTI) causes increased frequency and urgency of micturition, dysuria and pain in the perineum. Fever, chills and leucocytosis are generally absent. Such infections are generally self limiting. If the kidneys are also involved (pyelonephritis, upper UTI), the patient may have loin pain, fever, chills and leucocytosis. Urine is usually loaded with pus cells. Urine culture shows 'significant bacteriuria' (see later). Clinical distinction between bladder and renal infection is difficult and need special tests. UTI can cause septicaemia during pregnancy and puerperium, in patients on immunosuppressants and in those with lymphoproliferative disorders.</p>
<p>Inadequately treated acute UTI may lead to chronic pyelonephritis. Many patients with chronic infection, however, do not give a history of acute UTI.</p>
<p>Chronic infection: Patients with chronic infection may have few urinary symptoms unless renal failure has supervened, when polyuria and nocturnal frequency may be present. General loss of health and weight, anemia and hypertension are frequently present. It must be remembered that chronic pyelonephritis is an important cause of hypertension and chronic renal failure. The urine may show a few pus cells. Significant bacteriuria is demonstrable in most patients with active infection and is essential for diagnosis.</p>
<p>Patients having classical symptoms related to kidney infection, fever and pyuria, have definite bacterial invasion of the kidney. However, symptom-free patients with bacteriuria as well as those with symptoms related to the lower urinary tract may also have renal tissue involvement.</p>
<p>In infants and children, UTI often masquerades as fever of unknown origin, failure to thrive, unexplained vomiting or as vague abdominal pain. Hence, the diagnosis can be easily missed. Unlike in adults, it is difficult to distinguish between cystitis and pyelonephritis in this age group and hence, all UTI at this age should be treated as if they were pyelonephritis. Elderly patients with UTI may present with altered mental status and not with the usual signs and symptoms of UTI.</p>
<p>Pathogenesis and bacteriology: The bacteria commonly found in UTI originate in the rectum. Bladder infection in females is often preceded by the establishment of the infecting organisms in the vaginal introitus. From there, the organisms ascend to the urethra and the bladder. The few bacteria that normally gain access to the bladder are: (a) Washed out during urination.
(b) Inhibited in their growth by the low <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">(</mo><mn>5.5</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{pH}(5.5)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">pH</span></span><span class="mopen">(</span><span class="mord">5.5</span><span class="mclose">)</span></span></span></span></span>, the high urea content and the hyperosmolality of the urine; and</p>
<p>(c) Destroyed by a direct antibacterial action of the bladder mucosa.</p>
<p>Ninety-five percent of the cases of uncomplicated UTI in women are due to Gramnegative bacilli. E. coli is the commonest offender <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>80</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(80 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">80%</span><span class="mclose">)</span></span></span></span></span> and next to it are Proteus mirabilis, Klebsiella, Aerobacter and Pseudomonas aeruginosa, Enterococci, Streptococci and Staphylococci account only for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of cases. In men, Gram negative bacilli are responsible for about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of UTI, and E. coli causes less than half of the infections. Bacilli particularly involved include Proteus sp. and, to a smaller extent, Providencia sp. Gram positive organisms account for about a fifth of infections. Hospital infections are generally by organisms other than E. coli. Mixed infections are likely to be present in chronic cases, in diabetics, in those with obstructive uropathies and in those with indwelling bladder catheters. Such infections are more difficult to treat. Unusual microorganisms such as H. influenzae, Gardenella vaginalis may be suspected when a urine culture is negative but the patient has pyuria or persistent symptoms.</p>
<p>For chlamydia, see below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="significance-of-bacteria-in-the-urine">Significance of bacteria in the urine:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#significance-of-bacteria-in-the-urine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The normal urinary tract, except for the distal urethra, is sterile. A few bacteria may, however, be sometimes found even in properly collected urine of apparently healthy individuals. The most widely used method for identification of UTI is the quantitative culture (colony count) of urine. Colony counts equal to and above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">10^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span> per ml are designated as significant bacteriuria and are diagnostic of infection. Those below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>4</mn></msup></mrow><annotation encoding="application/x-tex">10^{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span></span></span></span></span></span></span></span></span> may be regarded as due to contamination. However, some women with acute cystitis may have more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>4</mn></msup></mrow><annotation encoding="application/x-tex">10^{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span></span></span></span></span></span></span></span></span> but fewer than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">10^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span> bacteria per ml of urine. A few apparently healthy individuals with normal urinary tract and those on corticosteroid therapy excrete in their urine bacteria in excess of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>5</mn></msup><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10^{5} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of urine. Such individuals are said to have asymptomatic bacteriuria. On the other hand women with frequency of urination, dysuria and pyuria due to urethritis (acute urethral syndrome) may have fewer than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">10^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span> bacteria per ml of urine or even a sterile urine on routine cultures (symptomatic abacteriuria). Many of them have gonococcal or chlamydial urethritis.</p>
<p>Investigations of a case of UTI:</p>
<ul>
<li>Urine obtained by midstream technique or by suprapubic bladder puncture is examined bacteriologically and isolated microorganism tested for its sensitivity to various antibacterial drugs.
However, the in vitro drug sensitivity of bacteria does not always correlate with the clinical response. The definition of significant bacteriuria applies to urine obtained by midstream technique. Any growth at all from urine obtained by bladder puncture is pathological. Catheterisation of the bladder for collection of urine is totally unjustified as it may lead to dangerous infection.</li>
</ul>
<p>Pre-treatment urine culture is not required in the first attack in young women with dysuria and pyuria, and without a known underlying abnormality of the urinary tract; such attacks can be treated straightaway as if they are due to E. coli. Urine culture should be done only if the UTI is recurrent!</p>
<p>In pregnant women incidence of bacteriuria is high and may cause growth retardation in fetus. Asymptomatic bacteriuria can also progress to pyelonephritis. Hence regular screening is required.</p>
<p>UTI is uncommon in men under the age of 50 years in the absence of an underlying</p>
<p>structural abnormality of the urinary tract or obstructive lesions. Children with UTI often have underlying congenital lesions including vesicoureteral reflux. Urine culture should always be done for these patients. In such patients:</p>
<ul>
<li>Diabetes mellitus must be ruled out.</li>
<li>Detailed urological investigation is mandatory for all men and in children with single attack and in women who get more than two recurrences in one year to detect parenchymal disease.</li>
<li>Infective focus in the prostate should be ruled out in men with UTI.</li>
</ul>
<p>Even a single UTI infection is a potentially serious condition and failure to treat it may lead to development of serious chronic pyelonephritis, hypertension and renal failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-uti">Drug Therapy of UTI<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-uti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Goals for the treatment of UTI are:
(a) To eradicate the infecting organisms.
(b) To provide symptomatic relief by altering the pH of urine and/or giving phenazopyridine.
(c) To prevent and treat recurrence; and
(d) To identify and treat predisposing factors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general-principles-of-therapy">General principles of therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-principles-of-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In acute cases, an appropriate drug may be started as soon as the urine has been collected for bacteriological examination. When the results of drug sensitivity of the pathogen grown are available, another drug may be substituted for the first one, if necessary. Although the symptoms are relieved quickly, the pyuria takes a longer time to clear.</li>
<li>In chronic cases, mixed infection is more likely and concomitant renal failure may modify drug therapy. In such cases, there is no desperate hurry to start drug treatment before the case is thoroughly investigated.</li>
<li>It must be noted that the significant infection is in the tissues and not in the luminal urine alone. This means that for successful treatment, the drug must achieve adequate concentration in the tissues as well as in the urine. Further, the effects of the antimicrobial agent on the vaginal flora are also important in the lasting eradication of bacteriuria. The concentration of trimethoprim and fluoroquinolones in the vaginal secretions is high enough to eradicate the E. coli while nitrofurantoin and beta-lactams are not effective. Bactericidal drugs are to be preferred for treatment.</li>
<li>The drug must be used in adequate doses and for adequate periods. The last dose should be given immediately before retiring, having emptied the bladder completely. This is important because the diminished urinary flow and frequency at night encourage bacterial growth. Duration of treatment will differ with the stage of the disease.</li>
<li>All pregnant women should be screened for bacteriuria in the first trimester and should be treated, if found, to reduce their increased risk of acute pyelonephritis, premature delivery and low birth weight newborn. In such cases, a 7-14 day course is recommended. Follow-up is necessary in order to detect a recurrence.</li>
<li>The growth of E. coli is optimum at pH 5.0 to 6.0 and is inhibited at pH below 5.5 and above 7.5. Alkalinisation of the urine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>H</mi><mo>&gt;</mo><mn>7.5</mn></mrow><annotation encoding="application/x-tex">p H&gt;7.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.5</span></span></span></span></span> ) must also be maintained at a level that would permit optimum antibacterial activity of the drug used and would prevent crystalluria in the case of sulfonamides. Alkalinisation also helps to reduce irritation of the urinary tract. Adequate alkalinisation is achieved by the administration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">2 \mathrm{~g}(1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mopen">(</span><span class="mord">1/2</span></span></span></span></span> teaspoon) of sodium bicarbonate, sodium citrate or potassium citrate, 4-6 times a day. Alkalinisation of urine enhances the antibacterial activity of penicillins, erythromycin and aminoglycosides.</li>
<li>It must be emphasised that infections due to proteus and sometimes other coliforms, Staph. albus and some diphtheroids, give rise to alkaline urine. This is because these organisms produce urease, an enzyme which splits urea to form ammonia. In such cases, acidifying drugs are ineffective and can cause fatality due to uncompensated acidosis and hence should not be used.</li>
<li>The fluid intake should be liberal as frequent emptying of the bladder (every 2-3 hours) helps to reduce the bacterial counts in the urine and as the growth of E. coli is reduced if the</li>
</ul>
<p>urine is very dilute.</p>
<ul>
<li>There is no satisfactory antibacterial drug to which all the strains of E. coli, the commonest causative organism, are invariably sensitive. Hence, the initial choice of the drug depends upon the relative cost and the known adverse effects of the drugs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-drugs">Classification of drugs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Bacteriostatic agents such as Sulfonamides, Doxycycline and Nitrofurantoin.
II Bactericidal agents such as Cotrimoxazole, Ampicillin, Extended spectrum penicillins, Aminoglycosides, Fluoroquinolones, Cephalosporins and Azithromycin.</p>
<p>Urinary antiseptics are the drugs which act as antibacterial agents only in the urinary tract e.g. Nitrofurantoin, Methenamine mandelate and Nalidixic acid.</p>
<p>SULFONAMIDES: Though sulfonamides are bacteriostatic against most of the common urinary pathogens including E. coli and produce effective urine and tissue levels, development of bacterial resistance is the major problem (Chapter 45). Hence, cotrimoxazole has replaced sulfanomides.</p>
<p>COTRIMOXAZOLE: This combination of sulfamethoxazole and trimethoprim (Chapter 45) is a potent and cost-effective bactericidal agent against many common urinary tract pathogens especially E. coli and Proteus species but not Pseudomonas. In acute uncomplicated UTI, it is used in the dose of 2 tablets bid for 7-10 days. In smaller doses (as low as one tablet twice a week) it has been claimed to be effective in eliminating chronic bacteriuria. As trimethoprim has been reported to be teratogenic in animals, cotrimoxazole should be avoided during pregnancy. Renal insufficiency leads to retention of trimethoprim and can alter the optimum 1:5 ratio of trimethoprim to sulfamethoxazole in urine. The fixed dose combination is, therefore, likely to be rendered less effective in renal insufficiency. As trimethoprim concentrates in the prostate much better than most other drugs, cotrimoxazole has been used successfully in eradicating the prostatic focus of infection, often responsible for recurrent UTI in adult men.</p>
<p>Trimethoprim alone 100 mg bid is also used.
DOXYCYCLINE: See Chapter 49.
AMPICILLIN: Ampicillin is effective both orally and parenterally. It is bactericidal to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span>. coli, Aerobacter, certain strains of Proteus and enterococci. Pseudomonas is resistant to it and it is ineffective against beta lactamase producing strains of Staph. aureus. It produces good tissue levels and is excreted unchanged in the urine in high concentrations. It is well tolerated.</p>
<p>When used in a dose of 0.5 g six hourly for 7-10 days, it eradicates majority of UTI due to E. coli. It is useful for treatment of UTI in pregnant women. However, many infections with E. coli, especially those acquired in the hospital are reported to be resistant to ampicillin. Amoxicillin-clavulanic acid or Ampicillin-sulbactum may be used if resistance is suspected.</p>
<p>CARBENICILLIN: In the dose of 1 gm IV four times a day, it is useful in Pseudomonas aeruginosa infection of the urinary tract in which it is combined with gentamicin. They must, however, not be mixed in the same vial or syringe because carbenicillin inactivates gentamicin (Chapter 46). It is now replaced by piperacillin.</p>
<p>PIPERACILLIN: It has a broad spectrum of activity against Gram negative organisms, especially Ps. aeruginosa. It is given IV in divided, daily, adult doses of 4-8 g for moderate infections in persons with normal renal function; the dose is raised to 12-16 g/day in life</p>
<p>threatening infections. It can be combined with gentamicin with synergistic effects. It is particularly useful in patients with renal impairment where aminoglycosides are to be avoided. Its use should be limited to severe UTI with life threatening septicemia (Chapter 46). Piperacillin-tazobactum combination is used in drug resistant cases.</p>
<p>AMINOGLYCOSIDE ANTIBIOTICS: Gentamicin and amikacin are the aminoglycosides commonly used in UTI. They are effective against E. coli, Proteus and Pseudomonas. They have to be given parenterally and can cause ototoxicity and renal toxicity. The nephrotoxicity can be considerably reduced by giving the entire daily dose as a single dose. Their use is reserved for complicated UTI (Chapter 47).</p>
<p>FLUOROQUINOLONES: These are considered ideal agents for nosocomial pyelonephritis and complicated UTI. They are useful even if renal function is very low. The high tissue and urine concentrations even in acid urine far exceed the bactericidal concentrations against most pathogens including Pseudomonas (Chapter 45). However their extensive misuse has resulted in fluoroquinolone resistant organisms.</p>
<p>CEPHALOSPORINS: These drugs are valuable in infections with E. coli and Proteus resistant to other antibiotics. They are the drugs of choice in klebsiella infections. The third generation cephalosporins are particularly effective against multi-resistant enterobacteria and Pseudomonas resistant to other antibiotics. Cephalosporins are particularly indicated in septicemic UTI. (Chapter 48). They are ineffective against enterococci.</p>
<p>FOSFOMYCIN: See later. Also see Chapter 47.
CARBAPENEMS: These compounds are reserved for complicated UTI due to Pseudomonas and enterococci. They can be combined with aminoglycosides (Chapter 48).</p>
<p>MONOBACTUM: Aztreonam, active against Gram-ve organisms including Pseudomonas is given for nosocomial infection where aminoglycosides are to be avoided.</p>
<p>AZITHROMYCIN: It is commonly used for chlamydial urethritis.
NITROFURANTOIN: Given orally, it achieves high urinary concentration but poor tissue levels (due to extensive protein binding). It is, therefore, unsuitable for treatment of renal parenchymal infections. It is mainly bacteriostatic against common urinary pathogens. Most strains of Pseudomonas and some strains of Proteus are resistant (Chapter 45). It is not recommended for acute UTI.</p>
<p>Nitrofurantoin given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for several weeks to months is useful as 'chronic suppressive therapy'.</p>
<p>As nitrofurantoin is mainly excreted by glomerular filtration and tubular secretion, it is not effective and more toxic in the presence of kidney damage. It is mainly useful in infections which are resistant to other, more commonly used drugs and in patients with mixed infections or infection accompanied by obstructive uropathy. It is generally safe in pregnancy.</p>
<p>Nitrofurantoin exhibits therapeutic antagonism with nalidixic acid.
METHENAMINE MANDELATE: (Mandelamine): This drug is a salt of mandelic acid and methenamine, and combines the antibacterial properties of both the drugs. It is rapidly absorbed from the GI tract and is excreted in urine. At an acid pH of less than 5.5, methenamine liberates formaldehyde which acts against many Gram negative pathogens and C. albicans. Mandelic acid helps to lower the urine pH . The drug is not effective against:
(1) Upper urinary tract infections as it is washed down too rapidly for therapeutic amounts of</p>
<p>formaldehyde to be generated;
(2) Proteus and pseudomonas species; and
(3) Acute infections.</p>
<p>However, it may be of some value in chronic suppressive therapy.
The drug is available as 500 mg and 1 g tablets. It is used in a dose of 500 mg four times a day.</p>
<p>Adverse reactions: Except gastric discomfort, they are rare. Bacteria do not develop resistance to it. It should not be used along with sulfamethizole as the latter drug forms an insoluble precipitate with formaldehyde. Large doses can cause acute inflammation of the urinary tract.</p>
<p>NALIDIXIC ACID: This drug, available in 0.5 g tablets, is sometimes used for chemoprophylaxis in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> per day (Chapter 45).</p>
<p>Choice of therapy: Choice of antibacterial therapy of UTI is determined by:</p>
<ul>
<li>The site of the infection.</li>
<li>Whether a predisposing cause such as diabetes mellitus or an abnormality of the urinary tract is absent (uncomplicated UTI) or present (complicated UTI); and</li>
<li>Whether the infection is caused by drug-sensitive or drug-resistant organisms.</li>
</ul>
<p>Factors influencing the choice of therapy are shown in Table 52.1. Lower UTI is often an uncomplicated infection whereas upper UTI is commonly a complicated infection in this sense.</p>
<p>Table 52.1
Choice of therapy in UTI</p>
<ul>
<li>The patient: Site of infection in urinary tract, symptomatic or not, age, sex, pregnancy, first attack or a recurrence, underlying abnormality of the urinary tract, renal function, and associated diseases such as diabetes mellitus.</li>
<li>The organisms (expected or isolated): Their identity, single or multiple species and their drug sensitivity.</li>
<li>The drug: The route of administration, cost, and adverse effects.</li>
</ul>
<p>Generally, fluoroquinolones should be reserved for complicated and resistant UTI; they should not be used routinely in uncomplicated UTI for fear of emergence of drug resistance. Misuse of fluoroquinolone has already resulted in resistance reporting. Cotrimoxazole and fluoroquinolones should be avoided during pregnancy (Chapter 80).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-lower-uti">Treatment of Lower UTI<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-lower-uti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute uncomplicated cystitis-urethritis: The first attack in a young, healthy woman is treated by three-day antibiotic therapy which reduces the rectal carriage of Gram negative bacteria and is not associated with increased recurrence rate in UTI. It appears optimum. Fluoroquinolones are not recommended as first line empirical treatment of uncomplicated cystitis. They are used if organisms are confirmed. Cotrimoxazole is perhaps the best initial choice for empirical therapy in a non-pregant woman. It is cost-effective and relatively safe. When low resistance to E. coli is known, nitrofurantoin 100 mg bid for 5-7 days is equally effective. More expensive alternative is fosfomycin 3 g as a single dose. The regimens used are shown in Table 52.2.</li>
</ul>
<p>Table 52.2
Suggested oral antimicrobial regimens (for 3 days or 7-14 days) for acute uncomplicated cystitis</p>
<ul>
<li>Cotrimoxazole 2 tablets bid.</li>
<li>Trimethoprim100 mg bid.</li>
<li>Nitrofurantoin 100 mg bid. ( 50 mg bid if wt <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;50 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) for 7 days.</li>
<li>Ampicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> qid.</li>
</ul>
<p>Three day therapy provides complete symptomatic relief but may not achieve 100% bacteriological cure. Extension of therapy to 7-14 days achieves both clinical and bacteriological cure. It is indicated in:</p>
<ul>
<li>Failure of the 3 day regimen</li>
<li>Symptomatic men</li>
<li>Recurrences in both men and women</li>
<li>Elderly (age more than 65 years)</li>
<li>Symptoms persisting more than 7 days</li>
<li>Pregnant women</li>
<li>Children and</li>
<li>Patients with underlying renal disease, urinary tract obstruction/abnormalities and diabetes mellitus.
Although a single dose cotrimoxazole, ampicillin/amoxicillin or fosfomycin has been used to treat first attack of UTI, such therapy gives low cure rate and leads to frequent recurrences. In addition, a single dose antibiotic regimen fails to eradicate Gram negative bacteria from the rectum, the major reservoir for recruitment of ascending uropathogens. Hence it is not recommended.</li>
</ul>
<p>In pregnant woman with cystitis, amoxicillin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> clavulanic acid), cephalexin, cefodoxime, ceftibuten and nitrofurantoin are treatment options. Single dose therapy with fosfomycin tromethamine ( 3 g ) has been advocated for uncomplicated, first attack of infection in a pregnant woman. Follow-up urine culture is done 1 to 2 weeks after treatment and then monthly until delivery.</p>
<ul>
<li>Recurrent infection manifested by repeated bacteriuria usually within 2 weeks of apparently successful treatment, is caused by the same organism which caused the first infection. In such patients, hidden source of infection or a urological abnormality should</li>
</ul>
<p>be looked for. The use of diaphragm, spermicides and vaginal tampons has been associated with recurrences in some patients. Recurrence should be documented by a culture at least once before starting therapy. Such women should receive treatment for at least 4-6 weeks with either co-trimoxazole or a fluoroquinolone. Other expensive alternatives are: amoxicillin + clavulanic acid; a third generation cephalosporin such as cefixime or cefpodoxime proxetil. It is important to eliminate the vaginal colonisation by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span>. coli.
In patients with suspected prostatic focus of infection, drugs like trimethoprim, erythromycin (for Gram positive bacteria), fluoroquinolones, doxycycline and aminoglycosides are recommended. Despite prolonged (6-12 weeks) therapy with these agents, failure rates in men with chronic bacterial prostatitis are usually 30-40%. It should be remembered that nonbacterial prostatitis is far commoner than proven bacterial prostatitis. The entity is diagnosed by evidence of prostatic inflammation with genitourinary symptoms but negative cultures of urine and prostatic fluid. Its cause is unknown.</p>
<p>Where bacteriuria cannot be eradicated, chronic suppressive therapy with 1 tablet of cotrimoxazole or 50-100 mg of nitrofurantoin once daily can suppress symptomatic infection. Trimethoprim alone should be avoided for suppression for fear of development of drug resistance.</p>
<ul>
<li>Chronic persistent infection may be obvious (pyuria and bacteriuria in the presence of an indwelling catheter, bladder stone) or may present itself only with chronic ill health and even renal failure; children show stunted growth as well. In such patients, only acute symptomatic infections should be treated with one of the 7-14 day regimens given above. Long term continued administration of antibacterial agents only leads to the emergence of drug resistant organisms. Attempt should be made to discontinue the catheter prior to starting antimicrobial therapy. If indwelling urinary catheter cannot be discontinued then catheter should be changed if the previous catheter is greater than 2 weeks old. Further, the indwelling catheters should be used sparingly.</li>
<li>Asymptomatic bacteriuria: Asymptomatic bacteriuria is often transient and resolves without treatment. The available data do not support routinely treating all men with asymptomatic bacteriuria. Treatment is appropriate (i) before genitourinary instrumentation in patients with congenital or acquired abnormality of the genitourinary tract; (ii) in infection with microorganisms with special virulence such as urea-splitting bacteria; and (iii) in immunocompromised host. Neutropenic patients with asymptomatic bacteriuria are treated for 6 weeks.
However, children and pregnant women with asymptomatic bacteriuria must be treated adequately to prevent chronic renal infection.</li>
<li>Post-coital cystitis: Some women seem to get a lower UTI following every sexual intercourse and in some of them it may produce symptoms. Such a patient should be initially treated by a full course of a suitable antibacterial drug. Following this, she should be advised to apply <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> cetrimide cream to the periurethral area before coitus and to empty her bladder immediately after the sexual act. This may be followed by a single dose of ampicillin 250 mg , nitrofurantoin 100 mg or a cotrimoxazole tablet after each coitus.
Acute urethral syndrome in women is often due to chlamydial infection. Its treatment is discussed in Chapter 53.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-upper-uti">Treatment of Upper UTI<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-upper-uti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is usually due to the same pathogens that cause lower UTI but is a more serious condition.</p>
<ul>
<li>Acute pyelonephritis is commonly associated with a predisposing factor such as obstructive uropathy or diabetes mellitus (complicated UTI). The patient may be septicaemic and severely ill. Urine and blood cultures are mandatory before starting the therapy; the results are helpful in modifying the initial therapy which is started without waiting for the culture report. The drugs used in mild cases are: ciprofloxacin 500 mg bid; cotrimoxazole 2 tablets bid; amoxicillin-clavulanate 500 mg bid or ampicillin 1-2 g orally or IV (especially in infection due to enterobacter); or a cephalosporin (Chapter 48). The duration of treatment is 10-21 days or occasionally even longer.
If fever and flank pain persist after 3 days of therapy, urine culture should be repeated and ultrasonography should be carried out to rule out a perinephric or intrarenal abscess, or an anatomical abnormality. Follow up urine culture is recommended after 2 weeks of therapy. In pregnant women, a parenteral cephalosporin and/or an extended spectrum penicillin are indicated.</li>
</ul>
<p>In severely ill patients and in those with recurrent, complicated UTI, empirical IV treatment should be started with:
(a) a Fluoroquinolone;
(b) a Carbapenem; or
(c) Piperacillin + Tozabactam or
(d) Cefotaxime/ceftriaxone 1 g IV followed by oral therapy with a fluoroquinolone.</p>
<p>The total duration of treatment is guided by urine culture and is usually longer than 21 days.</p>
<ul>
<li>Chronic pyelonephritis: This is a serious condition which can lead to chronic renal failure and secondary hypertension. An underlying cause such as obstruction must be carefully searched for. The antibacterial drug treatment must be prolonged and the choice of the drug is governed by the identity of the organisms and their drug sensitivity, and by the extent of renal impairment (see below).
It is difficult to treat. It is important to detect drug failure early so that an ineffective drug is discontinued; its continuation can only help superinfection with resistant organisms. In such cases, it may be better to use antimicrobials only during acute episodes. Suppressive therapy is rarely effective.</li>
<li>Renal impairment: Tetracyclines, except doxycycline, must be avoided in chronic renal failure. The dose of aminoglycosides and cephalosporins must be scaled down.
Nitrofurantoin and nalidixic acid do not achieve adequate urinary concentration in patients with renal failure.
Follow up: Successful treatment of an acute attack with an antibacterial agent leads to disappearance of bacteriuria within 24 hours; but pyuria and symptoms take longer to disappear. Post-treatment cultures are important in judging cure of the infection. Patients should be followed up for at least 6 months after treatment and urine cultures should be repeated at 1-2 month intervals. Cases with recurrent acute infection or with chronic infection need prolonged suppressive drug therapy (6-12 months) after the initial treatment. In such cases, follow up cultures should be done for about two years.</li>
</ul>
<p>Unarrested or repeated kidney infection not only leads to chronic pyelonephritis but also prevents the kidney growth in children. Results in children with kidney infections indicate that prophylactic antibiotics for UTI play a role especially in children with vesicoureteric reflux. Antibiotics maintain the urine sterile and prevent infections while awaiting spontaneous resolution of vesicoureteric reflux, which occurs over a time. Daily cotrimoxazole or trimethoprim or nitrofurantoin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) given for a prolonged period, reduces the incidence of pyelonephritis and helps to resotre the kidney growth. Nitrofurantoin is contraindicated in infants less than 3 months and in G6PD deficiency; cotrimoxazole should also be avoided in infant under 6 weeks and in G6PD deficiency. Trimethoprim or cephalexin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) is probably better and safer for this purpose. Older children with vesicoureteral reflux should be taught the practice of 'double micturition' to minimise residual bladder urine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-prophylaxis">Antimicrobial Prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is indicated:</p>
<ul>
<li>Following instrumentation of the urinary tract.</li>
<li>In patients with uncorrectable congenital anomalies of the urinary tract.</li>
<li>In patients with more than three symptomatic UTI attacks; and</li>
<li>In chronic prostatitis and pregnant women with asymptomatic bacteriuria.</li>
</ul>
<p>Cotrimoxazole, nitrofurantoin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tds) and ampicillin are the most commonly employed agents for this purpose. Nalidixic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{~g} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> and trimethoprim 100 mg OD have also been used. It must be remembered, however, that doses which are employed for long term suppressive therapy may not produce adequate tissue levels. Thus, although the urine may remain sterile, renal infection may continue to progress without being detected.</p>
<p>Short term catheterisation may be covered by giving the patient nitrofurantoin. Intermittent catheterisation carried out with aseptic precaution causes a lower incidence of bacteriuria than long-term indwelling catheterisation. During long term catheterisation, measures such as closed drainage are far more important than drugs.</p>
<p>PHENAZOPYRIDINE: This azo dye is used in the dose of 200 mg three times a day to relieve pain, burning, urgency and frequency associated with lower UTI. It does not act as a urinary antiseptic but can give symptomatic relief. The drug colours the urine red or orange and can stain clothing. Therapy with this drug is generally limited to one week.</p>
<p>53</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-sexually-transmitted-diseases">Chemotherapy of Sexually Transmitted Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-sexually-transmitted-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sexually transmitted diseases (STD) comprise a group of infections most commonly transmitted by sexual contact; accidental infection through fomites and infection of laboratory workers are rare modes of transmission. In the case of syphilis and AIDS, transplacental transmission to the foetus can occur.</p>
<p>Survey by WHO has indicated a worldwide rise in the prevalence of STD.
Permissiveness, homosexuality and changing sexual practices, particularly among the adolescents, are responsible for such increase in all societies, rich and poor. Hence, chemotherapy will continue to play an important role in their treatment. The concurrent presence of AIDS (HIV infection) complicates the management of STD by suppressing the immune system. Since more than one type of STD may commonly be present in a person at the same time, ideally all patients with suspected STD should be screened for HIV, syphilis, gonorrhoea and chlamydia. However, this is beyond the means of most third world countries.</p>
<p>The important STD are syphilis, gonorrhea, non-gonococcal urethritis (NGU), chancroid, lymphogranuloma venereum, granuloma inguinale, vaginitis, genital warts, genital herpes, AIDS (acquired immuno deficiency disease) and hepatitis B.</p>
<p>When concurrent, multiple, STD infection is suspected and laboratory facilities for making correct diagnosis are not available, it may be advisable to differentiate the disease into a few "Clinical syndromes" such as:</p>
<ul>
<li>Anogenital ulcer</li>
<li>Urethral discharge, dysuria and increased frequency (urethritis).</li>
<li>Vaginal discharge (vaginitis); and</li>
<li>Lower abdominal pain/dyspareunia (pelvic inflammatory disease, PID).</li>
<li>Warty lesion (genital warts).</li>
</ul>
<p>Each syndrome is then treated with multiple drugs to cover multiple pathogens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-syphilis">Drug Therapy of Syphilis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-syphilis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Syphilis is caused by the spirochete Treponema pallidum. Penicillin is the drug of choice for all stages of syphilis. With adequate treatment of early cases, almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of cases can be cured. Penicillin resistant T. pallidum is so far unknown.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinically-syphilis-manifests-as">Clinically, syphilis manifests as:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinically-syphilis-manifests-as" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Primary syphilis, characterised by genital or extra-genital, painless indurated ulcer (chancre), occurring within 3 weeks after the infection. This can be diagnosed easily by dark-field microscopy or direct fluorescent antibody test of the exudates.
(b) Secondary syphilis, characterised by skin and mucosal lesions occurring within 6 weeks to 6 months after the infection. This is diagnosed by serological tests (see below). Both these stages can resolve even without treatment.
(c) Latent syphilis is asymptomatic but with positive serological evidence. Early latency is diagnosed if the infection has been acquired within the preceding 1 to 2 years (WHO classification). After that, it is considered as late latency.
(d) Tertiary syphilis which manifests 4-5 years after the infection, and includes neurosyphilis (GPI, tabes dorsalis), cardiovascular syphilis and gummatous syphilis. This is called late syphilis.</p>
<p>There are several reasons for distinguishing between early (upto 4 years after infection) and late disease: 'Late syphilis' is not contagious but needs more prolonged treatment with higher doses of penicillin. Even with such doses, complete cure may not be possible. Moreover, Herxheimer reaction could be more severe, even leading to death. Reversal of positive serology to negative one is possible in early syphilis; it may not occur in late syphilis. Finally, syphilis is considered a great imitator, and almost every organ in the body can be affected.</p>
<p>Principles of therapy: The spirochete is extremely sensitive to penicillin, plasma concentrations as low as 0.03 unit per ml being spirocheticidal. The concentration must be continuously maintained (time dependent killing) for about 10 days in cases with early syphilis and about 14-20 days in late syphilis. The antibiotic is always given IM because orally given penicillin has two dangers:
(1) patients may not take the tablets regularly as advised and
(2) may try to save some tablets for self administered chemoprophylaxis in future.</p>
<ul>
<li>Before starting treatment, the diagnosis must be established with certainty. Dark-field microscopy of material from surface lesions is a must in the case of primary chancre and secondary syphilis. When surface lesions are absent, one has to rely on serological tests such as (1) Treponemal-specific tests such as T. pallidum particle agglutination test, fluorescent antibody-absorbed test (FTA-Abs. test); and (2) Nontreponemal tests such as Venereal Disease Research Laboratory (VDRL) test and Rapid Plasma Reagin (RPR) test. These tests may be false positive in less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of a non-infected population. A CSF examination is carried out only when CNS involvement is suspected.</li>
<li>Treated cases should be followed up for adequate period.</li>
<li>It is necessary to trace and treat contacts.</li>
</ul>
<p>Drugs therapy of syphilis :
I Primary and secondary syphilis (early syphilis) and early latent syphilis of less than one year's duration:</p>
<ul>
<li>Procaine penicillin 600,000 units IM daily for 10-15 days; or</li>
<li>Benzathine penicillin 2.4 mega units IM ( 1.2 mega units in each buttock) in a single dose. Benzathine penicillin is likely to be painful. Further, some patients may distrust such a regime consisting of a single injection, whereas others may take the disease lightly, knowing that it can be cured by a single injection.</li>
<li>Patients allergic to penicillin are treated with doxycycline 100 mg bid, or erythromycin 500 mg qid, on empty stomach, for 15-20 days. Single dose azithromycin is also claimed to be effective. Ceftriaxone may also be used.
All treated patients must be examined clinically and a quantitative serological test carried out at monthly intervals for three months, at three monthly intervals for one year, at six monthly intervals during the second year and at yearly intervals till the completion of four years from the beginning of the disease. The CSF must be examined at the end of the first year to rule out neurological involvement. If there is a relapse or a rise in the titre of the serological test, the penicillin course must be repeated.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-syphilis-except-neurosyphilis-of-more-than-one-year-s">II Syphilis (except neurosyphilis) of more than one year's<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-syphilis-except-neurosyphilis-of-more-than-one-year-s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>duration (late latent, and cardiovascular):
(a) Procaine penicillin 600,000 units IM daily for 15 days; or
(b) Benzathine penicillin 2.4 mega units IM once a week for 3 weeks.
(c) Patients allergic to penicillin should be treated with doxycycline 100 mg bid or erythromycin, 500 mg . orally, four times a day, on empty stomach for 30 days.
III Neurosyphilis: All clinical types of neurosyphilis are associated with CSF changes, and CSF cell count provides good monitoring for judging the effects of therapy. Ideally, penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>G</mi></mrow><annotation encoding="application/x-tex">G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">G</span></span></span></span></span> is given IV in the dose of 18-24 megaunits daily in 6 divided doses or as infusion, for 12-14 days. Alternatively, it may be treated with procaine penicillin 2-4 million units IM once a day, together with probenecid 500 mg . daily, for 10 days. Patients are followed clinically, serologically and with CSF examination at frequent intervals. The optimum duration of penicillin therapy for neurosyphilis is unknown. Persistently positive serology alone is not an indication for more treatment. If, however, the test becomes positive in a higher titre or if CSF abnormalities persist, treatment should be repeated.
Syphilis in HIV positive patients usually progresses rapidly and has higher risk of neurological complications and treatment failure.</p>
<p>Pregnancy and syphilis: Congenital syphilis is a completely preventable disease. Hence, syphilis detected during pregnancy should be treated with any of the regimes of penicillin described above for primary syphilis. Patients allergic to penicillin should be treated with erythromycin or ceftriaxone but not with tetracycline. Once a patient has received an adequate course of penicillin, she need not receive penicillin treatment during subsequent pregnancies.</p>
<p>Congenital syphilis detected in infants and children can be treated by injecting benzyl penicillin for 10 days. Interstitial keratitis, a complication of congenital syphilis, needs additional treatment with local or systemic glucocorticoids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions-and-contraindications-to-penicillin-treatment">Adverse reactions and contraindications to penicillin treatment:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions-and-contraindications-to-penicillin-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergy to penicillin is the only known contraindication to penicillin (Chapter 46).</li>
<li>Jarish-Herxheimer reaction: This consists of an initial exacerbation of lesions at any stage of syphilis following the first dose of a quick acting spirocheticidal drug like penicillin. Any reaction that occurs after subsequent injections of penicillin is unlikely to be due to Herxheimer phenomenon. This phenomenon is due to a rapid destruction of a large number of spirochetes with release of the endotoxin. It occurs in many cases of early syphilis, and leads to an aggravation of the mucocutaneous lesions and a mild systemic illness consisting of malaise, tachycardia and fever. Lymph nodes are enlarged and tender. It lasts for 2-6 hours and is harmless. The patient should, however, be forewarned about it as, otherwise, he might feel that wrong treatment was administered. The treatment with penicillin must be continued despite the reaction.
A sharp febrile reaction occurring within 24 hours of the use of penicillin in gonorrhoea suggests the possibility of concurrent syphilis as Jarisch-Herxheimer reaction is known to occur even in the incubation period of syphilis.</li>
</ul>
<p>In cardiovascular and neurosyphilis, however, a Herxheimer reaction may precipitate severe angina or CHF; and psychosis, convulsions, coma or optic atrophy respectively. Fatalities have occurred due to laryngeal edema or coronary occlusion.</p>
<p>Herxheimer reaction is an all or none phenomenon and cannot be prevented by starting treatment with small doses of penicillin. The first spirocheticidal dose is likely to precipitate it. An attempt can be made to prevent it in cardiovascular and late neurosyphilis by starting prednisolone in the single, daily dose of 30 mg in the morning, two days before starting penicillin. From the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>7</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">7^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day, the prednisolone dose can be tapered and the drug omitted with the end of penicillin therapy.</p>
<p>Other measures: In early syphilis, no other treatment than penicillin is required. Marriage is usually prohibited until four years have elapsed from the acquisition of the disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-gonorrhea">Drug Therapy of Gonorrhea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-gonorrhea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gonorrhoea is caused by gonococci, most strains of which remain sensitive to penicillin. Some strains, however, are known to be resistant to penicillin (penicillinase-producing N.gonorrhoeae, PPNG), tetracycline and spectinomycin. Quinolone resistance has now increased considerably.</p>
<p>Eradication of acute, uncomplicated gonococcal infection caused by penicillin sensitive organisms is relatively easy. When a local complication such as a periurethral abscess or prostatitis or a more distal complication such as salpingitis, parametritis or epididymoorchitis is present, or in case of penicillin resistant organisms, eradication of the infection is difficult.</p>
<p>Gonococcal infection is more difficult to diagnose and treat in females than in males. Further, acute pelvic inflammatory disease (PID) may be caused by other organisms (Chlamydia trachomatis, Mycoplasma hominins, vaginal flora including anaerobes, Gram negative organisms such as E. coli, and Group B streptococci) in addition to the gonococci; hence the treatment of acute PID must be undertaken with multiple drugs covering all the above potential pathogens.</p>
<p>Before starting chemotherapy, the diagnosis must be established by smear and culture of material obtained from the urethra and by prostatic massage in the males and the urethra, vagina, cervix or Bartholin's glands in the females. A quantitative gonococcal complement fixation test on patient's serum done at the beginning, serves as a guide to patient's progress after treatment.</p>
<p>Penicillin should be given first unless the patient is known to be allergic to it or harbours penicillin resistant gonococci. However, benzathine penicillin which gives low but prolonged plasma penicillin levels should not be used to treat gonorrhoea. Although doxycycline may be used to treat patients allergic to penicillin, it is ineffective against penicillin resistant gonococci.</p>
<p>An increasing number of organisms resistant to beta lactams and quinolones are being reported. Emergence of MDR organisms necess tates use of increasing doses of IM ceftriaxone or cefixime.</p>
<p>Acute uncomplicated cases: The various regimens used are given in Table 53.1. The response to treatment is usually prompt and dramatic. The patient should be advised abstinence from alcohol for about 2 weeks and sexual abstinence till he is cured.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-53-1">Table 53.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-53-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antimicrobial regimens for acute uncomplicated gonorrhoea</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>As NGU is known to be commonly associated with gonorrhoea, it is now recommended that any</p>
<p>of the above regimens should be followed by a 7 day course of doxycycline 100 mg twice a day or azithromycin 1 g single dose.</p>
<p>Complicated cases: The regimens shown in Table 53.2 have been recommended in gonorrhoea complicated by acute PID. The other measures that may be needed are: surgery, local irrigation with antiseptic lotions, local heat and prostatic massage.</p>
<p>Table 53.2
Antimicrobial regimens for gonorrhoea complicated by acute PID</p>
<ul>
<li>Procaine penicillin 2 mega units daily for 10 days plus doxycycline 100 mg bid for 14 days.</li>
<li>Cefoxitin IV 2 g every 6 hours plus doxycycline IV 100 mg every 12 hours continue drugs IV for at least 48 hours after substantial clinical improvement; then, continue doxycycline orally 100 mg bid to complete 14 days of total treatment.</li>
<li>Gentamicin IV or IM <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (loading dose) followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 8 hours (in patients with normal renal function) plus clindamycin 900 mg IV every 8 hours; 48 hours after the patient shows substantial clinical improvement, change over to oral doxycycline 100 mg 12 hourly, to complete 14 days of total treatment.</li>
<li>Ofloxacin orally 400 mg bid for 14 days plus clindamycin orally 450 mg qid for 14 days (or metronidazole orally 500 mg bid for 14 days). This regimen may be used in OPD patients.</li>
</ul>
<p>Table 53.3
Single dose regimens for treatment of STDs</p>
<table><thead><tr><th style="text-align: left;">Syphilis (early)</th><th style="text-align: left;">Benzathine penicillin 2.4 megaunits in two IM injections, one on each buttock once</th></tr></thead><tbody><tr><td style="text-align: left;">Gonorrhoea</td><td style="text-align: left;">See Table 53.1.</td></tr><tr><td style="text-align: left;">Chlamydial NGU</td><td style="text-align: left;">Azithromy cin 1 gm orally.</td></tr><tr><td style="text-align: left;">Chancroid</td><td style="text-align: left;">Azithromy cin 1gm or Ciprofloxacin 500 mg orally OR &lt;br&gt; Ceftriaxone 250 mg IM.</td></tr><tr><td style="text-align: left;">Trichomoniasis</td><td style="text-align: left;">Metronidazole 2 gm orally.</td></tr></tbody></table>
<p>Treated patients are followed up clinically, bacteriologically and serologically at frequent intervals for at least six months before they are declared as 'cured'. It must be remembered that, 'cure' is not synonymous with 'relief of symptoms'. The antibiotic course needs to be repeated if symptoms persist or recur or if the serum antibody titre rises during the follow up.</p>
<p>All patients treated for gonorrhea should be investigated regularly and frequently for the development of positive serological test for syphilis. This, however, is less practicable in practice where initial therapy with penicillin may mask the early manifestation of concomitant syphilitic infection. Therefore, penicillin should be used in full doses as recommended for syphilis, in all cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-non-gonococcal-urethritis-ngu">Drug Therapy of Non-Gonococcal Urethritis (NGU)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-non-gonococcal-urethritis-ngu" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Non-gonococcal urethritis may be due to:</p>
<ul>
<li>Infection with Trichomonas vaginalis (Chapter 58) or Mycoplasma genitalium.</li>
<li>A generalised urinary tract infection; or</li>
<li>Nonspecific urethritis: This common STD is caused by Chlamydia trachomatis in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the cases. The cause in the remaining cases is obscure. The patients complain of dysuria and a variable amount of urethral discharge; the disease shows a tendency to frequent recurrences. The diagnosis is by exclusion of gonococcal and trichomonal infections in cases of urethritis.
The treatment of choice is doxycycline 100 mg twice a day for 7 days. The macrolide, azithromycin, in the single oral dose of 1 g is highly effective and safe during pregnancy. The sexual partner of the patient should be treated at the same time to prevent a reinfection of the patient. During therapy, the patient should abstain from sexual intercourse and alcohol which may aggravate urethritis. For treatment of the newborn with conjunctivitis due to C.trachomatis, the drug of choice is systemic erythromycin for 14 Days.</li>
</ul>
<p>Erythromycin 500 mg six hourly for 7 days may also be effective but is likely to be inadequate for associated gonorrhoea. Azithromycin is also effective against M. genitalium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-lymphogranuloma-venereum">Drug Therapy of Lymphogranuloma Venereum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-lymphogranuloma-venereum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is a more invasive disease caused by chlamydia. Tetracycline 0.5 g six hourly or doxycycline 100 mg bid for 21 days is effective in curing the acute inguinal disease. In the chronic hypertrophic type, surgery may be needed in addition to tetracyclines for 6-8 weeks. Alternatively, erythromycin may be used. The prognosis in chronic cases is poor.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-chancroid">Drug Therapy of Chancroid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-chancroid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chancroid or soft sore is caused by H. ducreyi The diagnosis is made by clinical findings and a specific skin test.</p>
<p>The treatment of choice is erythromycin 500 mg qid for 7-10 days or azithromycin in the single, oral dose of 1 g . Alternative regimens are, cotrimoxazole 2 tablets bid for 7 days; or ciprofloxacin 500 mg bid for 3 days; or ceftriaxone 250 mg IM single dose. Ampicillin and tetracycline should not be used as resistance is likely to be present. In HIV positive patients, longer antibiotic courses are required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-granuloma-inguinale">Drug Therapy of Granuloma Inguinale<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-granuloma-inguinale" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Granuloma inguinale is caused by Calymmatobacterium granulomatis, which responds to doxycycline 100 mg bid or cotrimoxazole 2 tablets bid or ampicillin 500 mg 6 hourly for 3-4 weeks. Azithromycin 1 g once a week for 4 weeks is also effective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vaginitis-drug-therapy">Vaginitis - Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vaginitis-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is a common condition predominantly caused by 3 types of organisms</p>
<ul>
<li>C. albicans (fungus)</li>
<li>T. vaginalis (protozoon)</li>
<li>Gardenella vaginale (bacteria) and anaerobic organisms</li>
</ul>
<p>Sexual transmission is important in trichomoniasis, unimportant in candidiasis and unclear in bacterial vaginitis.</p>
<p>Candida vaginitis responds to intravaginal therapy with triazole compounds (Chapter 50), once each night for 3 to 7 days. A single oral dose ( 150 mg ) of fluconazole is as effective as several days of clotrimazole and miconazole locally. Asymptomatic carriers need no treatment.</p>
<p>Metronidazole is the drug of choice for trichomoniasis (Chapter 58).
Bacterial vaginitis also responds to metronidazole 500 mg bid for 7 days. Alternatively, clindamycin may be used. Similar regimens should be used to treat male partners, since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of them are urethral carriers of G. vaginale. Douches and local application of broad spectrum anti-microbials is not reliable for the treatment of vaginal infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-viral-std">Drug Therapy of Viral STD<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-viral-std" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Genital warts: This condition is due to local papilloma virus infection and is sexually transmitted in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of cases (condylomata acuminata). The warts grow rapidly in the presence of moisture and are inhibited by dryness. They are treated either by electric cautery under local anaesthesia or by applying podophyllum resin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> suspension in liquid paraffin or alcohol) or trichloracetic acid weekly. The surrounding skin must be protected by application of soft paraffin. Cryotherapy with liquid nitrogen is also effective.</p>
<p>Podophyllotoxin (Podofilox) 0.5% solution or gel applied twice daily for 3 consecutive days each week for 10-15 weeks is also effective. It should be avoided in pregnancy.</p>
<p>Imiquimod 5% cream, applied three times a week on alternate days for 10-15 weeks can eradicate about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of these anogenital warts. It acts by inducing the local production of interferon alpha along with pro-inflammatory cytokines interleukines 1, 6 and 8, and TNF alpha. It should be avoided during pregnancy.</p>
<p>Imiquimod ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream) applied three times a day for 5 days a week also resolves the lesions of a disease, molluscum contagiosum.</p>
<p>Sinocatechines is a watery extract of green tea leaves (Camellia sinensis); 15% ointment is used locally for external genital and perianal warts. The drug may cause erythema, pruritus, rash and erosions.</p>
<p>Genital herpes: Herpes simplex 1 (HSV 1) and Herpes simplex 2 (HSV 2) are known to infect the anogenital areas. Of these, HSV 2 causes most of the recurrent infections associated with itching, parasthesiae, and maculovesicular eruptions. HSV is one of the important causes of genital ulcers. The drugs used are acyclovir 250 mg orally tid, or famciclovir 250 mg tid or valaciclovir 1 g bid, for 7-10 days. Similar treatment for 5 days is given for recurrences (Chapter 59).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-hiv">Drug Therapy of HIV<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-hiv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Human immunodeficiency virus (HIV) infection and AIDS: is caused by a retrovirus, Human Immunodeficiency Virus (HIV-1 and 2) which is most commonly transmitted by sexual intercourse. The other modes of transmission are by contaminated syringes and needles, by blood transfusions and by blood products. It is also transmitted from an infected mother to the foetus during pregnancy, during childbirth or breast feeding. The virus is not spread by casual contact such as handshake with a sufferer, nor by aerial transmission, nor by fomites.
(a) On entering the body, viral outer glycoprotein (gp120) of HIV binds to CD4 receptors on the surface of T lymphocytes, monocytes, macrophages and brain dendritic cells (Fig 53.1). This is followed by binding to other chemokine receptors on the cell surface viz. CCR5 and CXCR4.
<img src="assets/images/image-20251214-11abf343.jpeg" alt="img-5.jpeg"></p>
<p>FIG. 53.1 Life cycle of HTV and site of action of antiretroviral drugs. CCR5, CXCR4 = Chemokine receptors; Target Sites: (1) for NRTI, NNRTI &amp; NTRI (2) for Integrase inhibitors, (3) for Protease inhibitors, (4) for Chemokine receptor antagonist, (5) for Fusion inhibitors.
(b) After attachment to CD4 and chemokine receptors, the virus fuses with the cell through viral glycoprotein, gp41 and the viral contents like single-stranded RNA, an RNAdependent DNA polymerase (also known as reverse transcriptase), and other enzymes are internalised.
(c) From the single-stranded viral RNA, reverse transcriptase synthesises a complementary strand of DNA and later a double-stranded DNA. Many mutations can occur in the conversion of RNA to DNA, which are responsible for HIV's ability to develop drug resistance.
(d) The double stranded DNA migrates to the host cell nucleus and is integrated into the host cell chromosome by an HIV enzyme called integrase.
(e) On activation of cell by antigens or cytokines, HIV replication starts using host DNA polymerase. This enzyme transcribes viral DNA into messenger RNA, and mRNA is then translated into viral proteins.
(f) These proteins assemble beneath the host cell membrane. The viral nucleocapsid is</p>
<p>formed surrounding these proteins, and the virus buds from the cell.
(g) After budding, the virus maturation takes place. HIV protease enzyme cleaves large polypeptides into smaller functional proteins. Only after maturation can the newly formed virus infect other cells.</p>
<p>During the process of viral replication, the CD4 cells suffer from functional impairment and the patient develops a defect in the cellular arm of the immune system. Impaired CMI makes the patient susceptible to opportunistic infections.</p>
<p>Antibodies to HIV develop in 2-8 weeks after infection. The viruses are also killed by cytotoxic T-lymphocytes or undergo apoptosis. However, within some cells, they may stay dormant for years. The incubation period is estimated to be 1 to 7 years (mean 4.5 years). Most of the subjects remain asymptomatic carriers for prolonged periods and can transmit the disease; a few develop a short febrile illness.</p>
<p>The next stage is of high rate of viral replication in lymph nodes and the development of a persistent generalised lymphadenopathy with or without infections such as oral candidiasis and herpes zoster.</p>
<p>In the final stage, the body cannot replenish. The patient suffers from opportunistic infections (tuberculosis, candidiasis, Pneumocystis jiroveci pneumonia, cryptococcal meningitis and CNS toxoplasmosis), repeated chronic GI infections and malignancies such as Kaposi's sarcoma, Burkitt's lymphoma and non-Hodgkins lymphoma. Severe neurological disorders such as dementia, encephalitis and meningitis can also occur. Death is inevitable.</p>
<p>None of the currently used drugs (Table 53.4) can eradicate HIV infection; but used in combination, they decrease the viral replication, improve immunologic status, delay onset of AIDs and prolong survival.</p>
<p>Table 53.4</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiretroviral-drugs">Antiretroviral drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiretroviral-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Nucleoside reverse transcriptase inhibitors (NRTI): Azidothymidine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Emtricitabine, Abacavir. II Non-nucleoside reverse transcriptase inhibitors (NNRTI): Nevirapine, Efavirenz, Delaviridine.</p>
<p>III Nucleotide reverse transcriptase inhibitor (NTRI): Tenofovir.
IV Protease inhibitors (PI): Saquinavir, Ritonavir, Indinavir, Amprenavir, Nelfinavir, Lopinavir, Atazanavir.
V Entry inhibitors : Enfuvirtide, Maraviroc VI Integrase strand transfer inhibitor (INSTI): Raltegravir, Dolutegravir, Elvitegravir.</p>
<p>Drug therapy of HIV is difficult because:</p>
<ul>
<li>It is difficult to eradicate HIV since the virus becomes an integral part of the T cells it infects; drugs only suppress the viral replication. The virus can remain quiescent (nonreplicating) in the affected cells for decades regardless of chemotherapy;</li>
<li>It infects the brain cells and many antiviral drugs do not cross the BBB.</li>
<li>The available drugs are toxic; and</li>
<li>The virus can develop drug resistance. The decision to start antiretroviral therapy (ART) is guided by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> cell count (less than 200 cells/microlitre), severity of clinical symptoms, and the plasma viral load (greater than 100,000 copies <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ). The classification of the drugs used in AIDS is outlined in Table 53.4.
The reverse transcriptase inhibitors block the RNA dependent DNA synthesis and thus</li>
</ul>
<p>prevent HIV replication. Non nucleoside reverse transcriptase inhibitors are more selective for HIV-1 reverse transcriptase. The nucleoside and nucleotide reverse transcriptase analogues on the other hand, also inhibit variety of DNA polymerization reactions and hence prone to cause more toxicity.</p>
<p>I Nucleoside reverse transcriptase inhibitors (NRTI): All these drugs are 2' 3' dideoxyribo-nucleoside analogues. Various NRTI differ in their intracellular action pathways and side effects. They block acute infection but are less active against chronically infected cells.</p>
<p>NRTIs can cause the potentially fatal metabolic syndrome known as HIV lipodystrophy syndrome. It is attributed to mitochondrial toxicity resulting from inhibition of mitochondrial DNA polymerase. It comprises of lactic acidosis with hepatic steatosis. It is less common with the newer NRTI (lamivudine and abacavir).</p>
<p>AZIDOTHYMIDINE (AZT, Zidovudine): Given orally, 3'-azido-3'-deoxy thymidine gets incorporated into DNA of the HIV and terminates chain synthesis of viral DNA. The viral DNA polymerase is about 100 times more susceptible to inhibition by AZT than of mammalian cells.</p>
<p>AZT is well absorbed orally; it can also be given IV. It is mostly metabolised in the liver. ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> one hour). It penetrates into CSF and amniotic fluid.</p>
<p>It causes GI upset, headache, myalgia and insomnia. Serious ADR include severe anaemia, granulocytopenia and thrombocytopenia. Rarely agitation, seizures, hepatotoxicity and myopathy have been reported.</p>
<p>The drug has been used in the dose of 200 mg orally, tid. More recent studies have shown that a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">500 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day ( 100 mg every 4 hours, while the patient is awake) is equally effective and less toxic.</p>
<p>Didanosine This nucleoside analogue of deoxyadenosine, with similar actions as AZT, has longer duration of action. It is non-toxic to the hemopoietic cells but can cause pancreatitis and peripheral neuropathy. The other ADR are headache, diarrhoea, nausea/vomiting, asthenia, insomnia, CNS depression, aches and pains, loss of taste, arthritis, alopecia, dizziness, retinal depigmentation and optic neuritis.</p>
<p>Stavudine has properties similar to those of didanosine, and should not be combined with it.
Zalcitabine is a cytosine nucleoside with less toxicity. It is combined with AZT in advanced HIV infection. The major side effects are peripheral neuropathy, hepatitis and stomatitis.</p>
<p>LAMIVUDINE is perhaps the best tolerated of the NRTIs. It is given in the dose of 150 mg bid. It is largely excreted by the kidney. It causes malaise, fatigue, and GI disturbances. Rarely, it can cause lactic acidosis and liver failure. Lamivudine-resistance emerges rapidly due to M184V mutation, following which cross resistance to zalcitabine, emtricitabine and abacavir occurs. It is also active against hepatitis B virus.</p>
<p>Emtricitabine is a fluorinated derivative of lamivudine. It is almost completely (93%) absorbed and has intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 39 hours. Hence, it is given once daily. It is hepatotoxic.</p>
<p>Abacavir (ABC) is a well tolerated NRTI with low affinity for human DNA polymerase and high therapeutic efficacy. The ADR include hypersensitivity reactions, sometimes fatal; this is genetically associated with HLA-B*5701 typing.</p>
<p>II Nonnucleoside reverse trancriptase inhibitors (NNRTI): These drugs, like NRTIs,</p>
<p>inhibit reverse trancriptase but by a different mechanism. Hence, they are usually combined with an NRTI. They are effective only against HIV-1.</p>
<p>They do not inhibit human DNA polymerase. HIV isolates resistant to NRTIs remain sensitive to these drugs. They are metabolised in the liver. They cause skin rash, hepatotoxicity and multiple drug interactions. Increased bleeding episodes have been noted in patients with hemophilia.</p>
<p>DELAVIRDINE: This NNRTI has high bioavailability and plasma protein binding capacity. ADR include headache, fatigue and diarrhea. It is also an inhibitor of CYP3A4 and CYP2C9 and can cause potential drug interactions. Delavirdine levels are decreased with concurrent use of fosamprenavir and rifabutin. The drug is teratogenic in rats and should be avoided in pregnancy.</p>
<p>EFAVIRENZ This NNRTI crosses the BBB, which most other anti-HIV drugs fail to do. The development of resistance to this drug is claimed to be slower than to the older drugs. It is given once a day ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>52</mn></mrow><annotation encoding="application/x-tex">t^{1 / 2} 52</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">52</span></span></span></span></span> hours). The adverse reactions comprise dizziness, insomnia, hallucinations, abnormal dreams and rarely pancreatitis. The drug is teratogenic in animals. It is a mixed inducer and inhibitor of CYP3A4.</p>
<p>NEVIRAPINE is more effective, and penetrates the CNS well. A single oral intrapartum dose to the mother, followed by a single dose to the newborn, is superior to AZT in preventing vertical transmission. It is a hepatic CYP3A4 inducer. It is considered as the drug of choice for women during child bearing age and pregnancy.</p>
<p>Etravirine and rilpivirine are other NNRTI usually used in combination with NRTI to treat resistant HIV infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-nucleotide-reverse-transcriptase-inhibitor-ntri">III Nucleotide, reverse transcriptase inhibitor (NTRI):<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-nucleotide-reverse-transcriptase-inhibitor-ntri" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TENOFOVIR is a prodrug. It is a potent inhibitor of HIV replication, and is given once daily. It appears to be effective against HIV strains resistant to other drugs. It is well tolerated; nephrotoxicity can occur in patients with pre-existing renal damage. It is also effective in hepatitis B.</p>
<p>IV Protease inhibitors (PI): These drugs are listed in Table 53.5 and they:</p>
<p>Table 53.5
Currently available protease inhibitors</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Dose</th><th style="text-align: left;">Remarks</th></tr></thead><tbody><tr><td style="text-align: left;">Amprenavir</td><td style="text-align: left;">1200 mg bid</td><td style="text-align: left;">NOT to be given with RTV</td></tr><tr><td style="text-align: left;">Indinavir</td><td style="text-align: left;">800 mg tid</td><td style="text-align: left;">Bid therapy, if with RTV</td></tr><tr><td style="text-align: left;">Nelfinavir</td><td style="text-align: left;">750 mg tid</td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">SaquinavirS</td><td style="text-align: left;">1000 mg tid</td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">Ritonavir</td><td style="text-align: left;">600 mg bid</td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">LopinavirS</td><td style="text-align: left;">400 mg bid</td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">Atazanavir</td><td style="text-align: left;">400 mg od</td><td style="text-align: left;">300 mg od, if with RTV</td></tr><tr><td style="text-align: left;">Darunavir*</td><td style="text-align: left;">600 mg bid</td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">Fosamprenavir*</td><td style="text-align: left;">1400 mg bid</td><td style="text-align: left;">700 mg bid, if with RTV</td></tr><tr><td style="text-align: left;">Tipranavir</td><td style="text-align: left;">500 mg bid</td><td style="text-align: left;">-</td></tr></tbody></table>
<p>RTV = Ritonavir (100-200 mg), $ Always with RTV
*For patients resistant to other PI, structural similarity to sulfonamide
"Prodrug of amprenavir and has replaced the latter.
(i) Inhibit aspartyl protease which cleave viral proteins and effectively arrest replication.
(ii) Block the infectivity of the nascent virions. and
(iii) Prevent subsequent waves of infection. They have no effect on cells already harbouring</p>
<p>integrated proviral DNA. Orally, they are well tolerated and metabolised by hepatic CYP3A4 (except Nelfinavir). Most of them inhibit CYP3A4; the most potent being ritonavir. Ritonavir allows reduction in the doses of other PI like saquinavir, lopinavir, fosamprenavir and atazanavir, when used concurrently. This boosted PI regimen is currently preferred.</p>
<p>Adverse reactions: Commonly, they cause nausea, vomiting, diarrhea and parasthesiae. Hepatotoxicity, insulin resistance, hyperglycemia, dyslipidemia, lipodystrophy (buffalo hump) and pancreatitis can occur. Indinavir may cause nephrolithiasis. Drug interactions are common.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-entry-inhibitors">V Entry inhibitors:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-entry-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Enfuvirtide is a synthetic HIV-derived peptide which selectively inhibits membrane fusion of HIV with cells and prevents their entry into cells. It is administered SC twice daily and is reserved for patients resistant to other drugs. Apart from local reactions, it may cause lymphadenopathy, peripheral neuropathy and suppression of IL-12.</p>
<p>Maraviroc: This drug is a chemokine receptor-5 (CCR-5) antagonist and prevents entry of CCR-5 tropic virus in the host cell.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vi-intergase-strand-transfer-inhibitors-insti">VI Intergase strand transfer inhibitors (INSTI):<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-intergase-strand-transfer-inhibitors-insti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Raltegravir: It blocks the enzyme HIV-1 integrase needed for viral DNA insertion into the host genome. It is used orally in combination to treat patients with MDR HIV-1 strains.</p>
<p>Elvitegravir, an another INSTI, is administered with a pharmakinetic enhancer cobicistat, which is an inhibitor of CYP3A4, CYP2D6 and P-glycoprotein. Elvitegravir is metabolised by CYP3A4. Co-administration with cobicistat increases its concentration favouring once daily administration. The combination is contraindicated with drugs which are metabolised by CYP3A4 (e.g. statins). Dolutegravir is yet another INSTI.</p>
<p>Bevirimat: This drug is a maturation inhibitor of HIV and is under development.
Drug combinations: As the chances of development of resistance to antiretroviral drug is very high, combination therapy is always preferred. The current trend is to begin combination Anti-Retroviral Therapy (ART) with two NRTI plus a third drug, either NNRTI or ritonavir boosted PI or INSTI. Regimen is modified in case of treatment failure, adverse reactions, drug interactions, poor patient compliance, pregnancy or comorbidity. Triple NRTI are recommended when the first line drugs cannot be used. The response to drug therapy is judged by measuring <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> count and viral load.</p>
<p>The toxicity of combination therapy, the need for adherence to it, the inconvenience of some regimens and the high cost of drugs necessitate initiation of drug therapy only in severely symptomatic patients and asymptomatic patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> counts of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>350</mn></mrow><annotation encoding="application/x-tex">&lt;350</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">350</span></span></span></span></span> cells/cu mm and/or very high viral loads and in pregnancy.</p>
<p>To improve adherence to ART, single tablet, fixed dose combinations are now available. They improve long term compliance, and help to reduce the viral load and emergence of resistant strains. One such single tablet once daily combination includes 4 drug therapy with elvitegravir, cobicistat, emtricitabine and tenofovir.</p>
<p>Sometimes, ART precipates immune reconstitution inflammatory syndrome (IRIS) especially in patients with advanced disease having subclinical mycobacterial, fungal and viral infections. IRIS may last for few weeks to a year and needs therapy with antiinflammatory agents.</p>
<p>AIDS and pregnancy: To prevent transmission of HIV to the fetus, chemotherapy of the</p>
<p>pregnant woman in full doses, started as early in pregnancy as possible, is recommended. Further, the newborn is also treated in the early weeks of life. Even AZT alone, taken orally for just 3-4 weeks before delivery and during labour, is reported to reduce the risk of transmission by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. The use of AZT during pregnancy has not been associated with fetal malformations, but mitochondrial dysfunction has been reported.</p>
<p>Many physicians, however, prefer to use a combination of AZT + an NRTI + a protease inhibitor during pregnancy. For women who are already in labour, a combination of AZT + lamivudine, given at the onset of labour and to the infant for one week, or a single dose of nevirapine to the mother and to the infant within 72 hours of birth, can also decrease the risk of perinatal transmission.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="std-prophylaxis">STD - Prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#std-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Avoidance of promiscuous sexual contact is the best method of preventing STD. Failing this, physical methods such as the use of a condom and thorough washing of the genitals and the surrounding areas with soap and water after an intercourse is recommended.</p>
<p>Chemoprophylaxis of STD: Procaine penicillin, IM 2.4 mega units into each buttock (a total of 4.8 mega units), preceded by 1 g of probenecid, helps to prevent both gonorrhoea and syphilis. However, it is advisable to keep the patient so treated under observation for the possible development of clinical manifestations and positive serology of syphilis.</p>
<p>In patients allergic to penicillin, doxycycline may be used in the dose of 100 mg bid for 15 days. It is also effective in preventing chancroid, granuloma inguinale and lymphogranuloma venereum. But, it is less effective than penicillin in preventing syphilis.</p>
<p>The general principles of prevention of STD also apply to AIDS. In addition, sterilisation of needles and syringes (preferably the use of disposable material), good blood banking practices and avoidance of pregnancy by women known or suspected to harbour the virus are important measures to check its spread. HIV is killed by sterilisation with pressurised steam (in an autoclave or pressure cooker) at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>121</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">121^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">12</span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> for at least 20 minutes and with boiling water <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mn>100</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(100^{\circ} \mathrm{C}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">10</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> for at least 20 minutes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="post-exposure-prophylaxis-pep">Post-exposure prophylaxis (PEP):<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#post-exposure-prophylaxis-pep" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Universal precautions against HIV infection are the best in its prophylaxis. However, treatment with antiretroviral drugs may be appropriate following occupational exposure (in health professionals) to HIV contaminated material such as blood or bloody fluids, infected needles, or contact of abraded skin or mucosa with the above material (Table 53.6).</p>
<p>Table 53.6
Antiretroviral drug regimens for PEP</p>
<table><thead><tr><th style="text-align: left;">Exposure status</th><th style="text-align: left;">Drugs</th></tr></thead><tbody><tr><td style="text-align: left;">Mild or moderate risk</td><td style="text-align: left;">Lamivudine 150 mg bid and AZT 300 mg bid (Basic regimen)</td></tr><tr><td style="text-align: left;">High risk</td><td style="text-align: left;">Above drugs plus Indinavir 800 mg tid &lt;br&gt; or &lt;br&gt; Nelfinavir 750 mg tid (Expanded regimen)</td></tr></tbody></table>
<p>(a) No treatment except local cleansing is required in persons with contamination of intact skin.
(b) Basic therapy (for 4 weeks) in persons with non-intact skin or mucosa contaminated with small or large volumes of infected material (mild or moderate risk).
(c) Expanded regimen (for 4 weeks) in persons with deep puncture wounds with hollow needles (high risk).</p>
<p>Important points to remember about STDs are outlined in Table 53.7.</p>
<p>Table 53.7
Points to remember about the management of STDs
-STDs often occur concunently.</p>
<ul>
<li>Compliance with treatment and followup are often dismal.</li>
<li>It may be better to treat even when an STD is suspected, preferably with single dose therapy (see Table 53.3).</li>
<li>Serious complications including infertility may occur from lack of adequate treatment.</li>
<li>Perfom serological test for syphilis on patients with other STDs.</li>
<li>Perfom pregnancy test on all females with STD.</li>
<li>Counsel patients about STD prevention and importance of HIV testing.</li>
<li>Advise all patients that the sexual partner must be treated to prevent re-infection.</li>
</ul>
<p>Drug therapy for HIV and PEP regimes are constantly revised and hence it is necessary to consult speciality clinics.</p>
<p>54</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-tuberculosis">Chemotherapy of Tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Tuberculosis (TB) is an infectious disease, caused by several species of mycobacteria. The important human pathogens of this class are M. tuberculosis and M. bovis. Tuberculosis has been described as 'Rajyakshmd' in the Vedas and was mentioned by Charaka and Sushruta, about 600 B.C. With the discovery of tubercle bacillus, the causative organism, by Robert Koch in 1882, the disease became known as tuberculosis.</p>
<p>It is the world's second commonest cause of death from infectious disease, after HIV/AIDS. Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of world's TB cases are from India, China, South Africa and the Russian Federation. India accounts for nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of global tuberculosis burden. The atypical mycobacteria are, in general, of low virulence but the disease caused is usually resistant to therapy.</p>
<p>Tuberculosis is a systemic disease, the commonest form in man being the chronic pulmonary variety. It spreads by droplet infection.</p>
<p>Unlike other bacterial infections, tuberculosis is a difficult disease to treat. The reasons are:</p>
<ul>
<li>Tubercle bacilli grow slowly, dividing only once in 1-2 days, even in the most favourable circumstances such as in an open cavitary, pulmonary lesion. In less favourable circumstances, such as a closed, caseous lesion, the bacteria become metabolically dormant and may 'persist' (persisters) for many years. Only rifampicin acts against such persisters. In an open cavity, there may be many bacilli resistant to one drug even before drug therapy is commenced.</li>
<li>The caseation and fibrosis tend to block the blood vessels supplying the necrotic area, making penetration by drugs difficult. The caseated material itself is impenetrable to many anti-TB drugs.</li>
<li>Tubercle bacilli remain viable and multiply even when ingested by macrophages. The chemotherapeutic agents (except INH, rifampicin, and pyrazinamide) penetrate poorly into the macrophages.</li>
<li>CMI develops 2-8 weeks after the infection in most infected patients. This gives some protection from its spread. Deficient CMI as in AIDs accelerates the spread.</li>
<li>The organisms tend to develop resistance to the chemotherapeutic agents by spontaneous chromosomal mutation. Multidrug resistant (MDR) bacilli are now on the rise.
Drug therapy for TB forms the most important aspect of its management. The drugs used are classified as:
I First line drugs:</li>
<li>Bactericidal: Isonicotinic acid hydrazide (H), Rifampicin (R), and Pyrazinamide (Z).</li>
<li>Bacteriostatic: Ethambutol (E).</li>
</ul>
<p>II Second line drugs:</p>
<ul>
<li>Bactericidal: Streptomycin (S), Amikacin (A), Capreomycin and Kanamycin (K); Fluoroquinolones (Q).</li>
<li>Bacteriostatic: Ethionamide (Et), Cycloserine (C), Thiacetazone (T), Paraminosalicylic acid (PAS).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-third-line-drugs">III Third line drugs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-third-line-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clarithromycin. Clofazimine, Linezolid
A single drug should never be used to treat tuberculosis, as this leads to the rapid development of drug resistant tubercle bacilli.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="first-line-drugs">First Line Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-line-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ISONICOTINIC ACID HYDRAZIDE (INH): This is the cheapest and one of the most effective antituberculous drugs (Fig 54.1). It is bactericidal and 'decimates' the population of tubercle bacilli within a few days of starting the treatment. It:
<img src="assets/images/image-20251214-90b039e3.jpeg" alt="img-6.jpeg"></p>
<ul>
<li>Acts on the bacilli multiplying in the walls of the cavities, as well as those inside the macrophages.</li>
<li>Is more effective than other drugs in preventing drug resistance to other drugs.</li>
<li>Is well tolerated, cheap and safe even in pregnancy.</li>
<li>Does not eliminate the persisters, which rifampicin does.</li>
</ul>
<p>Mechanism of action: INH is a prodrug. It is activated by the mycobacterial catalaseperoxidase to an active compound, which inhibits the synthesis of mycolic acid, a unique constituent of the mycobacterial cell wall. In addition, the drug inhibits the same catalaseperoxidase and makes the organisms susceptible to oxidative mechanisms. Although INH is an excellent bactericidal drug, it has poor sterilising activity as it fails to kill all viable organism.</p>
<p>INH resistance: Used alone, the mycobacteria rapidly develop resistance to INH by mutation in vitro. The importance of in vitro INH resistance, however, is doubtful as it does not correlate with the drug response in patients, where the drug can still continue to remain effective. INH, therefore, should not be discontinued because of apparent failure to achieve the therapeutic objectives or because of in vitro evidence of resistance.</p>
<p>Absorption, fate and excretion: INH is rapidly and completely absorbed on oral administration. Peak plasma levels are reached within an hour and effective blood levels may persist for as long as 24 hours. The absorption of the drug from the GI tract is so complete that oral and parenteral doses produce comparable plasma and tissue levels. Antacids interfere with its GI absorption. It is distributed throughout the body and penetrates well into the saliva, milk, pleural fluid and CSF. Its concentration in CSF in normal human volunteers is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of the plasma levels but in the presence of tubercular meningitis, higher ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ) concentrations are achieved. It can cross the placental barrier freely. Its concentration in the breast milk is similar to that in the plasma.</p>
<p>INH penetrates and acts intracellularly, and diffuses into macrophages and the necrotic centres, and even after its disappearance from tissues like brain and muscles, tissues like liver, skin, lungs and caseous material still retain an appreciable amount of the drug. Tuberculostatic concentrations of INH may persist for as long as 4 days in caseous masses, after a single oral dose, but these are not enough to destroy the persisters.</p>
<p>It is mainly metabolised in the liver by acetylation. Approximately 75 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of orally administered INH is excreted in the urine within first 24 hours, mainly as acetyl isoniazid and isonicotinic acid. In addition, small quantities are excreted after conjugation with</p>
<p>glycine and as isonicotinoyl hydrazone. Individuals may differ in their ability to metabolise INH. Thus,</p>
<ul>
<li>Rapid acetylator is one whose 6 hour serum level of active INH following a single test dose of 4 mg per kg is 0.2 mcg per ml or less.</li>
<li>Slow acetylator is one, whose 6 hour level is 0.8 mcg per ml or more after an equivalent dose.
Acetylation status is a genetically determined character. Rapid inactivation is found commonly in Japanese and Eskimos and has also been reported in Indians. Rapid acetylation is of no therapeutic importance when doses are administered daily; but subtherapeutic levels may result when once weekly dose is given.</li>
</ul>
<p>INH is safe in chronic renal failure and 300 mg ./day can be administered when plasma creatinine is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. Dose adjustment ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>2</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 2^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> ) is necessary in the presence of liver damage.</p>
<p>Adverse reactions: In general, INH is a remarkably safe drug. The clinically important ADR involve mainly the peripheral and the central nervous systems. They are:</p>
<ul>
<li>Allergy: These include fever, malaise, skin eruptions, sometimes, lymphadenopathy and jaundice and rarely blood dyscrasias and diffuse vasculitis.</li>
<li>Peripheral neuropathy: Being a structural analog of pyridoxine, it promotes excretion of pyridoxine. Thus, it causes peripheral neuritis leading to anaesthesia, paraesthesiae, burning and pain in extremities, sometimes accompanied by anemia and skin changes. Neuropathy is dose related and is more frequent in undernourished, chronic alcoholics, diabetic patients and slow acetylators. It is rare with the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day regimen. In the dose of 10-15 mg per day, pyridoxine prevents such neuropathy. Rarely optic neuritis leading to atrophy may develop; hence, it should be discontinued if visual disturbances develop.</li>
<li>Central nervous system: INH stimulates the CNS. Psychotic behaviour may be seen especially in patients with a history of epilepsy or psychosis. The psychic disturbances consist of euphoria, transient loss of memory, separation of ideas and reality, loss of self control and personality changes. Large doses may cause ataxia, muscle twitching, paraesthesiae and toxic encephalopathy.</li>
<li>Liver damage: The incidence of hepatitis is highest in individuals ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">&gt;50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> years). The liver shows bridging and multilobular necrosis. Acetylhydrazine may have some role to play. Patients receiving INH should be monitored for possible hepatotoxicity and the drug should be stopped if the SGPT increases to more than 3 times the upper limit of normal.</li>
<li>Miscellaneous: These include dryness of mouth and GI discomfort. INH inhibits the hepatic biotransformation of phenytoin, carbamazepine and ethosuximide and thus may raise their plasma levels. INH also interacts with disulfiram. Toxic doses ( 40 mg per kg or higher) may cause severe metabolic acidosis, hyperglycemia, seizures and coma.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Isoniazid tablet 100 and 300 mg . For doses, see text.
(ii) Isoniazid syrup, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per 5 ml .
(iii) Isoniazid injection, 100 mg per ml .</p>
<p>RIFAMPICIN (R): It is a semisynthetic derivative of rifamycin B, isolated from
Streptomyces mediteranei. It is:</p>
<ul>
<li>Effective against tuberculosis and leprosy.</li>
<li>Bactericidal and acts against both intra- and extra-cellular organisms.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="faster-than-inh-in-sterilising-effect">- Faster than INH in sterilising effect.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#faster-than-inh-in-sterilising-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Effective against tubercle bacilli resistant to other standard drugs and against some of the atypical mycobacteria; and</li>
<li>The only drug which acts on the persisters.</li>
</ul>
<p>Other bacteria: It is also active against Staph. aureus and albus and Cl. welchii. It is as effective as erythromycin or lincomycin against Streptococcus viridans and beta hemolyticus, Pneumococci, Bacillus anthracis, C. diphtheriae, N. gonorrhoeae and meningococci. It is only moderately active against H. influenzae and Streptococcus faecalis. It is active in vitro against many Gram-negative bacilli like E. coli, Proteus, Salmonella, Shigella, Pseudomonas aeruginosa and Brucella. However, organisms rapidly develop resistance to rifampicin.</p>
<p>Mechanism of action: Rifampicin acts by inhibiting bacterial DNA-dependent RNA polymerase, thus inhibiting RNA synthesis. Human RNA polymerase is not inhibited. Compared to INH, rifampicin is less bactericidal, but has potent sterilising activity.</p>
<p>Absorption, fate and excretion: Rifampicin is well absorbed from the gut. After a dose of 600 mg orally, given at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour before breakfast, the peak level is achieved within 2-3 hours and therapeutically useful concentration persists for more than 12 hours.</p>
<p>Food interferes with its absorption. Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of the drug gets bound to serum proteins. It is widely distributed throughout the body and is present in effective concentrations in many organs and body fluids including the CSF. It crosses the placenta. The drug is largely metabolised in the liver to an active metabolite desacetyl rifampicin which undergoes enterohepatic circulation. High concentrations of the drug occur in the bile and the saliva. It is largely ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> ) excreted in feces as desacetylated form. Small amount is excreted in the urine unchanged. Hence, dosage adjustment is not necessary in the presence of renal damage.</p>
<p>Adverse reactions: These occur in less than 5% of patients with the usual doses. They include skin rashes, diarrhoea, ataxia, hepatitis, jaundice, proteinuria, leucopenia and thrombocytopenia. It is advisable to check hepatic function before starting the drug. Patients on rifampicin therapy should be told that their urine, faeces, saliva, sputum, tears, sweat and even contact lenses may turn harmless orange red.</p>
<p>Acute hepatic and renal failure, allergic reactions including shock and a flu-like syndrome have been reported in patients taking large doses of rifampicin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>900</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;900 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">900</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) intermittently. Some of these may have immune mechanisms. However, intermittent therapy with smaller doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>450</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">450-600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">450</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) appears to be safe.</p>
<p>Rifampicin is a potent hepatic microsomal enzyme inducer and thus increases metabolism of several drugs, e.g., hydrocortisone, oral contraceptives, phenytoin, sulfonylureas, warfarin, digoxin, dapsone, verapamil, zolpidem, simvastatin, methadone, theophylline, nonnucleotide reverse transcriptase inhibitors and most protease inhibitors. This action is of less clinical importance when the drug is administered once a month as in leprosy.</p>
<p>It causes teratogenic effects in animals, and is better avoided during <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester of pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Rifampicin caps 150, 300, 450 and 600 mg . (ii) Rifampicin syrup for children.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Tuberculosis: Because of the likelihood of the emergence of resistant bacteria and availability of other potent antibiotics for the Gram-positive and negative organisms,</li>
</ul>
<p>rifampicin is mainly reserved for the treatment of tuberculosis (See later).
When re-starting rifampicin after it has been discontinued for any reason, it is advisable to start with a smaller dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) in order to prevent allergic reactions.</p>
<ul>
<li>Leprosy (Chapter 55).</li>
<li>Serious staphylococcal septicaemia resistant to the conventional drugs</li>
<li>Prophylaxis of meningococcal infection and infection with H. influenzae (type B) because of high concentration of rifampicin in the saliva.</li>
<li>Brucellosis (Chapter 47)</li>
<li>Legionnaire's disease</li>
</ul>
<p>RIFAPENTINE: This semisynthetic rifamycin antibiotic has a spectrum similar to that of rifampicin but it is longer-acting. Given orally, it is readily absorbed and is metabolised in the liver to the active metabolite 25 -desacetyl rifapentine. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of both rifapentine and its active metabolite is 13 hours. It is highly protein bound and is mostly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> ) cleared by the liver. It is also an enzyme inducer. Its toxicity is similar to that of rifampicin. It is administered in the dose of 600 mg once or twice weekly. It is not recommended for initial phase treatment of tuberculosis in HIV patients because of increased risk of acquired rifampicin resistance. It can be given during the continuous phase.</p>
<p>RIFABUTIN: See later.
PYRAZINAMIDE (Z): This drug, related chemically to thiosemicarbazones and nicotinamide, is effective orally against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. tuberculosis of human type resistant to streptomycin and INH but is ineffective against the bovine and atypical forms of tubercle bacilli.</p>
<ul>
<li>It is bactericidal and shows antitubercular activity in vitro at an acidic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">p</mi><mi mathvariant="bold">H</mi></mrow><annotation encoding="application/x-tex">\mathbf{p H}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8805em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathbf">pH</span></span></span></span></span></span>.</li>
<li>It is effective only against tubercle bacilli within macrophages (Intracellular effect)</li>
<li>It has good meningeal penetration.</li>
<li>In combination with streptomycin, INH and rifampicin, pyrazinamide exerts a potent sterilising effect on the tuberculous lesions during the first two months of therapy.
Mechanism of action: It is not definitely known. It is a prodrug and is converted to the active compound pyrazinoic acid which inhibits the bacterial synthesis of mycolic acid.</li>
</ul>
<p>Absorption, fate and excretion: Pyrazinamide is rapidly absorbed from the GI tract. The peak plasma levels are reached within 1 to 3 hours and the drug can be detected in the plasma upto 15 hours. It is widely distributed in the body and achieves a concentration in the CSF almost equal to the plasma levels. The drug is de-aminated in the liver. The degradation products and the free drug are excreted in urine.</p>
<p>Adverse reactions: Most patients complain of a metallic taste and sulfurous eructations. Apart from arthralgia, anorexia, nausea, vomiting, malaise, mild skin rashes and rarely photosensitivity resulting in bright red-brown discolouration of the exposed parts of the body.</p>
<p>Serious hepatotoxicity is major disadvantage. Toxic hepatitis may occur at any time during the treatment and is not dose-related. The drug, therefore, is contraindicated in the presence of hepatic insufficiency.</p>
<p>Rise in serum uric acid level due to increased tubular reabsorption of urates and precipitation of gouty arthritis have been reported.</p>
<p>Preparations and dosage: It is available as 500, 750 and 1000 mg tablets. Dose 25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day (not exceeding <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.5 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day) in one or two divided doses. For children: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></p>
<p>per kg daily.
Morphazinamide: This drug, related structurally to pyrazinamide has actions similar to those of pyrazinamide.</p>
<p>ETHAMBUTOL (E): Ethambutol is the dextrorotatory isomer of 2,2' (ethylenediamine)-di-l-butanol (Fig. 54.2). The levorotatory form is inactive against the mycobacteria but is equally toxic.
<img src="assets/images/image-20251214-47f54729.jpeg" alt="img-7.jpeg"></p>
<p>FIG. 54.2 Ethambutol</p>
<ul>
<li>It is effective orally against mycobacteria resistant to INH, streptomycin and ethionamide as well as against many atypical mycobacteria.</li>
<li>It is bacteriostatic.</li>
<li>Primary resistance to this drug has not been reported.</li>
<li>When used in combination, the bacterial resistance to other drugs is greatly delayed.</li>
</ul>
<p>Mechanism of action: It acts mainly against rapidly multiplying organisms in the walls of the cavities. It inhibits the synthesis of bacterial cell wall arabinosyl transferase.</p>
<p>Absorption, fate and excretion: Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the drug is absorbed after oral administration. It penetrates into erythrocytes which serve as the depot from which the drug is released into circulation. It, however, does not persist in other tissues and body fluids, the CSF level being only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the plasma level.</p>
<p>Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the oral dose is eliminated unchanged in urine within 24 hours; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of the drug is excreted in the form of two metabolites. It accumulates in the presence of renal damage.</p>
<p>Adverse reactions: The main adverse effect is retrobulbar optic neuritis on prolonged therapy. The early symptoms are blurring and haziness, followed by progressive decrease in visual acuity, contraction of the visual fields, central scotomas and poor colour discrimination, particularly, loss of ability to see green colour. The symptoms may disappear when the drug is discontinued. Optic neuritis is rare in patients receiving <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. Peripheral neuritis has also reported. The drug should be avoided in children below 8 years because of the difficulty in identifying early reduction in visual acuity in them. Other adverse reactions include nausea, anorexia, confusion, headache and allergic reactions.</p>
<p>Tests for visual acuity should be done before, during and after the treatment.
Preparations: Ethambutol as 200, 400 and 800 mg tab. For doses, see later.
Table 54.1 summarises properties of the standard antituberculosis drugs.</p>
<p>Table 54.1
Properties of standard antituberculosis drugs</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Oral absorption</th><th style="text-align: center;">Distribution</th><th style="text-align: center;">Disposal</th><th style="text-align: center;">Action</th><th style="text-align: center;">Action on persisters</th><th style="text-align: center;">CSF level</th><th style="text-align: center;">Serious toxicity</th></tr></thead><tbody><tr><td style="text-align: center;">H</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;">Wide (IC)</td><td style="text-align: center;">Hepatic</td><td style="text-align: center;">Cidal</td><td style="text-align: center;">None</td><td style="text-align: center;">Good</td><td style="text-align: center;">Neuro, Hepato</td></tr><tr><td style="text-align: center;">R</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;">Wide (IC)</td><td style="text-align: center;">Hepatic</td><td style="text-align: center;">Cidal</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Good</td><td style="text-align: center;">Hepato, Immuno</td></tr><tr><td style="text-align: center;">S</td><td style="text-align: center;">Neglibe EC</td><td style="text-align: center;">Mainly</td><td style="text-align: center;">Renal</td><td style="text-align: center;">Cidal</td><td style="text-align: center;">None</td><td style="text-align: center;">Poor</td><td style="text-align: center;">Neuro, Nephro</td></tr><tr><td style="text-align: center;">Z</td><td style="text-align: center;">Good (70%)</td><td style="text-align: center;">Wide (IC)</td><td style="text-align: center;">Hepatic</td><td style="text-align: center;">Cidal (IC)</td><td style="text-align: center;">None</td><td style="text-align: center;">Excellent</td><td style="text-align: center;">Hepato</td></tr><tr><td style="text-align: center;">E</td><td style="text-align: center;">Good (77%)</td><td style="text-align: center;">All tissues except CSF</td><td style="text-align: center;">Renal</td><td style="text-align: center;">Static</td><td style="text-align: center;">None</td><td style="text-align: center;">Fair</td><td style="text-align: center;">Ocular</td></tr></tbody></table>
<p>IC = Intracellular; EC = Extracellular; Neuro = Neurotoxicity; Hepato = Hepatotoxicity;
Nephro = Nephrotoxicity; Immuno = Immunological toxicity; Cidal = Bactericidal; Static = Bacteriostatic.
For full forms of drug names, see text.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="second-line-drugs">Second Line Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#second-line-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Majority of these antitubercular drugs are less effective and more toxic than the first drugs. Further, they need to be given daily.</p>
<p>STREPTOMYCIN (S): This aminoglycoside is considered in detail in (Chapter 47).</p>
<ul>
<li>It is not absorbed orally and must be administered IM. The injection is painful.</li>
<li>It is bactericidal to the tubercle bacilli rapidly multiplying at neutral pH in the walls of the tuberculous cavities.</li>
<li>It does not penetrate into the macrophages nor into caseous material. It is less potent than INH and rifampicin.</li>
<li>Its concentration in the CSF is poor.</li>
<li>It is much more toxic than INH and rifampicin (Chapter 47).</li>
</ul>
<p>Streptomycin should be used with caution in the elderly; 0.75 g daily is considered the preferred regime in such patients. It is better avoided in those with known renal insufficiency.</p>
<p>Kanamycin (K) and amikacin, aminoglycoside antibiotics, have been discussed in detail in Chapter 47. They are bactericidal and are active against mycobacteria resistant to streptomycin, INH and cycloserine.</p>
<p>CAPREOMYCIN: This antibiotic obtained from Streptomyces carpreolus, is a polypeptide, highly soluble in water. It is bactericidal. Its in vitro activity against mycobacteria is about half that of streptomycin but it is effective against mycobacteria resistant to the standard agents. Resistance to it occurs slowly. Its mechanism of action, pharmacokinetics and adverse reactions are similar to those of streptomycin, including nephrotoxicity.</p>
<p>Preparations and dosage: The recommended dosage for adults is 15 to 20 mg per kg (approximately 1 gm ) daily, IM for 60 days and then twice weekly for 18 months. Suggested dosage in children is 15 mg per kg given similarly.</p>
<p>FLUOROQUINOLONES (Q): See Chapter 45. Experimentally, ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin are active against M. tuberculosis, even those resistant to the other drugs. They are given orally or IV and are bactericidal. These drugs readily penetrate intomac-rophages. Levofloxacin and ofloxacin have long elimination half life and are given once daily. They are useful for treating infections with M. tuberculosis and M. avium complex (see later) resistant to first line drugs.</p>
<p>ETHIONAMIDE (Et): Ethionamide is structurally related to INH with the same mechanism of action. It is effective against tubercle bacilli resistant to other drugs and has proved effective in infections due to atypical mycobacteria. Resistance can develop both in vivo and in vitro. Such organisms show cross resistance to thiosemicarbazones.</p>
<p>Absorption, fate and excretion: It is absorbed fairly rapidly from the gut but is a GI irritant. Its distribution is similar to that of INH. It is metabolised in the liver to several metabolites. Only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> is excreted in the active form in urine.</p>
<p>Adverse reactions: The toxicity of ethionamide is considerable and makes drug withdrawal mandatory in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of cases. Allergic manifestations include skin rashes and alopecia; occasionally, serious manifestations like purpura and anaphylactoid shock may develop. GI disturbances occur in majority of the patients and include anorexia, nausea, vomiting and diarrhoea. To minimise this, it is given in a single dose after the evening meal or at bed time. The neurological disturbances are similar to those observed</p>
<p>following INH but occur more frequently. The drug also causes toxic hepatitis.
The miscellaneous adverse effects include endocrinological disturbances like gynecomastia, menorrhagia and impotence. Pellagra-like symptoms including stomatitis and diarrhoea occur in a few cases.</p>
<p>Preparations and dosage: Ethionamide 125 and 250 mg . tablets. The optimum dose of the drug is 1 g daily. It is administered initially in the dose of 250 mg twice daily and increased gradually by 250 mg every fortnight.</p>
<p>CYCLOSERINE: This antibiotic is used in the treatment of tuberculous as well as for Gram-negative infections. It is given orally. It is mainly tuberculostatic. Cycloserine acts by inhibiting the peptidoglycan synthesis and disrupts the bacterial cell wall. It is effective against tubercle bacilli resistant to INH or streptomycin and against atypical mycobacteria, although its antitubercular activity is less than that of these two drugs.</p>
<p>Absorption, fate and excretion: Cycloserine is rapidly absorbed from the gut; peak plasma levels are reached within 4 hours and decline by 12 hours. Repeated administration leads to accumulation of the drug in the plasma. It is distributed throughout the body and achieves the same concentration in the CSF as in the plasma, particularly when the meninges are inflammed.</p>
<p>Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the orally administered drug appears in the urine unchanged within 12 hours, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span> is excreted by the kidney within 72 hours. Renal impairment leads to high plasma concentrations.</p>
<p>Adverse reactions: The use of cycloserine is limited by its psycho-neuro-toxicity. The neurological effects include peripheral neuropathy, ataxia, slurred speech and seizures. The psychic effects include nervousness, insomnia, anxiety, psychotic reactions, delusions and hallucinations. Some patients become suspicious while others become paranoid and develop suicidal tendencies. Alcoholics, patients receiving INH and persons with chronic convulsive disorders are more prone to have seizures. Pyridoxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day may help to reduce neurotoxicity. The drug should be avoided in patients with a history of epilepsy or psychosis and in those with renal impairment.</p>
<p>Preparations and dosage: Cycloserine tartrate 250 mg . The recommended dose of the drug is 0.5 to 1 g daily, administered in two divided doses. A satisfactory regime is to start with 250 mg every 12 hourly, and to add 250 mg every ten days until the patient is receiving <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> daily in about 2 months. In children, a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per kg per day is used.</p>
<p>THIACETAZONE (T): Thiacetazone, a thiosemicarbazone derivative, is used as a companion drug to INH. Primary resistance to thiacetazone is uncommon. It is bacteriostatic. The drug is satisfactorily absorbed from the gut. It rapidly diffuses into the various body tissues and also crosses the placental barrier. It is partly metabolised and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> is excreted in urine within 48 hours. It is also secreted in milk.</p>
<p>Adverse reactions: These usually manifest itself within first 3 months of therapy. Anorexia, nausea and vomiting are common. Fever, skin rashes and Stevens-Johnson syndrome (erythema multiforme) appear occasionally. The serious toxic manifestations include progressive anemia, granulocytopenia and agranulocytosis; it also causes kidney and liver damage. It should never be used in HIV patients as it can cause severe and fatal skin reaction.</p>
<p>The usual recommended dose of the drug is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">.</mi><mo stretchy="false">(</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} .(2 \mathrm{mg} / \mathrm{kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">.</span><span class="mopen">(</span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span> daily in a single dose given with INH. Thiacetazone and INH tablet contains 50 mg of thiacetazone and 100 mg</p>
<p>of isoniazid.
Para-aminosalicylic acid (PAS): It is a bacteriostatic agent used for tuberculosis since 1940. It is a folate acid synthesis inhibitor but other mechanisms may be responsible for its effects. Its potency is much less than other drugs but may be useful in combination in the treatment of MDR TB. The usual adult dose is approximately 2 to 3 g four times a day ( 150 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day), which is bulky. The common ADR include nausea, vomiting, diarrhoea and occasionally hepatitis; the delayed-release formulation is available to overcome part of this problem.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="third-line-drugs">Third Line Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#third-line-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MACROLIDES: Newer macrolides, azithromycin and clarithromycin also have action against acid-fast bacilli. They are used to treat atypical mycobacterial infections (see later) and cases with relapse (Chapter 48).</p>
<p>Clofazimine: This antileprosy drug (Chapter 55), given in combination is reported to be beneficial in MDR-TB.</p>
<p>Linezolid is used in combination with other drugs for MDR/XDR infection (300-600 mg OD). Though bacteriostatic, it achieves adequate intracellular concentration (Chapter 46). Toxicity is dose-related and includes anaemia, neuropathies, hyperlactetemia and myelosuppression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="newer-drugs">Newer Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#newer-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bedaquiline (TMC 207): This new compound is a diarylquinoline. It acts by inhibiting mycobacterial ATP synthase, an enzyme essential for energy production in tuberculous bacilli. It is bactericidal against sensitive and MDR tuberculous bacilli. It also acts on dormant bacilli. ADR include nausea, anorexia, hepatic damage and arthralgia. QT prolongation can occur. It is metabolised by CYP3A4. It has long t1/2. It and accumulates in tissues. It is always administered with more than 3 drugs in MDR TB.</p>
<p>Delamanid: This nitro-dihydroimidazo- oxazole derivative is a mycolic acid synthesis inhibitor. It generates nitric oxide (NO) and also kills intracellular tuberculous bacilli. Given as an add-on therapy in a dose of 200 to 400 mg for 2 months, it has shown to increase sputum conversion rate among patients with MDR pulmonary TB. QT prolongation, however, is of concern. It is under evaluation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-pulmonary-tuberculosis">Management of Pulmonary Tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-pulmonary-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The presence of active pulmonary tuberculosis can be suspected from clinical features and routine laboratory investigations like the ESR; nevertheless, it should be confirmed by a skiagram and repeated sputum examinations. However, 15-20% of subjects with active pulmonary lesions have negative smears. Ideally, culture is required for definite diagnosis. Culture is also useful for drug sensitivity studies. Polymerase chain reaction (PCR) for mycobacterial antigen has been claimed to be highly sensitive and specific for identification of active TB, including TB meningitis. It is important to remember that an active disease can exist even in the absence of significant symptomatology. In difficult cases, a strong positive Mantoux test (induration more than 15 mm diameter) is helpful in diagnosis.</p>
<p>The aims of chemotherapy are:</p>
<ul>
<li>To kill the dividing bacilli in the lung lesions so as to render the sputum negative and the patient non-infectious.</li>
<li>To kill the 'persisters' so as to avoid relapse and to ensure total cure; and</li>
<li>To prevent emergence of drug resistance.</li>
</ul>
<p>Chemotherapy is the mainstay of the treatment of tuberculosis (Table 54.1) and all other forms of treatment like diet, climate and bed rest are only of secondary importance.</p>
<p>Activity, moderate exercise and work are not harmful in asymptomatic patients. But rest is necessary in very ill patients. The type of climate is not so important. Patients with diminished pulmonary ventilatory reserve should, however, avoid high altitudes. There is no special diet for tuberculosis; the patient should take a well balanced and adequate diet according to his or her purse and liking.</p>
<p>Necessity for hospitalisation will depend upon:</p>
<ul>
<li>The severity and extent of the lesion.</li>
<li>The general condition of the patient; and</li>
<li>The presence of complications such as pneumothorax and hemoptysis.</li>
</ul>
<p>Majority of the patients can now be treated successfully as out-patients. However, patients in the communicable stage of the disease should be strictly isolated from infants for a few weeks. Adequate chemotherapy makes sputum-positive patients 'non-infectious' within 3-6 weeks.</p>
<p>Upto 95% of drug-responsive new cases of pulmonary TB can be cured by standard DOTS therapy. The major difficulty is how to persuade patients to take drugs regularly for adequate periods of time. Majority of treatment failures are due to either failure to take prescribed therapy or infection with resistant bacilli.</p>
<p>Selection of chemotherapeutic regimen:
INH, rifampicin, streptomycin and pyrazinamide are the four bactericidal antituberculous drugs perferred for initial therapy. They are always administered in combination in order to:</p>
<ul>
<li>Delay the development of acquired resistance and prolong the effective therapy.</li>
<li>Eliminate persisters.</li>
<li>Shorten the course of therapy; and</li>
<li>Reduce ADR.</li>
</ul>
<p>There are many ways of combining the antituberculous drugs. The choice of the regimen depends upon:</p>
<ul>
<li>Administrative facilities for giving injections.</li>
<li>Drug tolerability.</li>
<li>Possibility of drug resistance.</li>
<li>Associated diseases such as DM.</li>
<li>Patient acceptability; and Cost.</li>
</ul>
<p>In many developing countries, the conditions of treatment vary from ideal to barely minimum and the optimal regimen may not always be practicable. Since streptomycin is to be given IM, it may be substituted by ethambutol (E) given orally. Tuberculosis is one of the diseases where the use of fixed dose drug combinations is justified. Its advantages are:</p>
<ul>
<li>Reduction in the number of pills to be swallowed.</li>
<li>Improvement in drug compliance; and</li>
<li>Convenience in mass-treatment of populations.</li>
</ul>
<p>On the large populations of bacilli actively multiplying at neutral pH in the walls of pulmonary cavities, INH, rifampicin and streptomycin are bactericidal; ethambutol is bacteriostatic; pyrazinamide is inactive. The most active drug against the small bacterial population that multiplies inside macrophages in an acid medium is pyrazinamide, followed by INH and rifampicin. Streptomycin is inactive in acid medium. Only rifampicin is active against intermittently multiplying persisters in solid caseous lesions; therefore, it is particularly effective in preventing a relapse.</p>
<p>Thus, from the bacteriological standpoint, INH + rifampicin is the most effective antituberculous combination. To enhance the effectiveness of this combination and avert the consequences of drug resistance, it is desirable to add one or two supplementary drugs (Z; or Z<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span>E; or Z<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span>S) in the initial intensive phase of treatment.</p>
<p>The initial intensive phase treatment should always be with three or four drugs, all bactericidal. The drugs are administered daily (if unsupervised) or thrice weekly (supervised). For short course chemotherapy (6-9 months), a minimum of three drugs must be given for the first 2 months. The duration of treatment must never be shorter than 6 months. The dosages of these drugs are given in Table 54.2.</p>
<p>Table 54.2
Dosage of commonly used drugs</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Adults (Daily dosage)</th><th style="text-align: center;"></th><th style="text-align: center;">Children (Daily dosage)</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;50 \mathrm{Kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Kg</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;50 \mathrm{Kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Kg</span></span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Rifampicin (R)</td><td style="text-align: center;">450 mg</td><td style="text-align: center;">600 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">;</mo></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg} ;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mpunct">;</span></span></span></span></span> Max. 600 mg</td></tr><tr><td style="text-align: center;">Isoniazid (I<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span>)</td><td style="text-align: center;">300 mg</td><td style="text-align: center;">300 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">;</mo></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} / \mathrm{kg} ;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mpunct">;</span></span></span></span></span> &lt;br&gt; Max. 300 mg</td></tr><tr><td style="text-align: center;">Pyrazinamide (Z)</td><td style="text-align: center;">1000 mg</td><td style="text-align: center;">1500 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Streptomycin (S)</td><td style="text-align: center;">0.75 g</td><td style="text-align: center;">1.0 g</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">;</mo></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg} / \mathrm{kg} ;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mpunct">;</span></span></span></span></span> &lt;br&gt; Max. 0.75 g</td></tr><tr><td style="text-align: center;">Ethambutol (E)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (see text)</td><td style="text-align: center;">-</td><td style="text-align: center;">Not recommended</td></tr><tr><td style="text-align: center;">Thiacetazone (T)</td><td style="text-align: center;">150 mg</td><td style="text-align: center;">150 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></td></tr></tbody></table>
<ol>
<li>All drugs are given in a single dose. 2. Use pyridoxine 10 mg daily as supplement when high doses of INH are used, as in miliary tuberculosis and meningitis. 3. Before starting streptomycin, check kidney function, particularly in patients over 60 years of age; reduce the dose accordingly, if necessary.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-various-regimens-used-are">The various regimens used are:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-various-regimens-used-are" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(1) Daily, combination drug therapy: A six month course consisting of daily <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">R</mi><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">Z</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">E</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{R}^{+} \mathrm{Z}^{+} \mathrm{E}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">R</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">Z</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord mathrm">E</span></span></span></span></span> for two months, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord mathrm">R</span></span></span></span></span> daily (self administered) or twice weekly (supervised) for 4 months is the preferred therapy for patients with fully susceptible organisms (usually newly diagnosed cases). Drugs may also be given three times a week throughout under supervision. During the initial intensive phase, most of the growing tubercle bacilli are killed and the patient becomes non-infectious. The continuation or sterilising phase (4 months) is necessary to eliminate the persisters and reduce the failure.</p>
<p>In patients who are unable to take Z, a nine month regimen consisting of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord mathrm">R</span></span></span></span></span> with or without E/S is given initially daily for 2 months, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord mathrm">R</span></span></span></span></span> daily or 3 times a week (supervised) for further 6-7 months.
(2) Directly Observed Treatment, Short Course (DOTS) chemotherapy in drug suceptible TB has proved to be highly cost effective. In this regimen, the drugs are administered under supervision, intermittently thrice weekly (Table 54.3). This ensures that the drugs are actually consumed. DOTS regimen:</p>
<p>Table 54.3
DOTS regimens* of RNTCP</p>
<table><thead><tr><th style="text-align: center;">Category</th><th style="text-align: center;">Patient type</th><th style="text-align: center;">Regimen (Duration in months)</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">Intensive</td><td style="text-align: center;">Mainte nance</td></tr><tr><td style="text-align: center;">I</td><td style="text-align: center;">New sputum smear positive &lt;br&gt; New sputum smear negative &lt;br&gt; New extrapulmonary &lt;br&gt; New others</td><td style="text-align: center;">HRZE (2)</td><td style="text-align: center;">HR (4)</td></tr><tr><td style="text-align: center;">II</td><td style="text-align: center;">Smear positive, relapse &lt;br&gt; Smear positive, failure &lt;br&gt; Smear positive treatment after default Others**</td><td style="text-align: center;">HRZES (2) &lt;br&gt; + HRZE (1)</td><td style="text-align: center;">HRE (5)</td></tr></tbody></table>
<p>*All drugs are administered thrice weekly. Higher doses are used : <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">R</mi><mo>−</mo><mn>450</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">Z</mi><mo>−</mo><mn>1500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">E</mi><mo>−</mo><mn>1200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{H}-600 \mathrm{mg}, \mathrm{R}-450 \mathrm{mg}, \mathrm{Z}-1500 \mathrm{mg}, \mathrm{E}-1200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">450</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">Z</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">1500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">E</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">S</mi><mo>−</mo><mn>750</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{S}-750 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">S</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. Patients who weigh more than 60 kg receive additional R-150 mg per dose. Patients older than 50 years and/or those weighing less than 30 kg receive S-500 mg.
**Others include patients who are sputum smear-negative or who have extra-pulmonary disease who can have recurrence or resonance.
(a) Achieves cure rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>
(b) Ensures high rate of treatment completion.
(c) Decreases the possibility of acquired drug resistance; and
(d) Prevents relapse.</p>
<p>DOTS is mandatory when drugs are prescribed less often than daily; when drugs are prescribed to be taken daily, the regimen is on self-administration basis.</p>
<p>In India, under Revised National Tuberculosis Control Programme (RNTCP) a National Strategic Plan is made to provide universal access to TB diagnostics and treatment for all pulmonary and extrapulmonary TB patients, including drug resistant and HIV associated TB. The basic principles of RNTCP are:
(a) Quality diagnosis primarily by sputum microscopy in patients complaining of cough.
(b) Regular and uninterrupted quality drug supply, including the use of a patient-wise carry-home box for drug-dispensing.
(c) Direct observation of consumption of every dose of treatment in the initial intensive phase of therapy and at least of the first dose of the week in the continuation phase of</p>
<p>treatment.
(d) Decentralised supervision by the healthcare givers of sub-district supervisory unit and accountability for every patient diagnosed; and
(e) In-built systems for monitring and evaluation.</p>
<p>The initial categorisation of treatment groups and regimen under RNTCP has been revised to have only 2 categories as (a) new cases and (b) previously treated patients (Table 54.3).</p>
<p>In the intensive phase of DOTS, all the
4 drugs are administered thrice weekly, on alternate days, under direct observation.
Medications for the continuation phase are packed into weekly blister packs, and the consumption of the first dose from each blister pack is directly observed. Evidence that the patient has taken the medicines is available by checking the empty blister packs. The programme is made domiciliary by appointing health workers or trained volunteers for supervision.</p>
<p>In tuberculous meningitis, ethambutol should be replaced by streptomycin. If level of INH resistance is high in the population and INH susceptibility testing is not done, then in the continuation phase HRE is an acceptable alternative to HR. Patients who are unable to take HR during the continuation phase for some reason can be given HE daily for 6 months. However, this regimen has high failure and relapse rates.</p>
<p>In any regimen which contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi></mrow><annotation encoding="application/x-tex">R</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span></span></span></span></span>, all the drugs are best administered together as single dose, half an hour before breakfast.</p>
<p>In patients with risk factors like big cavity, extensive disease, immunosuppression, as well as those with bone or joint tuberculosis, tubercular meningitis, miliary tuberculosis and those with HIV infection, it is advisable to extend the treatment beyond 9 months (usually 12-18 months).</p>
<p>Routinely, one should consider managing all patients with DOTS which is highly cost effective. However, it has been reported that in a population with high degree of drug resistance, a DOTS programme with first line drugs resulted in overall cure rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>54</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">54 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">54%</span></span></span></span></span> despite excellent compliance. Under such conditions DOTS therapy may simply be eliminating the drug sensitive strains of the mycobacterium leaving the more resistant strains to thrive.</p>
<p>Treatment regimens, except for dosage, are generally the same for children as for adults, except that ethambutol is avoided in young children below 8 years.</p>
<p>As a rule, reserve drugs are rarely required in the initial treatment. They may, however, be needed because of primary resistance to the basic drugs, or because of intolerance or toxicity. Combinations of drugs with similar toxic effects on liver or kidney should be avoided.</p>
<p>The response to chemotherapy depends on the duration of the lesion rather than the extent of the lesion. Lesions of recent origin, even though extensive, may be completely reversible. The response can be gauged by:</p>
<ul>
<li>Clinical improvement (usually within 2-3 weeks) as shown by improvement in appetite, weight gain and a feeling of well-being.</li>
<li>Bacteriological improvement: Negative sputum cultures on two occasions, one of which is at the end of 3 months of therapy, is considered as cure.</li>
<li>Radiological improvement: With adequate chemotherapy, cavity closure or its</li>
</ul>
<p>disappearance without surgical intervention has been reported in 75 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of patients within 3-6 months.</p>
<ul>
<li>Periodic determination of ESR. Ideally, in vitro susceptibility tests to determine the bacterial sensitivity to the drugs should be carried out before and during the therapy. This, however, is many times impracticable.
Apart from doing audit for efficacy of treatment, patients should be monitored for possible serious toxicity of drugs. H may cause neuropsychiatric syndromes. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo separator="true">,</mo><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}, \mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathrm">H</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">R</span></span></span></span></span>, and Z can cause liver damage. Pyrazinamide should not be used in patients with known chronic liver disease. In decompensated liver disease, R should be avoided. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi><mo separator="true">,</mo><mi>E</mi></mrow><annotation encoding="application/x-tex">S, E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>Q</mi></mrow><annotation encoding="application/x-tex">Q</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">Q</span></span></span></span></span> can be used in subjects with fulminating liver disease. Induction of autoimmune thrombocytopenia by R, impaired vision by E or H and gouty arthritis by Z mandate their withdrawal. The usual dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mo separator="true">,</mo><mi>R</mi><mo separator="true">,</mo><mi>Z</mi></mrow><annotation encoding="application/x-tex">H, R, Z</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">Z</span></span></span></span></span> can be given in renal failure as they are eliminated in bile or metabolised to nontoxic products.</li>
</ul>
<p>Tuberculosis during pregnancy: This should be treated with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>+</mo><mi mathvariant="normal">R</mi><mo>+</mo><mi mathvariant="normal">Z</mi><mo>+</mo><mi mathvariant="normal">E</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}+\mathrm{R}+\mathrm{Z}+\mathrm{E}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">Z</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">E</span></span></span></span></span> together with pyridoxine for 9 months. Streptomycin should be avoided.</p>
<p>Adjuvant therapy: If the tuberculosis is very extensive or is complicated by marked pulmonary insufficiency secondary to emphysema, chronic bronchitis or pulmonary fibrosis, oxygen or ventilatory assistance or both may be required. Cleansing of bronchopulmonary secretions, and a tracheostomy if necessary, may be life saving. Patients should avoid smoking and respiratory irritants. Secondary respiratory infection must be promptly treated with appropriate antibiotics; so also associated diseases like diabetes mellitus.</p>
<p>Dry, hacking, spasmodic cough can be controlled by codeine phosphate 15 mg bid.
Pulmonary haemorrhage leading to hemoptysis needs prompt evacuation of the bronchopulmonary secretions to prevent aspiration and bronchial spread of the disease. The bleeding lung should be kept in a dependent position to avoid such a spread. The commonly used positions are the semi-reclining or the lateral. Light sedation is advisable but over-suppression of the cough reflex favours atelectasis. If bleeding continues beyond 24 hours, blood transfusion maybe necessary.</p>
<p>Failure to obtain reversal of infectiousness (sputum or tracheobronchial secretions free of tubercle bacilli after smear and culture) after 3 months of therapy, or closure of cavities after 4 or 6 months demands revision in chemotherapy. Failure of drug therapy is likely to be due to several causes (Table 54.4) of which non-compliance is the most important.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-54-4">Table 54.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-54-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="causes-of-failure-of-drug-treatment-of-tuberculosis">Causes of failure of drug treatment of tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes-of-failure-of-drug-treatment-of-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Failure of the patient to take the drugs (Non-compliance).</li>
<li>Incorrect prescribing of drugs.</li>
<li>Primary drug resistance.</li>
<li>Secondary drug resistance.</li>
<li>Penistess which are dormant and therefore have not been affected by the drugs.</li>
<li>Poor general health due to malnutrition, diabetes or chronic alcoholism; and</li>
<li>Associated disease such as diabetes mellitus or AIDS.</li>
</ul>
<p>The reasons for non-compliance can be:</p>
<ul>
<li>Quick symptomatic relief giving a false sense of security.</li>
<li>Adverse reactions to the drugs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="having-to-attend-the-tb-clinic-repeatedly-with-loss-of-wages-and-the-inconvenience-of-travel-br-staff-attitude-towards-the-patients-br-lack-of-social-support-and-poverty-and-br-failure-to-educate-the-patient">- Having to attend the TB clinic repeatedly with loss of wages and the inconvenience of travel. &lt;br&gt; - Staff attitude towards the patients. &lt;br&gt; - Lack of social support and poverty; and &lt;br&gt; - Failure to educate the patient.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#having-to-attend-the-tb-clinic-repeatedly-with-loss-of-wages-and-the-inconvenience-of-travel-br-staff-attitude-towards-the-patients-br-lack-of-social-support-and-poverty-and-br-failure-to-educate-the-patient" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Failure rate after DOTS is around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> in categories I and II, respectively. In patients who have failed to respond to or shown relapse after first course of chemotherapy, drug resistance to R or H may be suspected. This could be due to:</p>
<ul>
<li>Inadequate/irregular drug therapy.</li>
<li>Patients coming from an area with high prevalence of drug resistance; or</li>
<li>Known exposure to a patient with drug resistant disease.</li>
</ul>
<p>In such patients, the proportion of bacilli still susceptible to standard anti-tuberculous drugs may be usually high. Bacteriological relapse after completion of a regimen containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>+</mo><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}+\mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span></span></span></span></span> is due to late replication of persisters, which have escaped the effect of the drugs by remaining dormant. Therefore, re-treatment regimen (i.e. of Category II) should be given for 8 months under direct observation. This can cure the majority of patients, having either still-susceptible bacilli or exhibiting resistance to INH and/or streptomycin, but still susceptible to rifampicin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mdr-tuberculosis-management">MDR Tuberculosis Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mdr-tuberculosis-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In patients who have failed to be cured after second course (supervised category II) of chemotherapy, the proportion of resistant bacilli is up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> and that of MDR bacilli about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. MDR is defined as resistance of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. tuberculosis to INH and rifampicin with/without resistance to other drugs. It is now widespread globally, often remaining undiagnosed. Treatment of MDR tuberculosis is complex, needs elaborate evaluation and drug sensitivity testing, and is best left to experts.</p>
<p>The sputum samples of MDR-TB suspects or patients, who have been diagnosed resistant using a rapid test (line probe assay and Xpert MTB/RIF) for INH and rifampicin or rifampicin alone within two days of specimen testing, are subjected to conventional mycobacterial culture and drug sensitivity tests. Until the results of such susceptibility tests are available, which need 1-3 months, a four-drug regimen, is started depending on the history of drugs used earlier and reported evidence of drug resistance in the health care setting. It consists of antimicrobial which the patient has never received before. WHO recommends that the regimen should include pyrazinamide, a later generation fluoroquinolone (levofloxacin, moxifloxacin, ofloxacin), an aminoglycoside (kanamycin, amikacin, capreomycin), ethionamide and cycloserine. PAS is used only if an additional drug is needed to achieve a five-drug regimen or if ethionamide or cycloserine cannot be used or are unlikely to be effective. Ethambutol is not a part of standard regimen but may be included. If needed, either: clofazimine, linezolid, amoxicillin/clavulanate, thioacetazone, clarithromycin or imipenem may be added.</p>
<p>However, addition of only one new drug at a time to an ineffective regimen must be avoided as resistance to that drug is bound to develop.</p>
<p>When results of susceptibility tests are available, treatment is selected depending on resistance pattern of isolated organisms from the patient or isolated from the patient or close contacts with MDR-TB.</p>
<p>The suggested intensive phase is of 8 months with total duration of therapy of 20 months for those who have not received previous treatment for MDR-TB. In patients who have received previous treatment for MDR-TB, it is extended to 30 months. It may vary, based on the patient's response to therapy. The best strategy for response monitoring is monthly sputum smear microscopy and culture rather than sputum smear microscopy alone.</p>
<p>Reserve drugs used to treat the resistant cases are less effective and more toxic; they need daily administration. Hepatic toxicity of pyrazinamide and the psychoses caused by cycloserine may occur at any time during the treatment. Cases for re-treatment with these drugs, therefore, should be hospitalised. Organisms rapidly develop resistance to the reserve drugs. Sputum should be examined every month. In most patients, sputum conversion occurs by 5 months. Persistent cavitation in the presence of positive sputum after 6 months of secondary chemotherapy or relapse calls for surgical intervention. Treatment programme for MDR-TB thus, uses individualised treatment regimens (ITRs) based on drug sensitivity test (DST) results in each patient.</p>
<p>However, many countries may not have adequate resources to manage MDR-TB in this manner. Hence the alternative strategy of treating all MDR-TB patients with standardised treatment regimen, based on common DST profile of the prevalent MDR-TB strains, is</p>
<p>adopted under 'Programmatic Management of Drug Resistant TB' (PMDT; erstwhile DOTS-Plus programme) of RNTCP. It takes care of diagnosis, management and follow up of drug resistant TB (DR-TB), which includes MDR-TB, XDR-TB (See below), second line drug resistance and poor treatment response.</p>
<p>MDR-TB suspects are identified based on specific criteria such as smear positive retreatment TB patients, new cases who have failed an initial first-line drug treatment and HIV-TB co-infected patients etc. Their sputum samples are processed at RNTCP accredited laboratory to confirm the diagnosis of MDR-TB.</p>
<p>On confirmation of diagnosis, the patient is switched to standardised regimen for MDRTB under RNTCP. It involves 6-9 months of intensive therapy with 6 drugs ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> Levofloxacin + Et + Z + E + Cycloserine), followed by 18 months of continuation phase with 4 drugs (Levofloxacin + Et + E + Cycloserine). In case of intolerance to kanamycin, capreomycin is added. PAS is included if any of the drugs is not tolerated. If there is baseline ofloxacin mono-resistance, then levofloxacin should be substituted by moxifloxacin and PAS. All the drugs except PAS (given twice a day) are administered as single daily dose with 100 mg pyridoxine under DOT 6 days a week. Therapy on Sunday is unsupervised. The results of 6 months intensive phase are reviewed.</p>
<p>The continuation phase is started if the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>4</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">4^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> month culture shows negativity; else the intensive phase is extended by a month. Such extension of intensive phase is allowed up to maximum of 3 months based on culture results of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">6^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>7</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">7^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> month's therapy. After the 9 months, continuation phase is started irrespective of the culture results. The treatment strategy remains the same for extrapulmonary MDR-TB.</p>
<p>Recently a combination of ethambutol, pyrazinamide, gatifloxacin and clofazimine given for 9-12 months supplemented by kanamycin, INH, Prothionamide during an intensive phase of 4 months have been reported to be as equally effective as 20 months therapy.</p>
<p>Extensively drug resistant TB (XDR-TB) is defined as resistance to at least INH and rifampicin (i.e. MDR-TB) plus resistance to any of the fluoroquinolones (ofloxacin, levofloxacin or moxifloxacin) and any one of the second-line injectable drugs (amikacin, kanamycin, or capreomycin).</p>
<p>XDR-TB regimen includes 6-12 months of intensive phase with 7 drugs (capreomycin, PAS, moxifloxacin, high dose INH, clofazimine, linezolid and amoxicillin/clavulenic acid) followed by 18 months of continuation phase with 6 drugs (PAS, moxifloxacin, high dose INH, clofazimine, linezolid and amoxicillin/clavulenic acid). Clarithromycin and thiaacetazone remain as reserved drugs, to be given if the patient is on PAS in previous regimen or is intolerant to any of the drugs mentioned above or exhibits resistant to capreomycin. The change from intensive phase to continuation phase is done only after achieving conversion i.e. 2 consecutive negative cultures taken one month apart. The follow up of these patients is extensive. Bone marrow suppression and anaemia can occur due to linezolid and capreomycin is nephrotoxic. Hence frequent monitoring of hemogram, serum creatinine along with liver function tests with chest X-ray is needed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-forms-of-tuberculosis">Other Forms of Tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-forms-of-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug regimens proven effective in pulmonary tuberculosis are effective in extrapulmonary tuberculosis as well. Some authorities, however, advocate that short courses should not be used to treat severe extra-pulmonary forms of tuberculosis. Severe forms of tuberculosis like tuberculous meningitis, tuberculous pneumonia, tuberculous pericarditis and acute miliary tuberculosis may require longer treatment with three or four drugs for 18-24 months. Glucocorticoids may be required to overcome severe toxemia.</p>
<p>Tuberculous meningitis: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>+</mo><mi mathvariant="normal">S</mi><mo>+</mo><mi mathvariant="normal">R</mi><mo>+</mo><mi mathvariant="normal">Z</mi></mrow><annotation encoding="application/x-tex">\mathrm{H}+\mathrm{S}+\mathrm{R}+\mathrm{Z}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">S</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">Z</span></span></span></span></span> is the preferred initial combination in this disease. INH is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. Intensive chemotherapy is administered till CSF returns to normal, followed by maintenance therapy. Total duration of chemotherapy may be of 2 years. Pyridoxine is prescribed to prevent INH neurotoxicity.</p>
<p>Steroids should be used in all severely ill patients, in those with a suggestion of cerebrospinal block and probably also in children under 1 year of age. The initial adult dose of prednisolone is 80 mg per day ( 1 mg per kg in children) in 4 equally divided doses. The dose should then be gradually reduced till a maintenance level of 25 to 30 mg daily is reached within 2 to 3 weeks. For withdrawal of glucocorticoids see Chapter 66.</p>
<p>The same regime including steroids is also applicable to miliary tuberculosis, tuberculous pericarditis and tuberculous pneumonia.</p>
<p>Tuberculous lymphadenitis: This condition which is often due to atypical mycobacteria usually responds unsatisfactorily to chemotherapy (see later). If no progress is apparent within 6 to 8 weeks, the glands may be removed surgically.</p>
<p>Miscellaneous tuberculous infections: Tuberculosis of the genitourinary tract, bones, joints, skin, larynx and intestine responds well to routine chemotherapy. INH and rifampicin are the safest drugs in the presence of renal failure. Streptomycin and ethambutol are retained in patients with renal failure and must be used with caution. For ocular tuberculosis, topical and systemic glucocorticoid therapy may be required in addition to systemic chemotherapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids-in-tuberculosis">Glucocorticoids in Tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids-in-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Glucocorticoids are known to impair host defence mechanism and promote dissemination of infection. However, their anti-inflammatory action may be helpful. They are useful when the excessive inflammatory reaction of the body is likely to threaten life or is likely to lead to extensive fibrosis on healing. They must never be used without cover of effective antitubercular chemotherapy. The indications are:</p>
<ul>
<li>To relieve toxic symptoms and hypoxemia in fulminating, rapidly progressive infection in pulmonary tuberculosis, tuberculous pneumonia or miliary tuberculosis.</li>
<li>To prevent bronchial stenosis in endo-bronchial tuberculosis.</li>
<li>To reduce toxemia, hasten the absorption of the exudate and prevent the formation of adhesions, arachnoiditis and hydrocephalus in tuberculous meningitis.</li>
<li>To hasten the reabsorption of fluid in tuberculosis of the serous membranes like the pleura and the pericardium. Use of glucocorticoids in abdominal tuberculosis, may be dangerous as it may lead to intestinal perforation.</li>
<li>As an adrenal cortical hormone replacement, e.g. in Addison's disease, when it occurs with tuberculosis elsewhere in the body.</li>
<li>To counter the hypersensitivity reactions to antituberculous drugs.</li>
<li>To arrest the dire consequences in rapidly enlarging mediastinal tuberculous lymph nodes.</li>
<li>To prevent the serious consequences of fibrosis in ocular and genito-urinary tuberculosis.
Also see Chapter 66.
Treatment of tuberculosis is essentially medical. Moreover, it must be emphasised that surgical removal of the lesion does not mean that the disease is completely eradicated. The patient must, therefore, be treated with adequate chemotherapy before, during and after such procedures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemoprophylaxis-of-tuberculosis">Chemoprophylaxis of Tuberculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemoprophylaxis-of-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chemoprophylaxis of tuberculosis means the use of anti-tuberculous drugs for its prevention. INH is the ideal drug for this purpose as it is cheap, effective orally and has acceptable toxic effects. Chemoprophylaxis can be:</p>
<p>Primary chemoprophylaxis: In this case, drugs are given to tuberculin negative, uninfected persons, particularly infants and children below the age of 3 years, who have had close contact with an infectious case of pulmonary TB (especially the mother). It reduces the risk of serious clinical tuberculosis in 60-90% of subjects. No immunity develops. INH is given in doses of 5 mg per kg daily usually for 3 months and at the end of this period, if the child is tuberculin negative, it receives BCG vaccine to provide active immunity. BCG vaccination should not be carried out during INH prophylaxis. However, INH resistant BCG vaccine, if available, may be used.</p>
<p>Secondary chemoprophylaxis: INH is given to high risk patients with the intention of preventing the development of disease after infection has already taken place and the tuberculin test has already become positive within preceding 2 years, or with the intention of preventing a breakdown of apparently inactive disease (latent infection) e.g. following an attack of measles or whooping cough. For this purpose, INH is administered in the dose of 5 mg per kg for a period of 1 year. This is particularly important in tuberculin positive children under the age of 5 years in whom the disease and its complications can be severe. Secondary chemoprophylaxis is also justified (a) in individuals showing recent tuberculin conversion from negative to positive, and (b) in ex-tuberculous patients, in whom the disease appears inactive at present, during treatment with glucocorticoids or immunosuppressants, and times of stress such as pregnancy, puerperium, surgery and serious intercurrent illness.</p>
<p>Alternative to INH, directly observed weekly administration of INH and rifampicin for 12 weeks has also been shown to be equally effective in adults without HIV.</p>
<p>BCG VACCINE: BCG is probably the safest among vaccines in use today. It is prepared from Bacille Calmette Guerin, a strain of bovine tubercle bacillus with greatly attenuated virulence, developed in France by Calmette and Guerin. The aim of the vaccination is to increase the patient's resistance by producing artificial primary tuberculous infection with an organism which causes only a local lesion and some swelling of the adjacent lymph nodes.</p>
<p>Before vaccination, a tuberculin test is carried out where 0.0001 mg or 5 test units of purified protein derivative (PPD) obtained from the mycobacterium is injected intradermally on the ventral surface of the forearm. If the test is negative, it is repeated after 6 weeks. If the tuberculin test still remains negative, 0.1 ml of the vaccine is injected intradermally in the deltoid region. This leads to the formation of a papule followed by an ulcer within 4 to 6 weeks. The regional glands are slightly enlarged. Healing occurs gradually thereafter, but the papule may be detectable upto a period of 12 months. After vaccination, the tuberculin test becomes positive within 6 to 12 weeks indicating the development of immunity.</p>
<p>A rare complication of BCG vaccination is a glandular cold abscess. This should be treated with chemotherapy in the usual way. Just an enlargement of lymph nodes needs no treatment. Still rarer is the occurrence of fatal disseminated tuberculosis mainly in children</p>
<p>with hypogammaglobulinemia. Hence, those with hypogammaglobulinemia or eczema should not be vaccinated.</p>
<p>For whom?: BCG vaccination has been shown to be useful in:</p>
<ul>
<li>Tuberculin negative school children.</li>
<li>Contacts of cases with active tuberculosis; and</li>
<li>Persons living in areas with high incidence of tuberculosis.</li>
</ul>
<p>When to use?: Ideally, it is given within first six months of life. Pretesting with PPD is not needed if BCG is given immediately after birth. Preliminary tuberculin testing can also be dispensed with during mass vaccination programme as administration of BCG to tuberculin positive children is not hazardous.</p>
<p>BCG has contributed to the control of tuberculosis. But, the efficacy of different BCG vaccines ranges from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0%</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> in different populations. Its efficacy is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> against serious form of disease in children (meningitis and miliary TB) but variable against pulmonary tuberculosis in adults. It must not be given to anyone with symptomatic HIV infection. BCG gives relative degree of resistance to clinical tuberculosis. The protection, is "not complete, nor permanent, nor predictable, nor measureable". Further, the presence of widespread infection with mycobacteria other than tubercle bacilli can interfere with the protection given by BCG.</p>
<p>BCG and host defence: BCG enhances the host defence mechanisms. It stimulates the reticuloendothelial system and increases resistance against bacterial and viral infections. Its administration can prevent the growth and cause regression of transplanted tumours in animals. In man, local intra-lesional injection of BCG or PPD has been observed to produce beneficial effects in superficial bladder cancer, malignant melanoma and reticulum cell sarcoma.</p>
<p>The mechanism of anticancer action of BCG is not well understood. It probably acts as an immunostimulant. It activates the natural killer cells and the production of hemopoietic stem cells. Macrophages affected by BCG become more active killer cells and more effectively clear antigens and immune complexes, and recruit other cells. Finally, BCG has been reported to cross react with cells of certain malignancies such as melanoma, leukemia and hepatoma.</p>
<p>BCG has also been shown to be useful in leprosy prophylaxis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nontuberculous-mycobacterial-infections">Nontuberculous Mycobacterial Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nontuberculous-mycobacterial-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These infections are caused by organisms such as M. kansasii, M. avium, M. murinum, and M. scrofulaceum; they are grouped under atypical mycobacteria. Of these, M. scrofulaceum causes cervical lymphadenitis especially in children; and M. marinum causes skin disease. Clinical signs and symptoms of M. kansasii infection resembles tuberculosis. M avium complex (MAC) infection is caused by M. avium and M. intracellulare. Though they can affect lungs of immunocompetent persons, the infection is disseminated in patients with HIV. The atypical mycobacteria are frequently resistant to many of the commonly used drugs. Whenever possible, surgical removal of the infected tissue is recommended, followed by chemotherapy. M. kansasii infection is treated with INH, rifampicin and ethambutol given as combination. MAC responds to combination therapy of clarithromycin/azithromycin and ethambutol.</p>
<p>Fluoroquinolones such as ciprofloxacin, ofloxacin and moxifloxacin have inhibitory activity against MAC. Ciprofloxacin is used in the dose of 750 mg bid and levofloxacin in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">500 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> once a day.</p>
<p>RIFABUTIN: is a semisynthetic antibiotic derived from rifamycin S. Its action is similar to that of rifampicin. It is more active than rifampicin against MAC and even against MAC stranis resistant to rifampicin. It is readily absorbed and tissue levels are 5-10 times higher than plasma concentration. CSF concentration is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> that of the plasma. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 45 hours, compared to 3-5 hours of rifampicin. It is mainly eliminated in bile and no dose adjustment is needed in the presense of kidney damage.</p>
<p>Adverse reactions: These include GI disturbances, neutropenia, myalgia and impairment of taste. Other adverse effects are similar to those of rifampicin. It too induces hepatic microsomal enzymes.</p>
<p>Therapeutic uses: It is given in a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">300-600 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day along with other drugs in pulmonary MAC infection for upto six months. Smaller doses are used for treating pulmonary TB and as a single agent for prophylaxis against MAC. It is used in place of rifampicin to treat HIV patients taking protease inhibitors as it does not affect the serum level of these drugs.</p>
<p>CLARITHROMYCIN: This macrolide is used in a dose of 500 mg bid, in combination with ethambutol and rifampin (Chapter 46). It is more potent than azithromycin but the latter has better intracellular penetration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tuberculosis-and-hiv-infection">Tuberculosis and HIV Infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tuberculosis-and-hiv-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HIV infection causes a specific and progressive destruction of the helper T lymphocytes (CD4 cells) and impairs the function of the B lymphocytes and macrophages. This makes an HIV infected person:</p>
<ul>
<li>More liable to have recurrence even after succesful treatment</li>
<li>To get a fresh infection; and</li>
<li>To progress rapidly from latent infection to active clinical tuberculosis.</li>
</ul>
<p>Further, the severity of tuberculosis increases as the destruction of the immune system by HIV progresses. Tuberculosis also increases HIV replication and aggravates it. Both M. tuberculosis and the MAC can infect these patients. The infection appears in the early stages of HIV infection, much before the other opportunistic infections do. Asymptomatic subclinical TB with negative sputum and chest radiograph with positive culture are the common features of HIV associated TB. About 25% of patients with HIV may have undiagnosed active TB. Hence, screening for tuberculosis is recommended for all patients with HIV infections.</p>
<p>Treatment of active TB is with the first line four drug regimen (INH, rifabutin, S/E and Z) for 9-12 months, pyrazinamide being dropped after the first two months. Rifampicin being hepatic enzyme inducer, renders protease inhibitors and NNRTI (except efavirenz) ineffective. Efavirenz regime is compatible with the rifampicin containing therapy.</p>
<p>WHO recommends that HIV infected persons with positive tuberculin skin test but without active TB and living in high burden population are to be treated with any one of the following regimes:
(a) Daily INH for 6-9 months.
(b) INH + rifampicin combination daily (INH: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo><mi mathvariant="normal">R</mi><mo>:</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">300 \mathrm{mg}+\mathrm{R}: 600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) or supervised twice weekly (INH: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>900</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo><mi mathvariant="normal">R</mi><mo>:</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">900 \mathrm{mg}+\mathrm{R}: 600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">900</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) for 3 months.</p>
<p>The antiretroviral therapy is started within the first 8 weeks after the initiation of anti-TB treatement. But patients with CD4 positive cell count <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;50 / \mathrm{cmm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50/</span><span class="mord"><span class="mord mathrm">cmm</span></span></span></span></span></span> should receive such therapy within 2 weeks.</p>
<p>Patients who are already receiving antiretroviral therapy should continue the same when treatment of TB is instituted. Occasionally, these patients may show temporary exacerbation of TB due to immune restitution inflammatory syndrome (IRIS). The latter can be treated with glucocorticoids.</p>
<p>For the treatment of disseminated MAC associated with HIV, at least 2 drugs viz. clarithromycin /azithromycin and ethambutol are used. Many experts prefer rifabutin, clofazimine, fluoroquinolone or amikacin as third or fourth agent. INH and pyrazinamide are not effective. Therapy needs to be continued for life if clinical and radiological improvement is observed. In general, the treatment is more difficult and relapses are frequent.</p>
<p>Prophylaxis against MAC with 300 mg rifabutin daily is started if CD4 count is &lt; 100/cmm. It is continued life time unless active MAC develops, which needs multiple drug therapy.</p>
<p>55</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-leprosy">Chemotherapy of Leprosy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-leprosy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leprosy is caused by Mycobacterium leprae which produces characteristic lesions in the skin and the peripheral nerves. M. leprae is an obligate intracellular acid fast bacilli and their ability to survive within the macrophages and Schwann cells is a key feature of their pathogenicity. The disease is common in South-East-Asia, Africa and other tropical and subtropical countries. Although the leprosy bacillus was discovered by Hansen in 1873, almost 12 years before the discovery of tubercle bacillus, the progress in the chemotherapy of leprosy has been much slower than in that of tuberculosis. This is because, until recently, it was not possible to culture the leprosy bacillus. Further, unlike tuberculosis, human leprosy cannot be transmitted to animals so easily.</p>
<p>Human leprosy bacillus from nasal washings and skin biopsies has now been cultivated successfully in the foot pads of mice; and the disease has been successfully transmitted to some species of armadillo. The infected armadillo tissues contain a large number of leprosy bacilli, thus, providing a good experimental model of human leprosy.</p>
<p>Types of leprosy: Clinically, there are four main types of leprosy:</p>
<ul>
<li>Lepromatous (LL).</li>
<li>Tuberculoid (TL).</li>
<li>Indeterminate (IL); and</li>
<li>Dimorphic (borderline, BL).</li>
</ul>
<p>They are determined by the degree of CMI (Cell mediated immunity) in the host against the lepra bacilli.</p>
<p>In LL, the CMI is low (negative lepromin test), the lesions abound in lepra bacilli and the disease progresses rapidly. The nerves are affected late in the disease. The disease affects mainly the face, nose, ears, eyes and lymph glands. The typical lesion of LL is a macule, a hypopigmented, circular, erythematous patch not associated with itching or hypoalgesia. Macules are usually small, smooth and symmetrically distributed. Eventually, the skin becomes furrowed and nodulated, giving a peculiar 'leonine facies'. Eyelashes fall off. Later, ulceration occurs with marked tissue destruction involving eyes, nose and larynx. Inspite of marked destruction, leprosy, per se, is rarely the cause of death. Histologically, the lesion of LL is essentially a granuloma consisting of many macrophages, called lepra cells, containing numerous bacilli.</p>
<p>In TL, the CMI is intact (strongly positive lepromin test), the organisms are few, nerves are predominantly affected first, and the progress of the disease is slow. The typical tuberculoid lesion is a large, flat, atrophic, hairless, hypopigmented skin area, with red, raised margin showing marked impairment of sensation. The peripheral nerves are thickened. Although <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of leprosy skin lesion have diminished sensation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of lesion are non-anaesthetic in patients with multi-bacillary disease (see later). The prognosis is better than in LL and gross mutilation occurs only secondary to nerve destruction and anaesthesia. Histologically, the lesion consists of focal masses of epitheloid cells and giant cells with lymphocytic infiltration. Since this picture resembles to that seen in tuberculosis, it is called tuberculoid leprosy.</p>
<p>IL or the confusing form is an early stage where the lesions are slight and do not give a clue about the type of disease.</p>
<p>BL is an unstable condition, where immunity is low and which becomes lepromatous if left untreated.</p>
<p>LL and BL forms have plenty of bacilli in the lesions and are called multibacillary leprosy, whereas TL and IL lesions show fewer bacilli and are called paucibacillary leprosy. In the field classification, the presence of more than five skin patches is treated as multibacillary.</p>
<p>The diagnosis of leprosy is essentially clinical, supported by bacteriological evidence from smears from the lesions, nodules, earlobes, or from scrapings of the nasal mucosa. All smear positives are multibacillary type. The lepromin test is of doubtful diagnostic value.</p>
<p>All patients with active leprosy should be treated with chemotherapy. It is, however, unjustifiable and even dangerous to treat this disease on mere suspicion. This not only exposes the patient to prolonged therapy with potentially toxic drugs but can also cause severe psychological trauma. In case of doubtful diagnosis, it is better to wait for definite diagnosis because little harm can be done by waiting. The important aims of therapy are:</p>
<ul>
<li>To achieve clinical cure.</li>
<li>To achieve bacteriological cure; and</li>
<li>To treat physical deformities resulting from nerve and tissue damage.</li>
</ul>
<p>The psychosocial aspect of the patient and his environment also need attention.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-leprosy">Drugs Used in Leprosy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-leprosy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Table 55.1 lists the drugs used in the treatment of leprosy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-55-1">Table 55.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-55-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-used-in-leprosy">Drugs used in leprosy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-leprosy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">- Sulfones Dapsone</th></tr></thead><tbody><tr><td style="text-align: left;">- Rifampicin</td></tr><tr><td style="text-align: left;">- Clofazimine</td></tr><tr><td style="text-align: left;">- Ethionamide/Prothionamide</td></tr><tr><td style="text-align: left;">- Fluoroquinolones Ofloxacin; pefloxacin</td></tr><tr><td style="text-align: left;">- Other antibiotics Minocycline;</td></tr><tr><td style="text-align: left;">- Clarithromycin</td></tr></tbody></table>
<p>SULFONES: Sulfones are derivatives of 4-4' diamino-diphenyl sulfone (DDS, Dapsone) (Fig. 55.1). It is interesting to note that DDS was first synthesised in 1908 but its antibacterial property remained unknown until 1937 and its value as an antileprotic drug was discovered only in 1941!
<img src="assets/images/image-20251214-c12473c2.jpeg" alt="img-8.jpeg"></p>
<p>Sulfones are chemically related to sulfonamides and although they are highly effective in experimental streptococcal infection, they are too toxic for use for this purpose in man. They are, however, very useful in the treatment of leprosy because the doses needed are very small. Among the various sulfones, dapsone still remains the drug of choice.</p>
<p>Mechanism of action: Sulfones are essentially bacteriostatic and act by inhibiting the de novo synthesis of folic acid by M. leprae. The action of DDS is antagonised by para-aminobenzoic acid similar to sulfonamides.</p>
<p>Sulfones have bacteriostatic action also against other bacteria susceptible to sulfonamides and against the tubercle bacilli. They are, however, not used in the treatment of other infections because of their toxicity.</p>
<p>Absorption, fate and excretion: DDS is slowly but completely absorbed from the GI tract. The peak plasma level is reached within 1-3 hours after oral administration and the drug remains detectable in the plasma for 8-12 days ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>27</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 27</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">27</span></span></span></span></span> hours). Sulfones are cumulative drugs. They are distributed throughout the body fluids and tissues and can be detected in the tissues upto 3 weeks after stoppage of therapy. Sulfones get concentrated more in the leprosy-affected skin than in the normal skin. These compounds are metabolised in the liver and excreted in urine as glucuronic acid conjugates. They are also excreted in large quantities in bile; this portion however, is reabsorbed. Excretion also occurs in human milk.</p>
<p>Dapsone resistance: Both primary and secondary resistance of M. leprae to dapsone is well established, and is associated with gene mutation. However, primary resistance to dapsone is rare.</p>
<p>Adverse reactions: These are similar to those due to sulfonamides. They commonly cause anorexia, nausea and vomiting. They can give rise to allergic reactions like dermatitis and drug fever. Skin sensitisation can occur in about 3% of dark skinned patients. Fatal exfoliative dermatitis (Stevens-Johnson syndrome) associated with drug fever, hepatitis and psychosis can rarely occur.</p>
<p>Sulfones are powerful oxidant drugs and can cause hemolytic anemia. Patients with G6PD deficiency are more susceptible. They can also cause anemia, methemoglobinemia and agranulocytosis. Other toxic effects include hematuria, liver damage and goitrogenesis.</p>
<p>Although the list of toxicity is formidable, sulfones are remarkably well tolerated by most of the leprosy patients in the dosage recommended.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Dapsone (DDS): 50-100 mg tablets. It is given in the dose of 100 mg daily. Such dosage results in peak plasma levels that exceed the MIC of dapsone against M. leprae by a factor of about 500. Such high levels inhibit the multiplication of mutants of M. leprae with low or moderate degrees of dapsone resistance.
(ii) Dapsone injection is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">20 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> suspension in arachis oil. Dose: 0.2 ml IM, weekly, gradually increased to a maximum of 0.8 ml weekly.</p>
<p>Other uses of sulfones: Dermatitis herpetiformis is a chronic disease characterised by intensely itching papules, urticaria-like lesions, vesicles and bullae on the extensor surfaces of the body. A gluten-sensitive enteropathy is observed in many patients with this disease. Dapsone, in the dose of 50 mg orally, daily, increased by 25 mg (daily dose) once in 10-15 days to 25 mg three to four times daily, rapidly controls the skin lesions. If the patient adheres strictly to the gluten-free diet, the dose of dapsone can be reduced.</p>
<p>Dapsone has also been used to treat Pneu-mocystitis jiroveci infection, and in combination with pyrimethamine, MDR falciparum malaria (Chapter 56).</p>
<p>RIFAMPICIN: This antituberculous antibiotic has been discussed in Chapter 54. Its introduction has revolutionised the management of leprosy. It is bactericidal and given orally, it is highly effective in leprosy. Few toxic effects have been reported so far in the case of monthly administration. Supervised administration of 600 mg of rifampicin single dose once a month is equally effective as daily administration. Bacterial resistance to rifampicin can occur.</p>
<p>ETHIONAMIDE: This drug is described in detail in Chapter 54. It is expensive and more toxic than dapsone but perhaps has faster bactericidal action against M. leprae than full dosage dapsone. It is administered orally, daily. Prothionamide has similar properties as ethionamide.</p>
<p>CLOFAZIMINE: This red-purple phenazine dye is well absorbed after oral administration. It is principally retained in tissues of the reticuloendothelial system and concentrated by macrophages of the skin. It acts by inhibition of mycobacterial DNA synthesis. It is probably bactericidal and has action against dapsone resistant organisms. It also possesses anti-inflammatory properties. Bacterial resistance to clofazimine is rare. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 70 days and is excreted in the urine slowly for several weeks.</p>
<p>It imparts a reddish black hue to the skin of patients, which persists for several months. Clofazimine is also deposited in the intestine where it may cause segmental thickening leading to crampy pain and diarrhoea. Otherwise, it is remarkably free of toxicity.</p>
<p>In the dose of 100 mg three times a day, it is useful in lepra reactions because of its simultaneous bactericidal and anti-inflammatory actions. It can effectively relieve the</p>
<p>agonising pain in lepra reactions in tuberculoid leprosy. It is also claimed that the drug enhances the ability of human macrophages to kill listeria.</p>
<p>It is also used in MDR-TB (Chapter 54).
New drug regimens: The currently available drugs for the treatment of leprosy can be arranged in decreasing order of in vitro bactericidal activity as: rifampicin, ofloxacin/ Pefloxacin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day), minocycline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day), clarithromycin, ethionamide prothionamide, clofazimine and DDS. Studies indicate that 100 mg of minocycline with 500 mg of clarithromycin given daily produces beneficial effects. Such regimens are particularly useful in patients allergic to DDS and those with resistant infection.</p>
<p>Chaulmoogra and Hydnocarpus oils, used previously, are now of historical interest.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-leprosy">Management of Leprosy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-leprosy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leprosy, which was once considered to be an incurable disease can now be cured completely. As in the case of tuberculosis, the main difficulty in the treatment of leprosy is in persuading the patient to continue the drug therapy regularly for a prolonged period. For best results it is essential to detect and treat cases in early stages. The medical treatment of leprosy can be wholly undertaken by practitioners or by trained medical auxiliaries in the majority of patients. Some knowledge about the natural history of the disease, details about the drug therapy and a compassionate outlook towards the patient are all that is necessary for managing the patients.</p>
<p>The disease is transmitted by prolonged and intimate contact with untreated, open lepromatous patients whose cutaneous lesions and mucosal discharges teem with leprosy bacilli. The multiplication time of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. tuberculosis is 18 hours whereas that of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>. leprae is 12 days. Therefore, rifampicin has to be given twice a week in tuberculosis whereas in leprosy even once a month regime is effective. A single dose of 600 mg rifampicin kills <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of lepra bacilli within 4 days and hence there is no public health problem after 4 days of therapy.</p>
<p>Majority of the patients can be treated as outdoor patients, in mobile clinics or in primary health centres. Only a few may need hospitalisation. Segregation must not be advocated very loosely as this would cause social disruption and considerable psychological trauma, particularly in a society ridden with prejudices and traditions where a patient may be outcast for life and made miserable. Usually, the patients developing reactions during drug therapy and those with impending eye or nerve damage need hospitalisation. Isolation is indicated in patients with LL who are untreated or in whom treatment has lapsed; these are the patients whose skin lesions and mucosal discharges teem with lepra bacilli. Such patients can be rapidly rendered non-infectious by using rifampicin. There is no danger in admitting other forms of leprosy patients to general hospital wards if simple principles of barrier nursing are observed and routine hygienic precautions are strictly followed.</p>
<p>Choice and duration of therapy: Although approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99.9%</span></span></span></span></span> of leprosy bacilli are killed in about 3-4 months by dapsone or clofazimine given daily and within 3-7 days by rifampicin given in a single dose of 600 mg , some bacilli may still persist for a long time. This is probably so because, though drug sensitive, the bacilli are not metabolically active. These persisters can cause relapse over 3-30 years. So far, no drug given alone can eliminate all "persisting" M. leprae. Hence, as in TB, combination of drugs is recommended in order to:</p>
<ul>
<li>Prevent drug resistance to monotherapy.</li>
<li>Eliminate persisting organisms; and</li>
<li>Reduce the required duration of effective therapy.</li>
</ul>
<p>Rifampicin, dapsone and clofazimine are the first line drugs in leprosy. All patients should receive a multidrug therapy (MDT) as recommended by WHO (Table 55.2). Tuberculosis must be excluded before starting monthly rifampicin.</p>
<p>Table 55.2
WHO recommended regimen for leprosy</p>
<table><thead><tr><th style="text-align: left;">Leprosy type</th><th style="text-align: left;">Drugs</th><th style="text-align: center;">Duration</th></tr></thead><tbody><tr><td style="text-align: left;">Tuberculoid (paucibacillary)</td><td style="text-align: left;">Dapsone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span>, unsupervised + Rifampicin 600 mg monthly (supervised)</td><td style="text-align: center;">6 months</td></tr><tr><td style="text-align: left;">Lepromatous (multi-</td><td style="text-align: left;">Dapsone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{d}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span><span class="mord">+</span></span></span></span></span> clofazimine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> (unsupervised) and + rifampicin 600 mg clofazimine 300 mg monthly</td><td style="text-align: center;">12 months</td></tr><tr><td style="text-align: left;">bacillary)</td><td style="text-align: left;">(supervised)</td><td style="text-align: center;"></td></tr></tbody></table>
<p>For low body weight (less than 35 kg ) multibacillary patient rifampicin is given 450 mg single dose monthly (supervised) and dapsone in the dose of 50 mg daily. Similar doses are used for adolescents. It is recommended that MDT be given for 1 year and be continued, when possible, upto smear negativity in LL cases. In case clofazimine is not acceptable because of its skin pigmentation, ethionamide in the dose of 250 mg . daily plus INH 300 mg daily (self-administered) may be given. Alternatively, minocycline 100 mg daily or ofloxacin 400 mg daily may be substituted for clofazimine.</p>
<p>In case of paucibacillary leprosy (tuberculoid and indeterminate), WHO recommends rifampicin 600 mg once a month (supervised) and dapsone 100 mg daily (self administered), for six months. Indian experience, however, suggests that for the best results, the duration of dapsone therapy should be extended to 12 months. In all cases, the maximum dosage of dapsone should be used from the start and need not be reduced during lepra reaction.</p>
<p>Doses recommended in children are given in Table 55.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-55-3">Table 55.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-55-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="suggested-doses-for-leprosy-in-children">Suggested doses for leprosy in children<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#suggested-doses-for-leprosy-in-children" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Age</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Drug</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">10-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> yrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">&lt;10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> yrs</td></tr><tr><td style="text-align: center;">Dapsone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</td></tr><tr><td style="text-align: center;">Rifampicin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>450</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">450 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">450</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> month (supervised)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">300 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> month (supervised)</td></tr><tr><td style="text-align: center;">Clofazimine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> month supervised and 50 mg on alternate days (unsupervised)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> month supervised; and &lt;br&gt; 50 mg twice a week (unsupervised)</td></tr></tbody></table>
<p>WHO recommends one time dose for treating a single skin lesion of paucibacillary leprosy, using rifampicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">600 \mathrm{mg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">+</span></span></span></span></span> ofloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">400 \mathrm{mg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">+</span></span></span></span></span> minocycline 100 mg , all taken together (ROM therapy). Smaller doses are used in children. Other experts do not recommend such a single dose regimen but advocate more intensive and prolonged regimens (daily dapsone and daily R) in all patients with leprosy.</p>
<p>Since leprosy is exacerbated during pregnancy it is important to continue the treatment with dapsone, rifampicin and clofazimine.</p>
<p>It must be pointed out that the above mentioned MDT may be beyond the reach of many of patients in developing countries. Hence, DDS in the dose of 100 mg daily may be the only drug available for mass use. Prolonged dapsone monotherapy for 1-2 years is claimed to be curative in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of TL cases. Dapsone, if used alone, should be continued for 2-3 years after the disease becomes inactive. In LL (which takes 2-6 years to become inactive) dapsone should be continued for 10 years after the disease becomes inactive. If, at this stage, the lepromin test is positive (indicating the presence of normal CMI), dapsone may</p>
<p>be discontinued. If it is negative, dapsone must be continued lifelong.
The disease is considered inactive when during a 12 month period:</p>
<ul>
<li>The disease is clinically inactive.</li>
<li>No acid fast bacilli are demonstrated by the slit-and-scrape samplings from the skin sites; and</li>
<li>Skin biopsies are negative for acid-fast bacilli.</li>
</ul>
<p>Clinical activity in tuberculoid leprosy is denoted by:
(a) Increase in the size of previous lesions or the appearance of new ones.
(b) Persistence of erythema or infiltration in the lesions.
(c) Progressive sensory impairment and motor loss; and
(d) Continuation or worsening of local tenderness of peripheral nerves.</p>
<p>In lepromatous leprosy, clinical activity is indicated by:
(a) Continued presence of hypopigmented macules or nodules; and
(b) Tenderness on peripheral nerves.</p>
<p>All patients should be periodically tested for sensory and motor nerve involvement in all four limbs. Prednisolone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) should be added to the specific chemotherapy promptly on suspicion of sensory or motor involvement. It should be tapered over a period of 8-12 months.</p>
<p>Following drug therapy, early lesions disappear completely. Late cutaneous lesions in LL show atrophy, tissue paper like wrinkling and scarring. In TL, nerves already damaged may remain permanently thickened. Local treatment may be necessary for neuropathic ulcerations of the extremities, caused by repeated trauma to insensitive tissues.</p>
<p>Minocycline and a fluoroquinolone can be substituted in dapsone-resistant cases.
Prognosis with early drug therapy is excellent and recovery is almost complete without any residual damage. Mild anemia is not a contraindication to dapsone therapy. Dapsone may be used (along with hematinics) to treat a patient with hemoglobin less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>.</p>
<p>Following adequate MDT, the tuberculoid or indeterminate leprosy rarely recurs and usually no treatment is necessary after the clinical cure. In case of lepromatous leprosy, patients should be followed up at regular intervals for detecting a possible recurrence. Impairment of nerve function can occur even during or after MDT, and needs to be monitored for 23 years.</p>
<p>The current challenges in the therapy of leprosy are poor compliance and emergence of rifampicin resistant strains.</p>
<p>Lepra reactions: The acute exacerbation that occurs during the course of leprosy is called lepra reaction. They are usually precipitated by anxiety, malaria, acute infections and during treatment with sulfones. They are of two types:</p>
<ul>
<li>Type I reaction; and</li>
<li>Type II reaction.</li>
</ul>
<p>Type I reaction, (Reversal Reaction):
(i) It occurs in patients with good CMI towards M. leprae.
(ii) Existing lesions show increased erythema, swelling and tender peripheral nerves. Loss of nerve function may occur.
(iii) The constitutional symptoms are not marked.
(iv) Often it leads to a decrease in the number of bacilli in the lesions.</p>
<p>This type of reaction usually occurs in tuberculoid leprosy. The mechanism of type I</p>
<p>reactions is thought to be delayed type of hypersensitivity. The treatment is mainly directed at controlling acute inflammation, reversing the eye and nerve damage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="type-ii-reaction">Type II reaction:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-ii-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) This is a more severe reaction than the first one.
(ii) It occurs usually in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of lepromatous leprosy and is characterised by erythema nodosum leprosum (ENL). The basic lesion is a vasculitis following deposition of (antigen + antibody) immune complexes. Suddenly, many crops of bright erythematous nodules and raised patches appear and the existing lesions become worse.
(iii) It may be associated with fever, iritis, neuritis, arthritis orchitis and lymphadenitis.
(iv) It is difficult to treat and lesions may actually spread.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-drugs-used-are">The drugs used are:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-drugs-used-are" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Clofazimine and prednisolone: They are administered in both types of reactions. They act as anti-inflammatory agents. Clofazimine is given in the dose of 100 mg tid for several days; and prednisolone in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>×</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\times 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">×</span><span class="mord">2</span></span></span></span></span> weeks, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>×</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\times 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">×</span><span class="mord">2</span></span></span></span></span> weeks, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>×</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\times 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">×</span><span class="mord">2</span></span></span></span></span> weeks, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>×</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\times 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">×</span><span class="mord">2</span></span></span></span></span> weeks and then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. The treatment is continued for 3-12 months, depending on the severity of the reaction. The severe pain in lepra reaction in tuberculoid leprosy, arising from swollen nerves, responds well to clofazimine and prednisolone. The earlier the introduction of prednisolone, the more likely is it to prevent permanent nerve damage.
DDS is continued in full doses throughout both types of lepra reactions.</li>
<li>Thalidomide, a selective TNF alpha inhibitor (Chapter 74), in the dose of 400 mg daily, is very useful and even better than steroids for managing acute severe and chronic ENL. It causes dryness of mouth, constipation and diarrhoea. It is highly teratogenic and is absolutely contraindicated in pregnancy. In chronic ENL, thalidomide may have to be given for many years. Severe type II reactions need prolonged treatment with prednisolone and thalidomide.
Leprosy prophylaxis: It is advisable to avoid skin to skin contact with patients with LL with open lesions. Pus from ulcers is highly infectious. Airborne droplet infection is a distinct possibility and mechanical transmission by biting insects cannot be ruled out.</li>
</ul>
<p>Antitubercular BCG vaccine (Chapter 54) has been shown to endow some protection against leprosy. Similarly, prophylactic dapsone at half the therapeutic dose is sometimes recommended in close contacts, particularly in children of leprotic mothers.</p>
<p>56</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-malaria">Chemotherapy of Malaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-malaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The term 'Malaria' is coined from the Italian phrase 'mal aria', meaning 'bad air'. The disease was very active in Rome for centuries, and at least four Popes are believed to have lost their lives due to malaria.</p>
<p>Malaria is caused by parasitic protozoa of the genus Plasmodium and is characterised by fever with rigor, anemia and splenomegaly. The morbidity due to malaria in Asia and Africa has been greatly underestimated. Currently, it is estimated that nearly half a billion people in the world suffer from malaria, and more than a million die from malaria every year, most of them from the developing countries. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the cases the world over are caused by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum.</p>
<p>Life cycle of plasmodium: There are four major types of plasmodia which infect man:</p>
<ul>
<li>P. vivax</li>
<li>P. falciparum</li>
<li>P. ovale; and</li>
<li>P. malariae
P. vivax causes benign tertian malaria which, though mild, has a tendency to relapse. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection results in malignant tertian malaria, a fulminating infection, which, if not treated, may result in death; but the disease, once cured, has no tendency to relapse. In both infections, the infected individual develops pyrexia with rigors every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day, and hence the term 'tertian'. P. ovale and P. malariae infections are usually mild; the individual develops pyrexia every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>4</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">4^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day and hence, it is described as 'benign quartan'. Recently, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. knowlesi has been shown to infect human beings. In order to understand the actions of antimalarials, it is necessary to know parasite life cycle.</li>
</ul>
<p>An individual is infected by malarial parasites through the bite of a female Anopheles mosquito. The disease can also be transmitted by transfusion of infected blood and from mother to the foetus across the placenta. The salivary glands of the infected mosquito contain a large number of sporozoites, which are introduced into of the host during mosquito bite (Fig 56.1). After the entry, the sporozoites develop further through various stages:</p>
<p><img src="assets/images/image-20251214-592ad0b1.jpeg" alt="img-9.jpeg"></p>
<p>FIG. 56.1 Life cycle of malarial parasite (P. falciparum)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-pre-erythrocytic-stage">(1) Pre-erythrocytic Stage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-pre-erythrocytic-stage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(2) Erythrocytic Stage;
(3) Development of sexual forms.</p>
<p>In the pre-erythrocytic stage, sporozoites disappear rapidly from the circulation and invade the hepatic cells (Hepatic cycle - Site I). The duration of the pre-erythrocytic stage varies with the species of plasmodium. It is 5 to 7 days for P. falciparum and 8 days to several months for P. vivax. The host does not develop any symptoms during this phase. At the completion of this phase, the infected reticuloendothelial cell, termed tissue schizont (primary exoerythrocyte) form) releases several thousand merozoites into the blood stream.</p>
<p>In the erythrocytic stage (Site II), merozoites invade the erythrocytes and undergo further development and multiplication, giving rise to erythrocytic schizonts (asexual erythrocyte forms). The infected RBCs eventually rupture, and release thousands of merozoites into the blood. This periodic release of merozoites is associated with paroxysms of fever with rigor. The merozoites thus released invade fresh erythrocytes, and the cycle of erythrocytic schizogony repeats.</p>
<p>Development of sexual forms starts with the differentiation of some of the released merozoites into male (macro) and female (micro) gametocytes (Site III). During a mosquito bite, these forms are sucked in from the blood and mature into gametes in the mosquito gut. The female gamete is fertilised by the motile male gamete to form a zygote. The zygote invades the gut wall of the mosquito to form an oocyst. The mature oocyst contains thousands of sporozoites. After about 1 to 4 weeks, depending upon the species of plasmodium, the oocyst ruptures releasing free sporozoites which reach the salivary glands of the mosquito and are ready to be injected in the host.</p>
<p>The above cycle in case of P. falciparum, terminates at this point. However P. vivax and P.</p>
<p>ovale have persistent hepatic cycle due to presence of hypnozoites, also known as latent tissue phase or exo-erythrocytic phase. The delayed formation of tissue schizonts from such latent hypnozoites explains the relapses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. ovale malaria. In case of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. malariae, the relapse may originate from erythrocytic forms remaining in the body for upto 30 years, due to no exoerythrocytic schizogony.</p>
<p>The larger number of merozoites released by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum and the short incubation period explain the high levels of parasitaemia and severity of this infection. If left untreated, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection lasts for less than one year and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. ovale infections usually take 3-4 years to die out. Infection due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. malariae may, however, persist for many years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-classification-of-antimalarial-drugs">Clinical classification of antimalarial drugs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-classification-of-antimalarial-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I True causal prophylactics: These are the drugs that would destroy the sporozoites before their invasion of the host reticuloendothelial cells. No drug of this type, however, is available. II Causal prophylactics: These drugs prevent the maturation of or destroy the sporozoites within the infected hepatic cells (Site I) and thus prevent erythrocytic invasion. They are also known as primary tissue schizonticides. Primaquine, pyrimethamine and proguanil act as causal prophylactics against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum but their efficacy against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax is doubtful. III Suppressives: These drugs (schizonticides) inhibit erythrocytic schizogony (Site II) and prevent the rupture of the infected erythrocytes. This leads to freedom from rigors and pyrexia (clinical cure). However, they do not eradicate the infection.</p>
<p>Suppressives can cure P. falciparum infection as the parasite does not undergo secondary exoerythrocytic schizogony but they do not affect the persistent tissue phase of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax (hypnozoites) and hence relapses can occur with the stoppage of suppressive therapy. The suppressive agents include:
(a) Rapidly acting quinine, 4-aminoquinolines, mefloquine, artemisinin, atovaquone and
(b) Slowly acting proguanil, pyrimethamine, sulfadoxine and tetracycline.</p>
<p>IV Radical curatives: These drugs eradicate both, erythrocytic and secondary exoerythrocytic schizogony so that relapse does not occur. For radical cure of vivax infection, primaquine and proguanil are effective (See later). Radical cure of falciparum malaria can be achieved with suppressives alone.
V Gametocytocidal drugs: The suppressives such as chloroquine, quinine and artesunate are effective against gametocytes of all species except P. falciparum. Primaquine is, however, highly effective against gametocytes of all species, including P. falciparum.</p>
<p>Proguanil and pyrimethamine do not destroy gametocytes but prevent their development in the mosquito. They are also known as sporonticidal drugs.</p>
<p>Chemical classification:
I Cinchona alkaloids: Quinine, Quinidine
II Quinoline derivatives:
(a) 4-Aminoquinolines: Chloroquine, Amodiaquine, Pyronaridine.
(b) 8-Aminoquinolines: Primaquine, Tafenoquine, Bulaquine.
(c) Quinoline methanol: Mefloquine,</p>
<p>III Phenanthrene methanol: Halofantrine, Lumefantrine.
IV Antifolates:
(a) Biguanides: Proguanil.
(b) Diaminopyrimidines: Pyrimethamine.</p>
<p>(c) Sulfonamides : Sulfadoxine.</p>
<p>V Artemisinin compounds: Artesunate, Artether, Artemether.
VI Antimicrobials: Doxycycline, Clindamycin, Atovaquone. Table 56.1 summarises the actions of the commonly used antimalarials.</p>
<p>Table 56.1
Actions of commonly used drugs on the life cycle of the malarial parasites</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Hepatic phase</th><th style="text-align: center;">Erythrocytic phase</th><th style="text-align: center;"></th><th style="text-align: center;">Latent tissue phase (responsible for relapse)</th><th style="text-align: center;">Development of gametocytes in the mosquito (sporosticidal action)</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">Asexual parasites</td><td style="text-align: center;">Sexual forms (gametocytes)</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Quinine</td><td style="text-align: center;">No action</td><td style="text-align: center;">Fast action</td><td style="text-align: center;">Active against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. malariae. No direct action on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum</td><td style="text-align: center;">No action</td><td style="text-align: center;">No action</td></tr><tr><td style="text-align: center;">Chloroquine &lt;br&gt; Amodiaquine</td><td style="text-align: center;">No action</td><td style="text-align: center;">Fast action</td><td style="text-align: center;">As quinine</td><td style="text-align: center;">No action</td><td style="text-align: center;">No action</td></tr><tr><td style="text-align: center;">Primaquine</td><td style="text-align: center;">Active and can be used for prophylaxis</td><td style="text-align: center;">Weakly active</td><td style="text-align: center;">Direct and fast action on all species but particularly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum</td><td style="text-align: center;">Highly active</td><td style="text-align: center;">Highly active</td></tr><tr><td style="text-align: center;">Proguanil</td><td style="text-align: center;">Active particularly on P. falciparum</td><td style="text-align: center;">Active but relatively slow</td><td style="text-align: center;">No direct action</td><td style="text-align: center;">No action</td><td style="text-align: center;">Highly active</td></tr><tr><td style="text-align: center;">Pyrimethamine</td><td style="text-align: center;">As proguanil</td><td style="text-align: center;">As proguanil</td><td style="text-align: center;">No evidence of direct action</td><td style="text-align: center;">Some action on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax</td><td style="text-align: center;">Little evidence</td></tr><tr><td style="text-align: center;">Sulfones and Sulfonamides</td><td style="text-align: center;">Possible action</td><td style="text-align: center;">Action slow</td><td style="text-align: center;">As pyrimethamine</td><td style="text-align: center;">Little evidence</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Mefloquine</td><td style="text-align: center;">No action</td><td style="text-align: center;">Marked but slow</td><td style="text-align: center;">As quinine</td><td style="text-align: center;">No action</td><td style="text-align: center;">No action</td></tr><tr><td style="text-align: center;">Artesunate</td><td style="text-align: center;">No action</td><td style="text-align: center;">Fastest acting</td><td style="text-align: center;">Active against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax</td><td style="text-align: center;">No action</td><td style="text-align: center;">No action</td></tr><tr><td style="text-align: center;">Atovaquone</td><td style="text-align: center;">No</td><td style="text-align: center;">More active than Chloroquine</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cinchona-alkaloids">Cinchona Alkaloids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cinchona-alkaloids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>QUININE is an alkaloid isolated from the bark of the cinchona tree, originally a native of Peru, South America, and known for many years as 'Jesuit's bark'. Quinine, the oldest of all the therapeutic agents used to treat malaria is still useful in the treatment of cerebral malaria and chloroquine-resistant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Antimalarial action: Quinine is schizonticidal and is useful only as a suppressive. It is also gametocidal against all species except P. falciparum. It has no effect on the sporozoites, the pre-erythrocytic stage and the persistent tissue forms.
Mechanism of action of quinine is like that of chloroquine (see later) but as the drug is not extensively concentrated in the parasites, other mechanisms may also be involved.</li>
<li>Quinine has been termed as a 'general protoplasmic poison'. It depresses various enzymatic processes, reduces ciliary activity, and inhibits phagocytosis and the growth of fibroblasts.</li>
<li>Local irritant action: Quinine causes pain, edema, and reactive fibrosis. Sterile injection abscesses and venous thrombosis may occur.</li>
<li>GI tract: Quinine has an intensely bitter taste and can cause nausea, vomiting and epigastric pain.</li>
<li>Cardiovascular actions: Like quinidine, another cinchona alkaloid, quinine is also a direct depressant of the myocardium. It reduces excitability, conductivity and lengthens the refractory period. Quinine IV can produce profound hypotension due to cardiac depression and dilatation of the arterioles.</li>
<li>Miscellaneous actions: It has a mild analgesic and antipyretic activity. It stimulates the uterine smooth muscle. However, in the doses in which it is used in malaria, it has hardly any adverse effect on the pregnant uterus. It has a curarimimetic action on the skeletal muscles.
Absorption, fate and excretion: Administered orally, it is almost completely and rapidly absorbed from the small intestine; and the peak plasma levels are reached within 1 to 3 hours. It readily crosses the placental barrier.</li>
</ul>
<p>Quinine is mainly metabolised in the liver. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 10 hours but it is usually prolonged in the acute stage of falciparum infection because of hepatic impairment. Approximately 5% of the total dose appears in urine unchanged.</p>
<p>Adverse reactions: The major reason for the decline in popularity of quinine is its toxicity. The salient toxic manifestations are:</p>
<ul>
<li>Cinchonism: This syndrome, which occurs when quinine is administered for a long time, resembles salicylism. Mild symptoms consist of ringing in the ears, nausea, headache and visual impairment. With large doses, tinnitus, deafness, vertigo, blurred vision, disturbances of colour vision and photophobia appear. Toxic amblyopia occasionally leading to total blindness has been rarely reported.
Severe intoxication causes, skin rashes, headache, fever, vomiting, diarrhoea, confusion and delirium. The respiration is depressed, BP falls, and eventually death may occur due to respiratory arrest. Even if the patient recovers, visual and auditory impairment may not be entirely corrected. The treatment is essentially symptomatic.</li>
<li>Idiosyncrasy: The commonest manifestation is intense flushing accompanied by</li>
</ul>
<p>generalised pruritus and urticaria. Quinine may precipitate angioneurotic edema or asthmatic attacks in sensitive individuals. Rarely, it causes thrombocytopenic purpura, hemolytic anemia and agranulocytosis.</p>
<ul>
<li>Cardiovascular toxicity: Quinine is a myocardial depressant and can cause cardiac arrest when given IV.</li>
<li>Black water fever: It is characterised by acute intravascular hemolysis, hemoglobinuria, fever and acute renal failure. It is encountered with chronic P. falciparum malaria. Focal hepatic necrosis may develop in severe cases. Blackwater fever may occur during the natural course of malaria, and is often triggered by quinine treatment. It is probable that the reaction has immunological basis and is caused by a state of hypersensitivity attributable to the presence of incompletely suppressed falciparum infection. It is important to continue appropriate antimalarial therapy in such a patient. Fresh blood transfusion to maintain hematocrit above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> may be necessary. The fluid and electrolyte imbalance, should be corrected along with treatment of hypotension. Alkalinisation of urine and use of glucocorticoids are controversial. Later, the patient should be evaluated for his G6PD status.</li>
<li>Hypoglycemia: Quinine can cause hypoglycemia by releasing insulin from the pancreatic beta cells.</li>
<li>Miscellaneous: Quinine IV may cause convulsions.</li>
</ul>
<p>Preparations and dosage:
(i) Quinine sulfate tablet 300 mg . Dose: 300 to 600 mg .
(ii) Quinine hydrochloride tablet 300 mg . Dose: 300 to 600 mg .
(iii) Quinine sulfate injection contains 300 mg of the salt per ml . It can be administered by IV infusion or by deep IM route. Dose: 300 to 600 mg .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Malaria: It is an important drug for treating severe falciparum infection (see later).</li>
<li>Myotonia congenita: This hereditary myopathy, characterised by tonic spasm of skeletal muscles, is often benefitted by 300 to 600 mg of quinine hydrochloride given orally twice or thrice daily.</li>
<li>Cramps: The drug has been used in the dose of 200 to 300 mg before retiring to prevent nocturnal muscle cramps.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-aminoquinolines">4-Aminoquinolines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-aminoquinolines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The 4-aminoquinolines constitute the mainstay of suppressive therapy of malaria. In addition, they are useful in a variety of other conditions. The therapeutically useful compounds of this class are chloroquine, hydroxychloroquine and amodiaquine.</p>
<p>CHLOROQUINE: This is the most frequently used compound (Fig 56.2) and is used as the diphosphate salt.
<img src="assets/images/image-20251214-fd2b9d0d.jpeg" alt="img-10.jpeg"></p>
<p>FIG. 56.2 Chloroquine
Mechanism of action: Malarial parasites digest haemoglobin in their lysosomes to utilise amino acids. The released heme is highly toxic but is converted by the parasitic polymerase to nontoxic hemozoin. Chloroquine, being a basic drug, concentrates in the acidic lysosomes and binds to released heme, thus preventing its polymerisation. This results in oxidative damage to organelles of parasites, causing death.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Antimalarial activity: As a suppressive, chloroquine is superior to quinine.
(i) It kills the erythrocytic forms of P. vivax and P. falciparum.
(ii) It is also effective against the gametocytes of P. vivax, P. ovale and P. malariae.</li>
</ul>
<p>However, it has no effect on the sporozoites, the pre-erythrocytic stage and the persistent tissue forms.</p>
<p>Resistance to chloroquine by P. falciparum develops due to an efflux mechanism by which the parasite pumps the drug out of the cell. Such organisms exhibit cross-resistance to other 4-aminoquinolines.</p>
<ul>
<li>Other antiparasitic actions: The drug is also effective in giardiasis, taeniasis and extraintestinal amoebiasis.</li>
<li>CVS: Like quinine, chloroquine is a direct cardiac depressant and may exert a direct relaxant effect on vascular smooth muscles causing hypotension.</li>
<li>Miscellaneous actions: It has some anti-inflammatory, antihistaminic and local anaesthetic activities.
Absorption, fate and excretion: Chloroquine is rapidly and almost completely absorbed from the gut. Effective plasma concentration is attained within 2-3 hours of oral dose and within 15 minutes of IM administration. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>55</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">55 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">55%</span></span></span></span></span> of the drug in plasma is protein bound. It is highly concentrated in the liver, spleen, kidney, lung and leucocytes. The brain and the spinal cord levels, however, are only 10 to 30 times the plasma levels. Because of its high volume of distribution, a loading dose is necessary to initiate therapy. Due to its affinity for the tissue proteins, the drug persists in the body for a long time after discontinuation. It is metabolised in the liver to the active metabolite 4-hydroxychlo-roquine. Acidification of urine hastens its renal excretion.</li>
</ul>
<p>Adverse reactions: Chloroquine used as an antimalarial is a relatively safe drug. Commonly it causes nausea and vomiting. The drug, however, may produce serious toxicity when used in large doses for prolonged periods as in RA. The important toxic manifestations are:</p>
<ul>
<li>Intolerance: Skin rashes with or without pruritus, angioneurotic edema, photosensitivity, pigmentation and even exfoliative dermatitis have been reported. Long term treatment may lead to bleaching of the scalp hair, eyebrows and eyelashes. Rarely, thrombocytopenia, and pancytopenia may occur.</li>
<li>Eye: Ocular complications can occur with the high dosage, prolonged chloroquine therapy of RA, discoid lupus and lupus erythematosus. They are very rare during the treatment of malaria. Temporary loss of accommodation with blurring of vision or diplopia may develop. Difficulties in focussing eyes have been reported in pilots taking chloroquine prophylactically. It is reversible on discontinuation. Lenticular opacities and posterior subcapsular cataracts have been reported. The retinal changes (retinopathy), consist of constriction of the retinal arteries, edema and abnormal blue-black pigmentation of the retina and depigmentation of the macula accompanied by macular degeneration. The field of vision is constricted. These changes are not reversible and need immediate discontinuation of the drug. Because of its prolonged sojourn in the body, the ocular changes may appear even a few years after discontinuation of chloroquine. Hence, patients on long term chloroquine therapy (as in RA) should undergo periodic ophthalmoscopic examination.</li>
<li>Central Nervous System: Insomnia and transient depression are common. Acute psychotic episodes, seizures and, rarely, neuromyopathy may occur. Ototoxicity has also been reported.</li>
<li>Cardiovascular System: Abnormalities of ST segment and T waves are reported. Chloroquine IV can cause abrupt hypotension and cardiac arrest especially in children. Preparations and dosage:
(i) Chloroquine phosphate tablet 250 mg ( 150 mg of the base). Dose: as a suppressive in acute attack: initial dose: 1 g followed by 0.5 g after 6 hours and 0.5 g daily thereafter for 2 days followed by 0.5 g once a week for 3 months. For prophylaxis in an individual who is going into an endemic area, 0.5 g weekly.
(ii) Chloroquine sulfate tablet contains 150 mg of chloroquine base. Dosage: same as above.
(iii) Chloroquine injection contains chloroquine phosphate or sulfate equivalent to 40 mg of the base per ml . Dose: 200 to 300 mg of the base IM, divided between two injection sites, or IV, slowly, diluted with 100 ml of glucose saline. The total parenteral dose within 24 hours should not exceed 900 mg of the base.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Malaria: It is still the first line of treatment for P. vivax malaria and uncomplicated falciparum malaria due to sensitive strains (See later). Chloroquine and amodiaquine are considered safe antimalarials during pregnancy.</p>
</li>
<li>
<p>Hepatic amoebiasis: Chapter 57.</p>
</li>
<li>
<p>Giardiasis: Although chloroquine phosphate, mepacrine and amodiaquine are effective in this condition, metronidazole is preferred (Chapter 58).</p>
</li>
<li>
<p>Clonorchis sinensis (Chinese liver fluke) infestation: Chloroquine phosphate, 250 mg daily, is given for 6 weeks.</p>
</li>
<li>
<p>Rheumatoid arthritis: Chapter 75.</p>
</li>
<li>
<p>Discoid lupus and disseminated lupus erythematosus: Chloroquine is useful only in the milder forms of this disease and as a supplementary therapy to glucocorticoids in severely ill patients. The arthritic and the cutaneous lesions improve markedly with chloroquine. Chloroquine phosphate is given in the dose of 250 to 500 mg daily for 1 to 4 weeks or until a clear response is obtained. The dose is then reduced to a maximum of 250 mg and maintained subsequently.
HYDROXYCHLOROQUINE: This drug is less toxic than chloroquine, and has similar properties and uses as chloroquine.</p>
</li>
</ul>
<p>AMODIAQUINE: This drug is as effective as chloroquine, in a single oral dose. Its pharmacological actions are similar to those of chloroquine. It is rapidly absorbed and is concentrated in the liver and the spleen. It is largely metabolised in the body. The adverse effects include GI disturbances, headache, photosensitivity reactions and rarely, agranulocytosis.</p>
<p>Amodiaquine tablet contains 250 mg of the salt. Dose : as a suppressive in an acute attack of malaria: 0.5 to 0.75 g ( 0.4 to 0.6 g of the base) on the first day and then 2 tablets daily for two days.
P. falciparum strains resistant to chloroquine may still be sensitive to amodiaquine. However, it is not recommended for prophylactic (chronic suppressive) therapy because of possible hepatitis and agranulocytosis.</p>
<p>Amopyroquine has similar properties as amodiaquine but can also be given parenterally.
Pyronaridine, structurally related to amodiaquine, developed in China, is given orally as well as parenterally. It has schizontocidal activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and is effective against chloroquine-resistant parasites. The drug needs further evaluation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="8-aminoquinolines">8-Aminoquinolines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#8-aminoquinolines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PRIMAQUINE: This drug (Fig 56.3) is effective against:
<img src="assets/images/image-20251214-69073ad8.jpeg" alt="img-11.jpeg"></p>
<p>FIG. 56.3 Primaquine</p>
<ul>
<li>The persistent tissue forms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax; and</li>
<li>The pre-erythrocytic (hepatic) and sexual forms (gametocytes) of all species of human malarial parasites.
Its precise mechanism of action is not known. It probably acts by generating toxic, reactive species and/or by interfering with electron transport in the parasite.</li>
</ul>
<p>Following the administration of primaquine, only a proportion of gametocytes in the blood are destroyed, while the rest are rendered incapable of undergoing further maturation in the mosquito. The drug has a weak schizonticidal activity against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax but exerts no effect on the schizonts of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum. It is, therefore, not effective as a suppressive but it is given along with a 4-aminoquino-line, to achieve radical cure in P. vivax infection.</p>
<p>Absorption, fate and excretion: Given orally, it is rapidly and completely absorbed. It is concentrated in the liver; large amounts are also present in the lung, brain, heart and the skeletal muscle. It is rapidly metabolised in the liver, and the products excreted in the urine; only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of the drug is excreted unchanged.</p>
<p>Adverse reactions: At the recommended dosage, toxicity is uncommon. The ADR are:</p>
<ul>
<li>Gastrointestinal: Epigastric distress and abdominal cramps can be minimised by taking the drug with or after food and by antacids.</li>
<li>Hemopoietic: Moderate doses cause mild anemia and leucopenia. Large doses may cause methemoglobinemia, cyanosis and agranulocytosis.</li>
<li>In patients with G6PD deficiency, it can cause intravascular hemolysis (Chapter 36).</li>
</ul>
<p>The drug should not be used in patients who have a tendency to granulocytopenia e.g. those suffering from RA or lupus erythematosus and in patients receiving other potentially hemolytic drugs. Proguanil potentiates its toxicity.</p>
<p>Although it has not been established that primaquine is teratogenic in humans, its use should be postponed till after delivery. It can cause hemolysis in G6PD-deficient fetuses.</p>
<p>Preparations and dosage: Primaquine tablet contains 7.5 mg of primaquine base. The dose for radical cure of vivax malaria is 15 mg . daily for 14 days given along with chloroquine 1 g on the first day and 500 mg daily for 2 days.</p>
<p>Bulaquine an analogue of primaquine, is claimed to be as effective as primaquine.
Tafenoquine is a new, long acting, potent, primaquine-like drug which achieves radical cure in 3 days. It is under evaluation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinoline-methanol">Quinoline Methanol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinoline-methanol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MEFLOQUINE is a quinoline methanol derivative. It probably acts like chloroquine. It:</p>
<ul>
<li>Acts on the erythrocytic stage.</li>
<li>Is highly effective in a single dose against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum including chloroquine resistant and MDR strains.</li>
<li>Can be given 12 hours after the last dose of quinine. However, because of long half life of mefloquine, quinine should not be administered after it as both are cardiotoxic.</li>
<li>Has no action on the persistent tissue forms.</li>
</ul>
<p>Given orally, mefloquine is rapidly and completely absorbed, is highly protein bound and is extensively distributed in the tissues. It has a very long plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 20 days. It is eliminated slowly in feces. The parasites can develop resistance to it.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>GI tract: Mefloquine commonly causes dizziness, nausea, vomiting, diarrhoea or abdominal pain; these generally resolve without specific treatment.</li>
<li>Neuropsychiatric disturbances: The most common of these are affective disorders, anxiety disorders, hallucinations and sleep disturbances. A single dose may cause light headedness and loss of concentration. Transient depressive feeling occurs more commonly with mefloquine than with chloroquine. Rarely, psychosis, toxic encephalopathy and convulsions have been reported. Patients treated a second time within a month after the first dose are at seven fold risk of adverse effects.</li>
<li>CVS: Like chloroquine and halofantrine, mefloquine causes bradycardia and sinus arrhythmia. Patients who have recently received mefloquine should not receive halofantrine, which hastens QT prolongation.</li>
<li>Teratogenicity: Mefloquine is teratogenic and should be avoided in the first trimester of pregnancy. However, it may be used in the second and third trimesters. The non-pregnant women of childbearing age, should be advised to avoid pregnancy for three months after the treatment. Women treated with mefloquine may continue breast-feeding.</li>
<li>Miscellaneous: Allergic skin reactions, hepatitis and blood dyscrasias can occur.</li>
</ul>
<p>Preparations and dosage: Mefloquine is available as 250 mg tablets. A single dose of 750 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg}(15 \mathrm{mg} / \mathrm{kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mopen">(</span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span> orally is sufficient in most areas to treat uncomplicated malaria. However, in certain areas, the same dose may have to be repeated in 6 hours to ensure a cure. In the single dose of 1.5 gm , mefloquine is uniformly effective in curing multidrug resistant (MDR) malaria in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> of patients. However, such a dose invariably causes severe nausea and vomiting. A second dose of 1 gm may have to be given to patients living in areas of mefloquine resistance.</p>
<p>Due to fear of the development of drug resistance, mefloquine is not recommended as a single drug for prophylaxis in endemic areas.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phenanthrene-methanol">Phenanthrene Methanol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenanthrene-methanol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HALOFANTRINE: This drug, was discovered in the forties, was restudied nearly 40 years later. It is:</p>
<ul>
<li>An erythrocytic schizonticide and is as effective as chloroquine against chloroquine sensitive strains of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum.</li>
<li>Also effective against strains resistant to chloroquine, pyrimethamine and quinine.</li>
</ul>
<p>The mechanism of action is like that of other quinolines.
Given orally, it is slowly and variably absorbed, peak concentration being reached 4-6 hours after ingestion. The drug should not be taken along with fatty foods. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 1-2 days, although its active N -desbutyl metabolite has a longer half-life of 3-5 days. Unlike most anti-malarials, the drug is palatable. It is given in three doses of 500 mg 6 hours apart, repeated after 1 week, if necessary. It is available for parenteral use.</p>
<p>Adverse reactions: These include nausea, vomiting, abdominal pain, diarrhoea and rise in liver enzymes. It's major disadvantage is that it causes prolongation of QT interval and even fatal ventricular arrhythmias; it should not be used in patients receiving quinine, chloroquine or quinidine, antidepressants and antipsychotics. It is not suitable for prophylaxis.</p>
<p>Lumefantrine is structurally similar to quinine. Used in combination with artemether, it is well tolerated and efficacious in uncomplicated falciparum malaria, and is used where resistance to monotherapies is being experienced. It can also be combined with mefloquine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="biguanides">Biguanides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biguanides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PROGUANIL (Chloroguanide): It is a prodrug. Its antimalarial action is attributed to its conversion into a cyclic ring triazine metabolite, cycloguanil, in the human body. This compound binds to an enzyme dihydrofolate reductase, which converts folic acid to folinic acid, more strongly in the malarial parasite than in the human tissues. Deficiency of folinic acid prevents the completion of schizogony. As the sulfonamides prevent the conversion of PABA into folic acid, they synergise with the antimalarial effect of proguanil. It:</p>
<ul>
<li>Is an effective schizonticide against both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum; but its action is slower than that of 4 -aminoquinolines.</li>
<li>Is effective against the primary pre-erythrocytic forms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum, and for causal prophylaxis of falciparum malaria.</li>
<li>Prevents the development of gametes encysted in the gut wall of the mosquito. It is, thus, valuable in sporonticidal prophylaxis.
West African strains of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum are usually genetically resistant to proguanil while all the varieties of plasmodia have developed an acquired resistance to this agent due to mutation in the parasite.</li>
</ul>
<p>Absorption, fate and excretion: Given orally, it is rapidly and adequately absorbed, mostly from the small intestine. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> is bound to proteins. The drug achieves a higher concentration within erythrocytes than in plasma. Its elimination is slow, mainly in the urine, with plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 12-21 hours.</p>
<p>Adverse reactions: Proguanil is free from significant toxic effects when used in therapeutic doses. GI disturbances, stomatitis, and mouth ulcers may develop occasionally. A reduction in the leucocyte count and megaloblastic anemia may occur rarely.</p>
<p>Preparations and dosage: Proguanil hydrochloride tablets 100 mg . The base content of the salt is approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>87</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">87 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">87%</span></span></span></span></span>.</p>
<p>Therapeutic uses: Given alone, it is not so useful for controlling an acute attack. For causal prophylaxis, a dose of 100 to 200 mg daily is used depending upon the sensitivity of the strain prevalent in the particular area.</p>
<p>Malarone is a combination of proguanil 100 mg with atovaquone 250 mg . It is used to treat MDR falciparum malaria. The combination is generally well tolerated. (For doses, see later) The drug appears to be safe during pregnancy but data is indequate. It can be combined with folinic acid 5 mg daily, to prevent megaloblastic anaemia. This does not affect its efficacy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diaminopyrimidines">Diaminopyrimidines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diaminopyrimidines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PYRIMETHAMINE: Like proguanil, it is selectively toxic to the malarial parasite by binding to its dihydrofolate reductase (Fig. 56.4). It is more potent than proguanil. Its antimalarial activity is enhanced by combination with sulfonamides. Unlike other antimalarials, it is tasteless and, therefore, suitable for children.
<img src="assets/images/image-20251214-0f42d1c6.jpeg" alt="img-12.jpeg"></p>
<p>Development of resistance to the drug in vivo has been reported and some degree of cross-resistance between pyrimethamine and proguanil can also occur. Chloroquine resistant strains of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum are frequently resistant to proguanil and pyrimethamine.</p>
<p>Absorption, fate and excretion: Pyrimethamine is completely but relatively slowly absorbed from the small intestine. It is extensively metabolised and slowly excreted by the kidney. Following a single dose of 25 mg , it persists in the plasma and gets excreted in the urine for more than 14 days.</p>
<p>Adverse reactions: The drug is relatively safe. It can cause GI disturbances, ataxia and megaloblastic anemia, which responds to oral folic acid. Folic acid does not block its antimalarial activity. The drug appears to be safe in antimalarial doses during pregnancy.</p>
<p>Preparations and dosage: Pyrimethamine tablet 25 mg . For relief of an acute attack of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax 50 mg on the first day followed by 25 mg daily for 2 days. However, it is not the drug of choice for acute attacks.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Malaria: It is generally used in combination with 500 mg sulfadoxine or with sulfadimethopyrazine; dose: 2-3 tab once weekly. Combination of pyrimethamine 12.5 mg with dapsone 100 mg is used for prophylaxis of P. falciparum. (See later).</li>
<li>Toxoplasmosis: It is used in the dose of 25 mg twice a day, followed by 25 mg once daily for one month, along with sulfadiazine 4 gm daily. A loading dose of 50-100 mg of pyrimethamine may be used in the event of ocular complications (Chapter 58).</li>
<li>Polycythemia vera.</li>
</ul>
<p>Trimethoprim has similar anti-malarial actions (anti-folate) as pyrimethamine but is much less potent (Chapter 45).</p>
<p>SULFONAMIDES: Sulfonamides and sulfones have antimalarial activity similar to pyrimethamine, but their mechanism of action is different (Chapter 45). Although they are effective against the asexual blood forms, their action is too slow. However, they potentiate the action of pyrimethamine or proguanil (DHF-reductase inhibitors). A long acting sulfonamide such as sulfadoxine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>200</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">200</span></span></span></span></span> hours) with pyrimethamine is usually preferred. These combinations have been used against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection resistant to chloroquine.</p>
<p>Sulfonamide-containing combinations are not recommended for prophylaxis because of StevensJohnson syndrome.</p>
<p>The sulfone, DDS, has been used in the dose of 25 mg daily for 4 weeks from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>7</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">7^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of illness onwards, in combination with quinine/chloroquine/pyrimethamine, to prevent recrudescence in chloroquine-resistant falciparum malaria.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="artemisinin-compounds">Artemisinin Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#artemisinin-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ARTEMISININ: This is obtained from the Chinese plant Artemisia annuta (Qinghaosu, sweet worm wood) which has been used in China for the treatment of fever for almost 2000 years. Chemically, it is a sesquiterpene lactone endoperoxide. The drug is lipophilic and poorly soluble in water. Derivatives of artemisinin include artesunate (water soluble), artether and artemether (both lipid soluble).</p>
<p>Mechanism of action: Artemisinin and related compounds covalently bind to parasitic proteins. Intraparasitic heme iron catalyses cleavage of endoperoxide bridge in artemisinin. The resultant free radicals damage parasitic proteins.</p>
<p>Artemisinin compounds act mainly as schizonticides against all malarial parasites, including those resistant to chloroquine and quinine. They reduce parasitemia rapidly and dramatically. They have no effect on the hepatic stage. Recrudescence may occur. They are also useful in cerebral malaria. So far, there is no evidence of high level resistance to this drug.</p>
<p>Absorption, fate and excretion: Orally, they are well absorbed and are metabolised to the active form, dihydro-artemisinin. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of artesunate is short - about 23 minutes, while that of artemether is about 45 minutes. This is a major disadvantage.</p>
<p>Adverse reactions: No serious adverse reactions have been reported. ADR include nausea, vomiting, abdominal pain, anorexia and leucopenia. Higher doses may produce bradycardia, prolongation of PR and QT and transient increase in SGOT/SGPT. They are contraindicated during the first trimester of pregnancy, lactation, and in immunocompromised patients.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Artesunate 50 mg tablets.</p>
<p>Artesunate injection for IV/IM use contains 60 mg . It is administered in a dose of 120 mg on day one, followed by 60 mg 12 hours later; and 60 mg once daily for the next 4 days. (ii) Artether is a synthetic ethyl derivative of artemisinin. Dose is 150 mg IM once daily for 3 consecutive days. Children are given <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> for 3 days.
(iii) Artemether injection containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">80 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in arachis oil. Dose is 80 mg IM on first day followed by 80 mg daily for the next 5 days.
(iv) They are available as suppository.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Artemisinin and its derivatives are safe and effective alternative to quinine in the treatment of falciparum malaria. However, its use should be restricted to the treatment of MDR malaria. It is recommended that artemisinin derivatives should be used only in combination with other drugs to prevent or slow down the development of drug resistance. For use of artemether in schistosomiasis, see Chapter 60.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobials">Antimicrobials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DOXYCYCLINE: This drug exerts a slow but potent action against the blood schizonts and the primary exo-erythrocytic forms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum, including those resistant to chloroquine and proguanil. It is used in combination in resistant cases as resistance to tetracyclines is rare (See later).</p>
<p>CLINDAMYCIN has also been found useful in combination with other drugs (see later).</p>
<p>ATOVAQUONE: This is a highly lipophilic, hydroxynaphthoquinone compound which has potent activity (in animal models) against P. jiroveci, Plasmodia and T.gondii. It acts by selectively interfering with mitochondrial electron transport in susceptible parasites. Proguanil potentiates the antimalarial activity of atovaquone.</p>
<p>Its oral absorption is slow and incomplete but is increased threefold by fatty foods. Its plasma t/is 2-3 days and it is excreted, mostly unchanged, in feces.</p>
<p>When used alone, the parasites develop resistance to it rapidly, by mutation.
Adverse reactions: These include fever, vomiting, anorexia, headache, diarrhoea, dose related maculopapular rash, anemia and neutropenia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Atovaquone + proguanil is useful as a prophylactic against P. falciparum and in treating MDR malaria. The combination is active against the circulating parasites but not the hepatic stage of plasmodium. It is claimed to be more effective than mefloquine.</p>
<p>The combination contains atovaquone 250 mg + Proguanil 100 mg for adult use and atovaquone 62.5 mg + Proguanil 25 mg for pediatric use. For prophylaxis, the dose is one tablet daily taken with food. For treatment of MDR malaria, it is 4 tablets as a single dose for 3 consecutive days. Tetracycline, rifampicin and metoclopramide decrease the efficacy of atovaquone.
(2) In the dose of 750 mg tid three times a day for 21 days, it is helpful in treating mild to moderate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. jiroveci pneumonia in AIDS patients.
(3) It is also used in toxoplasmosis (Chapter 58).</p>
<p>Table 56.2 shows the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of the commonly used antimalarial drugs.
Table 56.2
Half-life of the commonly used antimalarial drugs</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Half-life</th></tr></thead><tbody><tr><td style="text-align: left;">Chloroquine and amodiaquine</td><td style="text-align: left;">3 weeks</td></tr><tr><td style="text-align: left;">Quinine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">10-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Mefloquine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>33</mn></mrow><annotation encoding="application/x-tex">15-33</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">33</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Primaquine</td><td style="text-align: left;">8.5 hours</td></tr><tr><td style="text-align: left;">Pyrimethamine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">80-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Proguanil</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>21</mn></mrow><annotation encoding="application/x-tex">12-21</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">21</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Sulfadoxine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">100-200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Atovaquone</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Doxycycline</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>22</mn></mrow><annotation encoding="application/x-tex">18-22</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">22</span></span></span></span></span> hours</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-malaria">Management of Malaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-malaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Prophylaxis: When residents of a non-endemic area wish to travel to an endemic area, antimalarial drug (s) are recommended to prevent or suppress symptoms caused by malarial parasites. The choice depends on the likely strain of malarial parasites in the region and its known sensitivity pattern (Table 56.3). The therapy should be started before the start of the travel, continued during the travel in endemic area and even after departure from the area. Presumptive anti-relapse terminal prophylaxis to eliminate hepatic forms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">/ P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. ovale is indicated for persons who have had prolonged exposure in malaria-endemic areas.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-56-3">Table 56.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-56-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-regimens-for-malarial-prophylaxis">Drug regimens for malarial prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-regimens-for-malarial-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Drug, dose, frequency</th><th style="text-align: center;">When to start before entering endemic area</th><th style="text-align: center;">How long to continue after leaving the area</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Chloroquine sensitive P. falciparum' and P. vivax/P. ovale</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Chloroquine (base) 300 mg OW</td><td style="text-align: center;">1 week</td><td style="text-align: center;">4 weeks</td><td style="text-align: center;">Choice for infants/children/pregnant &amp; lactating mothers</td></tr><tr><td style="text-align: center;">Proguanil 200 mg OD</td><td style="text-align: center;">2 days</td><td style="text-align: center;">4 weeks</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Chloroquine - resistant P falciparum and MDR strains</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Mefloquine 250 mg OW</td><td style="text-align: center;">1 week</td><td style="text-align: center;">4 weeks</td><td style="text-align: center;">Same as above</td></tr><tr><td style="text-align: center;">Doxycycline 100 mg OD</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> days</td><td style="text-align: center;">4 weeks</td><td style="text-align: center;">Not in children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">&lt;8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> yrs/pregnant women.</td></tr><tr><td style="text-align: center;">Atovaquone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">250 \mathrm{mg}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> proguanil 100 mg ; one tablet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">D</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{OD}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">OD</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> days</td><td style="text-align: center;">7 days</td><td style="text-align: center;">Not in children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&lt;5 \mathrm{~kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> pregnant &amp; lactating women.</td></tr><tr><td style="text-align: center;">Terminal prophylaxis to prevent relapse of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax/P. ovale</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Primaquine 30 mg OD</td><td style="text-align: center;"></td><td style="text-align: center;">14 days along with post-exposure prophylactics (or after its completion).</td><td style="text-align: center;">Not in pregnancy In infants, children, and lactating mothers, after ruling out G6PD deficiency</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">D</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{OD}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">OD</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> once daily <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">W</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{OW}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OW</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> once weekly
*If not tolerated in the recommended doses, mefloquine, doxycycline or atovaquone + proguanil can be given
"If the traveler cannot tolerate any of these regimens, Primaquine 30 mg 1-2 days before, throughout the stay and 7 days after leaving
"Choice for mefloquine resistant malaria in Southeast Asia (Burma, China, Cambodia, Vietnam)
All infants and children travelling to endemic areas need antimalarial prophylaxis. Chloroquine is the drug of choice. For areas with resistant strains, mefloquine is an option. To use doxycycline, the age of the child should be above 8 years and for atovaqone/proguanil, weight should be at least 5 kg .</p>
<p>Ideally, pregnant women should be advised to avoid travel to endemic area. If it is not possible, chemoprophylaxis is given, which reduces the incidence of severe maternal anaemia and other adverse outcomes like abortion, still birth, prematurity, and low birth weight. Chloroquine remains the drug of choice for sensitive organisms, while mefloquine is currently the only medication recommended for chloroquine resistant organisms. Doxycycline is contraindicated and atovaquone/proguanil is not used because of insufficient safety data.</p>
<p>Very small amounts of chloroquine and mefloquine are excreted in the breast milk and hence can be given for prophylaxis in lactating women. Atovaquone/proguanil is not recommended. Limited data are available for doxycycline. Primaquine is given only after testing the infant for G6PD deficiency.</p>
<p>The traveller should also be urged to avoid contact with the night biting anopheles in</p>
<p>the endemic area by covering exposed parts, netting over the bed, fitting window-screens, using insecticides and mosquito repellents.</p>
<p>Such chemoprophylaxis is not <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> effective; hence the diagnosis of malaria should be considered in a patient who has visited an endemic area and gets fever after returning home though he has received chemoprophylaxis.</p>
<p>Treatment of an acute attack: The diagnosis of malaria is confirmed by microscopy of stained thick and thin blood films. The intracytoplasmic parasites should be identified (if the species is uncertain, it should be considered to be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum) and counted. In severe malaria, the developmental stage of the parasite should be noted. The prognosis worsens with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection, higher parasitic counts and more mature parasites. In serious cases smear examination should be repeated every 12 hours for monitoring the efficacy of therapy.</p>
<p>The initial treatment of acute malaria is the same irrespective of the species of parasite, unless the infection is severe and due to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum, particularly in children and in nonimmune subjects. It is the follow up therapy of relapsing malaria that differs.</p>
<p>The drug regimens used in an acute clinical attack of malaria with P. vivax, P. ovale, P. malariae and chloroquine susceptible <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum, in adults, are shown in Table 56.4.</p>
<p>Table 56.4
Treatment of chloroquine sensitive acute malaria
Chloroquine (base) 600 mg followed 6 hours later by 300 mg on day one; 300 mg once daily on days two and three. OR
Amodiaquine (base) 600 mg followed by 200 mg (base) on day one; 400 mg once a day on days two and three. OR
Quinine (salt) 300 mg tablets, 6 tablets daily for three days, followed by 4 tablets daily for the next 5-10 days.</p>
<ul>
<li>In patients who cannot take orally:</li>
</ul>
<p>Chloroquine IM <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 4 hours or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 6 hours (total dose not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base). OR
Chloroquine IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base over 4 hours, followed by 5 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base (given in a 2 hour infusion) every 12 hours (total dose not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 / \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base).</p>
<ul>
<li>In patients who can take orally:</li>
</ul>
<p>Chloroquine (base) 600 mg followed 6 hours later by 300 mg on day one; 300 mg once daily on days two and three.
OR
Amodiaquine (base) 600 mg followed by 200 mg (base) on day one; 400 mg once a day on days two and three.
OR
Quinine (salt) 300 mg tablets, 6 tablets daily for three days, followed by 4 tablets daily for the next 5-10 days.</p>
<ul>
<li>In patients who cannot take orally:</li>
</ul>
<p>Chloroquine IM <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 4 hours or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 6 hours (total dose not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base).
OR
Chloroquine IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base over 4 hours, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base (given in a 2 hour infusion) every 12 hours (total dose not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 / \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> base).
NB: For P. falciparum infection, primaquine (gamatocytocidal) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.75 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, (maximum 45 mg ) given as a single dose on first day of treatment, is a must to prevent spread.</p>
<p>Quinine still remains a potent and reliable antimalarial drug. Further, children tolerate it well. It can be given orally as well as parenterally. However, it takes longer to exert the full effects and hence, chloroquine is generally preferred. In case of severe P. falciparum infection, particularly in a non-immune individual, treatment must be immediate and IV quinine may be life-saving. Artemisinin suppositories can be used immediately at home before transferring the patient to the hospital.</p>
<p>Postural hypotension is common in uncomplicated malaria and is exacerbated by quinine and chloroquine. Febrile patients, both adults and children, should therefore be kept in the horizontal position. Mothers should be advised that febrile babies should not be carried vertically, especially after any of the above drugs is given parenterally.</p>
<p>In non-endemic areas, freedom from recrudescences of falciparum infection can be ensured by follow up treatment with 300 mg (one tablet) of chloroquine, taken once a week for three months.</p>
<p>Most of these anti-malarial drugs are very bitter and hence, they may be given along with milk or fruit juice. Care must be taken to ensure that the patient swallows the tablets and does not vomit later. This can be helped by prior administration of prochlorperazine (Stemetil) or a similar antiemetic drug, if necessary. If vomiting occurs within 1 hour of drug ingestion, repeat the full dose of the drug; in the case of mefloquine repeat half the initial dose. If vomiting occurs after one hour, it is not necessary to repeat the drug.</p>
<p>Since latent exoerythrocytic forms persist in the liver in infections with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. vivax and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. ovale, delayed true relapses occur in the majority of patients. In such cases, radical cure can be obtained by primaquine in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5.</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5 .-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7.5.</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily for 14 days, started after treating the acute attack. In this dosage, the drug is generally well tolerated and hemolysis, if it occurs, is mild and self-limiting. In some cases, higher doses of primaquine ( 30 mg daily for 14 days) may be needed; such regimen, however, needs supervision for possible adverse effects.</p>
<p>In P. falciparum malaria primaquine is used in a single dose of 45 mg to destroy falciparum gametocytes which are not affected by chloroquine or quinine.</p>
<p>In pregnant women and infants, chloroquine is given weekly as suppressive chemoprophylaxis for 3 months to prevent relapse of P. vivax or P. ovale infection.</p>
<p>Cerebral malaria with pronounced CNS symptoms occurs as a complication of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection and carries high mortality. It needs emergency treatment with excellent nursing care and repeated monitoring, preferably in ICU.</p>
<p>Currently parenteral artemether and arteether are preferred. Alternatively, quinine in high dilution is administered by very slow infusion (see later). If there are no facilities for IV infusion, quinine can be given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> in 20 ml glucose saline IV, over not less than 10 minutes by the clock. More rapid injection may cause a fall in BP, cardiac arrhythmias and cardiac arrest. Alternatively, quinine can be given IM provided the solution is sterile and nearly neutral in reaction.</p>
<p>Hypoglycemia, sometimes fatal, has been reported in patients with cerebral malaria; this complication does not respond well to glucose by IV bolus and to glucagon. A somatostatin analogue octreotide which inhibits the stimulatory effect of quinine on the beta cells of the pancreas may be useful.</p>
<p>Chloroquine is as good as quinine for susceptible <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. falciparum infection and in severe cases it can be given IV or IM in similar way as quinine. The single average adult IV dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of the base in a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution. Intramuscular route, however, is safer and is preferred. It can be repeated upto a total of 900 mg in 24 hours. In all these cases, oral therapy should be started as soon as possible.</p>
<p>Quinidine is as effective as quinine in the treatment of malaria. If quinine is not available, quinidine is an acceptable substitute for the emergency treatment. Doses and precautions are the same as with quinine.</p>
<p>Cerebral malaria sometimes causes coma and shock. Blood pressure should be maintained by IV fluids and dopamine. Management of coma is similar to that of coma due to other causes. However, in some cases, lumbar puncture to reduce intra-cranial tension may cause dramatic recovery. Convulsions are treated with diazepam.</p>
<p>Glucocorticoids, urea and mannitol which were used in the past to treat the cerebral edema of falciparum malaria, are of doubtful value and in fact may have deleterious effects in these cases; they are better avoided.</p>
<p>Treatment of malaria in children is essentially similar to that in adults. Quinine is better tolerated by children but its parenteral use is associated with high toxicity. Chloroquine injection may cause convulsions in infants and small children, and should be avoided. Relapsing vivax attacks in small children may be treated with pyrimethamine 12.5 mg base once a week, between the attacks. Primaquine should be avoided in the neonates for fear of hemolysis. Mefloquine should not be used in children under 15 kg of weight. For details see Table 56.5.</p>
<p>Table 56.5
Dosage schedule for oral treatment of moderate and severe malaria in children</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;">Dose, mg</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Drug</td><td style="text-align: center;">Upto 1 yr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">1-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> yr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> yr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>11</mn></mrow><annotation encoding="application/x-tex">7-11</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">11</span></span></span></span></span> yr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">12-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> yr</td><td style="text-align: center;">Regimen</td></tr><tr><td style="text-align: center;">Quinine</td><td style="text-align: center;">100-200</td><td style="text-align: center;">200-300</td><td style="text-align: center;">300-500</td><td style="text-align: center;">500-1000</td><td style="text-align: center;">1000-2000</td><td style="text-align: center;">Daily dose to be divided into 3 parts and continued for 7 days</td></tr><tr><td style="text-align: center;">Chloroquine (base) in mg</td><td style="text-align: center;">75</td><td style="text-align: center;">150</td><td style="text-align: center;">300</td><td style="text-align: center;">300</td><td style="text-align: center;">400-600</td><td style="text-align: center;">i) Loading dose</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">75</td><td style="text-align: center;">150</td><td style="text-align: center;">150</td><td style="text-align: center;">150</td><td style="text-align: center;">225-300</td><td style="text-align: center;">ii) Second one follow 6 hours after first</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">37</td><td style="text-align: center;">75</td><td style="text-align: center;">150</td><td style="text-align: center;">150</td><td style="text-align: center;">150-300</td><td style="text-align: center;">iii) One dose daily on day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">&amp;</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">2 \&amp; 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">2&amp;3</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Amodiaquine</td><td style="text-align: center;">50</td><td style="text-align: center;">100</td><td style="text-align: center;">150</td><td style="text-align: center;">200-300</td><td style="text-align: center;">400-600</td><td style="text-align: center;">i) Dose for first day</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">50</td><td style="text-align: center;">50</td><td style="text-align: center;">300</td><td style="text-align: center;">50-200</td><td style="text-align: center;">250-400</td><td style="text-align: center;">ii) Daily dose for day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">&amp;</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">2 \&amp; 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">2&amp;3</span></span></span></span></span></td></tr><tr><td style="text-align: center;">500mg Sulfadoxine + pyrimethamine 25 mg per tablet</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> tab</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> tab</td><td style="text-align: center;">1 tab</td><td style="text-align: center;">1 tab</td><td style="text-align: center;">2 tab</td><td style="text-align: center;">Single dose</td></tr></tbody></table>
<p>Modified from: The Clinical Management of Acute Malaria, WHO Reg. Pub., South East Asia Series No. 9, New Delhi.
Acute malaria during pregnancy can be treated with chloroquine or quinine in the usual doses. For chloroquine-resistant malaria, chloroquine + clindamycin combination is safe. Mefloquine is probably safe in the second and third trimesters and may be used when benefits outweigh the risk. Artemisinin has no deleterious effect on the fetus and can be considered, if the situation demands. However the data about its safety are inadequate. Maloprim should be avoided in the first trimester but may be used in second or third trimester with folic acid supplement. Associated anemia is treated with folic acid and iron. Primaquine, doxycycline and malarone should be avoided.</p>
<p>Malaria in G6PD deficient persons: Such patients should be treated with the usual doses of either chloroquine or quinine. If indicated, primaquine in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-45 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once a week for 4-8 weeks is an acceptable treatment in areas of milder variants of G6PD deficiency.</p>
<p>Chloroquine resistant malaria: Chloroquine resistant P. falciparum malaria is now widespread in many areas, including India. Chloroquine resistance should be suspected.</p>
<ul>
<li>In all patients with a complication of malaria such as cerebral malaria, severe anemia, jaundice or renal failure.</li>
<li>In any patient who has already received a full course of chloroquine within the last one month as that suggests the possibility of recrudescence from a resistance strain; and</li>
<li>When hemoglobin continues to fall in the absence of bleeding, and asexual forms of the malarial parasite persist, along with symptoms, after 48 hours of treatment. The persistence of gametocytes for several weeks after treatment does not represent failure of treatment.
In patients with falciparum malaria resistant to chloroquine and sulfadoxine-pyrimethamine, a combination therapy as the first line treatment is advocated. Artemisinin-based combination therapy (ACT) is preferred. Table 56.6 shows the drug regimens used in the treatment of chloroquine resistant malaria.</li>
</ul>
<p>Table 56.6
Treatment of chloroquine resistant malaria</p>
<p>Sodium artesunate 100 mg orally 12 hrly for 3 days plus mefloquine 750 mg on day 2 and then 500 mg on day 3 OR
Artmether ( 20 mg ) + Lumefantrine ( 120 mg ) 4 tabs twice daily for 3 days</p>
<p>OR
Quinine 600 mg orally tid for 5 days followed by SulfadoxinePyrimethamine 3 tablets as single dose</p>
<p>OR
Quinine 600 mg tid + doxycycline 100 mg bid/clindamycin 10 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bid for 7 days</p>
<p>OR
Sodium artesunate 100 mg orally + doxycycline 100 mg bid/clindamycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bid for 7 days</p>
<p>OR
Atovaquone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">250 \mathrm{mg}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9658em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>proguanil 100 mg combination; 4 tablets (single dose) daily for 3 days</p>
<ul>
<li>In patients who cannot take orally</li>
</ul>
<p>Quinine hydrochloride by IV infusion: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose-saline over 4 hours; followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> infused over 2 hours, every 8 hours, until the patient is able to swallow and parasite density is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>. Complete the therapy with oral quinine 600 mg tid till total therapy is of 7 days AND Tetracycline 250mg IM 6 hourly until patients start taking orally, followed by doxycycline 100 mg bid till total of 7 days</p>
<p>OR
Artemether or arteether IM (see text) AND Doxycycline OR Clindamycin.
--&gt;</p>
<ul>
<li>In patients who can take orally</li>
</ul>
<p>Sodium artesunate 100 mg orally 12 hrly for 3 days plus Sulfadoxine ( 500 mg ) + Pyrimethamine ( 25 mg ) 3 tabs as single dose on day one OR
Sodium artesunate 100 mg orally 12 hrly for 3 days plus mefloquine 750 mg on day 2 and then 500 mg on day 3 OR
Artmether <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">(20 \mathrm{mg})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> Lumefantrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">(120 \mathrm{mg}) 4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">4</span></span></span></span></span> tabs twice daily for 3 days OR
Quinine 600 mg orally tid for 5 days followed by Sulfadoxine- Pyrimethamine 3 tablets as single dose OR
Quinine 600 mg tid + doxycycline 100 mg bid/clindamycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bid for 7 days OR
Sodium artesunate 100 mg orally + doxycycline 100 mg bid/clindamycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bid for 7 days OR
Atovaquone 250 mg ' proguanil 100 mg combination; 4 tablets (single dose) daily for 3 days</p>
<ul>
<li>In patients who cannot take orally</li>
</ul>
<p>Quinine hydrochloride by IV infusion: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose-saline over 4 hours; followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> infused over 2 hours, every 8 hours, until the patient is able to swallow and parasite density is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>. Complete the therapy with oral quinine 600 mg tid till total therapy is of 7 days AND Tetracycline 250mg IM 6 hourly until patients start taking orally, followed by doxycycline 100 mg bid till total of 7 days
OR
Artemether or arteether IM (see text) AND Doxycycline OR Clindamycin.
In ACT an artemisinin derivative is given in combination with a long acting antimalarial (amodiaquine, lumefantrine, mefloquine or sulfadoxine-pyrimethamine) for 3 days or with rapidly eliminated agents (tetracyclines, clindamycin) for 7 days. ACT available in India is listed in Table 56.7, of which artesunate + sulfadoxine-pyrimethamine (SP) is used in the National Malaria Programme of India.</p>
<p>Multidrug resistant (MDR) malaria is always to be treated with drug combinations (Table 56.7).</p>
<p>Table 56.7
Currently used antimalarial drug combinations for MDR falciparum malaria</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Artesunate + SP/mefloquine/amodiaquine
</span>- Artemether + lumefantrine
- SP + chloroquine/amodiaquine/quinine/mefloquine
- Quinine + tetracycline/clindamycin
- Atovaquone + proguanil
- Chlorproguanil + dapsone
- Sulfadoxine + pyrimethamine (SP)</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Artesunate + SP/mefloquine/amodiaquine
- Artemether + lumefantrine
- SP + chloroquine/amodiaquine/quinine/mefloquine
- Quinine + tetracycline/clindamycin
- Atovaquone + proguanil
- Chlorproguanil + dapsone
- Sulfadoxine + pyrimethamine (SP)" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>SP is always given as a single dose. All other drugs are given for 3 days, except quinine + tetracycline combination, which is given for 7 days.
The combinations to which resistance has not been reported.
Radical cure: Radical cure should be aimed at only in infections occurring in a nonendemic area. Such a patient should receive primaquine in the dose of 15 mg of the base daily for 2 weeks. Simultaneously, he should continue to receive 300 mg of the chloroquine base weekly for suppression of an overt attack. Such primaquine therapy is essential mainly in vivax malaria.</p>
<p>Recrudescence: This may be due to inadequate therapy or persistence of hepatic forms. Early recrudescence of malaria (within 28 days of anti-malarial treatment) should not be treated by either mefloquine or halofantrine because of their enhanced cardiac toxicity. It should be treated with artemisinin.</p>
<p>Adjuvant therapy in malaria: Apart from shock, severe malaria can cause renal failure leading to oliguria, anuria and uremia. In the initial stages, the osmotic diuretic mannitol may be useful. However, later hemodialysis or peritoneal dialysis can be life saving. It is also important to remember the possibility of such a complication, since administration of</p>
<p>excess parenteral fluids during the period of unrecognised renal impairment can precipitate fatal pulmonary edema. Falciparum malaria can cause severe hypoglycemia; this should be remembered while treating such patients.</p>
<p>Chronic malaria is usually associated with iron deficiency anemia, which responds to oral iron therapy. In severe anemia, parenteral iron and even blood transfusion may be necessary.</p>
<p>Immunity in malaria: Development of partial immunity is recognised in P. falciparum infection. The immunity is basically humoral. Immune antibodies cross the placental barrier and confer passive immunity on the foetus, who is protected for some months after birth. The immunity operates against the erythrocytic stage, but is ineffective against other stages of the parasite. Immunity in malaria is not only species-specific, but to some extent also strain-specific. Thus, a person who has developed immunity to a P. falciparum strain in a particular area may get infected with a different strain when in another area. It is not absolute and diminishes when an immune adult moves for a year to a nonendemic area. The development of anti-malarial vaccine is still experimental.</p>
<p>Malaria eradication: This concept is based on the idea of completely eliminating the disease from a particular area so as to halt its transmission completely, at the same time, preventing the reintroduction of the disease from outside. Malaria eradication, therefore, envisages a vigorous attack on the parasites in human patients with the suppressive, causal prophylactic and radical curative drugs, along with eradication of the mosquitoes. Mosquitoes can transmit malaria as well as dengue and various types of encephalitis. Eradication of mosquitoes includes improving environmental hygiene and the use of insecticides and larvicides such as pyrethroids, DDT and organo-phosphorous compounds. However, in practice such measures are difficult to implement. Further mosquitoes have developed resistance to the first highly effective, reasonably safe and cheap insecticide DDT.</p>
<p>Mosquito repellents: Repellents are used on the skin to prevent mosquito bites. They also offer protection against ticks, which transmit Lyme disease. They do not kill mosquitoes but deter them from biting. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> protection against the hungry Anopheles mosquitoes cannot be ensured. They are sold as aerosols, creams, solids (sticks), pump sprays and liquids.</p>
<p>A simple remedy which acts as mosquito repellent by virtue of its fragrance has the following composition:</p>
<table><thead><tr><th style="text-align: left;">Cedar wood oil:</th><th style="text-align: left;">18 ml</th></tr></thead><tbody><tr><td style="text-align: left;">Citronella oil:</td><td style="text-align: left;">42 ml</td></tr><tr><td style="text-align: left;">Spirit of camphor to</td><td style="text-align: left;">100 ml</td></tr></tbody></table>
<p>Citronella oil can also be applied in the form of vanishing cream. It is non-irritant, nontoxic, cheap and not so unpleasant. Citronella-based repellents, however, provide only a short term protection for about 1 hr against mosquitoes and are not effective against ticks. Probably more effective is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> emulsion of dimethyl phthalate (DMP) which acts as an irritant to insect's feet. It must be rubbed into every part, avoiding eyelids, lips and scrotum.</p>
<p>Oil of lemon eucaleptus contains p-menthane 3, 8-diol and offer protection up to 6 hrs but it should be avoided in children below 3 years of age. Essential oils like clove, geraniol (from rose oil) and patchouli (from pach) in high concentrations may be used but can irritate the skin.</p>
<p>Other agents used are ethohexadiol, butopyronoxyl, DEET, n-butyl acetanilide, and</p>
<p>picaridin. These are also irritants and have an intensely bitter taste. They can cause allergic reactions and bronchial spasm</p>
<p>DEET, N, N diethyl-m-toluamide, in concentrations of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%-100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">5%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> repels mosquitoes as well as ticks, fleas, gnats and some flies. However, its efficacy does not increase above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. DEET offers protection for 90 min to12 hrs depending on the concentration. In concentration <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>, it is probably safe in children and infants <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">&gt;2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> months old. No effects have been reported on fetus when it is used by mothers during second and third trimester of pregnancy. However, it can damage synthetic fiber containing clothes and plastics on eyeglass frames and watch crystals.</p>
<p>Picaridin (5-20%) is used against mosquitoes, ticks, flies and chiggers. It appears to be as effective as equivalent concentrations of DEET but is better tolerated on skin and does not damage fabric or plastic.</p>
<p>Synthetic pyrethroids are used in antimosquito tablets and coils (Chapter 62). Permethrin-treated clothing, shoes, bed nets, tents and sleeping bags provide protection against mosquitoes and ticks. Permethrin repels and kills ticks, mosquitoes and other arthropods. It remains active for several weeks even after repeated laundering. It is available in liquid and spray forms (Chapter 62).</p>
<p>Highly effective, dependable and totally safe mosquito repellent is not yet available; nevertheless use of long sleeve shirts and pants, DEET or picardin application on exposed skin and permethrin-treated bed nets are considered the most effective existing remedies.</p>
<p>57</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-amoebiasis">Chemotherapy of Amoebiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-amoebiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amoebiasis is an infectious disease caused by the protozoan, Entamoeba histolytica. The disease, though labelled as 'tropical', is not uncommon in temperate zones. It primarily affects the colon, but other organs like liver, lung and brain may get secondarily involved. The disease is characterised by gastrointestinal and constitutional symptoms and has a tendency to chronicity. Acute amoebic dysentery is associated with bloody, mucoid stools, abdominal pain and tenesmus. Chronic amoebiasis usually presents with vague symptoms like anorexia, abdominal pain and intermittent diarrhoea or constipation. There may be tenderness over the caecal region. Many infected persons, who pass the cystic forms of the protozoan in feces, however, remain completely symptomless and act as 'carriers'.
E. histolytica usually lives as a harmless commensal in the lumen of human bowel, a state which might be termed asymptomatic amoebiasis. The parasite subsists on debris and bacteria and not on the tissues of its host. When it becomes a pathogen, the trophozoites become larger and hematophagous, having many erythrocytes in the endoplasm, and cause invasive amoebiasis. Invasion is mediated by the destruction of epithelial cells and killing of neutrophils and lymphocytes.</p>
<p>Intestinal amoebiasis results in ulceration of the colon. The regions involved in descending order of frequency are the caecum, the ascending colon and the rectosigmoidal area. In fatal cases, the entire colon and even the terminal portion of the ileum may be involved leading to acute necrotising colitis. Amoebic involvement of the caecum and appendix may cause a clinical attack of appendicitis. A granulomatous lesion of the caecum giving rise to a lump in that region (amoeboma), may cause obstructive symptoms.</p>
<p>Life cycle of E. histolytica: E. histolytica exists in two forms:</p>
<ul>
<li>The trophozoites, present in the intestinal lumen and in infected tissues; and</li>
<li>The cysts, which develop from the trophozoites within intestinal lumen.</li>
</ul>
<p>The trophozoites with amoeboid movements are the active form. However, they die rapidly after elimination in the stool. The cysts represent a dormant stage and are resistant to freezing and partial drying and transmit infection from person to person.</p>
<p>Cysts are usually ingested following fecal contamination of water or food. Bad hygiene and insects like flies assist in the propagation of infection. In the intestine of the host, the cyst wall is weakened by the intestinal enzymes and the trophozoites released invade the wall of the colon and enteroportal circulation. The organism may then find its way to the liver and other tissues, giving rise to extra-intestinal amoebiasis.</p>
<p>Antiamoebic drugs: Clinical classification I Drugs used only in intestinal amoebiasis (Luminal amoebicides):</p>
<p>Halogenated hydroxyquinolines, Diloxanide furoate, Paramomycin and Kurchi. II Drugs used in both intestinal and extraintestinal amoebiasis (Tissue/mixed amoebicides): Emetine, Dehydroemetine, Metronidazole, Tinidazole, Secnidazole. III Drugs used only in extraintestinal amoebiasis: Chloroquine.</p>
<p>Chemical classification:
I Imidazole derivatives: Metronidazole, Tinidazole, Secnidazole. II Quinoline derivatives:</p>
<ul>
<li>
<p>Halogenated hydroxyquinolines: Diiodohydroxyquinoline, Iodochlorohydroxyquinoline.</p>
</li>
<li>
<p>4-Aminoquinolines: Chloroquine.</p>
</li>
</ul>
<p>III Emetine group e.g. Emetine, Dehydroemetine and its resinate
IV Antibiotics: Tetracyclines, Paromomycin.
V Miscellaneous: Diloxanide furoate, Nitazoxanide and Kurchi.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="imidazole-derivatives">Imidazole Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#imidazole-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>METRONIDAZOLE: Metronidazole, a nitroimidazole derivative (Fig. 57.1), is the drug of choice in most forms of amoebiasis except in asymptomatic cyst passers. It is:
<img src="assets/images/image-20251214-43e0d601.jpeg" alt="img-13.jpeg"></p>
<ul>
<li>A potent amoebicide.</li>
<li>Effective in both intestinal and extra-intestinal amoebiasis</li>
<li>Relatively less toxic and cost-effective</li>
<li>Also highly effective against
(1) Anaerobic protozoa (T. vaginalis, G. lamblia and Balantidium coli); and
(2) Non-sporing, anaerobic, Gram positive and negative bacilli such as bacterioides, including the B. fragiles group, Clostridium difficile and H. pylori.
Metronidazole also has a radiosensitising effect on hypoxic tumour cells.
Mechanism of action: The susceptible organisms carry electron transport components (ferredoxins) that donate electrons to metronidazole, which reduces the 5 '-nitro group of metronidazole; the short lived intermediates of this reaction interact with the microbial DNA with a lethal effect. It is not activated by the aerobes and therefore does not affect them. Resistance to metronidazole has been reported in T. vaginalis and G. lamblia but not in E. histolytica infection.</li>
</ul>
<p>Absorption, fate and excretion: Metronidazole is rapidly and almost completely ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) absorbed from the small bowel. It is, therefore, relatively ineffective in the asymptomatic cystpassers and in chronic intestinal amoebiasis. Food does not affect its bioavailability. Protein binding is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> and except for placenta, the drug diffuses into all tissues. It also achieves concentrations lethal to the sensitive organisms in CSF, bile, bone and abscesses. It is metabolised mainly in the liver, into a relatively inactive acid metabolite; and a hydroxy metabolite active against anaerobes. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 8 hours. The metabolites are excreted by the kidneys, imparting a red colour to urine. Renal insufficiency does not significantly alter its kinetics, but hepatic insufficiency prolongs its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> The drug is secreted in the milk.</p>
<p>Adverse reactions: These, as a rule, are mild and seldom necessitate discontinuation of therapy. They include:</p>
<ul>
<li>Common: Marked nausea, anorexia, abdominal pain and metallic taste in the mouth.</li>
<li>Less common: Vomiting, diarrhoea, headache, stomatitis, cystitis, dizziness, vertigo, ataxia, urticaria, pruritus and flushing.</li>
<li>Rare: Muscular weakness, seizures and incoordination.</li>
<li>Mild blood dyscrasia in the form of neutropenia, associated with the nitro group in the drug. It is reversible.</li>
<li>Antabuse-like reactions on alcohol consumption (Chapter 6), during and for upto 3 days of metronidazole therapy.</li>
</ul>
<p>Possible tumorigenic and mutagenic effects occur in experimental animals but not reported in humans.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Tablets 200 and 400 mg for oral use.
(ii) Pediatric suspension <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">200 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.
(iii) Vaginal tablets containing 500 mg .
(iv) Rectal suppositories 1.0 and 1.5 g .
(v) Solution for IV use For doses, see text.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Intestinal and hepatic amoebiasis: It is a drug of choice (See later).</li>
<li>Anaerobic infections: Metronidazole is effective in chemoprophylaxis and treatment of infections due to nonsporing, Gram negative anaerobes (bacteroides) and has been used in combination with other antimicrobials in gynecological and colorectal surgery. Initially, it is given rectally as suppositories in the dose of 1 g eight hourly until oral feeding begins. It is then administered orally in the dose 800 mg initially, followed by 400 mg 8 hourly for 7-10 days. It can also be administered by IV infusion in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} / \mathrm{kg} 6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hourly. Each dose is infused over a period of 1 hour. In severe abdominal and pelvic sepsis, the combination of gentamicin with either metronidazole or clindamycin has been shown to be synergistic. It can also be used for surgical prophylaxis in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">400 \mathrm{mg}, 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">24</span></span></span></span></span> hours and 8 hours before surgery. For its use in pseudomembranous colitis, see Chapter 49.
Anaerobes are implicated in a multitude of infections including those of gut, soft tissues, skin ulcers, abscesses of the lung and brain and in septicemia, where metronidazole is useful. It is as effective as neomycin in hepatic encephalopathy.</li>
<li>Ulcerative gingivitis (Vincent's stomatitis): The causative organisms are a spirochaete, Treponema vincenti, and Gram-negative bacilli, Leptotrichia buccalis. The preferred treatment is with penicillin G. Metronidazole orally in the dose of 200 mg thrice daily for 3-4 days is also useful. Tetracycline and clindamycin are other drugs used.</li>
<li>H. pylori Infection ((Chapter 43)</li>
<li>Trichomoniasis and giardiasis (Chapter 58).</li>
<li>Dracunculosis: (Chapter 60)</li>
</ul>
<p>TINIDAZOLE: This analogue of metronidazole has a longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (13 hours) and is probably better tolerated than metronidazole. In acute amoebic dysentery, it is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">600-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">600</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> orally tid for 5 days or in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{~g}(50 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mopen">(</span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children) once daily for 3 days. In anaerobic infections, it is used orally in the dose of 2 g initially, followed by 1 g daily (single dose) for 5-6 days. For surgical prophylaxis, it is administered in the dose of 2 g once 12 hours before surgery.</p>
<p>SECNIDAZOLE: This analogue of metronidazole has a longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> and similar uses. In acute amoebic dysentery, it is administered orally in a single dose of 2 g . In children a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is used. In hepatic amoebiasis, the dose is 1.5 g per day for five days. In giardiasis, the single oral doses are: 2 g in adults; 500 mg in children weighing 10<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">;</mo><mn>750</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{~kg} ; 750 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">750</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> in children weighing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>26</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">16-26 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">26</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> and 1 g in those weighing over 26 kg .</p>
<p>ORNIDAZOLE: is an imidazole with similar properties as secnidazole. It is available as 500 mg tablets. The dose is 500 mg bid for 5-10 days. A single daily dose of 1.5 g for 3 days is also effective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinoline-derivatives">Quinoline Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinoline-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amongst these, diiodohydroxyquinoline, iodochlorohydroxyquinoline and broxyquinoline are halogenated hydroxyquinolines while chloroquine is a 4 -aminoquinoline derivative. They act by direct contact with the trophozoites of E. histolytica. All the halogenated oxyquinolines also have some antibacterial and antifungal properties. The mechanism of action of halogenated oxyquinolines is unknown.</p>
<p>DIIODOHYDROXYQUINOLINE: This halogenated quinoline (Fig. 57.2) is an effective luminal amoebicide, against both motile and cystic forms of the protozoan, more so against the former. Clearance of cysts is partially due to elimination of trophozoites. It is, however, not effective in extraintestinal amoebiasis.
<img src="assets/images/image-20251214-745002e2.jpeg" alt="img-14.jpeg"></p>
<p>FIG. 57.2 (a) Hydroxyquinoline nucleus, (b) Iodochlorohydroxyquinoline, (c) Di-iodohydroxyquinoline
Absorption, fate and excretion: Diiodohydroxyquinoline is insignificantly absorbed from the intestinal tract and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of it is excreted in feces.</p>
<p>Adverse reactions: These are mild and uncommon. The drug may occasionally cause headache, nausea, vomiting and diarrhoea. Chills, fever, skin eruptions and iodine dermatitis have been reported. It is contraindicated in patients with iodine intolerance.</p>
<p>Preparations and dosage: Di-iodohydroxyquinoline tablet 300 mg . Dose: 600 mg thrice daily for 15 days. Another course may be given after 2 to 3 weeks. In infants, the drug is given in the daily dose of 50 to 100 mg thrice daily; in children between 1 to 5 years, 150 to 300 mg 2 or 3 times daily and in those between 6 to 12 years, 300 mg thrice daily. It cannot be given as a retention enema because of its relative insolubility in water.</p>
<p>IODOCHLOROHYDROXYQUINOLINE: This drug resembles diiodohydroxyquinoline in anti-amoebic action. It is not much absorbed from the GI tract. It is probably more useful in cyst carriers. It also has antibacterial, antifungal and antitrichomonal actions.</p>
<p>Adverse reactions: These are usually mild and include diarrhoea or constipation, abdominal pain, anal pruritus and mild iodism. A neurological syndrome consisting of myelitis, peripheral neuritis and sometimes optic nerve involvement (Subacute MyeloOptic Neuropathy-SMON) has been reported in patients receiving this drug over prolonged periods. These cases were mostly reported from Japan in 1960. They are very rarely reported from other areas. Early symptoms can improve following the stoppage of the drug. Usually, oral daily doses of upto 750 mg for 8-10 days are considered relatively safe in adults. Larger doses and its frequent use should be avoided.</p>
<p>Preparations and dosage:
(i) Iodochlorohydroxyquinoline tablets 250 mg . Dose: 750 mg daily in 3 divided doses for</p>
<p>10 days. The course may be repeated once after a week. It may be used along with emetine or alternated with other drugs.
(ii) Retention enema: It is prepared by suspending 2 g of the drug in 200 ml of water. It is instilled on alternate nights for 5 times.
(iii) Iodochlorohydroxyquinoline 3% cream for topical dermal use.</p>
<p>Therapeutic uses: Besides its use as luminal amoebicide, it is also used topically in fungal infections of the skin. The major disadvantage of topical application is yellow staining of clothes and linen.</p>
<p>CHLOROQUINE: The pharmacology of chloroquine is discussed in Chapter 56. Given orally, it is completely absorbed and concentrated in the liver. It has a minimal effect in intestinal amoebiasis because of poor concentration in colonic lumen and wall. Its use in hepatic amoebiasis has declined following the availability of metronidazole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="emetine-group">Emetine Group<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emetine-group" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>EMETINE: Emetine is an alkaloid obtained from ipecac, the root of the plant Cephalis ipecacuanha. The other alkaloid, cephaline, though amoebicidal, is toxic for use.</p>
<p>Antiamoebic action: In vitro, emetine has a direct lethal effect on the trophozoites of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span>. histolytica in concentrations that can be achieved in the blood. It inhibits protein synthesis in trophozoites, which arrests their multiplication and leads to their phagocytosis. It has, however, little effect on the cystic forms.</p>
<p>Absorption, fate and excretion: Emetine has a bitter taste and is absorbed from the gut but because of its irritant nature, it is administered by deep IM injection. The drug gets concentrated in the liver. Significant amounts are also present in the lung, kidney and spleen. As it is slowly eliminated in urine, repeated injections can cause cumulation.</p>
<p>Adverse reactions: The major drawback of emetine is its toxicity. The adverse reactions are:</p>
<ul>
<li>Local reaction: These often appear when it is administered SC but are uncommon when the drug is given deep IM. It may cause local pain, tenderness, stiffness and weakness of the muscles, and rarely, an abscess.</li>
<li>GI system: Occurrence of nausea, vomiting, diarrhoea, headache, dizziness and prostration are common. Vomiting (hence the word "emetine") occurs both as a result of gastric irritation and stimulation of the CTZ.</li>
<li>Cardiovascular system: Emetine may cause tachycardia, precordial pain, hypotension, myocarditis and pericarditis. The ECG offers an early index of cardiotoxicity. It is advisable to confine the patient to bed during emetine therapy and to avoid undue exertion for three weeks thereafter. It is necessary to observe the pulse rate and BP during the therapy; ideally, an ECG should be taken before starting the therapy, repeated after the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> dose and again after a week.</li>
<li>Miscellaneous: It may cause weakness, aching and tenderness of the muscles, especially those of neck and limbs. The weakness is probably because of its blocking action on the neuromuscular junction.
Emetine should be avoided in patients with cardiac or renal damage, in pregnant women, in old people and in young children.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Emetine hydrochloride injection, 60 mg of the salt per ml . Dose: 30 to 60 mg daily by SC or deep IM injection.
(ii) Syrup of ipecac is the preferred agent for inducing emesis but never the liquid extract of ipecac which is too potent. Dose: 30 ml in adults.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) As a tissue amoebicide (see later).
(2) For the treatment of Paragonimus westermanii (lung fluke) and Fasciola hepatica infestations (Chapter 60).
(3) Ipecacuanha syrup as an emetic (Chapter 41).</p>
<p>DEHYDROEMETINE: This semisynthetic drug, claimed to be less toxic than emetine, is preferred to emetine. Dehydroemetine injection contains 60 mg of the drug per ml. Dose: 1 mg per kg IM daily for 5-7 days. Dehydroemetine resinate is a slow release preparation given orally. Dose : 50 mg daily for 10 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiamoebic-antibiotics">Antiamoebic Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiamoebic-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TETRACYCLINE: The intestinal bacteria are essential for the production of intestinal amoebic lesions. They probably act by creating an environment congenial to the growth of amoebae, by manufacturing certain metabolites and vitamins on which the protozoa thrive, and by producing secondary infection. Tetracycline, though exhibiting an antiamoebic action in vitro in large doses, probably acts in vivo by altering the intestinal bacterial flora and creating a medium unfavourable for the growth of amoebae. It may be administered in the dose of 0.25 g 6 hourly for 10-15 days, in combination with metronidazole to treat amoebic liver abscess particularly when bacterial co-infection is suspected.</p>
<p>PAROMOMYCIN: This aminoglycoside antibiotic (Chapter 47) given orally, is not absorbed. In the dose of 500 mg tid for 10 days, it is effective as luminal amoebicide (cure rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ). It has also been used parenterally in the treatment of leishmaniasis (Chapter 58).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-agents">Miscellaneous Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DILOXANIDE FUROATE: This potent direct amoebicidal drug (Fig 57.3) is highly effective in chronic intestinal amoebiasis, in cyst passers and partially useful in mild acute cases. It is of no value in extra-intestinal amoebiasis.
<img src="assets/images/image-20251214-dbd35cb9.jpeg" alt="img-15.jpeg"></p>
<p>Given orally it is hydrolysed to diloxanide which is partly absorbed. Nonabsorbable portion acts as a luminal amoebicide. The drug is well tolerated, safe and almost non-toxic. The adverse effects reported are mild and include mainly GI disturbances, particularly flatulence.</p>
<p>Diloxanide furoate is available as 500 mg tablets and is administered orally in the dose of 500 mg 3 times daily for 5-10 days. As the drug is non-cumulative, a second course may be given immediately following the first course.</p>
<p>Nitazoxanide is a prodrug. After absorption, it gets converted to an active metabolite, tizoxanide, which is active against E. histolytica. Adverse effects are mild GI disturbances. It is given to children in the dose of 100-200 mg bid for 3 days. It also acts against Cryptosporidium parvum and G. lamblia (Chapter 58).</p>
<p>KURCHI: Kurchi consists of the dried stem bark of Holarrhena antidysenterica. Kurchi has mild antiamoebic activity and is useful only in mild intestinal amoebiasis. It may produce nausea and vomiting but is otherwise well tolerated. Powdered roots of this plant are used as a household remedy in India for ages for 'abdominal pain and diarrhoea'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-amoebiasis">Management of Amoebiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-amoebiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amoebiasis, in general, is a difficult disease to treat because of its tendency to chronicity and the inability of various drugs to eradicate the cystic forms of the parasite completely.</p>
<p>The diagnosis of acute intestinal amoebiasis without demonstration of trophozoites in stools is rarely justified. This form is most readily found in diarrhoeal stools and a saline purgative may be used in cases with vague symptoms. Examination of the swab obtained on sigmoidoscopic examination is also useful in clinching the diagnosis. The stools should be examined promptly. It is important to distinguish the trophozoites from macrophages and even experts may find it difficult to identify an active amoeba as E. histolytica when it is seen without engulfed red blood cells.</p>
<p>Cysts are found in formed stools. However, the period of their formation varies in different individuals. A casual failure to identify cysts does not, therefore, exclude the presence of amoebiasis and repeated stool examination is necessary. ELISA assays that detect specific stool antigen can distinguish between pathogenic E. histolytica from non-pathogenic E. dispar; the latter needs no treatment.</p>
<p>Definitive diagnosis of amoebiasis can also be made by antigen detection by PCR and by detection of anti-amoebic antibodies in the serum. But, these tests have limitations.</p>
<p>In the presence of symptoms of hepatitis, demonstration of E. histolytica in stools aids the diagnosis. This is often not possible, particularly if the patient has received antimicrobial therapy empirically for fever. If the patient with hepatitis is acutely ill, it is justifiable to carry out a therapeutic test with metronidazole purely on clinical grounds.</p>
<p>Table 57.1 summarises the suggested treatment of amoebiasis.
Table 57.1
Summary of suggested treatment of amoebiasis
or
Diiodohydroxyquinoline 650 mg tid for 15 to 20 days.
or
Iodochlorhydroxyquinoline 250 mg tid for 10 days</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="invasive">Invasive:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#invasive" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Metronidazole 400 to 800 mg tid for 5 days.
or
Tinidazole 2 gm daily for 2 to 3 days.
or
Secnidazole 2 gm single dose followed by a luminal amoebicide for 10 to 20 days.
Severe cases and hepatic abscess:
Metronidazole IV or</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dehydroemetine">Dehydroemetine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dehydroemetine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>IM for 5 days. (See text).
--&gt;</p>
<table><thead><tr><th style="text-align: center;">Cyst passers:</th><th style="text-align: center;">Diloxanide furoate 500 mg tid for 10 days. &lt;br&gt; or &lt;br&gt; Diiodohydroxyquinoline 650 mg tid for 15 to 20 days. &lt;br&gt; or &lt;br&gt; lodochlorhydroxyquinoline 250 mg tid for 10 days</th></tr></thead><tbody><tr><td style="text-align: center;">Imasive:</td><td style="text-align: center;">Metronidazole 400 to 800 mg tid for 5 days. &lt;br&gt; or &lt;br&gt; Tinidazole 2 gm daily for 2 to 3 days. &lt;br&gt; or &lt;br&gt; Secnidazole 2 gm single dose followed by a luminal amoebicide for 10 to 20 days.</td></tr><tr><td style="text-align: center;">Severe cases and hepatic abscess:</td><td style="text-align: center;">Metronidazole IV or &lt;br&gt; Dehydroemetine &lt;br&gt; IM for 5 days. (See text).</td></tr></tbody></table>
<p>Acute intestinal amoebiasis: Metronidazole in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-600 \mathrm{mg}(15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mopen">(</span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children) three times a day for five to seven days is the treatment of choice. It is much less toxic than emetine and is effective orally. Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of patients with moderate amoebic dysentery respond clinically to oral metronidazole therapy. The symptoms are relieved within 24 hours. Severe cases may need IV metronidazole or IM emetine. Additional advantage of this drug is its effectiveness in hepatic amoebiasis which can never be entirely excluded in any case of amoebic dysentery.</p>
<p>Parasites persist in the intestine in almost 30-40% of the patients who receive only metronidazole. Therefore, metronidazole therapy should be followed by a course of a luminal amoebicide to ensure a cure. For this purpose, diloxanide furoate 500 mg tid for 10 days or diiodohydroxyquinoline 600 mg bid or 500 mg tid for 15 days is used.</p>
<p>In patients presenting with fulminating amoebic colitis with toxic symptom, it is advisable to use oral tetracycline in addition, to eliminate the intestinal bacteria. Emetine, though controls symptoms rapidly, is no more recommended due to its cardiotoxicity.</p>
<p>Adjuvant therapy includes the use of antispasmodics for relief of colicky pain and correction of dehydration in severe cases. A cardiac lesion should be excluded before starting emetine and strict bed rest should be enforced during its use. None of the regimens gives entirely satisfactory results, and relapse may occur even a month after apparent cure.</p>
<p>Asymptomatic cyst passers and chronic intestinal amoebiasis: The drug regimens recommended in such cases are:
(a) Diloxanide furoate 500 mg 3 times daily for 10 days.
(b) A combination of di-iodohydroxyquinoline 1.8 g daily and tetracycline 1 g daily, in divided doses for 10 days.</p>
<p>Chronic amoebic colitis is sometimes difficult to treat and usually more than one drug, given in rotation, is needed to achieve success. It must be remembered that some of the symptoms of colitis may be due to 'irritable colon' or certain pathological changes which may not regress rapidly, even though the colon is cleared of pathogens. Hence, other supportive and symptomatic therapy such as a high fibre diet and antispasmodics may be more useful.</p>
<p>Hepatic amoebiasis: Metronidazole is the drug of choice. Emetine hydrochloride and chloroquine diphosphate are other alternatives.</p>
<p>Metronidazole ( 800 mg three times a day for 10 days) rapidly controls hepatic amoebiasis in majority of cases. An alternative regime is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">2.4 \mathrm{~g}(30 \mathrm{mg} / \mathrm{kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mopen">(</span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span> in a single daily dose for two successive days. In this dose nausea is likely to be severe and should be prevented by administration of metoclopramide. Metronidazole may also be administered IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.75</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.75-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> for an adult) as a loading dose, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every six hours for 7-10 days. Each dose is infused slowly over one hour. Neutralised solutions should not be refrigerated, lest precipitation occurs.</p>
<p>Aspiration is usually necessary in addition to chemotherapy whenever an abscess is present. Simultaneous administration of tetracycline therapy may be beneficial.</p>
<p>Chloroquine diphosphate is much less potent than metronidazole. It is given in the dose of 500 mg thrice daily for 2 days followed by 250 mg twice daily for 2 to 3 weeks; however, the relapse rate is high.</p>
<p>Emetine hydrochloride or dehydroemetine may be given deep IM in the dose of 1 mg per kg of body weight for a period of 10 days. The above treatment should be followed by a course of a luminal amoebicide.</p>
<p>In patients in whom the diagnosis between amoebic and pyogenic liver abscess is not certain, metronidazole alone should be avoided because a pyogenic liver abscess may temporarily respond to metronidazole.</p>
<p>Other forms of extra-intestinal amoebiasis: These respond well to metronidazole.
Criteria for cure of amoebiasis: Failure to detect E. histolytica in stool specimens obtained at regular intervals for next 2 years is taken as the criterion for cure of amoebic infection. Clinical cure does not signify cure of the disease and relapses can occur.</p>
<p>Prevention: The cysts responsible for propagation of the disease are resistant to the agents routinely used to purify water. Chlorine, in the concentration employed to purify water, fails to kill them. It is, therefore, necessary to avoid fecal contamination of water by sanitary disposal of feces. Fly control and detection and treatment of carriers are equally important. The surest way to eliminate cysts from water is to boil it. There is no effective prophylactic therapy. Prophylactic use of small doses of luminal amoebicides has been tried. Although they have been claimed to be useful, such a procedure will have limited application, particularly in those areas where possibility of frequent reinfection is always present.</p>
<p>58</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-other-protozoal-infections">Chemotherapy of Other Protozoal Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-other-protozoal-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leishmaniasis is a vector-borne infection caused by intracellular protozoa of the genus Leishmania. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of world population is at risk of acquiring leishmaniasis. It presents as several clinical syndromes. The most common are:
(a) Visceral leishmaniasis (VL),
(b) Cutaneous leishmaniasis (CL) and
(c) Mucocutaneous (MCL) leishmaniasis, resulting from pathological changes in reticuloendothelial organs, dermis and muco-orophar-ynx respectively.</p>
<p>Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of cases worldwide are reported from India, Bangladesh, Nepal, Sudan and Brazil. From 30 mammalian infecting species of leishmania, 21 are responsible for human disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="visceral-leishmaniasis-or-kala-azar">Visceral Leishmaniasis or Kala-azar<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#visceral-leishmaniasis-or-kala-azar" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This form of the disease, produced by Leishmania donovani and L. infuntum (India, Nepal, Bangladesh and Sudan) and L. chagasi (Latin America) is transmitted by Phlebotomus sandflies. In most leishmania infections, dogs and rodents act as reservoir. Only patients with post-kala-azar dermal leishmaniasis (PKDL) and those with CL act as human reservoir for L. donovani and L. tropica respectively. In India, VL is found predominantly in Bihar, Assam, W. Bengal and Orissa.</p>
<p>VL can be asymptomatic, sub clinical and self-resolving or it can run an aggressive fatal course. Clinically, it is characterised by weight loss, hepatosplenomegaly, irregular fever, anemia, leukopenia and hypergamma-globulinemia and suppressed cellular immunity.</p>
<p>PKDL is sometimes observed as a syndrome after inadequate or early cessation of treatment of VL. The dermal lesions act as a source of reservoir for L. donovani spread.</p>
<p>Life cycle: During its life cycle, the protozoan exists in two forms:
(1) Leishmania forms, (amastigotes) found within the reticuloendothelial cells of the liver, spleen and lymph nodes, and within the macrophages of the infected person; and (2) Motile flagellated leptomonad forms (promastigotes) which develop from the leishmania forms within the digestive tract of the sandfly, after it has fed on the blood of an infected individual. The development of the leptomonad forms within the sandfly takes about 10 days. They are injected by the sandfly into man during its bite, whereupon they attack the reticuloendothelial cells, are phagocystosed by macrophages and get transformed into the leishmania forms.</p>
<p>Diagnosis of kala-azar depends upon the demonstration of the leishmania forms in the peripheral blood or in the aspirate obtained by sternal, splenic, liver or lymph node puncture. Blood culture is a more certain but time-consuming method of diagnosis.</p>
<p>The drugs used in leishmaniasis are :</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-pentavalent-antimony-compounds">I Pentavalent antimony compounds:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-pentavalent-antimony-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Sodium stibogluconate and Meglumine antimonate.
II Diamidine derivatives: Dihydroxy-stibamidine isethionate and Pentamidine isethionate. III Miscellaneous: Amphotericin B, Aminocidin, Paramomycin, Miltefosine. They are summarised in Table 58.1.</p>
<p>Table 58.1
Drugs for leishmaniasis</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Dose (adults and children)</th></tr></thead><tbody><tr><td style="text-align: left;">Sodium stibogluconate</td><td style="text-align: left;">20 mg of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">b</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{Sb} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">Sb</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, IV slowly over 5 min or IM for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>28</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">28-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">28</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Meglumine antimonate</td><td style="text-align: left;">Same as above</td></tr><tr><td style="text-align: left;">Amphotericin B</td><td style="text-align: left;">0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.0 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV, every second day for 15 infusions</td></tr><tr><td style="text-align: left;">Liposomal amphotericin B</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day on days <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>5</mn><mo separator="true">,</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">1-5,14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">14</span></span></span></span></span> and 21 (Total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>21</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">21 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">21</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> )</td></tr><tr><td style="text-align: left;">Pentamidine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily or every second day IV or IM upto 15 doses.</td></tr><tr><td style="text-align: left;">Miltefosine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day for 4 weeks.</td></tr></tbody></table>
<p>I Pentavalent antimony compounds: The pentavalent antimony compounds, discovered in 1912, exhibit little activity against the leptomonad forms of Leishmania in vitro. Their efficacy in vivo suggests their reduction into trivalent antimony compounds in the body.</p>
<p>SODIUM STIBOGLUCONATE: This is the drug most preferred for the treatment of leishmaniasis. It acts by suppressing both glycolysis and fatty acid metabolism and by</p>
<p>diminishing the net generation of ATP and GTP in the amastigotes. Given IV/IM, it is excreted in two phases: a short phase with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 2 hours and long phase with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of more than 24 hours (33-76 hours). The latter reflects slow release of trivalent antimony from the tissues, which contributes to prolonged effects of the drug. Leishmania can develop resistance to antimonials and high degree of resistance has been reported from Bihar in India.</p>
<p>Adverse reactions: The common adverse effects include a metallic taste in mouth, nausea, vomiting, diarrhoea, giddiness and local thrombosis. Myalgias, arthralgia, hepatitis, pancreatitis and rarely arrhythmia may occur. ECG may show flattening or inversion of T waves, and prolongation of QT interval. A few cases of anaphylactoid shock and renal failure have been reported.
II Diamidine derivatives: These drugs are more potent but more toxic than the pentavalent antimony compounds. However, they are not so effective in Indian Kala-azar. The mechanism of action is not known. They interfere with amino acid transport, disrupt the mitochondria and inhibit the transformation of amastigotes to promastigotes. They are also useful for prophylaxis against T. gambiense and in the treatment of early Gambian and Rhodesian trypanosomiasis.</p>
<p>PENTAMIDINE: Two pentamidine salts are available, isethionate (Pentamidine) and mesylate (Lomidine). They are administered IM.</p>
<p>It is concentrated in the liver; very little gets into the brain tissue. The drug can be detected in the urine for 6-8 weeks.</p>
<p>Adverse reactions: Following the IM injection, it may cause local irritation, breathlessness, nausea, vomiting, facial flushing, pruritus, arthralgia, myalgia, tachycardia, arrhythmia and hypotension. The systemic toxicity includes hepatotoxicity, leukopenia, thrombocytopenia and nephrotoxicity. About 5% of patients may develop insulin dependent diabetes mellitus. It appears to have a direct action on the pancreatic beta cells, resulting in initial insulin release followed by impaired insulin secretion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Visceral and mucocutaneous leishmaniasis resistant to pentavalent antimony therapy are treated with a course of pentamidine or amphotericin B.</li>
<li>Pneumocystis jiroveci pneumonia: Although cotrimoxazole is highly effective in P. jiroveci pneumonia, its increased toxicity in patients with AIDS makes some physicians prefer pentamidine. It is also used for prophylaxis. A dose of 300 mg aerosolised, given once every 4 weeks, appears to be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> effective in preventing the first episode of pneumonia in patients with AIDS. The other drugs used for the same purpose are daily cotrimoxazole and weekly combination of sulfadoxine and pyrimethamine, (Chapter 56).</li>
<li>Trypanosomiasis: See later.</li>
</ul>
<p>DIHYDROXYSTILBAMIDINE ISETHIONATE: This is given IV in the dose of 250 mg daily for 10 days. The course may be repeated after an interval of 2 weeks and a total dose of 7.5 g , should be given over a period of 4 to 5 weeks. Its toxicity is similar to that of pentamidine.
III Miscellaneous:
AMPHOTERICIN B: This antifungal antibiotic, (Chapter 50) is useful in patients not responding to antimony compounds. However, it is expensive, toxic and not easily available. The doses vary in different regions probably because differences in leishmania</p>
<p>species and their susceptibility.
Amphotericin damages an ergosterol-like membrane steroid of leishmania. It is considered the drug of choice for Indian Kala-azar. The disease can relapse but responds to repeat therapy. Freedom from relapse for 6 month indicates cure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Conventional amphotericin B (complexed with bile salt deoxycholate),
(ii) Amphotericin B colloidal dispersion,
(iii) Amphotericin B lipid complex and
(iv) Liposomal preparations. The latter are less toxic as they are targetted specifically toward macrophages, and may be preferred.</p>
<p>MILTEFOSINE: This phosphocholine derivative has been reported to be highly effective orally particularly in Indian visceral and cutaneous leishmaniasis. It acts by interfering with cell signaling pathways. This possibly results in altered lipid metabolism, inhibition of mitochondrial function, modulation of macrophage response and induction of apoptosis. It is administered as 50 mg bid for 4 weeks. For those with weight more than 50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{kg}, 50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid is recommended. Response rate to miltefosine is variable ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ). It is metabolized by the liver and has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 6-9 days. Adverse effects reported are vomiting, diarrhoea and transient hepatic and renal damage. It is teratogenic and should be avoided in pregnancy. Rapid development of drug resistance is a major disadvantage.</p>
<p>AMINOCIDIN (Paromomycin): This aminoglycoside antibiotic has been claimed to be useful in the treatment of visceral leishmaniasis. It is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15-20 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, in 3 divided doses IM, for 21 days. It needs further evaluation. (Chapter 47).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oriental-sore">Oriental Sore<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oriental-sore" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This condition is caused commonly by Leishmania tropica (L. major). The parasite is transmitted by another species of sandfly. It is characterised by nodular skin lesion that later ulcerates. Mild lesions may be left to heal by themselves. More severe cases require local as well as systemic antimonial therapy. Ketoconazole in the dose of 200-400 mg/day for 4-6 weeks may be useful.</p>
<p>Sores on the face and hands often get secondarily infected and tend to become chronic. This would need additional antibiotic therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="american-mucocutaneous-leishmaniasis">American Mucocutaneous Leishmaniasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#american-mucocutaneous-leishmaniasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is caused by Leishmania brasiliensis and L. mexicana. It is characterised by skin granulomas and ulcerative lesions of the nose, mouth and pharynx. The treatment is similar to that of visceral leishmaniasis. However, the disease is relatively resistant to antimonials. Amphotericin B is perhaps the best alternative.</p>
<p>Currently used drugs for leishmaniasis are generally toxic, need to be given for long time and do not eliminate persistent forms of the parasite from the host. There is a variation in therapeutic response depending on the leishmanial species. Organisms can develop resistance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="trypanosomiasis">Trypanosomiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trypanosomiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This disease, caused by parasites of the genus Trypanosoma, is characterised by chronic irregular fever, skin eruptions, lymphadenitis, and physical and mental lethargy. It can be divided into:
(1) African trypanosomiasis (Sleeping sickness) is caused by Trypanosoma gambiense and Trypanosoma rhodesiense transmitted by tse-tse and open woodland flies respectively.
(2) South American trypanosomiasis caused by Trypanosoma cruzi transmitted by blood sucking Reduviid bugs.</p>
<p>African trypanosomiasis: Therapeutic response is better if the treatment of sleeping sickness is undertaken in its earlier stage when the parasite has not invaded the CNS.</p>
<p>SURAMIN SODIUM: This drug, a complex organic urea compound, is particularly useful in treating the more acute rhodesian form of African trypanosomiasis and early infections with T. gambiense. It is also a useful prophylactic agent but has now been replaced by pentamidine for this purpose.</p>
<p>The mechanism of action is not clear. Parasites treated with the drug lose their infectivity but still survive in vitro for over 24 hours after exposure. In addition to trypanocidal activity, the drug is effective against the adult forms of Onchocerca volvulus.</p>
<p>Absorption, fate and excretion: Suramin is administered IV as the drug is not adequately absorbed from the gut; IM administration is painful. It gets extensively bound to plasma proteins and persists in the plasma for as long as 3 months after a single dose. It does not cross the blood brain barrier and is, therefore, useless in the encephalitic stage of the disease. The drug is excreted in urine.</p>
<p>Adverse reactions: These include nausea, vomiting, dermatitis, chills, fever, pruritus, paraesthesias, photophobia, polyuria and sometimes loss of consciousness. Blood dyscrasias may develop occasionally. The drug is nephrotoxic and may give rise to cylindruria, albuminuria and hematuria.</p>
<p>Preparations and dosage: A freshly prepared <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution in distilled water is given IV at intervals of 5 to 7 days for 5-6 injections. The initial dose is 0.5 g followed by 1 g in subsequent injections. A child under 3 years is usually given 0.25 g , from 3 to 10 years 0.5 g and those above ten years 1 g . As the drug is nephrotoxic, urine should be examined before each injection. For use of suramin in onchocerciasis (Chapter 60).</p>
<p>PENTAMIDINE ISETHIONATE: This drug may be used as a substitute for suramin. It is administered IV in the dose of 3 to 4 mg of the base per kg of body weight, on every alternate day for 10 doses. A single IM dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">300-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) once every 6 months has been shown to protect against the Gambian but not the Rhodesian disease. Hypotension and hypoglycemia are common adverse effects. The drug doses not cross the BBB.</p>
<p>The organic arsenical compounds used in African trypanosomiasis are Mel B and Mel W. These compounds are toxic and are mainly used to treat meningo-encephalitic stage of the disease.</p>
<p>MELARSOPROL (Mel B): This trivalent organic arsenical, dissolved in propylene glycol, is administered IV, slowly, in increasing doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.36</mn><mo>−</mo><mn>3.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.36-3.6 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.36</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per kg (upto a maximum of 200 mg ). The injection is given on alternate days for 3 days. The course may be repeated after an intermission of 3 weeks in cases with involvement of the CNS. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of the patients can be cured without serious complication, whereas 1-5% die during treatment.</p>
<p>The toxic manifestations include vomiting, abdominal colic, proteinuria, neuritis, blood dyscrasias, myocardial damage and arsenical encephalopathy.</p>
<p>Mel B is contraindicated in severely debilitated patients and in those with hepatic and/or renal damage.</p>
<p>MELARSONYL POTASSIUM (Mel W) : This water soluble derivative of Mel B is given as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution, by IM injection. The first dose is 2 mg per kg ; then 4 mg per kg given daily for 3 days. In severe cases, another course of 4 mg per kg daily for 4 days may be given after a week. The preparation is probably less toxic but also less effective than the parent compound in advanced T. rhodesiense infection, but may be equally effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>T</mi></mrow><annotation encoding="application/x-tex">T</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span></span></span></span></span>. gambiense infection. The drug is also useful in onchocerciasis.</p>
<p>NITROFURAZONE: The drug has been employed for trypanosomiasis in patients who have relapsed after other forms of treatment. It is given orally in doses of 500 mg tid for 7 to 10 days. For children, a dose of 30 mg per kg is recommended. The adverse manifestations include GI disturbances, peripheral neuritis, seizures and hemolysis in G6PD deficient patients.</p>
<p>EFLORNITHINE HYDROCHLORIDE (Difluoromethylornithine, DFMO) has been shown to give high cure rates in late stages of gambian trypanosomiasis. It causes irreversible inhibition of synthesis of polyamines required for cell division and differentiation. The drug can cause headache, alopecia, diarrhoea, anemia, leucopenia and thrombocytopenia. Hallucinations, convulsions and hearing loss may occur. It is teratogenic. It is administered by IV infusion in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in four divided doses for 14 days. It should be considered as an alternative in patients who relapse after melosoprol.</p>
<p>Eflorinthine cream has been found useful in reducing the rate of growth of facial hair in women; however it needs to be used for prolonged period (Chapter 69).</p>
<p>South American Trypanosomiasis (Chagas' disease): There is no effective and safe agent available for the treatment of this condition.</p>
<p>Two drugs nifurtimox and benznidazole, effective orally, appear to kill circulating trypanosomes.</p>
<p>Nifurtimox is given orally in a dose of 8 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per day in 4 divided doses, for 90 to 120 days. The drug may cause GI disturbances, weight loss, insomnia, arthralgia, neuropathy, leucopenia and seizures.</p>
<p>Benznidazole is administered in a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in two divided doses for 60 days. Generally it is well tolerated. It can cause GI disturbances, polyneuropathy and bone marrow suppression. They are not useful in chronic disease.</p>
<p>A variety of other drugs, including pyrimethamine, nitrofurans, amphotericin B and puromycin have been given a trial. None of these gives complete cure. They only cause a transient disappearance of parasitemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxoplasmosis">Toxoplasmosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxoplasmosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Toxoplasmosis is a common disease of birds and mammals, caused by infection with the obligate intracellular protozoan Toxoplasma gondii. The organisms are arc shaped (toxon=arc; gondii=the name of a North American rodent). Infection in the animal world occurs by ingestion of cysts that contain sporulated oocytes (bradyzoites) by an intermediate host such as the rat or the sheep. The bradyzoites released in the gut enter the epithelium of the small intestine and transform into rapidly dividing tachyzoites, which can infect all mammalian cells except the RBCs. Seven to 10 days after the tachyzoite infection, tissue cysts containing many tachyzoites are formed. The parasites' sexual phase (feline phase) takes place in the definitive host like the cat which ingests the infected rats. The infected cats may excrete millions of sporozoites containing oocytes which may remain viable for many years in the soil. Human infection occurs following ingestion of either soil contaminated with sporulated oocytes or undercooked meat containing tachyzoites. Cysts are commonly found in tissues such as the brain, and skeletal muscles.</p>
<p>Toxoplasmosis is largely asymptomatic and self-limiting, but a small percentage of patients get lymphadenopathy, fever and malaise. Retino-choroiditis forms an important manifestation (25-35%) in children but is rare in adults. Encephalitis, myocarditis and pneumonitis can occur. Repeated abortions can occur in infected women. There is no drug which will kill the trophozoites or eradicate the cysts. Spontaneous cure is known. No treatment is recommended for asymptomatic infection in immunocompetent subjects.</p>
<p>A combination of pyrimethamine and sulfadiazine is effective in inhibiting the trophozoites. Pyrimethamine, a DHF reductase inhibitor, is given orally in the initial dose of 75 mg . daily, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily. Sulfadiazine is used in the dose of 2 gm followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> orally every six hours. The combination treatment is given for 4-6 weeks. Pyrimethamine can also be combined with clindamycin or azithromycin. The other drugs used are cotrimoxazole, atovaquone, spiramycin and clarithromycin.</p>
<p>The regimen recommended in affected, pregnant women is spiramycin, a macrolide, in the dose of 1 g tid orally continued throughout pregnancy. In all cases, folic acid supplement should be given. Monthly ultrasonography is suggested to detect any fetal abnormality. The presence of hydrocephalus is an indication to terminate pregnancy.</p>
<p>Congenitally infected neonates are treated aggressively with oral pyrimethamine ( 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.0 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day) and sulfadiazine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day) along with folic acid for one year. Spiramycin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day) may also be useful. However, a macrolide alone may not be beneficial unless combined with pyrimethamine. Clindamycin can be substituted for sulfadiazine in patients allergic to sulfonamide.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="trichomoniasis">Trichomoniasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trichomoniasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vaginal discharge is a common complaint in general practice. It must be emphasised that many discharges are non-infective and hence it is wrong and may even be harmful to use systemic or local antimicrobial drugs unless proper diagnosis is made.</p>
<p>In women of the child-bearing age excessive vaginal discharge (leucorrhoea) may simply be due to pelvic congestion or increased secretion of the cervical glands as in cervical erosion or during oral contraceptive medication. In such cases bacteriological examination is negative and no drugs are indicated. What is needed is reassurance and advice on simple hygiene and cauterisation of the cervical erosion.</p>
<p>Vaginal discharge due to infection should be treated according to the causative organism. Trichomonas vaginalis is by far the commonest one, followed by C. albicans. Typically,
(a) Trichomoniasis presents as an intense vaginitis with a purulent, greenish yellow profuse, frothy, offensive discharge. Other symptoms include pruritus, burning, edema, dyspareunia and urinary frequency.
(b) Candidial vaginitis is less intense with thin and curd like or 'cheesy' discharge and adherent plaques on the vaginal wall.</p>
<p>Trichomonas vaginalis is the infectious protozoan most commonly associated with vulvovaginitis during reproductive years. Infection in males is often symptomless. The condition is diagnosed by microscopic examination of fresh material from the vagina, of semen, of prostatic fluid obtained by massage and of urinary sediment. The flagella of the protozoan can be identified in a wet smear.</p>
<p>Drugs for local treatment: They are useful when extravaginal sources of reinfection are not present. They include:
(a) Halogenated hydroxyquinolines like Iodochlorohydroxyquinoline, Diiodohydroxyquinoline;
(b) Agents like Furazolidone, surfactants like Sodium lauryl sulfate, Dioctyl sodium sulfosuccinate, Triclobisonium and Povidone iodine.</p>
<p>These drugs are discussed elsewhere. They are often combined with deodorizers like thymol, menthol, or eucalyptol. Other local agents like vinegar, boric acid and lactic acid are used to lower the vaginal pH to its usual acidity ( 3.5 to 4.5 ). This facilitates the growth of the normal vaginal flora and results in suppression of the trichomonal infection.</p>
<p>Drug for systemic therapy: Oral metronidazole is the drug of choice for trichomoniasis (Chapter 57).</p>
<p>Trichomoniasis responds well to oral metronidazole 400 mg twice daily for 7 days. A second course may be instituted after 4-6 weeks. A single dose of 2 g has also been reported to give equally good results. Since trichomoniasis is a urogenital infection, simply using local pessaries without systemic therapy is unsatisfactory. However, addition of topical treatment to systemic therapy increases local concentration, which may be beneficial in refractory cases.</p>
<p>Trichomoniasis is sexually transmissible and it is advisable to administer a course of metronidazole to the sexual consorts of the infected persons. It is advisable to avoid sexual intercourse until cure has been confirmed. Infections due to C. albicans and gonococcal and puerperal infections need appropriate antibiotic therapy (Chapter 53).</p>
<p>Metronidazole, given in the dose of 400 mg twice daily for 7 days, is also useful in the treatment of mixed vaginitis (non-specific vaginitis) due to an aerobe (Gardnerella vaginalis) and anaerobes. The infection causes a malodorous, off-white, vaginal discharge of high pH , giving a positive amine test. There is no inflammation of the vaginal wall.</p>
<p>Tinidazole and Secnidazole: These imidazoles are effective in a single oral dose of 2 g in the treatment of vaginal trichomoniasis and giardiasis (Chapter 57).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="giardiasis">Giardiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#giardiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Giardia lamblia is a flagellate protozoan parasite of the small intestine. Like E. histolytica, it has no animal host and is transmitted from man to man by fecal contamination of food and water. It can cause diarrhoea, anorexia, nausea, vomiting, abdominal pain and weight loss. Both the cysts and trophozoites may be found in the stools. Giardiasis is quite common and often exists in association with E. histolytica infection.</p>
<p>Metronidazole is the drug of choice in giardiasis. It is given in the dose of 200 mg tid for 5 days in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in 3 divided doses for 5 days in children.</p>
<p>Nitazoxanide is effective against metronidazole resistant G. lamblia. Other drugs used are tinidazole, 2 g single dose, furazolidone ( 100 mg qid for 7 days) and paramomycin.</p>
<p>59</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-viral-infections">Chemotherapy of Viral Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-viral-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Viral infections, in general, are difficult to treat. A virus is made up of a nucleic acid core enclosed in a protein coat called capsid which consists of repeating, identical subunits called capsomeres. Certain other constituents protect the nucleic acid moiety from the action of various body fluid enzymes. Viruses, unlike bacteria, have no cell wall and the enzyme systems associated with it.</p>
<p>Viruses are of two types (Table 59.1):</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-59-1">Table 59.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-59-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>DNA and RNA viruses</p>
<ul>
<li>DNA viruses: Herpes simplex; varicella-zoster; smallpox; hepatitis B; human cytomegalovirus (CMV).</li>
<li>RNA viruses: Rabies; rubella; measles; dengue; yellow fever; poliomyelitis; HIV; influenza.</li>
<li>Deoxyribonucleic acid (DNA) viruses;
and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ribonucleic-acid-rna-viruses">- Ribonucleic acid (RNA) viruses.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ribonucleic-acid-rna-viruses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most viruses survive outside the host cell only for a short time. After penetration into the target cell, viral replication occurs in following steps:
(a) Uncoating of viral nucleic acid strands
(b) Early, regulatory protein synthesis
(c) Replication of viral DNA/RNA
(d) Late structural protein synthesis
(e) Coating and maturation of viral particles; and
(f) Their release from the target cell. Antiviral drugs can act at any of these steps.</p>
<p>The major difficulties encountered in the chemotherapy of viral infections are:</p>
<ul>
<li>
<p>Viruses, unlike bacteria are intimately parasitic on host cells. They are obligatory intracellular agents. Hence, a drug that is expected to destroy the virus is likely to damage the normal host cells as well.</p>
</li>
<li>
<p>Certain viruses multiply in the cytoplasm while others do so in the nucleus of the infected cell. A drug which acts on a virus in the cytoplasm may not necessarily act on a virus that multiplies in the nucleus and vice versa.</p>
</li>
<li>
<p>The severity of infection produced by a virus and its response to a given chemotherapeutic drug differ considerably in different species of animals.</p>
</li>
<li>
<p>Precise diagnosis of many virus infections is difficult. The laboratory screening tests for antiviral compounds are also difficult. Further, in vitro efficacy of a new drug may not predict its therapeutic efficacy.</p>
</li>
<li>
<p>In many viral infections, the greater part of the viral multiplication takes place before the clinical diagnosis can be made. The antiviral compounds are usually most effective during the stage of replication of the virus, which is difficult to detect clinically.</p>
</li>
<li>
<p>Antiviral drugs inhibit viral replication. However, viruses start replicating after stopping the drug. This is a common problem in immunocompromised patients. Moreover, antiviral drugs may not eliminate nonreplicating or latent viruses.</p>
</li>
<li>
<p>Viruses undergo mutation and develop drug resistance.</p>
</li>
</ul>
<p>At the onset of infection, the viruses are usually adsorbed on to the surface of a host cell. In a few cases, they react with the cell membrane receptor sites specific for the virus. Viruses cause cell injury by:</p>
<ul>
<li>Direct lysis resulting from viral replication;</li>
<li>Lysis induced by antiviral antibody and the complement; and</li>
<li>Cell mediated immune mechanisms.</li>
</ul>
<p>In addition, viral infection may transform cells so that they may proliferate and produce tumours e.g. papiloma virus causing cervical cancer. Since the multiplication of a virus is heavily dependent on host cell mechanisms, an effective antiviral agent must act intracellularly and selectively.</p>
<p>Antiviral compounds - Classification:
I Compounds interfering with the nucleic acid synthesis, e.g., Idoxuridine, Acyclovir, Ribavirin, Trifluridine, and Azidothymidine (AZT).
II Inhibitors of attachment/penetration, e.g., Amantadine, Zanamivir.
III Inhibitors of reverse transcriptase e.g. Lamivudine.
IV Immunological agents e.g. Interferon, Gamma globulin and Monoclonal antibodies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-herpes-and-anti-cmv-drugs">Anti-herpes and anti-CMV Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-herpes-and-anti-cmv-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>IDOXURIDINE (5-Iodo-2'-Deoxyuridine): This compound is chemically related to thymidine and acts by competing with it in the synthesis of DNA, thereby preventing the utilisation of thymidine. The drug interferes with the synthesis of host cellular DNA and, hence, is too toxic for systemic use. It has been employed locally as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> drops or ointment in the treatment of herpetic keratitis. It is now superseded by drugs such as acyclovir.</p>
<p>TRIFLURIDINE: This nucleoside analogue has been used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> ophthalmic ointment to treat ocular herpes. It is less specific.</p>
<p>ACYCLOVIR: This guanosine analogue (Fig 59.1) is a potent antiviral drug of low toxicity.
<img src="assets/images/image-20251214-5ac84ab0.jpeg" alt="img-16.jpeg"></p>
<p>FIG. 59.1 Acyclovir
Mechanism of action: The drug is phosphorylated by viral-specific thymidine kinase to monophosphate derivative. Further phosphorylation by host cell kinase leads to the formation of acyclovir triphosphate, which inhibits viral DNA synthesis.</p>
<p>The antiviral spectrum includes Herpes simplex virus (HSV) 1 and 2, Varicella zoster virus (VZV) and Epstein barr virus (EBV). HSV and VZV can develop resistance to acyclovir, particularly in HIV positive patients.</p>
<p>Absorption, fate and excretion: Given orally, it has a bioavailability of 15-30%; the CSF level of the drug is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> that of plasma. Hence, for viral encephalitis it is given IV. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 3 hours. It is mostly excreted unchanged in the urine; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> is metabolised in the liver.</p>
<p>Adverse reactions: Locally it may cause stinging and reversible superficial keratopathy. Orally, the drug is generally well tolerated. Given IV, it may cause headache, thrombophlebitis and elevation of blood urea and creatinine (crystalline nephropathy). CNS toxicity includes delirium, tremors, abnormal EEG and hallucinations (Neuropsychiatric reaction).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Acyclovir tablets 200 mg . Dose 200-400 mg 4-5 times a day.
(ii) IV infusion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over 1 hour at 8 hour interval.
(iii) Acyclovir eye ointment 3%.
(iv) Acyclovir cream 5% for skin application.</p>
<p>Therapeutic uses: Both, HSV and VZV produce their effects by destroying the epithelial cells by replicating in them. Once the damage is done, the healing time in an immunocompetent individual is largely unrelated to the virus. Hence, to be effective, treatment must be started within 24 hours of the onset of the rash. Most of the herpes simplex lesions are mild and heal without any problems and do not need the drug.</p>
<p>In an immunocompromised person, however, failure to curtail viral replication may lead</p>
<p>to prolongation of the local lesions and dissemination of infection. In such patients, treatment with acyclovir should be begun at any stage of the infection. In these patients acyclovir reduces visceral complications but has no effect on healing of skin lesions or pain. The indications for use of acyclovir are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="herpes-simplex-virus-infection">- Herpes simplex virus infection:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#herpes-simplex-virus-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Primary and recurrent genital infections: It is highly effective in an oral dose of 200 mg 5 times a day for 7 days. It can be given IV.
(b) Gingivostomatitis and pharyngitis: also responds to above-mentioned regime.
(c) Keratoconjunctivitis: It is used topically.
(d) Meningitis and encephalitis: Acyclovir IV is the treatment of choice.</p>
<ul>
<li>Varicella zoster virus infection: VZV causes varicella (chicken pox) as primary infection. Reactivation of the virus, which remains latent in dorsal root ganglia, results in herpes zoster.
(a) Varicella: Acyclovir is not routinely used if VZV infection is uncomplicated in children. In adults, 800 mg orally 5 times a day for 7 days decreases time to crusting, its eruption and duration of fever. But treatment should be started within 24 hours of rash. IV therapy is needed for severe varicella pneumonia and encephalitis.
(b) Localised herpes zoster: Oral treatment with acyclovir in immunocompetent individuals should probably be reserved for those who have very early lesions and for those in whom the attack threatens to be widespread or in a critical area such as the face.
If given within 72 hours of rash, 800 mg acyclovir 5 times a day for 7-10 days decreases pain and healing time but does not reduce the intensity of post-herpetic neuralgia. It also decreases ocular complications of keratitis or uveitis. It may be life saving in patients with encephalitis. It can also be given by IV infusion.</li>
</ul>
<p>Both varicella and herpes zoster in the immunocompromised patient should always be treated with IV acyclovir.</p>
<ul>
<li>Prophylaxis with acyclovir: Prophylactic treatment with acyclovir is given to immunocompromised patients undergoing bone marrow transplant or chemotherapy.
Penciclovir has similar mechanism of action but its triphosphate has less affinity for viral DNA polymerase than acyclovir. It also does not cause chain termination. However, it achieves higher concentration in cells and has intracellular half life of 7-20 hr. Valacyclovir and famciclovir are prodrugs for acyclovir and penciclovir respectively and have similar applications.</li>
</ul>
<p>DOCOSANOL: is a saturated 22-carbon aliphatic alcohol and an OTC product, available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> cream. It is used for recurrent orolabial herpes simplex. It blocks the fusion between cellular and viral envelope membranes and thus inhibits viral replication.</p>
<p>The use of glucocorticoids in herpes zoster is best left to the specialists.
GANCICLOVIR: It is an acyclic nucleoside analogue of guanine with action similar to that of acyclovir. It is given orally or by IV infusion. Its concentration in infected cells is high and remains so for more than 24 hours. It is excreted unchanged in urine.</p>
<p>It is more toxic than acyclovir. ADR include GI disturbances, myclosuppression and aspermatogenesis. CNS symptoms like headache, behavioural changes and convulsions are also observed. It may also cause liver and renal dysfunction. It is carcinogenic, teratogenic and mutagenic in animals. Because of its toxicity, its use is limited to</p>
<p>immunocompromised host with serious cytomegalovirus (CMV) infection of the retina and colon.</p>
<p>Valganciclovir is a prodrug for ganciclovir.
CIDOFOVIR: This acyclic cytosine nucleotide has same mechanism as ganciclovir, but does not require viral enzymes for phosphorylation; hence it is active against thymidine kinase deficient or altered strains of CMV and HSV. Its active metabolite contributes to longer duration of action (intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>17</mn><mo>−</mo><mn>65</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 17-65 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">17</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">65</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ). Its CSF penetration is poor. The drug is eliminated by active renal tubular secretion.</p>
<p>The drug causes dose dependent renal tubular nephropathy. This can be reduced by use of probenecid and prehydration with normal saline to decrease its nephrotoxicity. The other ADR include uveitis, iritis, ocular hypotony and neutropenia. Concomitant administration of other nephrotoxic drugs and foscarnet are to be avoided.</p>
<p>Though cidofovir IV is used for CMV retinitis, its direct intravitreal administration is not recommended due to ocular toxicity.</p>
<p>It can also be used to treat Molluscum contagiosm in immunocompromised patients.
FOSCARNET SODIUM: This drug, an inorganic pyrophosphate compound, is given by IV infusion to treat CMV retinitis in patients with AIDS. It has potent activity against HIV as well. It inhibits DNA polymerase. It does not require activation by viral thymidine kinase and is effective against acyclovir-resistant and ganciclovir-resistant strains. The drug can cause GI toxicity, nephrotoxicity, anemia and CNS disturbances like headache. Hypocalcemia, hypokalemia and hypomagnesimia have also been reported.</p>
<p>FOMIVIRSEN, an oligonucleotide agent, is used IV for the treatment of difficult cases of CMV retinitis. It can cause vitritis, cataract and increase in intraocular pressure.</p>
<p>SORIVUDINE is a pyrimidine nucleoside analogue which can be used in both immunocompromised and immunocompetent patients with herpes zoster infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-hepatitis-b-drugs">Anti-hepatitis B Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-hepatitis-b-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LAMIVUDINE, an anti-HIV drug, has also been used for treating chronic HBV infection (Chapter 53).</p>
<p>ADEFOVIR is available as a prodrug, adefovir dipivoxil. It is an acyclic phosphonated adenine nucleotide analogue, which is phosphorylated by cellular kinases to active form. It is effective against HBV, HIV and herpes virus. It has prolonged intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> and is administered once daily. It is excreted by kidneys and requires dose adjustment in renal failure. It is nephrotoxic. Other ADR include headache, diarrhea, asthenia, lactic acidosis and occasionally hepatic steatosis. Compared to lamivudine, it is slower to suppress HBV DNA levels and cause seroconversion.</p>
<p>ENTECAVIR is an orally administered gaunosine nucleoside that competitively inhibits HBV DNA polymerase. It is more potent than lamivudine but may have less effect in lamivudine resistant strains. Bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> but decreases with food. Hence entecavir is administered on empty stomach. It is eliminated by kidneys. The ADR include headache, fatigue, nausea, and dizziness. It can cause drug interactions with drugs that compete for tubular secretion. It is tumorigenic in animals.</p>
<p>TELBIVUDINE, a thymidine nucleoside analogue, with similar action as entecavir, has bioavailability unaffected by food. It is widely distributed and has no documented drug interactions. It is potent than lamivudine. Adverse effects are mild like fatigue, headache and GI intolerance. Lactic acidosis, hepatic steatosis and peripheral neuropathy may occur.</p>
<p>TENOFOVIR, an antiretroviral NRTI can be used for chronic HBV infection. It shows better activity than adefovir. It is useful against lamivudine and entecavir resistant organisms.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-hepatitis-c-drugs">Anti-hepatitis C Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-hepatitis-c-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The standard therapy of chronic hepatitis C is pegylated interferon alpha administered SC and ribavirin given orally for 48 weeks (see later). Recently, two new oral protease inhibitors (PI). Telaprevir (to be given for 12 weeks) and boceprevir for 24-44 weeks) are introduced in combination with above-mentioned drugs for treatment of hepatitis C genotype 1 infection. The triple therapy increases the response rate, and also the adverse effects. Telaprevir causes rash, anemia, fatigue, pruritus, nausea, diarrhoea, dysguesia, haemorrohoids and Steven Johnson syndrome. Boceprevir produces anemia, dysguesia, nausea, headache and neutropenia. Both the drugs are inhibitors of CYP3A4 and Pglycoprotein and can cause drug interactions.</p>
<p>The new drugs introduced are Simprevir a long acting oral PI, Sofosbuvir - a nucleotide polymerase inhibitor and ledipasvir - an inhibitor of viral replication proteins.</p>
<p>For use of interferon in HDV, see later.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-influenza-drugs">Anti-influenza Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-influenza-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RIBAVIRIN: This purine nucleoside analogue has a broad spectrum antiviral activity against DNA and RNA viruses. It has been shown to be of some use against influenza A and B infections, respiratory syncytial virus (RSV) infection, Lassa fever and hepatitis C. It is administered orally or by inhalation. Aerosolization is generally well tolerated and its systemic toxicity is less because of poor systemic absorption.</p>
<p>Adverse reactions: It causes dose dependent anemia, bone marrow suppression, cardiac and neurological toxicity. Ribavirin has been shown to be teratogenic, mutagenic, embryotoxic and gonadotoxic in small animals, and is contraindicated in pregnancy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> woman must avoid conception for 6 months after cessation of ribavirin. Further, passive exposure to aerosolized ribavirin should be avoided by pregnant women.</p>
<p>Antiviral monoclonal antibody palivizumab, is used for prevention of RSV (Chapter 74).
AMANTADINE (1-Admantanamine hydrochloride): This drug acts by inhibiting uncoating of viral RNA of influenza A virus within infected cells, thus inhibiting viral replication. Clinically, it is useful in the prophylaxis and treatment of influenza A, but not influenza B. Its therapeutic usefulness, however, appears to be limited. To be effective, it must be administered within the first 24-48 hours after the onset of symptoms.</p>
<p>The drug is administered orally in the dose of 100 mg once or twice daily for 5-7 days.
Adverse reactions: They are not a major problem though the drug can cause confusion, high headedness, slurred speech, insomnia, hallucinations, urinary retention and skin rash. It is also used in parkinsonism (Chapter 15).</p>
<p>RIMANTADINE: This drug has actions similar to those of amantadine but is 4-10 times more active. The CNS toxicity occurs less often. No dosage adjustment is necessary in patients with renal impairment except in those with end stage renal failure. It has a long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>36</mn></mrow><annotation encoding="application/x-tex">24-36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">36</span></span></span></span></span> hours.</p>
<p>Both the drugs are teratogenic in animals.
OSELTAMIVIR is a prodrug of oseltamivir carboxylate, the first orally active and rationally designed, specific inhibitor of influenza neuraminidase enzymes. This enzyme cleaves sialic acid residues on newly formed virions, a process that helps their release from infected cell and facilitates spread of infection to other target cells. Inhibition of the neuraminidase prevents release of progeny virions.</p>
<p>It is effective against both types of influenza viruses (including the avian H5N1, swine origin H1N1 and H9N2 strains). Given orally in a dose of 75 mg bid within 36 hours of onset of symptoms, it can decrease the severity of influenza <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> and reduces respiratory complications. The duration of therapy is for 5 days. For chemoprophylaxis, it can be administered 75 mg once a day for 7 days to contacts of patients within 48 h of the onset of symptoms.</p>
<p>Adverse reactions: The ADR include nausea, vomiting, diarrhoea, abdominal pain, and headache. Rarely it may cause hepatitis, allergic rash, toxic epidermal necrolysis, seizures, and confusion. It is generally not recommended for use in children younger than one year and in pregnant women. However, in high risk pregnant patient it may be preferred than zanamivir.</p>
<p>ZANAMIVIR: This drug is a potent inhibitor of the viral neuraminidase. Used within 48 hrs, it has been shown to be useful against both type A and type B influenza viruses. It is</p>
<p>also effective for oseltamivir resistant infection. It is given as dry powder inhalation ( 10 mg bid for 5 days). It can be used prophylactically once daily by inhalation for the prevention of influenza. The drug can cause nausea, vomiting and bronchospasm. It is contraindicated in pregnancy.</p>
<p>Both zanamivir and oseltamivir remain effective against viruses resistant to amantadine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interferons">Interferons<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interferons" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Interferons (IFN) are species specific cellular glycoproteins, produced naturally by virusinfected cells, and have antiviral protective action. They are not virus specific and can interfere with a wide variety of DNA and RNA viruses. They are considered as potent, broad spectrum, antiviral compounds with a high therapeutic ratio. There are many interferons which vary from species to species. Each species produces at least three types of interferons:</p>
<ul>
<li>Alpha and Beta from nearly all cell types induced by viruses, double stranded RNA and cytokines like Il-1, Il-2 and TNF.</li>
<li>Gamma from immunologically stimulated T lymphocytes and NK cells.</li>
</ul>
<p>Each of these can now be produced by recombinant DNA technology. Virus-induced human interferon differs from the IFN produced by lymphocytes during immune response in several respects. Alpha and beta IFN have 166 amino-acids and molecular weight, ranging from 16,000 to 26,000 . Gamma interferon has 146 amino-acids with molecular weight 20,000 to 25,000 ; it is less antiviral and more immunoregulator.</p>
<p>Certain agents like the live attenuated measles virus, microbial extracts and anionic polysaccharides can stimulate the production of endogenous interferon.</p>
<p>Mechanism of action: IFN act by binding to specific, cell-surface receptors and inducing the production of new cellular RNA and proteins, which in turn inhibit protein synthesis of viruses. They inhibit several steps of viral reproduction including viral penetration, uncoating, synthesis of mRNA, translation of viral proteins and/or viral assembly and release. IFN also act as an immune modulator, thus increasing cytotoxic T lymphocyte activity, enhancing NK cell activity and activating macrophages. IFN has no effect on extracellular virus.</p>
<p>Little is known about the metabolism of interferons in man. They do not penetrate CSF readily. IFN-alpha predominantly undergoes proteolytic degradation in the renal tubules.</p>
<p>Adverse reactions: These include hypersensitivity reactions, fever, flu-like syndrome, lethargy, myalgia, arthralgia and ocular symptoms. Dose-related myelosuppression, nephrotoxicity and hepatotoxicity have also been reported. Larger doses cause alopecia, neurotoxicity, personality changes, depression, reversible hearing loss, retinopathy, thyroid dysfunction, azotemia and impaired fertility. Antibodies to IFN can decrease its therapeutic effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) IFN alpha 2b: 10 million units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> IM/SC injection.
(ii) IFN alpha 2a: 3-9 million units per ml injection.
(iii) Pegylated IFN alpha 2a and 2b: These are polyethylene glycol attached to interferons. They have prolonged absorption and reduced clearance resulting into increased <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> The higher and more sustained plasma levels allow once weekly dosages
(iv) IFN beta 1a: It is a glycosylated recombinant product from mammalian cells, 6 million units/ml injection.
(v) IFN beta 1b: It is a nonglycosylated recombinant product from mammalian cells, 6 million units/ml injection.
(vi) IFN-alpha-n1 (non-recombinant 'natural' IFN- alpha derived from lymphoblastoid cells), IFN alpha-n3 (purified, human leukocyte derivedinter-feron- alpha), IFN alfacon-</p>
<p>1(recombinant non-naturally occurring type-I interferon)
Therapeutic uses:</p>
<ul>
<li>Chronic hepatitis B: Recombinant IFN alpha 2b to prevent progressive liver damage, along with histological improvement.</li>
<li>Chronic hepatitis C and D: All forms of IFN</li>
<li>Condyloma acuminata: Intralesional IFN alpha-n3</li>
<li>Hairy cell leukemia: IFN alpha 2a and 2b</li>
<li>Chronic myelogenous leukemia to induce remission: IFN alpha 2a</li>
<li>Multiple sclerosis: IFN beta la and lb have shown to reduce both frequency and severity of exacerbations. They are currently recommended for relapsing/remitting MS (Chapter 15).</li>
<li>All severe viral infections: IFN given empirically.</li>
</ul>
<p>Experimentally, interferons restrain the growth of various tumours in mice. Partially purified IFN have been shown to produce some antitumour effects in osteogenic sarcoma, multiple myeloma, lymphoma and breast cancer nodules in human.</p>
<p>GAMMA GLOBULIN: It prevents viral adsorption to and their penetration into the target cell. (See Chapter 74).</p>
<p>Main uses of antiviral drugs are summarised in Table 59.2.</p>
<p>Table 59.2
Therapeutic uses of the commonly used antiviral (non HIV) drugs</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Route</th><th style="text-align: left;">Indications</th></tr></thead><tbody><tr><td style="text-align: left;">Idoxuridine</td><td style="text-align: center;">T</td><td style="text-align: left;">HSV keratitis</td></tr><tr><td style="text-align: left;">Trifluridine</td><td style="text-align: center;">T</td><td style="text-align: left;">HSV keratitis dermatitis</td></tr><tr><td style="text-align: left;">Acyclovir</td><td style="text-align: center;">T, O</td><td style="text-align: left;">Herpes genitalis; mucocutaneous HSV; local herpes zoster.</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">IV</td><td style="text-align: left;">Herpes simplex encephalitis; Severe herpes genitalis; herpes zoster in the immunocompromised</td></tr><tr><td style="text-align: left;">Ganciclovir</td><td style="text-align: center;">IV</td><td style="text-align: left;">CMV infections.</td></tr><tr><td style="text-align: left;">Foscarnet</td><td style="text-align: center;">IV</td><td style="text-align: left;">CMV retinitis; acyclovir resistant HSV infection.</td></tr><tr><td style="text-align: left;">Amantadine</td><td style="text-align: center;">O</td><td style="text-align: left;">Influenza A</td></tr><tr><td style="text-align: left;">Rimantadine</td><td style="text-align: center;">O</td><td style="text-align: left;">Influenza A</td></tr><tr><td style="text-align: left;">Zanamivir</td><td style="text-align: center;">Inhalation</td><td style="text-align: left;">Influenza A and B</td></tr><tr><td style="text-align: left;">Oseltamivir</td><td style="text-align: center;">O</td><td style="text-align: left;">Influenza A and B</td></tr><tr><td style="text-align: left;">Adefovir</td><td style="text-align: center;">O</td><td style="text-align: left;">HBV infection</td></tr><tr><td style="text-align: left;">Lamivudine</td><td style="text-align: center;">O</td><td style="text-align: left;">HBV infection</td></tr><tr><td style="text-align: left;">Ribavirin</td><td style="text-align: center;">Aerosol</td><td style="text-align: left;">Respiratory syncytial virus infection</td></tr><tr><td style="text-align: left;">Interferon</td><td style="text-align: center;">SC</td><td style="text-align: left;">Chronic hepatitis B</td></tr><tr><td style="text-align: left;">alpha 2a/2b</td><td style="text-align: center;">IV</td><td style="text-align: left;">C and D; condyloma acuminata</td></tr></tbody></table>
<p>T = Topical; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">O</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{O}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Oral; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">C</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{SC}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">SC</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Subcutaneous; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{IV}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Intravenous; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">V</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{CMV}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">CMV</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Cytomegalovirus; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{HIV}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">HIV</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Human immunodeficiency virus; HSV = Herpes simplex virus;</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiviral-drugs-used-to-treat-aids">Antiviral drugs used to treat AIDS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiviral-drugs-used-to-treat-aids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(HIV-infection) are discussed in Chapter 53.</p>
<p>60</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-helminthiases">Chemotherapy of Helminthiases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-helminthiases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Worm infestation (helminthiasis) is one of the major global public health problems, more so in tropical countries. Besides the environmental conditions peculiar to tropics, poverty, illiteracy, lack of adequate sanitary facilities and of pure water supply make total eradication of this problem very difficult. The commonest parasites observed are roundworms, hookworms, threadworms, tapeworms, filarial worms and schistosomes.</p>
<p>Worms can cause various GI and general symptoms. In addition, some of them cause blood loss, nutritional deficiencies, urticaria and other allergic manifestations, intestinal obstruction and hepatosplenomegaly. Roundworms have been implicated in the pathogenesis of bronchial spasm in endemic areas. Peripheral blood eosinophilia occurs in all nematode infestations (except enterobiasis). A careful examination of stool may often spare the unnecessary removal of teeth and tonsils, usually blamed for 'septic foci', in cases with 'resistant urticaria'.</p>
<p>The helminths are multicellular organisms possessing three germ layers and exhibiting a bilateral symmetry. They are classified into two major phyla (1) phylum nemathelminthes (roundworms: nematodes) and (2) phyllum platyhelminthes (flat worms: cestodes and trematodes). Anthelmintics are drugs used in the treatment of helminthiasis.</p>
<p>For a clinical trial of a potential anthelmintic agent, a well established anthelmintic drug with a similar spectrum should always be incorporated in the experimental design so as to ensure an effective comparison. The efficacy of the new drug can be gauged by counting the ova or eggs present in the stools. Efficacy of a drug against taeniasis, however, can only be judged by the appearance of the scolex in the stools. Patients suffering from multiple parasitic infestations are ideal for investigating a new anthelmintic drug claimed to have a broad spectrum of action.</p>
<p>In endemic areas, the main aim of anthelmintic treatment should be to reduce the load of infection below the level of clinical significance. Complete parasitological cure is often not possible. In achieving this, safety and economic considerations should guide the choice of the drug in mass therapy.</p>
<p>An anthelmintic drug which kills the worm is called vermicidal, while that which affects the worm in such a way that it is easily expelled is known as a vermifuge.</p>
<p>Many anthelmintics with either selective or broad spectrum actions and acceptable toxicity, relatively safe even in the undernourished individuals, are now available. They are convenient to administer as no prior preparation is necessary and no follow up purgation is required unless constipation is present.</p>
<p>The anthelmintic drugs used commonly for therapy are listed in Table 60.1.</p>
<p>Table 60.1
Common forms of helminthiasis and the drugs used in their treatment</p>
<table><thead><tr><th style="text-align: center;">Helminth</th><th style="text-align: center;">Common name</th><th style="text-align: center;">Drug of choice</th><th style="text-align: center;">Alternative drugs</th></tr></thead><tbody><tr><td style="text-align: center;">Nematodes (intestinal)</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ascaris lumbricoides</td><td style="text-align: center;">Roundworm</td><td style="text-align: center;">Albendazole Mebendazole</td><td style="text-align: center;">Pyrantel, Piperazine</td></tr><tr><td style="text-align: center;">Ancylostoma duodenale</td><td style="text-align: center;">Hookworm</td><td style="text-align: center;">Albendazole Mebendazole</td><td style="text-align: center;">Pyrantel, Thiabendazole</td></tr><tr><td style="text-align: center;">Enterobius vermicularis</td><td style="text-align: center;">Pinworm</td><td style="text-align: center;">Albendazole Mebendazole</td><td style="text-align: center;">Pyrantel, Piperazine</td></tr><tr><td style="text-align: center;">Trichuris trichura</td><td style="text-align: center;">Whipworm</td><td style="text-align: center;">Mebendazole</td><td style="text-align: center;">Albendazole, Thiabendazole</td></tr><tr><td style="text-align: center;">Strongyloides stercoralis</td><td style="text-align: center;">Threadworm</td><td style="text-align: center;">Ivermectin</td><td style="text-align: center;">Thiabendazole, Albendazole</td></tr><tr><td style="text-align: center;">Trichinella spiralis</td><td style="text-align: center;">Pork roundworm</td><td style="text-align: center;">Albendazole</td><td style="text-align: center;">Thiabendazole, Mebendazole</td></tr><tr><td style="text-align: center;">Nematodes (somatic)</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Wuchereria bancrofti</td><td style="text-align: center;">Lymphatic filarial worm</td><td style="text-align: center;">Diethylcarbamazine</td><td style="text-align: center;">Ivermectin</td></tr><tr><td style="text-align: center;">Onchocerca volvulus</td><td style="text-align: center;">Oculodermal filarial worm</td><td style="text-align: center;">Ivermectin</td><td style="text-align: center;">Diethylcarbamazine</td></tr><tr><td style="text-align: center;">Onchocerca loa loa</td><td style="text-align: center;">Oculodermal filarial worm</td><td style="text-align: center;">Ivermectin</td><td style="text-align: center;">Diethylcarbamazine</td></tr><tr><td style="text-align: center;">Dracuncula medinensis</td><td style="text-align: center;">Guineaworm</td><td style="text-align: center;">Metronidazole</td><td style="text-align: center;">Mebendazole</td></tr><tr><td style="text-align: center;">Cestodes</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tenia saginata</td><td style="text-align: center;">Beef tapeworm</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Tenia solium</td><td style="text-align: center;">Pork tapeworm</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Cysticercal cellulosaé</td><td style="text-align: center;">Larva of T. solium</td><td style="text-align: center;">Albendazole</td><td style="text-align: center;">Praziquantel</td></tr><tr><td style="text-align: center;">Diphyllobothrium latum</td><td style="text-align: center;">Fish tapeworm</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Hymenolepis nana</td><td style="text-align: center;">Dwarf tapeworm</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Echinococcus granulosus</td><td style="text-align: center;">Hydatid larva</td><td style="text-align: center;">Albendazole</td><td style="text-align: center;">Mebendazole</td></tr><tr><td style="text-align: center;">Trematodes</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Schistosoma hematobium</td><td style="text-align: center;">Blood flukes</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Metrifonate</td></tr><tr><td style="text-align: center;">S. mansoni</td><td style="text-align: center;">Blood flukes</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Osamniquine</td></tr><tr><td style="text-align: center;">S. japonicum</td><td style="text-align: center;">Blood flukes</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Flukes</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Fasciola hepatica</td><td style="text-align: center;">Liver fluke</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Clonorchis sinensis</td><td style="text-align: center;">Chinese liver fluke</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">F. busci</td><td style="text-align: center;">Giant intestinal fluke</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr><tr><td style="text-align: center;">Paragonimus westermani</td><td style="text-align: center;">Lung fluke</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Niclosamide</td></tr></tbody></table>
<p>'Glucocorticoids are administered concurrently to reduce edema.
Mechanisms of action of common anthelmintics are summarised in Table 60.2.</p>
<p>Table 60.2
Mechanisms of action of common anthelmintics</p>
<table><thead><tr><th style="text-align: center;">Site</th><th style="text-align: center;">Drug(s)</th><th style="text-align: center;">Mechanism</th></tr></thead><tbody><tr><td style="text-align: center;">Neuromuscular transmission</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(a) Ganglionic nicotinic ACh receptors at neuromuscular junction*</td><td style="text-align: center;">Levamisole, Pyrantel pamoate</td><td style="text-align: center;">Stimulation produces persistent depolarisation resulting in muscular contracture/paralysis</td></tr><tr><td style="text-align: center;">(b) GABA receptors at neuromuscular junction.</td><td style="text-align: center;">Piperazine</td><td style="text-align: center;">GABA agonist causing hyperpolarisation and flaccid paralysis</td></tr><tr><td style="text-align: center;">(c) Glutamate-gated, chloride channel at neuromuscular junction in invertebrates</td><td style="text-align: center;">Ivermectin</td><td style="text-align: center;">Causes tonic paralysis of microfilariae which are then immobilised and phagocytosed by RE cells</td></tr><tr><td style="text-align: center;">Acetyl cholinesterase</td><td style="text-align: center;">Metrifonate</td><td style="text-align: center;">Inhibition, causing muscular contracture</td></tr><tr><td style="text-align: center;">Cell membrane</td><td style="text-align: center;">Praziquantel</td><td style="text-align: center;">Increases Car* influx leading to muscular contracture</td></tr><tr><td style="text-align: center;">Microtubules in cytoskeleton</td><td style="text-align: center;">Mebendazole, Albendazole, Thiabendazole</td><td style="text-align: center;">Bind to beta-tubulin and inhibit polymerisation of microtubules</td></tr><tr><td style="text-align: center;">Mitochondria</td><td style="text-align: center;">Niclosamide</td><td style="text-align: center;">Inhibition of anaerobic phosphorylation of ADP leading to death</td></tr></tbody></table>
<p>The agonists cause contractions of the worm. Experimentally, it can be reversed by the ganglionic blocker mecamylamine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-roundworms">Drug Therapy of Roundworms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-roundworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MEBENDAZOLE: This broad spectrum anthelmintic is a benzimidazole derivative (Fig. 60.1). Given orally it is poorly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ) absorbed. It inhibits microtubule polymerisation by binding to beta-tubulin.
<img src="assets/images/image-20251214-a23387fe.jpeg" alt="img-17.jpeg"></p>
<p>FIG. 60.1 Mebendazole
It is highly effective in ascariasis, enterobiasis, trichuriasis and in hookworm infestation. It is the drug of choice in enterobiasis and in trichuriasis. It also has some action against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. stercoralis. The drug is slow acting and it may take 2-3 days for parasitic clearance from the gut. It also adversely affects the ova of the trichuris and the hookworm. It is effective in vivo against the larvae of Trichinella spiralis and exerts a lethal effect on the germinal membrane of the larvae of Echinococcus granulosus (Hydatid Worm).</p>
<p>Adverse reactions: These are usually mild and consist of abdominal pain, nausea and diarrhoea. Large oral doses, may cause vertigo, dizziness, headache and arthralgia. Benzimidazoles are embryotoxic and teratogenic in animals, and should be avoided in pregnancy.</p>
<p>Preparation and Dosage: It is available as 100 mg tablets and liquid suspension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Enterobiasis: A single dose of 100 mg repeated after one week</li>
<li>Hookworm and round worm infestation: 100 mg bid for 3 days</li>
<li>Taenia infestation: 300 mg tid for 3 days</li>
<li>Hydatid cysts of the liver: 400-600 mg tid for 21-30 days for regression of hydatid cysts. Such treatment, though rarely, may cause bone marrow aplasia. Hence albendazole is preferred.
ALBENDAZOLE: This broad spectrum benzimidazole has actions similar to those of mebendazole. It also has larvicidal actions in hydatid disease, ascariasis and ankylostomiasis and ovicidal properties in ascariasis, ankylostomiasis and trichuriasis.</li>
</ul>
<p>Given orally, it is rapidly absorbed and has better bioavailability than mebendazole. After absorption, it undergoes first pass metabolism in the liver to its active metabolite, albendazole sulfoxide. It is well distributed in tissues, bile, CSF and hydatid cyst. It has plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours. Its major advantage is that it is effective against many common intestinal worms in a single dose and is cost effective.</p>
<p>The drug is well tolerated and adverse reactions are mild, mainly GI disturbances. When used in hydatid disease for long term therapy, it may cause alopecia, liver damage and bone marrow depression.</p>
<p>Therapeutic uses</p>
<ul>
<li>Ascariasis, ankylostomiasis and trichuriasis: Usually 400 mg single dose. Hookworm and</li>
</ul>
<p>trichuriasis may need a repeat dose.</p>
<ul>
<li>Enterobiasis: 400 mg single dose, repeated after 4 weeks.</li>
<li>Hydatid disease: 400 mg bid for one months, repeated if necessary.</li>
<li>Strongyloidiasis: 400 mg twice daily for 3 days, repeated after 3 weeks if necessary.</li>
<li>Trichinella spiralis: 400 mg bid for 8-14 days.</li>
<li>Cysticercosis: It is considered the drug of choice because of short course, less toxicity than praziquantel, better penetration into CSF and cost. It is given 400 mg bid for 21 days. A glucocorticoid is started prior to albendazole to reduce the intensity of the inflammatory reaction to the dead parasites.
PYRANTEL PAMOATE: This drug, a tetrahydropyrimidine derivative, is highly effective against round worms and E. vermicularis and a little less effective against hookworms. It has a depolarising, neuromuscular blocking action and causes spastic paralysis of the worms. It is not much absorbed from the gut.</li>
</ul>
<p>In ascariasis and enterobiasis, it is usually given in a single dose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> upto a maximum of 1 g ); for hookworm infestation, the same dose is repeated on three successive days. The dose can be repeated after 2 weeks, if needed. It can be used during pregnancy.</p>
<p>Adverse reactions: These are usually mild and include GI disturbances, abdominal pain, headache, drowsiness and skin rashes.</p>
<p>Oxantel pamoate, an analogue of pyrantel, is also claimed to be useful in trichuriasis. It is given in a single dose.</p>
<p>PIPERAZINE: This drug (Fig 60.2) was extensively used in the therapy of ascariasis and enterobiasis.
<img src="assets/images/image-20251214-fd528dbb.jpeg" alt="img-18.jpeg"></p>
<p>FIG. 60.2 Piperazine
Mechanism of action: It acts as a GABA agonist and causes hyperpolarization of ascaris muscle resulting in faccid paralysis of the worms which are then easily expelled by peristaltic movements. This eliminates the danger of worm migration.</p>
<p>Absorption, fate and excretion: Piperazine is absorbed from the gut, to the extent of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>. The drug is partly metabolised in the body and partly excreted unchanged in the urine.</p>
<p>Adverse reactions: Piperazine has a wide margin of safety. Adverse effects are uncommon. They include nausea, vomiting, diarrhoea and urticaria. Neurotoxic effects, observed rarely; include vertigo, muscular incoordination, hypotonia, ataxia of cerebellar type ('worm-wobble'), paraesthesiae, blurring of vision and very rarely, seizures. The drug appears to be safe during pregnancy.</p>
<p>Preparations and dosage: A variety of piperazine salts are available for therapy. They are equally effective.
(i) Piperazine citrate as 300 mg tablets (equivalent to about 250 mg . of piperazine hydrate),</p>
<p>as an elixir containing 18 g of the salt in 100 ml of water and as a mixture for infants containing 720 mg of the drug per 5 ml .</p>
<p>For ascariasis in adults, a single dose of 5 g is administered. The equivalent dose of the elixir is upto 30 ml . For children, it is given in the dose of 75 mg per <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">\mathrm{kg}(5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mopen">(</span><span class="mord">5</span></span></span></span></span> to 7 ml of the mixture for infants per year of age to a maximum of 30 ml ) in a single dose. The drug is preferably administered in the evening and a saline purge may be given on the next morning to facilitate the expulsion of parasites. A purge, however, is not obligatory. (ii) Piperazine hydrate. Dose: Adults, 4 g as a single dose. Children, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">120 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, upto a total dose of 4 g .</p>
<p>The doses of other piperazine salts are expressed in terms of hydrate equivalents.
For use of piperazine in enterobiasis, see later.
LEVAMISOLE: Levamisole is l-tetramisole (Fig 60.3) and accounts for most of the antehelmintic activity of the racemic mixture, tetramisole. Like pyrantel, it causes sustained contracture of somatic muscles of the worm by an irreversible, non-competitive, depolarisation type of neuromuscular block. It is rapidly and considerably absorbed and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> is excreted in the urine, mostly as metabolites, within 24 hours.
<img src="assets/images/image-20251214-84f473ea.jpeg" alt="img-19.jpeg"></p>
<p>Levamisole also has immunostimulant properties (Chapter 74).
Levamisole is available as a single dose tablet containing 150 mg for adults and 50 mg for children. In ascariasis, it is given as a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5.0 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. It is also effective against hookworms though to a smaller extent. In trichostrongyloidiasis, a single dose is effective in over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of the cases.</p>
<p>Adverse reactions reported are usually mild and include nausea, vomiting, abdominal pain, diarrhoea, giddiness and drowsiness.</p>
<p>These drugs are not active against larvae and hence follow-up re-evaluation of treated patients is necessary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-hookworms">Drug Therapy of Hookworms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-hookworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. duodenale infestation is very common in tropical countries and represents an important cause of iron deficiency anemia due to intestinal blood loss. Acute clinical manifestations can be due to larval migration through various tissues and skin. The infestation often exists along with ascariasis. In such a situation, it is preferable to treat ascariasis first, as drugs used solely against ancylostomiasis may irritate the roundworms causing their migration or their aggregation into ball-like masses. The former may lead to invasion of the bile duct and the liver, while the latter may precipitate acute appendicular or intestinal obstruction. Hence, drugs effective against both roundworms and hookworms are to be preferred.</p>
<p>It should be noted that no single drug is able to eradicate all the hookworms in 100% cases, and it is necessary to repeat the same drug or give another drug after an appropriate interval. Albendazole ( 400 mg single dose), Mebendazole and Pyrantel are the preferred drugs in ancylostomiasis. (see above).</p>
<p>Bephenium hydroxynaphthoate: Single dose of this drug is effective in removing roundworms and hookworms of the species Ancylostoma doudenale. It is less effective against Necator americans. It is now rarely used.</p>
<p>Adjuvant treatment: Regular, oral administration of iron daily can prevent the anemia and maintain the hemoglobin levels near <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">12 \mathrm{~g} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> even without immediate treatment of worms. Provision of footwear to avoid larval penetration should be encouraged in endemic areas.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-therapy-of-pinworms">Drugs Therapy of Pinworms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-therapy-of-pinworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>E. vermicularis is a common parasite found in the caecum and the vermiform appendix. The infestation is more common in children. The majority of cases are asymptomatic. The gravid female worm deposits eggs on the perianal and perineal skin leading to intense itching. Scratching of this region may lead to autoinfection by ingestion of ova carried under the nails. To prevent this, patients should be advised to trim the nails and wash the hands thoroughly before the meals. Symptomatically, an antihistaminic cream applied around the anus relieves itching. Infection can also occur through underclothing, bed linen, lavatory contamination, water or food contamination. Infection can also be disseminated by inhalation or ingestion of dust.</p>
<p>Gravid female worms sometimes migrate into the female genital tract, causing pelvic pain, vulvo-vaginitis, pruritus and even granuloma.</p>
<p>Besides the drug therapy, additional measures are desirable in resistant cases. At night, the patient should wear pants under the pyjamas, and gloves which can be boiled. It may be useful to treat the whole family simultaneously.</p>
<p>Mebendazole 100 mg , or albendazole 400 mg single dose, repeated after 2 weeks, and pyrantel pamoate are the drugs of choice. Single doses of mebendazole produce 90-100% cure rates. The other alternative, piperazine is now rarely used.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-strongyloidiasis">Drug Therapy of Strongyloidiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-strongyloidiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The adult female of Strongyloides stercoralis lives in the mucosal epithelium of the duodenum and the jejunum. There is no parasitic male; the reproduction is parthenogenic. Ova passed by the adult worm develop into rhabditidiform larvae in the intestine. They metamorphose into the infective filariform larvae in the soil and invade the human host by penetrating the skin and travel through the venous circulation to the lungs. They migrate through the alveolar capillary walls, ascend the respiratory tract to the epiglottis, and are swallowed to reach the small intestine where they mature. Alternatively, the rhabditidiform larvae develop into infective larvae in the intestine; the latter penetrate the intestinal wall to reach the circulation (internal auto-infection). Internal autoinfection leads to persistence of the infection for upto 20 years.</p>
<p>In immunosuppressed or malnourished patients internal autoinfection may assume massive proportions with ectopic migration of larvae, resulting in hyper-infection syndrome. The intestinal parasites cause epigastric pain and diarrhoea; heavy infections may produce malabsorption. Hyperinfection syndrome is a serious complication with acute onset of fever, abdominal pain and distension, often accompanied by shock and pneumonitis.</p>
<p>As strongyloides ova do not appear in stools, diagnosis depends upon identification of larvae.
IVERMECTIN in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily for 2 days is considered the therapy of choice (see later).</p>
<p>Albendazole: is an another alternative (see earlier).
THIABENDAZOLE: This drug, a benzimidazole derivative (Fig 60.4), has a broad spectrum of activity and is effective against roundworms, hookworms, pinworms and strongyloid worms. It acts in the same way as other benzimidazoles.
<img src="assets/images/image-20251214-43b2f228.jpeg" alt="img-20.jpeg"></p>
<p>Thiabendazole is partly absorbed after oral administration and largely metabolised in the liver and excreted by the kidney as the hydroxylated derivative.</p>
<p>Adverse reactions: These occur in 15 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of patients and include skin reactions, anorexia, nausea, vomiting, epigastric distress, dizziness and fever. Other adverse effects are hypoglycemia and disturbances of colour vision. Blood pressure may fall; liver damage and crystalluria have also been reported.</p>
<p>In majority of cases with strongyloid infestation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children in 2 divided doses at 12 hourly intervals for 3 days are highly effective. It is now rarely used because of toxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-trichuriasis-whipworm">Drug Therapy of Trichuriasis (Whipworm)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-trichuriasis-whipworm" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Trichuriasis caused by Trichuris trichura (whipworm) is frequently encountered along with roundworms and hookworms. Trichuriasis is acquired after consumption of food contaminated with parasite eggs. Children are unusually susceptible and develop anemia.</p>
<p>Rarely, the worms may lodge in the appendix or may penetrate the bowel wall and cause peritonitis.</p>
<p>Mebendazole is highly effective. It is given orally as 100 mg twice daily for 3 days or as a single 500 mg dose. A second course may be given after 3 weeks with a cure rate of almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>.</p>
<p>Albendazole is less effective; it is given in a single daily dose of 800 mg for 4 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-filariasis">Drug Therapy of Filariasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-filariasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Filarial infections are caused by parasitic tissue-dwelling filarial nematodes, which are transmitted by biting insects (Table 60.3).</p>
<p>Table 60.3
Types of filariasis</p>
<table><thead><tr><th style="text-align: left;">Type</th><th style="text-align: left;">Species</th><th style="text-align: left;">Vector</th></tr></thead><tbody><tr><td style="text-align: left;">- Lymphatic</td><td style="text-align: left;">W. bancrofti B. malayi</td><td style="text-align: left;">Mosquitoes</td></tr><tr><td style="text-align: left;">- Subcutaneous and ocular</td><td style="text-align: left;">O. volvulus</td><td style="text-align: left;">Blackfly (simulium)</td></tr><tr><td style="text-align: left;">- Dermal</td><td style="text-align: left;">Loa loa</td><td style="text-align: left;">Biting flies (chrysops)</td></tr><tr><td style="text-align: left;">- Asymptomatic/pruritus, arthralgia, neurologic or ocular</td><td style="text-align: left;">M. perstans</td><td style="text-align: left;">Infected midge/black fly</td></tr></tbody></table>
<p>Different varieties of this worm infect over 250 million people in the world, causing elephantiasis and blindness in severe cases. In case of lymphatic filariasis, the adult worm resides within lymphatics and can remain active for 5-8 years. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of global cases of lymphatic filariasis are in India. In case of onchocerciasis, the adult worm resides in the subcutaneous or deeper tissues, forms a nodule and releases microfilariae that migrate to the skin and eye. Over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of global onchocerciasis burden exists in Africa and is a major cause of blindness.</p>
<p>The drugs used are diethylcarbamazine, ivermectin, albendazole and doxycycline.
DIETHYLCARBAMAZINE (DEC): This drug, a piperazine derivative (Fig. 60.5), though inactive in vitro, leads to a rapid disappearance of microfilariae of W. bancrofti, B. malayi and Loa loa from the human peripheral blood after oral administration. It has some action in ascariasis.
<img src="assets/images/image-20251214-20ec24af.jpeg" alt="img-21.jpeg"></p>
<p>The drug probably acts by sensitising the microfilariae so that they become susceptible to phagocytosis and are trapped by the fixed reticuloendothelial cells in the liver sinusoids. DEC also enhances CMI of the human host and thus resistance to the infestation. The microfilariae of W. bancrofti in a hydrocoele, however, are not affected. The drug also kills the adult worms of B. malayi and Loa loa and possibly those of W. bancrofti. However, this action is slow and needs longer/repeated course. It has no action against the adult worm of O. volvulus.</p>
<p>Absorption, fate and excretion: Diethylcarbamazine is rapidly absorbed from the GI tract. It is uniformly distributed in the body with the exception of fat. It is metabolised in the liver and eliminated in urine within 30 hours.</p>
<p>Adverse reactions: The drug is usually well tolerated. The common ADR include anorexia, nausea, vomiting, headache and drowsiness. These are rarely troublesome. Allergic reactions, due to release of foreign proteins in the tissues by the death of larvae or adult worms, include fever, tachycardia, bronchospasm, lymphadenopathy, muscular pains, arthralgias and urticaria. The severe allergic reactions may involve the eyes, particularly in onchocerciasis (Mazzoti reaction). This may start within a few hours of first oral dose and persist for 3-7 days. It is recommended, therefore, to start the therapy with a small dose ( 50 mg , single dose) and then increase it gradually. Severe ocular reactions can be controlled by instillation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> hydrocortisone drops. Administration of antihistaminics or glucocorticoids can minimise systemic allergic effects. Large doses may cause muscle tremors and convulsions.</p>
<p>Preparations: Diethylcarbamazine citrate as 50 mg or 100 mg tab or 10 mg per ml syrup. Therapeutic uses:</p>
<ul>
<li>Filariasis: DEC is a drug of choice for active lymphatic filariasis (W. bancrofti and Loa loa infestation). The recommended dose is 6 mg per kg body weight in single or divided doses daily for 12 days. The course may be repeated after one month. Although a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> may be useful, daily doses for 12 days are considered more effective. Combination of a single dose of DEC with ivermectin or albendazole is synergistic.</li>
<li>Filarial prophylaxis: (See later).</li>
<li>Tropical eosinophilia: Classical tropical eosinophilia with typical mottling in the lung, fever, anorexia, weight loss and attacks of dyspnoea resembling bronchial asthma is an inflammatory response to microfilaria. It is associated with leucocytosis and marked eosinophilia (more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3000</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3000 / \mathrm{cmm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3000/</span><span class="mord"><span class="mord mathrm">cmm</span></span></span></span></span></span> ). DEC in doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight daily orally for 7 to 10 days is highly effective. Resistant cases may need double the dose.
Pulmonary eosinophilia resulting from parasitic infestation on the other hand, occur as mild illness with fever and cough that last for a few days (Loeffler's syndrome). This is due to transient allergic pneumonitis in response to parasitic antigens during the invasive stage of larval migration of roundworm and hookworm. This responds to appropriate anthelmintic treatment.</li>
<li>Larva migrans (creeping eruption): In this condition, a dose of 3 mg per kg is given daily for 10 to 15 days. Albendazole 400 mg daily for 3 days or Ivermectin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">200 \mathrm{mcg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> as a single dose, is considered the treatment of choice.
Although DEC does have microfilaricidal effect in onchocerciasis, it often causes various adverse effects, including worsening of the ocular condition; hence ivermectin is preferred.</li>
</ul>
<p>IVERMECTIN: Ivermectin was originally obtained from Streptomyces avermitilis found in the soil sample of a Japanese golf course. This macrocyclic lactone has been found to be highly effective against a broad range of parasites and arthropods, and is extensively used in veterinary medicine.</p>
<p>Ivermectin is the drug of choice in onchocerciasis. It activates glutamate gated chloride channel and causes hyperpolarisation. This leads to tonic paralysis of microfilariae, which are then phagocytosed by reticuloendothelial system. Its efficacy to eliminate the microfilarie from the skin and ocular tissues is as good as that of DEC but perhaps more sustained. In addition, it has the advantage of being effective in a single dose. However, the drug has no lethal effect against adult worms.</p>
<p>Absorption, fate excretion: It is well absorbed and is highly protein-bound in the</p>
<p>plasma. More than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">97%</span></span></span></span></span> is metabolised in the liver and is mostly eliminated in the feces. Its elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>56</mn></mrow><annotation encoding="application/x-tex">12-56</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">56</span></span></span></span></span> hour.</p>
<p>Adverse reactions: Compared to DEC, it is better tolerated. It may cause itching, skin edema, arthralgia, headache and fever. The ADR are mostly due to the death of microfilariae (Mazzoti reaction), which causes ocular inflammation that may rarely, lead to blindness. Ivermectin has GABA agonistic activity, and hence it should be avoided in meningitis and along with CNS depressants.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Onchocerciasis: A single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, is highly effective. However as the adult worm is not killed, it is advisable to repeat the same dose once in 6-12 months for 10-14 yrs. If symptoms recur, then the same dose is given every 3 months instead of once a year, for the rest of the period. It appears that a single dose of ivermectin once every 6-12 months is useful in preventing this disease. When onchocerciasis and loiasis coexist, a single annual dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> can be used.
As a curative treatment of severe onchocerciasis, suramin (Chapter 58) is sometimes used. It kills the worm but is highly toxic. Doxycycline 200 mg daily for 6 weeks is claimed to be macrofilaricidal.</li>
<li>Lymphatic filariasis: Ivermectin in a single does of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is highly effective against the microfilairae of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>W</mi></mrow><annotation encoding="application/x-tex">W</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">W</span></span></span></span></span>. bancrofti. Single annual doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> are effective and safe for prophylaxis.</li>
<li>Intestinal nematode infection: Ivermectin as a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is used for strongyloidiasis. A higher dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150-200 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">150</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is used when ascariasis, trichuriasis and enterobiasis coexist.</li>
<li>Scabies and head-lice infestation: Given as a single oral dose (150-200 mcg/kg) it has been found to be highly effective.
ALBENDAZOLE 400 mg given in combination with DEC or ivermectin reduces the peripheral microfilarial load for longer time than monotherapy. There is no added effect on adult worm.</li>
</ul>
<p>DOXYCYCLINE: Filariae act as a host to endo-symbiotic Wolbachia bacteria. The growth, reproduction and survival of adult worm depends on Wolbachia. Wolbachia lipoprotein has been blamed for promoting chronic disease by provoking inflammatory reaction. The release of Wolbachia from dying microfilariae induces the systemic inflammatory response. Doxycycline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">200 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> for 6 weeks is reported to cause a long term sterilising effect in bancroftian filariasis; eventually causing death of the adult worm. Similar macrofilaricidal effect has been reported in onchocerciasis, with doxycycline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> for six months. However, it is not the drug of choice for treating filariasis, nor it is useful for mass treatment. It may be used to treat individual cases. It is contraindicated in children and pregnant women (see Chapter 49).</p>
<p>Mass treatment of filariasis: In endemic areas, mass treatment is given with the objective of reducing microfilariae to subinfective levels. DEC incorporated in table salt ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mo>−</mo><mn>0.4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2-0.4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.4%</span></span></span></span></span> of the base by weight) has been found to reduce the prevalence. Either (DEC 6 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">+</span></span></span></span></span> albendazole 400 mg ) or (ivermectin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">200 \mathrm{mcg} / \mathrm{kg}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">+</span></span></span></span></span> albendazole 400 mg ) in single doses every 6-12 months has shown to be more effective than either drug used alone in controlling the transmission of filariasis, including lymphatic filariasis. The combination of DEC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> and ivermectin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, given as a single dose, once a year, is also</p>
<p>reported to be effective. Recent Egyptian studies indicate that yearly rounds of DEC + albendazole for 5 consecutive years can possibly eliminate filariasis from an endemic area.</p>
<p>Mansonelliasis infection: Mansonella perstans, is usually asymptomatic and considered as minor filariasis. It is common in Africa. Effective treatment is, however, lacking. DEC is often ineffective. Long term doxycycline ( 200 mg daily for 6 weeks) has been claimed to be effective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-guinea-worm">Drug Therapy of Guinea Worm<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-guinea-worm" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dracunculus medinensis infestation is transmitted by drinking of water containing infected cyclops (water flea). The adult female usually remains in subcutaneous tissue and may come out through a small ulcer, usually on the foot. The treatment mainly consists of mechanical removal of the worm. Metronidazole is helpful in this process. Mebendazole in the dose of 200 mg tid orally for 7-10 days is also claimed to be effective in helping easy expulsion. The important treatment of dracontiasis, is preventive. This is very simple as the intermediate host, cyclops, can easily be filtered out from the drinking water by using a piece of cloth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-tapeworms">Drug Therapy of Tapeworms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-tapeworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This infestation is transmitted by ingestion of infected beef or pork and can be prevented by avoiding the ingestion of suspected meat or by its thorough cooking.</p>
<p>PRAZIQUANTEL: It is the drug of choice in taeniasis. In a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> it is highly effective against intestinal taeniasis, T. saginatum, T. solium and D. latum infections, as well as in cysticercosis of the brain. A single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. is used to treat <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. nana infection. For details, see later.</p>
<p>MEBENDAZOLE/ALBENDAZOLE: These drugs are used to treat hydatid disease of the liver (see earlier).</p>
<p>NICLOSAMIDE (Chlorsalicylamid): This drug (Fig 60.6) is effective in T. saginata, T. solium, D. latum and H. nana infestations. Given orally, it is not absorbed. It inhibits anaerobic phosphorylation of ADP by the parasitic mitochondria.
<img src="assets/images/image-20251214-39dbe452.jpeg" alt="img-22.jpeg"></p>
<p>Niclosamide is a vermicidal drug. The segments of the worm which are voided after its administration are partially digested by the action of the intestinal proteolytic enzymes; this makes identification of the scolex impossible. The criterion for cure with this drug, therefore, is absence of eggs and proglottids in the stools for 3 to 4 months after therapy. This is the period required for T. saginata to mature and shed mature proglottids from the scolex.</p>
<p>In T. solium infestation, identification of scolex is important as cysticercosis, (i.e., harbouring of the larval forms, cysticerci in the tissues) may develop, if the infestation is not completely eradicated. This makes it mandatory to use a purge within 1-2 hours after niclosamide is given, in order to prevent digestion of the segments. As niclosamide does not affect the ova, regurgitation of viable ova into the duodenum in case of Taenia solium exposes the patient to the risk of digestion of the ova, autoinfection with larvae and thus cysticercosis. Niclosamide is not effective against cysticercosis. Hence, in the treatment of infection with T. solium praziquantel is preferred.</p>
<p>The major advantage of niclosamide is its lack of serious toxicity. It causes mild GI disturbances.</p>
<p>After keeping the patient on a low residue diet on the day before and fasting overnight, 2 tablets of the drug ( 1 g ) are given in the morning on an empty stomach. The tablets should be chewed in order to ensure a thorough mixing of the drug with the intestinal contents. Another 1 g is given after 1 hour. A saline purge may be given 1 to 2 hours after the second dose but is not essential except in T. solium infestation. The dosage in children is 1 g for those between 2 to 8 years and 0.5 g under 2 years. Infestation with H. nana requires treatment for 5-7days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-schistosomiasis">Drug Therapy of Schistosomiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-schistosomiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Schistosomiasis (bilharziasis) is caused by blood flukes (Schistosomes) that parasitise the venous channels of the definitive hosts. The three common species are S. hematobium, S. mansoni and S. japonicum. Unlike the other infestations, schistosomal infestations can be considered as systemic, as the parasites are localised in organs other than the gut. Man and domestic animals act as hosts for schistosomes, the ova of which contaminate water. Hatched miracidia invade the water snail (intermediate host). Free living cercariae, emerging from the snail, penetrate the human skin and mature into the adult worms. The infection causes:</p>
<ul>
<li>Cercarial dermatitis (Swimmer's itch) due to repeated exposure to larvae.</li>
<li>Acute schistosomiasis or Katayama's fever, a serum sickness-like illness more common with S. japonicum; and</li>
<li>Chronic illness associated with the formation of egg granulomas in various tissues such as urinary bladder and intestines, leading to obstructive and inflammatory lesions. S. mansoni causes intestinal and hepatic schistosomiasis whereas S. hematobium causes urinary disease.
PRAZIQUANTEL: This pyrazino-iso-quinoline compound (Fig. 60.7) is highly effective against:
<img src="assets/images/image-20251214-77a6e3f1.jpeg" alt="img-23.jpeg"></li>
</ul>
<p>FIG. 60.7 Praziquantel
(a) Schistosomes, all species found in man, at all ages and in all areas.
(b) Flukes-liver, lung and intestinal; and
(c) Cestodes causing taeniasis and cysticercosis.</p>
<p>The drug increases the permeability of cell membrane to calcium ions, leading to strong muscular contractions and tegumental damage causing the schistosomes to detach from the wall of the vein. It has negligible effect on ova.</p>
<p>Absorption, fate and excretion: Given orally, praziquantel is rapidly absorbed, but significant proportion of the drug is metabolised during the first pass. Its absorption is increased by a high carbohydrate meal. It acts within 1 hour of ingestion. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of a dose is excreted in urine within 24 hours. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>1.5</mn></mrow><annotation encoding="application/x-tex">1-1.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span></span></span></span></span> hours.</p>
<p>Adverse reactions: These are dose dependent and are usually mild such as headache, anorexia, drowsiness, lassitude, colic and allergic reactions. Katayama fever, a hypersensitivity reaction is mainly treated with a glucocorticoid along with praziquantel. Rarely, it may cause hallucinations, excitement or psychotic symptoms, particularly in the Japanese. Experimental evidence indicates that it has no mutagenic, carcinogenic,</p>
<p>embryotoxic or teratogenic effect. It is considered safe in children and pregnant women. Therapeutic uses:</p>
<ul>
<li>Schistosomiasis: It is the drug of choice and is given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. hematobium infection and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">60 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> for S. mansoni and S. japonicum infections. The total dose may also be divided into two doses given four hours apart. It is very bitter and the tablet should be swallowed. A cure rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> has been claimed in S. hematobium infection and more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> in infection with the other species, at one year follow-up. Even in those in whom the disease is not cured, the egg count drops by more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>. The dose may be repeated after 6-8 weeks. Because of its short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>, it is not used for prophylaxis.
Prazequantel cannot kill the schistosomules (migrating larvae) that are 3-21 days old. Artemether does kill them during the first 21 days in the body, and may be given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 2 weeks. A combination of artemether and praziquantel is synergistic in killing the adult worm.</li>
<li>In taeniasis, a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> produces high cure rates. Praziquantel does not kill the ova and hence a post-treatment purge is advised in T. solium infection. A single dose of 20 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is highly effective in H. nana infection. Although it is effective in the treatment of cerebral cysticercosis in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in three divided doses for 14 days, albendazole (in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day for 8 days) is usually preferred. Treatment may be continued upto 30 days, if necessary.</li>
<li>In fluke infestations: See later.</li>
<li>Hydatid disease: It may be used as an adjunct to albendazole.</li>
</ul>
<p>OXAMNIQUINE: This, tetrahydroquinoline derivative, is well absorbed when given orally. It is effective only against S. mansoni (African) infestation. ADR include dizziness, somnolence, abdominal pain, headache and diarrhoea. It is better tolerated after meals. Rarely, it causes hallucinations and seizures. The urine may be coloured red. It should be avoided during pregnancy.</p>
<p>The dose varies according to the geographical region. In South America and the Caribbean islands, it is given as a single dose, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in adults and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in children under 14 years of age. The dose can also be split into 2 doses given 4-8 hours apart. In the Arabian peninsula and in East and Central Africa, a total dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is given, divided into 2 equal doses, administered on two consecutive days. Higher doses 40-60 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> are needed in countries like Egypt, Sudan, Zaire, Zimbabwe and Uganda; it is administered in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> single doses on 2-3 consecutive days. The cure rate is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>.</p>
<p>METRIFONATE: This prodrug owes its effects to its metabolite dichlorovas, which is a organophosphorous cholinesterase inhibitor (Chapter 19). It is effective only in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span>. hematobium infestation with a cure rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>. The ADR are mild and transient, usually GI disturbances.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-flukes">Drug Therapy of Flukes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-flukes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PRAZIQUANTEL: This drug has revolutionised the treatment of infestation with flukes (paragonimiasis). It is highly effective against lung and intestinal flukes. The recommended dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, divided into three doses given on the same day. The dose may be repeated (see above).</p>
<p>Thiabendazole as a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> for liver and lung flukes infestation, is also useful.</p>
<p>Bithionol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily for 5 days is also effective but more toxic. Also see Chapter 62.</p>
<p>61</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-of-malignancy">Chemotherapy of Malignancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-of-malignancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The etiology of cancer is complex and the incidence of various types of cancer in different population is highly variable, although age ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>65</mn></mrow><annotation encoding="application/x-tex">&gt;65</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">65</span></span></span></span></span> years) appears to be a significant factor. Various multiple factors are implicated in carcinogenesis; only in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> cases, it is genetically inherited. A series of somatic mutations in DNA (specific genes) cause unregulated cell growth and tissue invasion.</p>
<p>Chemotherapy of malignancy differs in some respects from that of infection:
(a) In infections, the invading microbe is biologically 'foreign' to the host and its metabolic reactions are so different from those of the host tissue cells that a chemotherapeutic agent can attack it selectively without affecting the host tissue cells. No such clear cut differences in metabolic reactions have been demonstrated between malignant and normal cells. Thus, many anticancer drugs lack the selectivity of the antimicrobial drugs.
(b) In infections, the body helps the antimicrobial drug with its own defence system in the form of antibodies, phagocytosis etc. Although antibodies have been demonstrated against certain cancer cells, such host defence is usually lacking or ineffective. It is necessary, therefore, to use the drugs to destroy all the malignant cells.</p>
<p>Cancer of the epithelial tissues is called carcinoma and that of the non-epithelial (mesenchymal) tissues is known as sarcoma.</p>
<p>The characteristics which distinguish the cancer cells from normal cells are:</p>
<ul>
<li>Uncontrolled (autonomous) proliferation.</li>
<li>Dedifferentiation and loss of function.</li>
<li>Invasiveness/Metastasis.</li>
</ul>
<p>The normal cell proliferates through a definite cell cycle, that causes programmed DNA replication. The mechanism of cell division is essentially the same in all dividing cells and is divided into five phases (Fig. 61.1). Thus, the cell successively goes through:</p>
<p><img src="assets/images/image-20251214-e31595b6.jpeg" alt="img-24.jpeg"></p>
<p>FIG. 61.1 Cell cycle and sites of action of drugs
(1) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">G</mi><mn>0</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{G}_{0}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (gap 0 or resting) non-proliferative phase.
(2) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">G</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{G}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (gap 1 i.e. presynthetic) phase, during which the cell determines its readiness to commit to DNA synthesis.
(3) S (synthetic) phase, involving DNA synthesis.
(4) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">G</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{G}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (gap 2 i.e. post-synthetic) phase, during which the accuracy of DNA replication is determined, and errors are corrected; and
(5) M (mitotic) phase, during which the replicated chromosomes are separated into two nuclei for the two daughter <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>G</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">G_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> cells. These cells may re-enter the cycle or pass into the resting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">G</mi><mn>0</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{G}_{0}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> phase.</p>
<p>Topoisomerases I and II play an important role during DNA replication. The cell-cycle transition between Gj and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span> and that between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">G</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{G}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> are so well regulated that the cell divides properly with a minimum of errors. Check points in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">G</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{G}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">G</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{G}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> determine whether the cell will enter <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>M</mi></mrow><annotation encoding="application/x-tex">M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>, respectively. These check points are regulated by protein kinases (cyclin-Dependent Kinases cDK) and kinase-associated proteins called cyclins.</p>
<p>Progress through the cell cycle depends on the balance between positive and negative regulatory forces. The positive forces include growth factors and a series of cyclins and cDKs. The negative forces are the proteins induced by genes such as tumour suppressor gene p53 (Guardian of genome). When there is damage to the DNA, these inhibitors halt the cycle, allowing repair. If repair fails, the cell undergoes degradation of nuclear DNA leading to death called apoptosis (programmed cell death). Apoptosis helps to eliminate abnormal cells that have become redundant during development and differentiation. It thus acts as the first line of defence against mutations and renewal of cells with abnormal DNA that could become malignant.</p>
<p>In the cancer cell, deregulation of the cell cycle control occurs by:</p>
<ul>
<li>
<p>Abnormal growth factor function.</p>
</li>
<li>
<p>Abnormal cDK function.</p>
</li>
<li>
<p>Abnormal DNA synthesis; and</p>
</li>
<li>
<p>Abnormal decreases in negative regulatory forces due to mutation in the tumour suppressor gene.
Anticancer Drugs - Classification
I Phase-specific, cell-cycle active e.g. Antimetabolites, Bleomycin, Taxane, Epipodophylotoxin and Vinca alkaloids.
II Phase non-specific e.g. Alkylating agents, Antitumour antibiotics Camptothecins and Platinum analogues.</p>
</li>
</ul>
<p>These can injure DNA at any phase of the cell cycle but appear to block the check points before the cell division.
III Hormones and antihormone; and
IV Miscellaneous eg Immunological agents: Monoclonal antibodies (mAb).
Since the cytotoxic drugs affect the cell division, they also attack all rapidly dividing normal cells leading to common toxicity such as:</p>
<ul>
<li>Bone marrow and immuno-lymphoreticular system suppression.</li>
<li>Damage to GI mucosa (enteritis and ulceration), nausea and vomiting.</li>
<li>Loss of hair (Alopecia).</li>
<li>Specific organ damage e.g. gonads, lungs.</li>
<li>Impaired wound healing.</li>
<li>Growth inhibition in children; and</li>
<li>Teratogenicity.</li>
</ul>
<p>The anticancer drugs can also be classified as:
I Alkylating agents:</p>
<ul>
<li>Nitrogen mustards, e.g., Mechlore thamine, Cyclophosphamide, Melphalan, and Chlorambucil.</li>
<li>Ethylenimines, e.g., Triethylene thiophosphoramide (Thio-TEPA).</li>
<li>Alkyl sulfonates, e.g., Busulfan.</li>
<li>Methylhydrazine derivative, e.g. Procarbazine</li>
<li>Triazenes, e.g. Dacarbazine (DTIC), Temozolomide</li>
<li>Nitrosoureas, e.g. Carmustine (BCNU), Bendamustine</li>
<li>Platinum coordination complexes, e.g. Cisplatin, carboplatin, oxaliplatin</li>
</ul>
<p>II Antimetabolites:</p>
<ul>
<li>Folic acid antagonists, e.g., Methotrexate.</li>
<li>Purine antagonists, e.g., 6-Mercaptopurine, Azathioprine.</li>
<li>Pyrimidine antagonists, e.g., Fluorouracil, Fluorodeoxyuridine, Cytosine arabinoside.</li>
</ul>
<p>III Radioactive isotopes, e.g., Radioiodine, Radiogold, Radiophosphorus.
IV Cytotoxic antibiotics, e.g., Actinomycin-D, Mitomycin-C, Rubidomycin, Doxorubicin, Bleomycin, and Mithramycin.
V Antimitotic natural products (Spindle poisons) - Vinblastine, Vincristine, Vindesin, Taxane, Etoposide, Camptothecin analogues.
VI Hormones and Anti-hormones:</p>
<ul>
<li>
<p>Glucocorticoids eg, Prednisolone.</p>
</li>
<li>
<p>Estrogens and Progestins.</p>
</li>
<li>
<p>Antiestrogens eg, Tamoxifen, Flutamide</p>
</li>
<li>
<p>Aromatase inhibitors eg, Letrozole.</p>
</li>
<li>
<p>GnRH agonists eg, Leuprolide, Goserelin</p>
</li>
<li>
<p>GnRH antagonist eg, Abarelix</p>
</li>
<li>
<p>Somatostatin analogues eg, Octreotide.</p>
</li>
</ul>
<p>VII Miscellaneous: Hydroxyurea, Mitotane, 1-Asparaginase, Tretinoin, Arsenic trioxide. VIII Molecularly targeted agents: monoclonal antibodies and tyrosine kinase inhibitors eg, Signal transduction inhibitors: Trastuzumab, Rituximab, Imatinib etc.
IX Biological response modifiers: Interferons (Chapter 59), Interleukins, BCG, Levamisole (Chapter 74).
X Proteasome inhibitors: Bortezomib, carfilzomib
Chemotherapy of cancer is a specialised field, to be handled only by an oncologist. Its detailed discussion is beyond the scope of this book. Only the guidelines and some important drugs used are described below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alkylating-agents">Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>NITROGEN MUSTARDS: The compound sulfur mustard was first used in 1917 in chemical warfare. It caused severe vesication of the skin and the mucous membranes, GI ulcerations and myelo-supression. The pharmacological properties of nitrogen mustards became known only after the end of World War II.</p>
<p>Mechanism of action: Nitrogen mustards are called alkylating agents because these compounds can transfer an alkyl radical to a suitable receptor site. Alkylating agents, in neutral or alkaline solution, form highly reactive quaternary ammonium derivatives, ethyleniminium cations (Fig. 61.2). These cations react with (alkylate) groupings like amino, sulfhydryl, hydroxy or phosphate in the physiologically important molecules in the cells and render them unavailable for the normal metabolic reactions. Depending upon the number of groups, the compounds are termed as di- or polyfunctional.
<img src="assets/images/image-20251214-6aa411fc.jpeg" alt="img-25.jpeg"></p>
<p>NITROGEN MUSTARD ETHYLENIMINIUM ION
FIG. 61.2 Mechanism of action of nitrogen mustard
Alkylating agents are cell cycle phase nonspecific drugs. They react with the nucleic acid bases and inhibit DNA synthesis. They also bring about a cross-linkage of DNA strands and thus interfere with cell replication.</p>
<p>Pharmacological actions common to various alkylating agents are:</p>
<ul>
<li>Cytotoxic action: In general, these drugs damage the nuclei of growing and multiplying cells. The hemopoietic system is highly susceptible to this action. Thus, they cause leucopenia, anemia, thrombocytopenia and, in toxic doses, aplasia of the bone marrow. The mode of action of individual drugs may differ. Thus, chlorambucil is more effective against the cells of lymphoid series while busulfan has predominant action against myeloid tissue.
These drugs also affect epithelial tissues such as those of cornea and the oral and intestinal mucosa causing ulceration. Hair follicles are also damaged causing alopecia. They impair spermatogenesis irreversibly in males and can cause amenorrhoea and fetotoxicity in females.</li>
<li>Immunosuppressant action: Alkylating agents suppress antibody production and hence act as immunosuppressants. They encourage opportunistic infections.</li>
<li>Miscellaneous actions: All the alkylating agents produce severe nausea and vomiting. In general, they are mutagenic and leukemiogenic.
Nitrogen mustards are also called Radiomimetic drugs as their actions resemble to some extent the biological effects of ionizing radiation. All alkylating agents, however, are not radiomimetic to the same extent.</li>
</ul>
<p>MECHLORETHAMINE: This is the first nitrogen mustard introduced in cancer therapeutics. Locally, it is a vesicant, the most susceptible tissues being those of the skin,</p>
<p>the eyes and the respiratory tract.
When dissolved in water, the drug undergoes very rapid intramolecular chemical transformation to the active form within a few minutes and hence, is given IV immediately. It is largely metabolised in the body. Extravasation of the drug into the tissues causes severe irritation and sloughing.</p>
<p>It is supplied as hydrochloride, 10 mg of which are triturated with 90 mg of anhydrous sodium chloride to increase the bulk.</p>
<p>Adverse reactions: Mechlorethamine is a very toxic drug. Commonly, it produces anorexia, severe nausea and vomiting. Hence it is usually administered at bed time along with a prophylactic antiemetic. Delayed toxicity involves anemia, myelosuppression and aplasia.</p>
<p>Therapeutic uses: Mechlorethamine and other alkylating agents are used in combination with other drugs to treat various hematologic and solid cancers and lymphomas.</p>
<p>CYCLOPHOSPHAMIDE: The pharmacological actions of this compound are mostly similar to those of mechlorethamine hydrochloride. It is a pro-drug. In contrast to nitrogen mustard, it is not a local irritant and it can be given orally as well as parenterally.</p>
<p>Absorption, fate and excretion: Cyclophosphamide is well absorbed from the GI tract. It is converted in the liver to active metabolites, hydroxyphosphamide and
aldophosphamide. They are metabolised further to inactive compounds. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">14 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">14%</span></span></span></span></span> of the drug appears in the urine unchanged.</p>
<p>Adverse reactions: Toxicity of cyclophosphamide is similar to that of mechlorethamine. Sometimes, it causes chemical cystitis and hepatic damage. The toxicity to the urinary tract epithelium is due to the metabolite acrolein. Mesna, a synthetic sulfhydryl compound, given simultaneously with cyclophosphamide and again 4 and 8 hours later, reacts with the toxic metabolite in the urinary tract, thus preventing hemorrhagic cystitis.</p>
<p>Preparations and dosage: Cyclophospha-mide is supplied as 50 mg tablets and in vials containing 100-200 mg of powder. Solution for injection is prepared by adding 5 ml of sterile water to 100 mg of the drug. The solution remains stable for 3 hours. The drug can be given IV, intrapleurally, intraperitoneally, intra-arterially and directly into the tumour. The usual daily dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per kg , orally or IV for 8 days, followed by the daily oral maintenance dose of 100 mg for 30-40 days. It can be repeated after 6-8 weeks.</p>
<p>Therapeutic uses: Commonly, cyclophosphamide is used as a part of a multiple-drug regimen to treat various malignancies such as chronic lymphatic leukemia, lymphomas and solid tumours. Because of the possibility of hemorrhagic cystitis, the patient is advised to take plenty of fluids and it is combined with mesna.</p>
<p>Its use as an immunosuppressing agent is discussed in Chapter 74.
MELPHALAN: This is a phenylalanine nitrogen mustard with properties similar to the other alkylating agents. It is effective orally. It is less irritant locally and rarely causes alopecia. Other systemic toxic effects are similar to those of mechlorethamine.</p>
<p>CHLORAMBUCIL: This compound, chemically related to mechlorethamine (Fig 61.3), has similar pharmacological and toxicological properties.</p>
<p>Chlorambucil, however, is the shortest acting nitrogen mustard. It is effective orally, predominantly against malignant cells of lymphoid series. It is not a local irritant and is less likely to cause alopecia even after prolonged use. Its myelosuppressive effect is dose dependent and usually reversible.</p>
<p>Chlorambucil is supplied as 2 mg tablets. It is given orally, usually in the dose of 0.1- 0.2 mg per kg of body weight daily for 3 to 6 weeks.</p>
<p>Therapeutic uses: The drug can be used for similar purposes as cyclophosphamide but is the drug of choice in the treatment of chronic lymphocytic leukemia.</p>
<p>THIOTEPA: The prototype of ethylenimines class has similar actions as mechlorethamine but is not a local irritant. It is not well absorbed orally and is given IV. It is also used by bladder instillation for superficial bladder tumours.</p>
<p>BUSULFAN: This alkyl sulfonate (Fig 61.4) differs from nitrogen mustards in its mechanism of action. The drug causes a selective depression of granulocyte and platelet production; it does not have a significant action on the intestinal epithelium or the lymphoid tissue. It is more effective against cells of the myeloid series.
<img src="assets/images/image-20251214-8d1fa0bb.jpeg" alt="img-26.jpeg"></p>
<p>Absorption, fate and excretion: Given orally it is well absorbed. Given IV, it disappears from the blood within 2 to 3 minutes. It is excreted in the urine as methanesulfonic acid.</p>
<p>Adverse reactions: These are similar to those of other alkylating agents. It causes much less nausea. Because of its selective action, the incidence of thrombocytopenia is higher. Prolonged administration may cause amenorrhoea, wasting, pigmentation, gynecomastia, anhydrosis and pulmonary fibrosis.</p>
<p>Therapeutic uses: It is used in combination in the treatment of chronic myeloid leukemia. The treatment is initiated with 2-8 mg daily orally and then, depending upon the leucocytic count, the dose is tapered to a daily maintenance dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<p>PROCARBAZINE HYDROCHLORIDE: It is a methylhydrazine derivative. It is activated in the liver. It has been found to be effective orally in the treatment of Hodgkin's disease. The toxic effects reported are: (a) CNS related - restlessness, drowsiness, nighmares and disorientation and (b) haematological: leucopenia, thrombocytopenia and anemia. It may cause disulfiram-like reaction following alcohol ingestion.</p>
<p>DACARBAZINE and TEMOZOLOMIDE: These traizene derivatives have mechanism of action and ADR similar to those of procarbazide. Dacarbazine is most commonly used to treat malignant melanoma, Hodgkin's lymphoma and soft tissue sarcomas while temozolomide is used for the therapy of malignant glioma and astrocytoma.</p>
<p>NITROSOUREAS: This class includes drugs such as lomustine (given orally) and carmustine (given IV). They are lipid soluble and penetrate the BBB. Hence, they are preferred for the treatment of brain tumours. Bendamustine is used in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its main limiting effect is myelosuppression.</p>
<p>Estramustine is a stable combination of an estrogen and mustine, designed to deliver mustine to the estrogen receptor site of a tumour e.g. prostate cancer. It has both local cytostatic effect and a hormonal effect due to its estrogen component.</p>
<p>CISPLATIN: It is a prototype platinum co-ordination complex given IV. In the cell, it gets converted into an active form, a potential mustard-like alkylating agent. It inhibits DNA biosynthesis and kills cells at any stage of cell-cycle. Used in combination with other drugs such as vinblastine and bleomycin, it produces prolonged remissions in a high percentage of patients with germ cell, colorectal, ovarian, and testicular tumours. It is also useful in many solid tumours.</p>
<p>Adverse reactions: It commonly causes marked nausea, vomiting and anemia. Prophylactic administration of an antiemetic is mandatory. Dose-related renal damage, autotoxicity, neuropathy and myclosuppression can occur. Aggressive hydration with saline plus mannitol/furosemide is recommended to reduce the nephrotoxicity.</p>
<p>Carboplatin and oxaliplatin are newer analogues claimed to be less toxic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimetabolites">Antimetabolites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimetabolites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chemical substances which take part in cellular metabolic reactions are called as metabolites. An antimetabolite is a chemical agent which, by virtue of its close structural similarity to the metabolite, blocks its actions. It can achieve this either by preventing the combination of the metabolite with its specific enzyme or by itself combining with the specific enzyme and thus getting transformed into a compound which is either metabolically inactive or harmful to the cell. They damage DNA indirectly.</p>
<p>Clinically useful growth inhibiting anti-metabolites are structural analogues of:</p>
<ul>
<li>Substances essential for the synthesis of the nucleic acid bases, e.g., folic acid antagonist methotrexate; and</li>
<li>Substances which get incorporated into the nucleic acid chains, e.g., purine and pyrimidine antagonists:
METHOTREXATE: This is a 4 -amino substituted folic acid analogue which acts as a folic acid antagonist.</li>
</ul>
<p>Mechanism of action: Folic acid is essential for the production of the coenzyme, tetrahydrofolic acid (THF). The conversion of folate to THF is carried out by an enzyme, folate reductase (Chapter 35). Methotrexate competes with folic acid for this enzyme and succeeds in binding the folate reductase irreversibly, thus restricting the production of THF. Lack of THF leads to inhibition of DNA synthesis and consequently of cell replication. It is, therefore, more toxic to tissues with a high proportion of rapidly dividing cells, e.g. the bone marrow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cytotoxic actions: Methotrexate has a predominant action on the bone marrow. It inhibits erythropoiesis, myelopoiesis and finally may cause aplasia of the bone. This causes marked granulocytopenia, reticulocytopenia and moderate lymphopenia. The drug also causes ulceration of the oral and intestinal mucosa. It can cross the placental barrier and interfere with embryogenesis causing foetal abnormalities and death.</li>
<li>Immunosuppressive action: Methotrexate is a potent immunosuppressant and acts by preventing the clonal expansion of both, B and T lymphocytes.</li>
<li>Anti-inflammatory action: In small doses, it reduces lymphocyte proliferation, rheumatoid factor production, and interferes with the release of inflammatory cytokines like IL-2, IL-6, IL-8 and TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. Thus it acts as an anti-inflammatory agent. It is used as a disease modifying drug in RA (Chapter 75).
Absorption, fate and excretion: Methotrexate is well absorbed from the intestines. It disappears from the blood rapidly and remains in the tissue longer than folate. It thus causes a prolonged inhibitory effect. Its concentration in the CSF is poor. About 50-90% of the dose is rapidly excreted via both, glomerular filtration &amp; tubular secretion. Renal impairment or intake of probenecid and NSAID can augment its renal toxicity.</li>
</ul>
<p>Adverse reactions: These are largely due to deficiency of THF and include megaloblastic anemia, thrombocytopenia, leucopenia, aplasia, oral and intestinal ulceration, nausea, vomiting and diarrhoea, alopecia, dermatitis, and liver damage. These cannot be reversed by giving folic acid as its conversion to THF is blocked. Ideally THF should be administered to antagonise its toxicity. Since THF is too unstable, a related compound folinic acid (N5-formyl THF) is used as calcium folinate or calcium levofolinate. It is</p>
<p>administered IM or IV, beginning 8-24 hours after the initiation of methotrexate therapy. It is given in the dose of 120 mg (in divided doses) in the first 24 hours, followed by 15 mg orally or by IM injection 6 hourly for the next 48 hours.</p>
<p>Simultaneous administration of ketoprofen and methotrexate may cause prolonged and striking elevation of plasma methotrexate level. It is possible that similar drug interactions may occur with other NSAID.</p>
<p>Preparations and dosage: Methotrexate is supplied as 2.5 mg tablets and as powder for injection. It can be given intrathecally, to treat meningeal infiltration in acute leukemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute lymphatic leukemia in children.</li>
<li>Choriocarcinoma: It is extremely useful in this condition where it has almost produced 'cure' in certain cases.</li>
<li>Soft tissue sarcoma, breast cancer and acute myeloid leukemia: It has some place in the treatment of these conditions.</li>
<li>Rheumatoid arthritis (Chapter 75).</li>
<li>Psoriasis (Chapter 71).</li>
<li>As an immunosuppressant in steroid resistant asthma, Crohn's disease and transplant rejection; and</li>
<li>For medical termination of pregnancy (Chapter 68).</li>
</ul>
<p>Premetrexed is a pyrrolopyrimidine analog which causes inhibition of DHFR and several other enzymes in purine and pyrimidine biosynthesis. Its main action is to inhibit thymidylate synthase. It is used in combination with cisplatin for non-small cell lung cancer and mesothelioma.</p>
<p>6-MERCAPTOPURINE: This purine analogue (Fig 61.5) is converted in the cells to ribonucleotide of 6-mercaptopurine, which then suppresses the de novo biosynthesis of purines and hence of DNA. Like methotrexate, it is mainly toxic to the bone marrow and intestinal epithelium.
<img src="assets/images/image-20251214-cfabb7cf.jpeg" alt="img-27.jpeg"></p>
<p>Absorption, fate and excretion: The drug is well absorbed orally. It is metabolised rapidly by xanthine oxidase, which is also required to synthesise uric acid. Use of the xanthine oxidase inhibitor allopurinol decreases the inactivation of 6-mercaptopurine (Chapter 75). Mercaptopurine and its metabolites are rapidly excreted by the kidneys. Its penetration into the CSF is poor.</p>
<p>Adverse reactions: These are similar to those of methotrexate and are mainly related to bone marrow and GI tract. Sometimes, it causes hepatic necrosis.</p>
<p>It can cause hyperuricemia with hyperuri-cosuria due to massive destruction of the cells of lymphoid tissues. Hence, urine should be maintained alkaline and its volume adequate.</p>
<p>Therapeutic uses: Mercaptopurine is useful in the treatment of acute leukemia,</p>
<p>particularly in children. It is supplied as 50 mg tablets. Mercaptopurine is also effective in choriocarcinoma and chronic myelogenous leukemia. Repeated use may lead to the development of resistance.</p>
<p>Other purine analogues like 6-thioguanine and azathioprine also possess cytotoxic actions. However, they have no distinct advantages over mercaptopurine. Azathioprine is usually favoured as an immunosuppressive agent in organ transplantation and in certain autoimmune diseases like hemolytic anemias, glomerulonephritis and rheumatoid arthritis (See Chapter 75).</p>
<p>5-FLUOROURACIL: This fluorinated analogue of pyrimidine acts by binding the enzyme thymidylate synthetase, thus preventing the production of thymine, the basic component of DNA. It also gets incorporated into RNA in place of uracil. It is toxic to the bone marrow, GI epithelium and CNS. It is usually administered by slow IV infusion to prevent its first-pass degradation in the liver. Fluorouracil and its derivative, fluorodeoxyuridine have been used in the treatment of carcinoma of stomach, colon, rectum, breast and ovaries. It is relatively a less toxic drug. It is available as solution 50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.</p>
<p>CYTOSINE ARABINOSIDE: This pyrimidine analogue is considered to be the drug of choice in inducing remission in acute myeloid leukemia, especially in adults. It is an 'S' phase specific antimetabolite and acts by interfering with pyrimidine synthesis. The toxic effects include nausea, vomiting, bone marrow depression and cerebellar ataxia.</p>
<p>GEMCITABINE an anti- metabolite, is an analog of deoxycytidine and is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span> phase specific. It is metabolized intracellularly to the active diphosphate and triphosphate nucleosides, which inhibit DNA synthesis. Another target for gemcitabine is the enzyme ribonucleotide reductase (RNR); irreversible enzyme inhibition blocks synthesis of deoxyribonucleotides required for DNA replication and repair, causing apoptosis of cells. Gemcitabine is used to treat non-small cell lung cancer, bladder and breast cancer. It is currently used to treat pancreatic cancer.</p>
<p>Gemcitabine is relatively well tolerated. Common ADR are flu-like symptoms, fever, fatigue, nausea, vomiting, hepatic damage and skin rash. The main dose-limiting toxicity is bone marrow suppression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="radioactive-isotopes">Radioactive Isotopes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#radioactive-isotopes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Radioactive isotopes act because of their physical property of emitting beta and gamma radiation. The radiations given out produce ionisation in the cells, thereby disrupting the cellular metabolism, and cell destruction. The therapeutically useful radio-isotopes are radio-iodine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span> and radio-phosphorus.</p>
<p>RADIOIODINE (Sodium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span> I): Given orally, it is concentrated by the thyroid gland and causes acinar destruction. It acts by emitting beta radiation. It is useful in those cases of thyroid carcinoma, which can concentrate enough radioiodine e.g. thyroid follicular carcinoma. In thyroid carcinoma, combined therapy with surgery followed by radioiodine can achieve excellent results in selected cases. Usually, the patient is allowed to develop myxedema before the adminitration of radioiodine. This ensures the maximum uptake by the left-over "thyroid tissue". Generally, 2-3 doses of 150 mCi , each at the interval of 2-3 months are considered adequate and the total dose should not exceed 500 mCi . As it is highly selective, its systemic toxicity is minimal. During radioiodine therapy, the patient must be isolated and special arrangements made for the disposal of urine in order to reduce the possible radiation hazard to other people (Chapter 64).</p>
<p>RADIOACTIVE PHOSPHORUS (Sodium phosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">{ }^{32} \mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span> ): Radioactive phosphorus is a beta emitting isotope. It is metabolised by the body like stable phosphorus and is distributed in different tissues in proportion to their total phosphorus content. It is taken up rapidly by those cells where the metabolic turnover of phosphorus is high e.g. multiplying cells, bone marrow, spleen and lymph nodes. It is deposited in bones and is incorporated in nucleoproteins of growing cells. Because of its wide distribution, it causes generalised body irradiation including that of lungs, GI tract and gonads. Excessive irradiation of bone marrow causes leucopenia, thrombocytopenia and anemia.</p>
<p>It is administered in the form of sodium phosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">{ }^{32} \mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span>, either orally or intravenously.
Therapeutic uses: Its important use is in the treatment of polycythemia vera. It is given orally. It suppresses the production of RBCs, platelets and leucocytes and thus reduces the risk of thrombosis. As it is leukemiogenic, it is now rarely used. Repeated phlebotomy is preferred.</p>
<p>The other drugs used to treat polycythemia vera are hydroxyurea and anagrelide (see later).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cytotoxic-antibiotics">Cytotoxic Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytotoxic-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This group of antibiotics derived from the Streptomyces species. They bind to DNA directly and often gererate free radicals leading to DNA damage. They also alter the topoisomerase function. Their cytotoxic property and ADR are similar to those of the polyfunctional alkylating agents.</p>
<p>DAUNORUBICIN (Dunomycin, rubidomycin): This antibiotic is obtained from a strain of Streptomyces coeruleorubidus. When used along with vincristine and prednisolone, it produces remission of acute leukemia in children. It is also useful in acute myeloblastic leukemia in adults. It causes bone marrow suppression and toxic cardiomyopathy.</p>
<p>BLEOMYCIN: This drug, derived from Streptomyces verticillus, is a mixture of glycopeptides. In addition to binding to DNA it forms complexes with iron, oxidation of which gives superoxide. It is useful in epidermoid carcinomas of the skin, the upper respiratory passages, the oral cavity and the genito-urinary tract and in lymphomas resistant to other drugs. It is not a vesicant and causes minimal myelosuppresion. Its main toxicity is nausea, vomiting, anaphylaxis, dermographia, scleroderma like changes in the skin, pneumonitis, and occasionally pulmonary fibrosis. It is used IV, IM or SC.</p>
<p>MITOMYCIN C: This antibiotic, obtained from Streptomyces caespitosus, has been employed by IV or oral route in the treatment of chronic myeloid leukemia and Hodgkin's disease. Like alkylating agents, it may cause local tissue necrosis on extravasation, severe bone marrow depression, bleeding, toxic hepatitis, pulmonary fibrosis and hemolytic uremic syndrome. The usual dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">m</mi><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">6-10 \mathrm{mg} / \mathrm{m}^{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">m</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span> IV bolus every 6 weeks. It is used intravesically to treat bladder cancer.</p>
<p>MITHRAMYCIN (Plicamycin): This drug derived from Streptomyces plicatus, is useful in embryonal cell carcinoma of the testis and in hypercalcemia due to malignant disease. It has high toxicity and causes myelosuppression, thrombocytopenia, liver and kidney damage and suppression of clotting factors.</p>
<p>DOXORUBICIN (Adriamycin): This antibiotic is obtained from Streptomyces pneuceticus. It acts as a nonspecific inhibitor of topoisomerase II, thus interfering with DNA replication. It produces remission in acute lymphoblastic leukemia and lymphoblastic lymphosarcoma. Its toxicity is similar to that of dounorubicin. It has also been used in other malignancies. It is used IV and by instillation into the bladder.</p>
<p>Epirubicin and Idarubicin are other analogues of doxorubicin.
Ixabepilone is derived from apothiline, a cytotoxic macrolide. It has actions similar to those of taxane but can be used in taxane resistant cases. It is used in combination to treat advanced metastatic breast cancer. It is a CYP3A4 substrate. It causes peripheral sensory neuropathy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimitotic-natural-products">Antimitotic Natural Products<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimitotic-natural-products" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>VINCA ALKALOIDS: From the various alkaloids isolated from periwinkle plant (Vinca rosea; Catharanthus rosens), three compounds, vinblastine, vincristine and vindesine, have been shown to be useful in the chemotherapy of malignancy. Vinorelbine is a semisynthetic derivative.</p>
<p>Mechanism of action: They bind to tubulin and prevent the formation of the mitotic spindle (antimitotic spindle poison). Thus, they cause cell-cycle arrest in mitosis.</p>
<p>Pharmacological actions: They have similar spectrum of cytotoxic activity. In spite of the close similarity, there is no cross resistance between these two agents.</p>
<p>Vinca alkaloids are not well absorbed orally. Being highly irritant, are administered through a freely running IV infusion. They are excreted primarily by the liver into the biliary tract.</p>
<p>Adverse reactions: Toxic effects include nausea, anorexia, vomiting and constipation. Signs of intestinal obstruction due to severe constipation with paralytic ileus may occur.</p>
<p>Vinca alkaloids produce certain neuropsychiatric effects. They affect neuromuscular transmission and cause peripheral neuropathy. They may also cause mental depression, ataxia and tremors. It should be noted that the molecules of these alkaloids contain indole and dihy-droindole groups, similar to psychotropic drugs like LSD.</p>
<p>Although these drugs are chemically related, their toxicity is relatively different. Thus, vinblastine is more toxic to the bone marrow while vincristine causes more neurotoxicity and alopecia. They are teratogenic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Vinblastine sulfate is mainly useful in Hodgkin's disease and other lymphomas, where it produces remission in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of cases. It can also be used in methotrexate resistant choriocarcinoma and lymphosarcoma.</p>
<p>Vinorelbine, a semisynthetic derivative of vinblastine is used for non-small cell lung cancer, breast cancer and ovarian cancer.</p>
<p>Vincristine is useful in the treatment of acute lymphatic leukemia in children.
PACLITAXEL: This drug has been isolated from the bark of the Western yew tree. It binds to the beta subunit of tubulin and forms stable non-functioning microtubule bundle, thus interfering with mitosis. This action differs from that of vinca alkaloids which inhibit microtubules. It also induces apoptosis and has anti-angiogenic property. It is metabolised in the liver. It is administered by infusion. It is mainly used to treat breast and ovarian cancer.</p>
<p>Adverse reactions: Mainly it affects the bone marrow. Commonly, it causes neutropenia and myalgias. Other ADR are asymptomatic bradycardia or episodes of silent ventricular tachycardia, alopecia, skin rashes, neuropathy and hypersensitivity reactions.</p>
<p>Docetaxel, an analogue of paclitaxel with similar properties but a longer half-life.
Camptothecin analogues: These have been isolated from the Chinese tree Camptotheca acuminata and include irinotecan and topotecan. They inhibit nuclear topoisomerase1 and thereby inhibit DNA replication. These drugs have been used in advanced colorectal and ovarian cancer. Their main adverse effects are neutropenia and diarrhoea.</p>
<p>ETOPOSIDE: It is a semisynthetic compound prepared from podophyllotoxin obtained from Podophyllum peltatum. It inhibits topoisomerase II, leading to DNA damage. It is</p>
<p>given orally or IV. The ADR are similar to those of radiomimetic agents.
Teniposide is a related agent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hormones-and-anti-hormonal-drugs">Hormones and Anti-Hormonal Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormones-and-anti-hormonal-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hormones act differently from the cytotoxic drugs and hence can be usefully combined with them in certain malignancies. They may act in one of the several ways:</p>
<ul>
<li>Inhibition of cell growth and differentiation, e.g., androgens in breast cancer and estrogens in prostatic cancer.</li>
<li>Stimulation of differentiation of cells which then regain their ability to respond to the body's controlling and inhibitory influence, e.g., estrogens in breast cancer in postmenopausal women.</li>
<li>Selective lysis of leukemic lymphocytes: Glucocorticoids because of their direct lympholytic action are effective in acute lymphatic leukemia. However, as they stimulate the granuloblasts, they are ineffective in acute myeloid leukemia.</li>
<li>Inhibition of the circulating concentration of a substance which stimulates the malignant cells, e.g., thyroxine is believed to suppress certain thyroid cancers by inhibiting TSH secretion.
Hormones do not directly kill the susceptible malignant cells, do not cause hyperuricemia and are slower in their effect.</li>
</ul>
<p>ESTROGENS: Carcinoma of the prostate is androgen dependent; bilateral orchidectomy, in patients with prostatic carcinoma can produce marked improvement. Similar beneficial effects are obtained by the administration of estrogens. The best results are obtained by combining estrogens with orchidectomy. Synthetic estrogens which are as effective as the natural ones but much cheaper are preferred. Diethylstilbestrol is used in the dose of 5 mg tid for several days and then reduced to 1 mg tid. Adverse effects due to estrogen therapy are described in Chapter 67. In males, these mainly include sexual impotence and gynecomastia:</p>
<p>Aromatase inhibitors: These nonsteroidal drugs inhibit the enzyme aromatase responsible for the conversion of the adrenal androgen androstenedione to estrone (Chapter 67). They markedly reduce the circulating estrogen levels. The currently used non-steroidal aromatase inhibitors are anastrozole and letrozole.</p>
<p>The aromatisation occurs in the body fat. Such estrogen synthesis may be important in the pathogenesis of breast cancer growth in postmenopausal women. Aromatase inhibitors are selective in action (selective medical adrenalectomy) and do not inhibit synthesis of adrenal glucocorticoids. They are given orally and are generally well tolerated. Adverse reactions are mild and include nausea, headache, fatigue, hot flushes and arthralgia.</p>
<p>They are now increasingly used as first line drugs in postmenopausal women to treat ER positive breast cancer, including that which has progressed inspite of tamoxifen therapy. They can be combined with other drugs.</p>
<p>Exemestane is a steroidal hormonal compound. It acts by irreversibly inactivation of aromatase and has similar uses as other aromatase inhibitors.</p>
<p>TAMOXIFEN: This nonsteroidal antiestrogen is structurally related to diethylstilbestrol.
Mechanism of action: It acts by competing with the circulating estrogens for binding to the cytoplasmic estrogen receptors (ER). The metabolites of tamoxifen have a much stronger affinity for the receptors and are not easily displaced by circulating estradiol. At low concentrations, they have a cytostatic effect on ER positive cells. Higher concentrations</p>
<p>cause cytotoxic effects characterised by cell death of ER positive and receptor negative cells.</p>
<p>Absorption, fate and excretion: Given orally, it is well absorbed. It is extensively metabolised in liver to active metabolites and undergoes enterohepatic circulation. With a standard dose of 10 mg twice a day, a steady state serum concentration is achieved by 4 weeks of treatment. The approximate biological half-life of tamoxifen and its metabolite N desmethyltamoxifen are 7 and 14 days, respectively. Hence, the drug can be detected in the serum for 4 weeks after treatment is discontinued. Approximately 30% of the dose is excreted in faeces.</p>
<p>Adverse reactions: The adverse effects are usually minimal. The most frequent side effect has been hot flushes. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the patients may experience mild nausea and vomiting. It may also give rise to vaginal bleeding and ocular toxicity. Rarely, it causes bone pain associated with hypercalcemia, particularly in patients with bone metastasis. Higher incidence of DVT and endometrial cancer has been reported in a few women on prolonged therapy.</p>
<p>Therapeutic uses: Tamoxifen is well tolerated, reasonably safe and of proven efficacy in patients with breast cancer. It is the adjuvant treatment of choice in the postoperative patients, irrespective of their age, pre-or post-menopausal status, the ER status of the excised tumour and whether the axillary lymph nodes are positive or negative; the results are better in patients with ER positivity.</p>
<p>The dose is 10 mg orally twice daily. The optimum duration of treatment is uncertain; but it is usually for 2-5 years. Larger doses are not more beneficial.</p>
<p>The observation that there is less osteoporosis in women treated with tamoxifen led to the development of a new series of its analogues called Selective Estrogen Receptor Modulators (SERM) such as raloxifene, which are used in osteoporosis (Chapter 70).</p>
<p>Fulvestrant: This selective estrogen receptor antagonist is an anti-cancer drug for metastatic breast cancer.</p>
<p>PROGESTINS: The endometrial carcinoma in humans is believed to be due to prolonged unopposed stimulation by estrogens. Hydroxy-progesterone caproate and megestrol acetate have been used with success in metastatic endometrial carcinoma. The former is usually given IM in the dose of 1-3 g at weekly intervals, and the latter orally in the dose of 40 mg four times a day. Medroxyprogesterone has also been used for this purpose in the dose of 100-500 mg per day orally (Chapter 67). Both agents have also been used to treat cachexia associated with cancer and AIDS.</p>
<p>FLUTAMIDE: This non-steroidal anti-androgen compound binds to androgen receptor and blocks the effects of testosterone. It exerts substantial anti-tumor activity in patients with metastatic cancer of prostate. The drug does not inhibit either the production of gonadotropins or adrenocortical steroidogenesis.</p>
<p>Given orally, it is rapidly and completely absorbed. Its adverse effects are nausea, vomiting, loss of libido, sexual impotence, hot flushes and rarely serious hepatotoxicity.</p>
<p>It has been used in conjunction with a GnRH analogue in the treatment of prostatic cancer. In this combination it blocks the effects of testosterone. The combination is as effective as but less toxic than stilbestrol. As flutamide blocks the inhibitory feedback of testosterone on LH secretion, the levels of plasma testosterone rise, and this partly offsets the direct beneficial effect of flutamide on prostatic cancer. However, flutamide, used as a</p>
<p>single drug in the dose of 250 mg tid is effective in the management of early prostatic cancer; it can also be used as the sole drug in orchidectomised patients, in whom it blocks the effects of the adrenal androgens.</p>
<p>Nilutamide and bicalutamide are other antiandrogen (Chapter 69).
LH-RH AGONISTS: Leuprolide and goserelin have been used to treat metastatic cancer of the prostate. (Chapter 67).</p>
<p>ABARELIX: This GnRH antagonist causes suppression of LH and FSH and lowers the testosterone levels. It is used for treating advanced prostatic cancer.</p>
<p>SOMATOSTATIN ANALOGUES such as octreotide and lanreotide are sometimes used in the treatment of carcinoid tumours.</p>
<p>GLUCOCORTICOIDS: Glucocorticoids like hydrocortisone and prednisolone have been shown to be useful in:
(a) Acute lymphatic leukemia in children and in malignant lymphoma. This is due to their direct lympholytic effect. Steroids are not useful in the myeloid and monocytic types of acute leukemias.
(b) Preventing the accelerated erythrocytic destruction and thus prevent anemia in disseminated cancer patients; further, they effectively counter the hemolytic and hemorrhagic complications (due to thrombocytopenia) accompanying chronic lymphocytic and myeloid leukemias, and malignant lymphomas.
(c) Treating cerebral edema due to intracranial tumour metastases.
(d) Controlling the hypercalcemia following cancer chemotherapy.
(e) Critically ill patients along with cytotoxic drugs to produce symptomatic relief and a sense of well being.
(f) Preventing/treating vomiting due to chemotherapy. Dexamethasone is useful as an adjunctive antiemetic.</p>
<p>Prednisolone is generally started in doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">60-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily in divided doses, and then, depending upon the response, reduced to a maintenance dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily.</p>
<p>I-THYROXINE SODIUM: Follicular and papillary types of thyroid carcinomas are probably dependent on thyroid stimulating hormone (TSH). The primary treatment of these conditions is surgical. Papillary carcinoma is very slow growing and metastasizes largely to cervical lymph nodes; post-operatively it has been treated lifelong with thyroxine. Follicular carcinoma metastasizes early and widely; post operatively it is best treated with radioactive iodine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-agents">Miscellaneous Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>L-ASPARAGINASE: This enzyme, which deaminates asparagine to aspartic acid is prepared from E. coli. Asparagine is a non-essential amino acid normally synthesised by the mammalian tissue cells. Certain malignant tumours, however, are unable to synthesize asparagine and consequently, are dependent on supplies from the host. Asparaginase acts by depleting asparagine from the host, hydrolysing circulating l-aspargine to aspartic acid, thus denying the malignant cells the essential metabolite. It is relatively nontoxic to normal cells. Given IV, it has produced relief in cases of lymphoblastic leukemia and reticulum cell sarcoma. It may cause hypersensitivity, pyrogenic reactions and skin rashes.</p>
<p>HYDROXYUREA (hydroxycarbamide) is mainly used in the management of myeloproliferative disorders. It acts by inhibiting the enzyme ribonucleoside diphosphate reductase which is responsible for the conversion of ribonucleotides to deoxyribonucleotides, (S-phase block). It inhibits myeloproliferation and normalises the platelet count. Hydroxyurea is almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> absorbed from the gut.</p>
<p>Adverse reactions: These include leukopenia, megaloblastic anaemia, thrombocytopenia, GI disturbances, skin reactions, stomatitis, alopecia, and neurological manifestations.</p>
<p>It is used in chronic granulocytic leukemia, polycythemia vera, thrombocytosis and sickle cell anaemia.</p>
<p>Anagrelide: This phosphodiesterase inhibitor given orally inhibits megakaryacytes maturation to platelets and causes lowering of platelets. Thus it helps to prevent thrombosis in primary thrombocythaemia and polycythemia. It also has been used in the treatment of chronic myeloid leukemia. The drug may cause headache, palpitation, cardiac arrhythmia and fluid retention.</p>
<p>Mitotane: This drug, structurally related to the insecticide DDT, gets selectively concentrated in the adrenal cortex and acts as adrenolytic. It has been used in the treatment of Cushing's syndrome due to adrenocortical carcinoma.</p>
<p>The adverse effects include anorexia, nausea, diarrhoea, somnolence and lethargy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tyrosine-kinase-inhibitors-and-monoclonal-antibodies-mab">Tyrosine Kinase Inhibitors and Monoclonal Antibodies (mAb)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tyrosine-kinase-inhibitors-and-monoclonal-antibodies-mab" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Identification of the molecular and genetic changes that cause malignant transformation has proved useful in developing new anticancer drugs. The family of Epidermal Growth Factor Receptor (EGFR) - tyrosine kinases on cell surface play an important role in translating messages to the nucleus and provides targets for chemotherapeutic agents. Many epithelial tumours, particularly breast cancer, express excess amounts of HER2 which is a member of the EGFR family and is associated with clinical resistance to cytotoxic and hormonal therapy. The intracellular domain of HER2 encodes tyrosine kinase which inhibits apoptosis and promotes metastases.</p>
<p>TRASTUZUMAB (Herceptin): This is a humanised, cDNA derived antibody against HER2. Blocking these receptor prevents the tumour growth. It can cause nausea, vomiting, fever, hypersensitivity reactions, delayed bone marrow suppression and cardiomyopathy. It is used in patients with breast cancer in combination with chemotherapy.</p>
<p>Pertuzumab binds to HER-2 receptors, inhibits dimerization and blocks HER-2 signaling, which leads to cell growth arrest. It is co-administered with trastuzumab for anticancer effect as both have different binding sites.</p>
<p>Panitumumab and Cituximab are humanised monoclonal antibodies. They target EGFR. They are used in the treatment of metastatic colorectal cancer. More than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of colorectal cancer patients have highly expressed EGFR.</p>
<p>Rituximab targets CD20 and is used to treat non-Hodgkin lymphoma and leukemia that express CD20. Alemtuzumab targets CD52 and is used to treat CD52 expressing lymphoid tumors and CLL; it depletes the leukemic and the normal lymphocytes by direct antibodydependent lysis (see also Chapter 74).</p>
<p>BEVACIZUMAB: This is a recombinant, humanised, monoclonal anti- VEGF (vascular endothelial growth factor) antibody, which prevents the latter's binding to endo-thelial receptors. VEGF binding initiates angiogenesis (endothelial proliferation and the formation of new blood vessels). Bevacizumab inhibits angiogenesis and thus retards further growth of all tissues including the metastases. Approved for the treatment of metastatic colorectal cancer, it has also been used for treating other cancers such as breast cancer, malignant mesothelioma and prostate cancer (off-label use). The ADR include proteinuria, hypertension and thromboembolism. It is administered by IV infusion. Intraocular injections are used to prevent angiogenesis and age related macular degeneration (AMD).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span> Iodine-Tositumomab is a monoclonal antibody labelled with radioiodine. Given IV, it is taken up more specifically by the tumour cells than by normal tissues and gives selective radiation to targeted cells. It is used in refractory non-Hodgkin lymphoma.</p>
<p>IMATINIB is the first tyrosine kinase inhibitor which is highly effective, orally, in the treatment of chronic myeloid leukemia (CML). Most of the patients with CML have a translocated, shortened chromosome 22, termed the Philadelphia chromosome. This translocation creates a tyrosine kinase fusion gene called BCR-ABL gene which phosphorylates effector proteins and drives cell proliferation. Imatinib acts specifically by binding to the BCR-ABL gene and blocks the phosphorylation of the effector proteins.</p>
<p>Imatinib mesylate is well absorbed orally and is highly protein bound. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is</p>
<p>18 hours and that of its active metabolite is about 40 hours. It is metabolised in the liver.
In patients with CML in the chronic phase imatinib induces a complete hematological remission in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>88</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">88 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">88%</span></span></span></span></span> and a complete cytogenic remission in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>. It is also useful in CML in the acute phase, and to a smaller extent in CML in blast crisis.</p>
<p>Adverse Reactions: These are usually mild and include nausea, vomiting, edema, muscle cramps and diarrhoea. Neutropenia, thrombocytopenia, and increased hepatic aminotransferases may be observed. Imatinib inhibits hepatic microsomal enzymes and may increase the serum concentration of warfarin, whereas the administration of itraconazole or erythromycin may increase its plasma concentration.</p>
<p>Nilotinib, a tyrosine kinase inhibitor, is claimed to be effective in CML patients intolerant of or resistant to imatinib. Dasatinib, a multiple tyrosine kinase inhibitor has activity against all phases of CML and Philadelphia chromosome positive acute lymphoblastic leukemia. Lapatinib is an oral inhibitor of HER2 and EGFR1. It is used to treat metastatic breast cancer. Ponatinib is claimed to be useful in subjects resistant to above drugs.</p>
<p>Crizotinib inhibits anaplastic lymphoma kinase associated with metastatic non-small cell lung cancer and patients intolerant to crizotinib can be treated with similar drug called Ceritinib.</p>
<p>Gefitinib and Erlotinib are other EGFR tyrosine kinase inhibitors. They are used to treat non-small cell carcinoma of the lung and pancreatic cancer.</p>
<p>Sunitinib, sorafinib, axitinib and pazo-panib are other oral, multiple tyrosine kinase inhibitors which target vascular endothelial growth factor receptors (VEGFR) and platelet derived growth factors receptors (PDGFR). They are used to treat renal cell carcinoma.</p>
<p>Several other oral tyrosine kinase inhibitors are now available for therapy of various malig-mancies such as resistant metastatic melanoma, lymphoma, leukemia and non-cell small cell lung cancer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="biological-response-modifiers">Biological Response Modifiers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biological-response-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>For immunostimulants and other biological modifiers such as BCG, levamisole, interleukins and interferon alpha, see Chapters 59 and 74.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="proteasome-inhibitors">Proteasome Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#proteasome-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Proteasome are large proteolytic complexes of the cell which play a role in the normal turnover of proteins. The regulation of cellular proteins like p53 protein is required to maintain cell cycle progression, growth, and survival. The proteins to be destroyed are linked to ubiquitin and delivered to proteasome. Proteasomes have 20S proteolytic core bearing active sites (chymotrypsin-like, trypsin-like and caspase-like sites). Inhibition of these sites lead to intracellular aggregation of unwanted proteins in cells. This induces apoptosis and cell cycle arrest.</p>
<p>Bortezomib is the first proteasome inhibitor used in multiple myeloma. Multiple myeloma cells produce very large quantities of protein, which make them unusually susceptible to this drug. Recently, a selective irreversible protesome inhibitor carfilzomib has been introduced, which is effective in myeloma refractory to bortezomib. These agents are given with immunomodulators such as lenalidomide (see Chapter 74). ADR include fatigue, vomiting, diarrhoea, fever, dyspnoea, peripheral neuropathy and myelosuppression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-malignant-diseases">Drug Therapy of Malignant Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-malignant-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chemotherapy has definitely improved the outlook of cancer therapy malady, and in a few cases, long term remissions (almost cure) can be obtained by chemotherapy. These are acute myeloid and lymphoid leukemia, Hodgkin's lymphoma, choriocarcinoma, Wilm's tumour, disseminated testicular cancer, ovarian cancer and histiocytic lymphoma. In majority of the conditions, however, it is purely suppressive and is used to help the patient to return to his near-normal mode of life. In some, it improves the survival and almost cures e.g. breast cancer, colorectal cancer and ovarian cancer.</p>
<p>A detailed discussion of drug therapy in malignancy is beyond the scope of this book. Certain principles, however, are outlined below:</p>
<ul>
<li>
<p>In general, irradiation is recommended in a localised malignant growth, after palliative surgery, wherever possible. This, if carried out early, may prevent the spread and also will cause less damage to healthy tissues. Generally, chemotherapy should not be given simultaneously with local irradiation. Usually the drugs acting on specific molecular targets are to be preferred.</p>
</li>
<li>
<p>Chemotherapy is used in conventional dose regime unless there is well documented indication for higher dose.</p>
</li>
<li>
<p>The drugs are always given in combination and the treatment is administered in 'cycles'. This allows the normal body tissues (especially the bone marrow) to recover from the ADR.
By the time a tumour is clinically detectable, only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the cells are actively proliferating and therefore susceptible to the action of anti-cancer drugs. The remaining <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> are in the resting phase but are known to re-start proliferating if the total tumour mass is reduced (by surgery or by radiotherapy) and become susceptible to the action of drugs.</p>
</li>
<li>
<p>A single dose of a cytotoxic drug kills not a fixed number of cancer cells but a constant proportion of those present. Hence, chemotherapy has the maximum chances of being curative when few tumour cells are present (small tumor volume). Once a clinical remission is obtained, continuation of chemotherapy (perhaps with a different drug) in the presence of inapparent, residual disease is highly effective.</p>
</li>
<li>
<p>Conditions like acute leukemia, certain sarcomas and Hodgkin's lymphoma which show rapid progression need prompt attention, while a condition like chronic lymphatic leukemia, particularly in old people, may progress so slowly that patients may enjoy good health and can survive almost a normal span of life without any chemotherapy.</p>
</li>
<li>
<p>In most cases, drugs have to be given in such doses that toxic effects are inevitable. Patients should have regular hematological supervision and with drugs like methotrexate, evidence of damage to the alimentary epithelium should be looked for.</p>
</li>
<li>
<p>All anticancer drugs have adverse effects and may even cause fatality. The most frequent adverse reactions are severe nausea, vomiting, infections and diarrhea, mucositis and myelosuppression. Hyperuricemia following the breakdown of large number of tumour cells can be prevented by using allopurinol.</p>
</li>
<li>
<p>Use of bone marrow growth factor e.g., G-CSF, GM-CSF erythropoietin and thrombopoietin may reduce the frequency and severity of anemia, neutropenia and thrombocytopenia (Chapter 35).</p>
</li>
<li>
<p>Cytotoxic drugs are contraindicated during pregnancy as they cause abortions or foetal abnormalities.</p>
</li>
<li>
<p>In choosing a drug regime one must always keep in mind its "cost effectiveness" as chemotherapy in general is very expensive. These drugs should not be used simply to prolong the 'act of dying' in terminal cases.
Response to chemotherapy may be judged by:
(1) Improvement of the sense of well-being of the patient.
(2) Decrease in tumour markers.
(3) Normalisation of organ function; and
(4) Shrinkage of the tumour mass.</p>
</li>
</ul>
<p>In general, the possibility of cure is inversely related to tumour volume and directly to the dose of the drug.</p>
<p>The best results are generally obtained in patients in good nutritional state and without severe metabolic disturbances or other complications. Ideally, the patient should have adequate hepatic, cardiac, renal and bone marrow function.</p>
<p>Chemotherapy is only a part of the overall approach to the care of terminally ill cancer patient. When one can neither cure an illness nor prolong life, one must strive to improve the quality of life of the patient. Towards this end, the following contribute significantly:</p>
<ul>
<li>Maintenance of nutrition.</li>
<li>Treatment of anemia and neutropenia (Chapters 34, 35) and cachexia.</li>
<li>Protection from infection. Chemotherapeutic agents, being immuno-suppressants, reduce the body's resistance to infection.</li>
<li>Control of symptoms particularly pain on a day to day basis (see Table 61.1).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-61-1">Table 61.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-61-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Palliative symptom control in the terminally ill cancer patient</p>
<ul>
<li>I'requent re-evaluation is important asymptomschange often.</li>
<li>Enquiring daily about frequency of bowel movements is more important than monitoring pulse, temperature and BP.</li>
<li>Never say "Nothing can be done". Consult or refer if the patient is uncomfortable.</li>
<li>Pain: See Chapter 10.</li>
<li>Anorexia: Prednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> or dexamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day.</li>
<li>Nausea and vomiting: See Chapter 41. This may be morphine-induced.</li>
<li>Dyspnoea: It may respond to morphine, diazepamor a glucocorticoid.</li>
<li>Headache: If severe, it may be due to raised intracranial tension and may respond to dexamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">16 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">16</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for a few days, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4-6 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Noisy upper respiratory secretions ('death rattle') are troubling to the family but not generally to the patient. They can be reduced by SC injection of atropine 200-400 mcg every 2-4 hours, as needed.</li>
<li>Convulsions: They are liable to occur in patients with cerebral tumours and should be treated with phenytoin or carbamazepine; when oral medication is no longer possible, rectal diazepam may be used. In very restless patients, midazolam may be used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> using syringe pump over 24 hours SC.</li>
<li>The treatment of other symptoms (constipation, cough, restlessness/confusion and pruritus) has been described elsewhere in the book.</li>
<li>Use of bone marrow growth factors can reduce the degree of neutropenia and protect against infection (Chapter 35).</li>
<li>Occupational and physiotherapy, and</li>
<li>Adequate emotional and spiritual support to the patient and the family. This is very important particularly in a condition like incurable cancer where the physician can hardly do anything specific but watch helplessly.</li>
</ul>
<p>62</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiseptics-disinfectants-and-insecticides">Antiseptics, Disinfectants and Insecticides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiseptics-disinfectants-and-insecticides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sterilisation can be defined as freeing an article, a surface or a medium, by removing or killing all micro-organisms including vegetative bacteria, spores, fungi and viruses.</p>
<p>Disinfection (high level disinfection) is the term used for destruction of all pathogenic organisms such as vegetative forms of bacteria, mycobacteria, fungi and viruses but not spores. If spores are killed during the process, only then it is equivalent to sterilisation.</p>
<p>A disinfectant or germicide is a chemical which causes disinfection. It may be bactericidal or bacteriostatic. They are generally used to disinfect inanimate objects. They are classified into:</p>
<ul>
<li>Bactericides.</li>
<li>Viricides; and</li>
<li>Fungicides.</li>
</ul>
<p>Drugs toxic to the external parasites are called ectoparasiticides.
An antiseptic is a chemical disinfectant (usually bacteriostatic in the concentration used) that can be diluted sufficiently to be safe for application to living tissues (intact skin, mucus membranes or wounds) while still retaining its antimicrobial property. Antiseptics and disinfectants are often added to easily available every day utilities like soaps, toothpastes, mouth wash and after-shave lotions. They are also used to disinfect excreta, fumigate rooms and bedding, and sterilise instruments (endoscopes) and complicated apparatus (heart lung machines and respirators) that cannot be sterilised by heat.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification">Classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(A) Physical agents e.g. heat, filtration and radiation.
(B) Chemical agents: They are classified as:</p>
<p>I Acids:</p>
<ul>
<li>Inorganic acids: Boric acid;</li>
<li>Organic acids: Benzoic acid, Salicylic acid.</li>
</ul>
<p>II Alkalies: Sodium and Potassium hydroxide.
III Alcohols: Ethanol and Isopropyl alcohol.
IV Aldehydes: Formaldehyde, Glutaraldehyde.
V Surfactants:</p>
<ul>
<li>Anionic: Soaps, Sodium lauryl sulfate, Sodium cetostearyl sulfate.</li>
<li>Ampholytic Surfactants.</li>
<li>Cationic: Benzalkonium, Cetylpyridinium, Dequalinium and Triclobisonium.</li>
<li>Nonionic: Polysorbates.</li>
</ul>
<p>VI Phenols and related compounds: Phenol, Cresol, Chlorocresol, Hexylre-sorcinol, Bithionol, Thymol, Hexachlorophane, Chlorhexidine.
VII Halogens and halogen containing compounds: Chlorine and chloramines; Iodine and Iodophors.
VIII Oxidising agents: Hydrogen peroxide and other Peroxides, Potassium and zinc permanganates. IX Dyes: Crystal violet, brilliant green, methylene blue, acriflavine, proflavine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span> Heavy metals: Silver nitrate, zinc compounds.
XI Gases: Ethylene oxide.</p>
<p>Mechanism of action: They may act by one or more of the mechanisms listed in Table 62.1.</p>
<p>Table 62.1
Mechanisms of action of disinfectants and antiseptics</p>
<ul>
<li>Coagulation of the bacterial proteins.</li>
<li>An alteration in the properties of the bacterial cell wall.</li>
<li>Binding of free sulfhydryl ( -531 ) groups essential for enzyme action; and</li>
<li>Competition with essential substrates for the important enzymes in the bacterial cell.</li>
</ul>
<p>Factors which determine the therapeutic efficacy of these agents are:</p>
<ul>
<li>Drug concentration and its therapeutic index: In general, antiseptic effect increases with a rise in concentration. Alcohol, however, is an exception and shows maximum antiseptic activity in a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> concentration. The potency of a particular concentration is meaningful only in relation to the tissue toxicity (Therapeutic Index). Presence of necrotic tissue reduces their penetration and lowers their effective concentration. Anionic surfactants like soaps reduce the effective concentration of cationic surfactants by chemical neutralisation.</li>
<li>Species susceptibility: Some forms, particularly spores and some species of bacteria, are resistant to many antiseptics. Viruses are susceptible to alkalies but resistant to phenol.</li>
<li>Temperature and duration of contact: A limited rise in environmental temperature and prolonged contact can enhance sporicidal activity. A rise of temperature by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">10^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> generally doubles the antibacterial activity of chemical agents whereas it increases that of moist heat a hundredfold.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="physical-agents">Physical Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physical-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(1) Heat applied at the right temperature and for optimum length of time is the best and most effective sterilising agent available. It may be applied either as moist heat or dry heat. Moist heat: Moist heat kills microorganisms by coagulating the proteins. It can be applied in several ways:</p>
<ul>
<li>Pasteurisation: This is commonly used to kill the pathogenic micro-organisms in milk.</li>
<li>Boiling: Boiling in water for 20 minutes is an efficient method of high level disinfection; spores are often resistant to boiling.</li>
<li>Steam: Steam is a very efficient means of sterilisation because of its high penetrating capacity and because it gives up a large amount of heat (latent heat). Steam may be used at atmospheric pressure (temperature <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>100</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">100^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">10</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> ) to sterilise culture media that decompose at higher temperatures. More commonly, steam is used at higher pressures ( 2 atmospheres) which raise its temperature to between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>108</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">108^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">10</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>147</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">147^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">14</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> for at least 20 minutes. By selecting the correct temperature and time cycle, a wide variety of materials can be sterilised.
Dry heat: Dry heat kills the organisms by oxidising their cell constituents. It can be used in several ways.</li>
<li>Hot air in an oven is commonly used to dry sterilise glass syringes, instruments, and glassware. Dry sterilisation must be carried at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>160</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mo>−</mo><msup><mn>180</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">160^{\circ} \mathrm{C}-180^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">18</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> for 60-120 minutes.</li>
<li>Flaming: i.e., direct heating in a bunsen flame, is commonly used in a bacteriology laboratory to sterilise inoculating wires, etc.</li>
<li>Incineration: This is suitable for soiled dressings, pathological material, animal carcasses and heavily soiled bedding.
(2) Filtration through different types of filters including the modern Millipore membrane filters is an efficient way of removing larger particles and bacteria from liquids that cannot be treated by other means, e.g., human serum albumin. It is also used to remove heatresistant, pyrogenic cell-wall endotoxins from other solutions prior to autoclaving them. However, viruses, especially the smaller ones, may pass through filters.
(3) Radiation used for sterilisation is of two types, non-ionising and ionising:
(a) Non-ionising radiation: Two types of non-ionising radiation are used for sterilisation:</li>
<li>Infra-red radiation is another form of dry heat sterilisation.</li>
<li>Ultra-violet radiation is absorbed by the proteins and nucleic acids and kills microorganisms by the chemical reactions it sets up in the bacterial cell. It has low penetrating capacity and its main application is to reduce the bacteria in air, water and on contaminated surfaces. All forms of bacteria and viruses are vulnerable to ultraviolet rays below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3000</mn><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">3000 \mathrm{~A}^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7473em;"></span><span class="mord">3000</span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">A</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7473em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span>. Excessive exposure of skin can produce serious burns. Care must be taken to protect the eyes while using UV radiation.
(b) Ionising radiation: The lethal action of ionising radiation is due to its effect on the nuclear DNA and on the other vital cell components. There is no appreciable rise in temperature. High energy gamma rays from cobalt-60 are used to sterilise articles such as foods, syringes, swabs, culture plates, catheters and plastic material including disposable plastic heart-lung machines.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acids-and-alkalies">Acids and Alkalies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acids-and-alkalies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>BORIC ACID: Boric acid and sodium borate (Borax), are weak bacteriostatic and fungistatic agents. It is soluble in water upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>. This concentration, however, inhibits phagocytosis. Locally, boric acid is not an irritant. Aqueous solutions of boric acid (2-4%) are used as mouth washes, eye and skin lotions. Mixed with starch, talc or zinc oxide, it is commonly used as a dusting powder (talcum powder).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Boric talc dusting powder contains 2.3 g of boric acid, 5 g of starch and 50 g of sterilised, purified talc.
(ii) Boric acid eye lotion contains 3.4 g of boric acid dissolved in 100 ml of freshly boiled and cooled purified water.
(iii) Borax glycerin: This contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">12 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of borax with glycerin and is used for painting throat and tongue.</p>
<p>BENZOIC ACID: This organic acid has antibacterial and antifungal properties; in a concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>, it is used as a preservative. The antimicrobial activity of the drug is decreased if the pH of the medium exceeds 5 . Taken orally, benzoic acid is conjugated with glycine in the liver to form hippuric acid which is excreted in the urine. Compound benzoic acid-salicylic acid ointment (Whitfield's ointment) has been used to treat ringworm infection (see Chapter 71).</p>
<p>SALICYLIC ACID: This drug has bacteriostatic, fungicidal and keratolytic properties. It is applied externally for the treatment of seborrhoeic dermatitis, acne, and fungal diseases. Further, it produces a slow and painless destruction of the epithelium; and it is applied in the form of a paint in a collodion base, or as a plaster, for the destruction of warts and corns. Its keratolytic property makes it useful in psoriasis (Chapter 71).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Salicylic acid ointment <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>.
(ii) Whitfield's ointment: See Chapter 71.
(iii) Salicylic acid compound dusting powder contains 1.5 g of salicylic acid and 2.5 g of boric acid, made up to 50 g with sterilised, purified talc, with or without camphor.
(iv) Salicylic acid ear drops contain 0.12 g of salicylic acid with 8 ml of glycerin and 15 ml of specially denatured spirit.
(v) Salicylic acid collodion contains 12 g of salicylic acid in 100 ml of flexible collodion.</p>
<p>Alkalies like sodium hydroxide and potassium hydroxide are used for disinfecting excreta from patients with poliomyelitis. Both these alkalis are caustic and may be used for removal of warts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alcohols">Alcohols<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alcohols" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ETHANOL: Ethyl alcohol in the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> is a skin antiseptic. It, however, exhibits poor activity against bacterial spores and hydrophilic viruses. It acts by denaturation of cellular protein. As it evaporates quickly, it exerts a cooling effect but it lacks residual activity. It should not be allowed to come in contact with cornea.</p>
<p>ISOPROPYL ALCOHOL: This is an inflammable secondary alcohol with an unpleasant burning taste. It is about twice as toxic as ethyl alcohol. As a germicide, it is slightly more potent than ethyl alcohol and has a marked degreasing action. It is used in the concentration of 68 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>72</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">v</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">72 \% \mathrm{v} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">72%</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span>, for disinfection of skin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aldehydes">Aldehydes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aldehydes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>FORMALDEHYDE: Formaldehyde, a gas at room temperature, is used as a fumigant or as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">40 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> aqueous solution containing methanol (Formalin). It acts by alkylation of proteins and nucleic acids. The solution, in the concentration of 1:200, is a highly effective disinfectant against several bacteria, viruses and fungi; a higher concentration and prolonged exposure are necessary to eliminate spores.</p>
<p>Formaldehyde solution has a pungent odour and is extremely irritant to the mucous membranes. It precipitates tissue proteins in high concentration. When applied to the unbroken skin, it hardens the epidermis.</p>
<p>Uses: A 10% solution is used for disinfection of excreta, sputa and brush bristles. It is sometimes used in dentistry as a mummifying agent for residual pulp tissue. A 3% solution is available for removal of warts on the palms and soles, and a 20 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> solution is employed to treat hyperhidrosis. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> solution in saline is a common preservative for pathological specimens.</p>
<p>Formaldehyde gas is obtained by heating formaldehyde solution or formalin tablets. It is used for sterilisation of those articles which cannot be wetted with solutions or subjected to high temperatures. It does not damage metal, plastics or fabrics.</p>
<p>GLUTARALDEHYDE: Glutaral-dehyde is a saturated aldehyde which produces a slightly acid solution in water. It is a potent bactericide, sporicide, viricide and fungicide. The solution must be alkalinised to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">H</mi></mrow><mn>7.4</mn><mo>−</mo><mn>8.5</mn></mrow><annotation encoding="application/x-tex">\mathrm{pH} 7.4-8.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">pH</span></span><span class="mord">7.4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8.5</span></span></span></span></span> for activation. The shelf life of activated solution is 14 days. A rise of pH above 8.5 causes polymerization of glutaraldehyde with loss of activity. It is less irritant than formaldehyde to the eyes and the skin. Unlike formaldehyde, it does not damage lenses and cementing material in endoscopes and is superior to it for sterilising rubber, plastic and metal appliances. It can also be used to sterilise complicated apparatus like respirators. It is available as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> solution which is buffered to a pH of 7.5-8.5 with sodium bicarbonate before use. As <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aqueous solution, it is used as a local application to treat idiopathic hyperhidrosis of palms and soles.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="surfactants">Surfactants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surfactants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Surfactants are chemical compounds which lower the surface tension of solutions, usually aqueous ones. They are also termed as detergents. They can be classified into:</p>
<ol>
<li>ANIONIC SURFACTANTS: Soaps belong to this category. Anionic surfactants dissociate in aqueous solution to form a relatively large and complex anion, which is responsible for the surface tension lowering activity. Soaps are mainly effective against Gram-positive and acid-fast organisms. It is likely, however, that their cleansing action is secondary to emulsification of the lipoidal secretions in which the bacteria are embedded; the micro-organisms are subsequently enmeshed in the lather and washed away with rinsing.</li>
</ol>
<p>Soft soaps derived by combination of unsaturated fatty acids with potassium hydroxide or sodium hydroxide are more efficient germicidal agents than hard soaps formed by the treatment of saturated fatty acids with sodium or potassium hydroxide. The disadvantages of soaps are their:</p>
<ul>
<li>Narrow antimicrobial spectrum.</li>
<li>Incompatibility with cationic surfactants.</li>
<li>Tendency to precipitation by hard water; and</li>
<li>Ability to cause drying and cracking of the skin.</li>
</ul>
<p>Preparations:
(i) One part of soft soap in 20 parts of warm water is used as an enema to soften impacted feces. Soap liniment which is an alcoholic solution of soft soap, camphor and lemon grass oil, is a mild counterirritant, and is used in the treatment of sprains and bruises.
(ii) Sodium lauryl sulfate: This anionic surfactant is effective in hard water. It is active in both acidic and alkaline media. It is used in medicated shampoos and as a preoperative skin cleanser, usually along with another antiseptic.
(iii) Sodium cetostearyl sulfate is used like sodium lauryl sulfate.</p>
<p>Other anionic surfactants include dioctyl sodium sulfosuccinate used as a fecal softening agent, and sodium tetradecyl sulfate used as a sclerosing agent for varicose veins. These are discussed elsewhere.
2. CATIONIC SURFACTANTS: This group is the most favoured of the antiseptics at present. Cationic surfactants dissociate into a large and relatively complex cation, which is responsible for the activity and a smaller inactive anion. The cation usually contains pentavalent nitrogen atom, which is often present as a quaternary ammonium, pyridinium or piperidinium group. In addition to emulsifying and detergent actions, the cationic surfactants have a marked bactericidal activity against both Gram-positive and Gramnegative organisms. They are less effective against spores, viruses and fungi.</p>
<p>The mechanism of their antibacterial activity is not clear. It is postulated that by lowering surface tension, they damage the cell membrane. They may also inactivate certain enzymes.</p>
<p>Cationic surfactants are most effective in neutral solution. They are incompatible with anionic surfactants like soaps. A significant quantity of these agents is absorbed by cotton, rubber and porous material resulting in a reduction in their effective concentration. As these agents combine readily with proteins, their activity is greatly reduced in the presence of serum, pus and other organic matter. When applied to skin, they tend to form a film</p>
<p>under which bacteria, particularly Pseudomonas aeruginosa and Mycobacterium tuberculosis, can remain viable.</p>
<p>The solutions of cationic surfactants are generally colourless, odourless, non-irritating and non-toxic in bactericidal concentrations. They remain stable for a long time and do not deteriorate on boiling or autoclaving.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Benzalkonium chloride: This occurs as a white or yellowish white amorphous powder or as gelatinous pieces. It has an aromatic odour, markedly bitter taste and is water soluble. (a) A 1:1,000 solution may be used for the pre-operative disinfection of intact, unbroken skin.
(b) A 1:1000 to 1:4,000 solution has been used for storing sterilised surgical instruments, usually along with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> sodium nitrite to retard rusting.
(c) A 1:8,000 solution is used for soaking baby napkins to prevent napkin rash.</p>
<p>Instruments and polythene tubes, treated with the drug must be thoroughly washed before use as the cationic surfactants have a deleterious effect on nerve tissue.</p>
<p>It is not recommended as an antiseptic because resistant pseudomonas and other Gram negative bacteria can grow in the antiseptic solution. It is used only as a disinfectant.
(ii) Cetrimide: A concentration of 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> in water is used for similar purposes as benzalkonium chloride. A 1:20,000 concentration is used as a preservative for eye drops. Cetrimide cream contains 5.0 g of cetrimide, 50.0 g of cetostearyl alcohol and 500 g of liquid paraffin made upto 1000 g with water. Cetrimide lotion contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cetrimide in water.
(iii) Miscellaneous: Other cationic surfactants available include cetylpyridinium chloride, dequalinium acetate and triclobisonium chloride.
3. AMPHOLYTIC SURFACTANTS: Ampholytic surfactants are derivatives of long chain Nsubstituted amino acids and can have anionic, non-ionic or cationic properties depending on the pH . They are anionic at a pH above their isoelectric point and cationic at a pH below it. They have the detergent properties of anionic surfactants and the antiseptic properties of cationic surfactants. They, however, are incompatible with both anionic and cationic agents. The compounds available for use include sodium N -dodecyl alanate, and dodecyldi-(aminoethyl)-glycine hydrochloride.
4. POLYSORBATES: The elimination of one molecule of water from the hexahydric alcohol sorbitol results in the formation of compounds termed sorbitans, while elimination of another water molecule results in the formation of sorbides. By esterification of these with fatty acids, non-ionic surfactants are produced. These are termed polysorbates. These substances are active water in oil emulsifying agents, while their polyoxyethylene derivatives are non-ionic, oil in water emulsifying agents.</p>
<p>The polysorbates and their polyoxyethylene derivatives such as Tween 80 are used in the preparation of cream, ointment and suppository bases and for emulsification of oils. They may be employed internally to improve the absorption of fat and fat soluble vitamins. They are also used as surface active agents in insecticides and fruit spraying solutions, as industrial detergents and in the manufacture of cosmetic creams. They are devoid of antiseptic activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phenols-and-related-compounds">Phenols and Related Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenols-and-related-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PHENOL (Carbolic acid): Phenol (Fig 62.1), one of the oldest antiseptics, was introduced into medicine in 1867 by Lord Lister. It occurs as pinkish, needle-shaped, deliquescent crystals, sparingly soluble in water but freely soluble in alcohol and has a typical odour. It is a potent bactericidal and fungicidal agent. It acts by denaturing the bacterial proteins and disrupting the cell wall. It is mainly effective against non-sporulating pathogens. All spores and most viruses are resistant. It rapidly penetrates the skin, the mucous membranes and other tissues and acts as a corrosive. It is extremely irritating to exposed tissues and may cause necrosis. The antiseptic and corrosive properties are greatly reduced if it is dissolved in alcohol, glycerine or a fixed oil. It is carcinogenic.
<img src="assets/images/image-20251214-11a491ff.jpeg" alt="img-28.jpeg"></p>
<p>Phenol is rapidly absorbed on oral administration. It can also penetrate intact skin. The degradation products, upon oxidation, impart a greenish tinge to the urine.</p>
<p>Ingestion of phenol results in severe GI corrosion, pain, vomiting and shock. Collapse occurs within a few minutes, body temperature falls and convulsions may occur; death is usually due to respiratory failure. Treatment is essentially symptomatic.</p>
<p>Uses: Phenol is not used even as a disinfectant because of its corrosive properties. It may, however be used as an in vitro deodorant. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> solution is occasionally used as antipruritic on the skin.</p>
<p>It has been occasionally used as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> oily solution in almond oil for sclerosing unprolapsed haemorrhoids.</p>
<p>CRESOL: Cresol is a mixture of the ortho, meta and para methyl derivatives of phenol. In the commercially available product, the meta isomer is the major constituent. Cresol is 10 times as active as phenol and has a wider margin of safety. It is an almost colourless to pale brownish yellow liquid, becoming darker on keeping or on exposure to light, and with a characteristic phenolic odour. It is sparingly soluble in water and is used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> solution.</p>
<p>LYSOL (Cresol with soap solution): This is prepared by saponification of a mixture of cresol with a vegetable oil or the mixed fatty acids derived therefrom. It contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">v</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">50 \% \mathrm{v} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50%</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of cresol. The bactericidal value of lysol varies according to the soap used in its preparation. Lysol is a useful disinfectant for hospital and domestic use. However, because of its highly irritant nature, it has largely been replaced by safer preparations like iodophors.</p>
<p>CHLOROXYLENOL: It is a less toxic chlorinated phenol. It is supplied as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4.8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4.8%</span></span></span></span></span> solution. It is effective against Gram-positive and Gram-negative organisms. Surgical dettol used for pre-operative preparation of skin contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.44</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.44 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.44%</span></span></span></span></span> of chloroxylenol; dettol used for disinfection of surgical instruments contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6.25%</span></span></span></span></span> of the agent while a 1-3% concentration is employed in the antiseptic cream.</p>
<p>BITHIONOL: This is a non-irritant bactericide, particularly effective against Gram-</p>
<p>positive cocci, usually employed in soaps and soap solution in a concentration varying from 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>.</p>
<p>THYMOL: Thymol and chlorothymol possess both antiseptic and antifungal properties. Both these, however, are irritating to wounds, have a poor water solubility and lose their bactericidal power considerably in the presence of proteins. They are usually used in mouth washes and antiseptic solutions.</p>
<p>HEXACHLOROPHANE (G-11): This chlorinated phenol exhibits bacteriostatic activity against a wide variety of organisms mainly Gram've organisms. It retains its activity in the presence of soaps but not so much in the presence of serum or pus.</p>
<p>It can get absorbed from burnt or denuded skin and from mucous membrane and even from the unbroken skin in premature infants. Severe neurotoxicity in the form of a myelopathy and cerebral edema has been reported in infants washed regularly with a 3% solution. Accidental ingestion or the application of high concentration (6%) to children has caused cardiovascular disturbances, convulsions and respiratory arrest.</p>
<p>Phenolic disinfectants are not to be used in the nursery.
CHLORHEXIDINE: It is a cationic biguanide with low water solubility. Chlorhexidine digluconate is water soluble. This compound acts against a wide range of Gram-positive and Gram-negative organisms and against fungi at pH 5.5 to 7.0. Bacterial spores are prevented from germinating but are not killed. It is effective even in the presence of blood or pus. It is rapid acting, non-irritating and has residual activity. It has low potential for producing contact dermatitis and photosensitivity. It is absorbed poorly. It is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> aqueous concentrate or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> water miscible cream. Its activity is reduced in the presence of neutral soap, surfactants and anionic agents. Oral toxicity is low because it is poorly absorbed. Chlorhexidine in alcohol is used for hand sanitisation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="halogens-and-halogen-containing-compounds">Halogens and Halogen Containing Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#halogens-and-halogen-containing-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chlorine-and-chloramines">CHLORINE AND CHLORAMINES:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chlorine-and-chloramines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chlorine is the most commonly used halogen, largely for purification of water. Chloramines, which release chlorine slowly, are used for disinfection. Chlorine exerts a bactericidal action against a variety of Gram-positive and Gram-negative organisms in a concentration as low as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.0002</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.0002 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.0002%</span></span></span></span></span>. The acid-fast organisms, however, require a much higher concentration. The agent also kills protozoa and viruses including HIV. The bactericidal action is significantly reduced in the presence of blood, serum, feces and other organic matter.</p>
<p>It is a strong oxidising agent and its antibacterial activity is due to the formation of hypochlorous acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{HOCl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">HOCl</span></span><span class="mclose">)</span></span></span></span></span>. Interestingly, the killing of bacteria ingested by neutrophils in the animal body involves synthesis of HOCl by the intracellular action of the enzyme myeloperoxidase on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and halide. Sodium hypochlorite <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5.25%</span></span></span></span></span> made up in tap water ( pH 7.5 ) retains activity for months. An alkaline medium greatly reduces the antiseptic activity of hypochlorous acid by causing dissociation of the acid molecule.</p>
<p>Chlorine poisoning is characterised by severe irritation of the respiratory passage leading to pulmonary edema, and by metabolic acidosis. Treatment is symptomatic.</p>
<p>Solutions of hypochlorous acid are corrosive to aluminium, stainless steel and silver.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Chlorinated lime and boric acid solution (Eusol) is prepared by dissolving 1.25 g of calcium hypochlorite and an equivalent quantity of boric acid and calcium hydroxide powder in 100 ml of water. The solution is irritating and should, therefore, be diluted with saline before using on denuded surfaces.
(ii) Chloramine: This is an organic chloride. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> solution of the agent is used for irrigation of wounds, while a 0.2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.55</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.55 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.55%</span></span></span></span></span> solution is recommended for mouth wash and for irrigation of bladder and urethra. The solution has to be freshly prepared for use. (iii) Chlorinated lime (Bleaching powder) is extensively used for purification of water.</p>
<p>IODINE: Iodine is probably the oldest and the most widely used of the antiseptics. It is the most potent bactericidal agent and in addition, also possesses high sporicidal, fungicidal, amoebicidal and a moderate viricidal activity. Its germicidal activity is less influenced than that of chlorine by pH , temperature and the time of contact. However, like chlorine, its activity is inhibited by reducing agents and organic material, whereas it is enhanced by alcohol.</p>
<p>Iodine stains the skin, is irritating, painful and may delay the healing. In rare cases, it causes severe reactions, such as bronchospasm, fever and skin eruptions. Elemental iodine, if ingested, can cause severe GI irritation and shock. Treatment consists of gastric lavage with a solution of soluble starch or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> sodium thiosulfate, and correction of dehydration.</p>
<p>Iodism, may occur following prolonged systemic use of iodides (Chapter 64).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Strong iodine tincture contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">10 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of iodine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">6 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of potassium iodide, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">\mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of water in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> alcohol.
(ii) Weak iodine tincture contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">2 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of iodine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">2.5 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of potassium iodide in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> alcohol.
(iii) Iodine compound paint contains 0.31 g of iodine and 0.62 g of potassium iodide with</p>
<p>mentha oil, water and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> alcohol in glycerin base. A slightly different composition, containing peppermint oil instead of mentha oil is termed as Mandl's paint.
(iv) Non-staining iodine ointment contains 5% iodine with arachis oil and yellow soft paraffin.
(v) Aqueous iodine solution (Lugol's solution) is used in thyrotoxicosis. (Chapter 63).</p>
<p>Uses: Iodine tincture may be employed for disinfection of skin prior to surgery. Iodine crystals have been used to sterilise water for drinking during hiking expeditions and water for soaking fresh vegetables to disinfect them before consumption. Iodine 1:20,000 solution is bactericidal in one minute and kills spores in 15 minutes.</p>
<p>Iodine glycerin preparation (Mandl's paint) is applied to the mucous membranes in the treatment of follicular tonsillitis and pharyngitis. Iodine ointments are used as counterirritants and have also been used locally as fungicides in the treatment of ringworm. Iodinated hydroxyquinolines are used in amoebiasis and as topical antifungal agents.</p>
<p>The use of iodides as expectorants and in the treatment of thyrotoxicosis is described elsewhere. Unlike iodine, iodides have no antibacterial action.</p>
<p>IODOPHORS: Iodophors are developed by complexing iodine with surfactants like nonionic detergents, quaternaries and macromolecules. The detergents act as solubilisers and carriers, combining detergent property with antibacterial activity. They are sporicidal on prolonged contact. They owe their germicidal activity to the slowly released elemental iodine. Compared to aqueous or tincture iodine, iodophors are non-irritating, non-staining, water-miscible in all dilutions, are less toxic and non-sensitising to the skin. The iodophors available are:
(i) Povidone-iodine 5% (Betadine): A complex of iodine with polyvinyl pyrrolidone, available as solution, ointment and eye-drops.
(ii) Undecoylium chloride iodine: A complex of iodine with the cationic surfactant undecoylium chloride.</p>
<p>Uses: Iodophors are now commonly used as mouth and hand washes, for preoperative skin preparation, as local antiseptics, in ringworm and in oral and vaginal moniliasis.</p>
<p>Povidone eye drops (5%) are sometimes used for dry eye conditions. Iodophors may also be used for disinfection of operation rooms, wards, nurseries, etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oxidising-agents">Oxidising Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oxidising-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HYDROGEN PEROXIDE: This colourless, odourless liquid is used mainly as a disinfectant and an antiseptic. It is a potent oxidiser and owes its action to its ready release of nascent oxygen, when applied to tissues. It has a broad spectrum of activity. Concentrations of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> are sporicidal. Vapour phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a cold gaseous sterilant and can be used as a substitute for formaldehyde.</p>
<p>Its application causes an effervescence which mechanically removes the tissue debris from other wise inaccessible regions. It does not combine with tissue proteins and its degradation product is non-toxic. The action, however, is of short duration. Solutions of hydrogen peroxide have poor power of penetration.</p>
<p>Hydrogen peroxide solution contains not less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.0</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">w</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">v</mi></mrow><annotation encoding="application/x-tex">6.0 \% \mathrm{w} / \mathrm{v}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6.0%</span><span class="mord mathrm" style="margin-right: 0.01389em;">w</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">v</span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, corresponding to about 20 times its volume of available oxygen and hence, is described as ' 20 volume'.</p>
<p>Peracetic acid prepared from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a more potent bactericidal and sporicidal agent used in food processing industry.</p>
<p>Uses: It is used for:
(i) Cleansing wounds and abscesses
(ii) Removal of adhering dressings
(iii) Irrigation
(iv) Cleaning septic sockets and root canals In dentistry
(v) Gargling as mouth wash and as deodorant (when diluted with 3 to 8 parts of water); and (vi) Softening of ear wax</p>
<p>Other peroxides: These include magnesium peroxide and the commonly used zinc peroxide. It releases nascent oxygen, leaving behind zinc oxide, which has a mild astringent action. It is applied locally as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> suspension for disinfecting, deodorising, and promoting healing of burns and wounds contaminated with anaerobic bacteria. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> suspension in water is used as a mouth wash to treat anaerobic infections.</p>
<p>POTASSIUM AND ZINC PERMANGANATES: These compounds possess oxidising and astringent properties. Zinc permanganate is more astringent than the potassium salt. The permanganates are caustic as crystals and concentrated solutions. Their ingestion may provoke severe GI irritation; potassium permanganate can also cause CVS depression and kidney damage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Potassium permanganate occurs as dark purple crystals, having a metallic lustre. It is moderately soluble in water.
(ii) Potassium permanganate gargle contains 25 mg of potassium permanganate in 100 ml of water ( 1 in 4000 ). It should be freshly prepared.
(iii) Zinc permanganate occurs as brownish-black iridescent deliquescent crystals soluble 1 in 3 parts of water.</p>
<p>Uses: It is used as a gargle, mouth wash or for vaginal irrigation; 1 in 10,000 to 1 in 5,000 for urethral irrigation and as wet dressings and in baths for acute dermatoses with a secondary infection. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution has been used locally in mycotic infections such as athlete's foot and in poison ivy dermatitis. A 5% solution has a powerful styptic action.</p>
<p>Because of its oxidising property, potassium permanganate as a crystalline insufflation has been employed topically to oxidise venom in case of snake and scorpion bite. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.02</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.02 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.02%</span></span></span></span></span></p>
<p>solution in water is used for stomach wash in the treatment of alkaloidal poisoning.
Potassium permanganate is commonly employed to purify well water and to disinfect vegetables and fruits.</p>
<p>Zinc permanganate, because of its greater astringent activity, is preferred to the potassium salt for urethral irrigation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dyes">Dyes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dyes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dyes have been used since ancient times in foods, medicines and cosmetics. The natural dyes have been replaced by the more stable synthetic dyes. These are used as antiseptics, chemotherapeutic, diagnostic and colouring agents. They are non-irritant. They are sometimes used as aqueous solutions or ointments to be applied topically in the treatment of burns, impetigo and chronic ulcers of the skin and mucous membranes. They are claimed to promote healthy granulation tissue and thus help in healing of ulcers. Used locally, they are almost non-toxic. They cause local staining. The commonly used dyes are: gentian violet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>, brilliant green <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-1.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.0%</span></span></span></span></span> and acriflavine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>.</p>
<p>METHYLENE BLUE: Methylene blue occurs as a dark greenish, crystalline powder with a metallic lustre. It is hygroscopic and soluble in water. Used in small doses, it facilitates the conversion of methemoglobin to haemoglobin and has been used as an antidote in the treatment of cyanide poisoning and drug induced methemoglobinemia. For this purpose, it is given IV as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution in doses of 1 to 4 mg per kg bodyweight. It is also used in the treatment of idiopathic methemoglobinemia in the dosage of 300 mg orally daily along with large amounts of ascorbic acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="heavy-metals">Heavy Metals<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heavy-metals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The pharmacology of heavy metals is discussed in Chapter 76. Heavy metal salts used exclusively as antiseptics destroy the micro-organisms in very low concentrations, an action referred to as the oligodynamic action. The antiseptic activity is due to precipitation of the bacterial proteins.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="silver-compounds">SILVER COMPOUNDS:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#silver-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Silver nitrate: This occurs as colourless or white crystals, extremely soluble in water.</p>
<p>Silver nitrate has antiseptic, astringent and caustic properties. If ingested, it produces severe GI irritation, vertigo, coma and convulsions. Applied to the skin, it stains the area.</p>
<p>The prophylactic use of aqueous solution containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of silver nitrate as eye drops (two drops) for conjunctivitis and ophthalmia neonatorum is still used. Aqueous solution of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> is sometimes applied on second and third degree burns as prophylaxis against infection.</p>
<p>Silver nitrate stick has been used to remove warts and other small skin growths and for cauterisation of wounds and trachoma follicles. The stick should be moistened before use. (ii) Silver sulfadiazine (Chapter 45).</p>
<p>ZINC SALTS: Zinc salts possess astringent, corrosive and weak antiseptic properties. The commonly used salts are:
(i) Zinc sulfate: Zinc sulfate occurs as odourless, colourless, efflorescent crystals or as a white crystalline powder. It has an astringent metallic taste and is soluble in water.</p>
<p>Externally, zinc sulfate is used as an astringent lotion for indolent ulcers and to assist granulation. Eye drops in the concentration of 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> are sometimes used in angular conjunctivitis and in chronic inflammation of the cornea. The salt is the major ingredient of many commercially available deodorant anhidrotics.
(ii) Calamine is a pink powder, almost odourless and tasteless and insoluble in water. Chemically, it is zinc carbonate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> ) with a small amount of ferric oxide which imparts the pink colour. It has mild astringent and antiseptic actions and is used as a lotion and a dusting powder in skin conditions like sunburns, eczema, insect bites, and urticaria, where it also acts as a soothing and protective agent.</p>
<p>Calamine lotion contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of calamine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> each of zinc oxide and glycerine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of bentonite, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> each of liquified phenol and sodium citrate, with rose water as the vehicle. It can also be used as oily lotion or cream (Chapter 71).
(iii) Zinc oxide is a common constituent of powders and creams, which are used as protectives to treat diaper rash, in calamine creams and anti-dandruff shampoos. (iv) Zinc phosphate is toxic and used as rat poison.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gases">Gases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ethylene oxide, formaldehyde and betapropiolactone in the gaseous form are powerful agents used for sterilisation. Betapropiolactone has been reported to have carcinogenic properties.</p>
<p>ETHYLENE OXIDE: This is colourless liquid with a boiling point of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10.7</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">10.7^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">10.</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. At normal room temperatures, it is a highly inflammable and highly explosive gas with a sweet ethereal smell. The explosive tendency can be limited by mixing it with an inert gas such as nitrogen or carbon dioxide and keeping down the concentration of ethylene oxide to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>.</p>
<p>A relative humidity of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> is necessary for satisfactory sterilisation. It has powerful bactericidal, sporicidal and viricidal properties and a high penetrating capacity. The presence of protein impairs its effectiveness. It is an excellent agent for sterilising complicated equipment like heart-lung machines and respirators as well as suture material. Its safe use necessitates special equipment. It is mutagenic and carcinogenic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="choice-of-method-of-sterilisation-and-disinfection">Choice of Method of Sterilisation and Disinfection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-method-of-sterilisation-and-disinfection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All instruments and apparatus to be sterilised should be first thoroughly cleaned by washing and scrubbing. The same applies to areas for fumigation as the presence of organic matter reduces the efficacy of chemical disinfectants.</p>
<p>Autoclaving is the method of choice for sterilising theatre appliances. Those which cannot withstand autoclaving are sterilised by chemical methods:
(a) Lysol, chloroxylenol or iodophor for surgical blades and scissors;
(b) Formaldehyde or gluteraldehyde for endoscopes and specialised rubber equipment;
(c) Ethylene oxide for heart-lung machines.
(d) Syringes are sterilised by autoclaving, hot air sterilisation or gamma radiation. Diabetics are commonly advised to keep their non-disposable syringe and needle permanently immersed in spirit and to boil them once a week.
(e) Gamma radiation is now increasingly used to sterilise disposable articles on a massive scale.
(f) Autogenous and some types of synthetic grafts used in cardiovascular surgery are sterilised with antibiotics.</p>
<p>It is customary to sterilise the air in operation theatres with ultra-violet radiation or with iodophor spray. Ultra-violet radiation is also used to sterilise the air inside sterile dispensing cabinets. Solutions of biological materials such as sera and antibiotics which cannot be sterilised by heat are often 'sterilised' by filtration. Laboratory glassware is ordinarily sterilised in a hot air oven after thorough, preliminary cleansing.</p>
<p>Wards, theatres and sick rooms and the contaminated furniture can be swabbed with formalin or iodophor solution, fumigated with gaseous formaldehyde or sprayed with iodophor solution or with a commercial mixture containing glutaraldehyde, chemically bound formaldehyde and benzalkonium chloride (Bacillocid). Books and bedding can be fumigated with gaseous formaldehyde or ethylene oxide. Cotton clothing and rubber mattresses can be autoclaved. Cotton mattresses, however, cannot be autoclaved and have to be exposed to sunlight and fresh air. Incineration is the method of choice for soiled dressings, pathological materials and animal carcasses. If facilities for incineration are not available they are best disinfected with lysol or iodophor. Lysol and iodophor can also be used for disinfecting the excreta of patients with infectious diseases before disposal.</p>
<p>The skin, especially its deeper layers, cannot be sterilised. The best method for reducing the bacterial count on the skin is thorough scrubbing and washing followed by the application of a suitable antiseptic. For preoperative preparation of the skin, the preferred antiseptics are tincture of iodine (mitis), aqueous iodophor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> ) solution and a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> solution of hibitane in alcohol.</p>
<p>Acriflavine and chloroxylenol are the popular wound antiseptics though heavily infected wounds are best treated with systemic antibiotics. Although Condy's lotion (a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> aqueous solution of potassium permanganate) is still the favourite for bladder washes, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> aqueous solutions of acetic acid and silver nitrate are far more effective for this purpose.</p>
<p>Chloroxylenol is a popular and effective disinfectant for hand-washing by attendants and for sick-room swabbing. Feeding utensils of patients with communicable diseases are best kept separate, washed and finally scalded with boiling water. Soiled bed linen and clothes of patients treated at home should be soaked in a disinfectant such as chloroxylenol and</p>
<p>then washed. After recovery of the patient, bed linen and clothes are best laundered.
Swimming pools and water supplies are generally disinfected by chlorination whereas potassium permanganate is a convenient domestic disinfectant for water, fruits and vegetables.</p>
<p>Table 62.2 summarises the chemical methods of high level disinfection. Boiling is used to disinfect, whereas steam, dry heat and radiation are used for sterilisation (see earlier).</p>
<p>Table 62.2
Some chemical methods of high level disinfection</p>
<table><thead><tr><th style="text-align: center;">Chemical</th><th style="text-align: center;">Concentration</th><th style="text-align: center;">Uses and comments</th></tr></thead><tbody><tr><td style="text-align: center;">Sodium hypochlorite</td><td style="text-align: center;">0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.0%</span></span></span></span></span></td><td style="text-align: center;">Efficient for disinfecting linen, clothing, spills, stainless steel instruments; syringes and needles before autoclaving/disposal. Solution must be freshly prepared as it is unstable. Cheapest disinfectant.</td></tr><tr><td style="text-align: center;">Chloramine T</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span></td><td style="text-align: center;">Similar to above. More stable.</td></tr><tr><td style="text-align: center;">Ethanol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td><td style="text-align: center;">Useful for hand washing, spills, instruments, equipment.</td></tr><tr><td style="text-align: center;">Cetrimide</td><td style="text-align: center;">Stock solution diluted 1:100 equipment.</td><td style="text-align: center;">Useful for furniture, spills, fittings,</td></tr><tr><td style="text-align: center;">Povidone iodine</td><td style="text-align: center;">One part of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution added to 3 parts of boiled water</td><td style="text-align: center;">Similar to ethanol. Immerse for 15 minutes</td></tr><tr><td style="text-align: center;">Formaldehyde</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mo>−</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35-40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">35</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> solution diluted 1:10</td><td style="text-align: center;">Disinfection after 30 minutes immersion; sterilisation after several hours. Toxic.</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Tablets releasing vapour</td><td style="text-align: center;">Requires special apparatus.</td></tr><tr><td style="text-align: center;">Glutaraldehyde</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span></td><td style="text-align: center;">30 minutes immersion for disinfection, 10 hours for sterilisation. Needs activation before use.</td></tr><tr><td style="text-align: center;">Hydrogen peroxide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span></td><td style="text-align: center;">Disinfection after 30 minutes of immersion.</td></tr></tbody></table>
<p>It is worth remembering the following points about disinfectants:</p>
<ul>
<li>Most are highly active against Gram positive bacteria.</li>
<li>Acid fast bacilli are less susceptible to these agents and need higher concentrations. They are resistant to chlorhexidine, oxidising agents and cresol.</li>
<li>Aldehydes, sodium hypochlorite and povidone iodine have action against fungi too.</li>
<li>Spores are usually resistant to all except aldehydes, sodium hypochlorite and high concentrations of povidone iodine.</li>
<li>Hydrophilic viruses are usually resistant except to aldehydes and high concentrations of sodium hypochlorite.</li>
<li>Prions are resistant to most agents except high concentrations of sodium hypochlorite.</li>
<li>Hand washing is the important method for preventing transmission of infection from person to person and is best done with soap and warm water, with or without a disinfectant, as a disinfectant can cause irritation, dryness and sensitisation of the skin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="insecticides">Insecticides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insecticides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These agents, primarily used to destroy insects, are important because of their toxicological properties.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification">Classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Organochlorines:
(a) Chlorophenothane (DDT) and related compounds
(b) Cyclodienes e.g. Aldrin, Endrin, Diledrin, Heptachlor, Chlorolane, Endosulfan, Chlordecone
(c) Gammabenzene hexachloride (Gammexane); and
(d) Toxaphene and related compounds.</p>
<p>All these compounds persist in the environment and can accumulate in the body tissues.
II Carbamate insecticides: Carbaryl, Dimetan, Pyrolan, Zectran and Carbofuran.
III Organophosphorus compounds: Malathion, Parathion, TEPP, and Diazinon (Chapter 19).</p>
<p>IV Botanical compounds: Pyrethrum, Limonoids and Rotenone.
I Organochlorines:
CHLOROPHENOTHANE (DDT, Dicophane), chemically dichloro-diphenyl-trichloroethane, (Fig 62.2) occurs as a white powder, practically insoluble in water but slightly soluble in alcohol and kerosene. It was the first highly effective and relatively safe insecticide discovered by Muller who was awarded the Nobel prize in Medicine in 1948.
<img src="assets/images/image-20251214-e4391bcd.jpeg" alt="img-29.jpeg"></p>
<p>FIG. 62.2 Dicophane (DDT)
DDT is lethal to many arthropods including fleas, body lice, houseflies and mosquitoes. It is absorbed through both the chitinous exoskeleton and the GI tract of the insect and thus acts as a stomach and contact poison. It causes titanic convulsions and paralyses the CNS.</p>
<p>DDT, because of its low volatility, retains its insecticidal action for a long time (residual effect). The agent does not have an immediate lethal effect like pyrethrum and rotenone, but these may be combined to advantage with DDT.</p>
<p>Absorption, fate and excretion: DDT is slowly and incompletely absorbed from the GI tract of man and other large animals. Although it does not penetrate the intact skin in powder form, when dissolved in the various organic solvents, appreciable percutaneous absorption can occur. Absorption may also occur through accidental inhalation in workers engaged in spraying the insecticide and in animals consuming the fodder dusted with DDT. Slow poisoning can occur due to consumption of animal milk/meat containing DDT.</p>
<p>Following absorption, large amounts of DDT are stored in body fat depots and in the liver. The drug is excreted unchanged in milk to some extent but most of it is slowly degraded in the tissues and the products eliminated in urine.</p>
<p>DDT stimulates the hepatic microsomal enzyme systems and this may enhance the biotransformation of drugs like barbiturates.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute poisoning: This is characterised by vomiting, diarrhoea, paraesthesiae, giddiness and fatigue followed by tremors, convulsions and coma; associated solvents like kerosene can cause pulmonary edema. Death occurs from respiratory arrest or from ventricular fibrillation as DDT sensitises the myocardium to adrenaline. The human lethal dose of the insecticide is estimated to be between 10 and 20 g .
Treatment of acute poisoning is symptomatic and includes gastric lavage, saline purgation, diazepam for the treatment of convulsions, artificial respiration and oxygen. Treatment has to be continued for many days in view of the possible drug storage. Milk, oily substances and sympathomimetic amines should be avoided. Workers engaged in spraying the insecticide should wear protective clothing and face masks.</li>
<li>Chronic poisoning: Early symptoms of chronic poisoning are loss of appetite, muscular weakness, fine tremors and mental apprehension. Rarely, it may cause motor neurone disease. Occasionally, anemia, leucocytosis, liver and kidney damage may develop. It has been shown to be carcinogenic in animals (bladder cancer).
Uses: DDT is useful for eliminating fleas, bugs, mosquitoes, cockroaches and body lice. For this purpose, a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> mixture of DDT with a suitable inert diluent like talc is employed. However, bugs and headlice have become resistant in many countries. Further, it is not ovicidal. The walls and furniture can be sprayed with a solution of DDT in kerosene; about 100 mg per square feet usually ensure effective control for about 6 weeks.</li>
</ul>
<p>DDT was widely used as pesticide in agriculture and in horticulture ( 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> aqueous suspension or a 5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> dust). However, its value as an insecticide has diminished considerably due to the development of resistance in many strains of insect species. Further, its storage in the body, its possible long term neurotoxicity and its carcinogenicity are a matter of great concern which has lead to a decrease in its use.</p>
<p>ENDRIN AND DIELDRIN: These compounds are more toxic than DDT particularly to fish and birds. Endrin is 2 to 3 times more toxic than dieldrin. These agents are employed for residual spraying, usually as 0.6 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.2%</span></span></span></span></span> suspension for similar purpose as DDT.</p>
<p>GAMMA BENZENE HEXACHLORIDE (Gammaxane): Chapter 71.
All organochlorine insecticides are CNS stimulants and can cause convulsions. As they are lipid soluble, they tend to concentrate in the tissues and have prolonged <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> They may also undergo enterohepatic circulation. Endosulfan ingestion causes prolonged convulsions, disseminated intravenous coagulation and myoglobinuria. Its treatment is mainly symptomatic: gastric lavage, activated charcoal and anticonvulsants like benzodiazepines. The patient may return after discharge for repeat convulsions a few days later, due to release of the compound from deposits in the fat.
II Carbamate insecticides: These agents act as acetylcholinesterase inhibitors and cause actions similar to the organophosphorus compounds (see below). However, they have shorter duration of action and larger margin of safety. They are considered as nonpersistent insecticides. (Chapter 19).
III Organophosphorus insecticides: The organophosphorus compounds such as malathion, chlorpyrifos and fenitrothion are effective against a variety of arthropods like lice, flies and mosquitoes. They cause irreversible cholinesterase inhibition. They act</p>
<p>against both the larvae and the adult insects and are widely used as agricultural and horticultural pesticides (For toxicity and treatment, see Chapter 19).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-botanical-compounds">IV Botanical compounds:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-botanical-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PYRETHRUM FLOWERS: These are the dried flower heads of Chrysanthemum cineratiaefolium. They owe their insecticidal activity to the two esters, pyrethrin 1 and pyrethrin ll. Pyrethrum flowers are mainly used in the form of an extract and are superior to DDT in being rapidly lethal to the insects.</p>
<p>Pyrethrum acts mainly by contact and has no appreciable effect on ingestion. It is neurotoxic and mainly affects the CNS of the insect.</p>
<p>It has relatively low human toxicity. Excessive ingestion, however, may cause initial stimulation of the CNS followed by paralysis. The agent also produces contact dermatitis.</p>
<p>Pyrethrum is usually sprayed as solutions containing 0.4 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.6%</span></span></span></span></span> of total pyrethrins. Its applications are similar to those of DDT.</p>
<p>PYRETHROIDS: Synthetic pyrethroids include allethrin, resmethrin, tetramethrin and permethrin. They are chemically related to natural pyrethrins and are esters of certain acids (e.g., chrysanthenic acid) and alcohols (e.g., allethrolone).</p>
<p>They serve as neuropoisons by acting on sodium channels in the axons in the peripheral and CNS. A single dose produces toxic signs, such as tremors, hyperexcitability, choreoathetosis, convulsions and paralysis in mammals. In small doses, the action is reversible but at near-lethal doses, they cause structural changes in the nervous system, such as axonal swelling and/or breaks and myelin degeneration. Such neurotoxicity is especially liable to occur in children.</p>
<p>Pyrethrum is absorbed following ingestion or inhalation but not significantly from the skin. Hence, when they are being heated they should be kept away from infants and children. Further, mats/coils containing pyrethroids, when heated, may cause irritation of the eyes, nose, throat and suffocation.</p>
<p>They are generally metabolised through ester hydrolysis, oxidation and conjugation and there is no tendency to accumulate in tissues.</p>
<p>In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. They are adsorbed on soil and sediments and hardly eluted with water. There is little tendency for bioaccumulation in organisms. Because of low application rates and rapid degradation in the environment, residue in food is generally low. For similar reasons, in the dose levels used as insecticides, no serious adverse effects have been noticed in fish, aquatic arthropods and honey bees.</p>
<p>Uses: Because of their excellent activity against a wide range of insect pests and their non-persistence in the environment, they are now extensively used as</p>
<ul>
<li>Agricultural insecticides and for control of household insects.</li>
<li>Ovicidal and pediculocidal agent as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream-rinse permethrin preparation, for 10 min local application. A single application eliminates head-lice infestation.</li>
<li>Scabicidal agent applied as 5% permethrin dermal cream (Chapter 71).</li>
</ul>
<p>LIMONOIDS: Limonoids are derived from the ancient Indian plant, neem (Azadirachta indica). Several biological active compounds have been isolated from the oil, seeds, bark and leaves of neem. Neem oil or neem leaves have been used for centuries by households and farmers in India to protect the foodgrains.</p>
<p>The limonoid azadirachtin and other similar compounds are highly effective in minute</p>
<p>quantities against a variety of insects. Since neem is a collection of active ingredients the development of resistance by insects is probably difficult. They appear to be harmless to humans and to useful insects such as honey-bees. Unlike the modern chemical insecticides, azadirachtin is not an instant killer but is a growth inhibitor, anti-feedant and repellant. Its biodegradability is an additional advantage. Neem oil is also claimed to possess spermicidal and antibacterial properties. A number of neem based pesticides are now available.</p>
<p>ROTENONE: Rotenone is the principal active insecticidal constituent of Derris or Tuba root. Rotenone is a stomach and contact insecticide. Its action is more rapid but less persistent than that of DDT and less rapid but more persistent than that of the pyrethrum.</p>
<p>Rotenone may cause GI irritation, conjunctivitis, pharyngitis and rarely, respiratory stimulation and convulsions. It is used either as a dusting powder diluted with talc or as an insecticidal wash.</p>
<p>For insect repellents see Chapter 56.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xiii">SECTION XIII<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xiii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs Used in Endocrine Disorders</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xiii-drugs-used-in-endocrine-disorders">SECTION XIII Drugs Used in Endocrine Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xiii-drugs-used-in-endocrine-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 63: Anterior Pituitary Hormones
Chapter 64: Thyroid Hormones and Antithyroid Drugs
Chapter 65: Pancreatic Hormones, Antidiabetic Drugs and Pharmacotherapy of Diabetes Mellitus
Chapter 66: Adrenal Cortical Steroids
Chapter 67: Gonadotropins, Estrogens and Progestins
Chapter 68: Antifertility Agents and Ovulation Inducing Drugs
Chapter 69: Androgens, Anabolic Steroids and Antiandrogens
Chapter 70: Calcium, Phosphorus, Fluoride and Magnesium Metabolism; Parathyroid Hormone and Vitamin D; Treatment of Osteoporosis</p>
<p>63</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anterior-pituitary-hormones">Anterior Pituitary Hormones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anterior-pituitary-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The important functions of growth, self preservation (homeostasis) and species preservation (reproduction) in a multicellular organism demand the highest degree of integration of the various body systems and adaptation to external environment. This integration is brought about by the 'neuroendocrine complex' consisting of the CNS, the ANS and the endocrine glands. The endocrine glands and the ANS serve to carry messages from the highest integrating authority, the CNS, to the body organs and cells. In turn, the ANS and the endocrine glands influence the functioning of the CNS. Finally, there is 'cross talk' between the endocrine system and the cells of the immune system. Thus, the glucocorticoids are potent immunosuppressants, whereas cytokines and interleukins exert profound effects on the functions of the various endocrine glands.</p>
<p>The introduction of the radioimmunoassay technique for measuring hormones in biological fluids, by Berson and Yallow in 1960, stimulated the research in endocrine physiology and revolutionised the diagnosis of endocrine disorders.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="endocrine-physiology-introduction">Endocrine Physiology-Introduction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#endocrine-physiology-introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The word hormone is derived from the Greek word Hormao which means 'to impel'. It is defined as a substance secreted by specialised cells and transported to a distant site to exert its action upon specific tissues.</p>
<p>The endocrine glands consist of groups of highly specialised cells located at various sites in the body. They synthesise and discharge their specialised secretions (hormones) directly into the circulation without the intervention of a duct (hence the name 'ductless' glands).</p>
<p>Hormones are secreted by well organised endocrine glands such as the thyroid and the adrenals, and by not so well organised endocrine cells in the GI tract which secrete gastrin, secretin, pancreozymin, ghrelin and cholecystokinin (gut hormones). Kidneys secrete renin and erythropoietin. 1,25 dihydroxycholecalciferol, the active metabolite of vitamin D synthesised by the kidney, also qualifies as a hormone. The heart is the major source of atrial natriuretic peptide (ANP).</p>
<p>Generally, a hormone is stored in the same gland which synthesises it. The hormones of the neurohypophysis, vasopressin and oxytocin, are, however, synthesised in the hypothalamus but are stored in the neurohypophysis. The hypothalamic regulatory hormones are synthesised in various areas of the hypothalamus but are stored in the median eminence.</p>
<p>The hormones of the endocrine glands can be grouped into five major classes:</p>
<ul>
<li>Amino acid derivatives e.g. Catecholamines, Dopamine and Thyroid hormones.</li>
<li>Peptides e.g. Hypothalamic regulatory hormones (TRH, GnRH, GHRH, CRH and others), Somatostatin and Vasopressin.</li>
<li>Proteins e.g. Insulin, GH and PTH.</li>
<li>Steroids e.g. Adrenocortical and Gonadal steroids.</li>
<li>Vitamin derived e.g. Vitamin D derivatives and Retinoids.</li>
</ul>
<p>A hormone may act:</p>
<ul>
<li>On other endocrine glands e.g. hypothalamic regulatory (releasing and release inhibiting) hormones; and trophic hormones of the anterior pituitary; or</li>
<li>Directly on the target tissues e.g. insulin, growth hormone (GH), prolactin (PRL), parathyroid hormone (PTH), and hormones of the adrenals and gonads.
Regulation and release of a hormone: A hormone is directly released into venous blood, generally in discrete pulses, at a slow basal rate, which in the case of many hormones, shows a natural diurnal rhythm. It is important to remember the pulsatile nature and rhythmic pattern of hormone production while interpreting their plasma levels. There are many factors which either increase or decrease the hormonal synthesis and secretion: (a) Various releasing and release-inhibiting hormones of the hypothalamus act on the anterior pituitary to modify the synthesis and release of its trophic hormones. They have an intrinsic diurnal rhythm. (Fig 63.1)</li>
</ul>
<p><img src="assets/images/image-20251214-56355fe5.jpeg" alt="img-30.jpeg"></p>
<p>FIG. 63.1 Hormone release and feedback mechanisms. AP = Anterior pituitary,- dotted lines indicate negative feedback
(b) Hormones of the anterior pituitary stimulate synthesis and release of hormones of the target glands - thyroid, adrenal cortex and gonads (feed forward regulation). In the absence of the former, the target glands cease functioning and undergo atrophy. Hence, these hormones are called trophic hormones. Elevated plasma concentrations of hormones produced by the target glands act on the hypothalamus to alter the rate of release of regulatory hormones and on the pituitary to reduce its responsiveness to the latter, and thus reduce the secretion of the respective trophic hormones viz. - TSH, ACTH, FSH, LH (feedback regulation). On the other hand, a fall in the plasma concentration of a target gland hormone leads to a greater release of the corresponding trophic hormone. Thus, in health, any change in the plasma concentration of a target gland hormone tends to correct itself by altering the anterior pituitary function. This mechanism of mutual regulation of hormone level helps to maintain the plasma concentration of the hormones within a delicately balanced narrow range. (Fig 63.1)
(c) The release of a hormone may also be influenced by changes in the concentration of non-hormonal chemical substances in the plasma. For example, hyperglycemia stimulates the release of insulin but suppresses the release of GH; hypoglycemia has the opposite effects. A decrease in the level of plasma calcium stimulates the release of PTH but suppresses that of calcitonin; an increase in plasma calcium has the opposite effect. (d) Besides the classical feedback, local regulatory systems also control hormonal secretion. Thus, - Paracrine regulation involves the release of a hormone by one type of cells that acts on adjacent cells in the same tissue e.g. somatostatin from the pancreatic islet D cells inhibits insulin secretion by the beta cells.</p>
<ul>
<li>Autocrine regulation involves the action of a hormone on the same cells that produce it e.g. insulin-like growth factor 1 (IGF 1) acts on many cells that produce it, including</li>
</ul>
<p>chondrocytes, gonadal cells and breast epithelial cells.
(e) Psychoneurogenic factors can alter the rate of secretion of hormones e.g. depression may inhibit gonadotropin secretion; acute stress increases the release of catecholamines from the adrenal medulla and cortisol from the adrenal cortex.
(f) Increased plasma level of GH is to be found in patients with malnutrition, anorexia nervosa and dwarfism due to end organ resistance to GH. In acromegaly, it is due to the activity of the pituitary tumour cells.</p>
<p>Role of hypothalamus: The hypothalamus synthesises and releases several chemical substances which reach the pituitary either along neurons (vasopressin and oxytocin) or via the portal circulation. Those which are of known chemical structure and are available as synthetic substances are called 'hormones'; others are called 'factors'. As a group, they are called hypothalamic regulatory hormones (Table 63.1). They are synthesised in the hypothalamus, and are stored in the median eminence. In response to appropriate stimuli, they are released into the portal circulation and travel to the anterior pituitary to exert their releasing or release-inhibiting actions on the trophic hormone producing cells.</p>
<p>Table 63.1
Hypothalamic regulatory hormones for pituitary hormones</p>
<table><thead><tr><th style="text-align: left;">Releasing hormone (RH) or factor (RF) for:</th></tr></thead><tbody><tr><td style="text-align: left;">- Thyrotrophin: TRH</td></tr><tr><td style="text-align: left;">- Luteinising hormone and follicular stimulating hormone: LH/FSHRH or GnRH</td></tr><tr><td style="text-align: left;">- Growth hormone: GHRH</td></tr><tr><td style="text-align: left;">- Corticotrophin: CRH</td></tr><tr><td style="text-align: left;">- Melanocyte stimulating hormone: MSH-RF</td></tr><tr><td style="text-align: left;">Release inhibiting hormone (RIH) or factor (RIF) for:</td></tr><tr><td style="text-align: left;">- Growth hormone: GH-RIH, Somatostatin</td></tr><tr><td style="text-align: left;">- Melanocyte stimulating hormone: MSH-RIF</td></tr><tr><td style="text-align: left;">- Prolactin: PIF-dopamine</td></tr></tbody></table>
<p>The hypothalamic releasing hormones and factors are released in nanograms or smaller quantities. They cause the synthesis and release of much larger, microgram quantities of pituitary trophic hormones. In turn, the trophic hormones cause synthesis and release of still larger, milligram quantities of target gland hormones. This can then be considered as a 'cascading amplifier' system of greatly multiplying the original hypothalamic signals. For posterior pituitary hormones, vasopressin and oxytocin see Chapters 39 and 44, respectively.</p>
<p>The hypothalamic neurons which secrete the regulatory hormones are themselves under the control of specialised monoaminergic, neurotransmitter neurons in the midbrain. Thus,</p>
<ul>
<li>Dopamine is concerned in the release of GH and inhibition of release of PRL.</li>
<li>Noradrenaline is concerned in the release of GH, TSH, and gonadotrophins.</li>
<li>Serotonin (5-HT) is concerned in the release of GH and PRL and inhibition of TSH release.
In turn, these midbrain nuclei are under the control of the 'visceral brain' and are responsive to stress and emotional disturbances. The pituitary secretion of some hormones (GH, ACTH and PRL) is primarily regulated (via hypothalamus) by intrinsic brain rhythms related to sleep-wake cycle or to change to lighting conditions rather than by any specific homeostatic requirements.</li>
</ul>
<p>The release of one pituitary hormone may be governed by different bioaminergic mechanisms under different circumstances e.g. it appears that sleep induced GH release is 5-HT mediated whereas hypoglycemia-mediated GH release is mediated by noradrenaline. Growth hormone and prolactin secretion appears to be controlled by the CNS itself while that of ACTH, TSH and gonadotrophins is regulated by complex feedback mechanisms.</p>
<p>Certain drugs (reserpine, chlorpromazine, 1-dopa, amphetamine, imipramine, bromergocriptine) act on the hypothalamus and influence the local monoamine concentration and thus, bring about alterations in the secretion of anterior pituitary hormones particularly prolactin. Thus, the hypothalamus can be regarded as the highest relay centre which integrates the endocrine and the ANS and ensures their smooth coordination by the cerebral cortex.</p>
<p>TRH, somatostatin and gut hormone containing neurons are widely distributed in the CNS outside the hypothalamus. Their exact role is not clear.</p>
<p>Transport and metabolism of hormones: The hormones are carried in the plasma partly protein bound and partly free. The free form is the active form. The bound form, though inactive, acts as a reservoir, releasing more free hormone as it is degraded.</p>
<p>The metabolic degradation of free hormones occurs in the liver, in the target endocrine glands and in the tissues on which they act. Conjugation of steroid hormones to sulfates and glucuronides occurs in the liver. Generally, metabolic degradation renders the hormone less active or inactive. With some hormones, however, metabolic transformation (e.g. thyroxine to tri-iodothyronine) renders the hormone biologically active. The kidney excretes conjugated steroid hormone and a trace of the free hormone.</p>
<p>Knowledge of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of the circulating hormones helps to establish effective, physiological, hormonal replacement therapy as the time required to achieve a steady state plasma level is generally related to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of the hormone(s). Most protein hormones such as insulin, ACTH and GH have very short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (minutes), whereas the steroids and the thyroid hormones have longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (hours to days).</p>
<p>The responses of body cells to hormones are considerably influenced by genetic as well as environmental factors. Important among these are species, race, age, sex, time of the day, season, temperature, nutrition, presence of disease and prior effect of other hormones.</p>
<p>The important differences between the peptide hormones and the steroid hormones are shown in Table 63.2. In general, catecholamines behave like the peptide hormones and the iodothyronines (with important differences) behave like the steroid hormones.</p>
<p>Table 63.2
Important differences between peptide and steroid hormones</p>
<table><thead><tr><th style="text-align: left;">Parameter</th><th style="text-align: left;">Steroids</th><th style="text-align: left;">Peptides</th></tr></thead><tbody><tr><td style="text-align: left;">Biosynthesis</td><td style="text-align: left;">Multiple enzymes</td><td style="text-align: left;">Single protein, prohormone</td></tr><tr><td style="text-align: left;">Storage in the gland</td><td style="text-align: left;">Minimal</td><td style="text-align: left;">Often substantial</td></tr><tr><td style="text-align: left;">Half life</td><td style="text-align: left;">Long (hours)</td><td style="text-align: left;">Short (minutes)</td></tr><tr><td style="text-align: left;">Binding proteins</td><td style="text-align: left;">Present</td><td style="text-align: left;">Less common</td></tr><tr><td style="text-align: left;">Peripheral transformations</td><td style="text-align: left;">Common</td><td style="text-align: left;">Do not occur</td></tr><tr><td style="text-align: left;">Initial binding site</td><td style="text-align: left;">Cytoplasmic receptor</td><td style="text-align: left;">Plasma membrane receptors</td></tr><tr><td style="text-align: left;">Principal site of action</td><td style="text-align: left;">Nucleus</td><td style="text-align: left;">Plasma membrane</td></tr><tr><td style="text-align: left;">Principal mechanism of action</td><td style="text-align: left;">Activation of genome</td><td style="text-align: left;">Activation of second messenger</td></tr><tr><td style="text-align: left;">Degradation products</td><td style="text-align: left;">Sometimes retain activity</td><td style="text-align: left;">Inactive</td></tr><tr><td style="text-align: left;">Administration</td><td style="text-align: left;">Oral, parenteral</td><td style="text-align: left;">Parenteral</td></tr><tr><td style="text-align: left;">Allergy</td><td style="text-align: left;">No</td><td style="text-align: left;">Yes</td></tr></tbody></table>
<p>Mechanism of action of hormones: Hormones act through specific receptors which may be divided into two major classes according to their specificity for hormone binding site: (1) Cell membrane receptors; and
(2) Nuclear receptors.</p>
<p>Generally, amino acid derivatives and peptide hormones interact with cell-surfacemembrane receptors; whereas steroidal and thyroidal hormones, vitamin D and its derivatives, and retinoids, which are lipid soluble, interact with nuclear receptors (Table 63.3). All receptors finally act to increase or decrease gene transcription.</p>
<p>Table 63.3
Different types of hormone receptors</p>
<table><thead><tr><th style="text-align: left;">Receptor type</th><th style="text-align: left;">Hormones</th></tr></thead><tbody><tr><td style="text-align: left;">Membrane receptors</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">(a) GPCR</td><td style="text-align: left;">Catecholamines, LH, FSH, TSH, ACTH, hypothalamic releasing factors, somatostatin</td></tr><tr><td style="text-align: left;">(b) Tyrosine kinases</td><td style="text-align: left;">Insulin, insulin-like growth factors, epidermal growth factor</td></tr><tr><td style="text-align: left;">(c) Cytokine regulated kinases</td><td style="text-align: left;">GH, PRL</td></tr><tr><td style="text-align: left;">(d) Serine kinases</td><td style="text-align: left;">Activin, transforming growth factor</td></tr><tr><td style="text-align: left;">Nuclear receptors</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">(a) Type Iin cytoplasm <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{ }</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.363em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.363em;"><span style="top: -2.363em; margin-right: 0.05em;"><span class="pstrut" style="height: 2em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Steroids e.g., glucocorticoids, estrogens, progesterone</td></tr><tr><td style="text-align: left;">(b) Type Ihin nucleus</td><td style="text-align: left;">Thyroid hormones, vitamin D, retinoids</td></tr></tbody></table>
<p>*All nuclear receptors ultimately act to increase or decrease gene transcription.
"After ligand binding, the ligand-cytoplasmic-receptor complex translocates to the nucleus.
The glycoprotein hormones TSH, FSH, LH and hCG consist of two subunits alpha and beta. The alpha subunit is common to all of them whereas the beta subunit of each one of them is distinctive and is responsible for its specific biological action. Structural similarities also exist between insulin and insulin-like growth factors, IGF I and IGF II. Such similarities among the hormones explain the overlapping actions of related hormones.</p>
<p>A persistent increase in the concentration of a hormone brings about a reduction in the concentration of its specific receptors (down regulation). A hormone may bind to more than one class of receptors e.g. insulin at high concentrations binds to somatomedin receptors and can have growth stimulating actions. Several clinical syndromes are due to mutational abnormalities in the receptors, e.g., GH resistance, resistance to thyroid hormones.</p>
<p>Hormones as drugs: Hormones and their analogues, prepared synthetically, are now widely used as drugs. Synthetic analogues have the following advantage(s):
(1) Abundant availability and are relatively cheap e.g. prednisolone, thyroxine;
(2) Improved bioavailability because of resistance to metabolic degradation;
(3) Longer or shorter duration of action as desired e.g. rDNA analogues of human insulin;
(4) Greater specificity because of elimination of trace contaminants e.g. rDNA-FSH. Hormones are used:</p>
<ul>
<li>For diagnostic purposes e.g. ACTH is used to diagnose Addison's disease, and dexamethasone to diagnose Cushing's disease. Rarely, they may be used for a therapeutic trial to confirm or refute a diagnosis when the laboratory tests are equivocal e.g. hypothyroidism.</li>
<li>For therapeutic purposes, either (a) as replacement therapy to supplement or replace a deficient natural hormone e.g. thyroxine in hypothyroidism; or (b) as pharmacotherapy</li>
</ul>
<p>e.g. glucocorticoids in asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-pituitary-gland">The Pituitary Gland<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-pituitary-gland" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The pituitary gland, together with the hypothalamus, forms a neuroendocrine relay station for messages from the brain to the rest of the body. It consists of adenohypophysis developed from the oropharynx and neurohypophysis developed from the floor of the third ventricle. The former consists of the anterior lobe, the pars tuberalis and the pars intermedia. The neurohypophysis consists of the posterior lobe and the infundibular stalk which connects it to the hypothalamus.</p>
<p>The pituitary gland has a rich arterial blood supply and also has a 'portal system' which connects it with the median eminence of the hypothalamus. The latter transmits the hypothalamic regulatory hormones to the pituitary via the portal system.</p>
<p>The anterior lobe of the pituitary contains three types of cells:</p>
<ul>
<li>Chromophobe,</li>
<li>Eosinophil; and</li>
<li>Basophil.</li>
</ul>
<p>Six adenohypophyseal hormones have been definitely identified (Table 63.4). These are GH and PRL (eosinophil cells); and ACTH, TSH, FSH, LH (basophil cells). Of these ACTH, prolactin and GH are peptides and TSH, LH and FSH are glycoproteins. The melanocyte stimulating hormone (MSH) exists in the pars intermedia of the anterior pituitary. Vasopressin and oxytocin are present in the neurohypophysis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-63-4">Table 63.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-63-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hormones of the anterior pituitary</p>
<table><thead><tr><th style="text-align: center;">Pituitary cell</th><th style="text-align: center;">Hormone produced</th><th style="text-align: center;">Stimulators</th><th style="text-align: center;">Inhibitors</th><th style="text-align: center;">Target gland</th><th style="text-align: center;">Biologic effects</th></tr></thead><tbody><tr><td style="text-align: center;">Somatotrope</td><td style="text-align: center;">GH</td><td style="text-align: center;">GHRH</td><td style="text-align: center;">Somatostatin, IGF 1</td><td style="text-align: center;">Liver, bone, muscles and other tissues</td><td style="text-align: center;">Growth promotion, IGF 1 production, insulin antagonism</td></tr><tr><td style="text-align: center;">Corticotrope</td><td style="text-align: center;">ACTH</td><td style="text-align: center;">CRF, AVP</td><td style="text-align: center;">Glucocorticoids</td><td style="text-align: center;">Adrenal cortex</td><td style="text-align: center;">Glucocorticoid production</td></tr><tr><td style="text-align: center;">Thyrotrope</td><td style="text-align: center;">TSH</td><td style="text-align: center;">TRH</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} \mathrm{T}_{\mathrm{H}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Dopamine, Glucocorticoids</td><td style="text-align: center;">Thyroid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} \mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis and release</td></tr><tr><td style="text-align: center;">Gonadotrope</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">H</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{FSH}^{\prime}, \mathrm{LH}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0196em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">FSH</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8251em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LH</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8251em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">GnRH,</td><td style="text-align: center;">Sex steroids, Inhibin</td><td style="text-align: center;">Testes, ovaries</td><td style="text-align: center;">Sex steroid production, follicular growth, germ cell maturation</td></tr><tr><td style="text-align: center;">Lactotrope</td><td style="text-align: center;">PRL</td><td style="text-align: center;">Estrogen, &lt;br&gt; TRH</td><td style="text-align: center;">Dopamine</td><td style="text-align: center;">Breast, other tissues</td><td style="text-align: center;">Milk production, metabolic effects</td></tr></tbody></table>
<p>AVP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Arginine vasopressin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Glycoproteins
The various tropic hormones are described in detail along with the respective target gland hormones elsewhere.</p>
<p>Effects of hypopituitarism: Manifestations of hypopituitarism depend upon the age of the subject.</p>
<ul>
<li>In children: Retardation of linear growth and of bone age are the two important effects of GH deficiency (GHD). They are due to IGF1 deficiency secondary to GH deficiency. These children appear normal at birth. As they grow, the deviation from normal height becomes more and more marked. They are small but intelligent, delicate and graceful. When GHD occurs as a part of panhypopituitarism, the associated deficiencies of ACTH</li>
</ul>
<p>and TSH make the clinical diagnosis easier. Panhypopituitarism may be idiopathic or may be due to destruction of the anterior pituitary by a granuloma or a tumour. Selective GHD is generally idiopathic and often genetic in origin. In some cases, manifestations of GHD are due to GH resistance in the peripheral target tissues as in undernutrition.</p>
<ul>
<li>In adults: Panhypopituitarism may be produced by destruction of the pituitary by a pituitary tumour, therapeutic hypophysectomy (for pituitary tumour) or postpartum pituitary necrosis (Sheehan's syndrome). It may also be due to continuation of childhood panhypopituitarism into adult life.
The clinical manifestations are due to deficiency of:
(a) Gonadotropins, such as infertility, impotence, amenorrhoea and total loss of sexual hair. (b) TSH, giving rise to hypothyroidism.
(c) ACTH, causing hypotension and fasting hypoglycemia; pigmentation of Addison's disease is not seen, and aldosterone production is relatively unaffected; and
(d) GH: These can be subtle and comprise fatigue, lethargy, and impaired physical performance, accompanied by reduction in muscle and bone mass, increased adiposity and increased cardiovascular mortality, emotional lability and feelings of social isolation.</li>
</ul>
<p>Treatment with human growth hormone (hGH) reverses many of these manifestations.
The patients become moderately plump but not obese.
Effects of hyperpituitarism: Excessive production of anterior pituitary hormones may occur in the presence of anatomically demonstrable pituitary disease or its absence. Such excessive production is associated with gigantism, acromegaly, one form of Cushing's syndrome, the galactorrhoea-amenorrhoea syndrome and rarely, hyperthyroidism. Excessive production of the anterior pituitary hormones (TSH, ACTH and Gonadotropins) also occurs in response to failure of function of the respective target glands.</p>
<p>High levels of plasma GH are seen in acromegaly. GH resistance, uncontrolled diabetes mellitus, anorexia nervosa and protein calorie malnutrition. In some cases, such excess of pituitary hormone may give rise to important clinical features e.g. pigmentation of Addison's disease, probably due to excess of ACTH.</p>
<p>GROWTH HORMONE (GH): A growth hormone is found in all vertebrates. In addition to its growth-promoting properties, it possesses several important metabolic effects which are essential for health.</p>
<p>Source and chemistry: It is synthesised and stored by the (eosinophil) somatotrophic cells of the adenohypophysis. It is present at all ages. Human growth hormone (hGH) is a polypeptide consisting of a series of 191 amino acids and has been synthesised. About 5-15 mg of hGH can be obtained from one anterior pituitary gland. It is now obtained by recombinant DNA technique.</p>
<p>The growth promoting effect of GH appears to be species specific. Thus, human being responds only to human GH.</p>
<p>Plasma levels and regulation of GH secretion: Plasma level of hGH is undetectable between GH pulses in an adult. It rises (as high as 25 ng per ml or higher) several times in spikes during the day, mostly during exercise, deep sleep (especially in children), and several hours after a meal. These spikes are higher in women than in men and can be distinguished from pathological increases in plasma GH levels by their suppression after glucose administration. Stimulated by the sex steroids, especially estrogen, GH levels rise during puberty.</p>
<p>GH secretion is profoundly influenced by nutritional factors and is stimulated by high protein diet.</p>
<p>Hypoglycemia is the most consistent stimulus to GH secretion and insulin-induced hypoglycemia is the gold standard for diagnosis of GHD. GH responsiveness to insulin hypoglycemia is depressed in obesity, hypopituitarism, hypothyroidism, chronic alcoholism and in individuals on glucocorticoid therapy. Clonidine, levodopa and arginine are the other stimuli to GH release.</p>
<p>The rate of release of GH by the pituitary is regulated by GH-RH and somatostatin (GHRIH). It is stimulated by ghrelin, a polypeptide, synthesised by the stomach. Ghrelin also causes increase in appetite and obesity. A substantial part of this occurs during the early hours of sleep and is probably important in the anabolic and repair processes of the body.</p>
<p>Pharmacological actions: Endogenous GH circulates in the blood with a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 20 minutes, though its metabolic effects last much longer. It exerts:
(I) Metabolic effects including lipolysis and neoglucogenesis, directly, by acting on the tissue GH receptors which are widely distributed in the body; and
(II) Growth related effects, predominantly indirectly, through IGF-1; most of which is generated in the liver.
I Metabolic effects:</p>
<ul>
<li>Carbohydrate metabolism: Effects on carbohydrate metabolism are complex. Plasma levels of glucose and insulin do not change during the diurnal peaks of hGH but after such peaks, the individual becomes resistant to insulin, and glucose tolerance is slightly and transiently impaired. Acute administration of hGH to normal subjects and to nondiabetic, hypo-physectomised individuals causes transient hypoglycemia. On the other hand, during chronic administration, it impairs glucose tolerance. Hypophysectomy ameliorates diabetic retinopathy; individuals so treated are prone to hypoglycemia.</li>
<li>Protein metabolism: GH has a strong anabolic action. It stimulates the transport of amino acids into the cells and accelerates intracellular protein synthesis. Retention of nitrogen, phosphate and potassium occurs. Blood urea falls and urinary excretion of hydroxypro-line rises indicating increase in muscle mass and collagen synthesis.</li>
<li>Fat metabolism: Acute administration cause a rise in the fasting plasma free fatty acid (FFA) level due to the lipolytic action of GH. Intracellular accumulation of FFA also occurs. In addition, during chronic administration, it inhibits lipogenesis from glucose and acetate. The FFA thus released are utilised by the tissues.
Under physiological conditions in which GH is secreted without concomitant release of catecholamines, as during sleep, there is little change in plasma fatty acids. GH may, therefore, be of minor importance in lipolysis in man (Chapter 65).</li>
<li>Mineral metabolism: It causes retention of potassium, sodium and phosphorus. Calcium absorption is increased. The hypercalciuric action of GH is not seen in the absence of endogenous parathyroid hormone activity.
II Growth-related effects: Growth is mediated mainly by the indirect action through IGF-1 and to a smaller extent by the direct actions of GH ; the former being the main mediator. Seventyfive percent of the circulating IGF-1 is synthesised by the liver in response to GH. It acts on specific IGF-1 receptors and produces widespread effects. The rest comes from the spill-over of that produced for paracrine action by numerous tissues (bone, cartilage, erythroid precursors, myocytes and kidneys). Unlike most other protein hormones, IGF-1</li>
</ul>
<p>circulates in the blood, bound to IGF binding proteins (IGFBPs 1 to 5), which act as carriers. The basic actions of IGF-1 are:</p>
<ul>
<li>Positive nitrogen and mineral balance; and synthesis and accretion of protein in most tissues; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cellular-proliferation">- Cellular proliferation.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cellular-proliferation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They are responsible for generalised, coordinated and balanced linear growth in childhood; and unbalanced, local growth such as wound healing at all ages and growth of the contralateral kidney after unilateral nephrectomy in childhood.</p>
<p>The other actions of IGF-1 are:</p>
<ul>
<li>Rise in GFR (25%)</li>
<li>Hypoglycemia if sufficient amount is given.</li>
<li>Marked increase in insulin sensitivity in type 2 diabetics.</li>
<li>Inhibition of GH secretion; and</li>
<li>Partial reversal of the catabolic effect of nutrient deprivation and glucocorticoids.</li>
</ul>
<p>The growth due to GH affects every tissue and organ in the body with the possible exception of the brain and the eye. In children whose epiphyses have not yet closed, it promotes linear bone growth without accelerating skeletal or sexual maturation. It acts on the epiphyseal growth plate but does not accelerate epiphyseal fusion. The increase in body mass produced by GH mainly affects the lean body mass, and is due to retention of nitrogen, minerals and water but not of fat.</p>
<p>The growth promoting effect is dramatic in young children with GHD. In most of such children, the effect continues during 8-10 years of hGH therapy, although a few become refractory after some months. It is noteworthy that hGH injected at intervals of 2-3 days will promote growth, although its metabolic effects are of short duration.</p>
<ul>
<li>Miscellaneous: GH induces visceromegaly as seen in patients with acromegaly. Rats receiving GH develop a variety of tumours.
Absorption, fate and excretion: GH is administered by SC or IM route. The peak plasma level after SC administration occurs after 2-4 hours, and the active blood level persists for 36 hours. It is metabolised in the liver.</li>
</ul>
<p>Adverse reactions: Recombinant hGH is well tolerated and safe, and causes a few adverse reactions. During treatment of GH deficient children, it may cause hypothyroidism which must, therefore, be looked for. It may cause increase in blood glucose and lipid levels, especially in adults.</p>
<p>The other adverse reactions in adults, not seen in children, are edema, myalgia and arthralgia. In diabetics, it may aggravate hyperglycemia and cause ketosis. Rarely, it may cause headache, seizures and benign intracranial hypertension, particularly after surgery in patients with craniopharyngiomas. Although antibodies to GH appear in about 30% patients on GH, they are present in low titre and rarely interfere with growth stimulation.</p>
<p>Preparations and dosage: The currently available hGH is produced by recombinant DNA technology. One mg of hGH equals three units. The preparations are:
(i) Somatrem (methionyl hGH); and
(ii) Somatropin (non-methionyl hGH) A long acting, encapsulated form of somatropin for injection once or twice a month is also available.</p>
<p>Somatrem and somatropin are therapeutically equivalent. The dose in children with GHD is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mcg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, IM or SC, given daily. The therapy is started with lower dose. If</p>
<p>growth acceleration is considered inadequate at the end of the first year, larger doses may be used. SC injections are as effective as and less painful than IM injections, and can be self administered. In adults, the daily dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-4 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>GHD with short stature in children: GH administration stimulates rapid linear growth and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{~cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span></span></span></span></span> of height may be added during the first year. This rate of growth slows down from the second year onwards. Most patients continue to respond for several years. A few, however, become refractory; in some of these, the refractoriness can be explained by the development of antibodies. Unlike with anabolic steroids, the advancement of bone age is not greater than the increase in linear growth with GH. Hypothyroidism may occur during hGH therapy.</li>
<li>GH deficiency in adults. In small doses it is claimed to improve the quality of life.</li>
<li>Turner syndrome; and</li>
<li>Chronic renal failure with short stature. It has been used in idiopathic short stature with variable results. When used in children, it is generally continued till closure of epiphyses. Since GH is prohibitively expensive, its use in short stature on suspicion of GHD is not recommended.
The utility of GH in the following conditions is not proven: old age; osteoporosis; athletes; and cachexia and other catabolic states.</li>
</ul>
<p>GH therapy is contraindicated in: (a) Acute critical illness; and (b) Patients with neoplasms.</p>
<p>MECASERMIN (IGF-1): This rDNA human IGF-1, is given SC. It is metabolised in the liver and the kidney. Its actions are similar to those of GH. The common ADR is hypoglycemia, occurring in over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of subjects. Overgrowth of fat, facial bones and kidney can occur after prolonged treatment. Other ADR are similar to those of GH.</p>
<p>It is used to treat severe IGF-1 deficiency, growth failure and patients resistant to GH because of antibodies. It is not recommended for GH responsive GHD subjects. It is contraindicated in patients with closed epiphyses. It is very expensive.</p>
<p>SOMATOSTATIN (GH-RIH): Somatostatin, a peptide containing 14 amino acids, is secreted by the hypothalamus and the delta cells of the islets of Langerhans, and is also found in the gut wall. It is widely distributed in the brain.</p>
<p>It inhibits the release of GH, insulin and glucagon from pancreas, and of GI peptides. It inhibits secretion of gastric acid independently of its action on the release of gastrin. It decreases the splanchnic blood flow and thus reduces portal pressure. It has a very short plasma half-life and hence cannot be used clinically.</p>
<p>OCTREOTIDE: This longer acting analogue of somatostatin is used to control severe diarrhoea due to carcinoid syndrome and metastatic vasoactive intestinal polypeptide tumors (VIPomas), and to treat glucagonomas, malignant insulinomas and pituitary tumour causing acromegaly. It is given as IV bolus and SC. Its ADR are nausea, flatulence, abdominal discomfort and gallstones.</p>
<p>Its other uses are dumping syndrome, acute pancreatitis and esophageal variceal bleeding. A long acting preparation with action for 30 days is available. Radiolabelled octreotide is used for localisation of neuroendocrine tumours.</p>
<p>Lanreotide is a long acting analogue of oc-teotride, effective for 7-14 days.
Pasireotide is a selective centrally acting somatostatin analogue which inhibits secretion</p>
<p>of ACTH. It is effective in Cushing disease (due to pituitary origin) in patients, wherein surgery is ineffective or contraindicated.</p>
<p>Pegvisomant, a genetically altered GH antagonist, has been found to be useful in the treatment of acromegaly. It binds to GH receptor and prevents its activation thus inhibiting IGF-1 production.</p>
<p>SOMATORELIN, (GH-RH): This polypeptide with 40 amino acids acts on the somatotrophs. It is used to test the ability of the anterior pituitary to synthesise and release hGH (hGH reserve).
rDNA synthetic analogues of GH-RH, unlike similar analogues of GnRH (Chapter 67), do not cause a down regulation of their own receptors in the pituitary somatotropes. Their use in children with short stature due to idiopathic (hypothalamic), GH deficiency is under investigation.</p>
<p>SERMORELIN is a GH-RH analogue with 29 aminoacids, that has been introduced for diagnostic test for GH secretion.</p>
<p>64</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thyroid-hormones-and-antithyroid-drugs">Thyroid Hormones and Antithyroid Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thyroid-hormones-and-antithyroid-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although the thyroid gland was discovered by Wharton in 1656, the manifestations of thyroid deficiency were described by Gull in 1874. In 1895, Magnus Levy reported increased basal metabolic rate (BMR) in patients with hyperthyroidism. The isolation and crystallisation of the thyroxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> was achieved by Kendall in 1915 and its chemical structure was determined by Harrington and Barger in 1926. Tri-iodothyronine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> was detected, isolated and synthesised by Gross and Pitt-Rivers in 1952.</p>
<p>The thyroid gland acini synthesise:</p>
<ul>
<li>Thyroxine and</li>
<li>Tri-iodothyronine.</li>
</ul>
<p>The third hormone, thyrocalcitonin, is secreted by the interstitial cells (Chapter 70). Chemically, thyroxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo separator="true">,</mo><mn>5</mn><mo separator="true">,</mo><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3,5,3^{\prime}, 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span> tetra-iodothyronine (Fig. 64.1), and tri-iodothyronine (T3) is 3, 5, 3' triiodothyronine (Fig. 64.1).
<img src="assets/images/image-20251214-c72c6d1e.jpeg" alt="img-31.jpeg"></p>
<p>Synthesis of thyroid hormones: Dietary iodide is absorbed from the upper GI tract and is carried in the plasma as inorganic iodide. The thyroid hormones are synthesised as follows (Fig 64.2):</p>
<p><img src="assets/images/image-20251214-c92a07f2.jpeg" alt="img-32.jpeg"></p>
<p>FIG. 64.2 Synthesis of thyroid hormone</p>
<ul>
<li>Iodide trapping: The thyroid selectively traps the plasma iodide circulating through it, against a concentration gradient between the thyroid follicular cells and the plasma. This active process is stimulated by thyroid stimulating hormone (TSH, Thyrotropin). It is competitively inhibited by thiocyanate and perchlorate ions. The other organs which compete with thyroid for iodide are the kidneys which excrete it in urine, and to a smaller extent the salivary glands, the gastric and intestinal mucosa, the liver, the placenta and the mammary glands.</li>
<li>Organic binding of iodine: The iodide is first oxidised by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thyroid peroxidase to hypoiodate. Hypoiodate iodinates the tyrosyl residues in the thyroglobulin (TG) to form mono- and di-iodotyrosine (MIT and DIT) successively. These two reactions are extremely rapid but may be defective in certain disease states and are inhibited by thioamides. Both reactions are stimulated by TSH.</li>
<li>Coupling: Thyroxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is formed by coupling of two molecules of DIT, and triiodothyronine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> by coupling of one molecule of MIT and DIT each. The coupling reactions occur while MIT and DIT are bound by peptide bonds within the thyroglobulin molecule. They are oxidative reactions and need the same peroxidase involved in oxidation of iodide to hypoiodate. They are inhibited by thioamides.</li>
<li>Hormonal release: TG which contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, is stored within the thyroidal follicular lumen. It is resorped by the thyroid follicular cells by endocytosis. Under the influence of TSH, a protease acts on the intracellular thyroglobulin to release <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}, \mathrm{~T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">T</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, MIT and DIT.</li>
<li>Fate of hormones: MIT and DIT are deiodinated and the iodine is reutilised for iodinating globulin while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> directly enter the circulation. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">T_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> released by the thyroid is converted by peripheral tissues and also in thyroid to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">T_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>; this accounts for almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formed in the body. Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> acts not only as a hormone but also as a prohormone.
About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the body iodine is in the thyroid gland, mainly as organic iodine. This large thyroidal pool of iodine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>5</mn><mo>−</mo><mn>7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(5-7 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> turns over very slowly at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> per day.</li>
</ul>
<p>Plasma iodine: The plasma in health contains about 0.2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.4</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.4 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.4</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of inorganic iodide and 4 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of hormonal iodine per 100 ml . The hormonal iodine is made up mostly of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (4<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">13 \mu \mathrm{~g} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">13</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ) and a small quantity of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo stretchy="false">(</mo><mn>80</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo><mi mathvariant="normal">.</mi><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}(80-200 \mathrm{ng} / \mathrm{dl}) . \mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span><span class="mord">.</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> circulate in the plasma partly protein bound and partly as free hormones. The major binding protein is thyroxine binding globulin (TBG) which accounts for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of the binding capacity of the plasma. The level of TBG is influenced by estrogens and rises during pregnancy and oral contraceptive use. The mean concentration of circulating free <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.8</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.8-2 \mathrm{ng} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.03</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.03 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.03%</span></span></span></span></span> of the total plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) and of free <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mn>145</mn><mo>−</mo><mn>348</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3} 145-348 \mathrm{pg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">145</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">348</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span></span></span></span></span> of the plasma total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ). The free hormones are physiologically active. In states of iodine deficiency, the thyroid synthesises <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">T_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in preference to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">T_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Similarly, in case of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> thyrotoxicosis, plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> alone is elevated.</p>
<p>About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the thyroid hormones ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) are metabolised in the body by deiodination; the remaining <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> are excreted in stools. Although the thyroid normally forms more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the latter is the physiologically active hormone, at least as far as most tissues are concerned. The peripheral conversion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is inhibited by drugs such as propylthiouracil, glucocorticoids and propranolol; as well as during chronic (rheumatoid arthritis, tuberculosis) and acute (myocardial infarct, stroke, burns) illnesses.</p>
<p>Reverse <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">r</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}\left(\mathrm{rT}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">rT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is principally a byproduct of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> mono-deiodination in peripheral tissues. It is metabolically inactive.</p>
<p>TG present in blood originates from the thyroid gland and its serum concentration rises with thyroid damage, in thyrotoxicosis, in thyroiditis and in some cases of metastatic thyroid carcinoma.</p>
<p>Pituitary thyroid relationship: Thyrotropic hormone (TSH), a glycoprotein, is synthesised and released by the thyrotropes in the adenohypophysis under stimulation by TRH from the hypothalamus. The circulating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (and to a smaller extent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) levels modulate the response of the pituitary to TRH. TSH acts on the TSH receptors in the follicular cell membrane and accelerates synthesis and release of thyroidal hormones. Its action on the thyroid is modulated by the thyroidal organic iodine content and is mediated by adenylyl cyclase-cyclic AMP mechanism. Repeated administration of TSH in animals:</p>
<ul>
<li>Increases the weight and vascularity of the thyroid gland.</li>
<li>Reduces its colloid and iodine content; and</li>
<li>Increases the height of its acinar epithelium as seen histologically.</li>
</ul>
<p>In the absence of adenohypophysis, the thyroid gland undergoes atrophy which is reversible on administration of TSH. The plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of TSH is about 1 hour and the estimated daily secretory rate between 50 and 200 mcg .</p>
<p>TSH secretion rises in the presence of low and falls in the presence of increased circulating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> levels, respectively. The mutual regulation of secretory activity by the adenohypophysis and the thyroid is called the feed-back system. The negative feed back is believed to occur at the level of the pituitary rather than the hypothalamus. It has been implicated in the pathogenesis of some cases of simple goitre, a non-inflammatory, nonmalignant enlargement of the thyroid gland. If, for any reason such as iodine deficiency, ingestion of goitrogens or genetic enzyme deficiency, thyroid hormone synthesis becomes impaired, the tendency of the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level to fall is countered by an increase in TSH secretion. This leads to goitre formation.</p>
<p>Plasma level of TSH (measured by an immunoassay) is:
(a) Undetectable or very low in hypopituitarism and in hyperthyroidism, and is
(b) Elevated in primary hypothyroidism. Although TSH may be initially responsible for the development of some forms of non-toxic goitre, plasma TSH levels are elevated only in goitrous patients who are hypothyroid.
rDNA TSH is now available and is used to enhance the uptake of radioactive iodine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left({ }^{131} \mathrm{I}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span> by the metastases of well differentiated thyroid cancer in patients who are being treated with radioiodine. This helps to ablate the metastases.</p>
<p>TRH: This synthetic substance is a trip-eptide, (pyro) Glu-His-Pro <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{NH}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Human, ovine, bovine and porcine TRH have the same chemical structure. Intravenous TRH results in a rapid rise in plasma TSH level. Its estimation may help in the diagnosis of subclinical thyrotoxicosis; it has now been replaced by highly sensitive plasma TSH assay.</p>
<p>Synthetic TRH also stimulates the release of prolactin, FSH (in men), LH (in women at luteal peak) and GH (in acromegaly).</p>
<p>Mechanism of action of thyroid hormones: Thyroid hormones interact with the cells at three thyroid receptor (TR) sites:
(1) The nucleus where they cause transcription of mRNA necessary for the synthesis of proteins (Genomic action). The affinity of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> for TRs is 10 fold higher than for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>The thyroid hormone receptors are classified as TR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and TR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>. TR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> are responsible for regulation of heart rate, body temperature, skeletal muscle function and bone and intestine development whereas TR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> are involved in liver metabolism, negative feedback mechanisms (at hypothalmo-pituitary-thyroid axis), retina and inner ear development. (2) The non-genomic actions of thyroid hormones at the plasma membrane and mitochondria occur early in the course of the exposure of cells to thyroid hormones. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> acts on TRs involved in cellular metabolism. It also stimulates NO production, which is responsible for vasodilation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> binds to plasma membrane receptors to activate MAP kinase.</p>
<p>Uncoupling of oxidative phosphorylation is not a physiological effect of thyroid hormones but plays a role in their calorigenic action in patients with thyrotoxicosis.</p>
<p>Difference between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> : The overall effects of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are qualitatively similar. Table 64.1 shows the important differences.</p>
<p>Table 64.1
Differences between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">T_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">T_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">Thyroxine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span></th><th style="text-align: center;">Triiodothyronine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{T}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: left;">Equipment doses</td><td style="text-align: center;">100 mcg</td><td style="text-align: center;">25 mcg</td></tr><tr><td style="text-align: left;">Free hormone (% ol total) in plasma</td><td style="text-align: center;">0.03</td><td style="text-align: center;">0.3</td></tr><tr><td style="text-align: left;">Onset of action</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Elimination t1/2</td><td style="text-align: center;">7 days</td><td style="text-align: center;">1 day</td></tr><tr><td style="text-align: left;">Wearing out of effect after cessation of therapy</td><td style="text-align: center;">Long</td><td style="text-align: center;">Short</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="physiological-and-pharmacological-actions-of-thyroid-hormones">Physiological and pharmacological actions of thyroid hormones:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-and-pharmacological-actions-of-thyroid-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Calorigenic action: The thyroid hormones stimulate oxygen consumption and heat production in all tissues except the brain, gonads, lymph nodes, spleen, thymus and dermis. Thus, they regulate the basal metabolic rate (BMR). The calorigenic response to externally administered thyroid hormones is most marked in the hypothyroid</li>
</ul>
<p>individual. However, there is a latent period of several hours or even days between the administration of the hormone and the response.</p>
<ul>
<li>Growth: The thyroid hormones are essential for intra-uterine tissue differentiation and as well as extra-uterine growth:
(a) Intra-uterine thyroid deficiency causes defective brain development leading to cretinism with mental retardation.
(b) Deficiency of thyroid hormones appearing after birth leads to retardation of physical growth, characterised by a marked delay in the bone maturation (retarded bone age). A characteristic epiphyseal dysgenesis, where calcification appears as multiple, small irregular foci causing stippled, porous, fluffy or fragmented appearance in X-rays, is also seen. It is associated with significant decrease in the serum alkaline phosphatase level.
Thyrotoxicosis occurring during childhood leads to a temporary acceleration of linear growth.</li>
<li>Metabolic actions: In physiological doses, the thyroid hormones promote growth and protein synthesis and are, therefore, anabolic in their effects. In excessive amounts, as in thyrotoxicosis, their effect is catabolic.
The thyroid hormones increase the rate of absorption of glucose from the gut.
Peripherally, they increase the rates of cellular entry and intracellular utilisation of glucose. Larger doses may cause glucose intolerance. The liver may be depleted of glycogen in hyperthyroidism.</li>
</ul>
<p>The thyroid hormones enhance cholesterol synthesis by the liver, its rate of biliary excretion, its conversion to bile acids and its faecal loss. The preponderance of increased synthesis over metabolic degradation accounts for the elevated levels of serum cholesterol in hypothyroidism. In hyperthyroidism, serum cholesterol is normal unless the individual is malnourished. The thyroid hormones also enhance the lipolytic action of catecholamines on the fat cells, though they do not exert a lipolytic action themselves.</p>
<p>They also affect the water and electrolyte metabolism. Thus, the hypothyroid subject retains water and sodium and cannot excrete an added load of water. Diuresis and natriuresis occur soon after starting thyroid medication.</p>
<ul>
<li>
<p>Cardiovascular system: Thyroxine acts on the myocardium partly by a direct genomic action and partly by sensitising it to the effects of catecholamines. It stimulates the rate and increases the force of contraction of the myocardium and the cardiac output. This action is inhibited by beta adrenergic blocking drugs.</p>
</li>
<li>
<p>Central nervous system: Thyroxine is essential for myelination of the CNS. Hence, its deficiency during foetal life leads to irreversible CNS damage. A variety of neurological changes such as mental retardation and slow tendon reflexes are seen in hypothyroidism, while increased irritability, tremors and hyperkinesia are characteristic of hyperthyroidism. Psychosis may also be present in hypothyroidism.</p>
</li>
<li>
<p>Gastrointestinal tract: Diarrhoea and constipation are common in hyper and hypothyroidism, respectively. Achlorhydria is frequent in both these conditions.</p>
</li>
<li>
<p>Reproductive tract and the breast: Gonadal function is disturbed in males as well as in females in hypothyroidism; menorrhagia is seen in women and infertility in both the sexes. No specific changes are observed in hyperthyroidism. In dairy animals, but not in humans, thyroxine is a potent galactopoietic.</p>
</li>
<li>
<p>Hemopoietic system: Anemia, correctable only by thyroid medication, as well as megaloblastic anemia, are seen in hypothyroidism.</p>
</li>
<li>
<p>Skin: Thyroxine deficiency causes deposition of a complex mucopolysaccharide material in the connective tissue of the skin which causes the pallor and roughness of the skin.</p>
</li>
<li>
<p>Miscellaneous actions: Excess of thyroxine impairs the conversion of creatine to creatinine and also the formation of phosphocreatine, leading to wasteful creatinuria. Various types of myopathies and periodic paralysis are seen in hyperthyroidism. Plasma level of creatine kinase (CPK), lactic dehydrogenase (LDH) and creatinine are increased in hypothyroidism. Conversion of carotene to vitamin A is defective in thyroid deficiency, while requirement of both water and fat soluble vitamins is enhanced in thyrotoxicosis.
In some species, these hormones have special functions such as stimulation of oxygen consumption in fish, metamorphosis in amphibia and plumage growth in birds.</p>
</li>
</ul>
<p>Absorption, fate and excretion: Both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo stretchy="false">(</mo><mn>40</mn><mo>−</mo><mn>75</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}(40-75 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75%</span><span class="mclose">)</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are well absorbed when given orally. The absorption is more complete when they are taken on an empty stomach but can be variable and incomplete when taken with food. Injected labelled thyroxine is concentrated mainly by the liver and the kidney, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> gets distributed to a variety of organs and tissues. The hormones are de-iodinated in the peripheral tissues and iodine thus liberated is returned to the extrathyroidal iodide pool for re-utilisation. Plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">T_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in health is 6-7 days and that of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is 1-2 days. These are shortened in hyperthyroidism and prolonged in hypothyroidism. The hormones are conjugated with sulfuric acid in the liver and are excreted in the bile. Oxidative deamination and decarboxylation also occur. Sulfates are partly hydrolysed and reabsorbed in the intestines. About 20-40% of the amount present in the bile is excreted in feces.</p>
<p>Adverse reactions: These are similar to the symptomatology of thyrotoxicosis and include hyperkinesia, weight loss, palpitation, tremor, irritability, diarrhoea, and occasionally anginal pain; agitation and even psychosis may occur. Administration of large doses for prolonged periods can cause osteoporosis, left ventricular hypertrophy; and pseudotumour cerebri. If a patient with combined hypothyroidism and hypocortisolism is not pretreated with a glucocorticoid, thyroxine can precipitate hypoadrenal crisis. The additive tartrazine in thyroxine tablets is sometimes associated with cutaneous allergic reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Thyroxine sodium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{mcg}, 50 \mathrm{mcg}, 100 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> and 200 mcg tablets. Dose: 0.05 to 0.2 mg once daily, on an empty stomach in the morning.
(ii) Levothyroxine sodium injection 200, 500 mcg. Dose in myxedema coma: 200-500 mcg IV on first day; 100-200 mcg on second day.
(iii) Liothyronine sodium (l-triiodothyronine sodium) 20 mcg tablets. Dose: 20 mcg 1-3 times a day.
(iv) Liothyronine sodium injection, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mcg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Dose in myxedema coma: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> IV.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is not used routinely as its rapid onset of action may precipitate angina or cardiac failure, especially in the elderly patients. Further, the longer half-life of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> maintains a substantial peripheral pool of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> from which <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is slowly formed. This provides a buffer against lapses in treatment. Because of its shorter half-life, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> lacks this buffering effect. Thyroid extract and thyroglobulin are no more used in therapy.</p>
<p>Although combinations of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are available for replacement therapy, claims for their superiority over thyroxine remain unsubstantiated.</p>
<p>Table 64.2 summarises the thyroid function tests in health and disease.</p>
<p>Table 64.2
Thyroid function tests (plasma levels) in health and disease</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">Normal</th><th style="text-align: center;">Hypothyroidism, primary</th><th style="text-align: center;">Hypothyroidism, secondary</th><th style="text-align: center;">Thyrotoxicosis</th><th style="text-align: center;">Euthyroid, sick syndrome <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>m&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {m }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">m&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Pregnancy, OC pill use</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: left;">Total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}(\mathrm{mcg} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>11</mn></mrow><annotation encoding="application/x-tex">4-11</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">11</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo><mi mathvariant="normal">/</mi><mi mathvariant="normal">N</mi></mrow><annotation encoding="application/x-tex">\uparrow / \mathrm{N}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord mathrm">N</span></span></span></span></span></td><td style="text-align: center;">N</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Free <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}(\mathrm{ng} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.8</mn><mo>−</mo><mn>2.0</mn></mrow><annotation encoding="application/x-tex">0.8-2.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.0</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo><mi mathvariant="normal">/</mi><mi mathvariant="normal">N</mi></mrow><annotation encoding="application/x-tex">\uparrow / \mathrm{N}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord mathrm">N</span></span></span></span></span></td><td style="text-align: center;">N</td><td style="text-align: center;">N</td></tr><tr><td style="text-align: left;">Total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}(\mathrm{ng} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>180</mn></mrow><annotation encoding="application/x-tex">60-180</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">180</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">N</mi></mrow><mi mathvariant="normal">/</mi><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{~N} / \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">N</span></span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">/</mi><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{N} / \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">N</span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">/</mi><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{N} / \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">N</span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Free <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}(\mathrm{pg} / \mathrm{dl})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>145</mn><mo>−</mo><mn>348</mn></mrow><annotation encoding="application/x-tex">145-348</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">145</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">348</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">N</mi></mrow><mi mathvariant="normal">/</mi><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{~N} / \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">N</span></span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">/</mi><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{N} / \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">N</span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;">N</td></tr><tr><td style="text-align: left;">TSH (micronat//ml)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>5.0</mn></mrow><annotation encoding="application/x-tex">0.5-5.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5.0</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;">N (inappropriately low)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">/</mi><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{N} / \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">N</span><span class="mord">/</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;">N</td></tr></tbody></table>
<p>*Normal values differ with different laboratories.
"Seen in chronic/severe acute, medical and surgical illness.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>As substitution therapy: In cretinism, therapy must be started as soon after birth, preferably within 4 weeks. With proper treatment, normal physical development and linear growth can be achieved. Some degree of mental retardation can, however, occur especially in the athyrotic cretins. In cretins with goitres, the thyroid deficiency is milder. Therapy is started with a small dose ( 25 mcg ) and is increased by 25 mcg only at fortnightly intervals. The entire daily dose is given once a day (see Table 64.3). Once started, thyroid medication must be continued lifelong. This must be impressed upon the parents.</li>
</ul>
<p>Table 64.3
Thyroxine substitution therapy in hypothyroid infants and children</p>
<table><thead><tr><th style="text-align: left;">Age</th><th style="text-align: center;">Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span></th><th style="text-align: center;">Total <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">y</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{day}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">day</span></span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: left;">Birth-6 months</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">10-15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">25-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span></td></tr><tr><td style="text-align: left;">6-12 months</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">6-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>75</mn></mrow><annotation encoding="application/x-tex">50-75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">75</span></span></span></span></span></td></tr><tr><td style="text-align: left;">1-5 years</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">75-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></td></tr><tr><td style="text-align: left;">6-18 years</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">3-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>150</mn></mrow><annotation encoding="application/x-tex">100-150</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">150</span></span></span></span></span></td></tr></tbody></table>
<p>The dose of thyroxine is adjusted to maintain plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> between 9 and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{mcg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">%</span></span></span></span></span>. When such facilities are not available, the dose is adjusted clinically. In the infant, the mental milestones are the crucial guide to adequacy of treatment. In older children, it can be monitored by the rate of linear growth and bone age.</p>
<p>Overtreatment can result in symptoms and signs of hyperthyroidism; worse, it can lead to premature craniosynostosis of the skull.</p>
<p>In adult hypothyroidism, a complete reversal of the physical and metabolic abnormalities can generally be achieved by adequate replacement therapy. However, this may not be possible in patients with coronary heart disease in whom angina or MI may be precipitated or aggravated by thyroxine. In the younger patients with no concomitant disease, therapy is started with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> of thyroxine per day. The daily dose is increased by 50 mcg once in three months until the plasma TSH becomes normal (1-5 microunits <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ). In most patients, the maintenance dose is 0.1 to 0.2 mg (about 1.5-2</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> per day. After the maintenance dose is determined, therapy can be monitored clinically and by plasma TSH.</p>
<p>The dose is smaller in older patients. It is also about 0.05 mg smaller in the hot summer months than during the cold winter months, in regions where the variations in ambient temperatures are marked e.g. North India. Thyroxine must be continued in slightly larger doses throughout pregnancy. In patients with ischemic heart disease, therapy is initiated with doses as small as 0.01 or 0.015 mg per day.</p>
<p>Therapy must be continued lifelong in most patients. In some situations, hypothyroidism is transient and thyroid replacement therapy may be omitted after a few months. In patients with secondary hypothyroidism, associated cortisol deficiency, if any, should be corrected.</p>
<ul>
<li>Non-toxic goitres: Normal plasma TSH levels are seen in most patients with nonendemic, simple goitres. Such goitre is thought to be due to locally generated growth factors. Hence, the mechanism of action of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in these patients is obscure; formerly, it was thought to encourage regression of the goitre by suppressing the plasma TSH. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> also corrects any associated hormonal deficiency. It is used in the dose of 100-200 mcg per day. The goitre regresses in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of the patients. The best response is seen in (a) the large, diffuse, soft, enzyme-deficiency goitres, and (b) the diffuse puberty goitres in patients who have not recently received iodine. In the former group, lifelong treatment is desirable. In the latter group, therapy is continued for 2-3 years but may occasionally have to be given lifelong. Similar dosage is used in the treatment of autoimmune thyroiditis (Hashimoto's disease) with hypothyroidism.</li>
<li>Hyperthyroidism: Thyroxine (100-200 mcg per day) given concurrently prevents/reverses the enlargement and the increased vascularity brought about by thioamides in the diffuse toxic goitre of Grave's disease.</li>
<li>Thyroid carcinoma: Surgery is the treatment of choice in all cases of thyroid carcinoma. It is followed by radioiodine therapy in patients with papillary and follicular carcinoma. Thyroxine has been used instead of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span> after surgery in patients with small, well differentiated carcinomas as they are TSH dependent. The dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is larger than that customarily used in hypothyroidism and the plasma TSH is maintained at unmeasurable level.</li>
<li>Therapeutic trial: Thyroxine may occasionally be used as a therapeutic test for hypothyroidism when laboratory investigations are not possible or fail to establish the diagnosis in clinically strongly suspected cases.</li>
<li>Antithyroid drug treatment during pregnancy: Thyroxine may be added to the antithyroid drug in a dose which maintains plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the upper range of the normal and TSH in the lower range of the normal during pregnancy to prevent hypothyroidism in the mother. However, thyroid hormones do not cross the placenta significantly whereas the antithyroid drugs do. Hence, it is necessary to keep the dose of the antithyroid drug to a minimum during pregnancy.
Thyroid hormone treatment does not appear to alter the course of the exophthalmos in Grave's disease, nor that of obesity.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-myxedema-coma">Treatment of Myxedema Coma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-myxedema-coma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Myxedema coma is a serious complication of long standing, untreated hypothyroidism. It is characterised by coma, hypothermia, marked bradycardia and hypotension. It is most likely to occur in elderly people and during cold season. Inadequate treatment, exposure to cold, infection and trauma act as precipitating factors. Alveolar hypoventilation with carbon dioxide narcosis, hypoglycemia, lactic acidosis and dilutional hyponatremia are important associated abnormalities. The diagnosis is essentially clinical and can be confirmed by plasma free <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and TSH estimation. Therapy should be started without waiting for the result of the tests. The principles of treatment are given in Table 64.4.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-64-4">Table 64.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-64-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-myxedema-coma">Principles of treatment of myxedema coma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-myxedema-coma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hospitalise, preferably in an ICU.</li>
<li>Glucocorticoids.</li>
<li>Levothyroxine in large dose IV/orally.</li>
<li>Triiodothyronine IV, if available.</li>
<li>Antimicrobials</li>
<li>Slow warming; and</li>
<li>Management of hypoventilation, hyponatremia and otherelectrolyte disturbances.</li>
</ul>
<p>Because of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> incidence of co-existing, decreased adrenal reserve, IV administration of glucocorticoid should precede that of thyroid hormones in all cases. If available, thyroxine sodium is given IV in a loading dose of 150-300 mcg, followed by 100 mcg IV every 24 hours. If IV thyroxine preparation is not available, 500 mcg can be given through a nasogastric tube as a loading dose. Some physicians prefer to add triiodothyronine in the dose of 10 mcg IV, every 8 hours, for a few days, because the peripheral conversion of thyroxine to tri-iodothyronine is diminished in severely hypothyroid patients. Over-aggressive treatment with thyroxine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&gt;500 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day) or triiodothyronine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&gt;75 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day) is associated with increased mortality rate. Prophylactic antibiotics are recommended in these patients.</p>
<p>Warming should be slow, with blankets. Hypoventilation, if present, should be treated by placing the patient on a respirator; and hyponatremia with fluid restriction rather than with hypertonic saline. Fluid and electrolyte balance should be carefully monitored to avoid overhydration. Therapy of myxedema coma remains unsatisfactory and mortality is high.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iodine-and-the-endemic-goitre">Iodine and the Endemic Goitre<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iodine-and-the-endemic-goitre" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Endemic goitre is a manifestation of iodine deficiency. The daily iodine requirement is 1-2 mcg per kg body weight and can be met with by ingestion of 200 g of sea fish 2-3 times a week. Sea-fish and unpurified common salt obtained from sea water are important dietary sources of iodine. As the common salt obtained by evaporation of sea water contains inadequate iodide, endemic goitre can be prevented by iodisation of the common salt by adding <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of sodium iodate to 1 kg of common salt. This provides <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">p</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{ppm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ppm</span></span></span></span></span></span> (parts per million) of iodine at the source of production. Considering the loss of iodine during storage to be about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi><mo separator="true">,</mo><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \%, 10 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">50%</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of salt, the usual daily consumption, provides about 150-250 mcg of iodine, which is the intended daily supplement. An alternative method is the administration of Lipiodol which is poppy seed oil with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>38</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">38 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">38%</span></span></span></span></span> by weight of iodine. It is administered IM in the dose of 1 ml every 2-5 years or orally in the same dose once a year; the latter is preferable. Treatment of pre-existing simple goitre with iodine is generally unsuccessful Therapy with thyroxine is more effective.</p>
<p>Excess of iodine can cause goitre <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> either hypothyroidism or hyperthyroidism (see later).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antithyroid-drugs">Antithyroid Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antithyroid-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The clinical manifestations of hyper-thyroidism are due to an excess of circulating thyroid hormones. They can be ameliorated by using Antithyroid Drugs, which interfere with the synthesis, release or action of thyroid hormones. They are classified as:
I Drugs which interfere with hormonal synthesis:
(1) Ion inhibitors which inhibit iodine trapping and binding e.g. Potassium perchlorate and Thiocyanate.
(2) Thioamides which inhibit thyroid peroxidase and block the synthesis of MIT, DIT; and prevent the coupling reaction e.g. Propylthiouracil, Carbimazole.
II Drugs that interfere with the hormonal release and promote its storage e.g. Iodides, Lugol's iodine; and III Radioactive iodine that destroys the acinii.</p>
<p>Antithyroid drugs such as iodide and propylthiouracil may act by more than one mechanism.</p>
<p>Drugs interfering with hormonal synthesis (Class I) reduce the plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> levels. This in turn stimulates TSH synthesis by the pituitary, stimulates the thyroid, which undergoes hypertrophy and hyperplasia; thyroid vascularity increases. The height of the acinar epithelium increases. Since this causes enlargement of the thyroid gland, these drugs are called goitrogens.</p>
<p>In addition, there are many compounds which disturb the thyroid function (drug induced thyroid disorder) as a side effect. When used for other clinical purposes, they may interfere with the interpretation of the thyroid function tests. Thus, sulfonamides, PAS, lithium and resorcinol interfere with thyroid hormone synthesis, while amiodarone, glucocorticoids and beta blockers block the conversion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Hepatic enzyme inducers such as rifampicin, phenytoin and carbamazepine promote rapid inactivation of the thyroid hormones. Further, excessive iodide and the iodine-containing contrast media can also interfere with thyroid function. These changes however are usually reversible (see later).</p>
<p>ION INHIBITORS: Potassium thiocyanate and perchlorate competitively inhibit the iodide trapping by the thyroid gland. This action is countered by an excess of iodide ions. Thiocyanate is not used in practice because of its potential toxicity but may be responsible for the goitrogenic action of certain staple foods (e.g. cassava).</p>
<p>Potassium perchlorate has been used in the treatment of hyperthyroidism, initially in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">600-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">600</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily in divided doses. The maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily. Its ADR includes gastric irritation, fever, skin rashes, lymphadenopathy, agranulocytosis and rarely aplastic anemia. Most patients tolerate the drug well; it is cheap but is not available easily. It is a useful alternative in patients allergic to the thioamides.</p>
<p>Perchlorate is also used to demonstrate defective organic binding of iodine in the thyroid gland in congenital goitrous cretinism and in Hashimoto's thyroiditis.</p>
<p>THIOAMIDES: The important drugs belonging to this group are methyl- and propylthiouracil, methimazole and carbimazole (Fig. 64.3). They have similar modes of action but differ in pharmacokinetics, dosage and the incidence of adverse reactions.</p>
<p><img src="assets/images/image-20251214-1294f424.jpeg" alt="img-33.jpeg"></p>
<p>Thiourea Propylthiouracil Carbimazole
FIG. 64.3 Thioamides
Mechanism of action: These drugs bind to and inhibit the thyroid peroxidase; they thus block thyroid hormone synthesis by inhibiting:</p>
<ul>
<li>Coupling of iodotyrosines.</li>
<li>Formation of MIT; and</li>
<li>Conversion of MIT to DIT.</li>
</ul>
<p>Propylthiouracil (but not carbimazole) in addition inhibits the peripheral deiodinase and prevents conversion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Carbimazole has also been claimed to encourage a remission in Grave's disease by suppressing the autoimmune process in the thyroid; the anti-TSH receptor antibodies decrease and the circulating suppressor T cells increase. The plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of propylthiouracil is about 75 minutes while that of carbimazole is 4-6 hours.</p>
<p>Absorption, fate and excretion: These drugs are rapidly absorbed (20-30 min) after oral administration. They are concentrated by the thyroid gland. The duration of action of a single oral dose is less than 8 hours. Hence, they are administered every six to eight hours. Some physicians, however, prescribe the entire daily dose of thioamides on a once a day basis.</p>
<p>They are partly metabolised in the liver and the thyroid and partly excreted in the urine unchanged. Carbimazole is metabolised to the active metabolite methimazole. They cross the placental barrier and are secreted in milk.</p>
<p>Adverse reactions: The incidence of the adverse effects is reasonably small and does not probably exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>. The milder ADR include drug fever, pruritus, urticaria, edema of the feet, arthralgia, lymphadenopathy and hair loss. The more serious effects are leucopenia, thrombocytopenia, liver damage and rarely agranulocytosis. The patient should be told to report any attack of sore throat, fever and oral ulceration during therapy. Hypothyroidism is an extension of the pharmacological action of these drugs, which is reversible</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Propylthiouracil: 50 mg tablets. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">300-600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily in divided doses.
(ii) Methimazole 5 and 10 mg tablets. Dose: 5 to 20 mg .
(iii) Carbimazole 5, 10 and 20 mg tablets; dose: for control 30 to 60 mg daily; for maintenance, 5 to 20 mg daily.</p>
<p>Therapeutic uses: For their use in hyperthyroidism, see later.
IODIDE: Iodide is the oldest remedy for thyroid disorders including hyperthyroidism. It is the quickest acting drug in hyperthyroidism and its action becomes apparent within 24 hours. The BMR falls at a rate comparable to that seen after subtotal thyroidectomy. The gland becomes less vascular and firm. The acinar cells become smaller in size and the colloid content increases. The maximum clinical benefit is seen within 10-14 days. The hyperthyroid state is, however, only partially controlled by iodide and after a variable period of time, the beneficial effects seem to wear off.</p>
<p>Mechanism of action: It influences iodine metabolism as follows:
(1) Iodide rapidly shuts off the release of the preformed thyroid hormones and promotes their storage. This effect (thyroid constipation) is availed of while using iodine in the management of thyrotoxic crises (see later).
(2) It inhibits synthesis of iodotyrosine and iodothyronine (Wolff-Chaikoff effect). This is due to high intracellular concentration of iodide. With time, there is an escape for this effect.
(3) It limits its own transport resulting in low iodide levels.
(4) When given along with a thiourea compound, it prevents the increase in the size and vascularity of the goitre which may occur following antithyroid drugs.</p>
<p>Adverse reactions: Chronic iodine intoxication (iodism) may occasionally occur in a susceptible individual, giving rise to skin rash, rhinorrhea, lacrimation and increased salivation. Iodide causes an escape of thyrotoxicosis if used in a patient on potassium perchlorate. Prolonged use of iodides (as in cough mixtures) has been reported to occasionally produce goitre and even myxedema. Iodides cross the placenta and may cause goitre/cretinism in the foetus. They must, therefore, be avoided during pregnancy.</p>
<p>They may precipitate thyrotoxicosis (Jod-Basedow effect) in an occasional patient with a non-toxic goitre, especially in iodine-deficient areas. This effect has been occasionally reported also after the use of an iodine-containing organic dye as for IVP or coronary angiography, as well as after the antiarrhythmic drug amiodarone.</p>
<p>Preparations and dosage: Preparations used are Lugol's iodine and saturated solution of potassium iodide (SSKI). The former is prepared by dissolving 5 g of iodine in 100 ml of 10 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span></span></span></span></span> solution of potassium iodide and it provides 150 mg of iodine per ml; the dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.1-0.3 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> three times a day. SSKI is prepared by dissolving 30 g of KI in 21 ml of water to give 30 ml of SSKI and it provides 1 g of KI per ml. The dose of iodine needed to control hyperthyroidism is about 6 mg per day; however, much larger doses are used in thyrotoxic crisis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Prevention of endemic goiter (See earlier)</li>
<li>Preoperative preparation: They are used in the preoperative preparation of a hyperthyroid patient to reduce the vascularity of the gland. This is the most important use of iodides. It is given for 10-14 days preoperatively in addition to a thiourea drug. Thyroxine given concurrently with antithyroid drugs can obviate the need for the pre-operative addition of iodide to therapy.</li>
<li>Rapid control of hyperthyroidism: Iodides along with a thioamide are used when it is imperative to control hyperthyroidism very rapidly as in a patient with thyrotoxic crisis or with CHF.
Patients with hyperthyroidism tend to have little hormonal iodine stored in their glands. Iodide administration can increase the hormonal content of the gland. If such a patient is then given a thioamide drug, it fails to act quickly because thioamide blocks synthesis but not release of thyroid hormones. Hence, iodide administration to a hyperthyroid patient should be commenced after first blocking thyroid hormone synthesis with a thioamide.</li>
<li>Blocking the thyroidal uptake: Iodide is used to block the thyroidal uptake before administration of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span> I labelled compound for the localisation of a pheochromocytoma and in cases of a nuclear accident with possible release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span> I into the environment.
IPODATE (Oragrafin): This is an organiciodine contrast dye, used in oral cholecystog-</li>
</ul>
<p>raphy. It suppresses thyroid function in normal and in hyperthyroid patients. Though it has iodide like action, it is not used in therapy of hyperthyroidism because of high rate of relapse. Recurrent hyperthyroidism after the use of ipodate is resistant to treatment with thioamides.</p>
<p>Lithium (Chapter 14) interferes with iodination of tyrosine but it is too toxic for therapeutic use in thyrotoxicosis.</p>
<p>RADIOACTIVE IODINE: Radioactive iodine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span>, is concentrated selectively by the thyroid gland. It emits gamma and beta radiations. Gamma radiation is used for measuring radioiodine uptake and for thyroid scan. Beta radiation are particles that penetrate only upto 3-5 mm in the soft tissues. Within this compass, they dissipate their energy and act as ionising radiation. They selectively destroy the thyroidal follicles, produce fibrosis and impair the ability of the remaining follicles to replicate.</p>
<p>Preparation and dosage: Radioiodine is available as a solution of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">\mathrm{Na}{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord mathrm">Na</span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span>. It is administered orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">i</mi></mrow></mrow><annotation encoding="application/x-tex">3-10 \mathrm{mCi}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mCi</span></span></span></span></span></span>., on an empty stomach or after a light breakfast. Patients can be treated on an out-patient basis but are instructed to dispose of their urine carefully into latrine and to avoid close contact with children for 2 weeks. The effect of a dose becomes apparent within 3 to 4 weeks with maximum effect by 3-6 months. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the patients become euthyroid after a single dose. Others may need a second or even a third dose. Decision about the need for a second dose is generally taken at the end of 4-6 months.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Focal soreness in the neck due to irradiation, and a transient aggravation of the hyperthyroid state are rare.</li>
<li>Hypothyroidism: This occurs in 40-60% of the patients in the long run. Hence, treated patients must be followed up for long periods. The incidence of hypothyroidism is lower when smaller and more conservative doses are used than with larger doses, but then so is the cure rate of hyperthyroidism.</li>
<li>Damage to the foetal thyroid: The foetal thyroid picks up iodine (and hence radioiodine) from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>16</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">16^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> week onwards. The foetal thyroid is extremely susceptible to radiation and may be quickly destroyed.</li>
<li>Thyroid carcinoma: Radiation is known to be carcinogenic and the possibility of development of thyroid cancer following radioiodine cannot be totally ruled out, especially if it is used to treat hyperthyroidism in children. Therefore, many physicians reserve radioiodine treatment for adult patients.</li>
<li>Genetic damage: So far, this has not been demonstrated.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-hyperthyroidism">Pharmacotherapy of Hyperthyroidism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-hyperthyroidism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> assays are helpful in confirming the diagnosis of thyrotoxicosis. Thyrotoxicosis may be due to:
(1) An excessive, ongoing production of thyroid hormones (hyperthyroidism, with elevated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span> I uptake) as in Grave's disease or the nodular toxic goitre, or
(2) May occur in its absence. Only the patients with hyperthyroidism benefit from treatment with antithyroid drugs and they alone should be treated with modalities (surgery or radioactive iodine) which destroy the thyroid gland.</p>
<p>Thyrotoxicosis without hyperthyroidism occurs in thyroiditis and during administration of excessive doses of thyroid hormones as treatment. These patients need withdrawal of thyroid hormone treatment and supportive treatment such as propranolol and a benzodiazepine, and in case of de Quervain's thyroiditis, an anti-inflammatory drug (NSAID or a glucocorticoid). As the thyroiditis is self-limiting, destructive forms of treatment are not used in such patients.</p>
<p>As the pathogenesis of hyperthyroidism is not known with certainty, the treatment is empirical and is aimed at reducing the production of the thyroid hormones. Plasma TSH levels are markedly suppressed in this condition. TSH receptor antibody (TSH-RAb [stim]), is demonstrable in the plasma of some patients with Graves' disease. It binds to the TSH receptor on the thyroid cells and stimulates the synthesis and release of thyroid hormones.</p>
<p>Grave's disease often undergoes spontaneous remissions and exacerbations. In some cases, the exacerbations are related to entry of large amounts of iodine into the body. Response to drug therapy is variable.</p>
<p>There are three forms of treatment available for therapy of hyperthyroidism. They are :</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-antithyroid-drugs">I Antithyroid drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-antithyroid-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-radioactive-iodine-and">II Radioactive iodine; and<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-radioactive-iodine-and" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-surgery">III Surgery<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-surgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advantages-of-thioamide-drugs">Advantages of thioamide drugs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-of-thioamide-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>They are well tolerated by most patients and are fairly rapidly effective; clinical benefits being apparent in about 2 weeks. The patient is rendered euthyroid in about 2-3 months. This state can be maintained as long as it is desired by the maintenance doses. If therapy is continued for 2 years, permanent remission is achieved in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the cases.</li>
<li>If hypothyroidism occurs, it is reversible.</li>
<li>They do not generally aggravate the endocrine exophthalmos.</li>
<li>They can be used safely in children in whom radioiodine is contraindicated and thyroidectomy is technically difficult.</li>
<li>They can also be used during pregnancy. The lowest possible dose should be used.</li>
<li>They can be used to perform a therapeutic test in patients with doubtful diagnosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disadvantages-of-drug-therapy">Disadvantages of drug therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disadvantages-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Prolonged treatment and follow up are essential. This is difficult in the case of uneducated or uncooperative patients.</p>
</li>
<li>
<p>In spite of adequate treatment, recurrence occurs in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of the cases. Such patients may need more definitive treatment with radioiodine or surgery.</p>
</li>
<li>
<p>In patients with severe CHF, their action is too slow. In such cases, iodide may be used along with a thiourea drug.</p>
</li>
<li>
<p>They rarely cause serious toxicity such as agranulocytosis.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advantages-of-radioiodine">Advantages of radioiodine:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-of-radioiodine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The treatment is convenient, effective and can be carried out on an out-patient basis. It can be used with certainty of effects even in unintelligent or undependable patients.</li>
<li>It is pleasant to take without any discomfort or fear and very acceptable to the patient. It avoids surgery and its attendant complications.</li>
<li>There is generally no fear of recurrence once the patient becomes euthyroid.</li>
<li>It is relatively inexpensive and safe. In many cases control can be achieved with a single dose.</li>
<li>It can be offered to patients in whom surgery is not possible and to those who refuse surgery. It can be used routinely in all patients past the age of 35-40 years.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disadvantages-of-radioiodine">Disadvantages of radioiodine:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disadvantages-of-radioiodine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Because of high incidence of hypothyroidism, it cannot be recommended for children.</li>
<li>It cannot be given to a woman of the child bearing age without ascertaining that she is not pregnant.</li>
<li>It is slow acting. However, the administration of radioiodine may be followed by a period of antithyroid drugs to achieve early clinical control.</li>
<li>There is a very rare possibility of late development of thyroid carcinoma.</li>
<li>Follow up for several years is necessary in order to detect late onset hypothyroidism.</li>
<li>Special facilities for handling the radioactive material are necessary, so also for disposing the urine.
Choice of therapy: Indications for various forms of therapy are outlined in Tables 64.5, 64.6 and 64.7. The treatment of thyrotoxicosis is essentially medical. In most instances, the choice rests between an antithyroid drug and radioactive iodine. Surgery is indicated in selected cases.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-64-5">Table 64.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-64-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Indications for antithyroid drugs</p>
<ul>
<li>Children.</li>
<li>Pregnant women: Propylthiouracil is preferred to carbimazole because it is more protein bound and crosses the placenta to a smaller extent.</li>
<li>Young adults with small goitres and mild thyrotoxicosis of recent onset.</li>
<li>Before thyroidectomy in all cases; and</li>
<li>After radioiodine therapy, for a few weeks, starting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days after <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span> dose.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-64-6">Table 64.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-64-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Indications for radioiodine</p>
<ul>
<li>All patients above the age of 35 years; in severe cases, the patient is first made euthyroid with a thioamide, before radioiodine administration.</li>
<li>Recurrent hyperthyroidism after an adequate course of thioamide drugs or after surgery.</li>
<li>Allergy to thioamides; and</li>
<li>In young patients in whom a severe, associated systemic disease contraindicates surgery and predicts shortening of the life expectancy.</li>
</ul>
<p>Table 64.7
Indications for surgery</p>
<ul>
<li>Multinodular toxic goitre.</li>
<li>Solitary toxic nodule.</li>
<li>A large diffuse, toxic goitre, especially when it fails to regress and disappear on thioamide treatment.</li>
<li>Recurrence after adequate treatment with a thioamide; and</li>
<li>When malignancy cannot be ruled out.</li>
</ul>
<p>Pregnancy is an absolute contraindication for radioiodine. It should also be avoided in children. Women who receive radioiodine treatment should be advised to avoid pregnancy for one year.</p>
<p>Supportive measures: These comprise:
(a) A sedative/tranquiliser to allay anxiety.
(b) Administration of calcium orally ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1000 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) may be helpful in avoiding possible osteoporosis.
(c) Propranolol (30-120 mg/day) to control, palpitation, tachycardia and tremor. It does nor correct the hyperthyroid metabolic state. Hence, propranolol alone should not be used for preoperative preparation of the patient.
(d) Treatment of CHF and AF; propranolol is the preferred drug.
(e) Vitamin supplements.</p>
<p>Treatment is generally ambulatory; rest at home is rarely required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thyrotoxic-crisis-treatment">Thyrotoxic Crisis - Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thyrotoxic-crisis-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is a manifestation of extreme hyper-metabolism in a thyrotoxic patient and may occur: (a) After thyroidectomy in an inadequately prepared patient (surgical storm); and (b) In the presence of an infection, injury or any surgical procedure other than thyroidectomy (medical storm).</p>
<p>The manifestations are hyperpyrexia, marked tachycardia, extreme irritability and delirium. Nausea, vomiting and diarrhoea may add to the dehydration caused by hyperpyrexia. It is a medical emergency and the treatment must be immediate (see Table 64.8). In spite of hectic treatment, mortality is still high; hence, it is best prevented by adequate therapy of every thyrotoxic patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-64-8">Table 64.8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-64-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-thyrotoxic-crisis">Principles of treatment of thyrotoxic crisis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-thyrotoxic-crisis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hospitalisation, preferably into an I.C.U.</li>
<li>Treatment of the precipitating cause.</li>
<li>Large doses of an antithyroid drug (propyithiouracil is preferred because it inhibits peripheral convertion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub><mo separator="true">,</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}, 200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> or carbimazole 20 mg every 4 hours.</li>
<li>Iodide, started a couple of hours after the thioamide drug. It may be given IV (sodium iodide 1 g by infusion) or through a nasogastric tube ( 0.3 ml of SSKI every 8 hours). These doses are in excess of that which controls hyperthyroidism.</li>
<li>Propranolol (IV) 2-10 mg repeated every 4 hours, or labetalol (IM) every 4-6 hours.</li>
<li>Supportive measures including dexa-methasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM 8 hourly oxygen, adequate intravenous fluids and glucose, B complex vitamins, antimicrobials, and treatment of hyperpyrexia with paracetamol and tepid sponging. Congestive heart failure, if present, needs to be treated with digoxin. Aspirin should be avoided as it can displace thyroid hormone from its binding proteins.</li>
</ul>
<p>Drug-induced thyroid disease: See earlier.
Amiodarone: This antiarrhythmic drug that is structurally related to thyroxine, contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>37</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">37 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">37%</span></span></span></span></span> of iodine by weight. Thus, patient taking <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">200 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> would receive nearly 75 mg of organic iodide daily. The drug is stored in the body fat and has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 54 days. During its metabolism substantial amount of free iodine gets into the circulation which can cause hypo- or hyper-thyroidism in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of patients. Hypothyroidism is reversible after stoppage of the drug. Hyperthyroidism (Type 1) that is caused due to increased synthesis of hormone, needs large doses of thioamides; the recovery is slow.</p>
<p>Thyrotoxicosis (Type 2) that is caused by chemical thyroditis is due to release of the hormone from the gland and is difficult to treat; it responds only to prednisolone, 40-60 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses for 1-3 months. If the mechanism is uncertain, combination of thioamide and prednisolone may be reasonable.</p>
<p>Glucocorticoids in thyroid disorders: Glucocorticoids are valuable in treating:</p>
<ul>
<li>Myxedema coma</li>
<li>Thyrotoxic crisis</li>
<li>Schmidt syndrome: Concurrent Graves disease and hypoadrenalism, both due to autoimmune disease.</li>
<li>de Quervain's subacute thyroiditis with low-uptake thyrotoxicosis.</li>
<li>Amiodarone-induced thyrotoxicosis but not hypothyroidism and</li>
<li>Graves' opthalmopathy.</li>
</ul>
<p>There is no evidence that the use of glucocorticoids benefits the average case of Graves' disease or Hashimoto's disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iodine-containing-contrast-media">Iodine-Containing Contrast Media<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iodine-containing-contrast-media" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Several iodine-containing, organic compounds are used for delineating the vascular tree in various parts of the body. Iodine forms about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> by weight of the contrast molecule.</p>
<p>The older ionisable contrast media iothalamate (Conray) and diatrizoate (Urografin) are liable to cause hyperosmolality-based, anaphylactoid reactions (see below). With the newer non-ionisable media metrizamide (Amipaque) and iopamidol (Niopam), such reactions are rare.</p>
<p>These reactions when they occur, may be either local or systemic:</p>
<ul>
<li>Local reactions comprise pain at the site of injection which may spread proximally in case of thrombophlebitis, and edema of the limb involved.</li>
<li>Mild systemic reaction may consist of a sense of warmth due to vasodilatation, itching and urticaria.</li>
<li>Severe anaphylactoid reactions (Chapter 2) comprising collapse, bradycardia, bronchospasm and hemolysis. The major pathogenic factor is the high osmolality of the contrast medium, causing endothelial damage.</li>
<li>Precipitation of hyperthyroidism (Jod Basedow phenomenon) has been reported especially in iodine-deficient persons.</li>
<li>Acute renal failure, especially in patients with longstanding diabetes mellitus. A test dose of 1 ml is, therefore, recommended.</li>
</ul>
<p>65</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pancreatic-hormones-antidiabetic-drugs-and-pharmacotherapy-of-diabetes-mellitus">Pancreatic Hormones, Antidiabetic Drugs and Pharmacotherapy of Diabetes Mellitus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pancreatic-hormones-antidiabetic-drugs-and-pharmacotherapy-of-diabetes-mellitus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diabetes mellitus (Madhumeha) as a disease is known for ages but its pharmacotherapy is just over 90 years old. The presence of sugar in the urine of diabetics was demonstrated by Dobson in 1755. In 1889, von Mering and Minkowski discovered that pancreatectomised dogs become diabetic in addition to developing digestive disturbances. The non-digestive part of the pancreas, islet cells, was thought to be responsible for the substance which prevented diabetes and it was christened 'insulin' by de Mayer (1909), long before its extraction by Banting and Best in 1921. There are few episodes in medical research as dramatic as the discovery of insulin, a life saving agent.</p>
<p>Synthalin A, a biguanide, was the earliest oral hypoglycemic agent, to be used in therapy but was too toxic. A chance observation by Janbon (1942) led to the discovery of hypoglycemic action of sulfonamides. This was confirmed by Frank and Fuchs in 1955, who observed the blood sugar lowering action of carbutamide, a sulfonamide, during its trial in infectious diseases. Since then many oral anti-diabetic drugs have been introduced in therapy.</p>
<p>Incidence of type 2 diabetes mellitus (DM) is increasing world-wide. Currently it is estimated 382 million people suffer from this disease, of which <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> are in developing countries. As for India, its incidence is believed to be 65 million, which is expected to increase to 109 million by 2035.</p>
<p>Physiology of energy metabolism: The main carbohydrates consumed by humans are starch, a polysaccharide, and sugar, a disaccharide. The ingested polysaccharides are split to a small extent by the salivary amylase, but largely by the pancreatic amylase, into oligosaccharides in the duodenum and upper jejunum. The oligosaccharides and disaccharides are cleaved by alpha-glucosidases in the brush border of the jejunal enterocytes into monosac-charides (glucose, fructose and galactose) which are promptly absorbed in the upper jejunum.</p>
<p>Glucose absorbed after a meal, is utilised preferentially by all tissues for energy production and/or storage. Tissues differ in their dependence on glucose and free fatty acids (FFA) for energy. The brain utilises only glucose while most other tissues can utilise glucose as well as FFAs. In fact, in the fasting state, the skeletal and cardiac muscle can derive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of their energy from FFA. By facilitating the entry of glucose into the cells, insulin makes possible its utilisation by tissues at lower blood glucose levels than would be possible without insulin. Deficiency of insulin causes DM.</p>
<p>Immediately on entry into the cell, glucose is phosphorylated by hexokinase to glucose-6phosphate (G-6-PO <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.{ }_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> (Fig. 65.1) which is further metabolised by:</p>
<p><img src="assets/images/image-20251214-b45f80b0.jpeg" alt="img-34.jpeg"></p>
<ol>
<li>Glycolysis; 2. Pentose-phosphate shunt; 3. Glucu-runoic acid pathway; 4. Glycogenesis; 5. Conversion to glucose
(1) Glycolysis (Triose phosphate pathway) which is an intracytoplasmic anerobic process by which G-6- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is converted to pyruvate. When pyruvate production exceeds the cell's oxidative capacity, it is reduced to lactate. When oxygen is available, lactate is converted back to pyruvate. Glycolysis is a relatively inefficient method of energy production. However, it is quantitatively a major mechanism in (a) the brain, (b) the red blood cells, (c) the exercising skeletal muscle and (d) the ischemic cardiac muscle.
(2) Pentose-phosphate shunt which is an aerobic multicyclic process that converts a part of G-6- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to 3-phospho-glyceraldehyde by a different pathway. This pathway is an important source of NADPH (reduced Nicotinamide Adenine Dinucleotide Phosphate). NADPH is important for lipogenesis; its deficiency causes impaired lipogenesis; and consequently contributes to ketoacidosis in DM.
(3) Glucuronic acid pathway which converts G-6- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to uridine diphospho-glucose (UDPG) via G-1-phosphate. UDPG is utilised for synthesis of glycogen and muco-polysaccharides and contributes glucuronic acid required for hepatic conjugation of many substances such as bile pigments and steroids.
(4) Glycogenesis whereby glycogen is derived from UDPG by the action of glycogen</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="synthetase">synthetase.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#synthetase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(5) Conversion to glucose: Liver and kidney are the only two organs which contain the enzyme glucose-6-phosphatase which converts G-6-phosphate to glucose. The reaction is irreversible. Muscle cannot convert glycogen to glucose but converts it by glycolysis to lactate which is either utilised locally for energy or is transported to the liver where, it is utilised for neoglucogenesis. NADH produced is required for neoglucogenesis in the liver.</p>
<p>The key enzymes in the liver are glucokinase, (an isoform of hexokinase), phosphorylase, glycogen synthetase, glucose-6-phosphatase and the enzymes concerned with neoglucogenesis.</p>
<p>In health, from the glucose derived from the daily ingested foodstuffs, about 3% is stored in the liver and muscle as glycogen; about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> is converted to fatty acids; the rest enters Kreb's cycle and is utilised partly for energy production and partly for synthesis of amino acids.</p>
<p>More than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the energy from glucose is derived from the aerobic oxidation of pyruvate by the tricarboxylic acid cycle (Kreb's cycle, Fig. 65.1). The citric acid formed in this cycle is further metabolised:
(a) To produce <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">H</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}, \mathrm{NADH}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">NADH</span></span></span></span></span></span> (reduced nicotinamide adenine dinucleotide) and FADH2 (reduced flavine adenine dinucleotide); the last two are concerned in the generation of ATP (adenosine triphosphate).
(b) To produce oxaloacetate which carries further acetate (acetylcoenzyme A) into the cycle.</p>
<p>Acetyl coenzyme A is derived by successive beta oxidation of long chain fatty acids. Further metabolism of acetyl coenzyme A can occur in various ways:
(a) It enters Kreb's cycle.
(b) It is re-synthesised to long chain fatty acids.
(c) It is converted by liver (but not by other tissues) to ketone bodies (acetoacetate, beta hydroxybutyrate and acetone) which are utilised by peripheral tissues, and during prolonged fasting by the brain, for energy production; and
(d) It is utilised for the synthesis of cholesterol and its derivatives such as bile salts, and adrenocortical and sex steroids.</p>
<p>Thus, pyruvate metabolism (Kreb's cycle) is the meeting ground for the metabolism of carbohydrates, fats and proteins.</p>
<p>Between meals, the liver converts the stored glycogen to glucose (Glycogenolysis) for release into circulation; it also converts non-carbohydrate sources (lactate; glucogenic amino acids-alanine and glutamine; and glycerol) to glucose (Neoglucogenesis or Gluconeogenesis). Insulin inhibits both, hepatic glycogenolysis and neoglucogenesis; its deficiency in DM leads to exaggerated neoglucogenesis. The liver also converts other sugars such as fructose, galactose and sorbitol to glucose.</p>
<p>INSULIN: Insulin is secreted by the beta cells of the islets of Langerhans. It was extracted from the pancreas by Banting and Best in 1921 and was isolated in crystalline form by Abel in 1930. Its chemical structure was determined by Sanger in 1951.</p>
<p>It is a polypeptide with a molecular weight of about 6000, consisting of two amino acid chains, A and B, linked by two disulfide bridges. The chains contain 21 and 30 amino acids respectively (Fig. 65.2). Insulin was traditionally obtained from bovine and porcine pancreas. 'Human' insulin biosynthesised by cultures of bacteria (E. coli) and yeasts (recombinant DNA or rDNA insulin) is now commonly used in practice. Its primary</p>
<p>structure (amino acid sequence), but not the secondary and tertiary structures, is identical with that of insulin derived from human pancreas. Synthetic, modified, human rDNA insulin analogues (lispro, aspart, glargine, etc) have different pharmacokinetic but the same pharmacodynamic properties as the native human insulin.
<img src="assets/images/image-20251214-10d44afd.jpeg" alt="img-35.jpeg"></p>
<p>Insulin is soluble in water but undergoes molecular aggregation to hexameric form at extremes of pH (3.2 and 10). Such aggregation is further enhanced by zinc which brings about its crystallisation. Insulin is relatively insoluble at the pH range of 4 to 7 .</p>
<p>Synthesis and storage: The islets constitute <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> by weight of the pancreas. They contain:</p>
<ul>
<li>Alpha or A cells which secrete glucagon.</li>
<li>Beta or B cells which secrete insulin.</li>
<li>Delta or D cells which secrete somatostatin; and</li>
<li>PP or F cells which secrete pancreatic polypeptide (PP)</li>
</ul>
<p>Insulin is synthesised within the beta cells as a single chain polypeptide precursor called preproinsulin which is converted to proinsulin. Proinsulin is biologically only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>8</mn></mrow><annotation encoding="application/x-tex">1 / 8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/8</span></span></span></span></span> th as active as insulin. It is not stored but is soon cleaved by proteolytic enzymes to form the single chain C peptide and double chain insulin. It is stored in the granules of beta cells.</p>
<p>The pancreas of a normal human adult contains about 200 units ( 8 mg ) of insulin. It secretes about 50 units of insulin in 24 hours, which enters the portal vein and passes to the liver. Of this, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> gets degraded. The remaining enters the systemic circulation. About half of the total daily insulin output is released at a slow rate, in repeated pulses, to provide a basal plasma insulin level; the other half is secreted after meals. The plasma level of insulin fluctuates throughout the day with peaks after meals.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-determining-insulin-release">Factors determining insulin release:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-determining-insulin-release" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Glucose: Glucose is the specific and the most potent stimulus for insulin synthesis and release. Even a small rise in glucose concentration in the pancreatic artery leads to insulin synthesis and release. There appears to be a threshold ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-90 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ) for pancreatic arterial plasma glucose level (corresponding to a blood glucose level of 45-80 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ), below which there is no glucose-induced insulin release. As the plasma glucose level rises, there is a progressive increase in insulin release which reaches its maximum at glucose level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>350</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">300-350 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">350</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>.</li>
</ul>
<p>Glucose enters the beta cells via the 'glucose transporters'. It is metabolised in the beta cells, raising the ATP/ADP ratio. As a result, the ATP dependent K channels in the cell membrane close, causing its depolarisation. When the depolarisation reaches a threshold value, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels open, causing an influx of calcium into the cell. The elevated cytoplasmic calcium brings about exocytosis of the insulin granules. The sensitivity of this insulin-releasing mechanism to glucose is dependent upon the prior carbohydrate intake. It is markedly depressed by restriction of dietary carbohydrate and by even short periods (48 hours) of fasting. Further, chronic hyperglycemia may cause selective unresponsiveness of beta cell to glucose (glucotoxicity).</p>
<ul>
<li>Other substrates: Amino acids, especially arginine, fatty acids, ketones and non-glucose sugars (fructose, mannose and ribose) also stimulate insulin synthesis and release.</li>
<li>Gut hormones: Ingestion of glucose or a meal causes the release into the portal circulation of:
(a) GIP and GLP-1 i.e. gastrin, secretin, pancreozymin and incretins like glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1); and
(b) Pancreatic hormones, insulin and glucagon. They modulate the plasma glucose level postprandially. GIP and GLP-1 accelerate and potentiate the glucose-mediated release of insulin from the pancreatic beta cells. This explains the larger and more prolonged insulin response to ingested than to IV glucose (Incretin effect). GLP-1 receptors are also present in brainstem nuclei involved in appetite regulation.</li>
<li>Other hormones: Glucagon, GH, thyroxine, ACTH, and glucocorticoids also stimulate insulin release, while somatostatin, adrenaline, noradrenaline and exogenously administered insulin inhibit it.</li>
<li>Nervous system: Insulin release is enhanced by parasympathetic (vagal) stimulation and by beta-1 adrenergic stimulation. It is under tonic inhibition by pancreatic alpha-2 adrenoreceptors; this is seen in conditions associated with increased sympatho-adrenal discharge such as hypoxia, severe burns, surgery and MI with shock.</li>
<li>Hypokalemia inhibits insulin release.</li>
<li>Drugs: Glucose-induced insulin release is enhanced by xanthines. Sulfonylureas stimulate insulin release. It is inhibited by thiazides, diazoxide and phenytoin.
Mechanism of action: There is no single action of insulin which accounts for its diverse effects. Insulin affects all aspects of energy metabolism. Many of its actions on protein and fat metabolism are independent of those on glucose metabolism.</li>
</ul>
<p>Insulin binds to specific insulin receptors present on the surface of target cells. The main target sites are the adipose tissue, the liver, and the skeletal muscles. The insulin receptor comprises two subunits:
(1) The extracellular alpha subunit which serves as the recognition site; and
(2) The transmembrane beta subunit which contains the tyrosine kinase.</p>
<p>Binding of insulin to the receptors activates tyrosine kinase, which gets phosphorylated. Tyrosine kinase phosphorylates insulin receptor substrate 1 (IRS1). The IRS1 then phosphorylates other protein substrates in the cell, thus initiating a cascade effect. Such phosphorylation activates some enzymes while it inactivates others. The cascade is responsible for multiple (pleotropic) effects of insulin on intermediary metabolism: (a) Immediate effects on carbohydrate, lipid and protein metabolism; and</p>
<p>(b) Long term effects: Mitogen-activated protein kinase (MAPK) pathway stimulates growth and mitogenic processes.</p>
<p>Stimulation of insulin receptors causes activation of:
(a) Glucose carrier-mediated transport by recruiting glucose transporters (GLUT) from the cytoplasm to the cell membrane. The liver cells are freely permeable to glucose which enters them via such glucose transporters. Insulin thus stimulates the uptake and utilisation of glucose by the liver cells and
(b) Glucokinase and glucophosphatase. Insulin also increases the glucose transport and promotes glucose utilisation by other tissues, mainly adipose and muscle tissues. The other resulting important metabolic effects include:
(a) Stimulation of protein synthesis and
(b) Inhibition of lipolysis. Lack of insulin causes excessive breakdown of fats and ketoacidosis.
Insulin also stimulates lipoprotein lipase on the surface of the vascular endothelium. The latter hydrolyses the triglyceride core of the chylomicrons and VLDL in circulation. The FFA thus released are taken up by the adipose tissue and reconverted to triglycerides.</p>
<p>Number of insulin receptors varies inversely with the insulin concentration at the site of action. With higher concentration, the receptor number is less (down-regulation); so also the response to insulin (insulin resistance as seen in T2DM). With low concentration, the number of receptors at the site increases with resultant increase in insulin sensitivity (upregulation).</p>
<p>The long term effects of insulin include stimulation of DNA transcription, cell proliferation and differentiation. These actions are mediated by IGF-1 and local growth factors. Examples of this action are:
(i) Stimulation of synthesis of GLUT and the hexokinases;
(ii) Hepatotrophic effect of insulin; and
(iii) Fetal growth</p>
<p>Pharmacological actions: Insulin modifies various metabolic processes in a dosedependent manner. Thus, it inhibits lipolysis at low plasma concentration (1-20 microunits per ml ) while higher levels of 10-50 microunits <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> are needed to suppress hepatic glucose production. Still higher levels (30-500 microunits/ml) stimulate peripheral glucose uptake by muscle and adipose tissue. Increased transport of potassium into cells requires even higher levels of plasma insulin, such as are achieved during IV glucose-insulin drip in the treatment of hyperkalemia.</p>
<p>The major biological effects of insulin on intermediary metabolism are summarised in Table 65.1.</p>
<p>Table 65.1
Actions of insulin on the major target organs</p>
<table><thead><tr><th style="text-align: center;">Metabolism</th><th style="text-align: center;">Adipose tissue</th><th style="text-align: center;">Liver</th><th style="text-align: center;">Skeletal muscle</th></tr></thead><tbody><tr><td style="text-align: center;">Carbohydrate</td><td style="text-align: center;">Increased glucose uptake.</td><td style="text-align: center;">Increased glycogen synthesis and storage. &lt;br&gt; Decreased glycogenolysis and &lt;br&gt; neoglucogenesis.</td><td style="text-align: center;">Increased glucose uptake and utilisation. Increased &lt;br&gt; glycogen synthesis and deposition.</td></tr><tr><td style="text-align: center;">Fat</td><td style="text-align: center;">Decreased lipolysis (antilipolytic action). &lt;br&gt; Increased formation of triglycerides &lt;br&gt; (lipogenesis)</td><td style="text-align: center;">Increased lipogenesis Decreased ketogenesis</td><td style="text-align: center;">Decreased lipolysis.</td></tr><tr><td style="text-align: center;">Protein</td><td style="text-align: center;"></td><td style="text-align: center;">Decreased protein breakdown. Increased protein &lt;br&gt; synthesis</td><td style="text-align: center;">Increased amino acid transport into the cell and &lt;br&gt; protein synthesis. Decreased protein breakdown.</td></tr></tbody></table>
<p>Effects on carbohydrate metabolism and regulation of blood glucose level: The blood glucose is measured by the specific glucose oxidase method. The capillary blood glucose level is similar to venous plasma glucose level in the fasting state; after ingestion of glucose or food, the former exceeds the latter by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-60 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span>.</p>
<ul>
<li>In the fasting state, the plasma glucose fluctuates between 60 and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span>. After a meal, it rises to a maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">140-150 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> and returns to the fasting level within 2-3 hours. The arterial blood glucose is maintained so as to supply glucose to brain which utilises only glucose as its fuel. Other tissues like renal medulla, RBCs and bone marrow also utilise only glucose.
The main determinants of the variations in the blood glucose are ingestion of food and the plasma levels of various hormones especially insulin. The central theme of these processes is:
(a) To promote storage of glucose and other metabolic fuels (fatty acids and amino acids), as well as their peripheral utilisation after a meal; and,
(b) To make glucose available to the brain by glycogenolysis and neoglucogenesis, and FFA to the other tissues, in the post-absorptive state.</li>
<li>Ingestion of a mixed meal: Absorption of food during the postprandial period results in elevation of blood glucose, amino acids and FFA. All of them induce insulin release.
Glucagon release is enhanced by amino acids but is inhibited by hyperglycemia and FFA.
Both insulin and glucagon are released into portal circulation and reach the liver in high concentrations. The overall effect of food ingestion and absorption is to increase the insulin/glucagon ratio. The reverse occurs during the post-absorptive period, during starvation and in severe diabetes.</li>
</ul>
<p>The liver plays a central role in regulation of the blood glucose level. The enhanced insulin/glucagon portal vein ratio during food absorption:
(a) Stimulates glucose uptake and glycogen formation, and
(b) Inhibits glucose output. This curbs the rising blood glucose level.</p>
<p>The reversal of insulin/glucagon release ratio in favour of glucagon in the post-absorptive state increases the hepatic glucose output. In the fasting state, this elevates levels of the other counter-regulatory anti-insulin hormones leading to stimulation of:
(a) Gluconeogenesis by GH, corticosteroids, catecholamines and thyroid hormones, and
(b) Glycogenolysis by catecholamines.</p>
<p>The peripheral utilisation of glucose results in the production of substances such as</p>
<p>pyruvate, NADPH, NADH and ATP. Many of the biochemical consequences of insulin deficiency can be explained by deficiency of these substances. Insulin is not necessary for glucose uptake by brain, leucocytes and RBCs, for its GI absorption nor for its renal tubular reabsorption.</p>
<ul>
<li>In the post-absorptive state:
(a) the anti-insulin hormones stimulate lipolysis with release of FFA into circulation. The tissues (except the brain, RBCs, renal medulla and bone marrow) utilise FFA as the main metabolic fuel and thus conserve glucose.
(b) Conservation of glucose is aided by the inhibitory action of catecholamines and FFA on tissue uptake of glucose, and
(c) Glucocorticoids by their anti-anabolic action make amino acids available for neoglucogenesis by the liver.
This hormonal profile is exaggerated during prolonged fasting and in severe insulin deficiency.</li>
<li>During pregnancy, the dominant theme is to make glucose available to the fetus. This is achieved by an excess of anti-insulin influences from mother's adrenal cortex as well as by insulin degradation. Pregnancy is, therefore, a potentially diabetogenic state.</li>
<li>During lactation, extraction of glucose by the breast for milk production further affects blood glucose level.
Effects on lipid metabolism: Insulin enhances fat storage by its antilipolytic, lipogenic and glycerogenic actions. The weight gain during insulin therapy is largely due to obesity. One of the earliest defects in diabetes (before the abnormality of carbohydrate tolerance) is elevated plasma FFA in the overnight fasting state and after exercise. The oxidation of these FFA in the liver to acetyl CoA provides the energy necessary for neoglucogenesis. Acetyl CoA is converted by the liver to ketone bodies. Ketogenesis is thus, a necessary accompaniment of neoglucogenesis.</li>
</ul>
<p>In the decompensated diabetic state, the greater availability of FFA from lipolysis leads to excess synthesis of ketone bodies by the liver. This causes ketoacidosis and possibly insulin resistance. Thus, in a diabetic who is overeating, hyperglycemia is unlikely to be accompanied by ketonuria; on the other hand, in a diabetic who is unable to eat due to an acute illness, hyperglycemia due to neoglucogenesis from oversecretion of the counter-regulatory hormones particularly glucagon is likely to be accompanied by ketonuria.</p>
<p>Effects on protein metabolism: Insulin is a protein anabolic hormone. Its deficiency leads to negative nitrogen balance by reducing the peripheral protein synthesis and by diverting the amino acids for neoglucogenesis. Insulin is also necessary for the anabolic action of GH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-actions-of-insulin">Other actions of insulin:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-actions-of-insulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Vascular actions: Insulin has vasodilatory properties, probably exerted via activation of endothelial NO production, which is impaired in diabetes. Hyperglycemia also may impair endothelium-dependent vasodilatation. Hyper-insulinemia of Type 2 DM, via the MAPK pathway, may stimulate the proliferation of vascular smooth muscle cells.</p>
</li>
<li>
<p>Anti-inflammatory action: Insulin quenches the inflammatory process, especially in the vasculature.</p>
</li>
<li>
<p>Fibrinolysis: Decreased fibrinolysis, associated with hyperinsulinemia and hypertriglyceridemia in uncontrolled T2DM, has been implicated in atherogenesis.</p>
</li>
<li>
<p>Growth: Insulin plays an important role in intra- and extra-uterine linear growth.</p>
</li>
<li>
<p>Steroidogenesis: Hyperinsulinemia may be responsible for the ovarian and adrenal hyperandrogenism in women with PCOS.
Factors modifying the actions of insulin:</p>
</li>
<li>
<p>Muscular Exercise: Exercise training increases the sensitivity of muscles to insulin and lowers the blood glucose.</p>
</li>
<li>
<p>Other hormones: Counter-regulatory hormones oppose the metabolic actions of insulin and elevate blood glucose.</p>
</li>
<li>
<p>Anti-insulin antibodies: These are present in the plasma of all individuals who have received insulin. Their presence in high concentrations can cause 'insulin resistance'.
Plasma insulin: Plasma insulin can be measured by radioimmunoassay (IRI or immunoreactive insulin) and by bioassay (ILA or insulin like activity).</p>
</li>
</ul>
<p>Immunoreactive insulin (IRI): The commercial kits measure both insulin and proinsulin. In healthy individuals, the fasting level of IRI is 5-30 microunits per ml of plasma. It rises sharply on IV glucose and less sharply but to higher levels on ingestion of glucose. In patients with mild T2DM, the rise of plasma IRI following glucose is sluggish initially but it reaches supranormal levels later (hyperinsulin response). This sluggish, initial response of plasma IRI is the primary defect in genetic diabetes and the subsequent hyperinsulin response is due to the excessive rise of plasma glucose due to the inadequate initial rise of IRI. A greater hyperinsulin response is also seen in some non-diabetic obese individuals.</p>
<p>A hypoinsulin response, on the other hand, is seen in patients with T1DM, those with diabetes due to pancreatectomy, chronic pancreatic disease, and in severe T2DM of long duration.</p>
<p>ILA: The term 'Insulin-like activity' indicates what is measured by the bioassay because the effect is the sum total of insulin itself, its potentiators and inhibitors. The adipose tissue methods give higher ILA values than the rat diaphragm method.</p>
<p>Absorption, fate and excretion: Oral insulin is ineffective due to degradation in GI tract. It must be given parenterally. Addition of zinc and/or protein slows down its absorption and prolongs its duration of action. Insulin released from the pancreas and that circulating in the plasma is in the monomeric form, which is highly diffusible and biologically active. Therapeutically used Standard Recombinant (SR) human regular insulin and very rapidly acting (VRA) analogue preparations (see later) contain insulin in tetrameric or hexameric form and are minimally diffusible; hence monomeric insulin must first be released from the injected insulin, thus delaying its onset of action.</p>
<p>Unlike naturally secreted insulin, insulin injected parenterally directly enters systemic circulation and is distributed to the liver as well as other tissues. It circulates in the plasma in a free form and disappears rapidly with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 5-6 minutes. It is degraded by the liver, kidneys and skeletal muscles. Sixty percent of exogenous insulin is degraded by the kidney while the hepatic clearance accounts for 30-40 % of the dose. The reverse is true in the case of endogenous insulin which is secreted directly in the portal circulation. Only traces of free insulin appear in the urine. In chronic kidney diseases, insulin degradation is retarded requiring dosage changes in these patients.</p>
<p>When insulin is injected in a concentrated solution, its release and absorption are slow. The absorption is fastest from the abdominal wall, less rapid from the arm and slowest from the thigh. Exercising the limb into which short acting insulin is injected speeds up</p>
<p>the absorption and may even cause hypoglycemia. Repeated injections at the same site can cause local fibrosis and delay absorption. Varying rates of absorption probably contribute to the variations in the degree of control of hyperglycemia.</p>
<p>Preparations: These are shown in Tables 65.2 and 65.3. VRA insulin analogues are absorbed very rapidly, and require no lag time. Further, the rate of their absorption is independent of the site of injection.</p>
<p>Table 65.2
Currently available human insulins
(a) Rapid acting Regular (Actrapid);
(b) Intermediate acting (NPH, Insulatard);
(c) Premade mixture of (a) and (b) (Mixtard),
(2) Human Insulin analogues, recombinant:
(a) Very Rapid Acting (VRA): Lispro; (Humalog), Aspart (Novolog), Glulisine (Apidra)
(b) Intermediate acting Premade mixtures, Lisproprotamine + Lispro (Humalog Mix); Aspart-protamine + Aspart (Novolog Mix)
(c) Long acting insulins: Glargine (Lantus); Detemir (Levemir)
(d) Ultra-long acting insulin: Insulin Degludec
(1) Standard Recombinant (SR) insulins:
(a) Rapid acting Regular (Actrapid);
(b) Intermediate acting (NPH, Insulatard);
(c) Premade mixture of (a) and (b) (Mixtard),
(2) Human Insulin analogues, recombinant:
(a) Very Rapid Acting (VRA): Lispro; (Humalog), Aspart (Novolog), Glulisine (Apidra)
(b) Intermediate acting Premade mixtures, Lispro-protamine + Lispro (Humalog Mix); Aspart-protamine + Aspart (Novolog Mix)
(c) Long acting insulins: Glargine (Lantus); Detemir (Levemir)
(d) Ultra-long acting insulin: Insulin Degludec</p>
<p>Tables 65.3
Properties of and comparison among available insulins</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Short Acting</th><th style="text-align: center;">Ultra Short Acting</th><th style="text-align: center;">Intermediate Acting</th><th style="text-align: center;">Long acting</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">SR regular insulin</td><td style="text-align: center;">VRA analogues: Lispro, Aspart and Glulisine (Gl)</td><td style="text-align: center;">SR NPH and Analogue mixtures</td><td style="text-align: center;">Glargine Gl Detemir (D)</td></tr><tr><td style="text-align: center;">Physical properties</td><td style="text-align: center;">Clear and neutral</td><td style="text-align: center;">Clear and neutral</td><td style="text-align: center;">Turbid and neutral</td><td style="text-align: center;">Clear G-acidic Dneutral</td></tr><tr><td style="text-align: center;">Route of Administration, timing</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">C</mi></mrow><mo separator="true">;</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow><mo separator="true">;</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow><mtext>&nbsp;%&nbsp;hr&nbsp;</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi></mrow></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{SC} ; \mathrm{IM} ; \mathrm{IV} \text { \% hr } \\ &amp; \mathrm{AC} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">SC</span></span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">IM</span></span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span><span class="mord text"><span class="mord">&nbsp;%&nbsp;hr&nbsp;</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">AC</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">SC; IM; IV 0-5 min AC</td><td style="text-align: center;">SC</td><td style="text-align: center;">SC</td></tr><tr><td style="text-align: center;">Can be mixed with</td><td style="text-align: center;">SRNPH</td><td style="text-align: center;">SRNPH</td><td style="text-align: center;">Bed time or before breakfast &amp; dinner SR regular, Lispro, and Aspart</td><td style="text-align: center;">G-24 hrly D-12 hrly None</td></tr><tr><td style="text-align: center;">Premised prep.</td><td style="text-align: center;">Regular+NPH</td><td style="text-align: center;">Lispro + Lispro protamine Aspart+ Aspart protamine</td><td style="text-align: center;">Regular+NPH</td><td style="text-align: center;">None</td></tr><tr><td style="text-align: center;">Onset of action</td><td style="text-align: center;">30-60 minutes</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> hes</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> hes</td></tr><tr><td style="text-align: center;">Peak action</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> hes</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">30-90</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span></span></span></span></span> min;</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">4-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> hes</td><td style="text-align: center;">No peak</td></tr><tr><td style="text-align: center;">Duration of action</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">8-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> hes;</td><td style="text-align: center;">Gl 1.5-5 hes Others 2-6 hes</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">18-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi mathvariant="normal">G</mi><mo>=</mo><mn>24</mn><mtext>&nbsp;hes&nbsp;</mtext><mi mathvariant="normal">D</mi><mo>=</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hes&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{G}=24 \text { hes } \mathrm{D}=12 \\ &amp; \text { hes } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord mathrm">G</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord">24</span><span class="mord text"><span class="mord">&nbsp;hes&nbsp;</span></span><span class="mord mathrm">D</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hes&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Hypoglycemia</td><td style="text-align: center;">Late during action</td><td style="text-align: center;">Early during action</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">4-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> hes</td><td style="text-align: center;">Uncommon</td></tr><tr><td style="text-align: center;">Weight gain</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Uncommon</td></tr><tr><td style="text-align: center;">Use during pregnancy</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Lispro and aspart may be used</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td></tr></tbody></table>
<p>Control of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{\mathrm{IC}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">IC</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is similar with SR insulins and insulin analogues. SR insulins are expensive; analogues are more expensive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>C</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">A C=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> ante ceburn (before meal). <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">H</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{NPH}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">NPH</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Neutral Protamine Hagedorn</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-human-insulins-are">The human insulins are:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-human-insulins-are" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pure-and-stable">- Pure and stable.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pure-and-stable" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Neutral in pH and less likely to cause subcutaneous fat atrophy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="less-antigenic">- Less antigenic.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#less-antigenic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Insulin analogues: (Designer insulins): These are molecules that differ from human insulin in amino acid sequence but act like native insulin. They are:
(1) Lispro: This short acting preparation exists as an insulin hexamer which, on injection, dissociates instantly into monomers. For its properties, see Table 65.3. It is injected immediately before or within 5 minutes of commencing a meal. Its advantages are:
(a) Rapid absorption,
(b) Effective in reducing the postprandial rise in blood glucose.
(c) Low incidence of hypoglycemic reactions
(d) No effect on absorption despite variation in the injection site. It is very effective for use in continuous SC insulin infusion, and is particularly useful in intensive insulin regimens.
(2) Aspart insulin short acting and has properties, uses and limitations similar to those of lispro, but with somewhat longer duration of action. Aspart insulin has also been protaminated to produce a long-acting insulin. It is injected SC twice a day within before or after five minutes of commencing the meals. A premixed preparation containing the rapid-acting and the long-acting aspart insulins (30:70) is available.
(3) Glulisine insulin: See Table 65.3.
(4) Glargine insulin is a long acting analogue (Table 65.3). It:
(a) Provides a prolonged, continuous, low, plasma insulin concentration (plateau; Fig 65.3).</p>
<p><img src="assets/images/image-20251214-9d204ed0.jpeg" alt="img-36.jpeg">
(b) Does not cause hunger pangs due to hypoglycemia between meals.
(c) Causes less or no weight gain.
(d) Cannot be mixed with any of the SR insulins, because of its acid pH (pH 4.1). It is given SC once a day, and a very short acting insulin is injected additionally before each major meal (basal-bolus regimen). This mimics the delivery of endogenous insulin in nondiabetics except that it is into systemic and not portal circulation.
(5) Detemir insulin has a fatty acid side chain that allows albumin binding, resulting in prolongation of its action. Its duration of action increases as the amount injected as a single dose increases. However, for most purposes it is shorter than that of insulin glargine, requiring twice daily injections in T1DM. Its efficacy is similar to that of NPH insulin (Table 65.3).
(6) Insulin degludec: This insulin when injected SC forms soluble multihexamers locally, from which monomers slowly separate and get absorbed. It provides a stable and flat pharmacokinetic profile like glargine. However, it has a longer duration of action (ultralong action) so that it can be given as three times a week with weekend-off dosing regimen. It is usually given in the evening (not earlier than 1 hour before last main meal). The glycemic control achieved is reported to be similar to that achieved by glargine.</p>
<p>Fig. 65.3 shows the time-action curves of various insulins.
Inhaled insulin: This new formulation, "Afrezza" when inhaled as dry powder is absorbed faster than injection of insulin lispro. It has a shorter duration of action. It is moderately effective in reducing HbA1C. Commonly it causes cough and hypoglycemia. Its long term use is reported to decrease FEV1 and cause pulmonary symptoms. It needs further evaluation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypoglycemia: Hypoglycemia is a common adverse effect of insulin. It is less frequent with rapid and long acting analogs than with regular insulin and NPH respectively. The common causes of hypoglycemia are:
(a) Too large a dose;
(b) Failure to eat;
(c) Vigorous physical exercise, and
(d) Ingestion of alcohol.</li>
</ul>
<p>It is more common during 'intensive insulin regimens', in T1DM, aged diabetics and in diabetics with nephropathy. Table 65.4 gives the important symptoms of hypoglycemia. Table 65.5 lists the important differences among hypoglycemic episodes on different types of insulin.</p>
<p>Table 65.4
Symptoms of hypoglycemia</p>
<ul>
<li>Sympathetic (Adrenergic) due to adrenaline liberation: hunger, anxiety, cold limbs due to vasoconstriction, tachycardia, palpitation, tremulousness, pallor, sweating, piloerection and subjective feeling of impending disaster. The body temperature tends to be lowered in hypoglycemic coma and this is of diagnostic importance.</li>
<li>Cerebral (Neuroglycopenia) due to the brain being starved of glucose confusion, bicarne behaviour, depression, coma, convulsions and focal lesions such as hemi-plegia or visual disturbances. Cerebral edema or organic damage may cause these symptoms to persist after correction of the low blood sugar level.</li>
<li>Non-specific: Nausea, headache.</li>
</ul>
<p>Table 65.5
Differences in hypoglycemic episodes on different types of insulin</p>
<table><thead><tr><th style="text-align: left;">Preparation</th><th style="text-align: left;">Hypoglycemia, onset</th><th style="text-align: left;">Important features</th></tr></thead><tbody><tr><td style="text-align: left;">Short acting</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Before a meal</td><td style="text-align: left;">After 3 hours; rapid in onset</td><td style="text-align: left;">Adrenergic symptoms predominate</td></tr><tr><td style="text-align: left;">Intermediate acting</td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Before breakfast</td><td style="text-align: left;">Late afternoon and evening; gradual in onset</td><td style="text-align: left;">Cerebral symptoms and may not be recognised as due to hypoglycemia</td></tr><tr><td style="text-align: left;">Before dinner or at bedtime</td><td style="text-align: left;">Early morning the next day</td><td style="text-align: left;">Cerebral symptoms predominate. Morning headaches</td></tr></tbody></table>
<p>Prior ingestion of a non-selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blocker like propranolol can delay the recovery from hypoglycaemia (hypoglycemia unresponsiveness). Selectiveß1-blocking agents like atenolol or metaprolol are less liable to do so.</p>
<p>Patients with T1DM of long duration may fail to recognise the symptoms of hypoglycemia (hypoglycemia unawareness). Table 65.6 lists its causes and Table 65.7 outlines its management.</p>
<p>Table 65.6
Causes of hypoglycemia unawareness</p>
<ul>
<li>Ignorance of symptoms of hypoglycemia.</li>
<li>T1DM.</li>
<li>Long duration of diabetes.</li>
<li>Repeatedsevere hypoglycemia.</li>
<li>Impaired glucose counter-regulation (but not autonomic neuropathy); and</li>
<li>Strict glycemic control.</li>
</ul>
<p>Table 65.7
Principles of management of hypoglycemia unawareness</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Prevention:
</span>    - Educating the patient about symptoms of hypoglycemia.
    - Strict avoidance of hypoglycemia (blood glucose less than 70 mg/dl in this context) aseven moderate hypoglycemia causes transient impairment of glucose counter-regulation for as long as 24 hours.
    - Between-meals and bedtime snacks.
    - Reduction in insulin dose before vigorousesercise.
    - Avoidance of glycated hemoglobin concentrations in the non-diabetic range.
    - Night-time insulin dose reduction after vigorousesercise; and
    - Regular blood glucose monitoring.
    Treatment:
    - Hospitalisation.
    - Blood glucose monitoring especially at 3 am, as hypoglycemia at that hour often goes unrecognized; and
    - At least three weeks of scrupulousavoidance of hypoglycemia can restore hypoglycemiasawareness.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Prevention:
    - Educating the patient about symptoms of hypoglycemia.
    - Strict avoidance of hypoglycemia (blood glucose less than 70 mg/dl in this context) aseven moderate hypoglycemia causes transient impairment of glucose counter-regulation for as long as 24 hours.
    - Between-meals and bedtime snacks.
    - Reduction in insulin dose before vigorousesercise.
    - Avoidance of glycated hemoglobin concentrations in the non-diabetic range.
    - Night-time insulin dose reduction after vigorousesercise; and
    - Regular blood glucose monitoring.
    Treatment:
    - Hospitalisation.
    - Blood glucose monitoring especially at 3 am, as hypoglycemia at that hour often goes unrecognized; and
    - At least three weeks of scrupulousavoidance of hypoglycemia can restore hypoglycemiasawareness." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Attacks of hypoglycemia must be prevented because:
(a) An unrecognised attack during night is followed by rebound hyperglycemia with glycosuria next morning (Somogyi effect): This is likely to lead to an increase in the dose of insulin with repetition of hypoglycemia. Such rebound hyperglycemia can occur at other times of the day as well.
(b) Hypoglycemia can be followed by hypoglycemia unawareness.
(c) They are harmful in patients with cardiovascular disease; and
(d) Frequent attacks may cause permanent neurological damage; and worsening of retinopathy.</p>
<p>Patients on insulin therapy should be explained the symptoms of hypoglycemia. They should be warned about the dangers of missed meals, unplanned vigorous exercise and alcohol. They should carry sugar with them at all times and swallow it at the first symptom of hypoglycemia. Finally, a patient started on insulin therapy should be forbidden to swim, to work near machines and to drive till the dose is stabilised.</p>
<p>Oral glucose/sucrose or, a sugar-containing food, can relieve hypoglycemic symptoms if it is administered early. In a comatose patient, IV glucose or IM glucagon ( 1 mg ) rapidly awakens the patient. If coma persists after correction of hypoglycemia, mannitol and large doses of glucocorticoids may be administered IV to relieve the cerebral edema.</p>
<p>Coma in a diabetic that is not diagnosable with certainty should be first treated with IV glucose ( 50 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ). A rapid arousal during the injection confirms the diagnosis of hypoglycemia.</p>
<ul>
<li>
<p>Insulin allergy: Allergy to insulin is IgE- mediated. It may consist of local itching, redness, swelling and pain. Generalised urticaria is uncommon. Anaphylactic reactions are rare. Allergic reactions are uncommon with non-protein containing insulins but can occur with any insulin preparation.</p>
</li>
<li>
<p>Insulin lipodystrophy: This occurs at the site of injection and is of two types:
(1) Lipohypertrophy presents as a spongy lump and is due to the lipogenic property of insulin injected repeatedly into the same area. The skin around the growth becomes anaesthetised, and this may encourage further injections in the same area. It is advisable to rotate the site.
(2) Lipoatrophy, in which there is a loss of fat tissue, is probably of immunological origin. The treatment consists of injection of human insulin at the borders of the lipoatrophic area. Resolution may take as much as 4-6 months.</p>
</li>
<li>
<p>Obesity: Insulin therapy without dietary restriction and exercise may increase the body weight <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(2-4 \mathrm{~kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span>. This increases the insulin requirement.</p>
</li>
<li>
<p>Insulin presbyopia: When hyperglycemia is rapidly controlled with insulin, the patient develops loss of visual accommodation due to alterations in the physical properties of the lens. It is reversible.</p>
</li>
<li>
<p>Insulin neuropathy: In an occasional patient, rapid control of hyperglycemia with insulin either precipitates peripheral neuropathy or worsens a pre-existing one.</p>
</li>
<li>
<p>Edema may be seen in some patients on initiating insulin therapy.</p>
</li>
<li>
<p>Hepatomegaly due to glycogen deposition occurs rarely.</p>
</li>
</ul>
<p>Route and time of administration of insulin preparations; rDNA insulins, insulin analogues and premixed insulin preparations are shown in Tables 65.2 and 65.3.
I Regular SR insulin and short-acting analogues are injected:
(a) SC premeal ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour in the case of SR regular insulin, and immediately premeal in the case of analogues).
(b) SC for multiple, daily injections (Intensive Insulin Therapy).
(c) SC or (preferably) by IV infusion (SR regular insulin, lispro, aspart and glulisine) in diabetic emergencies (see later),
(d) SC by insulin pump (SR regular insulin, lispro, aspart); and
(e) SR regular, lispro, aspart glulisine can be mixed with the intermediate acting NPH insulin in the same syringe (see below).
II Intermediate acting insulin (NPH) is used:
(a) Alone before dinner.
(b) Together with day-time OHA, at bedtime (BIDS); and
(c) It can also be mixed in the same syringe with SR regular insulin, lispro, aspart, glulisine for SC injection before breakfast and dinner (split-mixed therapy).
(d) Commercial pre-mixed preparations (SR regular + NPH i.e. Mixtard, lisproprotamine Mix and aspart-protamine Mix) can be used in a similar way as (c).
III Long acting preparations are used SC either
(a) Once a day, but at the same time of the day (every 24 hours); or
(b) Every 12 hours</p>
<p>Glargine and Detemir cannot be mixed with any other available insulin in the same syringe. Therapeutic uses:</p>
<ul>
<li>Idiopathic diabetes mellitus: discussed later in detail.</li>
<li>Secondary diabetes mellitus: Diabetes due to pancreatic diseases such as pancreatitis or hemochromatosis.</li>
<li>Glucose-insulin IV drip is used to treat hyperkalemia (Chapter 37).</li>
<li>Glucose-insulin-potassium (GIP) drip has been used to treat patients with MI complicated by arrhythmias due to hypokalemia. The drip drives potassium into the cells.</li>
<li>Insulin tolerance test with determination of plasma hGH to test pituitary reserve.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="non-insulin-antidiabetic-drugs">Non-Insulin Antidiabetic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-insulin-antidiabetic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The antidiabetic agents other than insulin can be classified according to their predominant mechanism of action (Fig. 65.4): and route of administration
<img src="assets/images/image-20251214-7d25aa20.jpeg" alt="img-37.jpeg"></p>
<p>FIG. 65.4 Mechanism of action of oral antidiabetic drugs</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-oral">A Oral:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-oral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Stimulators of insulin release by beta cells ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><msub><mrow></mrow><mtext>ATP&nbsp;</mtext></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}{ }_{\text {ATP }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9213em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">ATP&nbsp;</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> channel modulators) e.g., Sulfonylureas, Meglitinides
II Inhibitors of hepatic gluconeogenesis, (AMPK activators) e.g., Biguanides. (Metformin)
III Inhibitors of intestinal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-glucosidases, ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-glucosidases inhibitors) e.g., Acarbose, Miglitol.
IV Drugs which reduce insulin resistance, (PPAR activators) e.g., Glitazones
V Inhibitors of dipeptidyl dipeptidase-4 (DPP-4) e.g. Sitagliptin, Linagliptin
VI Inhibitors of SGLT2, e.g., Dapagliflozin, Canagliflozin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-parenteral">B Parenteral:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-parenteral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>VII Amylinomimetics, e.g., Pramlinitide
VIII GLP-1 agonists, e.g., Exenatide, Liraglutide
An ideal non-insulin antidiabetic drug should:
(a) Be effective orally;
(b) Be nontoxic; and most importantly
(c) Correct the metabolic defects in a diabetic as insulin does.</p>
<p>Although the drugs available at present do not meet all these requirements fully, they are useful for controlling T2DM.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-antidiabetic-agents">Oral Antidiabetic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-antidiabetic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SULFONYLUREAS: These compounds are chemically related to sulfonamides and have a common structure as follows (Fig. 65.5):
<img src="assets/images/image-20251214-a841a496.jpeg" alt="img-38.jpeg"></p>
<p>FIG. 65.5 General structure of sulfonylureas</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pancreatic beta cells: They act on sulphonylurea receptors (SUR) linked to the ATPdependent K channels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">P</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{\mathrm{ATP}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">ATP</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) in the cell membrane of the islet beta cells. Activation of the receptors causes the K channels to close and the cell membrane to depolarise. This results in a calcium influx into the cell, with release of stored insulin. They are effective only in the presence of a functioning pancreas.
Sulfonylureas release insulin slowly and for prolonged periods into the portal circulation; its primary action is on the liver.</li>
<li>Liver, muscle and adipose tissue: They probably increase the sensitivity of liver, muscle and adipose tissue to insulin. The hepatic output of glucose is decreased while muscle uptake is increased. The hepatic glycogen stores are increased.
The basic action of all the sulfonylureas is identical. They differ in their pharmacokinetic properties. Their plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> bear little relationship to the duration of their hypoglycemic effect.</li>
</ul>
<p>Pharmacological actions: These drugs:
(a) Lower the blood sugar in non-diabetics and selected diabetics.
(b) Lower the elevated FFA levels even before they lower the blood sugar.
(c) Normalise the metabolic state of the diabetic; and
(d) Promote weight gain.</p>
<p>The beneficial effects of sulfonylureas on the serum lipids and lipoproteins are due to improved control of diabetes.</p>
<p>Absorption, fate and excretion: Sulfonylureas are rapidly absorbed from the GI tract when taken on empty stomach. They are absorbed within 1-2 hours and peak levels are achieved in 4-6 hours. Food reduces their absorption. They are all extensively ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) protein bound and are mainly metabolised in the liver (Table 65.8).</p>
<p>Table 65.8
Commonly used sulfonylurea compounds*</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Tolbutamide</th><th style="text-align: center;">Chlorpropamide</th><th style="text-align: center;">Glipizide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>mM&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {mM }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">mM&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;">Glibenclamide (Glyburide)</th><th style="text-align: center;">Gliclazide</th><th style="text-align: center;">Glimepiride <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>mM&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {mM }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">mM&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: center;">Tablets</td><td style="text-align: center;">0.5 and 1.0 g</td><td style="text-align: center;">0.1 and 0.25 g</td><td style="text-align: center;">5 mg</td><td style="text-align: center;">5 mg</td><td style="text-align: center;">80 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1,2,4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Plasma half life (hrs)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">4-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span></td><td style="text-align: center;">35</td><td style="text-align: center;">4</td><td style="text-align: center;">12</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Duration of action (hrs)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">6-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>72</mn></mrow><annotation encoding="application/x-tex">24-72</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">72</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">12-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">12-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">12-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">16-24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Doses per day</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span></td><td style="text-align: center;">1</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;">1</td></tr><tr><td style="text-align: center;">Relative frequency of severe hypoglycemia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">&lt;1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">10-15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Daily dose (mg/day)</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Average</td><td style="text-align: center;">1500</td><td style="text-align: center;">25</td><td style="text-align: center;">5</td><td style="text-align: center;">5</td><td style="text-align: center;">80</td><td style="text-align: center;">2</td></tr><tr><td style="text-align: center;">Max.</td><td style="text-align: center;">2000</td><td style="text-align: center;">50</td><td style="text-align: center;">20</td><td style="text-align: center;">20</td><td style="text-align: center;">320</td><td style="text-align: center;">8</td></tr></tbody></table>
<p>*Sulfonylureas are best taken 15-30 minutes before meals; food may interfere with their absorption.
"Also available as a sustained release preparation Glytop SR ( 5 and 10 mg ). The tablets are swallowed intact.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>mM</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {mM}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">mM</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Rapid onset of action.
Gliclazide, glipizide and tolbutamide are largely metabolised by the liver and are hence preferred in patients with renal impairment.</p>
<p>Chlorpropamide is extensively metabolised by the liver. As <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> is excreted unchanged in the urine, renal impairment enhances its hypoglycemic effect. Because of its long half-life, 7-10 days are required for it to achieve plateau plasma levels. Hence, its dose should not be increased more often than once in 10 days. Further, the drug should be avoided in patients with chronic kidney disease.</p>
<p>Adverse reactions: In general, their toxicity is remarkably low. The important adverse reactions are:</p>
<ul>
<li>Weight gain: This is moderate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(2 \mathrm{~kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span>.</li>
<li>Hypoglycemia can be precipitated by an excessive dose, decreased food intake, vomiting or by associated liver/kidney disease. Drugs like oral anticoagulants and salicylates, potentiate their hypoglycemic effect by displacing them from protein binding. MAO inhibitors and propranolol produce a state of hypoglycemia unresponsiveness. Alcohol can produce dangerous hypoglycemia in patients on a sulfonylurea.</li>
<li>Allergic reactions: Sulfonylureas which are closely related to sulfonamides sometimes give rise to allergic skin rashes.</li>
<li>Liver: Chlorpropamide can rarely cause cholestatic jaundice.</li>
<li>CVS: These drugs act on SUR present on cardiac tissue and block ischaemic preconditioning via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel closure resulting in arrythmia. This is seen mainly with glyburide.
Drug interactions: They sometimes potentiate and prolong the CNS effects of barbiturates and other sedative-hypnotics. By potentiating the action of circulating ADH on the renal tubules, chlorpropamide causes water retention and hyponatremia. Alcohol induced flushing is seen in some patients on sulfonylureas, especially chlorpropamide.</li>
</ul>
<p>Preparations and dosage: Table 65.8. Therapeutic uses:</p>
<ul>
<li>T2DM (fresh cases): Sulfonylureas are useful in treating symptomatic patients with T2DM, including those who develop it during adolescence, and patients with Maturity Onset Diabetes of the Young (MODY), most of whom cannot be controlled by diet and</li>
</ul>
<p>exercise alone. Patients most eligible for sulfonylurea therapy have the profile shown in Table 65.9. Of those, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> show satisfactory response whereas the remaining are termed as primary failures.</p>
<p>Table 65.9
Profile of sulfonylurea-responsive patients</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Over 40 years of age and obese (or at least not underweight) at the time of diagnosis
</span>- Diabetes of recent onset.
- No significant ketonuria.
- Fasting blood sugar is less than 300 mg/dl.
- If on insulin, the daily requirement is less than 40 units.
- No acute complication likely to lead to ketoacidosis.
- No serious cardiac, kidney sor liver disease.
- Not candidates for surgery.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Over 40 years of age and obese (or at least not underweight) at the time of diagnosis
- Diabetes of recent onset.
- No significant ketonuria.
- Fasting blood sugar is less than 300 mg/dl.
- If on insulin, the daily requirement is less than 40 units.
- No acute complication likely to lead to ketoacidosis.
- No serious cardiac, kidney sor liver disease.
- Not candidates for surgery." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Usually, it takes 1-2 weeks to achieve the maximum effect of a given dose; hence the dose should not be increased more often than once in 1-2 weeks. In patients older than 60, with declining renal function, who are also liable to be forgetful about eating, a short acting sulfonylurea (tolbutamide/glipizide) is preferred.</p>
<p>Of the patients who are initially well controlled with sulfonylureas, 5-10% escape from control every year (secondary failure). The important causes of secondary failure are dietary excess, intercurrent disease, inadequate dose, poor compliance and progressive deterioration of pancreatic function. This can be partly treated by:
(a) Improving compliance;
(b) Changing over to another sulfonylurea;
(c) Addition of a biguanide or glitazone; or
(d) Addition of/change over to insulin.</p>
<p>If a patient with T2DM well controlled by less than 20 units of insulin wishes to change over to oral therapy, insulin can be stopped abruptly and a sulfonylurea introduced. However, if the insulin requirement is between 20 and 40 units daily, the dose of insulin is progressively reduced while that of a sulfonylurea is progressively increased, till the latter completely takes over. Such change over from insulin to oral drugs, if done repeatedly, can lead to the development of antibodies to insulin and insulin resistance because of intermittent insulin therapy.</p>
<ul>
<li>Some patients with T2DM may show a better response to sulfonylurea-insulin combination than to either drug alone.</li>
<li>Diabetes insipidus: Chlorpropamide has been used in diabetes insipidus (Chapter 39). Limitations of sulfonylureas: Table 65.10.</li>
</ul>
<p>Table 65.10
Limitations of sulfonylureas</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Sulfonylureas are ineffective in:
</span>    - IDDM.
    - Very long standing T2DM
    - Diabetic coma.
    - Diabetes due to pance atectomy or destruction of pancreas by disease.
    - Surgical diabetics and
    - The presence of infection and/or heavy ketomaria.
    - Further, they cannot be used in pregnant women and in patients with severe liver or kidney disease.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Sulfonylureas are ineffective in:
    - IDDM.
    - Very long standing T2DM
    - Diabetic coma.
    - Diabetes due to pance atectomy or destruction of pancreas by disease.
    - Surgical diabetics and
    - The presence of infection and/or heavy ketomaria.
    - Further, they cannot be used in pregnant women and in patients with severe liver or kidney disease." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Choice of the sulfonylurea preparation: Tolbutamide is well tolerated and is relatively safe. But it has to be taken 2-3 times a day. Chlorpropamide controls hyperglycemia in a single daily dose. Although doses larger than 500 mg per day are pharmacologically more effective, they may cause a disproportionate increase in adverse effects. Chlorpropamide is generally effective in 'primary and secondary failures' on tolbutamide therapy. Glipizide is intermediate between tolbutamide and chlorpropamide. Glibenclamide is effective in a single daily dose and may be effective in patients who are not controlled by maximum doses of chlorpropamide. However, its tolerated dose varies from 2.5 to 20 mg per day and it can cause a higher incidence of hypoglycemia than chlorpropamide, glipizide and glimepiride. It is, therefore, used in divided doses when more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day is being used. In patients with renal impairment, tolbutamide or gliclazide is the preferred drug. For routine use glipizide appears to be cost effective and safe. If good glycemic control is not achieved with maximum doses of sulfonylureas, one should use combination oral drug therapy or change to insulin.</p>
<p>Meglitinides (Glinides): These drugs, chemically unrelated to sulfonylureas, have the same mechanism of action. They binde to a site adjacent to SUR and stimulate insulin secretion. However, they do not stimulate further release of insulin in patients on maximum dose of a sulfonylurea. They also cause hypoglycemia but the risk is less than sulfonylurea. They can be used in patients with decreased renal function. Their usefulness is similar to that of sulfonylureas. They are:</p>
<p>REPAGLINIDE: It has a rapid onset and a short duration of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> hour). It controls postprandial hyperglycemia effectively. Because of its short duration of action, it is less likely than sulfonylureas to cause hypoglycemic attacks. It is cleared primarily by the liver. It must be taken any time 30 mins before each major meal to just at the start of a meal in the dose of 0.5 to 4.0 mg .</p>
<p>Nateglinide is unrelated chemically to repaglinide. Its onset of action and duration of action (2-3 hours) are shorter.</p>
<p>BIGUANIDES: The general chemical structure of biguanides is shown in Fig. 65.6. A free guanidine radical is thought to be essential for the hypoglycemic effect of biguanides.</p>
<p><img src="assets/images/image-20251214-4bef3d1d.jpeg" alt="img-39.jpeg"></p>
<p>Metformin is the biguanide currently used.
Mechanism of action: The exact mechanism of action of metformin is not clear. It does not stimulate insulin release from the pancreas and the presence of either exogenous or endogenous insulin is necessary for its action. Several mechanisms may be involved in the antidiabetic effect of metformin. It:</p>
<ul>
<li>Inhibits hepatic neoglucogenesis and decreases hepatic and renal glucose output. This is considered as its major action. It acts on the enzyme adenosine monophosphateactivated protein kinase (AMPK).</li>
<li>Increases the peripheral glucose utilisation by enhancing anaerobic glycolysis, and increases the activity of glucose transporters (GIUT-4).</li>
<li>Acts as insulin sensitisers in the muscle and adipose tissue, and reduces hyperinsulinemia. This action plays a relatively minor role.</li>
<li>Delays glucose absorption; and</li>
<li>Reduces the appetite, which may be helpful in obese subjects.</li>
</ul>
<p>Pharmacological actions: Metformin does not lower the blood sugar in normal subjects. By itself, it does not produce hypoglycemia in diabetics. However, it potentiates the hypoglycemic action of insulin and sulfonylureas.</p>
<p>It does not inhibit ketogenesis in the liver. Hence, diabetics on metformin may develop ketoacidosis with minimum hyperglycemia and glycosuria. Further, metformin decreases the glycogen content of the liver.</p>
<p>It reduces plasma total and LDL cholesterol and triglyceride levels, and increases plasma fibrinolytic activity. Lipolysis, FFA production and lipid oxidation are reduced. Protein break down and aminoacid turnover are not affected.</p>
<p>Weight loss is due to reduction in appetite. Its main benefit is prevention of weight gain in contrast to sulfonylureas.</p>
<p>Absorption, fate and excretion: Metformin is absorbed rapidly from the GI tract and gives adequate plasma levels. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1.5-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> hours. It is largely excreted unchanged in urine.</p>
<p>Adverse reactions: Metformin is generally well tolerated. In 20% of the patients, it produces bitter or metallic taste, anorexia, nausea, and abdominal discomfort. This can be minimised by starting with a small dose and giving it with, rather than before, meals. It also produces lethargy and muscular weakness. The drug may produce vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> deficiency during long term use. Severe allergic reactions are rare.</p>
<p>Lactic acidosis, though reported rarely during metformin therapy, could be lethal during an acute illness such as a severe infection. Before prescribing metformin to an elderly patient, serum creatinine should be measured to assess the renal function. Patients undergoing a radiocontrast study (CT scan or coronary angiography) should be advised to omit metformin one day before and for 48 hours after the procedure. Metformin should be omitted and insulin substituted the day before major surgery. It may be resumed after</p>
<p>normal renal function is demonstrated. Its use is contraindicated in patients with liver disease, chronic kidney disease, COPD, CHF and chronic alcoholism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Metformin 500 and 850 mg . tablets. It is generally started in the dose of 250 mg 2-3 times a day with major meals, and the dose increased gradually upto 2000 mg per day. Fixed dose combinations with a sulfonylurea do not allow individualisation of the doses of the two drugs and should generally be avoided. (ii) Metformin SR 500 mg tablet once a day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Obese patients with T2DM, who could be controlled with diet alone but find this therapy unacceptable. In such patients, the anorectic action of metformin is of additional help in making the patients lose weight.</li>
<li>Secondary sulfonylurea failure: Metformin may be combined with a sulfonylurea in cases of secondary failure (see above).</li>
<li>Polycystic ovaries syndrome (PCOS): In obese patients with PCOS and oligo-ovulation, regular ovulation may be restored, leading to conception. (Chapter 68).</li>
<li>Non-alcoholic steato-hepatitis (NASH).</li>
</ul>
<p>UGDP and UKPDS studies: The UGDP study showed that morbidity and mortality from vascular disease were higher in patients treated with tolbutamide or phenformin than in those treated with diet alone or with diet plus insulin. This conclusion was not universally accepted, nor was it substantiated by the subsequent UKPDS study. Both studies, however, focussed attention on the importance of diet and exercise, with or without insulin, in controlling hyperglycemia. 1% reduction in HbA1c with sulfonylurea/insulin reduces risk of microvascular complications by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> but not of macrovascular complications. Metformin given to obese patients of DM reduces both the risks.</p>
<p>ALFA GLUCOSIDASE INHIBITORS: Acarbose is an oligosaccharide of microbial origin.</p>
<p>Mechanism of action: It binds competitively to carbohydrate binding sites of alpha glucosidases enzymes in the brush border of the enterocytes in the jejunum. It thus inhibits the absorption of carbohydrates but not of glucose because it does not interact with the intestinal sodium dependent glucose transporter.</p>
<p>Pharmacological actions: Given orally, acarbose reduces postprandial hyperglycemia which is claimed to activate coagulation cascade.</p>
<p>It is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, chewed and swallowed after eating the first few morsels during each meal. At least 3 doses are required per day. As acarbose interferes with the digestion of sucrose, patients receiving insulin or a sulfonylureas as well as acarbose should carry glucose not sucrose.</p>
<p>Adverse reactions: These include flatulence abdominal discomfort and loose stools due to undigested carbohydrates. Occasionally, liver enzymes may be elevated.</p>
<p>Therapeutic uses: The drug is useful in patients on high carbohydrate diet and is generally used in combination with other drugs.</p>
<p>Miglitol and Voglibose have similar actions.
Alfa glucosidase inhibitors are contraindicated in patients with chronic intestinal disease, including IBD and intestinal obstruction.</p>
<p>THIAZOLIDINEDIONES (Glitazones): The introduction of glitazones in the treatment of T2DM was a major breakthrough since the introduction of sulfonylureas in 1950s.</p>
<p>Pioglitazone is the only glitazones available currently.
Mechanism of actions: Glitazones are potent agonists (stimulants) of the nuclear receptors Peroxisome Proliferator-Activated Receptors gamma (PPAR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> ), abundantly present in the adipose tissue and also present in the liver, heart and skeletal muscle. After binding to the receptor PPAR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span>, glitazones modulate gene expression involved in glucose and lipid metabolism, insulin signal transduction, and adipocyte differentiation and proliferation. Thus they reduce peripheral insulin resistance.</p>
<p>Since their action is genetic regulation, their maximum effect is seen after weeks or months. They synergise with sulfonylureas and metformin, as well as insulin in their antidiabetic effects.</p>
<p>Pharmacological actions: These drugs:</p>
<ul>
<li>Reduce peripheral resistance to insulin and increase the insulin sensitivity of the adipose tissue, liver and muscle (insulin sensitisers). Thus, they ameliorate hyperinsulinemia and thereby may protect the body from the damaging effects of chronic endogenous hyperinsulinemia. Exogenous insulin therapy has no such long term ill effects.</li>
<li>Reduce the production of the pro-inflammatory cytokines by the visceral adipocytes and increase the adipose tissue production of adiponectin. This further increases the insulin sensitivity of other insulin responsive tissues such as liver and muscle.</li>
<li>Increase the subcutaneous, small-adipocyte mass, and divert the triglyceride storage from the visceral adipocytes to the subcutaneous adipose tissue.</li>
<li>Lower the hepatic fat content and ameliorate dyslipidemia.</li>
<li>Lower the hepatic glucose production and increase glucose uptake by skeletal muscle.</li>
<li>Preserve and enhance beta cell and vascular function by reducing FFA and cytokine induced islet cell damage in the body.
By themselves, they do not cause hypoglycemia.
Overall, they enhance insulin action (directly) and beta cell function (indirectly). They are classified as insulin sensitisers, and, by definition, require the presence of endogenous insulin. Hence, they can be used only in T2DM but not in T1DM.</li>
</ul>
<p>Absorption, fate and excretion:
Pioglitazone is generally prescribed for use once daily. It is completely absorbed and is metabolised extensively by the liver. The metabolites of pioglitazone are more active and are excreted in the bile.</p>
<p>Adverse reactions: These are
(a) Liver: These drugs cause elevation of hepatic enzymes, which mandates periodic monitoring. Fatal hepatotoxicity was reported with earlier glitazone troglitazone. Pioglitazone induces hepatic drug metabolising enzymes and can decrease the effectiveness of the drugs which are substrates of these enzymes e.g. oral contraceptives. (b) Weight gain: All glitazones cause weight gain ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) in dose dependent manner. It is caused by proliferation of new adipocytes and redistribution of fat stores, plus fluid retention.
(c) Fluid retention/CHF: Fluid retention may precipitate or worsen CHF. It is more common with concomitant insulin therapy.
(d) Cardiovascular toxicity: Cardiovascular safety is questionable. A meta-analysis has concluded that "rosiglitazone was associated with a significant increase in the risk of death from myocardial infarction and stroke".</p>
<p>(e) Miscellaneous: These drugs may cause very unpleasant hunger sensation, especially when they are used in combination with other antidiabetic drugs. Retarded fetal development has been noted in animals; hence they are not recommended during pregnancy. They can decrease the BMD and increase risk of fractures and bladder cancer.</p>
<p>Before prescribing a glitazone it is necessary to check for cardiac, renal and hepatic status.
Preparations and dosage:
(i) Pioglitazone: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">15-45 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in single or bid.
(ii) Rosiglitazone: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4-8 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in single or bid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>T2DM: As monotherapy, they are generally less effective than sulfonylurea or metformin. Their use should be restricted to replacement for metformin or sulfonylurea in patients who for some reason cannot take these drugs. They may be used in combination with other OHA. They should be used cautiously, if at all, in combination with insulin.</li>
<li>Other insulin resistant states such as polycystic ovary syndrome.</li>
<li>Non-alcoholic steatohepatitis (NASH)</li>
</ul>
<p>Incretinomimetics: Intestinal L-cells derived GLP-1 and GIP:
(i) Stimulate pancreatic beta cells and potentiate glucose-dependent insulin secretion
(ii) Suppress glucose dependent inappropriate post-prandial hyperglucagonemia
(iii) Slow gastric emptying
(iv) Promote satiety; and
(v) Cause weight loss.</p>
<p>In animals they stimulate islet growth, differentiation and regeneration.
GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) and has a t1/2 of 2-5 minutes. Hence drugs are now available that:
(1) Act as agonist of GLP-1(See later) or
(2) Amplify the endogenous GLP-1activity by inhibiting DPP-4.</p>
<p>DPP-4 INHIBITORS: Sitagliptin, Saxagliptin, vildagliptin linagliptin and alogliptin administered orally inhibit DPP-4 enzyme and thus prolong the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of endogenous GLP-1 and GIP and thereby increase insulin levels. They have been used in combination with an oral antidiabetic drug (metformin, a sulfonylurea or a glitazone). They are primarily excreted in the urine. Hence dose adjustment is necessary in presence of kidney damage. They are less effective than the established OHAs; and have no extra-hypoglycemic benefits.</p>
<p>Adverse reactions: Apart from mild GI upset, they sometimes cause severe hypersensitivity reactions including anaphylaxis, pancreatitis and hepatotoxicity. Their long term safety is not known. DPP-4 is involved in the regulation of immune functions and degradation of cytokines, hormones, neuropeptides and growth factors. Their inhibition has been associated with increased attacks of infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Sitagliptin: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo separator="true">,</mo><mn>50</mn><mo separator="true">,</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25,50,100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablets; 100 mg once daily. Dose is 25 mg if GFR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. Available in combination as 50 mg sitagliptin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>500</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+500 / 1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">500/1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> metformin. The dose is bid with meals.
(ii) Saxagliptin: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo separator="true">,</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5,5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablets; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once daily. The dose is 2.5 mg if GFR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">&lt;50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> or patient is taking concomitant CYP3A4 inhibitors. Available in combination as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5 / 5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5/5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> saxagliptin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>500</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+500 / 1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">500/1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> metformin.</p>
<p>(iii) Linagliptin: 5 mg tablets; 5 mg once daily. Also available in combination as 2.5 mg Linagliptin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>500</mn><mi mathvariant="normal">/</mi><mn>850</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+500 / 850 / 1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">500/850/1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> metformin. The dose is bid with meals.
(iv) Alogliptin is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.25</mn><mo separator="true">,</mo><mn>12.5</mn><mo separator="true">,</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6.25,12.5,25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">6.25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">12.5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablets; 25 mg once daily. Available in combination as 12.5 mg alogliptin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>500</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+500 / 1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">500/1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> metformin. The dose is bid with meals. The combination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mi mathvariant="normal">/</mi><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5 / 25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12.5/25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> alogliptin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>15</mn><mi mathvariant="normal">/</mi><mn>30</mn><mi mathvariant="normal">/</mi><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+15 / 30 / 45 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">15/30/45</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> pioglitazone is also available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They may be used as alternative to sulfonylurea or pioglitazone in combination with metformin, in those patients who do not achieve their glycemic control with metformin alone.</p>
<p>SGLT-2 INHIBITORS: Kidneys are involved in renal gluconeogenesis and reabsorption of glucose from glomerular filtrate. The transport of filtered glucose in the renal tubule into tubular epithelial cells involve a renal membrane protein called 'Sodium-glucose cotransporter 2 (SGLT-2).' It is a high capacity low affinity glucose transporter in the proximal tubule and is responsible for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of glucose reabsorption. By inhibiting SGLT-2, renal reabsorption of glucose can be reduced and its urinary excretion can be increased; thus lowering the blood glucose. The currently available SGLT-2 inhibitors are Canagliflozin and Dapagliflozin. They are given orally. They reduce blood glucose, body weight and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mn>1</mn></msub><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. They are usually combined with metformin. The frequency of hypoglycemia is claimed to be less.</p>
<p>Adverse reactions: These include osmotic diuresis, increased genitourinary tract infections, increased serum creatinine, hyperkalemia, hyperphosphatemia and hypermagnesemia. Their long term safety is not known. Dapagliflozin is suspeceted to cause increased risk of breast and bladder cancer. Their effectiveness wanes as GFR declines with disease progression and associated renal impairment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Canagliflozin: 100 and 300 mg tablets; the initial dose is 100 mg once daily before the first meal and can be increased to 300 mg . In renal impairment the dose should not exceed beyond 100 mg .
(ii) Dapagliflozin: 10 mg tablet; one tablet per day. Available in combination as 5 mg dapagliflozin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>850</mn><mi mathvariant="normal">/</mi><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+850 / 1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">850/1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> metformin; dose of 1 tablet bid.</p>
<p>Oral antidiabetic drug combinations: These have advantages such as:</p>
<ul>
<li>Additive effect because of different mechanisms of actions.</li>
<li>Lower incidence of ADR of individual drugs; and</li>
<li>Effectiveness in patients showing resistance to monotherapy.</li>
</ul>
<p>These combinations target the primary defects in T2DM- insulin resistance and insulin deficiency e.g. metformin, an insulin sensitiser is given with sulfonylurea, an insulin secretor or incretin based therapy or exogenous insulin.</p>
<p>However, fixed-dose combinations of metformin with a sulfonylurea, a glitazone or sitagliptin lack the flexibility of dose adjustment of the individual drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="parenteral-non-insulin-antidiabetic-agents">Parenteral Non-Insulin Antidiabetic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parenteral-non-insulin-antidiabetic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amylinomimetics: The polypeptide, amylin, is co-secreted with insulin and is markedly reduced in diabetics. It helps to control postprandial hyperglycemia by:
(a) Suppressing endogenous glucagon production, especially postprandially;
(b) Slowing the gastric emptying rate; and
(c) Inducing centrally mediated satiety, by opposing the action of ghrelin.</p>
<p>Pramlintide, a synthetic amylin analogue, has been used as an adjunct in treating T1DM and T2DM patients in whom the post-prandial hyperglycemia is difficult to control. It is injected SC. It is now replaced by exenatide.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="glp-1-agonists">GLP-1 agonists:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glp-1-agonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>EXENATIDE is a longer acting synthetic analogue of GLP-1 (incretinmimetic). It binds to GLP-1 receptors in islets, GI tract and the brain and exerts actions like GLP-I It is administered SC 60 min before lunch and dinner in the treatment of T2DM with resistant postprandial hyperglycemia. Extended release formulations are now available which can be given once a week. It lowers the blood glucose and HbA 1C (1%) modestly. It causes weight loss. By itself, it does not cause hypoglycemia.</p>
<p>Liraglutide is a long acting exenatide analogue ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>13</mn></mrow><annotation encoding="application/x-tex">t^{1 / 2} 13</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">13</span></span></span></span></span> hours) with similar properties, uses and limitations. Dose: 1.8 mg SC once a day.</p>
<p>Other longer acting GLP-1 agonists are dulaglutide and albiglutide, which are injected SC once a week.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-reactions-of-glp-1-agonists">Adverse reactions of GLP-1 agonists:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions-of-glp-1-agonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) GI disturbances: Nausea, vomiting, diarrhea
(ii) Upper respiratory symptoms
(ii) Injection site reactions, and rarely
(iii) Acute pancreatitis and hypersensitivity reactions</p>
<p>Therapeutic uses: GLP-1 agonists are more effective in postprandial hyperglycemia and not for those who have only fasting hyperglycemia. They may be used as an add-on drug with metformin or a sulfonylurea; but not with insulin. In obese diabetics not responding to metformin, GLP-1 agonists may be added as they cause weight loss without hypoglycemia. However, such therapy is very expensive.</p>
<p>The majority of elderly T2DM patients can be well controlled by diet, exercise and metformin (for obese) or sulfonylurea (for non obese) as monotherapy. Those who do not respond can be treated with their combination. These drugs are in use for several years and are effective, cheap with acceptable safety profile. Those who fail to respond to combination may receive pioglitazone in addition or as monotherapy. The newer drugs have been in use for much shorter periods and their long term safety data are lacking. Glitazones may cause edema, weight gain and possible cardiovascular toxicity. Exenatide has to be injected and may cause pancreatitis and renal toxicity. DPP-4 inhibitors like sitagliptin are less effective. Further, they are all expensive. However, these drugs may be useful as an adjunct in a few selected resistant cases.</p>
<p>Insulin substitutes: Often, claims are made about the usefulness of the indigenous preparations derived from plants or metals, found to possess hypoglycemic action in experimental diabetes. As hyperglycemia and glycosuria are prominent manifestations of DM, a potential antidiabetic agent is usually tested for its ability to correct these</p>
<p>abnormalities. However, DM is not synonymous with hyperglycemia and glycosuria. It is a disease due to deranged total energy metabolism and a new drug must help to correct the fundamental defects in metabolism as insulin does. While accepting such an agent, therefore, one should know the mechanism of its hypoglycemic action and about its long term safety. Using a drug simply to lower the blood sugar is like applying a dye to the hair "which though it helps one to look younger, does not reverse the fundamental process of senescence".</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-diabetes-mellitus">Pharmacotherapy of Diabetes Mellitus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-diabetes-mellitus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diabetes mellitus (DM) is a chronic metabolic disorder caused by a variable combination of insulin deficiency and insulin resistance. The result is disordered utilisation and storage of the proximate nutrients (carbohydrates, proteins and fats) and reduced production of ATP. Hyperglycemia is its most easily measured laboratory marker and the liability to chronic degenerative disease in almost all body tissues is its hallmark.</p>
<p>The etiology of DM is still obscure although it has a strong genetic basis. However, with proper management with diet, exercise and drugs a diabetic can enjoy an almost normal life.</p>
<p>Clinically, DM is classified as:
(1) Type 1 DM (T1DM): This is insulin dependent (IDDM) and the patient's survival depends upon uninterrupted insulin therapy.
(2) Type 2 DM (T2DM): This is not insulin dependent (NIDDM) and the patient's survival (except in emergencies) does not depend upon insulin therapy. It has strong genetic predisposition.
(3) Type 3 DM which is due to other hormonal disorders/drugs e.g. pancreatitis, genetic defects, acromegaly etc. and glucocorticoids; it may often respond to oral antidiabetic agents; and
(4) Type 4 DM (Gestational DM; GDM); this must be treated with diet with or without insulin.</p>
<p>T2DM occurs in obese or normal weight adults, is stable and less likely to cause ketoacidosis than T1DM. It also occurs in adolescents and even pre-adolescents. T1DM, on the other hand, occurs mostly in younger, underweight persons, in whom it often starts during childhood, is labile and is often complicated by ketoacidosis. In T1DM, there is an absolute deficiency of insulin. T2DM, on the other hand, is characterised by insulin resistance and relative insulin deficiency, specifically loss of post-prandial insulin secretion. Other varieties usually lie in between these two extremes.</p>
<p>Symptoms such as polyuria, polydipsia and polyphagia along with a random plasma glucose of 200 mg make the diagnosis of T2DM. In the absence of symptoms, American Diabetic Association defined criteria listed in Table 65.11 may be used.</p>
<p>Table 65.11
ADA diagnostic venous plasma glucose values in T2DM</p>
<table><thead><tr><th style="text-align: left;">Plasma venous glucose (PVG) mg/dl</th><th style="text-align: center;">Fasting</th><th style="text-align: center;">2 hr post glucose*</th><th style="text-align: center;">Random</th></tr></thead><tbody><tr><td style="text-align: left;">Normal</td><td style="text-align: center;">Less than 100</td><td style="text-align: center;">Less than 140</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Impaired fasting glucose (IFG)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>125</mn></mrow><annotation encoding="application/x-tex">100-125</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">125</span></span></span></span></span></td><td style="text-align: center;">Less than 140</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Impaired glucose tolerance (IGT)</td><td style="text-align: center;">Less than 100</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>199</mn></mrow><annotation encoding="application/x-tex">140-199</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">199</span></span></span></span></span></td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Diabetes mellitus (DM)</td><td style="text-align: center;">126 or more</td><td style="text-align: center;">200 or more</td><td style="text-align: center;">200 or more*</td></tr></tbody></table>
<p>IFG/IGT may occur independently of each other.
*75g oral glucose load
*= Plus symptoms of DM; ADA: American Diabetic Association
In the early stages, T2DM subjects, especially the obese ones, have a relative excess of</p>
<p>insulin in their plasma in response to a glucose load, due to peripheral insulin resistance in the adipose tissue and muscles.</p>
<p>Overeating leads to excessive insulin secretion which reduces the concentration and affinity of insulin receptors (down-regulation) in peripheral tissues; the insulin sensitivity normalises after diet control and weight reduction. In T2DM, a progressive age-dependent diminution of the beta cell function/regeneration is responsible for the development and worsening of diabetes. By the time diabetes is diagnosed (FBS <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>126</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;126 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">126</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of the beta cells have been destroyed.</p>
<p>On the contrary, the plasma of patients with T1DM lacks measurable insulin. The destruction of the pancreatic islets is usually due to autoimmune 'insulitis'.</p>
<p>Pathogenesis of T1DM: Genes on chromosome 6 determine the susceptibility to T1DM. In predisposed persons, immunological insulitis with beta cell damage and antibody formation start and progress insidiously; there is progressive diminution in insulin secretion during this preclinical stage which may last for years. Islet cell antibodies are present in the plasma of some of these patients. Certain HLA phenotypes are found to be present frequently in T1DM. The disease manifests acutely, commonly following a virus infection. By that time, serious damage to the insulin synthesising/secreting capacity has already occurred.</p>
<p>Pathogenesis of T2DM: T2DM has multifactorial pathogenesis (polygenic). The two basic mechanisms involved are:
(1) Insulin resistance; and
(2) Impaired insulin secretion.</p>
<ul>
<li>Insulin resistance (IR): The term insulin resistance indicates inadequate response to a given dose/level of insulin. Obesity is a major antecedent of IR. In obesity, increased intra-adipocyte triglyceride stores, especially in the visceral fat, promote the growth of large, intrinsically insulin-resistant, intra-abdominal adipocytes. The adipocytes release FFA and inflammatory cytokines (IL-1, IL-6 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ) which interfere with the insulin signaling cascade in the tissues and contribute to IR. This inhibits insulin-induced suppression of lipolysis. Endogenous glucose production is accelerated in spite of hyperinsulinemia. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> enhances lipolysis in the peripheral adipose tissue. Circulating FFA and glycerol aggravate IR in the skeletal muscle and the liver. The current evidence indicates that hepatic insulin resistance is the key event in the pathogenesis of T2DM.
The concentration of the adipose-specific adiponectin, which increases insulin sensitivity, diminishes in T2DM, adding to IR. Adiponectin acts via AMP kinase, an enzyme involved in various metabolic responses such as suppression of hepatic neoglucogenesis, glucose uptake in the exercising skeletal muscles, fatty acid oxidation and inhibition of lipolysis.</li>
</ul>
<p>A decrease in the mitochondrial oxidation of FFA in the liver and the muscle, leading to triglyceride accumulation, has also been suggested. Further, it has been suggested that a genetic variant of the normal PPAR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> (see later) results in/contributes to IR, primarily in the adipose tissue and secondarily in the liver. In predisposed individuals, an insulin secretory defect could be aggravated by obesity, acute illness or simple ageing leading to the onset of T2DM.</p>
<ul>
<li>Insulin deficiency: The normal pancreatic beta cells respond to IR by secreting more insulin (hyperinsulinemia) and maintaining the plasma glucose at or just above the upper limit of normal. Over a period of time, the beta cells develop insulin secretory</li>
</ul>
<p>defect as a result of progressive elevation of plasma glucose (glucotoxicity) and elevated FFA levels (lipotoxicity). Hyperglycemia may be toxic to the beta cells by inhibiting fatty acid oxidation (substrate competition) and local accumulation of FFA.
High fasting glucose levels indicate excessive hepatic glucose production due to either impaired insulin secretion or glucagon excess. Postprandial hyperglycemia, on the other hand, reflects impaired peripheral utilization of glucose which depends on sensitivity of the tissues to insulin.</p>
<p>A glycosylated hemoglobin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{HbA}_{1 \mathrm{C}}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6.5%</span></span></span></span></span> or higher (to be confirmed by repeat test) is now considered to be an additional independent criteria for diagnosis of DM.</p>
<p>In addition to IR, genetic predisposition, age, severe stress, multiple pregnancies and treatment with certain drugs, especially glucocorticoids, diminish the capacity of the beta cells to secrete insulin. Unless treated aggressively, the insulin secretory capacity of the beta cells continues to deteriorate, which is responsible for the progressive worsening of the disease.</p>
<p>Deficiencies of glucose regulating hormones like amylin and incretins (GLP-1and GIP) are also evident.</p>
<p>There is an increasing evidence that T2DM in various ethnic groups such as Asians and Africans may have probably different pathophysioogy.</p>
<p>Insulin deficiency results in:</p>
<ul>
<li>Decreased peripheral utilisation of glucose.</li>
<li>Decreased production of ATP.</li>
<li>Decreased synthesis of glycogen in liver and muscle.</li>
<li>Increased protein catabolism and neoglucogenesis.</li>
<li>Increased lipolysis with increased plasma levels of FFA; and decreased lipogenesis.</li>
<li>Increased neoglucogenesis with increased hepatic glucose output.</li>
<li>Increased ketogenesis; and</li>
<li>Depressed cell mediated immunity (CMI).</li>
</ul>
<p>Untreated, diabetes can cause impairment of general health, increased susceptibility to infections, retinal, renal, cardiovascular and neurological complications, diabetic coma and premature death. The aims of therapy are given in Table 65.12.</p>
<p>Table 65.12
Aims of therapy of diabetes mellitus</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- To control symptoms with diet, exercise and drugs
</span>    - To maintain the optimum body weight.
    - To correct the metabolic disturbances; and
    - To prevent or delay the degenerative vascular complications
    - To maintain normal growth in children.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- To control symptoms with diet, exercise and drugs
    - To maintain the optimum body weight.
    - To correct the metabolic disturbances; and
    - To prevent or delay the degenerative vascular complications
    - To maintain normal growth in children." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="an-ideally-controlled-diabetic-should">An ideally controlled diabetic should:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#an-ideally-controlled-diabetic-should" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Be free from classical diabetic symptoms of polyuria, polyphagia and polydipsia.
(b) Have steady, ideal body weight.
(c) Have venous plasma glucose levels as near normal (fasting less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>110</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">110 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">110</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> and postprandial less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">140 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">140</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ) as is possible without getting frequent/severe hypoglycemia. However, in old people and in patients with severe liver and kidney disease, cardiac disease and cerebrovascular disease, one often has to be satisfied with higher levels of blood glucose. A similar compromise is generally necessary in insulin dependent patients (especially long</p>
<p>standing) in order to avoid repeated hypoglycemia.
(d) Have less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.5</mn><mi mathvariant="normal">%</mi><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">6.5 \% \mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9em; vertical-align: -0.15em;"></span><span class="mord">6.5%</span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level is an index of the 'time averaged' blood sugar level over the previous 8-12 weeks (Blood Sugar Memory). In patients with history of severe hypoglycemia, advanced micro- or macrovascular complications, comorbidities, dementia and limited life expectancy HbA1C levels <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> are acceptable. Same holds true for elderly and young children at risk.
(e) Have not developed ketoacidosis without severe provocation (T2DM only); and
(f) Have normal plasma lipid levels. Diabetic children should have normal growth; and diabetic women should have normal pregnancies, and normal babies.</p>
<p>Table 65.13 summarises the venous plasma glucose and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> criteria for judging the level of metabolic control. Capillary blood glucose values are higher than venous plasma glucose values.</p>
<p>Table 65.13
Venous plasma glucose and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi>c</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 c}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">c</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> criteria for the degree of metabolic control</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">Good</th><th style="text-align: center;">Acceptable</th><th style="text-align: center;">Fair</th><th style="text-align: center;">Poor</th></tr></thead><tbody><tr><td style="text-align: left;">Venous plasma glucose:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Fasting</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>110</mn></mrow><annotation encoding="application/x-tex">&lt;110</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">110</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">120-140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>180</mn></mrow><annotation encoding="application/x-tex">140-180</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">180</span></span></span></span></span></td><td style="text-align: center;">Above 180</td></tr><tr><td style="text-align: left;">Postprandial</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">&lt;140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>180</mn></mrow><annotation encoding="application/x-tex">140-180</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">180</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>180</mn><mo>−</mo><mn>235</mn></mrow><annotation encoding="application/x-tex">180-235</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">180</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">235</span></span></span></span></span></td><td style="text-align: center;">Above 235</td></tr><tr><td style="text-align: left;">Hemoglobin</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">A</mi><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathbf{A}_{1 \mathrm{C}} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">&lt;6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>7.5</mn></mrow><annotation encoding="application/x-tex">6-7.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.5</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mo>−</mo><mn>9</mn></mrow><annotation encoding="application/x-tex">7.5-9</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">9</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>9</mn></mrow><annotation encoding="application/x-tex">&gt;9</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">9</span></span></span></span></span></td></tr></tbody></table>
<p>'Not to be attempted in T1DM. Good/excellent control mandatory during pregnancy.
Education of the patient is important and must include an understanding of his own disease, diet control, exercise, urine examination, insulin administration, adjustment of the insulin dosage, symptoms of hypoglycemia, the danger of neglecting the disease and the rewards of adherence to the prescribed regimen. Home blood glucose monitoring (HMBG) helps to improve the control.</p>
<p>The diet should be adjusted to bring the weight down to optimum and to maintain it there. Weight reduction in obese diabetics is accompanied by considerable improvement in hyperglycemia. In growing children, one must consider their continually changing caloric requirements. The total calories are generally divided as follows: protein calories 10<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>, fat calories <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> and carbohydrate calories <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>. Sugar consumption must be limited to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of the total daily calories consumed; and most of the carbohydrates be derived from starchy foods (complex carbohydrates). Also refer to Chapter 40.</p>
<p>The total daily intake should be divided into three meals and two snacks. The distribution of calories among the meals should be constant from day to day; this is of critical importance in those on insulin. Overeating and fasting must be avoided. Guar gum (Carbotard) in the dose of 5 g in 200 ml of water before each meal or sprinkled on food is used to slow the absorption of glucose derived from the meal.</p>
<p>Daily, physical exercise reduces insulin requirement. Sudden, unaccustomed, vigorous exercise, however, may precipitate hypoglycemia especially in patients on insulin; if it is unavoidable, extra food ( 15 g of carbohydrate for each hour of anticipated exercise) should be eaten prophylactically. Vigorous exercise can precipitate ketoacidosis in the juvenile diabetic</p>
<p>who has omitted insulin.
Along with lifestyle modification, prophylactic aspirin, unless contraindicated, is recommended in all patients with T2DM. A statin may be needed, regardless of the baseline lipid levels, in those who are at higher risk for CVD or have CVD, but not routinely.</p>
<p>Not all diabetics need insulin all the time. The choice of pharmacological therapy depends on whether it is T1DM or T2DM. The distinction between the two may sometimes not be clear. Further, what appears T2DM at the onset may sometimes be the earliest stage of late onset T1DM. Many T2DM patients in addition to diet and exercise, also need OHA to maintain glycemic control. After a variable lengths of time, they may also need insulin. T2DM patients also need insulin temporarily in the presence of a complication (Insulin Requiring DM, IRDM). T1DM patients need insulin lifelong for survival. Hence, phenotyping the patients into IDDM, NIDDM or IRDM can help in choosing the therapy, "insulin" or "no insulin." The indications for insulin are listed in Table 65.14.</p>
<p>Table 65.14
Indications for insulin therapy</p>
<ul>
<li>T1DM.</li>
<li>T2DM patientsnewly diagnosed with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">c</mi></mrow><mo>&gt;</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{HbAlc}&gt;10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7335em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">HbAlc</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">G</mi></mrow><mo>&gt;</mo><mn>260</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{HBG}&gt;260 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">HBG</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>, who are under-we ight, those who have a history of onset before 30-35 years and those whose diabetes is of long standing.</li>
<li>All diabetics with complications such as ketosis, infection, intractable pruritus, gangrene, congestive cardiac failure or progressive retinopathy.</li>
<li>During surgical procedures.</li>
<li>Diabetic pre-coma and coma.</li>
<li>Primary or secondary failure following oral antidiabetic therapy; and</li>
<li>Pregnant diabetics.</li>
</ul>
<p>Insulin therapy: Every diabetic may require insulin at some time in his life and it is lifesaving in some situations. Although no insulin preparation available can mimic the needoriented release of insulin by the patient's own pancreas, majority of diabetics can be managed by a judicious use of the available preparations. With the modern insulin syringes ( 1 ml divided into 40 or 100 parts), insulin dose can be adjusted in multiples of 1 unit.</p>
<p>Choice of insulin preparation: Commonly, the intermediate acting preparation, NPH and regular insulin (Table 65.3) are used.</p>
<p>The merits of regular (also called plain or soluble) insulin are rapid onset and short duration of action. This makes it convenient in
(a) Diabetic coma;
(b) Intensive insulin treatment (See later);
(c) Unstable diabetes and
(d) Postoperativel period.</p>
<p>For the same reason, it must be used when an illness such as infection, vomiting or diarrhoea prevents regular intake of meals and the patient is likely to get hypoglycemia with longer acting insulins. When it is decided to change over from short to intermediate acting insulin, it is desirable to commence therapy with a dose of the latter only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">2/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the total daily dose of the former.</p>
<p>The synthetic, human rDNA insulin analogues (lispro, aspart, glargine) have much to offer in terms of flexibility of the daily routine; but they are more expensive than the conventional and the SR insulins.</p>
<ul>
<li>T1DM: Diabetes in these patients tends to be severe and unstable. These patients tend to be unpredictable in their eating habits, sporadic in their exercise and prone to emotional outbursts, all of which can precipitate either diabetic coma or hypoglycemia. Added to this are the overanxious parents of a diabetic child.
Most patients need:
(a) An injection of regular insulin before each major meal with or without an additional dose of NPH before dinner or at bed time;
(b) A mixture of regular with NPH insulin (50:50 rather than 30:70) before breakfast and before dinner (Split-mixed regimen). This method with a minimum of 2 blood tests (before breakfast and before dinner) is perhaps the simplest and the most convenient way to control blood glucose levels over 24 hrs; or
(c) An injection of glargine insulin at bed time + an injection of lispro, aspart or SR regular insulin before each major meal, which can offer the patient the maximum flexibility. This, however, is an expensive regimen.</li>
</ul>
<p>Long acting insulin formulations provide constant basal background insulin level whereas short acting ones are given to cover the prandial peaks.</p>
<p>In some unstable, poorly controlled patients, regular insulin has to be injected SC several times a day (intensified insulin treatment) under guidance from blood sugar determination (by patient) on capillary blood, using finger prick and a portable reflectance meter, several times a day (home blood glucose monitoring, HMBG). Such therapy is also educative for the patient; he can see the blood sugar values instantly, correlate them with his symptoms and can learn to take corrective measures by increasing or decreasing the dose of insulin.</p>
<p>Studies have demonstrated that aggressive treatment of T1DM and probably T2DM to achieve tight control of hyperglycemia reduces the microvascular complications of DM but not IHD. Rigorous control of BP is more effective for the latter purpose. However, such regimens demand intelligent, highly motivated and disciplined patients, which is difficult in practice, particularly in elderly. In ederly, an attempt to achieve such tight control is associated with potential harm. In them, the mantra is "treat the patient and not the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Pay more attention to the risk factor, particulary hypertension". It is wise to aim for a target <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> concentration up to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">8 \mathrm{gm} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">%</span></span></span></span></span> in patients older than 65 years with comorbidities.</p>
<p>Although battery operated, computerised, portable, insulin pumps have been used to deliver insulin under the skin, their use is tedious, inconvenient, and needs careful supervision.</p>
<p>A needle-free system (Jet injection) for SC delivery of insulin is available.</p>
<ul>
<li>Management of an adult with T2DM without any complication: In most such patients, diabetes is stable and relatively mild.
It can be controlled with diet and exercise with or without oral antidiabetic drugs (OHA). Table 65.15 outlines a suggested plan for the routine management of uncomplicated T2DM.</li>
</ul>
<p>Table 65.15
Management of uncomplicated T2DM</p>
<table><thead><tr><th style="text-align: center;">Initial treatment:</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Diet and exercise</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">If poor response</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Initial drug treatment</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">FPG (mg/dl)</td><td style="text-align: center;">Bodily habitus</td><td style="text-align: center;">Drug</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">&lt;140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;">Normal weight or obese</td><td style="text-align: center;">Metformin</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">&lt;140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;">Underweight</td><td style="text-align: center;">Insulin or sulfonylurea</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">&gt;140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;">Moderately or severely obese</td><td style="text-align: center;">Metformin</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>140</mn></mrow><annotation encoding="application/x-tex">&gt;140</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">140</span></span></span></span></span></td><td style="text-align: center;">Underweight</td><td style="text-align: center;">Insulin or sulfonylurea</td></tr><tr><td style="text-align: center;">If poor response</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Underweight &lt;br&gt; - Normal weight or obese</td><td style="text-align: center;">Add insulin/glitazone Add sulfonylurea or metformin</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">If poor response</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Underweight &lt;br&gt; - If normal weight or mildly obese &lt;br&gt; - If moderately or severely obese</td><td style="text-align: center;">Change to insulin Pre-breakfast and bedtime NPH Add pre-dinner mixture (30:70) of plain and NPH insulin</td><td style="text-align: center;"></td></tr></tbody></table>
<p>FPG = Fasting plasma glucose
For use of acarbose and glitazones, see text. Some authorities use a glitazone as the first line drug in T2DM.
*Use of insulin from the diagnosis is now favoured by many authorities (see text).
Table 65.16 summarises the important drugs used in T2DM. For patients needing insulin often a single injection of NPH given before breakfast can control the disease. If this does not help, regular insulin has to be added to NPH insulin as followos:</p>
<p>Table 65.16
Drugs used in T2DM</p>
<table><thead><tr><th style="text-align: center;">Drug Class</th><th style="text-align: center;">Site of action</th><th style="text-align: center;">FPG</th><th style="text-align: center;">PPG</th><th style="text-align: center;">HbA &lt;br&gt; reduction</th><th style="text-align: center;">ADR</th><th style="text-align: center;">Weight &lt;br&gt; gain</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Insulin</td><td style="text-align: center;">Several</td><td style="text-align: center;">Excellent</td><td style="text-align: center;">Excellent</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>÷</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1 \div 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">÷</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;">Hypoglycemia</td><td style="text-align: center;">Marked</td><td style="text-align: center;">Adx 1. Useful in emergency situations &lt;br&gt; 2. Long term reduction in microvascular risk; Disade: Available as injectable only</td></tr><tr><td style="text-align: center;">Sulfonylureas &lt;br&gt; (Gliptzide, &lt;br&gt; glimeperide)</td><td style="text-align: center;">Beta cells</td><td style="text-align: center;">Good</td><td style="text-align: center;">Good</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;">Hypoglycemia</td><td style="text-align: center;">Moderate</td><td style="text-align: center;">Adx 1. Inexpensive &lt;br&gt; 2. Long term reduction in microvascular risk; Disade: Possible aggravation of myocardial ischemia</td></tr><tr><td style="text-align: center;">Nonsulfonylureas &lt;br&gt; (Repaglinide)</td><td style="text-align: center;">Beta cells</td><td style="text-align: center;">Fair</td><td style="text-align: center;">Good</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.5</mn></mrow><annotation encoding="application/x-tex">0.5-1.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span></span></span></span></span></td><td style="text-align: center;">Hypoglycemia (occasional)</td><td style="text-align: center;">Moderate</td><td style="text-align: center;">Adx Short acting &lt;br&gt; Disade: To be taken just before each meal</td></tr><tr><td style="text-align: center;">Metformin</td><td style="text-align: center;">Liver</td><td style="text-align: center;">Good</td><td style="text-align: center;">Good</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">1-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span></td><td style="text-align: center;">Anorexia, nausea</td><td style="text-align: center;">Less gain or loss</td><td style="text-align: center;">Adx 1. Prevention of weight gain &lt;br&gt; 2. No hypoglycemia Disade Causes GI intolerance</td></tr><tr><td style="text-align: center;">Alpha glucosidase inhibitors (Acarbose)</td><td style="text-align: center;">Intestine</td><td style="text-align: center;">Poor</td><td style="text-align: center;">Excellent</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.3</mn></mrow><annotation encoding="application/x-tex">0.5-1.3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.3</span></span></span></span></span></td><td style="text-align: center;">Bloating</td><td style="text-align: center;">Less gain</td><td style="text-align: center;">Adx Reduces postprandial hyperglycemia Disade: GI intolerance</td></tr><tr><td style="text-align: center;">Glitazones &lt;br&gt; (Pioglitazone)</td><td style="text-align: center;">Muscle adipocytes</td><td style="text-align: center;">Good</td><td style="text-align: center;">Good</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">0.5-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span></td><td style="text-align: center;">Hepatotoxicity</td><td style="text-align: center;">Moderate</td><td style="text-align: center;">Adx Increases insulin sensitivity &lt;br&gt; Disade: CVS safety doubtful and possible risk of bladder cancer</td></tr><tr><td style="text-align: center;">DPP-4 inhibitors (Sitagliptin, Vildagliptin)</td><td style="text-align: center;">GIT</td><td style="text-align: center;">fair</td><td style="text-align: center;">good</td><td style="text-align: center;">0.5</td><td style="text-align: center;">Hypoglycemia can occur when added to insulin or sulfonylureas, pancreatitis, hypersensitivity reactions, hepatic failure</td><td style="text-align: center;">Less gain or loss</td><td style="text-align: center;">Adx No effect on weight &lt;br&gt; Disade 1. Less effective than sulfonylureas or GLP analogs &lt;br&gt; 2. ADRs can be fatal</td></tr><tr><td style="text-align: center;">SGLT2 inhibitors (Dapagliflozin, Canagliflozin)</td><td style="text-align: center;">Kidney</td><td style="text-align: center;">good</td><td style="text-align: center;">good</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">0.5-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;">Genital mycotic infections, UTI, volume depletion</td><td style="text-align: center;">Less gain or loss</td><td style="text-align: center;">Adx Low risk of hypoglycemi Disade: Frequent UTI</td></tr><tr><td style="text-align: center;">Amylinomimetics (Pramlintide)</td><td style="text-align: center;">GIT, central</td><td style="text-align: center;">fair</td><td style="text-align: center;">good</td><td style="text-align: center;">0.5</td><td style="text-align: center;">Hypoglycemia, nausea vomiting, abdominal pain, decreased appetite, fatigue</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;Loss&nbsp;by&nbsp;</mtext></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>1</mn><mo>−</mo><mn>1.5</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} \text { Loss by } \\ 1-1.5 \\ \mathrm{~kg} \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 4.5em; vertical-align: -2em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;Loss&nbsp;by&nbsp;</span></span></span></span><span style="top: -3.16em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">1.5</span></span></span><span style="top: -1.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Adx 1. It is added to meal time insulin decreasing insulin dose &lt;br&gt; 2. Reduces postprandial hyperglycemia Disade: Cannot be mixed with insulin in same syringe</td></tr><tr><td style="text-align: center;">GLP-1 agonists (Exenatide)</td><td style="text-align: center;">Beta cells, GIT</td><td style="text-align: center;">Fair</td><td style="text-align: center;">excellent</td><td style="text-align: center;">1</td><td style="text-align: center;">Nausea, vomiting, diarrhea, URTI, pancreatitis, renal toxicity, hypersensitivity reactions</td><td style="text-align: center;">Less gain or loss</td><td style="text-align: center;">Adx 1. Causes weight loss 2. Long acting &lt;br&gt; Disade 1. Available as injectable only &lt;br&gt; 2. ADRs can be fatal</td></tr></tbody></table>
<p>FPG= Fasting glucose, PPG= Postprandial glucose, Adv: Advantage, Disadv: Disadvantage
(1) The intermediate acting NPH insulin is started with 5-10 units SC daily half an hour before breakfast. Blood sugar is determined while fasting, before lunch, before dinner and at bed time (day-profiling).
(2) The dose of insulin is increased by 2-5 units once in 3-4 days till pre-dinner blood sugar is normal.
(3) If the pre-lunch blood sugar is still high, a small dose (5-10 units) of regular insulin is</p>
<p>added to the pre-breakfast dose of NPH.
(4) Persistence of hyperglycemia at bedtime is treated by giving an additional dose of regular insulin before dinner.
(5) If the dose of NPH given before breakfast does not control next morning's fasting hyperglycemia while normalising the blood sugar at other times, a small dose of NPH should be added before dinner or at bed time.</p>
<p>Some patients may ultimately need a mixture of regular and NPH before breakfast and before dinner with or without regular insulin before lunch. In some of these, addition of an oral antidiabetic drug may improve the diabetic control.</p>
<p>Some physicians initiate therapy with a small (5-10 units) dose of NPH at bedtime, to normalise the fasting blood glucose. Some patients may be controlled by BIDS (Bedtime Insulin and Daytime Sulfonylurea) regimen.</p>
<p>Persistent elevations of post-prandial blood sugars contribute in a major way to the occurrence of chronic degenerative complications of diabetes. Very short-acting insulin analogues, lispro and aspart, are effective in controlling postprandial hyperglycemia even when injected immediately before or within 5 minutes of commencing a meal. This makes them easier to use than SR insulin preparations.</p>
<p>Currently, it is felt that early insulin therapy is preferable to OHA in young patients because although tablets are easier to take, early initiation of insulin may result in lower <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">A</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{HbA}_{1 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HbA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> levels and better long term preservation of endogenous insulin secretion as compared to oral antidiabetic drugs.</p>
<ul>
<li>
<p>Management of an adult with T2DM on insulin and a complication such as acute infection: Under these conditions, insulin requirements go up and ketoacidosis may develop. If the patient can continue to take his normal meals, the insulin regimen need not be changed. If the patient cannot take his normal meals, he must be given a liquid diet containing plenty of salt and about 200 g of carbohydrates per day (Sick Day Dietary Regimen). He is encouraged to take portions of this every 3-4 hours and regular insulin (10-50 units) is given SC every 6 hours after appropriate blood sugar determination. Salted buttermilk, vegetable soup, milk, fruit juice, with added sugar, are suitable items of food for these patients. As soon as the patient can take solid food, he can resume his original insulin regimen.
Insulin resistance is defined as the requirement of more than 2 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">/ \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. It may be acute or chronic.
(a) Acute insulin resistance is associated with surgical or other trauma, emotional disturbance or infection. It is treated with elimination of its cause and administration of as much insulin as is required to attain normal blood sugar levels.
(b) Chronic insulin resistance may be due to:</p>
</li>
<li>
<p>Noncompliance.</p>
</li>
<li>
<p>Associated medical/endocrine disorders such as acromegaly or hypercortisolism.</p>
</li>
<li>
<p>Genetic, insulin-receptor abnormality: This is associated with hyper-insulinemia, hypertriglyceridemia, hypertension and IHD (Reaven Syndrome), a precursor of T2DM.</p>
</li>
<li>
<p>Insulin antibodies; Insulin antibodies develop in all persons who receive the available preparations of insulin. They are likely to develop in high titre in patients who have received insulin intermittently rather than continuously. Such resistance may respond to prednisolone (60-100 mg daily)</p>
</li>
<li>
<p>Lipoatrophic type of diabetes.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-emergencies-in-the-diabetic">Management of Emergencies in the Diabetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-emergencies-in-the-diabetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Keto-acidotic diabetic coma: T1DM patients are ketosis prone and diabetic coma can be precipitated by merely omitting insulin. In T2DM, it is likely to be precipitated by a severe infection or acute MI.</p>
<p>Pathophysiology: The deficiency of effective insulin action under these circumstances brings about:</p>
<ul>
<li>Failure of peripheral glucose utilisation, increased mobilisation of muscle protein and increased neoglucogenesis, leading to hyperglycemia.</li>
<li>Impaired oxidation of glucose leading to non-availability of pyruvate.</li>
<li>Excessive mobilisation of FFAs (lipolysis) from the adipose tissue, leading to excessive production of ketone bodies acetoacetic and beta-hydroxy butyric acids. These organic acids contribute to (a) metabolic acidosis and (b) by being excreted as salts of sodium and potassium in the urine, deplete the body sodium, potassium and water.
Metabolic acidosis causes a shift of potassium and phosphorus out of the cells. Their loss in the urine can result in severe potassium and phosphate depletion.</li>
<li>Depletion of liver glycogen due to increased hepatic glycogenolysis.</li>
<li>Dehydration due to solute diuresis due to hyperglycemia, glycosuria and acidosis.</li>
</ul>
<p>The urine is loaded with sugar and ketone bodies and the breath smells of acetone. The blood sugar is commonly in the range of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">600-800 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">600</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. Plasma bicarbonate is markedly reduced and the blood pH is lowered.</p>
<p>Management: The diagnosis must be confirmed before starting treatment. If hypoglycemic coma cannot be ruled out, IV glucose ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi><mo separator="true">,</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50 \%, 50 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">50%</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) should be tried first.</p>
<p>On admission, blood is withdrawn for the following estimations, which must be repeated every 2 hours: glucose, bicarbonate, serum potassium, sodium, creatinine and hematocrit.</p>
<p>The following clinical data are recorded on admission and one hourly after that : pulse rate, blood pressure, temperature, fluid intake and output, glycosuria, ketonuria and ketonemia.</p>
<p>The principles of management of ketoacidotic diabetic coma are outlined in Table 65.17.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-65-17">Table 65.17<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-65-17" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Principles of management of diabetic ketoacidosis</p>
<ul>
<li>Rapid correction of dehydration.</li>
<li>Rapidly acting regular insulin, early and enough.</li>
<li>Correction of acidosis.</li>
<li>Treatment of precipitating cause, if found.</li>
<li>Correction of hypokalemia and hypophosphatemia.</li>
<li>Nusing management.</li>
<li>Measure capillary glucose every 1-2 hily and electrolytesevery 4 hily for 24 hrs.</li>
<li>Correction of dehydration: Normal saline is infused as follows: 1.5 litre in the first hour; one litre per hour for the next 3-4 hours; and 1 litre every 4 hours, thereafter. Half strength ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> ) saline is used only if the initial plasma sodium is more than 150 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mEq} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span></span></span></span></span> litre. In elderly patients and in those with cardiovascular disease, titrate the rate of infusion according to the CVP. Plasma expanders may be used to treat severe hypotension. When blood glucose reaches <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>, glucose and potassium should be added to</li>
</ul>
<p>the saline infusion.</p>
<ul>
<li>Insulin: Continuous, low dose, insulin infusion (CLDII) is effective, physiological and safe. Administration of 5-10 units (generally 0.1 unit/kg) of regular insulin per hour by continuous IV infusion maintains the plasma insulin at about 100-200 microunits/ml, which is effective in correcting the ketoacidosis. In general, patients with infection show insulin resistance due to:
(a) Acidosis and
(b) Mainly by infection itself. Advantages of CLDII are listed in Table 65.18.</li>
</ul>
<p>Table 65.18
Advantages of CLDII</p>
<ul>
<li>It provides a predicTable fall of blood glucose, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-100 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> per hour. In the presence of infection, the rate of fall is lower.</li>
<li>It is safe and rarely causes hypoglycemia, hypokalemia or cerebral edema. Stopping the insulin drip quickly corrects the hypoglycemia, should it develop.</li>
<li>Previous insulin therapy does not affect the response to it.</li>
<li>It has sound pharmacokinetic basis; and</li>
<li>It is simple to use and can be administered by trained running staff.</li>
</ul>
<p>With minor modifications, the same regimen can be used to treat hyperglycemic, hyperosmolar, nonketotic diabetic coma.</p>
<p>Possible adsorption of insulin to the glass bottle and the tubing can be overcome by addition of albumin to the infusate. In actual practice, isotonic saline serves the purpose equally well. About 20-50 ml of insulin in saline should be run through the infusion set before connecting it to the patient.</p>
<p>Operationally, an insulin infusion may be set up as follows:
(a) Add 100 units of regular insulin to 1000 ml of isotonic saline solution. Start a drip through a pediatric scalp vein set, the needle being inserted into a forearm vein.
(b) Infuse at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">40-50 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> hour ( 10 drops/minute). This works out to 5-6 units/hour. Taking into account the adsorption of insulin to the glass and the tubing, the effective rate of delivery may be 3-4 units per hour.
(c) If blood glucose shows no response at the end of 2 hours, double the rate of insulin infusion.
(d) When blood glucose comes down to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>, (i) decrease insulin to 3 units per hour; and (ii) add 50 g of glucose and 20 mEq of potassium to each litre of infusion fluid.
(e) Continue the infusion till the patient starts eating normally. Then, start SC insulin 30 minutes before discontinuing the infusion.
Nothing else should be added to the insulin saline drip. It is advisable to run this drip as a side drip into the tubing of the main fluid drip.</p>
<p>If IV infusion of insulin is not possible, regular insulin may be injected IM (Not SC) in the dose of 20 units initially, followed by 5 units once every hour. When IM route is used, rehydration becomes critical, Usually, one litre of isotonic saline is given rapidly followed by another litre in one hour.</p>
<p>Subcutaneous insulin as used in the past often failed to be absorbed in the presence of dehydration and shock, thus creating an apparent initial picture of 'insulin resistance'. Further, after correction of shock, large quantities of insulin were absorbed rapidly, causing hypoglycemia. On the other hand, because of short half life of insulin, intermittent, large, IV doses of insulin produce markedly fluctuating plasma insulin levels. Hence, the rate of reduction of blood glucose could not be controlled.</p>
<p>An excessively rapid reduction in blood glucose should be avoided as it can cause:
(a) Severe hypoglycemia.
(b) Hypokalemia, as the extracellular potassium accompanies glucose into the cell; and
(c) Cerebral edema as the plasma osmolality diminishes rapidly. This complication is abated by rapid correction of acidosis.</p>
<ul>
<li>Correction of acidosis: Acidosis, if severe (arterial blood pH less than 7.0), is corrected by 50 mEq IV sodium bicarbonate (Chapter 37).</li>
<li>Treatment of the precipitating cause: Infection is treated with antibiotics. Routine administration of antibiotics prophylactically is, however, not recommended.</li>
<li>Potassium and phosphorus: As soon as urine output is satisfactory, 20 mEq of potassium per hour through the drip is started. It is generally given as potassium chloride ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo>=</mo><mn>26</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{~g}=26 \mathrm{mEq}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">26</span><span class="mord"><span class="mord mathrm">mEq</span></span></span></span></span></span> of K). If available, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>2</mn></msub><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{2} \mathrm{HPO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">HPO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (equivalent to 20 mEq of potassium) may be added to the drip instead of KCl . It gives not only potassium but also phosphorus which is depleted in such cases. As soon as the patient can take orally, milk can be given as a rich source of phosphorus, and fruit juice and soups can provide potassium.</li>
<li>Nursing care: Excellent nursing care is essential in the management of a patient in diabetic coma. Attention to skin, mouth, position and bladder are a must. Catheterisation of bladder should be avoided. After second day of the recovery, the patient should return to his</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="normal-food-and-insulin-regimen">normal food and insulin regimen.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-food-and-insulin-regimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hyperglycemic, hyperosmolar, nonketotic coma: This is a less common form of metabolic coma which occurs in aged diabetics who have just enough (exogenous or endogenous) insulin to prevent ketosis but not hyperglycemia. The blood sugar level may be in excess of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1000 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> and may be as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2700</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2700 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">2700</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. Dehydration is severe. The treatment is similar to that of diabetic coma except that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> sodium chloride solution is required in very large quantities. Heparin is given to prevent clotting. Insulin should be omitted when the blood sugar reaches about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>.</p>
<p>Surgery in a diabetic: Patients detected to be diabetic just before an emergency operation, T1DM patients, and patients with T2DM on insulin and on oral antidiabetic drug should be managed with low dose continuous insulin infusion during and after major surgery. Those on oral antidiabetic drug and undergoing minor surgical procedures such as cataract surgery (after which the meal pattern will not change) can be managed with drug alone. Those on diet alone should receive insulin as and when necessary after surgery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hyperglycemic-agents">Hyperglycemic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hyperglycemic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>GLUCAGON: Glucagon is a single-chain polypeptide made of 29 amino acids, with a molecular weight of 3485 . It is synthesised, stored and secreted by the alpha cells of the islets of Langerhans in response to a fall in blood glucose and a rise of plasma amino acids.</p>
<p>Pharmacological actions: Glucagon is the most potent glycogenolytic hormone known and produces a rapid rise in blood glucose by activating the hepatic phosphorylase via cyclic AMP. It is the body's second defence against hypoglycemia in healthy people, the first being reduction in plasma insulin level in response to diminishing blood glucose concentration; the latter is not operative in patients receiving either insulin or an oral antidiabetic drug. Glucagon stimulates neoglucogenesis only in the presence of glucocorticoids and stimulates lipolysis in the peripheral tissues, which, in turn stimulates ketogenesis.</p>
<p>Glucagon also has a significant positive inotropic action on the heart by stimulating adenylyl cyclase.</p>
<p>Absorption, fate and excretion: Given orally, it is degraded by proteolytic enzymes. After parenteral administration, it is absorbed rapidly but has a short plasma half life (3-6 min). It is degraded mainly in the liver, kidneys and plasma.</p>
<p>Preparations and dosage: Injection glucagon hydrochloride, 1 mg Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> SC, IM or IV.</p>
<p>As glucagon may infrequently cause nausea and vomiting, it should be injected when the patient is lying down on one side.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>For treating insulin hypoglycemia. Glucose IV is the treatment of choice. Glucagon is administered IM in the dose of 1 mg . If consciousness is not regained, 1 mg IV may be injected. In about 45 min from onset of coma, liver glycogen gets exhausted and use of glucagon after this period is ineffective.</li>
<li>To diagnose the hepatic form of glycogen storage disease wherein it fails to raise the blood sugar level on IV injection.</li>
<li>In beta-blocker toxicity with shock (Chapter 31).</li>
<li>Bradycardia in cardiogenic shock unresponsive to atropine: 2-10 mg IV in 5% glucose followed by an infusion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} / \mathrm{kg} / \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span>.
DIAZOXIDE: This benzothiadiazine analogue is a potent oral hyperglycemic agent. Its effects are reversible.</li>
<li>It inhibits the insulin release from the beta cells of the pancreas by an alpha-adrenergic mechanism.</li>
<li>It stimulates release of catecholamines from the adrenal medulla. The latter also inhibit insulin release by beta cells.</li>
<li>It increases the hepatic glucose output, through a beta-adrenergic mechanism; and</li>
<li>It is a direct vasodilator when administered IV (Chapter 30).</li>
</ul>
<p>The important adverse effects are water retention with edema, hirsutism and with high doses nausea, vomiting and hypotension.</p>
<p>The oral dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3-5 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day in 2-3 divided doses. A thiazide diuretic is commonly given along with it to prevent edema.</p>
<p>Therapeutic uses:</p>
<ul>
<li>In the treatment of resistant hypoglycemias such as those due to insulinoma, glycogen storage disease and leucine-sensitive hypoglycemia.</li>
<li>In hypertensive emergencies (Chapter 30).</li>
</ul>
<p>Table 65.19 lists the drugs which affect the blood glucose level.
Table 65.19
Drug induced hyperglycemia and hypoglycemia</p>
<ul>
<li>Drugs which cause hyperglycemia: Hormones: Glucagon, GH glucocorticoids; thyroid hormones; estrogens; progestogens; adrenaline and noradrenaline. Other drugs: Beta adrenergic receptor agonists; diazoxide; phenytoin; Atypical antipsychotics; Amphotericin B; thiazides; Calcineurin inhibitors; Protease inhibitors; nicotinic acid in large doses.</li>
<li>Drugs which cause hypoglycemia: MAO inhibitors; beta adrenergic receptor blockers; disopyramide; alcohol; ACE inhibitors; quinine; lithium; large doses of salicylates; Ranolazine.</li>
<li>Drugs which cause hypoglycemia unawareness: Nonselective beta adrenergic blockers, e.g., propranolol.</li>
<li>Drugs which cause hypoglycemia/hyperglycemia: Fluoroquinolones; Pentamidine.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sweetening-agents">Sweetening Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sweetening-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are non-carbohydrate substances devoid of food value, used as sugar substitutes in diet and beverages. Used in small amounts, they are considered harmless even in pregnancy. They do not contribute to dental caries. They are:
(1) Saccharin: It is commonly employed as the sodium salt which is comparatively free from the unpleasant after-taste of saccharin. Saccharin tablet contains 12 mg of saccharin. One tablet is approximately equivalent to 1 teaspoonful of sugar ( 7.5 g sucrose).
(2) Aspartame (Equal, Sugar-free Gold): Aspartame is a dipeptide formed by a synthetic combination of two natural amino acids, L-aspartic acid and the methyl ester of phenylalanine. It is 200 times sweeter than sucrose. It decomposes if exposed to high temperatures as in cooking and then loses its sweet taste.
(3) Neotame: This analogue of aspartame is water soluble and more heat stable at neutral pH . It is, therefore, suitable for use in cooked food. It is about 30-60 times sweeter than aspartame, and is claimed to have 'flavour enhancing' property. It increases the perception of flavours such as fruit flavours.
(4) Sucralose (Splenda, Sugar-free Natura): This zero calorie trichlorinated sucrose is 600 times as sweet as the native sucrose. The body does not recognise it as either carbohydrate or fat. It is not absorbed, nor metabolised, and is excreted unchanged in the faeces. Currently it is perhaps the most popular sweetening agent.
(5) Natural product: Extract of Stevia rebaudiana is a natural sweetener and is used widely over the world as OTC product. It has been used by the Guaraní people of South America for more than 1,500 years. Although it has 'sweetish' taste, it is not 'sweet' like other sweetening agents. It s long term safety is not known.</p>
<p>66</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenal-cortical-steroids">Adrenal Cortical Steroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenal-cortical-steroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Publication by Thomas Addison's in 1855 on 'The Clinical Picture of Adrenal Destruction' attracted the attention of physiologists to the importance of the adrenal cortex. Subsequent experiments established that the adrenal gland was necessary for survival and that the cortex and not the medulla was essential for survival. Of the steroids isolated from the cortex, hydrocortisone, cortisone, corticosterone, desoxycorticosterone, dehydrocortisol and aldosterone were shown to be biologically active. In the meanwhile, adrenocorticotropin (ACTH) or corticotropin, isolated from the adenohypophysis (1943), was shown to be responsible for the structural and functional integrity of the adrenal cortex. The work by Hans Selye, regarding the relationship between the adrenal cortex and stress, stimulated extensive research in adrenal physiology. Observation of the relief of symptoms of rheumatoid arthritis during pregnancy led to the use of cortisone (1948) in its treatment by Hench, who received the Nobel prize in medicine, jointly with Kendall and Reichstein.</p>
<p>The adrenals consist of an outer cortex and an inner medulla, which are structurally and functionally different from each other. The adrenal cortex consists of three zones; from without inwards, they are zona glomerulosa, zona fasciculata and zona reticularis.</p>
<p>Pituitary-adrenal relationship: The hypothalamus, pituitary and the adrenal cortex form the HPA axis. ACTH maintains the structure and regulates the function of the adrenal cortex. It is secreted by the pituitary basophil cells (corticotrophs) and is a polypeptide with 39 amino acids. The first 24 amino acids which determine its biological activity are common to the hormone obtained from cattle, pig, sheep and man. The arrangement of the remaining 15 amino acids shows species variation. Melanocyte stimulating hormone (MSH) from the anterior pituitary has a sequence of amino acids identical with that of the first 13 of ACTH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenocorticotropin">Adrenocorticotropin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenocorticotropin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Regulation of ACTH release: A corticotropin releasing hormone (CRH), formed by hypothalamus, is stored in the medial eminence, and from there reaches the anterior pituitary via the portal circulation. It stimulates the synthesis and release of ACTH. 5-HT probably plays an important role in the release of ACTH. Cyproheptadine, a 5-HT antagonist, inhibits the normal rise of plasma cortisol following insulin-induced hypoglycemia. Further, its oral administration causes a significant depression in the plasma cortisol level.</p>
<p>The term cortisol refers to the native hormone of the adrenal cortex present in the biological fluids; whereas the term hydrocortisone is used to refer to the synthetic substance used therapeutically.</p>
<p>Diurnal fluctuations in the rate of release of ACTH regulate the rates of secretion of cortisol and corticosterone. The plasma level of cortisol modulates the rate of release of CRH and in turn that of ACTH by negative feedback mechanism. Thus, increased plasma level of cortisol inhibits ACTH release and reduces its store in the adenohypophysis. Decreased plasma level of cortisol, as in Addison's disease, stimulate ACTH secretion. This delicately balanced mechanism thus regulates the plasma level of cortisol within normal limits.</p>
<p>Under stressful situations, neuronal impulses from higher centres stimulate release of CRH which ultimately elevates the output of cortisol to meet the increased demands of the body. This important homeostatic mechanism which overrides the diurnal variations in ACTH secretion as well as its regulation by plasma cortisol level is deranged in various disease states and in the functional suppression of the HPA complex by glucocorticoid administration.</p>
<p>The rate of secretion of cortisol is maximum in the early hours of the morning, declines during the day and reaches a minimum at about midnight, the plasma level being highest at about 6 am . Synthetic CRH is a 41 amino acid polypeptide that can be used to evaluate ACTH reserve of the anterior pituitary.</p>
<p>In addition to CRH, arginine vasopressin (Chapter 39) also stimulates the release of ACTH from the corticotropes. It plays an important role in the full magnitude of the stress response.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-action-of-acth">Pharmacological action of ACTH:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-action-of-acth" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>On the adrenal cortex: ACTH stimulates the adrenal cortex to synthesise and secrete cortisol and corticosterone, and weak androgens. In hypophysectomised animals, the adrenal cortex undergoes atrophy and secretion of cortisol is markedly depressed and does not rise in a normal fashion in response to 'stressful' stimuli. Such atrophy can be prevented by administration of ACTH. Secretion of aldosterone is, however, relatively unaffected after hypophysectomy.
ACTH stimulates the steroidal synthesis by adrenal cortex by acting on the cell membrane receptors, activating the adenylyl cyclase system and increasing intracellular cyclic AMP. Further, it accelerates the intracellular conversion of cholesterol to pregnenolone, the rate limiting step in the synthesis of adrenocortical steroids.</li>
</ul>
<p>Prolonged elevation of ACTH level causes hyperplasia and hypertrophy of the adrenal cortex with increased secretion of cortisol, corticosterone and weak androgens. The pharmacological actions of ACTH are in fact the pharmacological actions of these hormones,</p>
<p>mainly cortisol. (See later).</p>
<ul>
<li>Extra-adrenal effects: These are of less clinical importance and include cutaneous pigmentation, lipolysis in adipose tissue, ketosis and insulin resistance.
Absorption, fate and excretion: ACTH is administered IM/IV. It is well absorbed after IM injection with plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 15 minutes. It is rapidly metabolised and only a negligible amount appears in the urine. The quantitative response to a given dose of ACTH is greater when it is given:</li>
<li>In the morning than in the evening; and</li>
<li>By slow IV infusion than as an IV bolus.</li>
</ul>
<p>Adverse reactions: Apart from the rare allergy, all other adverse actions of ACTH are due to increased secretion of adrenocorticosteroids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Synthetic ACTH: This contains the first 24 of the 39 amino acids of natural ACTH. The biological activity of 1 mg is equal to 10 units of the natural preparation. The preparations are:
(i) Cosyntropin solution, 250 mcg for IM or IV injection.
(ii) Cosyntropin zinc-phosphate suspension, 1.0 mg IM.</p>
<p>Uses of ACTH:</p>
<ul>
<li>Diagnostic: Short ACTH stimulation test is performed by injecting 250 mcg of cosyntropin IM or as an IV bolus and measuring plasma cortisol at 60 minutes; a level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">18 \mathrm{mcg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> or higher indicates normal functioning of the HPA axis.
It is no more used in therapeutics.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hormones-of-the-adrenal-cortex">Hormones of the Adrenal Cortex<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormones-of-the-adrenal-cortex" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The adrenal cortex is divided into three zones which elaborate corticosteroids (mineralocorticoids and glucocorticoids) and weak androgens. The zones are:</p>
<ul>
<li>Zona glomerulosa which synthesizes aldosterone and desoxycorticosterone (mineralocorticoids).</li>
<li>Zona fasciculata which secretes cortisol (glucocorticoid) mainly; and</li>
<li>Zona reticularis which forms dehydroepiandrosterone (DHEA) and androstenedione (androgens) and traces of estrogens.
Chemistry and synthesis: The adrenal cortical hormones are steroids (Fig. 66.1) consisting of cyclopentanophenanthrene ring with various functional groups ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mi mathvariant="normal">H</mi><mo separator="true">,</mo><mo>−</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></mrow><annotation encoding="application/x-tex">-\mathrm{H},-\mathrm{CH} 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">−</span><span class="mord mathrm">H</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathrm">CH</span></span><span class="mord">3</span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo separator="true">,</mo><mo>=</mo><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">\mathrm{OH},=\mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">O</span></span></span></span></span> ) attached to carbon atoms. All steroid hormones have similar basic structure, with minor differences which, however, cause striking alteration in their biological activity. They are sparingly soluble in water and circulate in association with binding proteins.
<img src="assets/images/image-20251214-2a8c6eb9.jpeg" alt="img-40.jpeg"></li>
</ul>
<p>FIG. 66.1 Cyclopentanophenanthrene ring
All the steroids can be synthesised basically from 2-carbon acetate chains via cholesterol. Cholesterol is converted through pregnenolone to progesterone. Progesterone is an intermediary in the synthesis of other steroids and is not secreted by the adrenal cortex. After progesterone, the synthetic pathways for the three groups of hormones separate out (Fig. 65.2). These steroids are secreted into the blood as they are formed, and are not stored in the adrenal cortex in any significant quantities. Administered cortisone is converted in the body to the active compound cortisol.</p>
<p>Secretory rate of cortisol is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day and that of corticosterone that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.
The various steps in the synthesis of these steroids are governed by specific enzymes. These enzymes, especially those concerned in synthesis of cortisol, are sometimes congenitally deficient, leading to a deficiency of cortisol and an excess of ACTH and the adrenal androgens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="steroidal-synthesis-can-be-reduced-by">Steroidal synthesis can be reduced by:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#steroidal-synthesis-can-be-reduced-by" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Metyrapone which selectively inhibits synthesis of cortisol and corticosterone. It was used for testing adrenal function.</li>
<li>Aminoglutethimide which acts by blocking the conversion of cholesterol to pregnenolone. It reduces the synthesis of all steroid hormones.</li>
<li>Ketoconazole, an antifungal agent (Chapter 50), which is a nonselective inhibitor of adrenal and gonadal steroid synthesis. It is sometimes used in Cushing syndrome;</li>
<li>Mitotane, an anticancer drug, which causes necrosis of the adrenal cortex (see Chapter</li>
</ul>
<p>61); and</p>
<ul>
<li>Mifepristone, an antiprogestin, (Chapter 68) which in large doses blocks the glucocorticoid receptors. It has been used in Cushing syndrome due to adrenal carcinoma.</li>
<li>Cyproheptadine and etomidate are steroidogenesis inhibitors which are useful in treating hypercorticism.
Regulation of the secretion of adrenal cortical hormones: The rate of secretion of the glucocorticoids is regulated by the variations in the blood levels of ACTH. Physiologically aldosterone output is independent of ACTH. Aldosterone secretion is mainly regulated by Angiotensin II, and serum potassium levels. A reduction in salt intake and a contraction of circulating blood volume are potent stimuli, acting via the RAAS pathway to aldosterone secretion (Chapters 25 and 31). Increase in the intake of potassium stimulates aldosterone synthesis and release.</li>
</ul>
<p>Metabolism and excretion of adrenal corticoids: The adrenal corticoids circulate in the plasma partly free and mostly bound to cortisol binding protein. The former is the biologically active form, the latter, a reserve form. These steroids are metabolised in the liver and the metabolites are excreted in the urine as conjugates with sulfuric and glucuronic acids. The corticosteroids being water insoluble, are excreted in the urine only in traces. The urinary metabolites can be estimated as neutral 17-ketosteroids and 17ketogenic steroids (Fig. 66.2). Aldosterone is excreted in urine partly as free aldosterone and partly as conjugates of tetrahydroaldosterone.
<img src="assets/images/image-20251214-fc030a75.jpeg" alt="img-41.jpeg"></p>
<p>FIG. 66.2 Synthesis and metabolism of steroid hormones</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids-and-mineralocorticoids">Glucocorticoids and Mineralocorticoids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids-and-mineralocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adrenocorticoids exert a wide variety of physiological effects and pharmacological actions. They enable the organism to withstand various noxious stimuli and environmental changes termed as 'stress'. In the absence of the adrenal cortex, survival is possible only under rigidly controlled and protected conditions wherein food and salt are available in plenty at all times and the environmental temperature is regulated. When exposed to 'stress', the adrenalectomised animal dies quickly unless pre-treated with a glucocorticoid. Under optimum conditions, a small dose of hydrocortisone is sufficient to maintain such animal in a state of well being, while under conditions of 'stress' larger doses of steroids are needed for survival.</p>
<p>Experimental evaluation of synthetic steroids: The easily quantifiable actions of adrenocorticoids are:</p>
<ul>
<li>Sodium retention in adrenalectomised animals.</li>
<li>Liver glycogen deposition.</li>
<li>Suppression of HPA axis; and</li>
<li>Anti-inflammatory action.</li>
</ul>
<p>The ability of a corticosteroid to maintain life in an adrenalectomised animal parallels its sodium retaining potency. On the other hand, the potencies based on suppression of HPA axis, liver glycogen deposition, anti-inflammatory action, work capacity of the skeletal muscles and involution of the lymphoid tissue parallel one another. There can be, however, in the case of synthetic steroids, a dissociation between sodium retaining potency and liver glycogen deposition potency.</p>
<p>A corticosteroid with predominantly sodium retaining effects is called a mineralocorticoid e.g. aldosterone and desoxycorticosterone. A corticosteroid with predominantly liver glycogen depositing and neoglucogenetic actions is called a glucocorticoid e.g. hydrocortisone, cortisone and most of the newer synthetic steroids. Corticosterone, a natural corticosteroid and 9-alpha fluorohydrocortisone, a synthetic steroid, have marked mineralocorticoid as well as some glucocorticoid activities.</p>
<p>Structure-activity relationship: The natural glucocorticoids like cortisone and cortisol are pregnane derivatives with ketone groups at 3 and 20, a hydroxyl group at 21 and are unsaturated between carbon atoms 4 and 5 (Fig. 66.3). Introduction of an aldehyde group in the 18th position increases the mineralocorticoid potential markedly, e.g. aldosterone. The anti-inflammatory and glucocorticoid potency is markedly increased by introduction of a double bond between 1 and 2 carbon atoms as in prednisone or prednisolone, by alpha-methylation in the 6 position as in 6 alpha methyl prednisolone (Fig 66.4) and by 9 alpha fluorination and substitution at 16 position as in triamcinolone, dexamethasone and betamethasone (Fig 66.5).</p>
<p><img src="assets/images/image-20251214-bf51318d.jpeg" alt="img-42.jpeg"></p>
<p>GLUCOCORTICOIDS: The important glucocorticoid secreted in man is cortisol. It has some mineralocorticoid activity too. Since the pharmacological actions of hydrocortisone (cortisol) are, in fact, its physiological actions, they are discussed together.</p>
<p>Mechanism of action: Glucocorticoids act by a complex mechanism involving cytosolicnuclear actions and membrane bound receptors, thus producing genomic and nongenomic actions, respectively. They enter the cell as free molecules and bind to cytosolic steroid receptors. The complex translocates to the nucleus and the steroid binds to the glucocorticoid responsive element (GRE) in the regulatory region of the concerned gene. The interaction is responsible for the genomic effects, executed through activation or repression of DNA transcription. Repression of DNA transcription is believed to be responsible for anti-inflammatory actions of glucocorticoids while up-regulation of gene transcription which occurs with higher doses is believed to cause undesirable effects.</p>
<p>Pharmacological actions: Glucocorticoids exert a variety of physiological effects and pharmacological actions with supra-physiological doses. Those effects of corticosteroids</p>
<p>that involve concerted actions with other regulatory hormones are termed permissive.
Metabolic effects: The glucocorticoids affect the metabolism of carbohydrates, proteins, fats, electrolytes, water and calcium.</p>
<ul>
<li>Carbohydrate and protein metabolism: Glucocorticoids:
(i) Inhibit the peripheral utilisation of glucose by skeletal muscle and adipose tissue.
(ii) Inhibit the incorporation of amino acids into protein in the peripheral tissues (antianabolic action) and
(iii) Promote the conversion of amino acids into glucose (neoglucogenesis) in the liver.</li>
</ul>
<p>All these help to maintain an adequate glucose supply to the brain. The plasma amino acid level rises significantly due to muscle catabolism. Simultaneously, the plasma glucagon level also rises markedly during chronic but not acute administration.</p>
<p>The adrenalectomised animal cannot maintain normal blood sugar level while fasting; while chronic administration of glucocorticoids causes hyperglycemia and glycosuria.</p>
<p>In physiological doses, glucocorticoids stimulate protein and RNA synthesis in the liver; large supraphysiological doses cause catabolic and antianabolic effects in the skin, muscles, lymphoid and connecting tissues. This leads to wasting of muscle, thinning of the skin and osteoporosis.</p>
<ul>
<li>Fat metabolism: Glucocorticoids play a 'permissive' role in the mobilisation of fat from the peripheral fat depots by adrenaline and GH. Prolonged administration of excessive glucocorticoid causes a re-distribution of body fat, with a loss from the extremities and a deposition in the neck (buffalo hump), supraclavicular area and face (moon face).</li>
<li>Electrolyte and water metabolism: Hydrocortisone has a relatively weak salt retaining and potassium wasting effect. However, when large doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">300 \mathrm{mg} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/24</span></span></span></span></span> hours) are used, sufficient salt retention occurs to make the concurrent use of a mineralocorticoid unnecessary. Hydrocortisone, 25 mg has the same mineralo-corticoid activity as 0.1 mg of fludrocortisone.
Physiologically, cortisol is essential for excreting a water load. Adrenalectomised animals cannot excrete a water load and tend to develop water intoxication. This is corrected by a small dose of hydrocortisone.</li>
<li>Calcium metabolism and bone: In pharmacological doses, glucocorticoids antagonise the action of vitamin D on the gut and reduce absorption of calcium. Large doses for prolonged periods may interfere with the development of cartilage and inhibit linear growth in children. Due to the protein catabolic action, glucocorticoids inhibit formation of new bony tissue. The continuous resorption which occurs as a part of bone remodelling leads to severe osteoporosis in chronic states of hypercorticism.
Cardiovascular system: The cardiovascular changes which occur in adrenal insufficiency are partly due to mineralocorticoid deficiency which affects electrolyte and water metabolism, and partly due to glucocorticoid deficiency. Usually, the blood volume and blood pressure diminish and blood viscosity increases. These defects are only partially corrected by administration of sodium chloride and/or a mineralocorticoid; addition of a glucocorticoid completely restores the circulation to normal.</li>
</ul>
<p>Glucocorticoids potentiate the pressor response of blood vessels to adrenaline and NA by upregulating the adrenergic receptors in the vessel wall. In pharmacological doses, they have a positive inotropic action on the heart. The absence of glucocorticoids leads to increase in capillary permeability, inadequate vasomotor responses of smaller blood</p>
<p>vessels and reduction in the cardiac output.
Hypertension is seen during chronic administration of glucocorticoids and in the patients with Cushing's syndrome. In the latter condition, it is an important cause of death.</p>
<p>Muscles: Permissive concentration of cortisol is necessary for the normal functioning of the skeletal muscle. Muscular weakness is an important feature of Addison's disease. It is largely due to inability of the circulatory system to respond to the stress of exercise. It is specifically corrected by a glucocorticoid. On the other hand, the muscle weakness of hypercortisolism is due to hypokalemia and to muscle wasting (steroid myopathy) (see later).</p>
<p>Central nervous system: Patients with Addison's disease show apathy, depression, irritability and sometimes psychosis. All these are corrected by a glucocorticoid.</p>
<p>Patients on large doses of glucocorticoids may show mood elevation, euphoria, nervousness, restlessness, depression and even psychosis. These are all reversible.</p>
<p>Hematological action: Glucocorticoids cause an increase in the number of circulating RBCs, platelets, neutrophils and a decrease in the number of lymphocytes, monocytes, eosinophils and basophils in the blood. This is brought about by a redistribution of the cells between the blood and other compartments; there is no lysis of lymphocytes in normal persons. However, in patients with acute lymphoblastic leukemia, the lymphocytes are rapidly destroyed by the pharmacological doses of the glucocorticoids. A mild secondary polycythemia is common in Cushing's syndrome.</p>
<p>GI tract: Glucocorticoids inhibit the secretion of prostacyclin and increase both basal and nocturnal gastric acid secretion.</p>
<p>Anti-inflammatory action: Glucocorticoids prevent or suppress the symptoms and signs of inflammation such as local heat, redness, swelling and tenderness. At the tissue level, they suppress the early phenomena (edema, fibrin deposition, capillary dilatation, and migration of leucocytes into the inflamed area) as well as the late manifestations (capillary proliferation, fibroblastic proliferation, deposition of collagen and cicatrisation). They interfere with wound healing. Fibrous tissue, once formed, is not affected.</p>
<p>The mechanisms which possibly contribute to their anti-inflammatory action are:
(a) Inhibition of leucocyte migration into the inflammed tissue.
(b) Suppression of the proinflammatory cytokines and chemokines.
(c) Inhibition of the release of arachidonic acid from phospholipids by inhibiting the enzyme phospholipase-A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, (see Fig. 25.4 in Chapter 25) and hence decrease in the production of proinflammatory PGs, LTs, PAF and related cytokines.
(d) Decrease capillary permeability by reducing the amount of histamine released by the basophils and mast cells.
(e) Diminution of chemotaxis and lysosomal enzyme synthesis by neutrophils and monocytes. This decreases the recruitment of neutrophils and macrophages into the affected area.
(f) Stabilisation of lysosomal membranes, at high concentrations, thus preventing the spillage of hydrolytic enzymes.</p>
<p>This anti-inflammatory effect of glucocorticoids forms the basis for their clinical use in many different conditions.</p>
<p>Immunosuppressive and anti-allergic actions: Glucocorticoids in large therapeutic doses</p>
<p>(40-60 mg of prednisolone per day):</p>
<ul>
<li>Inhibit the function of macrophages and reduce their ability to respond to antigens. This affects phagocytosis and bactericidal action. Further, production of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>, some interleukins and interferons is reduced.</li>
<li>Inhibit the activation of cytotoxic T lymphocytes and their proliferation; they cause transient peripheral lymphopenia.</li>
<li>Cause lysis of the T lymphocytes.</li>
<li>In humans, the complement is not affected but its effects are inhibited.</li>
<li>Suppress cell-mediated hypersensitivity reaction. The glucocorticoid doses that modify CMI usually do not suppress the antibody production. (Humoral immunity); and</li>
<li>Prevent homograft rejection;</li>
</ul>
<p>Large doses (100-200 mg of prednisolone/day) diminish the effective concentration of specific IgG antibodies.</p>
<p>Although glucocorticoids do not, in moderate doses, interfere with antibody production or with antigen-antibody union nor with the liberation of histamine from the tissues damaged by such union, they do suppress the inflammatory response to it. This last action is important in the suppression of such allergic phenomena as urticaria, allergic rhinitis and bronchial asthma.</p>
<p>Clinically, glucocorticoids modify the course of many diseases involving the immune responses. They do not modify the basic disease process, but suppress the inflammatory response to injury and thus, protect the tissues. However, they increase the susceptibility to a variety of bacterial, fungal, viral and parasitic superinfections.</p>
<p>It was thought in the past that the antiinflammatory and immunosuppressive actions of glucocorticoids were limited to pharmacological doses. It is now realised that glucocorticoids produced normally, as a part of the response to stress, exert a beneficial antiinflammatoryimmunosuppressive effect and help to limit the damage caused by such reactions. Further, they may prevent possible cardiovascular collapse due to the depressant action of released immune mediators on the vascular tone (physiological action).</p>
<p>Miscellaneous actions: Glucocorticoids have uricosuric and non-specific antipyretic effects. Their analgesic effect depends upon their anti-inflammatory action. Glucocorticoids markedly increase the activity of phenyl-ethanolamine-Nmethyltransferase, an enzyme located almost exclusively in the adrenal medulla and which catalyses the conversion of NA to adrenaline. They play an important role in the maturation of the fetal lung.</p>
<p>Inhibition of HPA axis: Supraphysiological doses of glucocorticoids for longer than one week suppress the HPA axis and cause adrenocortical atrophy. Such patients, during therapy, and for long periods (as long as 12 months) thereafter, are unable to increase the endogenous cortisol output in response to stress. During this period the pituitary function recovers first; plasma ACTH progressively reaches supranormal levels in 4-5 months. Only then the atrophic adrenal cortex starts recovering its function. But it can take the HPA axis as long as 8-12 months to be able to respond normally to stress. This recovery of the HPA axis is not accelerated by administration of exogenous ACTH. However, physiological doses of a glucocorticoid ( 20 mg of hydrocortisone or 5 mg of prednisolone, per day) may be used for prolonged periods after cessation of prolonged, large dose glucocorticoid therapy, without interfering with the recovery of HPA axis.</p>
<p>Patients who are on small doses of any glucocorticoid ( 20 mg of hydrocortisone or equivalent doses of other glucocorticoids per day) and those who are on high doses of intermediate acting glucocorticoids (see Table 66.1) on alternate days show little or no suppression of the HPA axis. When large doses are used daily and for prolonged periods, the suppression is most marked when the entire daily dose is given at bed time and is least when it is given on rising in the morning. The other advantage of the alternate day therapy is the minimisation of the nitrogen and calcium imbalance. It, therefore, permits safer administration of much larger total dosage of glucocorticoids. Hence, whenever possible, in patients requiring high-dose, prolonged glucocorticoid therapy, the alternate day regimen should be attempted. Because of their very prolonged action, the long acting glucocorticoids are not suitable for alternate day administration.</p>
<p>Table 66.1
Comparison of various glucocorticoids</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Biological half-life (hours)</th><th style="text-align: center;">Glucocorticoid activity</th><th style="text-align: center;">Mineralo-corticoid activity</th><th style="text-align: center;">Pituitary suppression</th><th style="text-align: center;">Comparative doses'(mg.)</th><th style="text-align: center;">Affinity</th></tr></thead><tbody><tr><td style="text-align: left;">Short acting</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Cortisone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">0.8</td><td style="text-align: center;">1</td><td style="text-align: center;">1</td><td style="text-align: center;">25</td><td style="text-align: center;">1</td></tr><tr><td style="text-align: left;">Hydrocortisone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">1</td><td style="text-align: center;">1.25</td><td style="text-align: center;">2.5</td><td style="text-align: center;">20</td><td style="text-align: center;">100</td></tr><tr><td style="text-align: left;">Intermediate acting</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Prednisolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>36</mn></mrow><annotation encoding="application/x-tex">18-36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">36</span></span></span></span></span></td><td style="text-align: center;">4</td><td style="text-align: center;">0.5</td><td style="text-align: center;">5</td><td style="text-align: center;">5</td><td style="text-align: center;">220</td></tr><tr><td style="text-align: left;">Methylprednisolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>36</mn></mrow><annotation encoding="application/x-tex">18-36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">36</span></span></span></span></span></td><td style="text-align: center;">5</td><td style="text-align: center;">0</td><td style="text-align: center;">8</td><td style="text-align: center;">4</td><td style="text-align: center;">1350</td></tr><tr><td style="text-align: left;">Triamcinolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mo>−</mo><mn>36</mn></mrow><annotation encoding="application/x-tex">18-36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">18</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">36</span></span></span></span></span></td><td style="text-align: center;">5</td><td style="text-align: center;">0</td><td style="text-align: center;">-</td><td style="text-align: center;">4</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Long acting</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Dexamethasone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>36</mn><mo>−</mo><mn>54</mn></mrow><annotation encoding="application/x-tex">36-54</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">36</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">54</span></span></span></span></span></td><td style="text-align: center;">25</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">100-200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span></td><td style="text-align: center;">0.75</td><td style="text-align: center;">540</td></tr><tr><td style="text-align: left;">Betamethasone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>36</mn><mo>−</mo><mn>54</mn></mrow><annotation encoding="application/x-tex">36-54</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">36</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">54</span></span></span></span></span></td><td style="text-align: center;">25</td><td style="text-align: center;">0</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">100-200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span></td><td style="text-align: center;">0.75</td><td style="text-align: center;">400</td></tr></tbody></table>
<p>Therapeutic efficacy in inflammatory disorders is proportional to the glucocorticoid activity.
These dose relationships apply to oral and intravenous administration of these compounds but not to intramuscular or intraarticular administration of these compounds or their derivatives.
*Affinity for human, intracellular, glucocorticoid receptor.
The long acting compounds such as dexamethasone, however, are eminently suited for uniform and continuous suppression of ACTH secretion in the syndrome of congenital, virilizing, adrenocortical hyperplasia. As the peak secretion of ACTH occurs at night (in this condition as in normal persons), the entire daily dose of the long acting glucocorticoid should be given at bedtime.</p>
<p>Patients on long term glucocorticoid treatment should be considered to be suffering from adrenal insufficiency and during stress the dose of the glucocorticoid should be increased.</p>
<ul>
<li>During minor stress, such as a febrile illness, severe exercise, bouts of gastroenteritis with vomiting and diarrhoea, and minor surgery, the normal adrenals respond by secreting about 100 mg of hydrocortisone per day; this then is the requirement of hydrocortisone (or an equivalent dose of another glucocorticoid) during such situations. The dose can be abruptly reduced to the maintenance dose as soon as the stressful event is over.</li>
<li>During major stress, such as major surgery, severe burns and MI, the daily</li>
</ul>
<p>requirement of 300-400 mg of cortisol can be met with by giving 100 mg by IV infusion every six to eight hours on the first day. From the next day onwards, the dose is halved every day till the physiological maintenance dose is reached, if the recovery is uneventful.
While withdrawing long term glucocorticoid therapy, the reduction upto the physiological maintenance dose may be as rapid as the disease will permit. Too rapid a reduction can cause (a) a flare up of the disease under treatment; and (b) nonspecific 'withdrawal symptoms' comprising fever, malaise, myalgia and arthralgia.</p>
<p>After reaching the physiological maintenance dose, it should be continued upto 1 year in order to allow the HPA axis to recover its function fully; during this period, any stressful situation is covered by larger doses of a glucocorticoid to prevent an acute adrenal crisis. Patients undergoing surgery should always be asked for history of glucocorticoid therapy during the past 1 year.</p>
<p>The placenta metabolises hydrocortisone and prednisolone to the inactive cortisone and prednisone. Unlike the mother, the fetus cannot convert cortisone and prednisone to hydrocortisone and prednisolone. By contrast, dexamethasone and betamethasone cross the placenta to achieve high concentrations in the fetal circulation and can suppress the fetal HPA axis. Therefore, if a pregnant woman needs treatment with a glucocorticoid, prednisolone is preferred.</p>
<p>Absorption, fate and excretion of hydrocortisone and the synthetic glucocorticoids: The oral bioavailability of hydrocortisone is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> and variable (30-90%) on administration as an enema. The absorption from aqueous suspension of acetate given IM is slower than that of orally administered hydrocortisone and hence the effect lasts longer. Absorption of prednisolone is almost complete ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> ) after both oral and rectal administration. It is worth noting that as much as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of intraarticular prednisolone, administered in patients with RA, is absorbed into systemic circulation. Dexamethasone is well absorbed ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) orally. The bioavailability of oral methylprednisolone is variable (50-80%).</p>
<p>Cortisone acts in the body after conversion to hydrocortisone, and prednisone to prednisolone, in the liver. Hydrocortisone is highly protein bound in the plasma and so is prednisolone. Dexamethasone is less protein bound than hydrocortisone.</p>
<p>Hydrocortisone is largely metabolised by conversion to tetrahydrocortisone and conjugation; prednisolone by hydroxylation and conjugation. The pharmacokinetic parameters of methylprednisolone are similar to those of prednisolone.</p>
<p>The concentration of prednisolone in breast milk is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> that of plasma concentration, and no restriction on breast feeding is considered necessary when the mother is receiving upto 20 mg of prednisolone per day.</p>
<p>The biological <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of the glucocorticoids and their relative affinity for human, intracellular, glucocorticoid receptor are given in Table 66.1.</p>
<p>Adverse reactions: These are related to individual susceptibility, dosage and duration of therapy.</p>
<p>Single large doses of prednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> or equivalent doses of other glucocorticoids, are generally harmless and may, therefore, be used without hesitation in situations where life is threatened by adrenocortical or pituitary insufficiency or by cerebral edema. Short term therapy (generally 1-2 weeks) with moderate doses is unlikely to produce any harmful effects.</p>
<p>Prolonged therapy with glucocorticoids in doses higher than 20-30 mg of hydrocortisone or equivalent doses of other steroids per day is liable to cause adverse effects. Hence, this is the generally recommended maximum maintenance dose in prolonged glucocorticoid therapy. The only exception is life threatening conditions where doses large enough to suppress the clinical manifestations of the disease are needed, and then one accepts adverse effects as the price one has to pay for keeping the patient alive.</p>
<p>The ADR, other than sodium retention, are shared by all glucocorticoids. However, certain adverse effects seem to be unique to triamcinolone; these are: anorexia; muscle wasting; weight loss; sedation and depression. It should be avoided in renal disease.</p>
<p>The important adverse effects are:</p>
<ul>
<li>Gastrointestinal tract: Acute erosive gastritis with hemorrhage may occur during intensive therapy, and peptic ulceration may be troublesome during prolonged therapy. Intestinal perforation and pancreatitis are the other reported GI complications.</li>
<li>Endocrine system: These are an extension of their pharmacological actions and comprise hypercortisolism.</li>
<li>Metabolic effects: Clinical manifestations (including, ketoacidosis and non-ketotic, hyperglycemic, hyperosmolar coma) of idiopathic diabetes mellitus can be precipitated. Pre-existing diabetes, however, is not an absolute contraindication to glucocorticoid therapy and development of hyperglycemia during therapy in itself does not warrant cessation of treatment. Some patients develop hyperlipidemia and hypophosphatemia.
Prolonged therapy causes central obesity with moon face and buffalo hump. Pink florid striae appear on the abdomen, hips and pectoral regions and the skin may become friable. The patient may get spontaneous ecchymosis and bruise easily (Cushingoidism).</li>
<li>Suppression of inflammation and immune responses: Glucocorticoids may mask the clinical features of a serious illness e.g. fever and abdominal rigidity may be absent when a patient on these drugs develops acute peritonitis, which may, therefore, be missed. Further, preexisting infections like tuberculosis can spread and superinfection with other organisms can occur.</li>
<li>Retardation of linear growth occurs in children who receive high doses. In equivalent therapeutic doses prednisolone is twice and dexa-and beta-methasone are thrice as growth inhibiting as hydrocortisone.</li>
<li>Cardiovascular and renal system: Hypertension, salt and water retention and rarely hypokalemic alkalosis can occur. They are uncommon with dexamethasone, betamethasone and triamcinolone.</li>
<li>CNS: Glucocorticoids readily enter the brain and can influence mood, sleep patterns and EEG activity; patients may complain of insomnia. Acute psychotic reactions may occur especially during intensive therapy. Benign intracranial hypertension and aggravation of epilepsy particularly in children can occur.</li>
<li>Musculoskeletal effects: Proximal myopathy and osteoporosis with compression fractures of the vertebrae are serious complications. Bisphosphonates are reported to prevent the osteoporosis. Occasionally, acute avascular necrosis of bone may occur.</li>
<li>Eyes: Glaucoma occurs in some patients during local glucocorticoid therapy, and posterior subcapsular cataract has been reported during their long term systemic use.</li>
<li>Inhibition of HPA axis: Discussed earlier.</li>
<li>Miscellaneous changes: These include hypercoagulability of blood with thromboembolic</li>
</ul>
<p>complications, acne, hirsutism, loss of scalp hair, subcutaneous atrophy and delayed wound healing.
Rapid IV injection of large pulse doses (see later) can cause flushing of the face and chest, vasoactive reaction, cardiac arrest and seizures.</p>
<p>The Cushingoidism produced by glucocorticoid therapy differs in certain respects from Cushing's syndrome produced by endogenous hypercortisolism. Pseudotumour cerebri, glaucoma, cataract, pancreatitis, aseptic necrosis of bone, panniculitis and vasculitis are almost unique to the iatrogenic form of Cushing's syndrome.</p>
<p>Table 66.2 shows the important adverse reactions to topical use of glucocorticoids on the skin. They are especially likely to occur:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-66-2">Table 66.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-66-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adverse skin reactions to topical glucocorticoids</p>
<ul>
<li>Epidermal and dermal atrophy (thinning of the skin, striae, telangiectases superficial fissures and purpura)</li>
<li>Acne, folliculitis, miliaria</li>
<li>Hypertrichosis</li>
<li>Hypopigmentation</li>
<li>Allergic contact dermatitis(uncommon).</li>
<li>Rebound of the lesion under treatment, on abrupt withdrawal especially of the potent steroids</li>
<li>Masking or aggravation of dermatophytoses, impetigo or scabies
(a) In infants, children and the elderly.
(b) With the use of potent steroids, especially when used in large doses for prolonged periods.
(c) With the use of occlusive dressings; and
(d) When used in areas with thin skin, e.g. face.</li>
</ul>
<p>Drug interactions: See Table 66.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-66-3">Table 66.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-66-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interactions-of-glucocorticoids">Drug interactions of glucocorticoids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-of-glucocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Glucocorticoid dosage is decreased: Antibiotics (erythromycin, trioleandomycin), cyclosporin, isoniazid and ketoconazole reduce the metabolic clearance of glucocorticoids. Estrogens increase the levels of corticosteroid binding protein and thus reduce the free fraction; they also reduce the clearance.</li>
<li>Glucocorticoid dosage is increased: Cholestyramine decreases the intestinal absorption. Antiepileptic drugs (barbiturates, phenytoin, carbamazepine), rifampicin, aminoglutethimide increase the metabolism by inducing hepatic microsomal enzymes.</li>
<li>Glucocorticoid dosage needs adjustment: Antianxiety and antipsychotic drugs: Recurrent or poor control of CNS symptoms due to inherent glucocorticoid effects.</li>
<li>Anticholinesterases: May precipitate my asthenic crisis.</li>
<li>Anticoagulants: Effectiveness of anticoagulants decreases.</li>
<li>Antihypertensives: Their effectiveness decreases.</li>
<li>Oral hypoglycemics: Their effectiveness decreases.</li>
<li>Sympathomimetics: Their effectiveness increases.</li>
<li>Salicylates: Their clearance is increased.</li>
</ul>
<p>Synthetic glucocorticoids: The synthetic glucocorticoids include prednisone, prednisolone, triamcinolone, paramethasone, dexamethasone, betamethasone and 6methyl prednisolone (Table 66.1). Prednisone is converted in the body to the active compound prednisolone. The last four synthetic steroids show negligible or almost absent mineralocorticoid activity. However, none is safer than prednisolone with respect to the peptic ulceration, osteoporosis and hyperglycemia. All of them are potent pituitary inhibitors. In addition, triamcinolone has a greater propensity to cause myopathy while</p>
<p>the incidence of increased capillary fragility and ecchymosis is more with triamcinolone, dexamethasone and betamethasone. Hence they are not recommended for routine use.</p>
<p>The synthetic glucocorticoids are rapidly absorbed orally. Their long-acting esters used topically and intra-articular injection are poorly absorbed. Like hydrocortisone, they are metabolised by the liver but more slowly.</p>
<p>The synthetic steroids have pharmacological actions and adverse effects identical with those of hydrocortisone except the mineralocorticoid actions. They are less extensively protein bound and hence diffuse more completely into the tissues. They are effective in smaller doses. Such smaller doses, however, should not be construed to give them any superiority over the older preparations as in equivalent therapeutic doses their adverse effects are similar. However, as esters they are useful for topical application and local injections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="for-systemic-use">- For systemic use:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#for-systemic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Cortisone acetate tablets, 25 mg Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>37.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-37.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">37.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> (replacement therapy).
(ii) Cortisone injection, a suspension of cortisone acetate ( 25 mg per ml ). Dose: 50 to 200 mg daily IM in single or divided doses.
(iii) Hydrocortisone tablet, 10 mg and 20 mg
(iv) Hydrocortisone hemisuccinate being readily water soluble is administered IM, by IV infusion or as a retention enema. Approximately 133 mg of the salt contains 100 mg of hydrocortisone. Hydrocortisone 100 mg by IV bolus lasts for 4 hours only. A continuous infusion <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> hour provides adequate plasma levels ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">30-40 \mathrm{mcg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ) for surgical cover. For retention enema, a dose equivalent to 100 mg of hydrocortisone, dissolved in 120 ml of normal saline is given each night.
(v) Prednisone tablet, 5 mg . Dose: 10 to 100 mg daily in divided doses.
(vi) Prednisolone tablet 5 mg or an equivalent amount of prednisolone acetate. Dose: 10 to 100 mg daily in divided doses.
(vii) Prednisolone acetate suspension, 25 mg per ml . It is administered by IM, intraarticular or peri-articular injection.
(viii) Prednisolone or prednisone pediatric drops, 5 mg of prednisolone or prednisone per ml Dose: new-born, 0.3 to 0.4 mg per kg per dose; infants, 0.2 to 0.3 mg per kg per dose; older children, 0.15 to 0.2 mg per kg per dose.
(ix) Prednisolone sodium phosphate, in contrast to prednisolone or its acetate, is soluble in water. Approximately 27 mg of the salt are equivalent to 20 mg of prednisolone. Dose: equivalent to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of prednisolone IV and 20 mg by retention enema.
(x) Methylprednisolone, 4 mg tablets. Dose: 2-40 mg daily in divided doses.
(xi) Methylprednisolone sodium succinate. Dose: equivalent to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-120 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of methylprednisolone base IM or IV, 40 to 120 mg as a retention enema; pulse dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">500-1000 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> by slow IV infusion.
(xii) Methylprednisolone acetate injection for IM use.
(xiii) Triamcinolone tablet, 4 mg . Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>24</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-24 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">24</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily in divided doses.
(xiv) Triamcinolone diacetate injection for IM or intra-articular use. Dose: 5 to 40 mg .
(xv) Betamethasone tablet, 0.5 mg . Dose : 0.5 to 5 mg daily.
(xvi) Betamethasone sodium phosphate, a water soluble salt is available as tablets and</p>
<p>for injection; nearly 1.3 mg of the salt is equivalent to 1 mg of betamethasone. Dose: equivalent to 0.5 to 5 mg of betamethasone by mouth; for acute adrenal insufficiency, 10 to 20 mg by IV or IM injection daily in divided doses.
(xvii) Dexamethasone tablet 0.5 mg . Doses similar to betamethasone tablets.
(xviii) Dexamethasone 21-phosphate injection contains 4 mg of the salt per ml .
Roughly 1.3 mg of the salt is equivalent to 1 mg of the base. Dose: 4 to 20 mg of the base by IM or IV injection.</p>
<ul>
<li>For topical use: Numerous preparations containing either the glucocorticoids alone or in combination with antibiotics are available for topical therapy. The topical skin preparations can be divided into four groups in increasing order of potency (Table 66.4). The potency of the topical preparations is proportional to their ability to cause vasoconstriction and cutaneous blanching on local application.</li>
</ul>
<p>Table 66.4
Topical glucocorticoid preparations
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>; Hydrocortisone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> (Wycort)
Potent: Betamethasone valerate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>;
Hydrocortisone butyrate
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span>; Fluocinolone acetonide
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span>; Triamcinolone acetonide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.2%</span></span></span></span></span>
Very potent: Clobetasol propionate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Mild: Hydrocortisone 1\%
</span>Moderately potent: Clobetasone buty rate
    \(0.05 \% ;\) Hydrocortisone \(2.5 \%\) (Wycort)
Potent: Betamethasone valerate \(0.1 \%\);
    Hydrocortisone buty rate
    \(0.1 \% ;\) Fluocinolone acetonide
    \(0.025 \% ;\) Triamcinolone acetonide \(0.2 \%\)
Very potent: Clobetasol propionate \(0.05 \%\)</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Mild: Hydrocortisone 1\%
Moderately potent: Clobetasone buty rate
    \(0.05 \% ;\) Hydrocortisone \(2.5 \%\) (Wycort)
Potent: Betamethasone valerate \(0.1 \%\);
    Hydrocortisone buty rate
    \(0.1 \% ;\) Fluocinolone acetonide
    \(0.025 \% ;\) Triamcinolone acetonide \(0.2 \%\)
Very potent: Clobetasol propionate \(0.05 \%\)" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>The skin preparations as creams or ointments and topical preparations for nasal, conjunctival and intra-articular use are available.</p>
<p>Beclomethasone dipropionate, budesonide and fluticasone as inhaled steroids in bronchial asthma are discussed in Chapter 27.</p>
<p>Hydrocortisone oral paste <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> may be useful in treating painful, nonherpetic, oral ulcers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Replacement therapy: This is used in the management of adrenocortical (AC) insufficiency arising from adrenal disease (Addison's disease; primary AC insufficiency) or hypopituitarism (secondary AC insufficiency). Either may be chronic or acute.</p>
<ul>
<li>Chronic adrenal insufficiency due to Addison's disease is treated with replacement doses of a glucocorticoid. They are given in a dose that reduces hyperpigmentation and</li>
</ul>
<p>abolishes postural hypotension which is the hallmark of adrenocortical insufficiency. Hydrocortisone with its moderate salt retaining property is preferred; however, prednisolone in equivalent doses can also be used. The replacement dose of hydrocortisone in Addison's disease may vary from 10 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day, because of its very short half life. Generally it is given in the dose of 30 mg daily, divided into two doses, 20 mg in the morning and 10 mg . in the evening.
Once the patient is regulated on hydrocortisone, addition of 9-alpha-flurohydrocortisone ( 0.1 to 0.2 mg daily) helps to complete the replacement therapy. Alternatively, the same purpose may be achieved by prescribing additional intake of salt ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> per day). Additional quantities of salt must not be prescribed to patients taking mineralocorticoids.</p>
<p>In patients with adrenocortical insufficiency secondary to hypopituitarism, smaller maintenance doses are sufficient; and a mineralocorticoid is not required.</p>
<p>It is essential to explain to the patient that treatment of this condition is lifelong and that it is dangerous to stop it abruptly. In times of stress, the dose must be rapidly increased 3 to 4 fold.</p>
<ul>
<li>Acute adrenal insufficiency may arise
(a) as a result of an acute infection, injury or surgery in a previously known</li>
</ul>
<p>Addisonian patient;
(b) following abrupt withdrawal of glucocorticoids from a patient taking large doses; or
(c) in a fulminating meningococcal infection, which is a medical emergency requiring energetic and immediate treatment. The principles of therapy are shown in Table 66.5.</p>
<p>Table 66.5
Principles of treatment of acute adrenal insufficiency</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Hydrocortisone hemiuccinate by IV infusion, 100 mg every 4-6 hours.
</span>- Dextrose in normal saline in adequate amounts.
- Vasopressor drugs to maintain blood pressure; and
- Antibiotics.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Hydrocortisone hemiuccinate by IV infusion, 100 mg every 4-6 hours.
- Dextrose in normal saline in adequate amounts.
- Vasopressor drugs to maintain blood pressure; and
- Antibiotics." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>As the large doses of hydrocortisone cause sufficient salt retention, mineralocorticoids are not needed at this stage. Following recovery, 4th-5th day onwards, hydrocortisone is given orally in maintenance doses, together with 9-alpha-fluorohydrocortisone.</p>
<ul>
<li>Septic shock: Chapter 32.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-pharmacological-therapy">II Pharmacological therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-pharmacological-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pulse therapy: Methylprednisolone IV, in dose of 150-300 mg, injected over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour, once daily, for three consecutive days, is useful in threatened acute rejection of a renal graft, vision-threatening Graves' exophthalmos and similar dire emergencies.
Methylprednisolone in similar IV doses for 3-5 days can shorten the duration of relapse, and accelerate recovery from an acute exacerbation of multiple sclerosis. Long term course of the disease is not altered. Rapid IV administration of such large doses can cause cardiac arrhythmias. High dose oral prednisolone is probably equally effective. The drug is combined with immunosuppressive and immunomodulatory drugs (Chapters 15 and 74).</li>
<li>Intensive short term therapy can save life and reduce morbidity in certain potentially lethal conditions in which the inflammatory or the metabolic response of the body itself threatens life. These conditions include: allergic emergencies such as anaphylactic</li>
</ul>
<p>shock; status asthmaticus; circulatory collapse unresponsive to pressor amines; acute necrotising vasculitis; water intoxication; central hyperthermia; and acute hypercalcemia accompanying vitamin D intoxication or hormone therapy of metastatic breast cancer. In status asthmaticus, the glucocorticoids take several hours to act and their use supplements that of the bronchodilators. In circulatory failure a single massive dose (preferably of a long acting compound) sometimes restores the blood pressure to normal. In hypercalcemic crisis (Chapter 70), glucocorticoids take several days to reduce the plasma calcium and must be used along with other quicker acting measures. Glucocorticoids used as adjuncts have been shown to be effective in preventing or minimising the long term sequelae (such as deafness) of acute bacterial meningitis. In all these conditions, large doses such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg}(1-2 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mopen">(</span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span> of prednisolone per day may have to be used but therapy with such doses seldom lasts longer than 48-72 hours. In such cases, the adverse effects mainly consist of burning and itching at the mucocutaneous junctions, and rarely of multifocal ventricular premature beats, precipitation of ketoacidotic coma in idiopathic diabetes, and acute erosive gastritis with hemorrhage.</p>
<ul>
<li>Cerebral edema: Glucocorticoids are life saving in cerebral edema due to neoplasms, either primary or metastatic. Their value in treating cerebral edema due to head injury, stroke and cerebral malaria is unproven; in fact they may be harmful. Also see Chapter 39.</li>
<li>Prolonged, high-dose, suppressive therapy is indicated in severe acute rheumatic fever, severe ulcerative colitis, coeliac disease not responding to gluten-free diet, subacute hepatic necrosis, chronic active hepatitis, alcoholic hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, acute lymphatic leukemia, disseminated Hodgkin's disease, nephrotic syndrome, acute homograft rejection, pemphigus and collagen diseases (Vascultitis and SLE). In these diseases, the initial dose may be as high as 100-200 mg of prednisolone per day, the therapy continues longer than 7-10 days and the maintenance dose may be 15 mg of prednisolone or more per day. The fear of adverse reactions is utmost in this group and the patients need close supervision. A rapid reduction in the dose can cause an acute exacerbation of the disease being treated. On the other hand, abrupt cessation is dangerous and can precipitate acute adrenocortical insufficiency; the patients must be warned about this possibility. In order to minimise the suppression of the HPA axis during such prolonged, high-dose therapy, the alternate day regime should be tried once the clinical improvement has stabilised; if it is unable to maintain the clinical remission, the entire daily dose may be given in the morning with the same objective in mind.</li>
<li>Low-dose, chronic, palliative therapy consists of the use of small doses of a glucocorticoid (2-10 mg of prednisolone per day) as an adjunct to some other drug e.g. an NSAID in RA. Here, total relief of symptoms is not aimed at, in order to avoid the adverse effects of the glucocorticoid. Such low-dose therapy should not be tried on alternate days as it is ineffective in controlling the disease adequately. As the therapy is generally prolonged, sometimes lifelong, the patients need close supervision. The dose of the glucocorticoid should be raised 2-4 times during such stress as surgery or a severe infection.</li>
<li>Chronic, suppression of ACTH secretion is indicated in congenital, virilising, adrenocortical hyperplasia. This is achieved with the use of a long acting compound</li>
</ul>
<p>such as dexamethasone or betamethasone in the dose of 0.5 mg at bedtime daily. Such therapy adequately suppresses the plasma level of 17 hydroxyprogesterone and rarely causes any adverse effects. It must be impressed upon the parents of such a child that the therapy must continue lifelong.</p>
<ul>
<li>Neonatal respiratory distress syndrome (prevention): Lung maturation in the fetus is influenced by fetal cortisol secretion. This may be affected by prematurity.
Betamethasone is administered to pregnant women in the dose of 12 mg , to be repeated after 18-24 hours (Chapter 44), to prevent neonatal respiratory distress syndrome when delivery is anticipated before the 34th week of gestation (pre-term).</li>
<li>Topical application is valuable in many dermatological, ocular and external ear conditions. Ocular conditions benefited by local therapy are interstitial keratitis, phlyctenular conjunctivitis, spring catarrh, iritis and iridocyclitis, whereas, posterior uveitis and sympathetic ophthalmia need systemic medication.
Local steroid therapy is valuable in inflammatory dermatoses and for controlling exacerbations of pruritic eczema and psoriasis. It is not recommended for urticaria. Unfortunately, steroid ointments are misused as a dermatological panacea because they give dramatic relief in inflammatory and pruritic skin conditions. Their indiscriminate use, is not only wasteful but also harmful. Application of a steroid ointment for such conditions as herpes simplex, herpes zoster, fungal infections and impetigo leads to their exacerbation.</li>
</ul>
<p>Glucocorticoids accelerate the fungal growth, and cause local skin atrophy with resultant telangiectasia, purpura and striae. Systemic toxicity including adrenal suppression can occur following local therapy, more so in infants; and hence, potent preparations like betamethasone valerate, triamcinolone acetonide, fluocinolone acetonide and clobetasol propionate should not be prescribed for treating infantile eczema. Similarly, potent steroids should not be applied to facial skin as atrophy and telangiectasia occur more quickly on the face.</p>
<p>The practice of adding a glucocorticoid to antibiotics and antifungal agents is difficult to justify. The same is true of use of glucocorticoids in ointments for hemorrhoids.</p>
<ul>
<li>Intra-articular and intratendinous use: Long acting esters of glucocorticoids have been used locally by infiltration to treat painful osteoarthritis and painful tender fascial nodules. It has the added advantage of minimum systemic absorption. Such injections should not be given more than 3 times a year.
Glucocorticoids have been used empirically in a wide variety of conditions such as Bell's palsy, acute infective polyneuritis, encephalitis, infective hepatitis, complete heart block, hypsarrhythmia and so on. Their usefulness in such conditions is doubtful.</li>
</ul>
<p>Precautions during corticosteroid therapy: These apply especially to the prolonged, high dose, suppressive therapy and are listed in Table 66.6. There are no absolute contraindications to glucocorticoid therapy other than Cushing's syndrome and ocular herpes zoster. Proper precautions have to be taken in using them in diabetes mellitus, peptic ulcer, hypertension, CHF, osteoporosis; in debilitated or old patients; and in the presence of infection.</p>
<p>Table 66.6
Precautions during glucocorticoid therapy</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Before starting therapy
</span>    - Enquire about and check for peptic ulcer, diabetes mellitus, tuberculosis, any other infection (especially one not amenable to chemotherapy).
    During therapy
    - Prescribe the drug with food.
    - Diet low in calories and sodium, and high in potassium.
    - Check periodically for weight gain, edema, hyperglycemia, hypertension, infection, Gl bleeding, hypokalemia, ocular changes.
    - Monitor growth in children.
    - Instruct the patient not to stop the drug abruptly.
    - Increase the dose in case of any stress(severe infection, major surgery).
    - Prescribe oral calcium and vitamin D supplements; alendronate; (Chapter 70); antacids; H, receptor blockers
    While stopping therapy
    - Taper therapy slowly (see text).</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Before starting therapy
    - Enquire about and check for peptic ulcer, diabetes mellitus, tuberculosis, any other infection (especially one not amenable to chemotherapy).
    During therapy
    - Prescribe the drug with food.
    - Diet low in calories and sodium, and high in potassium.
    - Check periodically for weight gain, edema, hyperglycemia, hypertension, infection, Gl bleeding, hypokalemia, ocular changes.
    - Monitor growth in children.
    - Instruct the patient not to stop the drug abruptly.
    - Increase the dose in case of any stress(severe infection, major surgery).
    - Prescribe oral calcium and vitamin D supplements; alendronate; (Chapter 70); antacids; H, receptor blockers
    While stopping therapy
    - Taper therapy slowly (see text)." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Choice of the glucocorticoid: For routine systemic use, prednisolone is the drug of choice as it is effective orally, relatively safe and cheap. When a potent glucocorticoid is indicated, dexa/betamethasone is preferred; they do not cause sodium retention.</p>
<p>MINERALOCORTICOIDS: The important natural mineralocorticoids are aldosterone (Fig 66.6) and desoxycorticosterone. They have identical effects on electrolyte and water metabolism and on cardiovascular system except that aldosterone is thirty times more potent than desoxycorticosterone.
<img src="assets/images/image-20251214-0eeb7999.jpeg" alt="img-43.jpeg"></p>
<p>FIG. 66.6 Aldosterone</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="physiological-and-pharmacological-actions-of-aldosterone">Physiological and pharmacological actions of aldosterone:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-and-pharmacological-actions-of-aldosterone" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Electrolyte and water metabolism: Physiologically, the major stimulators of aldosterone production are angiotensin II and potassium. Aldosterone secretion rises after consumption of foods rich in potassium and after vigorous exercise that causes release of potassium from the exercising muscle.
Single doses of aldosterone promote sodium resorption and increased excretion of potassium by the kidney, intestine and sweat and salivary glands. On repeated administration of aldosterone, and in patients suffering from an aldosterone producing adenoma (primary hyperaldosteronism) however, the subject escapes from the sodium retaining effect; potassium loss, however, continues.
The results of aldosterone deficiency are clearly seen in Addison's disease. In aldosterone deficiency, the distal renal tubule is unable to conserve sodium, causing marked sodium loss with associated osmotic diuresis and a fall in plasma sodium. The extracellular fluid space becomes contracted and at the same time hypo-osmolar. As a result, water moves into the cells which become over-hydrated. Contraction of the blood</li>
</ul>
<p>volume may lead to azotemia and even collapse. Potassium excretion by the kidneys is impaired. Hyperkalemia and acidosis add to the burden of metabolic disturbances. Increased intake of salt or administration of a mineralocorticoid corrects all the above abnormalities, but the muscular weakness still remains and the patient is unable to withstand stress. Addition of a glucocorticoid is necessary for complete correction of circulatory instability and muscular weakness in Addison's disease.</p>
<p>Aldosterone exerts similar effects on cellular sodium transport at other sites such as the intestines. Further, although aldosterone is primarily produced by the adrenal gland, its local production by the endothelial cells and the vascular smooth muscle cells of the heart and the blood vessels has been demonstrated. The production of aldosterone by the heart is regulated by angiotensin II. (Fig. 66.7).
<img src="assets/images/image-20251214-b0609dca.jpeg" alt="img-44.jpeg"></p>
<p>FIG. 66.7 Pathogenesis and deleterious effects of secondary hyperaldosteronism in CHF
ENDO = Vascular endothelium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>K</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">K=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Kidney
AGTG = Angiotensinogen AD = Adrenal gland
AGT I = Angiotensin I AGT II = Angiotensin II
ACE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Angiotensin converting enzyme
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Heart <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Small arteries and arterioles</p>
<ul>
<li>Cardiovascular effects: Along with angiotensin II, aldosterone also plays a role in blood coagulation, in contraction of systemic arterioles and in stimulating thirst. They are also involved in regulating inflammatory and reparative processes that follow tissue injury. The excess of aldosterone in congestive heart failure (secondary hyperaldosteronism) can cause widespread damage. In the initial stages of LV dysfunction, the patients have compensated heart failure, with natriuresis due to the natriuretic peptide secreted by the cardiac atria. When moderate or severe reduction in renal perfusion occurs because of worsening (decompensated) heart failure, the kidneys secrete an excess of renin with</li>
</ul>
<p>resulting excess of circulating angiotensin II and consequent hyperaldosteronism. This overrides the beneficial effects of the atrial natriuretic peptide. With angiotensin II causing sodium reabsorption in the proximal renal tubule and aldosterone in the distal tubule, salt retention is almost complete. The combination of hyperaldosteronism and an excess of salt causes widespread periarterial fibrosis in the heart and the arterioles including the renal arterioles (Fig 66.7), ensuring a progressive worsening of heart failure. This can be prevented by the aldosterone antagonist spironolactone in doses as small as 25 mg per day.</p>
<ul>
<li>Hypertension: Hypertension is a characteristic feature of primary hyperaldosteronism. Hypertension due to excessive production of desoxycorticosterone is seen in one form of congenital adrenal hyperplasia.
Aldosterone is practically devoid of glucocorticoid effects.
Adverse reactions: These are related to the potent sodium retaining and potassium depleting actions and consist of weight gain, edema, hypertension and hypokalemia. Patients with Addison's disease are extremely sensitive to these effects and hence, the dose of a mineralocorticoid has to be adjusted carefully.</li>
</ul>
<p>Preparations and dosage: Aldosterone, because of very transient action is not therapeutically useful. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mi>α</mi></mrow><annotation encoding="application/x-tex">9 \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">9</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-Fluorohydrocortisone is available as 0.1 mg . tablets. Dose: in adults: 0.05 - 0.30 mg daily; in children upto 12 years, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mcg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. The dose in patients with Addison's disease is best adjusted to maintain plasma potassium ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> plasma renin activity) within normal limits.</p>
<p>Therapeutic uses: Fludrocortisone is used in the treatment of:</p>
<ul>
<li>Addison's disease</li>
<li>Salt losing congenital adrenal hyperplasia</li>
<li>Hyporeninemic hypoaldosteronism as in chronic kidney disease due to diabetes mellitus and other causes; and</li>
<li>Severe postural hypotension from autonomic neuropathy of any etiology.</li>
</ul>
<p>Hyperaldosteronism: Aldosterone output may be raised in two entirely different groups of conditions:</p>
<ul>
<li>Primary hyperaldosteronism (Conn Syndrome): This is generally due to an adenoma of the adrenal cortex. The patient suffers from hypertension, hypokalemia, polyuria, alkalosis, periodic paralysis and occasionally abnormal glucose tolerance. Edema is very rarely seen. Serum sodium and total body sodium may remain within normal limits as the kidneys escape from the sodium retaining effects of aldosterone after the first few days. The treatment is essentially surgical. Spironolactone is used for preparing the patient for surgery.</li>
<li>Secondary hyperaldosteronism: This refers to an increased production of aldosterone in response to activation of the renin-angiotensin system or because of decreased metabolism of aldosterone by the damaged liver. It occurs in edematous patients with hepatic cirrhosis, CHF and nephrotic syndrome. It is likely to occur after sodium depletion in response to vigorous diuretic therapy. Spironolactone is used to treat these patients (Chapter 38).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenal-function-tests">Adrenal Function Tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenal-function-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The plasma levels of cortisol, 17 alpha-hydroxyprogesterone, aldosterone, and the adrenal androgens are measured by immunoassays, under basal conditions and during dynamic tests. Examples of such tests are:</p>
<p>Short, ACTH stimulation test: This has already been described earlier.
Overnight dexamethasone suppression test: Plasma cortisol level is measured the morning after administration of 1 mg of dexamethasone orally at 10 p.m. A level of less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mcg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">%</span></span></span></span></span> indicates normal suppression.</p>
<p>67</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gonadotropins-estrogens-and-progestins">Gonadotropins, Estrogens and Progestins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gonadotropins-estrogens-and-progestins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The role of the anterior pituitary in regulating the gonadal function was established by Harvey Cushing, in 1911 using hypophysectomised dogs. The first substance with gonadotropic activity was isolated from the urine of pregnant women by Zondek and independently by Fluhmann in 1929.</p>
<p>The anterior pituitary secretes two distinct gonadotropic hormones They are:
(1) Follicle stimulating hormone (FSH)
(2) Luteinising hormone (LH), also known as interstitial cell stimulating hormone (ICSH).</p>
<p>The molecular weights of human FSH and LH are estimated to be about 33,000 and 28000, respectively. Secretion of FSH and LH is regulated by a hypothalamic gonadotropin releasing hormone-GnRH.</p>
<p>Physiology of pituitary gonadotropins: Complex interactions between the hypothalamus, the anterior pituitary and the gonadal sex steroids regulate the ovulation in women and spermatogenesis in men. This system is controlled by three feed-back mechanisms:</p>
<ul>
<li>Long feed-back mechanism: Gonadal sex hormones act on the hypothalamus by way of negative feed-back mechanism (estrogen, progesterone, testosterone) or a positive feedback mechanism (estrogen).</li>
<li>Short feed-back mechanism: This involves a direct action of the sex hormones on the anterior pituitary, regulating the secretion of FSH and LH, and,</li>
<li>Ultra-short negative feed-back mechanism: This comprises regulation of the hypothalamic GnRH by the pituitary FSH and LH.
Dopamine found at the nerve endings in the hypothalamus is involved in the release of GnRH, which in turn affects both FSH- and LH-secretory cells of the anterior pituitary. Secretory activities are modulated differently by estrogen, progesterone and testosterone. The mode of action of GnRH is believed to be similar in both sexes except for its cyclicity in women.</li>
</ul>
<p>The regulatory mechanisms in the hypothalamus reside in two centres: (a) the tonic centre in the ventromedial nucleus and the arcuate nucleus and (b) the cyclic centre in the pre-optic suprachiasmatic area. In males the tonic centre is dominant and causes activation of the pituitary and thereby a stimulation of the testes, producing spermatogenesis and testosterone synthesis. In females, it is probably the lack of the androgenic influence, which allows the development of the 'hypothalamic clock', essential for the cyclic release of the gonadotropins. Thus, the cyclic centre is dominant in the female. This centre is sensitive to external and internal stimuli. In the presence of female sex hormones, it is activated (or suppressed) and indirectly activates the tonic centre producing an increased release mostly of LH from the anterior pituitary and consequently ovulation.</p>
<p>The natural GnRH isolated from the human, porcine, ovine and bovine hypothalami is a decapeptide. They are identical in structure and have been synthesized. It regulates the synthesis and secretion of both FSH and LH. Since it predominantly causes release of LH, it is also known as LH-RH.</p>
<p>The sequence of various hormonal changes that occur during a normal 28 days menstrual cycle in women is shown in Fig. 67.1. Day one is defined as the first day of</p>
<p>menstrual flow, while the day preceding the first day of the next menstrual flow is designated as the last day of the cycle. Generally, cycles between 21 and 35 days (average 28 days) are accepted as normal, the duration of menstrual flow being 2-7 days.
<img src="assets/images/image-20251214-1651b6e9.jpeg" alt="img-45.jpeg"></p>
<p>FIG. 67.1 Hormonal changes in blood and urine during the menstrual cycle in human female. Dotted line denotes the day of LH surge.</p>
<p>Pulsatile release of GnRH from the hypothalamus initiates a normal menstrual cycle. Ovarian follicular growth, once initiated by FSH, proceeds independently to the preovulatory phase. A rise of FSH early in the cycles is followed by a rise in blood estradiol. Under the influence of FSH alone, the follicle cells do not secrete estrogens unless a small amount of LH is also present. Most FSH-stimulated follicles undergo atresia whereas one follicle (the dominant follicle) per menstrual cycle becomes the graffian follicle and ovulates.</p>
<p>The ovulatory peaks of FSH and LH occur between days 11-23 of the menstrual cycle (Fig. 67.1). Its timing has no relationship to the length of the cycle. Following this large quantity of LH (LH surge), the follicle size increases resulting in follicular rupture and release of an ovum. LH surge suppresses the granulose cell proliferation and triggers the induction of progesterone release. The peaks of plasma estradiol and 17-alpha hydroxyprogesterone precede the mid-cycle LH peak. This indicates that theca interna cells which</p>
<p>predominantly synthesise estradiol produce 17-alpha hydroxyl-progresterone as an intermediate product. Estimation of these hormones, therefore, gives some idea about the follicular function.</p>
<p>Following rupture, the follicle undergoes reorganisation to form a corpus luteum, which secretes mainly progesterone, and also 17-alpha hydroxy-progesterone, estradiol and some other steroids.</p>
<p>Although GnRH is a major regulator of LH and FSH, the synthesis of FSH is also controlled by the gonadal peptides inhibin and activin. They belong to the family of Transforming Growth Factor Beta. Inhibin beta selectively suppresses FSH (-ve feedback). Inhibition of GnRH secretion by estradiol and progesterone and selective inhibition of FSH by inhibin are critical for development of single mature oocyte.</p>
<p>Corpus luteum (CL) is an independent endocrine organ. In rodents, CL has a limited life span of 3-4 days unless prolactin is secreted by the pituitary. In this species, prolactin acts as luteotropic hormone (LTH), necessary for initiation and maintenance of CL. Such role of prolactin, however, has not been demonstrated in human females in whom LH itself is luteotropic. The life span of CL during a non-pregnant cycle in humans averages about 11 days, while the functional life span of the CL of pregnancy is 9-10 weeks. Since 17-alpha hydroxyprogesterone is synthesised mainly by the CL (not by human placenta) its blood level reflects the function of CL during pregnancy.</p>
<p>It appears that the preovulatory LH surge is partly initiated by an increase in the pituitary sensitivity to GnRH. This increase in sensitivity is the result of the high estradiol levels present at this time of the cycle. Thus, in response to the 'ovarian signal' (in the form of estradiol) a large quantity of LH is released abruptly (LH surge) leading to ovulation and the subsequent formation of CL. Unlike that of most other mammals, the human CL secretes estradiol as well as progesterone, the latter in larger quantities. The increased estrogen and progesterone following ovulation suppress the sensitivity of the hypophysis to GnRH, in addition to suppressing the hypothalamus. In the absence of conception, the progesterone and estrogen levels remain high for eight days and then following degeneration of CL, fall abruptly leading to menstruation. These hormonal changes before and after ovulation are associated with the characteristic proliferative and secretory changes, respectively, in the endometrium.</p>
<p>Although it is difficult to predict the day of ovulation in a given cycle in a human female, the reproductive cycle shows a remarkable regularity and in the majority, it is repeated every 26-30 days. What keeps the system cycling so regularly is not well understood. As progesterone is thermogenic, body temperature rises just after ovulation, However, the usual way of judging ovulation clinically by noting the rise in basal body temperature (BBT) may not be accurate.</p>
<p>Gonadotropic hormones stimulate the biosynthesis of sex steroids in the gonads. LH increases the accumulation of adenosine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime}, 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>-monophosphate (cyclic AMP) as one of its early effects. Cyclic AMP triggers synthesis of various sex hormones starting from the C27 compound cholesterol leading to the formation of various C21, C19 and C18 sex steroids (Fig. 67.2). As seen in this figure progesterone is necessary for the synthesis of androgens, and androgens are obligatory precursors of estrogens.</p>
<p><img src="assets/images/image-20251214-c7bb741b.jpeg" alt="img-46.jpeg"></p>
<p>FIG. 67.2 Biosynthesis of sex steroids in the gonads.
(A) = Aromatase</p>
<p>The non-pregnant human female synthesises two biologically active estrogens estradiol (E2) and estrone (E1) and much larger amounts of prohormone estrone sulfate. The last is converted to estrone in the peripheral tissues. The third, weakly active estrogen, estriol (E3), is synthesised by the placenta.</p>
<p>Apart from estrogens and progesterone, the ovarian extract also contains 17-alpha-hydroxy-progesterone, and androstenedione, a precursor of testosterone.</p>
<p>Although the ovaries normally cease their gametogenic and hormonal function in the fifth decade of life, leading to menopause, postmenopausal women have some circulating estrogen. This is due to conversion of the adrenal androgens into estrogens in the peripheral adipose tissue.</p>
<p>Hypothalamo-pituitary-ovarian relationship: In addition to the cyclical release in relation to the menstrual cycle in women, LH is released in discreet bursts (pulses) every 12 hours, separated by periods of little or no release. Similar pulsatile release is also seen in men. This is probably based on a similar, pulsatile release of GnRH from the hypothalamus. This intermittent release of a hormone permits the regeneration of its receptors in the end organ and maintenance of their sensitivity to the concerned hormone.</p>
<p>The secretion of pituitary LH and FSH is regulated by the interaction between the sex steroids and hypothalamic GnRH. Both progesterone and testosterone suppress the discharge of LH and FSH stimulated by GnRH (negative feedback). In contrast, estrogen appears to exert a biphasic effect on the pituitary response to hypothalamic GnRH. As the follicular phase in women progresses, the rising plasma FSH levels cause the plasma estradiol level to rise. The sharp rise in the estradiol level at the end of follicular phase exerts a positive feedback on the pituitary and is responsible for the midcycle LH surge. The decline in the levels of estradiol and progesterone in the late luteal phase are responsible for the commencing rise in the plasma FSH level even before the menstrual bleeding commences, an example of negative feedback. The increased levels of gonadotropins after</p>
<p>the menopause are due to the loss of the estrogen's inhibitory influence.
Pharmacological doses of an estrogen exert only a negative feedback on the pituitary, causing inhibition of gonadotropin release in a dose dependent manner.</p>
<p>GnRH (LH-RH): The first lot of GnRH was isolated by Schally in 1971 by extracting and processing one million pig hypothalami! The GnRHs of sheep, pigs, cows and human origin are identical in structure. GnRH is a decapeptide. It is also found in human placenta. Placental GnRH may be involved in the synthesis and release of human CG (hCG). Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 2-8 minutes.</p>
<p>The main function of GnRH is the promotion of synthesis and release of LH and FSH from the anterior pituitary. The relative amounts of FSH and LH released after administration of GnRH are related to the puberal status of the individual. Prior to the onset of puberty, FSH is the predominantly released gonadotropin, whereas after puberty it is LH which is predominantly released. Given in an intermittent, pulsatile manner, GnRH increases the responsiveness of the pituitary gonadotropes to GnRH itself. This self-priming effect is not observed following a continuous GnRH infusion, which results in an initial increase for a short time, followed by a sustained and progressive dedine in LH secretion. This is due to a 'downregulation' of the GnRH receptors.</p>
<p>Clinically, pulsatile GnRH can restore the normal gonadotropin release pattern in patients with hypothalamic hypogonadism. The pituitary's response to Gn-RH varies throughout the menstrual cycle, being maximum at mid-cycle.</p>
<p>Preparations and dosage: Synthetic GnRH (Gonadorelin) is not easily available. It is administered by pulsatile subcutaneous infusion, 10-20 mcg over 1 minute, to be repeated every 90 minutes, for the treatment of amenorrhoea and infertility due to abnormal release of endogenous LH-RH. For assessment of pituitary function, lower strength is to be used.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Assessment of the function of the pituitary gonadotropes to distinguish between delayed puberty and hypogonadotropic hypogonadism; the results of this test are often inconclusive.</li>
<li>Induction of ovulation in patients with polycystic ovary syndrome not responding to clomiphene.</li>
<li>Treatment of males and females with idiopathic, hypothalamic, hypogonadotropic hypogonadism (Kallman syndrome).
GnRH (LH-RH) ANALOGUES: The analogues are of two types:
(1) Agonists; and
(2) Antagonists</li>
</ul>
<p>The agonists bind to the GnRH receptors on the pituitary gonadotropes. Prolonged receptor occupation during their continuous use causes their down-regulation and reduces gonadal secretion. Unlike the GnRH antagonists, the agonists enhance the release of gonadotropins initially; this is a disadvantage in the treatment of the hormone dependent cancers. Exogenous estrogens, progestins and androgens inhibit the GnRH release, but only progestin exerts this effect at doses that do not have marked hormonal effect.</p>
<p>GnRH analogues are administered SC/IM and by nasal spray. They have higher receptor affinity and are longer acting.</p>
<p>Adverse reactions: These include hot flushes, sweating, vaginal dryness, headache and occasionally diminished libido and depression. Prolonged treatment causes osteoporosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The long acting GnRH agonists (Table 67.1) are used in the treatment of:
Table 67.1
Some clinically used GnRH agonists</p>
<table><thead><tr><th style="text-align: left;">Name</th><th style="text-align: center;">Potency</th><th style="text-align: center;">Half life (minutes)</th><th style="text-align: left;">Dose and mode of administration</th></tr></thead><tbody><tr><td style="text-align: left;">GnRH (Gonadorelin)</td><td style="text-align: center;">1</td><td style="text-align: center;">5</td><td style="text-align: left;">See text</td></tr><tr><td style="text-align: left;">Leuprorelin acetate</td><td style="text-align: center;">15</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>180</mn><mo>−</mo><mn>220</mn></mrow><annotation encoding="application/x-tex">180-220</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">180</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">220</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">C</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">M</mi></mrow></mrow><annotation encoding="application/x-tex">3.75 \mathrm{mg} \mathrm{SC} / \mathrm{IM}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord"><span class="mord mathrm">SC</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">IM</span></span></span></span></span></span> monthly</td></tr><tr><td style="text-align: left;">Buserelin acetate</td><td style="text-align: center;">20</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>85</mn></mrow><annotation encoding="application/x-tex">75-85</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">85</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">300 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day, in divided doses, intranasally; or 1 mg SC daily</td></tr><tr><td style="text-align: left;">Nafarelin</td><td style="text-align: center;">150</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">120-160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> intranasally</td></tr><tr><td style="text-align: left;">Triptorelin microspheres</td><td style="text-align: center;">144</td><td style="text-align: center;">-</td><td style="text-align: left;">3 mg IM monthly</td></tr><tr><td style="text-align: left;">Goserelin acetate polymer</td><td style="text-align: center;">100</td><td style="text-align: center;">-</td><td style="text-align: left;">3.6 mg SC monthly</td></tr></tbody></table>
<ul>
<li>Certain hormone dependent cancers e.g. cancer of the prostate and the breast for suppressing gonadotropins.</li>
<li>Central precocious puberty.</li>
<li>Endometriosis.</li>
<li>Large uterine fibroids; and in</li>
<li>IVF regimens, as an adjunct to GnRH, in order to inhibit untimely release of LH.</li>
</ul>
<p>The GnRH antagonists act by competitive inhibition of the binding of endogenous GnRH to the GnRH receptors and suppress the release of LH and FSH from the onset of administration. They are more expensive; further, they often act as releasers of histamine.</p>
<p>Ganirelix and Cetrorelix GnRH antagonists, are claimed to cause less histamine release than the other antagonists. They are usually given SC. Currently, they are used during IVF regimen as a means of preventing LH surges during ovarian stimulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gonadotropins">Gonadotropins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gonadotropins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All the gonadotropins are glycoproteins. They have different plasma half lives and undergo metabolic degradation by plasma proteases. The gonadotropins available for human therapy are:
(1) Human chorionic gonadotropin (hCG), and
(2) Human menopausal urinary gonadotropin (hMG).</p>
<p>They can elicit antibody formation.
Bioassay: These are usually conducted on hypophysectomised immature rats and mice, and are based on the measurement of increase in ovarian or uterine weight (for FSH), increase in weight of the ventral prostate (for LH), or histological changes in the ovary, uterus and vagina. In the past, biological tests based on the detection of hCG in the urine were used in the diagnosis of pregnancy. These tests are based on observation of (a) ovulation in the rabbit (Friedman test), or in the mouse (Ascheim Zondek test); (b) ovarian hyperemia in immature rats; or (c) presence of spermatozoa in the cloaca of the male frog (Frog test), a few hours after the injection of the urine sample in these animals.</p>
<p>These have now been replaced for clinical purpose by more precise and convenient immunological assays.</p>
<p>HUMAN CHORIONIC GONADOTROPIN (hCG): This glycoprotein hormone of human pregnancy is secreted by the foetal placenta. It can be detected in the maternal plasma several days before the first missed period. Sufficient amounts of it is absorbed into the blood and sustains luteal function until the placenta starts secreting estrogen and progesterone by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> month of pregnancy and helps to maintain CL. Its physiological role after that time is unknown.</p>
<p>The amino acid sequences of the alpha subunits of the human glycoprotein hormones are identical but those of the beta subunits differ. LH and hCG have biologic activities in common, reflecting the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> structural homology between their beta subunits. hCG, however, differs chemically from LH mainly in that it has additional 32 amino acids.</p>
<p>Besides the placenta, certain tumours secrete hCG. Gestational trophoblastic tumours, derived from the placenta, are invariably associated with abnormally high hCG blood levels and its serial estimation is valuable for monitoring therapy and detecting tumour recurrence. Similarly, it has been used as a tumour marker to diagnose recurrence and to monitor therapy in men with nonseminomatous germinal cell tumours.</p>
<p>Pharmacological actions: Like pituitary LH, small doses of hCG can preserve the CL and prolong the secretory phase of the menstrual cycle. This is associated with an increased urinary excretion of pregnanediol. The hCG can induce a decidual reaction in the endometrium even in the absence of conception (pseudo-pregnancy). It does not promote follicle maturation in humans; however, in immature animals, it can evoke follicular growth and induce ovulation.</p>
<p>Injected into the males, hCG stimulates the interstitial cells of the testes to secrete androgen.</p>
<p>Adverse reactions: These include headache, edema, gynaecomastia and occasionally depression.</p>
<p>Preparation and dosage: (i) hCG 1500 IU, 5,000 IU, with 10 ml of diluent; IM or SC. (ii) Choriogonadotropin alpha: is a recombinant hCG; 6500 IU/ 0.5ml; SC depending on</p>
<p>patient's response.
Therapeutic uses:</p>
<ul>
<li>Ovulation induction: hCG therapy can induce ovulation in an adequately developed follicle following endogenous FSH or exogenous hMG, leading to conception. (see later).</li>
<li>Cryptorchism: Cryptorchism denotes failure of the testes to descend into the scrotum. hCG is used to promote this descent. It is given in doses of 3000-5000 IU every 3-4 days for total of 4 injections. If descent does not occur, orchidopexy is indicated. Evidence indicates that non-descent of the testes into the scrotum can damage them from very early age, and hence treatment should be initiated as early as 2-3 years of age. The hormone should not be used if mechanical obstruction is present.</li>
<li>Delayed puberty in boys: This is treated with 500-1000 IU of hCG 3 times a week for 4 weeks, repeated, if necessary, after several months. Once initiated, the puberty progresses without further treatment. If such progression fails to occur, hypogonadotropic hypogonadism is diagnosed.</li>
<li>Testing the responsiveness of the immature testes to gonadotropins: For this purpose, serum testosterone is measured before and 3-4 days after an injection of 5000 IU of hCG. A post-injection level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> is considered a normal response. It also confirms the presence of testicular tissue in a patient in whom the testes are not palpable and not demonstrable by imaging techniques.</li>
<li>Treatment of hypogonadotropic hypogonadism: For this purpose, 2000 IU are injected 23 times a week for prolonged periods. Enlargement of the testes and development of secondary sex characters are stimulated. Addition of hMG may be necessary for inducing spermatogenesis.</li>
<li>Treatment of luteal phase defect: hCG may be used to support the production of adequate amounts of progesterone in the luteal phase of the menstrual cycle in patients with luteal phase defect. Alternatively, progesterone has been used to supply the deficient hormone.
HUMAN MENOPAUSAL URINARY GONADOTROPIN (hMG, Menotropins): This is prepared from the urine of menopausal women and is available in ampoules containing 75 IU of FSH and equal amounts of LH. It is used, together with hCG, to induce ovulation in women with anovulation due to pituitary-hypothalamic disorders but with normal ovaries, and those with polycystic ovaries. Various regimens have been used with monitoring of the follicular growth by ultrasonography and plasma estradiol levels. Generally, the regimes involve daily injections of FSH and LH starting on day 2 or 3 of the menstrual cycle. When two or three follicles inrease in diameter size by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>18</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">16-18 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> as seen on transvaginal ultrasound, 5000-10,000 IU of hCG is injected IM to induce ovulation followed by inrautrine insemination and/or natural intercourse 24-36 hours later. Ovulation can be successfully induced in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of selected cases, and pregnancy occurs in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>; of these, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> end in abortion and multiple births may occur in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>. Such regimen can also be used in IVF technique. The growth and development of children so born have been normal.
hMG has also been used with variable success in males with idiopathic oligospermia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Menotropins is an unpurified preparation, it is injected IM and not SC, in order to reduce the possible allergic reactions.</p>
<p>(ii) Purified FSH preparation (Metrodin HP, devoid of LH activity) injected IM or SC
(iii) Follitropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold-italic">α</mi></mrow><annotation encoding="application/x-tex">\boldsymbol{\alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4444em;"></span><span class="mord"><span class="mord"><span class="mord boldsymbol">α</span></span></span></span></span></span></span> and follitropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> rDNA moncomoponent FSH products, used either IM or SC.
(iv) Recombinant LH preparation lutropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold-italic">α</mi></mrow><annotation encoding="application/x-tex">\boldsymbol{\alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4444em;"></span><span class="mord"><span class="mord"><span class="mord boldsymbol">α</span></span></span></span></span></span></span> is monocomponent, used IM/SC.</p>
<p>Adverse reactions: The main complication of this therapy is hyperstimulation syndrome after hCG injection. The ovaries become very large and friable due to maturation of many follicles. This causes abdominal pain, nausea and vomiting. If the friable ovary ruptures into the abdomen, the patient may develop ascites and shock. The management is conservative. Prevention implies:
(a) Keeping the dose of hMG low; and
(b) Not injecting hCG if the plasma estradiol level exceeds <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2000</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2000 \mathrm{pg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.</p>
<p>PROLACTIN: The lactotropes of pituitary gland secrete prolactin (hPRL, MW 21500, amino acids 198). Unlike with the other pituitary hormones, the secretion of prolactin is under control of a hypothalamic prolactin-inhibiting factor (PIF), now identified as dopamine in the median eminence. In the pituitary, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are predominant and mediate the inhibition of PRL synthesis and release. The normal adult serum PRL levels are about 10<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">25 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in women and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in men.</p>
<p>Serum hPRL concentration increases during the last 2 trimesters of pregnancy and remains elevated during postpartum period and breast feeding. Breast feeding and stimulation of the nipple cause a reflex rise in serum hPRL. Increased levels are also seen following exercise, psychological and surgical stress.</p>
<ul>
<li>Endocrine actions: PRL acts on a receptor belonging to type-I cytokine receptor family. Physiologically, the main actions of prolactin are the preparation of the breasts for lactation, and the initiation and maintenance of lactation. Following prolactin, the lobuloalveolar epithelium of the breast proliferates. The mechanism that converts the developed and potentially secretory mammary gland into an active secretory organ at delivery is not well understood; but other hormones such as estrogens, corticosteroids, insulin and thyroid are also necessary for galactopoiesis.
Supraphysiological levels of prolactin inhibits reproductive function and suppresses sex drive, by suppressing GnRH and consequently gonadotropin secretion. It impairs gonadal steroid production and blocks the development of the ovarian follicles, causing anovulation. Its direct luteolytic effect leads to inadequate luteal phase. In men, it causes low plasma testosterone and decreases libido and spermatogenesis.</li>
<li>Metabolic actions: PRL increases calcium absorption and mobilises calcium from the bone. Hyperprolactinemia is associated with increased bone loss and osteoporosis. PRL receptors are present in the osteoblasts of developing bone. Hypoestrogenemia present in hyper-prolactinemic women probably causes increased bone loss. PRL also induces pancreatic beta cell growth. By acting centrally, it increases appetite and is probably involved in parenting behaviour.
Hyperprolactinemia is seen in hypothyroidism and in prolactin secreting pituitary adenomas. It causes galactorrhoea, amenorrhoea and infertility in women, and sexual impotence in men. It can also be drug induced (Table 67.2). Its rational therapy involves the use of drugs that decrease the hPRL secretion. The drugs used are: dopamine agonists Bromoergocriptine, Lisuride, Cabergoline and Quinagolide.</li>
</ul>
<p>Table 67.2
Drugs causing hyperprolactinemia</p>
<ul>
<li>Blockers of dopamine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) receptors:</li>
</ul>
<p>Antipsychotic phenothiazines; haloperidol; metoclopramide; domperidone.</p>
<ul>
<li>Dopamine synthesis inhibitors: a methyldopa.</li>
<li>Central dopamine depletors: Reserpine.</li>
<li>Antidepressants: MAOI, Imipramine, amitryptiline, fluoxetine.</li>
<li>Hormones: TRH; oral contraceptives; antiandrogens.</li>
<li>Miscellaneous: Cimetidine; verapamil; opiates.</li>
</ul>
<p>BROMOERGOCRIPTINE (Bromocriptine): This semisynthetic ergot alkaloid is a selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist. Since dopamine is a neurotransmitter or local hormone at various sites in the brain, bromocriptine can produce various motor, behavioural and endocrine effects. Its oxytocic and cardiovascular actions, however, are negligible.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hormonal actions: Dopamine (PIF), released by the hypothalamus, inhibits prolactin release from pituitary. Bromocriptine, acting as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist, inhibits synthesis and release of prolactin and decreases the replication of the tumorous lactotrophs. Given to patients with hyperprolactinemia, it causes a marked fall in serum prolactin levels, accompanied by restoration of the normal cyclic release of gonadotropins.
Bromocriptine causes a brief rise in plasma GH in normal subjects but a sustained fall in patients with acromegaly.</li>
<li>Motor effects: Bromocriptine causes a reduction in dopamine turnover with a decrease in concentration of the dopamine metabolites and an increase in dopamine content of the brain. It thus produces beneficial effects in Parkinson's disease (Chapter 15). But the doses required are almost 10 times higher than those which suppress prolactin.</li>
<li>Behavioural effects: Prolonged treatment, particularly with larger doses, can cause altered behaviour and awareness, sometimes accompanied by hallucinations. This probably results from hydrolysis of the LSD fragment of the bromocriptine molecule.</li>
<li>CVS: These drugs cause vasodilatation (see adverse reactions below).</li>
</ul>
<p>Absorption, fate and excretion: The drug is rapidly and almost completely absorbed from the gut and readily crosses the BBB. Following a single dose, plasma level remains high for several hours and low levels can be detected for upto four days. The drug is extensively metabolised and only 6 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> is excreted in the urine. The rest appears in the bile and feces.</p>
<p>Adverse reactions: These include postural syncope, gastric upset, nausea and drowsiness. Continuous high doses may cause constipation, nasal congestion, cramps in legs, hallucinations, dystonic reactions, arrhythmias and postural hypotension. The drug should be avoided in patients with a history of mental illness, IHD and peripheral vascular disease. Long term use may rarely produce retroperitoneal fibrosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Bromocriptine mesylate tablets 2.5 mg .
(ii) Bromocriptine mesylate inj. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">40 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. This is used IM in cases of prolactinomas compressing the optic chiasma (See below).
(iii) Vaginal preparation may be useful in patients intolerant of oral bromocriptine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hyperprolactinemia-galactorrhoea syndrome: Given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily in divided doses, it restores serum prolactin levels to normal and stops galactorrhoea in patients with prolactinomas and those with functional hyperprolactinemia.
Amenorrhoea is corrected and fertility is restored in women, within 4-12 weeks of therapy. It is, however, not effective in amenorrhoea due to gonadotropin deficiency or ovarian failure.
In patients with prolactinomas, bromocriptine in the dose 2.5 to 10 mg . daily produces tumor regression and resolution of visual field defects. It is considered a specific and safe primary treatment for prolactin-secreting adenomas. However, recurrence can occur after stopping even a prolonged drug treatment.</li>
<li>Prolactinoma with impotence in males: It lowers serum prolactin levels and restores potency in these patients.</li>
<li>Acromegaly: Bromocriptine in the dose of 15-20 mg daily causes a sustained, doserelated decrease in plasma GH levels and the hormonal, metabolic and clinical responses have been maintained for upto five years in individual cases. However, complete clinical remission occurs in only a minority of patients.</li>
<li>Parkinson's disease: Though it has a more prolonged action than levodopa, it causes higher adverse reactions (Chapter 15).
Its use to suppress puerperal lactation has caused hypertension, seizures, stroke and psychosis. Hence, the use of bromocriptine and other <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists should also be avoided.</li>
</ul>
<p>LISURIDE: This drug has properties and uses similar to those of bromocriptine. It is available as 0.2 mg tablets.</p>
<p>CABERGOLINE: This long acting analogue of bromocriptine, can be administered 500 mcg once a week, increased by 500 mcg increments, upto a maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> week. The adverse reactions to this drug are different from those to bromocriptine: palpitation, epigastric and abdominal pain, epistaxis, hemianopia, syncope and hot flushes. Patients resistant to bromocriptine may respond to this drug. Cabergoline is now preferred in clinical practice.</p>
<p>As it is longer acting it should be avoided when fertility is desirable.
QUINAGOLIDE: This drug has properties, ADR and uses similar to bromocriptine. It is used in the daily dose of 25 mcg at bedtime, increased weekly to a maximum daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> at bedtime.</p>
<p>As <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi>B</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 B}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.05017em;">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonists, pergolide and cabergoline can cause fibrosis of the cardiac valves during long term therapy of parkinsonism wherein high doses are required (Chapter 15). In hyperprolactinemia smaller does are used, which are considered as safe.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="placental-hormones">Placental Hormones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#placental-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The placenta serves the important function of sustaining the growth and nutrition of the developing embryo. It is also an endocrine organ secreting hormones. One of these, the chorionic gonadotropin (hCG), has already been discussed.</p>
<p>Another placental peptide related to human pituitary GH has been isolated. It has lactogenic, luteotropic and growth promoting activities. It is present in human serum, urine and amniotic fluid during pregnancy and disappears immediately after delivery. The hormone is named 'placental growth hormone or placental lactogen (hPL)'. It is believed to act as a anabolic hormone in the mother and the fetus.</p>
<p>During pregnancy (probably from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> month), the placenta produces large amounts of estrogen and progesterone. The progesterone, besides having a physiological effect on maternal organs, also acts as a precursor for foetal corticosteroids and androgens.</p>
<p>During pregnancy, the urinary excretion of estrogen shows a great preponderance of estriol over that of estrone and estradiol. Since the fetus plays a specific role in the synthesis of estriol, assay of the level of estriol in maternal urine provides useful information about the well-being of the foetus. A fall in urinary estriol level may denote foetal distress or retarded foetal growth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="estrogens">Estrogens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#estrogens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In humans, the estrogens are produced mainly by the ovary and the placenta; small amounts may be produced by the adrenals and testes. The synthesis of estrogens from acetate and cholesterol is shown in Fig. 66.2. In certain animals like the horse, large quantities of estrogens are produced by the testes. Estrogens are also present in various plants and seeds. The natural estrogens are steroids. However, typical estrogenic activity is also shown by chemicals which are not steroids. Hence, the term 'estrogen' is used as a generic term to describe all the compounds having an estrogenic activity.</p>
<p>The pituitary gonadotropins regulate the production of the ovarian steroids. LH stimulates the production of the androgens, androstenedione and testosterone by the theca cells of the ovarian follicles. These two androgens are taken up by the adjacent granulosa cells of the ovarian follicles. The granulosa cells proliferate and express aromatase under the influence of FSH. Aromatase converts the androgens into estrogens, estrone and estradiol. The liver and the adipose tissue also contain aromatase and convert the circulating androgens into estrogens. Unlike in the gonads, estrogen production in other sites is unregulated.</p>
<p>During childhood, small amounts of the pituitary gonadotropins keep up a limited output of estrogenic and androgenic hormones which bring about the normal, gradual development of the genitalia. At puberty, increased output of gonadotropins leads to an increased production of the ovarian estrogens.</p>
<p>Physiological functions of estrogen: It</p>
<ul>
<li>Promotes development of female reproductive tract (uterus, fallopian tubes and vagina).</li>
<li>Promotes development of female secondary sex characters, such as breasts (ductal growth), body contours, hair, skin and voice. They are also responsible for the psychological and emotional get up typical of femininity.</li>
<li>Stimulates the proliferative or preovulatory phase of endometrium. The role of estrogens during the normal menstrual cycle is discussed earlier.</li>
<li>Causes vasodilatation of capillaries in general and those of the endometrium in particular.</li>
<li>Induces metabolic effects such as retention of nitrogen, sodium and fluid in tissues.</li>
<li>Exerts cardioprotection in women of the reproductive age; this is mediated by maintenance of the LDL levels at a lower level than in males, as well as probably by other mechanisms. Menopausal women lose this protective influence of estrogen, leading to increased incidence of IHD.</li>
<li>Maintains the integrity of the skeleton in women of reproductive age; following menopause women suffer from osteoporosis.</li>
<li>Promotes the union of the epiphyses with the metaphyses thus controlling the height. The epiphyseal fusion is accelerated following the onset of menarche and once fused, no further increase in height can occur.</li>
<li>Supports pregnancy and parturition by inducing favourable changes in the endometrium, vaginal and cervical mucosa and uterine growth and contraction.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-estrogens">Classification of Estrogens:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-estrogens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Natural estrogens Estradiol (Fig. 67.3), Estrone and Estriol and their esters.</p>
<p><img src="assets/images/image-20251214-26a5e65d.jpeg" alt="img-47.jpeg"></p>
<p>FIG. 67.3 Estradiol</p>
<p>II Semisynthetic estrogens e.g. Ethinyl estradiol.
III Synthetic estrogens:
(a) Those which are steroids e.g. Mestranol;
(b) Those which are not steroids but derivatives of diphenylethylene (stilbene e.g. Stilbestrol, and Triphenylethylene e.g. Chlorotrianisene (TACE) (Fig. 68.1).</p>
<p>Stilbestrol and chlorotrianisene are sometimes used only to treat patients with carcinoma of the prostate (Chapter 61).</p>
<p>All the estrogenic compounds produce similar pharmacological actions and hence, are discussed together.</p>
<p>Mechanism of action: Estrogens bind to the nuclear estrogen receptors in estrogen responsive tissues. The steroid-receptor complex undergoes conformational change and binds to the estrogen responsive element (ERE) located on the target gene, where it brings about changes in transcription. There are two types of estrogen receptors:
(1) ER <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold-italic">α</mi></mrow><annotation encoding="application/x-tex">\boldsymbol{\alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4444em;"></span><span class="mord"><span class="mord"><span class="mord boldsymbol">α</span></span></span></span></span></span></span>, present in the female genital tract, breasts, hypothalamus, endothelial cells and vascular smooth muscle and
(2) ER <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold-italic">β</mi></mrow><annotation encoding="application/x-tex">\boldsymbol{\beta}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord boldsymbol" style="margin-right: 0.03403em;">β</span></span></span></span></span></span></span>, present in bone, brain, prostate and ovaries.</p>
<p>The vascular actions of estrogen do not require gene activation and are mediated by the membrane receptors.</p>
<p>Pharmacological actions: These drugs, when used as substitution therapy, produce actions similar to the physiological actions of natural estrogens.</p>
<ul>
<li>Menstruation: In women with deficient ovarian function, estrogens in appropriate doses produce proliferative changes in the endometrium. Following these changes, withdrawal of estrogens causes menstrual flow known as withdrawal bleeding. This obviously cannot be compared with the natural menstruation where progesterone withdrawal plays an important role. The response depends upon the size of the dose and the duration of treatment. With very small doses irregular bleeding can occur even without the interruption of the drug (break-through bleeding).</li>
<li>Gonadotropin inhibition: Continuous administration of estrogens suppresses the secretion of FSH and also of midcycle LH surge resulting in inhibition of ovulation. In males, it inhibits spermatogenesis. The testes may undergo atrophic changes and the secretion of androgen is reduced.
Administration of estrogens, however, even in large doses, after the ovulation, does not alter the course of normal menstrual cycle.</li>
<li>Suppression of lactation: Estrogens suppress lactation without affecting prolactin levels.</li>
<li>Metabolic actions: They have a weak anabolic action. Given over a long period, they may cause sodium and water retention. Estrogens reduce the level of plasma cholesterol but increase that of triglycerides. They promote urate reabsorption by the proximal renal</li>
</ul>
<p>tubule.
Large doses of estrogens given to children for long periods inhibit the growth of epiphyseal cartilage, and may cause epiphyseal fusion.</p>
<ul>
<li>Bones: Estrogens have a positive effect on the bone mass which is mediated by complex actions. Osteoblasts and osteoclasts express both ER <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and ER <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>. The former play a major role.
(a) Estrogen directly regulates the osteoblasts and brings about their differentiation.
(b) It increases the osteoblast and osteocyte survival by inhibiting their apoptosis.
(c) The major effect is to decrease the number and activity of the osteoclasts via altering the cytokine signals from the osteoblasts. Estrogen prevents differentiation of osteoclast precursors into osteoclasts; and increases osteoclast apoptosis. This results in prevention of bone resorption by the osteoclasts.</li>
<li>Carcinogenicity: Estrogens are carcinogenic in animals, and are implicated in the genesis of cancers of the endometrium, breast, liver and vagina in women (see later).</li>
<li>Antiandrogenic action: Estrogens have been found to be beneficial in prostatic cancer which is androgen dependent (Chapter 61).
Absorption, fate and excretion: Both the natural and synthetic estrogens can get absorbed through the skin and the mucous membranes and can cause systemic effects. Given orally, estrogens are well absorbed but the natural estrogens are not so effective as they are metabolised during their passage through the liver (first pass). Enterohepatic circulation of estrogens does occur.</li>
</ul>
<p>About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span> of the dose is excreted in the urine, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of which is estradiol and the rest as metabolites. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the dose is recoverable in feces; the fate of the remaining is unknown. Liver plays an important role in the conjugation of steroidal estrogens. Nonsteroidal estrogens such as diethylstilbestrol are not metabolised so easily and hence a large fraction of is excreted in urine in free state.</p>
<p>Estrogen esters like benzoate and dipropionate when injected, are absorbed slowly and are effective for several days or weeks.</p>
<p>Bioassay: The crystalline pure estrogenic preparations need no bioassay. The activity of estrogenic substances is bioassayed in rats by the method of Allen and Doisy, which is based upon the observation of typical cornified vaginal smear following estrogen administration. This test is very sensitive, particularly if the agent is applied locally into the vagina. Immunoassay is now used in clinical practice.</p>
<p>Adverse reactions: These are:
(a) Following physiological doses in hormone replacement therapy (HRT); and
(b) Following pharmacological doses in oral contraceptives (see Chapter 68).</p>
<p>Small doses as in HRT may cause nausea, vomiting and anorexia. These are similar to those occurring in pregnancy. They can be minimised by taking the drug with food or at bedtime. Sodium and water retention can cause edema, and fullness and tenderness of the breasts; this generally indicate excessive dosage. Intermittent vaginal bleeding may occur in some women on HRT. Any active ectopic endometrial tissue (endometriosis) and uterine fibroids can undergo deterioration during this therapy. Uncontrolled hypertension and migraine may worsen when the patient is on estrogen. Greater cholesterol concentration in the bile predisposes to gall stone formation. Estrogens can cause an increase in the plasma triglyceride in those with familial tendency to hypertriglyceridemia.</p>
<ul>
<li>HRT does not cause a deterioration of glucose tolerance. It lowers the plasma levels of LDL and of total plasma cholesterol, while increasing those of plasma HDL. It causes only minimal elevation of the binding proteins (thyroxine binding protein, corticosteroid binding protein, sex hormone binding protein and renin substrate).
HRT is not contraindicated in women with diabetes mellitus, controlled hypertension or varicose veins. It is unsafe in patients with CHD, TIA or stroke and in those with history of it (See later).</li>
<li>Prolonged, unopposed, estrogen therapy increases the risk of endometrial and breast cancer and stroke significantly with any type of HRT. It has recently been suggested that HRT in postmenopausal woman can increase the incidence of ovarian cancer. The administration of diethylstilbestrol to pregnant women caused a variety of genital abnormalities, including vaginal adenosis and vaginal adenocarcinoma, in the female offsprings of such women. The use of 'synthetic' non-steroidal estrogens for other purposes than prostate cancers is now obsolete.</li>
<li>Pharmacological doses of estrogens administered to prepuberal girls can cause:
(a) Premature breast enlargement (thelarche): and precocious puberty; and
(b) Stunting of linear growth of the long bones and hence of final height by accelerating the closure of the epiphysial plate.
Preparations and dosage:</li>
<li>Natural estrogens and their esters:
(i) Estradiol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg}, 2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablets
(ii) Estradiol, micronised, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg}, 1 \mathrm{mg}, 2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tablets for oral use. For IM use, it is available as injection <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.
(iii) Estradiol valerate, 1 and 2 mg tablets.
(iv) Estradiol patch: These are self-adhesive, estradiol patches, releasing 25, 50 or 100 mcg of estradiol per 24 hours for 3-4 days. They should not be applied near the breasts for fear of causing breast cancer. They are very expensive.
(v) Estradiol transdermal spray <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.53</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.53 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.53</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> spray is available for women with hot flushes. It is claimed to cause fewer side effects.
(vi) Estradiol gel.
(vii) Estradiol implant, 25 mg .
(viii) Estradiol vaginal tab 25 mcg .
(ix) Estriol succinate 2 mg tablets and vaginal cream ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> ).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="semisynthetic-steroidal-estrogens">- Semisynthetic steroidal estrogens:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#semisynthetic-steroidal-estrogens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Ethinyl estradiol tablets <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.01</mn><mo separator="true">,</mo><mn>0.025</mn></mrow><annotation encoding="application/x-tex">0.01,0.025</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.01</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">0.025</span></span></span></span></span> and 0.05 mg . In the treatment of prostatic cancer the dose recommended is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily.
(ii) Mestranol, the 3-methyl ether of ethinyl estradiol, is a prodrug, converted to ethinyl estradiol.</p>
<ul>
<li>Conjugated equine estrogens: This preparation is a mixture of numerous water soluble conjugated estrogens, mainly esters of estrone and equilin, obtained from pregnant mares' urine. They are available as 0.625 and 1.25 mg tablets, as an injection containing 20 mg of the drug in 5 ml SC and as vaginal cream ( 0.625 mg in 1 g base) The dose for control of excessive menstrual bleeding is 20 mg by slow intravenous injection.
Cenestin (Synthetic conjugated estrogens A): This preparation contains "nine of the ten known conjugated estrogens present in Premarin." They are water soluble, well absorbed</li>
</ul>
<p>in the GI tract and are metabolised in the liver. Their precautions, adverse effects and contraindications are similar to those of other estrogen preparations. The preparation appears to be safe and effective in the dose of one to two 0.625 mg tablets, for short term treatment of vasomotor symptoms of menopause.</p>
<ul>
<li>Synthetic nonsteroidal estrogens: Diethylstilbestrol tablet contains 1, 5 and 25 mg . For prostate cancer: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1-3 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day and for breast cancer: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10-25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Cosmetic preparations: Topical preparations containing physiological amounts of estrogens or natural progesterone have been promoted as cosmetic, 'rejuvenating' creams. There is no evidence that the hormone creams are any more effective than simple emollients in relieving the dryness of the skin or in improving the facial appearance. However, systemic effects may follow their excessive use.
TIBOLONE: This synthetic steroid is a prodrug and undergoes tissue-selective conversion to estrogenic, progestogenic or mildly androgenic metabolites. Its precautions and contraindications are similar to those of the standard estrogenic preparations. In the dose of 2.5 mg (one tablet) daily, it is used in:
(a) The treatment of vasomotor symptoms and prophylaxis of osteoporosis in menopausal women. It is given continuously and concurrent administration of a progestin is not necessary. It is unsuitable for use in the first 12 months after the last menstrual period as it may cause irregular bleeding; and
(b) The treatment of vasomotor symptoms in premenopausal women who are being treated with a GnRH analongue.</li>
</ul>
<p>Its superiority over the standard estrogenic preparations is not established. It is expensive.</p>
<p>Phytoestrogens: These are nonsteroidal compounds such as isoflavones and lignans present in plants such as soy, flaxseeds, red clover and cohosh; they are converted in the intestines to compounds with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>10</mn><mo separator="true">,</mo><msup><mn>000</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 10,000^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">00</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> the estrogenic activity of estradiol. Some of them also have antiestrogenic activity. Phytoestrogens have been commercially promoted for use in postmenopausal women for prevention of osteoporosis, breast cancer and IHD. The evidence in their favour is largely epidemiological in that women from certain Asian countries whose daily diet contains substantial quantities of soy have a lower prevalence of the above ailments. Current evidence suggest that commercial expensive supplements are inadequate in controlling vasomotor or other post menopausal symptoms.</p>
<p>Selective Estrogen Receptor Modulators (SERMs): Unlike the predominantly estrogenic compounds (the classical steroidal and non-steroidal estrogens) and the purely antiestrogenic compound (clomiphene), SERMs exert pharmacological actions on binding to the two estrogen receptors ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">R</mi></mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{ER} \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">ER</span></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">R</mi></mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\mathrm{ER} \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">ER</span></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ), and are tissue-selective. They are partially estrogenic in some tissues with antiestrogenic activity or no activity in others e.g. tamoxifen (Chapter 61) has antiestrogenic action on the breast but estrogenic action on the bone and the endometrium. Raloxifene is more selective and has estrogenic action on the bone, antiestrogenic action on the breast and negligible action on the endometrium (see Chapter 70).</p>
<p>Like Raloxifene, another SERM Bazedoxifene has estrogenic effects on bone and antiestrogenic effect on the uterus. It is available as FDC with conjugated estrogens for the treatment of vasomotor symptoms and prevention of osteoporosis in postmenopausal women. Bazedoxifene inhibits the stimulating effect of conjugated estrogens on</p>
<p>endometrial and breast tissue but does not have the positive effects on vasomotor symptoms, vulvovaginal atrophy and bone mineral density. Thus SERM + estrogen combination is devoid of ADR such as breast pain, vaginal bleeding seen with estrogen and progestin combination</p>
<p>Toremifene is chemically related to tamoxifen and is used in the treatement of breast cancer.</p>
<p>Ospemifene: acts as estrogen agonist on vaginal epithelium, endometrium and bone. It has antiestrogenic action on breast. It is used in the dose of 60 mg OD administered with food for the treatment of moderate to severe dyspareunia in postmenopausal women with vulvovaginal atrophy due to lack of estrogen. In addition, progestin is coadministered in all postmenopausal females with intact uterus. The adverse effects include hot flushes, vaginal discharge, muscle spasms, hyperhidrosis, endometrial thickening, uterine polyps and DVT. The drug is contraindicated in thromboembolic disease. It is metabolized by CYP3A4 and CYP2C9.</p>
<p>Therapeutic uses of estrogens: The preparations commonly employed are ethinyl estradiol, and mestranol for pharmacological therapy and conjugated estrogen, estriol and estradiol for replacement therapy. Their therapeutically equipotent doses are shown in Table 67.3. Transdermal, nasal sprays and vaginal preparations are also available. Parenteral preparations are now rarely used.</p>
<p>Table 67.3
Therapeutically equivalent daily doses of estrogens</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>-Ethinyl estradiol (oral) 5-10 mcg
</span>- Conjugated estrogen (oral) 0.625 mg
- Micronised estradiol (oral) 1 mg
- Estradiol (oral) 2 mg
- Estradiol (transdermal) 50 mcg</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="-Ethinyl estradiol (oral) 5-10 mcg
- Conjugated estrogen (oral) 0.625 mg
- Micronised estradiol (oral) 1 mg
- Estradiol (oral) 2 mg
- Estradiol (transdermal) 50 mcg" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Low dose estrogen therapy (vaginal cream and oral estriol in the dose of upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) relieves menopausal hot flushes and genitourinary symptoms but does not offer protection either to the bones or to the heart; low dose therapy does not stimulate the endometrium either; it can be used without concurrent administration of a progestogen.</p>
<ul>
<li>Amenorrhoea: Amenorrhoea may be (a) primary due to failure of establishment of menstruation; or (b) secondary, which occurs after the menstruation is established.
(a)Primary amenorrhoea (Replacement therapy): Hypogonadism is diagnosed when a girl without any abnormality of the genital tract does not start menstruating by the age of 18 years. Although delayed menarche may often be constitutional, a girl who does not start menstruating by the age of 15 years needs to be investigated. Undernutrition and systemic disease are common causes of such delay and need to be treated. If the girl shows good development of secondary sex characters, she can be reassured that things will work out well, and she should be encouraged to wait. But, if breast development has not occurred, the possibility of hypogonadism should be considered. An attempt should be made to distinguish between ovarian causes (primary or hypergonadotropic hypogonadism) and pituitary-hypothalamic causes (secondary or hypogonadotropic hypogonadism). If hypogonadism is the final diagnosis, such patients will need hormone replacement therapy (HRT).</li>
</ul>
<p>The commonest cause of primary hypogonadism is gonadal dysgenesis (Turner syndrome) due to a sex chromosome abnormality. Most of such patients are short, in addition to being sexually infantile.</p>
<p>In patients who are not short, replacement treatment is started with ethinyl estradiol 10 mcg or conjugated estrogen 0.3 mg per day. This is continued till the first vaginal bleeding (usually spotting) occurs; breast start developing during that period. Then, the patient is prescribed either (a) a low dose combined oral contraceptive pill (see Chapter 68), for 21 days every month; or (b) conjugated estrogen 0.625 mg daily, without a break, plus a progestin (medroxyprogesterone 10 mg . per day) for 10 days out of every month. The advantages of adding a progestin are:
(i) Better breast development.
(ii) More complete shedding of the stimulated endometrium every month; and
(iii) Prevention of endometrial cancer which has been reported in patients who were treated with unopposed estrogen regimen for long periods of time. Such protection is not complete.</p>
<p>In patients with gonadal dysgenesis who are short, treatment should begin with ethinyl estradiol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{ng} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, uninterruptedly) at about the age of 12 years. Such doses have been found to cause stimulation of linear growth without promoting the development of secondary sexual characters. Therapy with larger, feminising doses ( 10 mcg and more) of ethinylestrediol should be initiated only after the linear growth comes to a halt.</p>
<p>Females with secondary hypogonadism are treated in an identical manner as those with primary hypogonadism; but they may require replacement therapy with other hormones thyroxine and hydrocortisone.
(b)Secondary amenorrhoea: The important causes are: pregnancy; menopause (normal or premature); systemic disease; chronic anovulation (ovarian cause or other endocrine causes); and pituitary-hypothalamic failure (functional or structural disorder). Severe stress such as occurs in competitive sports needs to be kept in mind as a cause of secondary amenorrhoea. If the patient is hypoestrogenic, she needs hormone replacement as described above. If she is hyperestrogenic, as in polycystic ovary syndrome, she only needs periodic withdrawal bleeding with a progestin. The cause, if found, needs to be treated in addition to the hormone treatment. If she desires to become pregnant, ovulation inducing drugs may have to be used.</p>
<ul>
<li>Menopause: With age, the ovarian function decreases and finally ceases, resulting in menopause. The menstrual irregularity observed just prior to the menopause is due to anovulatory cycles and can be treated by cyclic administration of progestins.
Menopause often presents with symptoms as:
(i) Vasomotor: Hot flushes, daytime disconfort, fatigue, muscle cramps, vertigo.
(ii) Genitournary: Vaginal and vulval irritation dyspareunia, incresed risk of UTI, urinary urgency or incontinence.
(iii) General: Insomnia, depression, myalgia and arthalgia and;
(iv) Long term complications: Osteoporosis, incresed liability to IHD, urogenital atrophy, senile vaginitis, kraurosis vulvae.</li>
</ul>
<p>Mild cases need only proper explanation of the natural physiological process, reassurance and perhaps a tranquilliser for short term. Hot flushes respond to oral estriol, which has no other estrogenic effects. Patients with symptoms due to urogenital atrophy</p>
<p>without systemic symptoms of estrogen deficiency do well with topical estrogen. Local application include:
(a) Vaginal estrogen cream - 0.1 mg estradiol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">/ \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span> or 0.625 mg conjugated estrogens/g
(b) Vaginal tablet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mn>0.01</mn><mi mathvariant="normal">/</mi><mn>0.025</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">-0.01 / 0.025 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord">0.01/0.025</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> estradiol
(c) Vaginal ring - 0.0075 / 0.05/0.1 mg estradiol / day.</p>
<p>Vaginal estrogens cause less systemic adverse effects than oral estrogens. Oral therapy includes conjugated estrogens, E'P tablets or ospemifene.</p>
<p>Estrogen is absorbed from the vaginal mucosa and may rarely produce systemic effects. Gynecomastia has been reported in the sexual partners of women using vaginal creams.</p>
<p>Patients with more troublesome symptoms need short term oral estrogen replacement treatment. The optimal dose and duration of therapy are not known. Subject with intact uterus who are on systemic estrogens shuuld be given progestin so as to reduce the risk of possible endometrial hyperplasia or adenocarcinoma. Those on low dose vaginal estrogen need no additional progestins. Antidepressants and vaginal lubricants are useful as adjective treatment.</p>
<p>Prevention and treatment of menopausal osteoporosis: (Chapter 70).
Long term Hormone Replacement Therapy (HRT) has been advocated to treat menopausal symptoms and to prevent the long term complications, starting in the perimenopausal period.</p>
<p>Estrogens are potent inhibitors of osteoclastic bone resorption. They are (a) more effective in the preventing the worsening of bone status than in the management of established osteoporosis; and (b) more effective in Type I osteoporosis (early postmenopausal years) than in Type II osteoporosis (late postmenopausal years). However, that they reduce fracture rate has not been established.</p>
<p>Long term studies clearly indicate that HRT increases the risk of endometrial and breast cancer, venous thromboembolism, gall bladder disease and possibly that of CHD and stroke. Thus, its disadvantages outweigh whatever small benefits it offers. Hence, its use is now restricted to women with severe menopausal symptoms and that too treated with smallest possible dose for limited period. HRT should not be used routinely to treat menopause, a natural phenomenon.</p>
<p>Before starting long term HRT (5 years or longer), the patient should be examined for any contraindication to such therapy (Table 67.4). She should be told what to expect as a result of the treatment including a possible risk of developing breast cancer. She is advised to report any untoward symptoms, especially vaginal bleeding. Regular, periodic monitoring, including breast examination, every 6-12 months while on HRT is mandatory.</p>
<p>Table 67.4
Contraindications to HRT in menopausal women</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Unexplained vaginal bleeding.
</span>- Endometrial or breast carcinoma.
- Family history of carcinoma of breast.
- Active endometriosis(unopposed estrogen).
- Chronic impairment of liver function.
- Familial hypertriglyceridemia; serum triglyceride above 250 mg/dl.
- Uncontrolled hypertension.
- Any evidence of cardiovascular pathology.
- Seizure disorder.
- Recent thrombophlebitis.
- Unreliable subject.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Unexplained vaginal bleeding.
- Endometrial or breast carcinoma.
- Family history of carcinoma of breast.
- Active endometriosis(unopposed estrogen).
- Chronic impairment of liver function.
- Familial hypertriglyceridemia; serum triglyceride above 250 mg/dl.
- Uncontrolled hypertension.
- Any evidence of cardiovascular pathology.
- Seizure disorder.
- Recent thrombophlebitis.
- Unreliable subject." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Table 67.5 lists the HRT regimens in menopausal women; combined preparations which may be used for the same purpose are: Estradiol valerate 2 mg plus levonorgestrel 75 mcg , and conjugated estrogen 0.625 mg plus levonorgestrel 75 mcg .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-67-5">Table 67.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-67-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hrt-regimens-for-menopausal-women">HRT regimens for menopausal women<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hrt-regimens-for-menopausal-women" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In women with intact uterus</p>
<ul>
<li>Conjugated estrogen 0.625 mg or an equivalent amount of another estrogen preparation daily for 25 days out of every month plus medroxyprogesterone acetate (MPA) 10 mg daily for the last 10 days of the estrogen cycle.</li>
<li>Estrogen (as above) daily, uninterruptedly plus MPA (as above) 10 days every month. The above two regimens are associated with a return of monthly menstrual bleeding, which is unacceptable to most women.</li>
<li>Ethinyl estradiol 20 mcg and norethisterone 350 mcg daily, both given without interruption. This regimen causes endometrial atrophy and may be associated with frequent breakthrough bleeding, especially during the first 6 months of the copy.
In women who have had hysterectomy</li>
<li>Estrogen as above, given continuously.</li>
</ul>
<p>Norethisterone 1 mg , levonorgestrel <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mo>−</mo><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150-250 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">150</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span>, or dehydrogesterone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> may be used in place of MPA.
The use of estrogens with the intention of offering cardioprotection is no longer recommended because of increase in morbidity and mortality in those with pre-existing cardiovascular disease.</p>
<p>Routinely used doses in HRT do not provide contraception and woman can remain potentially fertile for two years after her last period. Hence, when younger woman ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">&lt;50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> yrs) who needs HRT should use a low estrogen combined OC pill, which will relieve the menopausal symptoms as well as provide contraception.</p>
<ul>
<li>
<p>Vulvo-vaginitis in children: In this condition, the infection persists because of alkaline vaginal pH at this age and the columnar epithelium both of which are not hostile to the growth of pathogens. Following estrogen therapy, the vaginal epithelium cornifies with the deposition of glycogen. The glycogen is converted into lactic acid by the Doderlein bacilli, resulting in acidic pH , which prevents growth of bacteria. Ethinyl estradiol in the doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.02</mn><mo>−</mo><mn>0.05</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.02-0.05 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.02</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.05</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. daily for 6-7 days along with a proper antibiotic is usually recommended. The hormone can also be used topically.</p>
</li>
<li>
<p>Acute severe dysfunctional uterine bleeding: 20 mg of conjugated, equine estrogen given IV every 4 hours for 4-6 doses are occasionally used in this condition. Bleeding usually ceases in 4-24 hours. In patients with an atrophic endometrium, e.g., those on prolonged progestin medication for the treatment of dysfunctional bleeding, concurrent administration of an estrogen preparation may prevent intermittent bleeding from an atrophic endometrium. A progestin such as norethisterone can also be used to treat DUB (see later).</p>
</li>
<li>
<p>As contraceptives: Chapter 68.</p>
</li>
<li>
<p>Prostatic cancer: Chapter 61.</p>
</li>
<li>
<p>Hirsutism: Chapter 69.</p>
</li>
<li>
<p>Miscellaneous uses: Estrogens can be used for treatment of acne in women (Chapter 71). SERMs are used in osteoporosis (Chapter 70). Estrogens can suppress lactation and relieve the breast engorgenment. However, evacuation of the breasts by breast pump is preferred.
For antiestrogenic agents clomiphene, see Chapter 68 and for tamoxifen and fulvestrant, see Chapter 61.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="progesterone-and-other-progestins">Progesterone and Other Progestins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#progesterone-and-other-progestins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The first effective progestational substance was isolated by Corner and Allen (1930) from the corpus luteum. They also described the 'progestational proliferation' of the endometrium and showed that corpus luteum was necessary for the preparation of the uterus for successful nidation of the fertilised ovum. The hormone, however, could not be used therapeutically because of its short action, ineffectiveness by oral route and short supply. The introduction of orally effective, synthetic progestational drugs (progestins) has revolutionised pharmacotherapeutics in gynecologic endocrinology.</p>
<p>Progesterone is naturally secreted by the ovaries, CL and placenta. It is also synthesised by the adrenals and testes where it acts as a precursor of steroid hormones. (Fig. 67.2)</p>
<p>Physiological functions of progesterone: It</p>
<ul>
<li>Decreases the estrogen-driven, proliferation of the endometrium (antiestrogen action), and promotes the development of secretory endometrium.</li>
<li>Promotes the development of the alveolar (acinar) system of the breast;</li>
<li>Prepares the endometrium for the implantation of the fertilised ovum and to induces decidual reaction;</li>
<li>Causes changes in the vaginal epithelium and secretion, characteristic of progestational effect (See below).</li>
<li>Helps to maintain pregnancy.</li>
<li>Induces various metabolic changes including the midcycle rise in basal body temperature (BBT). This rise is correlated with ovulation and natriuresis.
Bioassay of progestational activity: Various procedures now available are based on the technic used originally by Corner and Allen. In this method, an isolated female rabbit in estrous is castrated following the coitus and then given the unknown extract in divided doses for five days. The endometrium is then examined histologically for the degree of secretory changes induced. None of the techniques, however, can give an unequivocal estimate of the progestational activity of the newer compounds as it may have estrogenic and/or androgenic properties as well. Immunoassay is now employed to assess progestational activity.</li>
</ul>
<p>Classification of progestins:
I Progesterone.
II Derivatives of progesterone:</p>
<ul>
<li>Esters of 17-alpha hydroxyprogesterone such as caproate or acetate.</li>
<li>C6-substituted 17-alpha hydroxyprogesterone derivatives e.g. Medroxyprogesterone acetate (MPA), Megestrol and Chlormadinone acetate.</li>
<li>Dydrogesterone or dehydrogesterone</li>
</ul>
<p>III Derivatives of testosterone, e.g. Ethisterone and Dimethisterone.
IV Derivatives of 19-nortestosterone (testosterone without the 19-methyl group Fig. 67.4), e.g., Norethisterone (Norethindrone), Norethisterone acetate, Norethynodrel, Ethynodiol diacetate, Norgestrel, Lynestrenol, Desogestrel, Norgestimate and Gestodene.</p>
<p><img src="assets/images/image-20251214-af4577a9.jpeg" alt="img-48.jpeg"></p>
<p>Progesterone
<img src="assets/images/image-20251214-5fae87d4.jpeg" alt="img-49.jpeg"></p>
<p>Testosterone
FIG. 67.4
<img src="assets/images/image-20251214-3163f50b.jpeg" alt="img-50.jpeg"></p>
<p>19-Nortestosterone</p>
<p>The progestational actions of the testosterone derivatives are, in general, similar to those of progesterone except that they are modified by the associated estrogenic and/or androgenic properties of these compounds. Hence, progestins can also be classified as: I Pure progestins e.g. Progesterone, Dehydrogesterone, Esters of 17-alpha hydroxyprogresterone, Chlormadinone, Megestrol and Medroxyprogesterone. II Progestins with less or negligible androgenic effects e.g., Norgestrel, Desogestrel, Gestodene, and Norgestimate.
III Progestins with androgenic effects e.g. Norethisterone.
IV Progestins with estrogenic effects e.g. Norethynodrel.
V Steroids of uncertain status e.g. Ethynodiol diacetate.
VI Spironolactone analogue: Drospirenone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Endometrium: Progesterone, administered to the estrogen primed hypogonadal patients duplicates the changes of luteal phase of the menstrual cycle. Its continuation prolongs the luteal phase and induces decidual changes, characteristic of early pregnancy. With testosterone derivatives and 19-nor compounds, however, the histological changes are not so classical, on account of their additional estrogenic and/or androgenic action.</li>
<li>Vaginal epithelium and secretion: Progesterone prevents cornification of the vaginal epithelium and brings about increased glycogen deposition. The epithelial cells show increased folding and elongation of nuclei (Fig. 67.5). Complete maturation of cells cannot take place and increased number of cells are desquamated. Thin, watery and profuse vaginal secretion, so characteristic of estrogenic action, becomes thick, viscid and scanty.
<img src="assets/images/image-20251214-7e28ab1c.jpeg" alt="img-51.jpeg"></li>
</ul>
<p>A
Estrogenic effect
FIG. 67.5</p>
<p><img src="assets/images/image-20251214-29be9870.jpeg" alt="img-52.jpeg"></p>
<p>B
Progestogenic effect</p>
<ul>
<li>Mammary gland: Exogenous progesterone can promote acinar growth in estrogen primed mammary glands.</li>
<li>Ovulation inhibition: Progesterone inhibits ovulation only in large doses. The synthetic 19-nor testosterone derivatives however, are potent gonadotropin and ovulation inhibitors; this could be partly due to their estrogenic activity.</li>
<li>Metabolic actions: Exogenous progesterone can raise the BBT similar to that observed during the midcycle. Synthetic progestins such as testosterone derivatives and dehydrogesterone are not thermogenic.
Progesterone causes increase in the basal and postglucose insulin secretion. It promotes glycogen deposition and ketogenesis. It stimulates lipoprotein lipase and causes fat deposition.</li>
</ul>
<p>Progesterone probably has some catabolic action and has been shown to promote nitrogen loss. It also promotes sodium and chloride loss by competing with aldosterone in the kidney. Synthetic progestins, however, have no such consistent effects. In the doses in which they are used in HRT, levonorgestrel and MPA can cause insulin resistance and impairment of glucose tolerance. Norethisterone seems to be relatively inert in this respect.</p>
<ul>
<li>Maintenance of pregnancy: Natural progesterone probably helps in the maintenance of pregnancy. In in vitro studies, progesterone exerts a blocking effect on uterine contractions.</li>
<li>Antineoplastic action: There is some evidence to indicate that progesterone can suppress estrogen induced fibromyomata in animals. When added to estrogen as a part the HRT, progestins help to prevent possible development of endometrial carcinoma. Progestins have been used to treat advanced cancer of the breast and the endometrium.</li>
<li>Other actions: Progesterone causes mental depression and hypnotic effects. Some of the synthetic progestins have associated estrogenic, androgenic and/or anabolic actions (Tables 67.6 and 68.3).</li>
</ul>
<p>Table 67.6
Progestins in current use</p>
<table><thead><tr><th style="text-align: center;">Preparation</th><th style="text-align: center;">Dosage"</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Progesterone</td><td style="text-align: center;">Functional uterine bleeding: 5 to 10 mg IM daily; habitual abortion: 1-2 mg daily; threatened abortion: 5-10 mg daily.</td><td style="text-align: center;">Mildly catabolic</td></tr><tr><td style="text-align: center;">Derivatives of progesterone:</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hydroxyprogesterone caproate</td><td style="text-align: center;">Threatened and habitual abortion: 125 to 500 mg weekly IM; functional uterine bleeding: same dose.</td><td style="text-align: center;">Mildly catabolic, long acting (8-14 days)</td></tr><tr><td style="text-align: center;">'Medroxy progesterone acetate</td><td style="text-align: center;">Functional uterine bleeding: 5 to 10 mg daily; threatened and habitual abortion: 10-40 mg daily orally or 50 to 100 mg IM weekly.</td><td style="text-align: center;">Mildly catabolic.</td></tr><tr><td style="text-align: center;">Dydrogesterone</td><td style="text-align: center;">Dysmenorrhoea: 10 to 25 mg daily; same dose also used in threatened abortion and in functional uterine bleeding; in endometriosis: 30 mg daily.</td><td style="text-align: center;">Does not inhibit ovulation. Mildly catabolic.</td></tr><tr><td style="text-align: center;">Allylestrenol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Megestrol</td><td style="text-align: center;">Used in oral contraceptive combination pills.</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Derivatives of testosterone:</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">'Dimethisterone</td><td style="text-align: center;">15 mg daily.</td><td style="text-align: center;">Mildly estrogenic</td></tr><tr><td style="text-align: center;">Derivatives of 19 nor- &lt;br&gt; testosterone:</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">'Norethisterone</td><td style="text-align: center;">Primary and secondary amenorrhoea: 5-15 mg daily; functional uterine bleeding: 10-30 mg daily; endometriosis: &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily;</td><td style="text-align: center;">Androgenic and anabolic actions.</td></tr><tr><td style="text-align: center;">'Norethisterone acetate</td><td style="text-align: center;">2.5 to 15 mg daily. Indications similar as norethisterone.</td><td style="text-align: center;">Mildly androgenic and anabolic.</td></tr><tr><td style="text-align: center;">'Norethynodrel</td><td style="text-align: center;">Primary and secondary amenorrhoea: 5 to 10 mg daily; endometriosis: 20 to 30 mg daily.</td><td style="text-align: center;">Estrogenic.</td></tr><tr><td style="text-align: center;">Ethynodiol diacetate</td><td style="text-align: center;">Used in combination OC pills:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Lynestrenol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily.</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Desogestrel</td><td style="text-align: center;">Used in combination OC pills</td><td style="text-align: center;">Prodrug (No androgenic or antiestrogenic action)</td></tr></tbody></table>
<p>*Also used as oral contraceptive.
"For various regimen details, see text. For Progestasert and Mirena IUCDs, see text.
Absorption, fate and excretion: Progesterone is not effective orally, owing to extensive bio-degradation during its first passage. Further, it has a relatively short biological halflife. It is rapidly absorbed when injected in oily solution. The rate of turnover of progesterone in the body is very rapid. Although other metabolites are also excreted in the urine, estimation of pregnanediol gives valuable information regarding progesterone secretion. The synthetic progestins, however, are effective orally as they are not easily degraded during their first pass and have long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> They are mainly metabolised in the liver.</p>
<p>Adverse reactions: Apart from their pharmacological actions which may modify the menstrual cycle (spotting, breakthrough bleeding) and decrease the flow, progestins, in general, are relatively safe drugs. Derivatives of testosterone and 19-nor testosterone can cause nausea, breast discomfort, headache, fatigue and rarely liver damage.</p>
<p>Some of the synthetic progestins such as norethisterone may cause androgenic actions on developing female foetus and hence, should be avoided during pregnancy. For the same reason, they may cause weight gain, acne and hirsutism.</p>
<p>Preparations and dosage: Table 67.6.
The newer progestins desogestrel, gestodene and norgestimate are derivatives of norgestrel. Desogestrel and norgestimate are prodrugs. As progestins:</p>
<p>(1) In therapeutic doses they are extremely potent inhibitors of ovulation without any androgenic or antiestrogenic effect.
(2) In large doses, they have a weaker androgenic and antiestrogenic action than the earlier progestins.
(3) They cause fewer metabolic changes.
(4) Because of their selectivity of action, they may be preferred in patients with hyperandrogenemia (Chapter 68).</p>
<p>Drospirenone is a spironolactone analogue with progestogenic, anti-mineralocorticoid and antiandrogenic activities. It is a constituent of a combined oral contraceptive pill, Yasmin (Chapter 68). It can cause hyperkalemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-progestins">Therapeutic uses of progestins:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-progestins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Dysfunctional uterine bleeding (DUB): Primary DUB is not a single entity but a group of diseases. It may be defined as abnormal bleeding from the uterus in the absence of organic disease of the genital tract and extragenital causes. The disorder is common especially at the beginning and the end of reproductive life.
In many cases, the bleeding is irregular and associated with anovulatory cycles. However, in some cases heavy but regular menstrual bleeding (menorrhagia) can be encountered in ovulating women. Blood loss of more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">y</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">e</mi></mrow></mrow><annotation encoding="application/x-tex">80 \mathrm{ml} / \mathrm{cycle}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">cycle</span></span></span></span></span></span> is defined as criteria for menorrahagia. The most common dysfunction is some disorder of the endocrine or vascular mechanism, involved in menstruation. Human endometrium synthesises PGs locally and the endometrial dysfunction could be related to the excessive formation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Significantly higher amounts of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mn>2</mn></msub><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2} \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> in menstural fluid have been reported in patients with menorrhagia, dysmenorrhoea and endometriosis. Diagnosis of DUB is usually made by exclusion with curettage or endometrial biopsy and hysteros-copy to rule out organic disease.</li>
</ul>
<p>The main clinical manifestation, other than menstrual abnormalities, is iron deficiency anemia and infertility in anovulatory women. A detailed history and physical examination help to establish the diagnosis and type (ovulatory or anovulatory) in most women. Counselling of the patient is very helpful, so is correction of anemia with oral iron. Severe cases may require hospitalisation.</p>
<p>Symptomatically, a woman with DUB may present with:
(i) Oligomonorrhoea - intervals greater than 35 days.
(ii) Polymenorrhoea - intervals less than 24 days.
(iii) Menorrhagia - regular, normal intervals with excessive flow and duration.
(iv) Metrorrhagia - Irregular intervals, excessive flow and duration.</p>
<p>The three major types of bleeding in DUB are:
(a) Estrogen withdrawal bleeding, associated with anovulatory cycle; the flow is heavy (menorrhagia) and usually painful.
(b) Estrogen break-through bleeding due to sustained estrogenic, stimulation of the endometrium, not interrupted by cyclic progesterone secretion. This is the most common type of DUB.
(c) Progestin break-through bleeding due to abnormal P/E ratio in the blood.</p>
<p>Table 67.7 summarises management of DUB.</p>
<p>Table 67.7
Management of DUB</p>
<table><thead><tr><th style="text-align: left;">- Specific drug treatment:</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">(a) Non-hormonal:</td><td style="text-align: left;">NSAID; Tranexamic acid; Ethamsylate Ormeloxifene;</td></tr><tr><td style="text-align: left;">(b) Hormonal:</td><td style="text-align: left;">Combined OC pill; Norgestrel-releasing IUCD; Progestin; Danazol</td></tr><tr><td style="text-align: left;">- Correction of anemia: Iron</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">- Non-drug treatment: Counselling</td><td style="text-align: left;"></td></tr></tbody></table>
<p>PG-synthetase inhibitors such as mefenamic acid and ibuprofen diminish menstrual bleeding in normal as well as DUB women. They are the first line treatment of DUB, particularly in those who ovulate but bleed heavily. These drugs are given for 3-4 days, starting with the onset of bleeding. Other non-hormonal agents used are: tranexamic acid and ethamsylate given for 3-4 days (Chapter 33). When contraception is desired, a combined OC pill or a levonorgestrel releasing IUD may be preferred. In most patients hormonal disorder cannot be demonstrated and hence, such therapy only helps to control the bleeding without correcting the cause. If the DUB is persistent or recurrent despite hormonal therapy, subjects should be investigated to rule out local causes such as submucous myomas or endometrial polyps or a possible coagulation disorder.</p>
<p>Norethisterone 5-10 mg. 4-6 hourly will stop the bleeding within 24 hours. It is usually continued in doses of 5 mg bid for 1-2 weeks. The patient should be warned that the first period which follows cessation of the progestin is likely to be heavy. If the uterine bleeding is severe, estradiol valerate 10 mg plus hydroxyprogesterone caproate 100 mg IM usually controls the bleeding. In order to prevent recurrence of excessive bleeding, cyclical progestin should be commenced on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">4-5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the withdrawal bleeding and continued till the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">25^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day, for 3 cycles. In patients with endometrial hyperplasia/anaplasia, it is advisable to continue daily progestin for 9-12 months.</p>
<p>Alternatively, a low dose combination OC pill (Chapter 68) is administered in the dose of 1 pill 4 times a day for 5 days. The full course should be given even if the bleeding stops earlier. This is followed by cyclic administration of the same pill once daily from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">25^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the cycle for 3-6 cycles. Patients in whom combination OCs are contraindicated may be prescribed danazol 200 mg daily on a continuous basis (Chapter 68). Ormeloxifene, the SERM, is also used in DUB because of its antiestrogenic action (Chapter 68). It is given for 6 months.</p>
<p>IUCDs incorporating progesterone (Progestasert) or levonorgestrel (Mirena) release the drug slowly. The serum levels achieved are low and suppress the ovarian function. In <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of the subjects, the cycles are ovulatory. The locally released progestin causes endometrial thinning and atrophy; the cyclical changes related to the menstrual cycle are abolished. Thirty-five percent of the women become amenorrhoeic at one year. These changes are, however, reversible and normal menstruation is restored 1-2 months after removal of the device. They can be used to produce endometrial ablation in severe menorrhagia where hysterectomy is contraindicated. They have also been used to control bleeding in uterine fibroids. They are considered highly effective ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ), relatively safe and usually well tolerated. However in practice, many women desire to have normal cycle control and may not opt for this chemical ablation.</p>
<ul>
<li>Dysmenorrhoea: Some women complain of either discomfort or pain (either dull or colicky) in the lower abdomen before or during menstruation (dysmenorrhoea). 'Dysmenorrhoea' is only a symptom and not a diagnosis. It is common in the teenagers but also occurs in the older women and is usually associated with ovulatory cycles. Before starting drug treatment, one should make certain that a local cause such as an IUCD is not responsible for the symptom.
The primary spasmodic dysmenorrhoea of the teenager generally disappears with increasing age. It is probably due to excess of PG production in the uterus. Most girls with this symptom are helped by physical exercise, explanation, reassurance, and NSAID, given either alone or together with an antimuscarinic drug. When the symptom is severe and incapacitating, it can be abolished by inhibiting ovulation with a 'combination pill' given daily from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">25^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the menstrual cycle for 4-6 cycles. While dispensing such pills to unmarried girls, care should be taken not to label the container as 'contraceptive pills'. In most cases the symptom does not recur after stopping the treatment. If inhibition of ovulation is considered undesirable for some reason, oral dehydrogesterone 5-10 mg twice a day may be used from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>8</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">8^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">25^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the cycle.</li>
</ul>
<p>Patients not responding to the above therapy and all older women with secondary dysmenorrhoea need careful gynaecological investigation to exclude local lesions such as endometriosis, fibroids and infection. Dysmenorrhoea may be a presenting symptom in pelvic tuberculosis.</p>
<p>Membranous dysmenorrhoea is rare and often familial. The menstrual endometrium is painfully shed in large strips or even as a complete cast. Although the oral combination pills can be used to treat these cases, the results are less rewarding; curettage is also unhelpful. Norethisterone 10 mg daily given for five, immediately premenstrual days may produce beneficial effects in some patients.</p>
<ul>
<li>Amenorrhoea: If a woman presents with amenorrhoea, progestogen withdrawal test is helpful in distinguishing between patients with normal and low circulating estradiol levels. In the former case, administration of medroxy-progesterone or norethisterone (5 mg twice a day) for 5 days is followed by withdrawal bleeding within 7-10 days. Such bleeding, in patients with primary amenorrhoea, also establishes the patency of the lower genital tract. If there is no withdrawal bleeding, the possibilities are either very low estrogen levels or an abnormality of the uterus or vagina. This test is useful but should be performed only after ruling out pregnancy in sexually active women of the reproductive age. The same regimen may be used once in 1-2 months in patients with severe oligomenorrhoea due to chronic anovulation from polycystic ovary syndrome (PCOS).</li>
<li>Endometriosis: It is a chronic, estrogen dependent disorder associated with pain and infertility. It is due to the presence of extrauterine, endometrial deposits. The aims of therapy are (1) relief of pain and (2) restoration of fertility. This is done by suppressing ovarian function and limiting growth and activity of the lesions. The drugs (Table 67.8) are used for a limited period ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">&lt;6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> months) because of unacceptable ADR.</li>
</ul>
<p>Table 67.8
Drugs used in endometriosis</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Oral Progestins
</span>    - Danazol (Chapter 68).
    - GrillHanalogues(see earlier).
    - Combined OC pills(Chapter 68)</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Oral Progestins
    - Danazol (Chapter 68).
    - GrillHanalogues(see earlier).
    - Combined OC pills(Chapter 68)" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Oral progestins, given continuously, are highly effective in this condition. They cause marked regression of the endometrium. Norethisterone 20 mg can be used daily increasing by 10 mg daily if vaginal spotting occurs. Amenorrhoea can be maintained by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily dose for 3 to 9 months depending upon the severity of the case.
Medroxyprogesterone 20 mg daily is also useful. Both these drugswill ultimately cause endometrial atrophy. For use of danazol in endometriosis, see Chapter 68. In addition, for symptomatic relief of pain, NSAIDs are prescribed, if necessary.</p>
<ul>
<li>Fibrocystic disease of the breast: This condition in young women is believed to be associated with excessive estrogen and/or prolactin action on the breast tissue. The clinical features range from mastodynia (painful breasts) through nodularity of the breasts to a large discrete lump that needs to be distinguished from breast cancer.
Danazol is the most effective drug for use but it is expensive and may cause side effects (Chapter 68). A cheaper, though less effective, alternative is one of the progestins given orally. Any of the following may be used in divided, daily doses from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>14</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">14^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>28</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">28^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the menstrual cycle: medroxyprogesterone, 20 mg ; norethisterone, 20 mg ; or norethisterone acetate, 10 mg . If the patient has elevated prolactin level, bromocriptine may be tried in the dose of 2.5 mg once to thrice a day. The treatment should generally last for 6 months or longer.
Gamolenic acid, an essential unsaturated fatty acid for cell membrane, has been claimed to be useful. It is believed to act by inhibiting cellular prolactin uptake.</li>
<li>As oral contraceptives: (Chapter 68).</li>
<li>Precocious puberty: Medroxyprogesterone is useful in treating children with central precocious puberty. It acts by inhibiting the pituitary gonadotropin release and has to be used regularly for several years Its use has been replaced by that of GnRH agonists (see earlier).</li>
<li>Postponement of menstruation: Progestins can be used to prolong the luteal phase of the menstrual cycle and thus to postpone the onset of menstruation. Norethisterone orally 5 mg daily is adequate if the subject comes early in the second half of the menstrual cycle. If, however, she seeks advice only a few days before the due date, higher doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid) are needed. Hydroxyprogesterone caproate ( 250 mg IM) along with small oral doses of norethisterone can also be effective.</li>
<li>Endometrial carcinoma: Chapter 61.</li>
<li>Post-menopausal syndrome: As a part of the HRT regimen (see earlier).</li>
<li>Male sex offenders: Large doses of medroxyprogesterone are used as an adjunct to psychosexual counselling.</li>
<li>Miscellaneous: Progesterone is used to treat short luteal phase. Oral dehydrogesterone 10 mg bid or micronised progesterone 100 mg bid (orally or vaginally) or progesterone IM 25-50 mg daily can be used to provide luteal support when needed. Usefulness of</li>
</ul>
<p>progestins in the treatment of threatened and habitual abortion is doubtful.</p>
<p>68</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antifertility-agents-and-ovulation-inducing-drugs">Antifertility Agents and Ovulation Inducing Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antifertility-agents-and-ovulation-inducing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>According to the Population Division of the United Nations Department of Economic and Social Affairs, total fertility is expected to fall globally, from 2.52 children per woman in 2005-2010 to 2.17 in 2045-2050 and to 2.03 in 2095-2100. Even with this decline, the world population is expected to reach 9.3 billion in 2050 and 10.1 billion in 2100 . Considering the world resources, such a growth in population can create major problems unless fertility is controlled.</p>
<p>Fertility control is very essential for maintaining satisfactory standards of living and for raising the existing standards in developing countries. Furthermore, it is equally important for family planning which is defined as "the limitation and spacing of births in the best interests of the mother, the child and the rest of the family". The problem is essentially interdisciplinary and can only be tackled by the concerted efforts by biologists, sociologists and educationists; the use of drugs for this purpose is but one aspect of the whole programme.</p>
<p>Physiology of human reproduction: The reproductive cycle in the human, in whom ovulation is a key event, is the result of the interplay of the hypothalamus, the pituitary and the ovaries. With respect to ovulation, the mammalian females can be divided into two groups:
I Reflex ovulators e.g. rabbits, cats, ferrets and minks, in whom the sensory stimulus of mating or electrical stimulation of cervix induces ovulation; and
II Spontaneous ovulators like cows, monkeys and women, in whom ovulation occurs in the absence of any immediate sensory stimulus.</p>
<p>At the time of puberty, the human ovaries contain about 3,00,000 immature follicles of which only about 400 mature during the reproductive life of about 30 years. Of these, only a few get fertilised and lead to successful pregnancies.</p>
<p>Under the influence of pituitary FSH, the ovarian follicle matures and considerable amounts of estrogen are produced. The sudden midcycle spurt of luteinising hormone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{LH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">LH</span></span><span class="mclose">)</span></span></span></span></span> is followed by ovulation, releasing the ovum. Ovulation usually occurs on day 14 ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\pm 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">±</span><span class="mord">2</span></span></span></span></span> ) of a 28 day cycle (Fig. 67.1). The oocyte enters the fallopian tube and within 12 hours it reaches the ampullary region where it can be fertilised by the sperm. By <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>18</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">18^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the cycle, the fertilised ovum is converted into a blastocyst which reaches the cavity of the uterus. By <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>21</mn><mtext>st&nbsp;</mtext></msup><mo>−</mo><msup><mn>23</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">21^{\text {st }}-23^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8769em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of the cycle, the blastocyst begins to get implanted (nidation) beneath the surface of the uterine endometrium. The implantation stage is completed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>35</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">35^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">3</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day from the first day of the last menstrual period; at this time the fetal placental circulation starts developing. This means that pregnancy may be considered as existing only 5 weeks after the onset of last menstrual cycle.</p>
<p>Ovulation can be judged by noting:</p>
<ul>
<li>Changes in the cervical mucus,</li>
<li>Vaginal cytology (Fig. 67.5):</li>
<li>Serum progesterone level</li>
<li>Endometrial biopsy; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rise-in-basal-body-temperature">- Rise in basal body temperature.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rise-in-basal-body-temperature" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All these changes reflect the production of progesterone by the corpus luteum.
The cervical mucus is an alkaline gel, rich in protein and fructose. During the follicular phase it is clear, thin, copious, acellular and elastic. This property permits the mucus to be stretched into threads from 5 to 15 cm in length. The mucus assumes a characteristic fernlike pattern when dried on a glass slide. Clinically, ferning and 'thread test' (spinnbarkeit) are utilised to judge the estrogen influence. Just before the ovulation, its consistency is considered to be the most ideal for the transport of sperms into the uterus. Soon after the ovulation, under the influence of progesterone, the cervical mucus becomes tough, viscous and translucent and the sperms may find it difficult to penetrate it. The ferning disappears and it cannot be stretched without breaking. Some women experience unilateral low abdominal pain near midcycle which is attributed to the occurrence of ovulation.</p>
<p>Although all these parameters are useful clinically, none of them can be considered as a definite evidence of ovulation. The only definite evidence of ovulation is either recovery of the ovum or pregnancy.</p>
<p>Extra-hypothalamic regions of the CNS, acting via the hypothalamus, exert a modulating influence on ovulation. The menstrual rhythm and probably ovulation in the human female are influenced by emotional and environmental factors. Thus, irregular menstrual periods are known in nurses on night duty and in air hostesses travelling great distances.</p>
<p>The exact duration of survival of sperms in the vagina is not known but is believed to be about 1-2 hours while they can remain active in the cervix and uterine cavity for about 4550 hours.</p>
<p>Fertility Control: Apart from the coitus interruptus, theoretically, the fertility control can be achieved by:</p>
<ul>
<li>Preventing the union of sperm with ovum by using physical or chemical barriers.</li>
<li>Controlling the central mechanisms; and</li>
<li>Modifying other physiological mechanisms of reproduction;</li>
</ul>
<p>Since the hypothalamus is known to play an important role in controlling the secretion of pituitary gonadotropins, emotional factors and certain drugs acting on the hypothalamus can block or induce ovulation by modifying the secretion of GnRH. Thus, lactation amenorrhoea due to suckling reflex and amenorrhoea in young women due to stress are well known. Tranquilisers like chlorpromazine and reserpine can modify the menstrual cycle in women; and suppresses menses (Chapter 13). The conception is delayed in women who breast-feed their babies exclusively probably because of elevated levels of PRL. Breast-feeding thus acts as a natural birth spacer. It is believed that more births are prevented by breast feeding than by all other forms of contraception put together!</p>
<p>Birth control by using physical and/or chemical barriers to prevent the union of sperm with ovum is not new. In the Ebers Papyrus of 1550 B.C., the preparation of a tampon treated with a spermicide has been described; and Arabs were using some intrauterine foreign body to prevent the conception in saddled camels for ages. Currently, various physical barriers like condoms, pessaries or intrauterine contraceptive devices (IUCD) and chemical barriers in the form of spermicidal gels and foam tablets are used. Such spermicides are simple to use and involve little genital manipulation. Most of the spermicides contain the surfactant nonoxynol 9, which interferes with sperm motility. Some of these methods, however, are not very reliable and often inconvenient to practise.</p>
<p>Use of condoms and IUCD have definite points in their favour: (i) They are cheap, safe and readily available, (ii) They require no planned programme as is necessary in the case of oral contraceptives; and (iii) Condoms offer protection against STD/HIV.</p>
<p>Fertility can be controlled by using drugs which can act by:</p>
<ul>
<li>Inhibiting ovulation.</li>
<li>Modifying the cervical mucus.</li>
<li>Interfering with the implantation.</li>
<li>Slowing down the rate of egg transport.</li>
<li>Preventing the ovum maturation and sperm capacitation.</li>
<li>Immunological methods (vaccine); and</li>
<li>Inhibiting spermatogenesis in males. The drugs which are currently in use act mainly by the first three mechanisms and are discussed below.
Oral contraception is a highly effective and acceptable method. In this method, either an estrogen-progestin combination or a progestin alone is used.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="estrogen-progestin-combination-pill">Estrogen-Progestin Combination Pill<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#estrogen-progestin-combination-pill" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Since the first clinical demonstration of usefulness of such an oral combination for contraception by Pincus (1955), several commercial preparations have been available. The following attributes have made these combination pills popular among the educated, higher and middle class women:</p>
<ul>
<li>Remarkable efficacy</li>
<li>Relative safety</li>
<li>Ease of administration and</li>
<li>Cost-effectiveness</li>
</ul>
<p>Combination oral contraceptive (COC) pills (now tablets) contain:
(a) Ethinylestradiol (EE) or its 3-methyl ether (mestranol) as the estrogen; and
(b) A progestin belonging to 19-nortestosterone group (norethisterone, norgestrel or ethynodiol acetate), one derived from progesterone (megestrol acetate) or a derivative of norgestrel (desogestrel).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="methods-of-administration">Methods of administration:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methods-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fixed dose combination pills (Monophasic pills): Commonly one pill containing both an estrogen and progestin is administered daily, at bed time, for 21 days, from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">5^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>25</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">25^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of a 28 day cycle. The next course is started 7 days after the last dose. If the patient forgets to take a 'pill', and she remembers it within 12 hours, she should take the forgotten pill immediately, and then return to the usual schedule. If more than 36 hours have passed between that last (regular) 'pill' taken and the delayed consumption of the missed 'pill', the course should be continued but along with the use of barrier method or abstinence for 7-10 days to prevent conception. If more than one pill is forgotten, the woman should consider herself similarly unprotected and take other measures to prevent conception.</li>
<li>Biphasic and triphasic combination pills: These are combination pills containing varying proportions of an estrogen and a progestin and are designed to simulate the hormonal profile of the normal menstrual cycle. This allows lower doses of both synthetic steroids in the early part of the cycle. Slightly higher doses later in the cycle help to prevent breakthrough bleeding. They are, however, more complex to use, offer little, if any, advantage over the monophasic pills, and are more expensive.</li>
<li>Extended cycle COC: (a) A COC pill containing 30 mcg of ethinyl estradiol and 150 mcg of levonorgestrel (Seasonale) is taken daily for 84 days, followed by a placebo pill for 7 days. This allows withdrawal bleeding once in 3 months i.e. four times a year compared to 13 times during the use of conventional, monthly, COC pills. Spotting may occur more frequently with this method. The major advantage is that it reduces the number of menses and hence appears to be acceptable to many women.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="extended-cycle-coc">Extended cycle COC:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extended-cycle-coc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(b) COC containing 30 mcg ethinyl estradiol +150 mcg levonorgestrel administered daily for 84 days followed by 10 mcg ethinyl estradiol tablet for 7 days.
(c) Low dose COC containing 20 mcg ethinyl estradiol +100 mcg levonorgestrel administered daily for 84 days followed by 10 mcg ethinyl estradiol tablet for 7 days.
(d) COC (with increasing ethinyl estrogen content)containing 20 mcg ethinyl estradiol + 150 mcg levonorgestrel administered daily for 42 days followed by 25 mcg ethinyl estradiol</p>
<p>+150 mcg levonorgestrel administered daily for 21 days followed by 30 mcg ethinyl estradiol +150 mcg levonorgestrel administered daily for 21 days and lastly 10 mcg ethinyl estradiol tablet for 7 days.
(e) Another pill available contains EE 20 mcg and levonorgestrel 90 mcg . It is taken daily, uninterruptedly, for 365 days a year. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of the women develop amenorrhoea within an year. Breakthrough bleeding and spotting are common initially, but decrease subsequently. After stopping the drug, menses resume within 2-3 months in over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of women. The potential long term ADR are not known.</p>
<p>Mechanism of action: The mechanism of the contraceptive action of these agents is complex. The combination type suppresses both FSH rise (due to the estrogen component) and LH peak (due to the progestin component) observed during the normal menstrual cycle, by inhibiting the release of GnRH. Thus, follicular growth is not initiated and ovulation does not occur. Although estrogen alone can be effective it is not suitable as it may cause profuse, irregular bleeding. The progestin in the pills:</p>
<ul>
<li>Increases the certainty of the contraceptive effect. In fact, it plays the major role in ovulation inhibition.</li>
<li>Modifies the cervical mucus, making it thick, tenacious and hostile to the sperms.</li>
<li>Prevents breakthrough bleeding.</li>
<li>Ensures predictable withdrawal bleeding after each cycle of treatment; and</li>
<li>Reduces the menstrual blood loss.</li>
</ul>
<p>Pharmacological actions of COC pills:</p>
<ul>
<li>Endometrium: The effect produced by the COC pills is similar to that of 'luteal phase'. The full secretory activity of the endometrial glands is achieved within 3-4 days of starting these pills, leading to predecidual changes. Later, the endometrium becomes thin and hypoplastic over a period. The changes are reversed 2-3 months after stoppage of treatment.</li>
<li>Cervical mucus: Continuous administration of a progestin increases the thick cervical mucus, causing a 'cervical barrier' hostile to sperm penetration.</li>
<li>Pituitary-ovarian axis: Prolonged administration of these drugs does not seem to cause any permanent structural changes in the pituitary or ovary, although during therapy ovaries may appear smaller and their secretion may practically cease. The conception may be delayed but the pill does not cause permanent infertility.</li>
<li>Metabolic effects are:
(1) Hyperglycemia, glycosuria and mildly impaired glucose tolerance along with a rise in the post-absorptive serum immunoreactive insulin levels have been reported. However, an increased incidence of clinical diabetes mellitus has not been established. The mechanism of these actions is not clearly defined but is believed to be an increased resistance to the peripheral hypoglycemic action of insulin. The incidence of abnormal GTT is related to the dose and potency of progestin. The newer progestins such as desogestrel have little, if any, effect on carbohydrate metabolism.
(2) Increase in cholesterol and low-density lipoprotein (LDL) and lowering of high density lipoprotein (HDL) has been observed following the progestins. Because the estrogen component has an effect opposite to that of the progestin, no significant alterations in the cholesterol level has been observed. The data indicate that the use of COC containing 50 mcg of estrogen by healthy, non-smoking women up to the</li>
</ul>
<p>age of 35 is not associated with an increased risk of serious cardiovascular disease. The pill also causes a slight increase in plasma triglycerides in some women.
(3) Acceleration of platelet aggregation and adhesion and reduction of the activity of the fibrinolytic system. The estrogen component is thought to be responsible for these changes.</p>
<ul>
<li>Other endocrine glands: As in pregnancy, the plasma total thyroxine (T4) is raised and so also thyroxine binding globulin. Thus, the concentration of free hormone is not altered. There is also an increase in the cortisol binding globulin, transcortin. A slight but definite rise in the free plasma cortisol level and a reduction in the rate of hepatic cortisol metabolism have been reported.
Adverse reactions: The earlier preparations (in 1970s) contained higher doses of both estrogen and progestin; some of the adverse effects described with those pills may not be relevant to the lower dose pills that are currently in use.</li>
<li>General: Nausea, anorexia and vomiting are common and are due to the estrogen component. The pill should be taken at bedtime on a full stomach, to minimise them. The estrogen may also be responsible for other effects like breast engorgement, mastalgia, chloasma and increased vaginal secretion (leucorrhoea). Excessive estrogen also suppresses lactation.
In certain individuals, the anabolic action of these compounds causes weight gain. In others, the weight gain is due to sodium retention and edema, mostly due to estrogens. Although the compounds from the 19-nortestosterone group have androgenic actions, the latter are rarely evident with therapeutic doses. However, there is a rare chance of masculinisation of a female fetus, if preparations containing 19-norsteroids are used.</li>
</ul>
<p>Blurring of vision and mental depression have also been rarely reported. The risk of depression is greater in women with past history of depression. It appears to be related to estrogen-induced alteration in vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> metabolism and may respond to pyridoxine (vit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) in the dose of 20 mg twice a day.</p>
<p>Oral contraceptive use increases significantly, though to a small extent, the risk of vaginal infection, particularly candidiasis.</p>
<p>The 'pill' decreases serum levels of pyridoxine, folic acid, vitamin C, calcium and zinc whereas those of vitamin A, copper and iron are elevated.</p>
<ul>
<li>Bleeding irregularities: Cycle control is usually excellent. A large proportion of women experience regular cycles and relief from dysmenorrhoea, premenstrual tension and excessive menstrual blood loss. This is beneficial. Occasionally, however, bleeding similar to that of a normal menstrual period occurs during the course of medication (breakthrough bleeding). In such cases, the tablets are stopped and a new course started five days later with a preparation containing larger quantity of progestin. Spotting is characterised by intermittent blood-stained trickling during the therapy. Its incidence appears to be higher with low estrogen or no estrogen pills. Occasionally, temporary amenorrhea for 1-2 cycles may occur and is of no significance.</li>
</ul>
<p>The return of the menstruation following stoppage of the 'pill' may be delayed for 6-8 weeks. Informing the patient about this in advance can spare her many anxious days. Conception may be delayed for 3-12 months after stopping the 'pills'. There is no increased risk of permanent infertility, miscarriage or birth defects.</p>
<ul>
<li>Thromboembolic phenomena: There appears to be a definite relationship between the use of COC pill and the incidence of deep vein thrombosis, cerebral thrombosis and pulmonary embolism. This is related to the concentration of the estrogen component.</li>
</ul>
<p>The risk is more in women over 35 years of age, especially in those who smoke. A dose of 50 mcg of ethinyl estradiol seems to be the safe upper limit beyond which the risk increases. The currently used low ethinyl estradiol ( 30 mcg ) pills have considerably reduced this risk. A similar risk is also present in normal pregnancy. In women on the pill, a complaint like persistent headache may be a warning of an impending cerebrovascular accident. If COC pill is to be started during postpartum period, it should be after 42 days of delivery.
COC are contraindicated in subjects with history of thrombophlebitis, thromboembolic disorders or cerebral ischaemia.</p>
<ul>
<li>Hypertension: The reported incidence of hypertension has been as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>. It is reversible within about three months of its discontinuation. It is probably due to the estrogen-induced increase in plasma angiotensinogen. Before treating the hypertension in a female patient, the 'COC pill' as a cause should be ruled out.</li>
<li>Liver: The hepatic abnormalities induced are usually reversible and are basically alterations in the bile-secreting function of the hepatocytes (cholestatic). Usually, the 'pill' produces no clinical problem, but a substantial number of women may have abnormal liver function tests; only a few develop cholestatic jaundice. A previous history of jaundice is not a contraindication to oral contraceptives. But, if a woman on the 'pill' develops acute hepatitis the drug should be stopped and should be resumed only after the liver function tests have been normal for at least six months. Rarely, benign vascular hepatomas may occur.</li>
<li>Uterine fibroids: Uterine fibromyomata can undergo enlargement during therapy with pills, and hence the presence of fibroids is a relative contraindication.</li>
<li>Carcinogenicity: Although estrogens are carcinogenic, the evidence regarding breast cancer following COC pill use is controversial. However, they are absolutely contraindicated in the presence of estrogen dependent malignancies such as breast cancer, in Hodgkin's disease and in malignant melanoma. Further, it is a wise precaution to examine the breasts and the cervical smear for malignancy before starting the treatment and then periodically during the therapy.
Table 68.1 lists the absolute contraindications to the use of combined COCs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-68-1">Table 68.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-68-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="absolute-contraindications-to-combination-oc">Absolute contraindications to combination OC<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absolute-contraindications-to-combination-oc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pregnancy</li>
<li>Estrogen dependent cancers (breast, endometrium)</li>
<li>Cardiovascular (CHF, ischemic heart disease, severe uncontrolled systemic hypertension, cardiomyopathy, most types of valvular heart diseases, pulmonary hypertension, vascular malformation of brain, arterial thrombosis, venous thrombosis or known proneness to it)</li>
<li>Severe or focal migraine</li>
<li>Diabetes for 20 years or diabetes with end organ disease</li>
<li>Hyperlipidemias and</li>
<li>Active liver disease</li>
</ul>
<p>COC has protective effect against endometrial cancer and epithelial ovarian cancer. Women who use COC for at least a year show a significant protection which persists for at least 15 years after the use of COC ceases.</p>
<p>Currently used OC pills carry very small risk to undiagnosed pregnancy/fetus.
Drug interactions: See Table 68.2.</p>
<p>Table 68.2
Drug interactions of combination OC pills</p>
<ul>
<li>Decreased efficacy of the other drug: Coumarin anticoagulants; Thyroid hormone; Oral hypoglycemics.</li>
<li>Increased efficacy/toxicity of the other drug: Theophylline; Imipramine; Cyclosporine; Glucocorticoids (pharmacological doses).</li>
<li>Decreased efficacy of OC pills: Barbiturates; Antiepileptic drugs; Rifampicin; Griseofulvin; Ampicillin and Tetracyclines.</li>
<li>Increased efficacy of OC pills: Ascorbic acid I g daily.</li>
<li>Hypercoagulable state: Aminocaproic acid.</li>
</ul>
<p>Preparations: Tables 68.3, and 68.4. Though commonly termed as pills, the available preparations are tablets and not the pills.</p>
<p>Table 68.3
Comparative biologic properties of synthetic progestins in experimental studies</p>
<table><thead><tr><th style="text-align: left;">Properties</th><th style="text-align: center;">Norethisterone</th><th style="text-align: center;">Norethisterone acetate</th><th style="text-align: center;">Norgestrel</th><th style="text-align: center;">Lynestrenol</th><th style="text-align: center;">Norethynodrel</th><th style="text-align: center;">Ethynodiol diacetate</th><th style="text-align: center;">Deso' gestrel</th></tr></thead><tbody><tr><td style="text-align: left;">Progestogenic</td><td style="text-align: center;">++</td><td style="text-align: center;">++</td><td style="text-align: center;">++++</td><td style="text-align: center;">++</td><td style="text-align: center;">++</td><td style="text-align: center;">+++</td><td style="text-align: center;">++++</td></tr><tr><td style="text-align: left;">Estrogenic</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">+</td><td style="text-align: center;">++</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Antiestrogenic</td><td style="text-align: center;">+</td><td style="text-align: center;">+</td><td style="text-align: center;">++</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Androgenic</td><td style="text-align: center;">+</td><td style="text-align: center;">++</td><td style="text-align: center;">++</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: left;">Anabolic</td><td style="text-align: center;">+</td><td style="text-align: center;">+</td><td style="text-align: center;">+</td><td style="text-align: center;">+</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td></tr></tbody></table>
<p>'Prototype of third generation progestins (the others being gestodene and norgestimate) which are derivatives of norgestrel.</p>
<p>Table 68.4
Some commercial combination oral contraceptives</p>
<table><thead><tr><th style="text-align: center;">Name</th><th style="text-align: center;">Progestin</th><th style="text-align: center;">(mg)</th></tr></thead><tbody><tr><td style="text-align: center;">(A) With EE 0.02 mg</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Loestrin 1/20</td><td style="text-align: center;">Norethisterone acetate</td><td style="text-align: center;">1.0</td></tr><tr><td style="text-align: center;">Ferulion</td><td style="text-align: center;">Desogestrel</td><td style="text-align: center;">0.15</td></tr><tr><td style="text-align: center;">(B) With EE 0.03 mg</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Eugynon 30</td><td style="text-align: center;">Levonorgestrel</td><td style="text-align: center;">0.25</td></tr><tr><td style="text-align: center;">Microgynon, Ovral L Triquilar' (Varying E E and levonorgestrel)</td><td style="text-align: center;">-Do-</td><td style="text-align: center;">0.15</td></tr><tr><td style="text-align: center;">Primovlar 30, Mala D,</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Choice</td><td style="text-align: center;">Norgestrel</td><td style="text-align: center;">0.30</td></tr><tr><td style="text-align: center;">Novelon</td><td style="text-align: center;">Desogestrel</td><td style="text-align: center;">0.15</td></tr><tr><td style="text-align: center;">Yasmin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Drospirenone</td><td style="text-align: center;">3.0</td></tr><tr><td style="text-align: center;">(C) With EE 0.05 mg (high dose) and less progestogenic</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Eugynon 50, Duoluton,</td><td style="text-align: center;">Norgestrel</td><td style="text-align: center;">0.5</td></tr><tr><td style="text-align: center;">Ovral G &gt;</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ovral, Primovlar 50</td><td style="text-align: center;">Levonorgestrel</td><td style="text-align: center;">0.25</td></tr><tr><td style="text-align: center;">Minovlar ED,</td><td style="text-align: center;">Norethisterone</td><td style="text-align: center;">1.0</td></tr><tr><td style="text-align: center;">Orlest</td><td style="text-align: center;">acetate</td><td style="text-align: center;">1.0</td></tr><tr><td style="text-align: center;">Orthonovin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>50</mn><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">1 / 50^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="mord">1/5</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Norethisterone</td><td style="text-align: center;">1.0</td></tr><tr><td style="text-align: center;">(D) With EE 0.05 mg (high dose) and more progestogenic</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Orgalutin</td><td style="text-align: center;">Lynestrenol</td><td style="text-align: center;">2.5</td></tr><tr><td style="text-align: center;">Norlestrin 2.5/50</td><td style="text-align: center;">Norethisterone acetate</td><td style="text-align: center;">2.5</td></tr><tr><td style="text-align: center;">Gynovlar 21</td><td style="text-align: center;">-Do-</td><td style="text-align: center;">3.0</td></tr><tr><td style="text-align: center;">Anovlar 21</td><td style="text-align: center;">-Do-</td><td style="text-align: center;">4.0</td></tr></tbody></table>
<p>Most progestins are derivatives of 19-nortestosterone.
Triphasic pill.
"Can cause hyperkalemia (Chapter 67).
"Contains mestranol 0.05 mg and not EE.
Newer combination OC preparations have been marketed with shorter hormone-free intervals than the conventional preparations. The rationale is to reduce the hormone withdrawal symptoms, particularly the withdrawal bleeding, and to decrease the risk of ovulation and unwanted pregnancy. An example is Seasonique with 84 tablets containing levonorgestrel 0.15 mg and EE 30 mcg each, and 10 tablets containing EE 10 mcg each. Other examples are: Loestrin 24 Fe and Yaz, containing 24 active tablets and 4 inert tablets; the active tablets of both contain EE 20 mcg each. The former contains norethindrone as the progestin whereas the latter contains drospirenone. They appear to have largely served their avowed purposes. But their contraceptive efficacy and comparative liability to cause thromboembolic complications is not yet known. With the 20 mcg EE-containing preparations, breakthrough bleeding and breakthrough ovulation may be a problem. In women chronically taking a preparation containing the mineralocorticoid drospirenone, concurrent use of drugs that increase the serum potassium (ACEI, ARB and NSAID) increases the risk of hyperkalemia.</p>
<p>Therapeutic uses:</p>
<ul>
<li>As oral contraceptives: From the therapeutic point of view, the COC can be grouped into those which are strongly progestogenic and those which are weakly progestogenic in action. Compared on weight basis, the activities of various synthetic progestins differ markedly. Thus, in their progestogenic activity, norethisterone acetate, ethynodiol diacetate and norgestrel are almost twice, 15 times and 30 times as active as norethisterone, respectively. However, in practice, the net pharmacological effect produced by a 'combination pill' probably depends upon the relative progestogenic, estrogenic and androgenic properties of its individual constituents (Table 68.3). Since the same combinations are also useful in controlling certain menstrual disorders in a woman with an associated menstrual irregularity, a proper combination can be selected. Thus, in women with normal menstrual cycles, a combination containing 0.03 mg or less of ethinyl estradiol with the minimum effective dose of a progestin (Group A/B) is to be preferred. In patients receiving hepatic microsomal enzyme inducing drugs, pills with 50 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span> ethinyl estradiol are recommended. A patient with excessive acne, hirsutism, abdominal and leg cramps, and scanty vaginal secretions may benefit from a less progestogenic combination (Group C). Premenstrual tension, edema, cyclic weight gain, irregular bleeding and heavy periods suggest an estrogen excess which can be countered by the strongly progestogenic pill (Group D) (Table 68.4)
In general these pills appear to be safe, highly effective and acceptable. Usually, they do not affect the libido; in fact, the removal of the fear of pregnancy may greatly improve the sexual as well as the marital relationship. Subsequent fertility is not affected. They can be used by women of all ages from menarche to menopause. The non-contraceptive health benefits associated with COC pill are listed in Table 68.5.</li>
</ul>
<p>Table 68.5
Non-contraceptive benefits of combination OC pills</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Menstrual benefitssuch as less menstrual blood loss, less iron-deficiency, lower incidence of menorthagia, dysmenorrhoea and pre-menstrual syndrome.
</span>- Lowered incidence of benign breast disease, endometrial cancer, ovarian cyst, ovarian cancer and osteopenia.
- Protection against pelvic inflammatory disease; and
- Abolition of the risk of tubal (ectopic) pregnancy because of anovulation.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Menstrual benefitssuch as less menstrual blood loss, less iron-deficiency, lower incidence of menorthagia, dysmenorrhoea and pre-menstrual syndrome.
- Lowered incidence of benign breast disease, endometrial cancer, ovarian cyst, ovarian cancer and osteopenia.
- Protection against pelvic inflammatory disease; and
- Abolition of the risk of tubal (ectopic) pregnancy because of anovulation." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>However, the cost and the necessity of following a strict regimen make the acceptance of these drugs as the sole method of contraception difficult. Further, these hormones lack specificity in that they also affect other tissues and alter various metabolic processes.</p>
<p>Before starting the pill, it is essential to go through the personal history and to carry out a detailed examination to exclude any medical contraindication especially cardiovascular risk factors. Women over 35 years of age who smoke should be encouraged to seek alternative methods of contraception. However, COC pills containing 20 mcg of EE (Loestrin 1/20 and Femilon) (Group A) and those containing 15 mcg of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">E</mi></mrow><mo>+</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EE}+60 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">EE</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> of gestodene are now becoming popular as contraceptives in the older women who are nonsmokers. When the last pill mentioned above is used with only 4 day pillfree interval, it seems that ovulation is prevented as effectively as with the conventional OC pills.</p>
<p>After the start of oral contraceptive, the woman should be initially seen during the second or third cycle of medication in order to check that all is well and that she really understands how to take the drug. Thereafter, she may be called after 6 months and still</p>
<p>later annually. The observations should include:
(a) Blood pressure and weight
(b) Liver function and glycosuria
(c) Cervical and breast abnormalities
(d) Evidence for thrombophlebitis
(e) Changes in the retinal blood vessels
(f) Psychological changes.</p>
<p>It is advisable to stop the pill for 1 month before any elective surgery, since it increases the vascularity and causes edema of the tissues and elevates the plasma concentration of some clotting factors. As a result, deep vein thrombosis is more common in post-operative period.</p>
<p>The pill should be avoided in breast feeding women as it interferes with lactation. If the woman is exclusively breast feeding the baby at regular intervals, including night time (full breast feeding), the pill may be started in the third post partum month. If the breastfeeding is partial or not done at all, it can be started in the third post partum week; it is not necessary to start it earlier as ovulation is unlikely to occur for 4 weeks after delivery. However, the 'pill' may be started on the very day of an abortion or a medical termination of pregnancy.</p>
<p>When used properly the 'pill' is the most effective (99-100%) contraceptive available.
Since the pill is capable of causing various systemic effects, a history of taking the pills should form a part of the routine medical history in women of the child-bearing age and this information should be made available to any other doctor to whom the case may be referred.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-uses-of-combination-oc-pills">Other uses of combination OC pills:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-uses-of-combination-oc-pills" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Postcoital contraception (see below).</li>
<li>Polycystic ovary syndrome (see later).</li>
<li>Dysfunctional uterine bleeding (Chapter 67).</li>
<li>Premature menopause (Chapter 67).</li>
<li>Turner syndrome: This is characterised by primary amenorrhoea, lack of secondary sex characters and short stature, with or without certain dysmorphic abnormalities due to a chromosomal defect, most commonly an XO karyotype. After initial cautious treatment with small doses of an estrogen (Chapter 67), the patient may be treated with a COC pill.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="progestins-alone-as-contraceptives">Progestins Alone as Contraceptives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#progestins-alone-as-contraceptives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LEVONORGESTREL: This 19, nor-testosterone compound possesses very potent progestational activity. In the daily oral dose of 30 mcg (Microval) continuously, it prevents conception. The drug reduces the sperm penetrability of the cervical mucus and impairs luteal function. Norgestrel, a racemic dl mixture, is only half as potent as levonorgestrel as the latter alone is active.</p>
<p>The other progestin only pills (POP) are norgestrel 75 mcg (Norgest), norethisterone 350 mcg (Micronor) and ethynodiol diacetate 500 mcg (Femulen). The advantages of such 'minipills' are:
(a) The usual estrogen-induced adverse effects such as alterations in coagulation factors, suppression of lactation and rise in triglyceride metabolism are low.
(b) There is no delay in conception following cessation of POP; and.
(c) They can be used during breast feeding. However, all of them cause irregular and generally short bleeding intervals and spotting in a high proportion of cases. Concurrent use of enzymeinducing drugs such as rifampicin can render POP ineffective.</p>
<p>Further even one pill is forgotten or is delayed by 3 hours or longer by a woman who is not breast feeding, intercourse should be considered as unprotected and an alternative method such as a condom should be used.</p>
<p>The use of progestin alone for contraception is much less reliable than that of COCs. Hence, 'progestin-only' pills are used only in patients with a specific contraindication to estrogen, in breast-feeding mothers and in those who find other contraceptive measures unacceptable.</p>
<p>The progestin only pill should be started by a breast-feeding mother 6 weeks after childbirth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiestrogenic-agents">Antiestrogenic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiestrogenic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ORMELOXIFENE (Centchroman, Saheli): This chroman derivative is a SERM. It shows weak estrogenicity (in bone), potent anti-estrogenicity (in uterus, breasts), and is devoid of progestogenic or androgenic activity. It causes asynchrony in the menstrual cycle between ovulation and development of the uterine lining.</p>
<p>Given orally, it is well absorbed and is metabolised in the liver. The plasma half life after a single dose of 60 mg is 169 hours. It is given twice weekly for 3 months followed by 30-60 mg once a week. However, it is less effective than COC pill and failure rate may be high.</p>
<p>The drug appears to be well tolerated. The main side effect is prolongation of the menstrual cycle. It may cause enlargement of ovaries. It should be avoided in polycystic ovarian disease, renal and hepatic disorders, tuberculosis and lactating mothers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="injectable-contraceptives">Injectable Contraceptives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#injectable-contraceptives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Injectable progestational preparations, depot-medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN), are highly effective, long acting and produce reversible effects. They enter the circulation directly without passing through the liver. They may lower the sex drive in less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of women; they do not cause any birth defects. To get the best results the woman must return in time for the next injection. They, however, have certain disadvantages (Table 68.6).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-68-6">Table 68.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-68-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Contraindications to injectable progestin contraceptives</p>
<ul>
<li>Likely pregnancy</li>
<li>Unexplained vaginal bleeding</li>
<li>Past or current breast cancer</li>
<li>Severe high blood pressure</li>
<li>Coronary heart disease</li>
<li>Diabetes mellitus with vascular complications</li>
<li>H/O thrombosis, past stroke</li>
<li>Severe liver disease</li>
<li>The patient wants to conceive in the next 6 months; or</li>
<li>The patient does not want weight gain or changes in the pattern of vaginal bleeding.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></li>
<li>The patient has one of the following medical conditions</li>
<li>Likely pregnancy</li>
<li>Unexplained vaginal bleeding</li>
<li>Past or current breast cancer</li>
<li>Severe high blood pressure</li>
<li>Coronary heart disease</li>
<li>Diabetes mellitus with vascular complications</li>
<li>H/O thrombosis, past stroke</li>
<li>Severe liver disease</li>
<li>The patient wants to conceive in the next 6 months; or</li>
<li>The patient does not want weight gain or changes in the pattem of vaginal bleeding.</li>
</ul>
<p>MEDROXYPROGESTERONE ACETATE (MPA) is a potent progestational compound which is effective both orally and parenterally. Unlike 19-norsteroids, it is not metabolised to estrogen in the body. The long acting, slowly absorbed, depot preparation DMPA is given IM. It exerts its effect primarily by inhibition of pituitary LH, leading to suppression of ovulation. Its action on the endometrium, the fallopian tubes and the cervical mucus may also contribute to the contraceptive effect. It is excreted in the breast milk but does not suppress lactation.</p>
<p>Repeated injections of DMPA cause prolonged inhibition of ovulation for several months, even after discontinuation.</p>
<p>Adverse reactions: The major drawback is the disruption of the normal menstrual cycle</p>
<p>that occurs in two thirds of the recipients. It causes bleeding irregularities, spotting and prolonged amenorrhoea. Severe bleeding, however, is uncommon. Unlike the COC, it has negligible metabolic actions; however, weight gain is common. When it is used in large doses to treat cancer or precocious puberty, adrenal suppression may occur; but this has not been observed during contraceptive usage. It can cause moon face during prolonged use.</p>
<p>NET-EN: This C-18 progestin has properties and mechanism of action similar to DMPA; it, however, has to get hydrolysed to become biologically active. It has a relatively short duration of action. It also causes menstrual disturbances similar to DMPA.</p>
<p>DMPA and NET-EN therapy may be initiated</p>
<ul>
<li>Any time the physician is reasonably certain that the patient is not pregnant, e.g., within the first 7 days of the menstrual bleeding.</li>
<li>Immediately after an abortion or after a childbirth if the mother chooses not to breastfeed the baby; it should be delayed by 6 weeks in those planning to breastfeed. Table 68.7 lists the available injectable contraceptives. Preparations containing EE are probably more effective and cause regular vaginal bleeding pattern. Further, fertility returns sooner after stopping these preparations.</li>
</ul>
<p>Table 68.7
Injectable contraceptives and their doses</p>
<table><thead><tr><th style="text-align: left;">Formulation</th><th style="text-align: left;">Brand name</th><th style="text-align: left;">Injection schedule</th></tr></thead><tbody><tr><td style="text-align: left;">DMPA 150 mg IM</td><td style="text-align: left;">Depo-Provera</td><td style="text-align: left;">Every 3 months</td></tr><tr><td style="text-align: left;">DMPA 104 mg SC</td><td style="text-align: left;">DMPA-SC</td><td style="text-align: left;">Every 3 months</td></tr><tr><td style="text-align: left;">NET-EN 200 mg IM</td><td style="text-align: left;">Noristerat</td><td style="text-align: left;">Every 2 months</td></tr><tr><td style="text-align: left;">DMPA 25 mg + estradiol cypionate 5 mg IM</td><td style="text-align: left;">Cyclo-lem</td><td style="text-align: left;">Every month</td></tr><tr><td style="text-align: left;">NET-EN 50 mg + estradiol valerate 5 mg IM</td><td style="text-align: left;">Mesigyna</td><td style="text-align: left;">Every month</td></tr></tbody></table>
<p>LEVONORGESTREL IMPLANT (Norplant): It consists of six, flexible, silastic rods containing levonorgestrel ( 36 mg per capsule) in crystalline form. The rods are inserted under the skin, usually on the inside of the woman's upper arm. They slowly release norgestrel in progressively diminishing quantities for upto 5 years. The original Norplant implant is now replaced by a Norplant-2 implant containing only 2 rods; it has similar efficacy.</p>
<p>Adverse reactions: Local infection may occur if the implant is inserted without a proper aseptic technique. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the users experience irregular bleeding or amenorrhoea. Irregular bleeding is mostly seen during the first year of use. Users have few pregnancies; however, many of them are likely to be ectopic. Other adverse effects are headache, nervousness, nausea, skin rash, acne, hirsutism, breast tenderness, weight gain and enlarged ovarian follicles. It involves an invasive procedure and needs trained personnel and monitoring.</p>
<p>Two, small, flexible, match-stick sized plastic rod implants are also available. They release progestin, either levonorgestrel (Jadelle) or etonogestrel (Implanton) slowly. Jadelle is a two rod system (for 5 years), whereas Implanton has a single rod (for 3 years). They do not interrupt an existing pregnancy and can be removed any time as per the woman's wish.</p>
<p>PROGESTIN-IUCD: Progestasert consists of progesterone micro-crystals in a silicone fluid, surrounded by a release-rate-limiting membrane. The device releases pre-</p>
<p>determined, minute quantities of the drug over a period of one year. There is no suppression of ovulation and the menstrual pattern is not disturbed. The incidence of ectopic pregnancy has, however, been reported to be higher than in the general population. A norgestrel-releasing IUCD (Mirena) is not only an effective contraceptive but is also useful in treating menorrhagia (Chapter 67).</p>
<p>Transdermal contraceptive system (TCS): This three layer patch contains norelgestromin and ethinylestradiol. Norelgestromin is the active metabolite of norgestimate. When applied once a week for 3 successive weeks in a month, it delivers the contained hormones continuously and allows withdrawal bleeding. It is as effective as the COC but less so in very obese women.</p>
<p>From among the various methods of contraception, in a given subject/situation, one method may be considered better than the others. Hence, it is better to have a 'cafeteria type' approach, where the woman concerned is allowed to choose the method after being adequately informed about the advantages and disadvantages of various procedures. "A happy, knowledgeable and communicating couple, especially if they have a sense of humour, can get along with almost any method". Women who cannot be relied upon to take pills regularly should be advised methods such as IUCD or surgical sterilisation.</p>
<p>IUCD is a useful and effective method of contraception for parous women, specially those who want more children or do not wish to undergo sterilisation. It is particularly useful for women over the age of 35 years, in whom the risks associated with the use of COC and the effectiveness of IUCD are both increased. Non-hormonal IUCD like Copper T is commonly used and is cost-effective. Its effects remain for 10 years.</p>
<p>The complications of IUCD are:</p>
<ul>
<li>Increased menstrual blood loss and dysmenorrhoea.</li>
<li>Increased risk of upper genital infection and pelvic inflammatory disease which can lead to ectopic pregnancy or infertility; and</li>
<li>Rarely, perforation of the uterus.</li>
</ul>
<p>For the above reasons, the use of IUCD is contraindicated in nulliparous women.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiprogestins">Antiprogestins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiprogestins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MIFEPRISTONE (RU 486): This derivative of norethisterone has antiprogestin activity.
Mechanism of action: It acts as a potent competitive antagonist of progesterone receptors in the presence of progesterone, and also of glucocorticoid receptors. It is an agonist in the absence of progesterone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Administered to women in early and late luteal phases of the menstrual cycle, it:
(a) Shows luteolytic property.
(b) Causes inhibition of the uterine glandular secretory activity; and
(c) Accelerates degenerative vascular changes, leading to menstrual bleeding within 72 hours (progesterone withdrawal bleeding).
Hence, it can be used as an emergency contraceptive. Larger doses, however, block the proliferative action of estradiol on the endometrium, and causes endometrial atrophy, suggesting a progestin-like property.</li>
<li>Administered during pregnancy, it:
(a) Binds to the progesterone receptor with high affinity and inhibits transcription resulting in down-regulation of progesterone-dependent genes. It causes decidual necrosis and detachment of the products of conception.
(b) Damages the endometrial blood vessels.
(c) Inhibits PG dehydrogenase activity thereby increasing the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level which stimulates uterine contractility; and
(d) Causes cervical dilatation.</li>
<li>Doses higher than those needed to produce antiprogestin effects block the effects of glucocorticoids at the level of the tissues. Thus, it ameliorates the manifestations of hypercortisolism in patients with Cushing's syndrome.
Absorption, fate, excretion: Mifepristone is administered orally or parenterally. Given orally, its plasma level peaks at 1-2 hours. It is metabolised slowly by the liver and is excreted in the bile with an elimination plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 20 hours. The plasma level is lower but is sustained longer after intravaginal than after oral administration. The metabolites also have antiprogestin and antiglucocorticoid activity.</li>
</ul>
<p>Adverse reactions: Single doses may cause nausea, vomiting, abdominal pain (in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> subjects), and sometimes heavy prolonged bleeding. Long term use of mifepristone can cause fatigue, anemia, weight loss, thinning of hair, menstrual disturbances, decrease in libido and gynecomastia. Mifepristone-PG combination should be used cautiously in subjects with heart disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Post-coital contraception: Mifepristone in a single dose of 10 mg is as effective as a combination of 100 mcg of ethinylestradiol and 0.5 mg of levonorgestrel given twice in a day.</p>
</li>
<li>
<p>Induction of abortion (see later): For this purpose, mifepristone is used in a single dose of 600 mg followed by a vaginal suppository of gemeprost 48 hours later.</p>
</li>
<li>
<p>Cervical dilatation: It is useful for preoperative preparation of women for surgical abortion late in the first trimester or in the second trimester. It is as effective as PGs and has fewer side effects.</p>
</li>
<li>
<p>Induction of labour after intrauterine fetal death.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="postcoital-contraception">Postcoital Contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#postcoital-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A possible method of contraception by preventing implantation of the fertilised ovum offers some attractive features. Such a drug need not be taken daily but only after coitus. So far, an ideal anti-implantation drug is not available. The various post-coital contraceptives recommended are given in Table 68.8.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-68-8">Table 68.8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-68-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="various-regimens-for-postcoital-contraception">Various regimens for postcoital contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#various-regimens-for-postcoital-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>One levonorgestrel 0.75 mg tablet, as soon as possible (certainly within 72 hours), repeated 12 hours later or 2 tab once.</li>
<li>Two COC pills containing 50 mcg of EE each (Table 68.8) as soon as possible (certainly within 72 hours) after intercourse, and the same dose 12 hours later.</li>
<li>Mifepristone 10 mg once within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>72</mn><mo>−</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">72-120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">72</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span> hours (see text).</li>
<li>Ulipristal 30 mg as soon as possible (within 5 days).</li>
<li>Copper-containing IUCD (see text).</li>
</ul>
<p>The emergency oral contraceptives, other than mifepristone, probably act by interfering with tubal transport, preventing implantation, or by causing regression of the corpus luteum. As these drugs are administered within hours of intercourse and implantation occurs only about 7 days after ovulation, their use is not equivalent to therapeutic abortion. It does not disrupt an existing pregnancy.</p>
<p>The regimen may cause nausea and vomiting and the treatment may fail if the drug is not retained. A pre-existing pregnancy must be ruled out before such treatment is initiated. If such hormonal form of postcoital treatment fails, there is possibility of harm to the embryo and this should be explained to the subject before such therapy. In case of failure, the pregnancy should be terminated by other methods.</p>
<p>Although postcoital contraception is safe to use more than once, this method should not be used in place of standard methods of contraception. It should be used only as an emergency method e.g. following rape. There is no age bar to using this technique.</p>
<p>Mifepristone in large doses is the only drug which interrupts pregnancy after implantation has occurred (see later).</p>
<p>Ulipristal acetate is a selective progesterone receptor modulator (SPRM) for emergency contraception. It blocks or delays ovulation and also delays the maturation of the endometrium. The efficacy is comparable to levonorgestrel but it is effective when taken within 5 days. Ulipristal acetate is metabolised by CYP3A4. It should not be taken in the presence of severe liver diseases. Breast feed should be avoided within 36 hours of taking the drug. Common adverse effects include abdominal pain and menstrual disorder.</p>
<p>Copper-containing IUCDs inserted within 5 days from the day of sexual intercourse is also effective as post-coital contraceptive agents. Such IUCDs, therefore, are to be preferred if hormonal treatment is contraindicated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="male-contraception">Male Contraception<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#male-contraception" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In males, spermatogenesis can be inhibited by androgens, estrogens and progestins. Although steroid combinations can inhibit spermatogenesis, such therapy has adverse effects. Vasectomy, carried out in properly selected cases, would be the most economical, reliable and relatively safe procedure for the males. It does not affect the libido. The other alternative is to use a condom.</p>
<p>GOSSYPOL: This is a polyphenolic compound obtained from the cotton seed. In rats, gossypol acetic acid causes dose dependent damage to germinal cells of testes; long term treatment damages spermatogonia leading to sterility. The drug, however, does not damage the Leydig cells. No genetic damage or hormonal disturbances have been reported. Clinical studies from China indicate that gossypol is an effective male antifertility agent. It takes 2-3 months to achieve the desired effect. However, its major ADR include decreased libido, occasional hypokalemic paralysis, and atrophy of seminiferous tubules, which are not acceptable.</p>
<p>It is quite justifiable to ask why only women should take chemical contraceptives! Why not men too?</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medical-termination-of-pregnancy-mtp">Medical Termination of Pregnancy (MTP)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medical-termination-of-pregnancy-mtp" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although termination of pregnancy has been legalised in many countries it is estimated that 20 million pregnancies are terminated illegally often by quacks, with more than 78,000 deaths, each year. Use of drugs for post-coital contraception is described earlier. Drugs used for MTP during the early part of the first trimester can be classified as:
I Progesterone synthesis inhibitors:
Epostane and Trilostane.
They competitively antagonise ovarian and placental 3-beta-hydroxysteroid dehydrogenase and inhibit progesterone synthesis. They are under investigation.
II Antiprogestins, eg., Mifepristone (See above).
III Antiestrogen, e.g., Tamoxifen (See Chapter 61).
IV Trophoblast inhibitors, eg., Methotrexate.
V Oxytocics, eg., Prostaglandins and Oxytocin (Chapter 44).
VI Miscellaneous, eg., Ethacridine, Hypertonic saline (Chapter 44).
Although PGs can be given alone to terminate pregnancy with a success rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>, the high doses needed cause a high incidence of adverse effects such as nausea, vomiting, diarrhoea, pain and dizziness, requiring supplements of opioid analgesics. Hence, they are combined with mifepristone or methotrexate. The synthetic PGE compounds misoprostol and gemeprost are generally preferred. Misoprostol can be stored at room temperature and is relatively inexpensive. It is administered orally or vaginally. Gemeprost is more expensive and thermolabile. It is given as vaginal pessary.</p>
<p>Mifepristone + misoprostol combination is highly effective in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> of the pregnant women. Mifepristone is given orally as a single dose of 400-600 mg, (in contrast to 10 mg for emergency contraception, see earlier) followed 48 hours later by misoprostol 400 mcg or gemeprost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> vaginally. Misoprostol given orally is less effective. The common ADR include backache, headache and uterine cramps. They are not dose-related. Severe side effects include prolonged and sometimes excessive vaginal bleeding. Women with severe asthma, adrenal insufficiency and those on long-term glucocorticoid therapy should not be given this combination because of its antiglucocorticoid action. It should be used cautiously in subjects with DM, severe anemia, hemorrhagic disorders and those on anticoagulants.</p>
<p>Methotrexate (Chapter 61), 25-50 mg given orally and followed 3-7 days later by misoprostol 800 mcg vaginally, is effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mo>−</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85-95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">85</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> of women with pregnancy of less than 8 weeks duration. The combination may cause nausea, vomiting, pain (due to misoprostol) and stomatitis and oral ulcers (due to methotrexate). This treatment is contraindicated in women over 35 years of age and in those with cardiac risk factors, as it can precipitate heart failure.</p>
<p>The advantages of above combinations are:</p>
<ul>
<li>The termination can be carried out on outpatient basis-first dose is given in the clinic and misoprostol is self-administered at home.</li>
<li>Relatively safe, do not require anaesthesia and hence highly acceptable.</li>
<li>Effective on average in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> of subjects with less than 8 weeks' pregnancy. The treatment failure rate rises with menstrual delay of 35 days or more.
The disadvantages are that they are not <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> effective; further they can sometimes cause prolonged and severe bleeding.</li>
</ul>
<p>Tamoxifen 20 mg once daily for 4 days, followed by vaginal misoprostol 800 mcg , is also reported to be effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of women.</p>
<p>Ethacridine Lactate (Emcredil, Vecredil): This acridine compound has been used extraamniotically for second trimester abortion. GI adverse effects and bleeding may occur but serious toxicity is claimed to be rare. It is instilled in the dose of 10 ml . of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> solution for each gestational week upto a maximum of 150 ml . On an average, it takes 30 hours to effect abortion.</p>
<p>Medical termination, however, is more painful and less effective in women with pregnancy of more than 8 weeks duration. In such cases, vacuum extraction is more acceptable and safer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ovulation-inducing-drugs">Ovulation Inducing Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ovulation-inducing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is estimated that infertility occurs in about 15 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> of couples. The problems of infertility is a joint one and both the partners need detailed examination. Nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of these problem are due to female factors, another <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> are due to male factors and for the remaining third, the cause is unknown. The male must be examined first before deciding to treat the feamle.</p>
<p>Unexplained infertility in women with advanced reproductive age is believed to be due to diminished quality and quantity of oocytes. It should be remembered that 20-30% of infertile but otherwise normal women ovulate spontaneously.</p>
<p>Generally, in women with anovulatory cycles and normal hypothalamic-pituitary-ovarian function, fertility can be induced by clomiphene, letrozole or FSH-HCG combination. In women with hypothalamic amenorrhea, administration of FSH- LH combination is used from the beginnng.</p>
<p>Deficiency of the thyroid hormone is an uncommon cause probably responsible in less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of anovulatory cycles.</p>
<p>As mentioned in Chapter 67, estrogens may be responsible in triggering an ovarian signal for midcycle LH release. Experimentally estrogen administration has been demonstrated to cause LH release usually after a preceding period of LH suppression. Hence, low dose estrogen may be useful in cases where some follicular activity is present but midcycle LH peak is lacking or corpus luteum is inadequate. An estrogen can be tried along with clomiphene.</p>
<p>Progestins are not useful except perhaps in patients with inadequate corpus luteum and endometriosis.</p>
<p>Dexamethasone in small doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily) induces ovulation in some patients with PCOS, by suppressing the adrenal androgen contribution.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-ovulation-inducing-drugs">Classification of ovulation inducing drugs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-ovulation-inducing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Synthetic GnRH: (Chapter 67).
II Human menopausal and chorionic gonadotropins (Chapter 67).
III Bromergocriptine (Chapter 67).
IV Antiestrogenic compound: Clomiphene citrate.
CLOMIPHENE CITRATE: This is a triphenylethylene compound, with structural resemblance to stilbestrol and chlorotrianisene (Fig. 68.1). It was synthesised during the search for a potent estrogenic compound but was found to possess potent antiestrogenic effects. In rats, it stops the estrous cycle, decreases the secretion of gonadotropins and reduces the size of the ovaries. However, it is effective in inducing ovulation in women with anovulation.</p>
<p><img src="assets/images/image-20251214-e096e38e.jpeg" alt="img-53.jpeg"></p>
<p>FIG. 68.1 Structural resemblance between nonsteroidal estrogens and the antiestrogen clomiphene
The available clomiphene preparation contains 'cis' as well as 'trans' forms. It is the 'cis' form which is related structurally to estrogens and is more potent than the racemic form.</p>
<p>Mechanism of action: Clomiphene acts by competing with the circulating estrogen for receptor sites in the hypothalamus and the pituitary. Being a weak estrogen agonist, its binding to the estrogen receptor result in estrogen antagonist actions (partial agonist). This prevents the negative feedback of native estrogen leading to release of pituitary FSH and LH and ovulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antiestrogenic action: In addition to ovulation induction, clomiphene produces regression of estrogen induced proliferative endometrium and counters the keratinisation of vaginal epithelium. It can prolong the luteal phase in normally menstruating women and nullify the ovulatory inhibition produced by OC pills.</li>
<li>Miscellaneous actions: It has a weak estrogenic action, on the bone and endometrium. Given to premenopausal women, it causes hot flushes.
Absorption, fate and excretion: The drug is well absorbed orally. It is concentrated in the bile and excreted in the intestines, from where it is reabsorbed. It is mainly excreted in the feces and only a small amount appears in the urine. Half of the dose is excreted within 5 days.</li>
</ul>
<p>Adverse reactions: It causes hot flushes, GI disturbances, breast discomfort, blurring of vision, abnormal uterine bleeding and alopecia. The important drawback is that it causes (1) ovarian enlargement (and ovarian hyperstimulation) and cyst formation which may rarely lead to rupture and internal hemorrhage; and (2) multiple ovulation, resulting in</p>
<p>multiple pregnancies and fetal wastage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Ovulation induction: Clomiphene is indicated in the treatment of anovulatory infertility; in such cases, adequate endogenous estrogenic activity is present. Clomiphene is given orally in doses of 50 to 200 mg at bed-time for 5-7 days. It is started between day 2 and 5 of the menstrual cycle. Nearly 70 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> anovulatory patients ovulate, of which 30 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> will become pregnant. Most of these pregnancies occur after 3 to 6 consecutive cycles. Lack of response after this period indicates clomiphene resistance and hence the drug should not be repeated.
Ovulation usually occurs 2-12 days after completion of the treatment. In case of an amenorrheic patient, the drug can be given at any time but it is customary to start it on the 5th day of withdrawal bleeding after a course of medroxyprogesterone ( 5 mg bid for 5 days).</li>
</ul>
<p>The multiple pregnancy rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> with clomiphene is distinctly lower than that with gonadotropin therapy ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ). The pregnancy wastage rate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ) is, however, similar with both therapies. As compared to human pituitary gonadotropin, clomiphene is less effective but less hazardous, and is much less expensive. It is claimed that the incidence of abortions can be reduced by using progesterone (micronised 100 mg bid for 14 days) soon after the existence of conception is confirmed.</p>
<p>There is no rationale for the use of clomiphene for 'menstrual regulation' if conception is not desired by the patient, because it can cause dangerous hyperstimulation of the ovaries. Further, treatment in an individual patient should be limited to 12 cycles in the lifetime because of the reported increase in the incidence of ovarian cancer following longer treatment.</p>
<ul>
<li>Polycystic ovary syndrome (PCOS): This is characterised by polycystic ovaries associated with anovulation, hyperandrogenism, and infertility. It has a familial basis and many patients show insulin resistance. The current management of PCOS includes lifestyle modification; diet control and exercise for weight reduction in obese patients; and cessation of smoking; this treatment often can induce ovulation. Metformin can improve insulin resistance, regulate the menstrual cycles and cause ovulation in patients with glucose intolerance. It is administered in the dose of 500 mg OD and increased to 500 mg tid. If it is not effective in 3-5 months, clomiphene may be added for further 6 months. Metformin should be stopped when pregnancy is confirmed. If the treatment fails after 12 cycles, gonadotropin therapy may be considered. Cauterisation of the ovarian cysts may be done only as a last resort.</li>
<li>Oligospermia: Clomiphene has also been used in males with low sperm counts with variable results.
Cyclofenil: This compound has a structure similar to clomiphene and is used for similar purposes. It does not exert a peripheral anti-estrogenic effect. Given cyclically in the dose of 200 mg twice a day for 10 days, starting on the third day of menstrual bleeding, it can induce ovulation.</li>
</ul>
<p>Letrozole: This non-steroidal aromatase inhibitor (Chapter 61) was used for ovulation induction in patients with PCOS resistant to clomiphene. It acts by inhibiting aromatase and thus reducing the production of estrogen. Suppression of estrogen stimulates release of FSH and LH leading to ovulation. Though effective, it is not approved for ovulation induction because it may cause foetal malformation besides arthralgia and myalgia.</p>
<p>Table 68.9 lists some drugs which may impair fertility.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-68-9">Table 68.9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-68-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs which impair male and female fertility</p>
<table><thead><tr><th style="text-align: center;">Drugs</th><th style="text-align: center;">Male</th><th style="text-align: center;">Female</th></tr></thead><tbody><tr><td style="text-align: center;">Cytotoxics,</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Methotrexate, cyclophosphamide</td><td style="text-align: center;">Azoospermia</td><td style="text-align: center;">Ovarian failure</td></tr><tr><td style="text-align: center;">Drugs of dependence</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Alcohol, opioids, marijuana</td><td style="text-align: center;">Decreased testosterone and sperm abnormalities</td><td style="text-align: center;">Menstrual irregularities</td></tr><tr><td style="text-align: center;">Nicotine (tobacco)</td><td style="text-align: center;">-</td><td style="text-align: center;">Premature ovarian failure</td></tr><tr><td style="text-align: center;">Hormones</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Estrogens</td><td style="text-align: center;">Suppression of pituitary and hypothalamus</td><td style="text-align: center;">Menstrual irregularities</td></tr><tr><td style="text-align: center;">Androgens</td><td style="text-align: center;">See 'Abuse of anabolic steroids by athletes'</td><td style="text-align: center;">Anovulation</td></tr><tr><td style="text-align: center;">Prednisolone</td><td style="text-align: center;">Decreased sperm count</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Levothyroxine</td><td style="text-align: center;">-</td><td style="text-align: center;">Anovulation with large doses</td></tr><tr><td style="text-align: center;">Antipsychotics,</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Phenothiazines Risperidone</td><td style="text-align: center;">Hyperprolactinemia, impotence</td><td style="text-align: center;">Hyperprolactinemia, menstrual irregularities</td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">Same as above</td><td style="text-align: center;">Same as above</td></tr><tr><td style="text-align: center;">Miscellaneous</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cimetidine</td><td style="text-align: center;">Antiandrogen, azoospermia</td><td style="text-align: center;">Menstrual irregularities</td></tr><tr><td style="text-align: center;">Spironolactone</td><td style="text-align: center;">Antiandrogen, decreased testosterone</td><td style="text-align: center;">Menstrual irregularities</td></tr><tr><td style="text-align: center;">Sulphasalazine</td><td style="text-align: center;">Decreased sperm count</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Phenytoin</td><td style="text-align: center;">Decreased sperm count</td><td style="text-align: center;">-</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antigonadotropic-compounds">Antigonadotropic Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigonadotropic-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DANAZOL: This is a synthetic derivative of ethisterone.
(a) It has antigonadotropic activity but no estrogenic or progestational properties. Thus, in normal women it eliminates the midcycle LH and FSH surge by acting as selective pituitary gonadotropin inhibitor; and in postmenopausal women it prevents the compensatory increase in FSH and LH.
(b) Peripherally, it binds to androgen (partial agonist), progesterone and glucocorticoid receptors; thus it has some androgenic and anabolic effects.
(c) It also inhibits directly the ovarian enzymes involved in the estrogen synthesis.</p>
<p>Danazol, thus, induces a hypoestrogenic-hypoprogestational state. Complete ovarian suppression occurs only with doses of 600 mg or more per day; and at lower doses its other actions may predominate.</p>
<p>Absorption, fate and excretion: It is well absorbed and is extensively metabolised in the liver; the metabolites are excreted in the urine. Its elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 4-5 hours. Therapeutic effect starts only after 4 weeks.</p>
<p>Adverse reactions: These are</p>
<ul>
<li>General, such as muscle cramps, rash, benign intracranial hypertension, altered hepatic and lipid metabolism.</li>
<li>Androgenic and anabolic, such as weight gain, acne, hirsutism and voice change; and</li>
<li>Hypoestrogenic, such as hot flushes, atrophic vaginitis and mental depression.</li>
</ul>
<p>Therapeutic uses:</p>
<ul>
<li>Endometriosis: Danazol is used to treat endometriosis. It causes atrophy of endometrial tissue including that at the ectopic sites, and amenorrhoea. Ovulation and menstruation are re-established promptly on cessation of therapy, and pregnancy may be achieved in the first cycle before menstruation occurs. Therefore, contraception should be practised after stopping danazol treatment if pregnancy is not desired. It is administered orally in the dose of 200-800 mg daily for 3-9 months. The treatment is initiated during a menstrual period. (Chapter 67).</li>
<li>Benign fibrocystic breast disease</li>
<li>Gynecomastia</li>
<li>Menorrhagia (Chapter 67);</li>
<li>Hereditary angioedema and</li>
<li>Idiopathic thrombocytopenic purpura</li>
</ul>
<p>Gestrinone is an analogue of danazol for the treatment of endometriosis. The dose is 2.5 mg twice a week for 6 months, starting during a menstrual period.</p>
<p>69</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="androgens-anabolic-steroids-and-antiandrogens">Androgens, Anabolic Steroids and Antiandrogens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#androgens-anabolic-steroids-and-antiandrogens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The early knowledge regarding the relationship between the testes and the secondary sex characters in male was obtained from the studies in castrated animals. It was demonstrated that the typical signs of castration could be reversed by transplantation of gonads. The first pure hormone with androgenic activity-androsterone-was isolated from the male urine by Butenandt in 1931. This was followed by the isolation of urinary androgenic steroid, dehydroepiandrosterone. The active principle of testes, testosterone, was isolated in pure form in 1935. The urine contains androsterone and etiocholanolone, the metabolites of testosterone. Steroidogenesis also occurs in the ovary, the adrenal cortex and the placenta.</p>
<p>Physiological actions of androgens: Androgens determine the differentiation of the foetal external genitals in the male direction. Further, in males they prevent the development of the hypothalamic cyclic release of LH. At puberty, hypothalamic GnRH release in discrete pulses, increases the pituitary FSH and LH. Increased LH acts on Leydig cells to stimulates synthesis and secretion of testosterone markedly, which is responsible to convert a boy into a man.</p>
<p>It is associated with (a) a marked rise in intratesticular testosterone which is essential for spermatogenesis and (b) elevated plasma testosterone which promotes the development of external genitalia and secondary sexual characters.</p>
<p>FSH acts on the seminiferous tubules and is responsible for the growth of the testes. It promotes spermatogenesis and stimulates the Sertoli cells. It is thus gametogenic in action. Sertoli cells also secrete inhibin beta, which selectively suppresses FSH. Thus, both FSH and LH play an important role in initiating and maintaining the normal testicular functions. These are :</p>
<ul>
<li>Development of male external genitals (penis and scrotum), and secondary sex characters (pubic hair and beard) and change in voice.</li>
<li>Development of the male internal genitals: seminal vesicles, prostate and epididymis. - Maintenance of spermatogenesis.</li>
<li>Development of skeletal musculature and emotional make up of male type; and</li>
<li>Anabolic and growth promoting effects.</li>
</ul>
<p>Failure of the testicular function causes male hypogonadism.
The daily testosterone production by male adults is between 4 and 12 mg . This gives a plasma level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">4-10 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. A small proportion of the circulating testosterone may arise by extra-adrenal conversion of the weak adrenal androgens dehydroepiandrosterone and androstenedione. In the female, the latter is an important source of plasma testosterone which measures <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>.</p>
<p>Testosterone is converted in androgen-responsive tissues to the active metabolites, 5adihydrotestosterone and small amount of estradiol. Testosterone circulates in the blood, mainly bound to albumin and partly to sex hormone binding globulin; small amount is present in free form. Testosterone and dihydrotestosterone bind to a cytoplasmic androgen receptor protein before acting on the nucleus in a similar manner as estrogen. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span></p>
<p>of testosterone is converted to estrogen in the body. In men nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of circulating estradiol is derived from testosterone</p>
<p>Male hypogonadism: Failure of testicular function can be either (a) primary, due to testicular failure or (b) secondary, due to failure of the HP (hypothalamic-pituitary) complex. In primary testicular failure, gonadotropin secretion is increased, producing hypergonadotropic hypogonadism, while in HP failure, the gonadotropin secretion does not increase, causing hypogonadotropic hypogonadism.</p>
<p>The testicular deficiency could be selectively gametogenic or both gameto- and androgenic. In the former, the individual is sterile but has normal secondary sex characters; in the second case both the functions are impaired.</p>
<p>Failure of the testes before puberty (pre-puberal hypogonadism) causes infantile penis, feminine distribution of fat (more on buttocks, breast and hips) and arrest of laryngeal and sexual hair growth. The muscles remain soft; skin becomes smooth and there is a lack of sex drive. Intelligence is not affected.</p>
<p>In a patient with post-puberal hypogonadism, the general body proportions and size of the penis are not altered. But the body hair become sparse and silky, voice becomes high pitched and libido is greatly reduced. Skeletal muscles become flabby and weak and there is a tendency to develop obesity. However, the life expectancy is not shortened nor is premature senility produced. The volume of semen is markedly decreased and there is a change in the emotional make up, anxiety, fear and inferiority complex replacing self confidence.</p>
<p>TESTOSTERONE and its synthetic analogues act intracellularly in target cells (see earlier).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Direct: Testosterone and its most potent metabolite, dihydrotestosterone produced by 5 alpha reductase, activate the androgenic receptors. They bring about the development of male sexual organs, prostate, increase in muscle mass and strength and promote erythropoeisis.</li>
<li>Indirect: effects are through other active metabolite, estradiol produced by its aromatization, which acts on both the estrogen receptors. This causes regulation of body fat and prevention of bone loss. Estrogen deficiency causes fat accumulation mostly as intraabdominal fat.</li>
<li>Both, testosterone and estrogen regulate the sexual function, maintain normal libido and erectile function.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are dose related. There appears to be a variation in tissue sensitivity to androgens.</p>
<ul>
<li>
<p>Androgenic action: Administration of testosterone in pre-puberal hypogonadism reverses most of the changes of hypogonadism. The secondary sex characters develop, muscle strength increases and sex desire and erections occur normally. The testes do not enlarge and spermatogenesis does not occur.
In females, testosterone causes increased libido as well as masculinisation, e.g. hirsutism, growth of clitoris and change in voice (male type). The development of proliferative phase of the endometrium may be inhibited and large doses can suppress the ovulation and lactation. Administered during pregnancy, androgenic compounds can masculinise the external genitals of the female foetus.</p>
</li>
<li>
<p>Anabolic actions: Protein synthesis (anabolism) and protein breakdown (catabolism) are the important functions of a cell.
Adequate supply of nutrient material is necessary for protein synthesis. The anabolic (protein synthetic) action of androgens is demonstrated by the fact that the male is more muscular than the female and that castration in male causes reduction in muscle mass. Testosterone promotes nitrogen retention and increases the appetite, muscle mass and body weight especially in eunuchoid men, in prepuberal boys and in women. It is insignificant in normal healthy male adults. Along with nitrogen, potassium, sulfur and phosphorus are also retained, while the urinary excretion of calcium and creatinine is decreased.</p>
</li>
<li>
<p>Bones and epiphyses: Testosterone in small doses can promote growth of epiphyseal cartilage, particularly in boys with short stature due to hypogonadism. However, large doses brings about early epiphyseal fusion and reduces the final adult height.
Androgens may reduce bone resorption and cause beneficial effects in senile osteoporosis. This effect is probably due to estradiol.</p>
</li>
<li>
<p>Effect on pituitary: Testosterone exerts a negative feed back effect on LH and a smaller one on FSH. LH and FSH levels rise in primary hypogonadism. The LH inhibiting action could be due to the small quantities of estrogen to which testosterone is converted in the pituitary. Mesterolone, a testosterone analogue, which is not converted into estrogen, lacks this property.</p>
</li>
<li>
<p>Hemopoietic action: They stimulate erythropoietin secretion by the kidneys, and directly stimulate heme synthesis in the bone marrow.</p>
</li>
<li>
<p>Miscellaneous actions: Androgens increase appetite and cause a feeling of well being. They can cause sodium retention. They also cause growth and increased secretion of the sebaceous glands, clinically manifested as acne.
These compounds generally antagonise many of the actions of estrogens in females.
Absorption, fate and excretion: Testosterone is well absorbed orally but is largely inactivated by the liver (first pass) and hence, is therapeutically ineffective. Its 17-methyl derivatives methyltestosterone and fluoxymesterone are much less degraded by the liver and are effective orally.</p>
</li>
</ul>
<p>Ninety-eight percent of plasma testosterone is in bound form. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 1020 minutes. It is largely metabolised in the liver, and small amount in prostrate and skin. It is excreted in the urine, mostly as androsterone and etiocholanolone, as sulfates and glucuronides. The plasma testosterone levels are a useful indicator of androgen production in the male.</p>
<p>Esters of testosterone with weak organic acids like propionic acid, when injected, produce prolonged action for 2-3 days, while cypionate and enanthate are effective for 1-2 weeks. Pellets of testosterone implanted under the skin are slowly absorbed and their therapeutic effect lasts for 6-8 months.</p>
<p>Assay: For clinical purposes, androgens are measured by radioimmunoassay. The androgenic activity of a compound can be bioassayed by the measurement of growth of the seminal vesicles or the prostate in castrated rats.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>In large doses, testosterone can cause precocious puberty in boys, and masculinisation (deepening of voice, hirsutism, acne, baldness and clitoromegaly) in girls and women.</li>
</ul>
<p>Some of these changes may be irreversible.</p>
<ul>
<li>In young children, prolonged use of these drugs may bring about early closure of the epiphyses and thus stop the growth.</li>
<li>In pubertal boys, androgens can cause gynecomastia.</li>
<li>Large doses can suppress spermatogenesis and may even cause degeneration of seminiferous tubules.</li>
<li>Androgens aggravate a pre-existing cancer of the prostate. They can also aggravate bladder neck obstruction in patients with benign prostatic hypertrophy.</li>
<li>Large doses can cause retention of sodium and edema.</li>
<li>Methyl testosterone, fluoxymesterone and many anabolic steroids are potentially hepatotoxic and can cause cholestatic jaundice.</li>
<li>Hepatic adenocarcinoma has been reported in patients of aplastic anemia receiving 17alkyl derivatives for prolonged periods.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Testosterone esters: Parenteral forms are all <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>17</mn><mi>β</mi><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow></mrow><annotation encoding="application/x-tex">17 \beta \mathrm{OH}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">17</span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord"><span class="mord mathrm">OH</span></span></span></span></span></span> ester derivatives of testosterone.
(a) Testosterone propionate injection. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM three times a week.
(b) Testosterone phenylpropionate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM every 7-14 days, usually combined with other testosterone esters.
(c) Testosterone cypionate 100-200 mg IM every 14 days.
(d) Testosterone enanthate 200 mg IM every week.
(e) Testosterone undeconate in tea seed oil or castor oil 250 mg depot IM injections every month</li>
<li>Oral preparations: Testosterone undecanoate 40 mg per capsule. Dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>160</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">120-160 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">160</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses.</li>
<li>Transdermal preparations: Testoderm patch ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">300 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> for 24 hr ) and androgel ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / 5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> tube) for rubbing are available for application to the scrotal skin daily.</li>
<li>Testosterone implants 100-200 mg Dose: 100-600 mg doses every 4 months.</li>
</ul>
<p>Therapeutic uses: It is used either for its androgenic and antiestrogenic actions or for its anabolic effects. The uses are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-for-replacement-therapy">I For replacement therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-for-replacement-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypogonadism: In primary testicular failure, the treatment should be started at puberty. Full replacement therapy requires at least 10 mg of testosterone per day; this is met with by giving 25 mg of the propionate ester IM three times a week, or cypionate or enanthate 200 mg every 2 weeks. For sustained effect, the long acting esters are preferred to the shorter acting ones. The starting dose for the first 6-12 months should be 50-100 mg once a month. Other preparations can also be used but more frequent administration is necessary. Oral preparations are not very effective in initiating sexual development but are often adequate for maintenance therapy.
The diagnosis of hypogonadism in young children should be made cautiously because of marked variations in age of maturation in different individuals. Testosterone should not be used routinely to hasten the onset of puberty and sexual maturation in otherwise normal boys.</li>
</ul>
<p>In post-puberal hypogonadism, only replacement therapy is needed and long acting testosterone preparation is given in the dose of 200 mg every 2 weeks; some patients need 'low dose' replacement therapy in the form of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of the same preparation(s) IM once every 2 weeks. Oral preparations need to be given daily.</p>
<p>In men receiving long term testosterone treatment, hematocrit, serum testosterone, lipids and prostate specific antigen (PSA) should be monitored.</p>
<p>In hypopituitarism in children, the cost of hGH makes it necessary to use small doses of an androgen as a substitute. Hydrocortisone and thyroxine may be added if necessary.</p>
<ul>
<li>Male climacteric (Andropause): Although there is no such clear-cut parallel to 'female climacteric' in elderly males, testicular function declines as the age advances. This is manifested as muscular weakness and tendency to obesity. In such cases small doses of testosterone may be useful. However, the criteria for the diagnosis of this condition are very vague.
II For pharmacological therapy:</li>
<li>As anabolic steroid: To promote anabolism. This is discussed below.</li>
<li>Impotence: Sexual impotence may be defined as inability for a man to have satisfactory sexual intercourse. This can be due to:
(a) Lack of sexual desire (libido),
(b) Inability to achieve or maintain an erection (erectile dysfunction, ED). See below; or
(c) Failure of ejaculation.</li>
<li>Refractory anemias, particularly aplastic anemia</li>
</ul>
<p>Testosterone and anabolic steroids are absolutely contraindicated in carcinoma of prostrate and breastin males.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erectile-dysfunction">Erectile Dysfunction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erectile-dysfunction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The normal erectile response is mediated by a combination of psychogenic (central) and reflexogenic (peripheral) stimuli. The CNS plays an important role by either stimulating or inhibiting the spinal pathways that mediate erectile function and ejaculation. The physiological mechanism of erection involves release of nitric oxide (NO) from the vascular endothelium and the nitrergic nerves into the corpora cavernosa of the penis during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpora cavernosa and penile arteries, and allowing inflow of blood. The cGMP is metabolically degraded by the enzyme phosphodisterase-5 (PDE-5) present in the corpora cavernosa. Isoenzymes of PDE are also present in other tissues: PDE-3 in the heart and PDE-6 in the retina. In addition to NO, locally synthesised <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>a</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight">a</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> also contribute to the relaxation of the cavernosal smooth muscle cells.</p>
<p>The parasympathetic (cholinergic) input to the penis is pro-erectile, whereas the sympathetic (adrenergic) input is anti-erectile. Emission, which is the deposition of the seminal fluid into the posterior urethra, is regulated by activation of the sympathetic system. The pro-erectile afferent stimuli from the perineum and the lower urinary tract to the penis, and the efferent ejaculatory stimuli to the levator ani muscles (which cause rhythmic ejaculation of the semen out of the penile urethra) are carried through somatic sacral reflex arc.</p>
<p>The basic mechanisms involved in ED are:
(a) Failure to initiate, due to psychological, endocrinological or neurogenic causes.
(b) Failure to fill blood into cavernosa, due to arteriogenic causes; or
(c) Failure to hold adequate blood volume in the cavernosa (vaso-occlusive dysfunction).</p>
<p>An organic cause can be found in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the cases of ED; the rest are either psychogenic or are due to a psychiatric illness such as depression. Systemic disease such as chronic liver or kidney disease and drug abuse are other important causes. Only a few cases are due to androgen deficiency and they alone benefit from treatment with testosterone. The adult replacement dose is 200 mg of a long acting ester of testosterone such as cypionate or enanthate once in 2 weeks or 300 mg once in 3 weeks. Testosterone improves the libido, but not erectile failure in patients with normal libido.</p>
<p>Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the patients with ED may have drug induced ED. Hence before starting such treatment, drug induced sexual dysfunction should be ruled out (Table 69.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-69-1">Table 69.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-69-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some drugs causing sexual dysfunction
Sedative-hypnotics, Antipsychotics Antidepressants, Antiparkinson drugs Antihistaminics, Opioids.</p>
<ul>
<li>Anticholinergics</li>
<li>Antihypertensives: including, Beta-adrenergic blockers.</li>
<li>Diuretics.
-H <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hormonal-agents">- Hormonal agents:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormonal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Estrogens, Antiandrogens, Spironolactone, GnRH agonists</p>
<ul>
<li>Fibrates</li>
<li>Cytotoxic drugs: e.g. Methotrexate</li>
<li>Recreational drugs: e.g. Alcohol, Cocaine, Cannabis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span>
<img src="assets/images/image-20251214-9f4edb94.jpeg" alt="img-54.jpeg"></li>
</ul>
<p>In many instances, sexual impotence is temporary and situational; and in the patient, expectant waiting is as good a treatment as any drug. Counselling and change of environment are often beneficial.</p>
<p>Table 69.2 shows drugs used in the treatment of sexual impotence. Yohimbine, which acts by blocking central alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors is no longer recommended.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-69-2">Table 69.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-69-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-used-in-the-treatment-of-sexual-impotence">Drugs used in the treatment of sexual impotence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-the-treatment-of-sexual-impotence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral: Sildenafil; Tadalafil; Trazodone Bromocriptine; Yohimbine.
IM: Testosterone.
Intracavernosal injection: Papaverine; Phentolamine; PGE (alprostadil).
Transurethral injection: PGE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.
'Act as local Vasodilators
SILDENAFIL: This methylpiperazine compound inhibits the enzyme PDE-5 in the corpora cavernosa of the penis, thereby prolonging the life of cGMP at that site. This causes relaxation of the smooth muscle of the corpora cavernosa permitting inflow of blood into the sinuses resulting in better erection. The presence of NO is essential for this action. It does not improve sex desire (libido), orgasm or ejaculation. By itself, it does not bring about erection but it improves the quality and duration of erection in response to sexual stimulation.</p>
<p>It is not of much value in subject with loss of erection due to spinal or other damage to innervation, and in those who lack libido.</p>
<p>Sildenafil has also been found effective in reducing clinical symptoms as well as pulmonary artery pressure in patients with primary pulmonary hypertension.</p>
<p>Absorption, fate and excretion: After a single oral dose, peak plasma level is reached in 30-120 minutes with bioavailability of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>. High fat meal delays its absorption. The plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 2-4 hours and its clinical effectiveness lasts for 4 hours. It is metabolised in the liver by CYP3A4. It is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> on empty stomach, an hour before the intended coitus.</p>
<p>Adverse reactions: Sildenafil causes headache, dyspepsia, nasal congestion and priapism. The drug potentiates the hypotensive effects of nitrates, and hence its administration to persons who are using nitrates in any form is dangerous. Further, there is some cardiac risk of angina or MI associated with sexual activity, especially in the elderly. As many users of drugs for impotence are likely to be elderly, although such therapy may increase the patients' 'vigour' and make them feel 'younger' it can also increase the risk of morbidity and mortality during sexual activity.</p>
<p>It occasionally imparts bluish tinge to vision due to its effect on the PDE-6 in the retina. It is contraindicated in persons with retinal degenerative disorders. The drug has been reported to cause Non-Arteritic-Ischemic Optic Neuritis (NAION), leading to acute loss of vision.</p>
<p>The plasma levels of sildenafil and its ADR increase in subjects over age 65, those with renal/hepatic impairment and in those who are being concurrently treated with CYP3A4 inhibitors such as erythromycin.</p>
<p>Vardenafil, chemically related to sildenafil, has properties and duration of action similar to those of sildenafil. Its bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>.</p>
<p>TADALAFIL: This drug, chemically unrelated to sildenafil, has a longer duration of action. Like sildenafil, it selectively inhibits PDE-5; it has less affinity for PDE-6 present in the retina, but greater affinity for PDE-11 present in the skeletal muscle, heart, prostate and kidney. It is claimed to cause less ocular toxicity.</p>
<p>Food does not interfere with its absorption. It has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 17.5 hours, with clinical effect lasting for almost 36 hours. Adverse reactions are similar to those of sildenafil. When given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> twice a week, its effect is almost continuous and the patient can attempt intercourse any time at will, without planning.</p>
<p>All PDE-5 inhibitors can potentiate hypotension especially when used concurrently with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> blockers such as doxozosin or tamsulosin which are often prescribed in BPH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anabolic-steroids">Anabolic Steroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anabolic-steroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although testosterone has potent anabolic activity, it cannot be used freely for this purposes because of its androgenic action. Hence, various steroids were synthesised with anabolic actions but reduced virilising effects. The clinically used anabolic steroids are given in Table 69.3. Chemically, they are derivatives of testosterone or methyl testosterone. With the exception of methenolone and nandrolone, they are all C17 alkyl substituted steroids. None of the presently available compounds, however, is selectively anabolic, without an androgenic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>D</mi><mi>R</mi></mrow><annotation encoding="application/x-tex">A D R</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-69-3">Table 69.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-69-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anabolic-steroids">Anabolic steroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anabolic-steroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Generic name (Trade name)</th><th style="text-align: center;">Recommended adult dose</th></tr></thead><tbody><tr><td style="text-align: left;">Nandrolone phenyl propionate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every week</td></tr><tr><td style="text-align: left;">Nandrolone decanoate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>T&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {T }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">T&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every three weeks</td></tr><tr><td style="text-align: left;">Methenolone acetate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Osymetholone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Methandienone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Ethylestrenol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Norethandrolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Osandrolone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Osymesterone</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr><tr><td style="text-align: left;">Stanozolol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily</td></tr></tbody></table>
<p>These are given IM; the rest are given orally. The first three are derivatives of testosterone, the rest of methyltestosterone.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∼</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\sim}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6198em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6198em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mrel mtight">∼</span></span></span></span></span></span></span></span></span></span></span></span></span> Not converted to estrogen.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>3</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span></span></span></span></span></span></span></span></span> Available in the market; the rest of the preparations are not freely available currently.
Pharmacological actions: In therapeutic doses, the anabolic action is predominant. The androgenic effect becomes more apparent during prolonged therapy, particularly in females.</p>
<ul>
<li>
<p>Protein anabolism: Anabolic steroids promote protein anabolism, as manifested by increase in the muscle mass and the body weight. Protein catabolism or negative nitrogen balance is observed in various conditions such as caloric deficiency, protein deficiency, fever, infections, all forms of stress, prolonged immobilisation and following broad spectrum antibiotics. In majority of these conditions correction of the cause and providing adequate calories and nutrients including proteins will accelerate anabolism. Anabolic steroids are certainly not effective during the acute phase of the illness or continuing stress. Used during recovery from such conditions, they may stimulate appetite and the sense of wellbeing nonspecifically, and promote weight gain.
What is usually needed for tissue repair following injury and illness is enough protein intake in the diet; the necessary anabolic drive is provided by the body. There is no lack of anabolic drive both in men and women recovering from illness; and the necessity of anabolic steroids in such conditions is highly questionable.</p>
</li>
<li>
<p>Anticatabolic effects: In short term studies, anabolic steroids have been shown to produce positive nitrogen balance in individuals on prolonged glucocorticoid therapy. However, their routine use in combination with glucocorticoids may be dangerous as ADR due to glucocorticoids such as hypertension, acne, hirsutism and sodium retention may be potentiated by anabolic steroids.</p>
</li>
<li>
<p>Progestational effects: Some of the anabolic steroids like norethandrolone have significant progestational activity.</p>
</li>
<li>
<p>Miscellaneous actions: Like testosterone, anabolic steroids may reduce bone resorption and thus may prevent osteoporosis.
Adverse reactions: These are due to their androgenic action and are similar to those produced by testosterone. They are most likely to occur in children and females and need monitoring. The use of anabolic steroids in pregnancy has led to virilisation of the foetus and advanced bone age. In addition, the orally active anabolic steroids which have a substituted alkyl group at C17 can cause cholestatic jaundice, and liver damage. Prolonged treatment may cause sodium and water retention.</p>
</li>
</ul>
<p>Preparations: See Table 69.3. The pediatric doses of these drugs are: methandienone 0.04 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day; ethylestrenol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.1-0.2 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day; oxandrolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Chronic illness: They have been used during chronic illness especially HIV cachexia to improve appetite and the sense of well being.</li>
<li>Growth: They are used to promote growth in hypogonadal children. If available, oral oxandrolone is the preferred drug. Their place in the treatment of short stature from other causes is very limited. They should not be used in girls.</li>
<li>Renal failure: They are sometimes used in acute or chronic renal failure, along with protein restriction, to reduce blood urea and thus to decrease the nitrogen load on the kidneys.</li>
<li>Anemias: They are claimed to be effective in certain refractory anemias associated with bone marrow hypoplasia or aplasia.
Causes of failure to gain weight by apparently healthy individuals are often undetectable. Use of anabolic steroids to increase the body weight in these otherwise healthy children or adults is disappointing; even some of those who appear to benefit lose the weight after the drug is stopped. Anabolic steroids are not tonics and should not be used to treat nonspecific symptoms like anorexia and loss of weight without investigating the cause. They are not useful in the absence of adequate protein-calorie intake.</li>
</ul>
<p>Abuse of anabolic steroids by athletes: Anabolic steroids in large doses are commonly misused by athletes in order to improve their athletic performance. When large doses of these drugs are combined with intense athletic training and proper diet, muscles increase in size and strength; the muscle fibres are, however, structurally abnormal. The other perceived benefit is a heightened aggressive tendency ('killer instinct'). The adverse reactions are the well known hepatotoxicity of the orally administered 17 alpha methylated steroids; virilisation in women athletes; diminution in LH and testosterone levels in male athletes; decreased spermatogenesis and testicular size; gynecomastia; insulin resistance and glucose intolerance. Hallucinations, delusions and manic episodes have been reported in athletes who self-administer large doses of anabolic steroids. Puberty may be induced in young boys whose final adult height may be compromised. Hypertension can occur as a result of salt and water retention. Finally, abnormalities of lipid and lipoprotein metabolism, which are potentially atherogenic, can occur in these athletes. Such misuse of anabolic steroids is unfair, illegal and is to be deprecated medically.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiandrogens">Antiandrogens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiandrogens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Any compound which antagonises or interferes with the action of androgens at the tissue level is referred to as an antiandrogen. Estrogens and potent progestins such as medroxyprogesterone block the synthesis of androgens by their central gonadotropin inhibiting action and thus acts as antiandrogen (Chapter 67). Drugs which act as antiandrogens are:
I Steroid synthesis inhibitors: Ketoconazole; relatively toxic in the doses needed and hence not used;
II 5-Alpha-Reductase inhibitors: Finasteride (see below);
III Non-competitive androgen receptor antagonists: Cyproterone; and
IV Competitive androgen receptor antagonists: Flutamide and Spironolactone.
FINASTERIDE: See later.
CYPROTERONE ACETATE: This drug has potent progestogenic, moderately potent antiandrogenic and mild glucocorticoid actions. Its antiandrogenic action is due to competitive antagonism of dihydrotestosterone in the target cells. By its marked progestogenic effect, it reduces the plasma level of gonadotropin and testosterone. Cyproterone, unlike cyproterone acetate, exerts only the peripheral antiandrogenic action.</p>
<p>Cyproterone acetate is used orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day to reduce libido and sexual potency in deviant hypersexuality in males. It has been used in precocious puberty in boys; in female hirsutism; and in carcinoma of the prostate as an adjunct to GnRH analogues (Chapter 61). In combination with ethinyl estradiol, it can be used to treat acne in females.</p>
<p>FLUTAMIDE: This non-steroidal antiandrogen, given orally, is converted to its active metabolite 2-hydroxyflutamide which acts as a competitive antagonist at the androgen receptor. It is used to treat prostatic cancer (Chapter 61). Its use in hirsutism is discussed below.</p>
<p>Bicalutamide and Nitutamide are newer analogues of flutamide, used for prostrate cancer. The former has a longer t1/2 (6 days) and is claimed to be less hepatotoxic.</p>
<p>SPIRONOLACTONE: This aldosterone antagonist (Chapter 39) blocks the binding of androgens to the androgen receptor competitively; in larger doses it also inhibits the synthesis of androgen in the ovaries. It is used in the treatment of hirsutism (see below).</p>
<p>Therapeutic uses of antiandrogen: (1) Hirsutism (see below); (2) Benign prostatic hyperplasia (see below); (3) Prostate cancer (Chapter 61); (4) Acne (Chapter 71); (5) Androgenetic alopecia (Chapter 71).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-hirsutism">Management of Hirsutism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-hirsutism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The physiology of hair growth is discussed in Chapter 71. Hirsutism implies the excessive growth of androgen dependent (male pattern) hair in children and adult women due to either inappropriately elevated plasma androgen levels or increased sensitivity of the hair follicles to their normal levels. It occurs mostly in the back and lateral aspects of face. Hirsutism is commonly accompanied by the occurrence of acne. By contrast, hypertrichosis is increase in terminal hair density mainly located on forehead and the temporal region and may be accompanied by growth of hair in non-androgen-dependent areas. Hypertrichosis can be due to: drugs (phenytoin, diazoxide, glucocorticoids, danazol and minoxidil); hypothyroidism; acromegaly; multiple sclerosis; encephalitis and metabolic disorders such as porphyria; or it may accompany congenital conditions such as Hurler's syndrome and trisomy 18 .</p>
<p>Hirsutism in childhood is always due to inappropriate androgen production or administration, and needs to be investigated thoroughly. The treatment is specific and depends on the cause. In adult women, drugs (androgens, anabolic steroids and 19-nor steroidal progestins), adrenal disease (late onset congenital adrenal hyperplasia, Cushing's syndrome) account for a small proportion of cases. They require cessation of the offending drug, treatment of the cause and cosmetic treatment. The majority of cases in adult women however are either idiopathic or due to PCOS.</p>
<p>Patients with idiopathic hirsutism need treatment with local cosmetic measures, and sometimes with an antiandrogen. If a woman with PCOS desires to conceive, the treatment is ovulation induction with drugs (Chapter 68). If she does not wish to become pregnant, her treatment depends on the degree of hirsutism.</p>
<p>Virilization is always associated with high androgen levels and additional signs and symptoms and suggests the possible presence of adrenal or ovarian tumours.</p>
<p>Management: Table 69.4 summarises the principles of management of hirsutism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-69-4">Table 69.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-69-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="management-of-hirsutism">Management of hirsutism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-hirsutism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Rule out drugs and neoplasmas cause</li>
<li>Reassurance</li>
<li>Cosmetic treatment</li>
<li>CombinedOC</li>
<li>Glucocorticoids</li>
<li>Spironolactone</li>
<li>Bromocriptine</li>
<li>Cyproterone acetate (Reverse sequential regimen)</li>
<li>Flutamide</li>
<li>Finasteride; and</li>
<li>GelfH analogues</li>
<li>In mild cases not accompanied by menstrual dysfunction, cosmetic treatment such as shaving, waxing, bleaching, chemical depilation, electrolysis or laser therapy is sufficient. Contrary to popular belief, shaving does not stimulate faster hair growth. Cosmetic treatment can also be used in moderate and severe cases.
Eflornithine: This anti-trypanosomal drug (Chapter 58) inhibits the synthesis of the hair cuticle and is effective in inhibiting the growth of hair as long as it is used. It is massaged locally as a cream twice a day, five minutes after hair removal from the hirsute (hairy) area,</li>
</ul>
<p>and is washed 3-4 hours later. It needs to be applied for several weeks before the result is seen. Hair removal is continued throughout its use. It is well tolerated generally, but may cause local irritation in some patients.</p>
<ul>
<li>In moderate cases, especially when the menses are irregular and acne is troublesome, the treatment of choice is a COC pill taken from day 5 to day 25 of the menstrual cycle, for at least one year. The combined OC pill containing 2 mg of cyproterone acetate (Diane/Dianette/Ginette) is preferred. A pill containing norgestrel, levonorgestrel, norethisterone or norethisterone acetate should not be used as these drugs have androgenic action and reduce the plasma level of sex hormone binding protein. A pill containing desogestrel (see Chapter 68), would be preferable. Spironolactone, in the dose of 100-200 mg per day may be used to supplement therapy of PCOS with the COC pill; spironolactone has an antiandrogenic action at the level of the hair follicles. As spironolactone is liable to cause irregular vaginal bleeding, it is commonly prescribed together with a COC pill. Further, the COC pill prevents conception in these patients; this is desirable as the antiandrogenic action of spironolactone may cause genital abnormalities should the woman conceives a male fetus.</li>
<li>The severe cases need treatment with cyproterone acetate. It is used in the reverse sequential regimen. It is administered on days 5 to 15 of the cycle in the dose of 50 to 200 mg daily, together with ethinylestradiol in the dose of 50 mcg or an OC pill from day 5 to 26 of the cycle; the initial dose should be kept down to 50 mg in patients with acne as well, as acne may be exacerbated by initial larger doses. Bromoergocriptine is useful when hirsutism is a part of hyperprolactinemia - amenorrhoea syndrome. Flutamide, finasteride and GnRH analogues are reserved for resistant cases.
Once a hair follicle in an androgen dependent area is stimulated to form terminal hair, it remains sensitive to low levels of androgens throughout its life. Therefore, the response of hirsutism to treatment, even after complete surgical ablation of an androgen producing tumour, is slow and takes many months. The patient should be informed about this at the onset of treatment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benign-prostatic-hyperplasia">Benign Prostatic Hyperplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benign-prostatic-hyperplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Benign prostatic hyperplasia (BPH) has two components:</p>
<ul>
<li>A static component that is related to the enlargement of the prostate (obstructing urethra); and</li>
<li>A dynamic component that represents the tone or the degree of contraction of the smooth muscle within the prostate. It is mediated by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors (and is increased in BPH due to increase in muscle mass). This resists urine outflow.
The drugs used in treating BPH are listed in Table 69.5. Of these, GnRH agonists decrease libido and may cause impotence.</li>
</ul>
<p>Table 69.5
Drugs used in BPH
(a) Short acting-Prazosin; Alfuzosin.
(b) Long acting-Terazosin; Doxazosin.</p>
<p>Selective alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>A</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic antagonists:
Tamsulosin; Silodosin.
Androgen antagonists:
(a) GnRH agonists;
(b) Antiandrogens; 5-alpha Reductase inhibitor e.g. Finasteride; Dutasteride.
Miscellaneous: Tadalafil
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p>Non-selective Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic antagonists:
(a) Short acting-Prazosin; Alfuzosin.
(b) Long acting-Terazosin; Doxazosin.</p>
<p>Selective alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>A</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic antagonists:
Tamsulosin; Silodosin.
Androgen antagonists:
(a) GnRH agonists;
(b) Antiandrogens; 5-alpha Reductase inhibitor e.g. Finasteride; Dutasteride.</p>
<p>Miscellaneous: Tadalafil
The alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic antagonists are more effective and less toxic; further, their action is immediate. They act on the dynamic component (Chapter 18) and relax smooth muscles in prostatic capsules, bladder neck (trigone) and urethra. Thus they reduce the bladder neck resistance to the urine outflow. They also have additional antihypertensive effect.</p>
<p>Selective alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>A</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (and alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) antagonists: Tamsulosin and Silodosin are usually preferred. In the doses used, they rarely cause hypotension and syncope, which may occur</p>
<p>following less selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists due to their action on vascular smooth muscle. Tamsulosin may however, cause diminished or retrograde ejaculation.</p>
<p>Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-blockers remain effective for long period of time as tolerance does not develop easily. They are also available as extended release preparation given once daily. Intraoperative Floppy Iris syndrome (IFIS) has been reported during cataract surgery in patients taking alpha blockers. Hence history of intake of tamsulosin or other <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers should be elicited prior to catract surgery. The other ocular adverse effects include blurred vision and ambylopia.</p>
<p>Other Uses: As <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic blockers cause relaxation of the ureteric muscle and may allow the passage of a small stone, tamsulosin has been used to treat patients with ureteral stones measuring less than 1 cm , especially those in the distal ureter.</p>
<p>FINASTERIDE: This drug is an inhibitor of the enzyme 5-alpha reductase and blocks the conversion of testosterone to dihyidrotestosterone especially in male external genitalia. It is effective only in patients with palpably enlarged prostate, in contrast to alpha1 adrenergic antagonists which are effective in patients with and without such enlargement.</p>
<p>Adverse reactions: It can cause occasional decreased libido, diminution in semen volume and impotence. Women of child bearing age should avoid handling crushed or broken tablets as the drug, after absorption through the skin, can cause abnormalities of the external genitals of a male fetus, should the woman be pregnant. As finasteride is excreted in the semen, the use of a condom is recommended if the sexual partner is pregnant or is likely to become pregnant. It is contraindicated in patients with obstructive uropathy or cancer of the prostate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Benign prostatic hyperplasia: Given orally in the dose of 5 mg daily, it causes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> improvement in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the patients after several months of use. Hence it is combined with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker.</li>
<li>Androgenetic alopecia in men: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
</ul>
<p>Dutasteride, an analogue, has similar properties as finasteride. Dose 0.5 mg OD.
Tadalafil, a PDE-5 inhibitor 5 mg OD has been reported to relieve some urinary symptoms of BPH but does not significantly improve the urinary flow rate. It is much less effective than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers.</p>
<p>70</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calcium-phosphorus-fluoride-and-magnesium-metabolism-parathyroid-hormone-and-vitamin-d-treatment-of-osteoporosis">Calcium, Phosphorus, Fluoride and Magnesium Metabolism; Parathyroid Hormone and Vitamin D; Treatment of Osteoporosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calcium-phosphorus-fluoride-and-magnesium-metabolism-parathyroid-hormone-and-vitamin-d-treatment-of-osteoporosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Calcium, apart from forming an essential constituent of bones, plays an important role in body homeostasis. Disturbances in calcium metabolism are associated with derangement of various cellular functions. Food is the only important source of calcium. Milk and milk products are an excellent source of completely assimilable calcium. Green leafy vegetables and cereals are rich in calcium but their calcium is less well utilised because of the concurrent presence of oxalates and phytates, respectively. Ragi is especially rich and rice (especially highly polished one) very poor in calcium. In certain areas, drinking water contains calcium.</p>
<p>The recommended daily calcium intake is: 500 mg in infants; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>600</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">600-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">600</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> in children of age <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">4-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> years; 1200 mg in children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>18</mn></mrow><annotation encoding="application/x-tex">10-18</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span></span></span></span></span> years; 1 g in adults including pregnant and lactating women; and 1200 mg in adults over 50 years of age. Mature foetus contains about 30 g of calcium which constitutes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3-4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of the total calcium in the mother. Most of it is deposited during the last trimester of pregnancy; loss of maternal calcium during lactation is even larger, which needs correction by consumption of 1 g of calcium supplement daily. A one year old baby contains about 100 g of calcium, a gain of 70 g over the total calcium content at birth; most of this increment is supplied by milk.</p>
<p>Normal dietary intake of calcium in Americans varies between 400-1500 mg/day. The average daily diet of Indians, which is based mainly on milled rice and very little milk, may contain as little as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>500</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-500 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of calcium.</p>
<p>Body distribution: An adult human body weighing 70 kg contains about 1.2 to 1.4 kg of calcium. Ninety-nine per cent of it is present in bones; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> in the soft tissues, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> in the body fluids. The bone mineral exists in the form of a complex salt containing calcium, phosphate and carbonate, and it constantly contributes to the maintenance of extracellular levels of calcium and phosphorus by two processes:</p>
<ul>
<li>Exchange between the newly deposited bone mineral and the extracellular ionic calcium; and</li>
<li>Constant and concurrent resorption and formation of bone (remodeling), controlled by parathyroid hormone (PTH), calcitonin and vitamin D.
Blood calcium: Calcium is essentially distributed extracellularly, its concentration being maintained within narrow limits by:</li>
<li>Intestinal absorption</li>
<li>Deposition or release from the bone; and</li>
<li>Renal tubular reabsorption</li>
</ul>
<p>Most of the calcium in the blood is present in the plasma. The human plasma contains 9 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">11 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">11</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. It is present as:</p>
<ul>
<li>Ionized calcium ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span> of total)</li>
<li>Protein bound calcium; and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calcium-bound-to-citrate-and-other-organic-acids">- Calcium bound to citrate and other organic acids.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calcium-bound-to-citrate-and-other-organic-acids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The protein bound fraction is physiologically inactive and is not filtered in the glomeruli. The rest of the plasma calcium is ultra-filterable. Of this, the ionic fraction, 4.5<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">5.4 \mathrm{mg} / 100 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, is diffusible, physiologically active, and exchanges with the bone calcium; it is also the fraction which is affected by bone formation and resorption and which regulates the rates of secretion of the PTH and calcitonin. It is the ionic calcium that plays a critical role in variety of cellular functions involved in neuromuscular activity, secretions and signal transduction.</p>
<p>Intracellular (cytoplasmic) calcium content is very low, 0.4 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4.0 \mathrm{mcg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">4.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">%</span></span></span></span></span>. Most of this is sequestered in the mitochondria and (in the muscles) in the sarcoplasmic reticulum. Though very low in concentration, it is important in regulating the functions and metabolic processes of cells, such as stimulus-contraction coupling in the muscles and stimulussecretion coupling in most exocrine and endocrine glands.</p>
<p>Absorption of calcium: Ingested calcium must be dissolved before it is absorbed. Calcium is absorbed passively (5%), primarily from the distal small bowel, but significant quantities (30-70%) are absorbed actively from the proximal small bowel. This latter is controlled by a calcium binding protein in the cells of the mucosal villi, the level of which is regulated by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span> (calcitriol), the active metabolite of vitamin D. The active absorption is stimulated by low calcium intake (Table 70.1), while high intake reduces synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span> and thus decreases its own absorption.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-70-1">Table 70.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Agents and conditions that stimulate the absorption of calcium</p>
<table><thead><tr><th style="text-align: left;">- Low calciumintake</th></tr></thead><tbody><tr><td style="text-align: left;">- Vitamin D</td></tr><tr><td style="text-align: left;">- PTH (indirectly)</td></tr><tr><td style="text-align: left;">- Negative calciumbalance</td></tr><tr><td style="text-align: left;">- Acid residue in the intestines</td></tr></tbody></table>
<p>Absorption of calcium is at best partial. The net calcium absorption on a daily diet containing 1 g of calcium is about 200-300 mg. However, by virtue of an adaptive mechanism, comprising PTH and calcitriol even in the presence of lower calcium intake of less than 1 g , net absorption remains within normal limits. Taking calcium in doses of 500 mg or less with food increases its absorption, particularly in patients with diminished gastric acidity. Calcium absorption declines after puberty, especially in old age. Table 70.2 enumerates substances and conditions that interfere with calcium absorption.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-70-2">Table 70.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Agents and conditions that interfere with calcium absorption</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-3" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Fat does not interfere with calcium absorption in normal subjects.
Human milk contains proportionately less phosphorus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo>:</mo><mi mathvariant="normal">P</mi><mo>=</mo><mn>2.2</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{Ca}: \mathrm{P}=2.2: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">P</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> ) than cow's milk with</p>
<p>a Ca:P ratio of 1.1:1. Hence, in infants the calcium absorption from human milk is more efficient than from cow's milk. Mean calcium content of cow's milk, however, is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">125 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> as against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>33</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">33 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">33</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> in human milk.</p>
<p>Excretion of calcium: Calcium is excreted in feces, urine and sweat. The total amount of calcium secreted into the intestinal tract is about 200 mg daily, of which 130 mg is excreted in feces. Zero dietary calcium intake (as in starvation) and lack of vitamin D will thus cause marked calcium deficiency as the fecal loss continues.</p>
<p>Ninety-nine percent of the calcium filtered by the glomeruli is reabsorbed by the proximal tubules. The absorption of the rest in the distal tubule is under the influence of vitamin D and PTH. Calcitonin inhibits proximal tubular reabsorption of calcium and increases its urinary excretion. PTH promotes calcium absorption. The urine contains 2 to 4 mg of calcium per kg body weight per 24 hours. A rise in plasma ionic calcium from any cause (Table 70.5) increases its urinary excretion.</p>
<p>Table 70.5
Common causes of hypercalcemia</p>
<ul>
<li>Hyperparathyroidism (primary or tertiary)</li>
<li>Malignancy with or without bone metastases</li>
<li>HypervitaminosisD</li>
</ul>
<p>The factors which prevent the precipitation of calcium in normal urine are known incompletely; low calcium concentration and adequate citrate concentration in the urine are two important factors. In alkaline urine, calcium is precipitated as calcium phosphate.</p>
<p>Excretion of calcium in the sweat is negligible in the temperate climate but may be significant in the tropics because of excessive sweating.</p>
<p>The causes of hypercalciuria and hypocalciuria are shown in Tables 70.3 and 70.4, respectively.</p>
<p>Table 70.3
Causes of hypercalciuria</p>
<ul>
<li>Hypercalcemia from any cause (primary hyperparathyroidism, malignancy)</li>
<li>Metabolic acidosis</li>
<li>Hyperthyroidism</li>
<li>Acromegaly</li>
<li>Hyperadrenocorticism</li>
</ul>
<p>Table 70.4
Causes of hypocalciuria</p>
<ul>
<li>Hypocalcemia from any cause (vitamin D deficiency, hypoparathyroidism)</li>
<li>Chronic renal failure</li>
<li>Metabolic alkalosis</li>
<li>Dietary calciumdeficiency</li>
</ul>
<p>If intestinal absorption and renal tubular reabsorption of calcium are insufficient to maintain the plasma calcium within the normal range, it is mobilised from the bone,</p>
<p>following the increased levels of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span> and PTH.
Physiological functions:</p>
<ul>
<li>Excitability: Calcium is an important component of the cell membrane and controls its permeability and electrical properties. Calcium ions compete with sodium ions for sites on the membrane. An excess of extracellular calcium reduces the permeability of the membrane to sodium and raises the critical level of depolarisation at which sodium permeability is increased and at which the action potential is fired off. This stabilises the membrane and reduces its excitability. Hypercalcemia thus reduces the excitability of nerves and muscles. Hypocalcemia increases membrane permeability to sodium and reduces its excitation threshold, leading to tetany.</li>
<li>Coupling between excitation and response (Second messenger): Calcium is essential as a coupling agent between excitation and contraction in all forms of muscle and between stimulus and secretion in certain endocrine glands, e.g., release of ADH by nerve impulses to the neurohypophysis and of catecholamines from the adrenal medulla by acetylcholine. In mediating these responses, calcium enters the cytoplasm to activate the contractile processes or to cause release of stored hormone from the granules. Further, certain drugs acting on the heart owe their action to promotion (digoxin) or inhibition (CCB) of entry of calcium ions into the cell.
In the visceral smooth muscle, the acetylcholine released upon stimulation of the cholinergic nerves binds to muscarinic receptors, resulting in increased influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> into the myocytes and their contraction.</li>
<li>Automaticity: The automaticity of the cardiac pacemaker tissues (nodal and conducting) is dependent predominantly upon the slow, inward calcium current (Chapter 28).</li>
<li>Formation of bone and teeth: Calcium is essential for proper formation of bone and teeth; calcium deficiency during intra-uterine life and extra-uterine growth period leads to delayed and defective dentition and to poor bone formation.
A negative calcium balance leads to osteoporosis, in which the bones are normal in chemical composition but the total bone mass is reduced. It also results in stimulation of the parathyroid glands with consequent secondary hyperparathyroidism. Excess PTH, by acting on the liver, increases the metabolic degradation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">25(\mathrm{OH}) \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose">)</span><span class="mord mathrm">D</span></span></span></span></span> (see later); this seems to be an important mechanism of the occurrence of osteomalacia and rickets in sunny countries such as India. Other mechanisms are deficient intake of vitamin D, vitamin D resistance and hypophosphatemia.</li>
<li>Coagulation of blood: Plasma ionic calcium is essential for the conversion of prothrombin to thrombin (see Chapter 33).</li>
<li>Renal concentrating mechanism: Ability to concentrate the urine maximally is impaired in hypercalcemia and in hypokalemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acting-as-cofactor-to-many-enzymes">- Acting as cofactor to many enzymes.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acting-as-cofactor-to-many-enzymes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pharmacological actions of calcium: They are best illustrated by a description of the effects of hyper and hypocalcemia.</p>
<p>Hypercalcemia: Table 70.5 lists the common causes of hypercalcemia. The effects of hypercalcemia include lethargy, anorexia, weakness, muscular hypotonia, nausea, vomiting and severe constipation. Kidneys show inability to concentrate the urine leading to polyuria and dehydration. Heart may show irregularities. Excess calcium gets deposited in tissues (metastatic calcification) such as arteries, cornea, muscles and kidneys. The</p>
<p>development of mental changes indicates severe hypercalcemia (over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">.</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} . \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">.%</span></span></span></span></span> ) and is a medical emergency.</p>
<p>Hypocalcemia: Table 70.6 lists the causes of hypocalcemia. It is characterised by increased neuromuscular irritability with paraesthesiae, tetany, seizures, and laryngeal spasm. Teeth show hypoplasia. Skin and nails may show atrophy. Most of these effects are reversible on treatment.</p>
<p>Table 70.6
Common causes of hypocalcemia</p>
<table><thead><tr><th style="text-align: left;">- Vitamin D deficiency</th></tr></thead><tbody><tr><td style="text-align: left;">- Abnormal vitamin D metabolism</td></tr><tr><td style="text-align: left;">- Vitamin D resistance</td></tr><tr><td style="text-align: left;">- Chronic renal failure</td></tr><tr><td style="text-align: left;">- Severe Hyperphosphatemia</td></tr><tr><td style="text-align: left;">- Hypoparathyroidism</td></tr></tbody></table>
<p>Adverse reactions: Oral calcium supplements are generally well tolerated but may produce constipation, abdominal bloating and rarely intestinal obstruction. Calcium chloride solution is irritating by all routes. Extravasation of calcium salts during IV administration may lead to local sloughing. Rapid IV calcium can cause nausea, tingling, sweating, hypotension, irregular heart beat, and cardiac arrest. Shortening of QT interval can occur. Potassium counters cardiac effects of excess of calcium. In digitalised patients IV calcium can cause cardiac arrhythmias and cardiac arrest. Prolonged excessive consumption of calcium has recently claimed to cause hypercalcaemia and increased risk of CAD.</p>
<p>Preparations and dosage: The oral preparations are given in Table 70.7. Calcium carbonate has the highest calcium content (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ). It is tasteless and is generally preferred for clinical use. Calcium lactate has a sour taste and is sparingly soluble in water. Calcium citrate is tasteless and water soluble.</p>
<p>Table 70.7
Calcium content of various calcium salts</p>
<table><thead><tr><th style="text-align: left;">Calcium Salts</th><th style="text-align: center;">Ca content mg per g of salt</th><th style="text-align: center;">Grams required to provide 1 g of Ca</th></tr></thead><tbody><tr><td style="text-align: left;">Carbonate</td><td style="text-align: center;">400</td><td style="text-align: center;">2.5</td></tr><tr><td style="text-align: left;">Phosphate (dibasic)</td><td style="text-align: center;">230</td><td style="text-align: center;">4.4</td></tr><tr><td style="text-align: left;">Citrate</td><td style="text-align: center;">211</td><td style="text-align: center;">4.7</td></tr><tr><td style="text-align: left;">Glycerophosphate</td><td style="text-align: center;">162</td><td style="text-align: center;">6.2</td></tr><tr><td style="text-align: left;">Lactate</td><td style="text-align: center;">130</td><td style="text-align: center;">7.7</td></tr><tr><td style="text-align: left;">Gluconate</td><td style="text-align: center;">89</td><td style="text-align: center;">11</td></tr><tr><td style="text-align: left;">Heptagluconate</td><td style="text-align: center;">82</td><td style="text-align: center;">12</td></tr></tbody></table>
<p>The oral dose of calcium salts depends on the condition under treatment. Salts containing about 1 g of elemental calcium per day, in divided doses, with meals, are needed for the prevention and treatment of osteoporosis and in the treatment of osteomalacia due to vitamin D deficiency; while higher doses of 2-3 g/day, are used in malabsorption, and in hypocalcemia due to hypoparathyroidism.</p>
<p>Parenteral calcium preparations are:
(i) Calcium gluconate 1 g in 10 ml Dose: 1 to 2 g IV.
(ii) Calcium laevulinate: IM or IV as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution. Its calcium content is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">13 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13%</span></span></span></span></span>.
(iii) Calcium chloride is an ingredient of Ringer-lactate infusion. It is given diluted with</p>
<p>saline as a slow infusion.
While prescribing calcium supplements one must remember that:
(1) It should be taken in doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≤</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\leq 500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> at a time. At higher doses absorption of calcium is proportionately less.
(2) It is the elemental calcium contents of the salt that is important; not its weight.
(3) All calcium salts are poorly absorbed and their elemental calcium content (per gm of salt) varies. But there is little evidence that any of them is therapeutically superior to other.
(4) Calcium carbonate is best absorbed with food as it requires acidic medium for solubility.
(5) Calcium deficiency causes vitamin D deficiency and vitamin D is necessary for calcium absorption. Hence, vitamin D supplementation with calcium is useful.
(6) Overdosing with calcium and vitamin D must be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-calcium-salts">Therapeutic uses of calcium salts:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-calcium-salts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>To prevent or correct calcium deficiency, oral supplements of calcium are used in:
(a) Growing children, pregnant women and lactating mothers.
(b) Individuals with dietary deficiency.
(c) Post-menopausal osteoporosis, and osteoporosis due to Cushing's syndrome and long term glucocorticoid therapy.
(d) Patients with vitamin D deficiency rickets and osteomalacia, who are prescribed vitamin D; and
(e) Following removal of a parathyroid adenoma.</li>
<li>In the treatment of hypocalcemic tetany: Calcium gluconate (10%) 10-20ml IV very slowly, followed by IV infusion 40 ml in 1 litre saline over 4-8 hours.</li>
<li>Osteoporosis: See later.</li>
<li>As an antacid (Chapter 43).</li>
<li>As phosphate binders in chronic kidney disease (CKD): Chronic renal failure is associated with hypocalcaemia, hyperphosphatemia and secondary hyperparathyroidism. Serum calcitriol level is low. Main treatment is replacement of vitamin D, which corrects secondary hyperparathyroidism and normalises serum calcium. As the hyperphosphatemia of CKD causes secondary hyperparathyroidism leading to renal osteodystrophy, restraining the former is important. In addition to dietary phosphate restriction, the commonly used drugs are calcium carbonate and acetate. Both are effective but sometimes cause hypercalcemia. In resistant cases and in those with hypercalcemia, sevelamer may be used (see later). The carbonate of lanthanum, a rare earth metal, can also control hyperphosphatemia efficiently.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lead-colic">- Lead colic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lead-colic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Hypermagnasemia (See later)</p>
</li>
<li>
<p>Hyperkalemia (Chapter 37)</p>
</li>
<li>
<p>Cardiac arrest: Intracardiac injection of calcium in cardiac arrest is for the specialist and should not be attempted outside ICCU; and</p>
</li>
<li>
<p>Placebo: Calcium gluconate IV produces a feeling of warmth which spreads as a wave all over the body. In view of its adverse cardiac effects, it is not recommended as placebo.
Hypercalcemia management: Mild to moderate, asymptomatic hypercalcemia can be treated by:</p>
</li>
<li>
<p>Control of the underlying causative factors</p>
</li>
<li>
<p>Hydration; and</p>
</li>
<li>
<p>Reduction of GI calcium absorption by restriction of calcium intake, oral neutral phosphate mixture and cellulose phosphate. For glucocorticoids, (see below).
Severe hypercalcemia with serum calcium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">14 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">14</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> or higher requires emergency intensive management (Table 70.8). It is started with:</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-70-8">Table 70.8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Principles of treatment of severe hypercalcemia</p>
<ul>
<li>Correct dehydration: Isotonic saline IV.</li>
<li>Increase the renal excretion of calcium: Isotonic saline with or without Furosemide.</li>
<li>Inhibit bone resorption: Bisphosphonates; Calcitonin;</li>
<li>Reduce the GI absorption of calcium: Reduction in calciumintake; oral Phosphate; Corticosteroids; Cellulose phosphate.</li>
<li>Promote uptake of calcium by bones and other tissues: Phosphate.
(a) Isotonic saline IV infusion (2-4 litres in the first 24 hours) to correct the dehydration and establish adequate urine output ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">u</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">100-150 \mathrm{ml} / \mathrm{hour}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hour</span></span></span></span></span></span> ). It is continued at the rate 1.5-2 lit/day until plasma calcium levels reaches near normal level. The calcium is co-excreted in the urine along with sodium. Its action lasts as long as the infusion. Overloading of the circulation should be watched during the infusion. Once diuresis is established (but not earlier), furosemide 20-40 mg IM 6-12 hourly can lower serum calcium by inhibiting its resorption in the distal renal tubules. However, as it may cause electrolyte disturbances and can worsen hypercalcemia, its use should be restricted to patients who, additionally, have either heart failure or renal insufficiency.
(b) Bisphosphonates Pamidronate or zolendronic acid or ibandronate are the drugs of choice and are given by IV infusion. They inhibit osteoclastic bone resorption. The onset of their action is slow (5-6 days) but duration is prolonged (weeks). They are particularly useful in hypercalcemia of malignancy. Oral biphosphonate is not useful in acute severe hypercalcemia.
(c) Calcitonin IM which inhibits the osteoclastic bone resorption and directly increases the urinary calcium excretion. Its action is rapid (hours) but short lived (days).</li>
</ul>
<p>All the above three agents must be started concurrently for optimum result.
(d) Neutral phosphate mixture orally helps by binding calcium in the GI lumen. It is appropriate in patients with serum phosphate less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span>.
(e) Glucocorticoids (e.g. prednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) lower serum calcium in vitamin D intoxication, granulomatous disease, lymphoma and myelomatosis, but not in primary hyperparathyroidsism, and in most malignant solid tumours. They are effective slowly and cannot be relied upon in acute, severe hypercalcemia.</p>
<p>Patients with life-threatening hypercalcemia or severe renal insufficiency may need hemodialysis or peritoneal dialysis to reduce serum calcium.</p>
<p>All these measures are for temparary use. Because of their toxicity, plicamycin, gallium nitrate and IV phosphate are no more recommended for treating hypercalcemia.</p>
<p>Long term treatment of hypercalcemia involves use of an oral ion-exchange agent, sodium cellulose phosphate. It has selective affinity for calcium in the gut. The complex is excreted in the feces. It is useful for subjects who over-absorb dietary calcium</p>
<p>CINACALCET: This calcimimetic drug inhibits PTH secretion by binding to and stimulating the calcium sensing receptor on the parathyroid cells; the latter is rendered</p>
<p>more sensitive to serum calcium. Orally, it is well absorbed and is metabolised by the liver and excreted primarily ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> ) in the feces. No dose adjustment is required in CKD. The adverse reactions are nausea, vomiting and diarrhoea. Hypocalcemia can occur and can precipitate seizures in seizure-prone individuals. The drug has been used to treat hypercalcaemia secondary to chronic kidney disease, and parathyroid carcinoma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phosphorus-metabolism">Phosphorus Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phosphorus-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phosphorus is abundantly present in almost all foods: milk, meat, fish, cereals, pulses and nuts. A part of the phosphorus in cereals is present as phytate and is unassimilable. Its daily intake varies with the diet and is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>1000</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">500-1000 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1000</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</p>
<p>Dietary requirements: It is estimated at about 0.9 g in adults. It is higher in growing children, pregnant women and lactating mothers.</p>
<p>Body distribution: The total phosphorus content of the average adult human body is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>600</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">500-600 \mathrm{~g}, 75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">75%</span></span></span></span></span> of which is in bones and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> in other tissues. Most of the body phosphorus is in the organic form; the small amount that is inorganic is the source of ATP.</p>
<p>The RBCs contain far more phosphorus than the plasma; hence, even slight hemolysis gives fallaciously high plasma phosphorus values. The plasma phosphorus is present as:</p>
<ul>
<li>Inorganic phosphorus 3 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>.</li>
<li>Ester phosphorus 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.7 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1.7</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>; and</li>
<li>Lipid phosphorus 7 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>.</li>
</ul>
<p>The term 'plasma phosphate' usually means the plasma inorganic phosphate measured as phosphorus. Its plasma concentration varies with age, dietary intake and in relation to meals. It is intimately related to carbohydrate metabolism and falls significantly during glucose utilisation. Phosphorus in other tissues is present in the form of nucleoproteins.</p>
<p>Absorption, fate and excretion: Absorption of phosphorus is more complete than that of calcium. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the dietary phosphorus is absorbed in the small bowel. Vitamin D stimulates the GI absorption of calcium and phosphorus. A high calcium intake and aluminium hydroxide in large doses interfere with its absorption. Like calcium, phosphorus filtered by glomeruli is largely reabsorbed by proximal tubules. The rate of tubular reabsorption determines the serum phosphate level. Its urinary excretion varies directly with dietary intake while its reabsorption is affected by hypocalcaemia, hypomagnsemia and severe hypophosphatemia. Low serum level directly stimulates tubular synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="physiological-functions">Physiological functions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-functions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Formation of bone and teeth: Along with calcium, phosphorus is essential for the formation of bones and teeth. Phosphorus needed for this is made available 'on site' by the action of alkaline phosphatase on organic phosphates.</li>
<li>Phosphorylation: Phosphorylation of a chemical compound is the transfer to it of a phosphate group from an inorganic or organic phosphate. It is an essential preliminary step in the metabolism of almost all substances in the body including enzyme regulation, energy transformation and storage, and in the regulation of the delivery of oxygen to the tissues.</li>
<li>Buffer: Phosphates are important intra- and extracellular buffers in the body and regulate the renal excretion of H ions.</li>
<li>Miscellaneous: Phosphorus forms an integral part of the structure of the nuclei and cytoplasm. Further, chemical energy is stored in the form of 'high energy phosphate bonds'. It is a major component of several organic phosphate compounds.
Pharmacological actions: Mild to moderate hypophosphatemia may occur after severe dietary deprivation of phosphorus, during long-term use of aluminium antacids, in primary hyper parathyroidism, in vitamin D deficiency, in patients with phosphaturia (isolated or as a part of deficiency of tubular reabsorption in Fanconi syndrome) and in the</li>
</ul>
<p>rare syndrome of familial rickets. The hypophosphatemia interferes with calcification of the osseous matrix, leading to rickets or osteomalacia. The hypophosphatemia of primary hyperparathyroidism is without a direct metabolic effect.</p>
<p>Severe hypophosphatemia (serum inorganic phosphorus less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">.</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} . \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">.%</span></span></span></span></span> ) can occur in chronic alcoholism and diabetic ketoacidosis. Intracellular shift of phosphorus as a result of administration of glucose and/or insulin unmasks the severe hypophosphatemia. Severe hypophosphatemia is a life threatening condition and can cause hemolysis, muscular weakness, mental changes, decreased myocardial contractility and respiratory failure.</p>
<p>Hyperphosphatemia is seen in hypoparathyroidism, renal failure and active acromegaly. In renal failure, the elevated plasma phosphorus level depresses that of calcium and causes secondary hyperparathyroidism and metastatic calcification.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypophosphatemia: Neutral phosphate solution is used orally to treat familial hypophosphatemic rickets. Its composition is: disodium hydrogen phosphate 3.66 g , sodium dihydrogen phosphate 1 g , orange syrup 16 ml , water to make 60 ml . Sixty ml of this solution gives 1 g of phosphorus. Therapy is commenced with 5 ml thrice daily and increased slowly to tolerance but not exceeding 60 ml tid. Larger doses can cause diarrhoea and hyperparathyroidism. Severe hypophosphatemia may be treated by IV neutral phosphate solution.</p>
<ul>
<li>Hypercalcemia: Oral neutral phosphate may be used to treat chronic hypercalcemia except in the presence of concurrent hyperphosphatemia.
Sevelamer (RenaGel) is a cationic polymer that binds phosphate through ion exchange. Thus, it acts as an effective phosphate binder and lowers plasma phosphate in patients with CKD. It causes hypercalcemia less frequently. Its use is reserved for resistant cases and those with hypercalcemia.</li>
</ul>
<p>PARATHORMONE (PTH): This hormone is secreted by the chief cells of the parathyroid glands. It is secreted as an 84 amino acid polypeptide but is cleaved in the plasma.</p>
<p>The secretion of PTH is directly stimulated by a fall and is inhibited by a rise in the plasma ionic calcium level via the calcium sensing membrane receptor (GPCR) in the chief cells. The level of plasma inorganic phosphorus alters the secretion of PTH indirectly through changes in the plasma calcium level. Circulating calcitriol inhibits synthesis of PTH by gene suppression. For pharmacological suppression of PTH synthesis by paricalcitol and 22-oxacalcitriol, see later.</p>
<p>Mechanism of action: PTH acts on the cell membrane to:
(a) Stimulate the formation of cyclic AMP and
(b) Increase its permeability to calcium ions which then move intracellularly. In the bone, it stimulates the conversion of mesenchymal cells into osteoclasts and regulates the activity of osteoclasts and osteoblasts during remodelling of bone; further it inhibits the osteoblasts and hence collagen synthesis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="physiological-and-pharmacological-actions">Physiological and pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-and-pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All the actions of PTH are directed towards maintaining the ionic calcium of the plasma and ECF. It probably influences ion movements in other tissues.</p>
<ul>
<li>Gastrointestinal tract: It enhances the synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> vitamin D in the kidneys and thus indirectly promotes the active absorption of calcium and phosphorus from the</li>
</ul>
<p>gut.</p>
<ul>
<li>Bones: In physiological doses, PTH binds to receptors on the osteoblasts which then secrete cytokines that activate the osteoclasts. This initiates bone remodeling, minute zones of osteoclastic resorption followed by osteoblastic bone formation. Such remodeling cycles repeat themselves all over the bone tissue throughout life. After the age of 20, bone formation slightly falls short of bone resorption in each cycle; this is the basis of age related bone loss in adult life.
Clinically, administration of small intermittent doses of PTH (1-2 hrs/day) stimulates bone formation (anabolic action; see teriparatide later). This process requires a normal vitamin D intake to permit calcification of the matrix laid down during bone formation.</li>
</ul>
<p>Continuous high plasma levels of PTH as in hyper-parathyroidism increase activity of osteoclasts and cause excessive bone loss.</p>
<ul>
<li>Kidney: The effect on the kidney is of more rapid onset than that on the bone, and is exerted at multiple sites.
(a) PTH promotes the calcium reabsorption (distal tubules), inhibits phosphate absorption (proximal tubules) and stimulates the conversion of calcifediol to calcitriol, the active metabolite of vitamin D, by stimulating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi>α</mi></mrow><annotation encoding="application/x-tex">1 \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-hydroxylase in the proximal renal tubules.
(b) It increases the urinary excretion of sodium, potassium, bicarbonate and citrate; and decreases the excretion of hydrogen and magnesium; and
Absorption, fate and excretion: Given SC, its peak effect is seen in 18 hours and the response lasts upto 36 hours. It is partly degraded by liver and partly excreted in urine.</li>
</ul>
<p>Adverse reactions: Higher doses can cause orthostatic hypotension, hypercalcemia and anaphylactic reactions.</p>
<p>Preparation and dosage: rDNA synthetic PTH (Teriparatide). Dose: 20-40 mcg once SC daily.</p>
<p>Therapeutic uses of PTH: Its use to treat postmenopausal osteoporosis with fractures is described later.</p>
<p>CALCITONIN: Calcitonin, a 32 amino acid polypeptide is a hypocalcemic hormone produced by C cells in the mammalian thyroid.</p>
<p>C cells are also present in the parathyroids and thymus. Hence, thyroidectomy has no effect on plasma calcium level. Calcitonin is secreted in response to increased plasma levels of ionic calcium. It acts on the calcitonin receptors present on the osteoclasts and the renal tubules. The receptors are also present in brain, GIT and immune system.</p>
<p>In humans, salmon calcitonin has the most potent pharmacological action. Given SC/IM: (a) It rapidly lowers the plasma calcium and phosphorus by blocking the PTH induced bone resorption by direct anti-osteoclastic action. Calcium from the circulation is shunted to bone.
(b) It also acts on the renal tubules and reduces reabsorption of calcium, sodium, potassium and phosphorus. Its action of lowering plasma calcium level is rapid and of short duration.
(c) By its central action, it alleviates osteoclastic bone pain.</p>
<p>Antibodies can develop to calcitonin particularly that from pork.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Calcitonin (Pork): Dose SC/IM 80 units three times a week to 4 units/kg daily.</p>
<p>(ii) Salcalcitonin (Salmon calcitonin): Dose SC/IM 50 units three times a week to 400 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hourly.
(iii) Salcalcitonin nasal spray. Dose 200 units once daily.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypercalcemia: Salcalcitonin 5-10 units/kg daily to 400 units 6-8 hourly SC/IM. It may also be administered by slow IV infusion in the dose of 5-10 units/kg over at least 6 hours.</li>
<li>Paget's disease: Pork calcitonin 80 units SC/IM three times a week to 160 units daily or Salcalcitonin 50 units three times a week to 100 units daily. Therapy may be extended to six months in patients with bone pains or nerve compression. (also see later).</li>
<li>Bone pain in metastatic cancer</li>
<li>Menopausal osteoporosis with unremitting bone pain: 100 units SC/IM daily, together with calcium and vitamin D, till pain subsides or maximum of 4 weeks.
VITAMIN D: The term vitamin D is applied to a group of related sterols which have the common property of preventing and curing rickets and osteomalacia.</li>
</ul>
<p>Chemistry and source: Many sterols develop the antirachitic property on ultraviolet (UV) irradiation. They are fat soluble and have the same general structure (Fig. 70.1).
<img src="assets/images/image-20251214-610cadae.jpeg" alt="img-55.jpeg"></p>
<p>Solar UV-B irradiation of 7-dehydro-cholesterol present in the secretion of sebaceous glands converts it to Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (cholecalciferol). Vitamin D of animal origin as from fish oil and irradiated milk is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Irradiation of ergosterol present in yeast produces Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (ergocalciferol).</p>
<p>In human beings <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> have similar actions, qualitatively and quantitatively and hence, both are referred to as vitamin D for discussion.</p>
<p>In the liver, vitamin D is hydroxylated to yield 25-hydroxy vitamin D [ 25 OHD or 25 cholecalciferol D or calcefediol]. Its estimations are used to assess Vitamin D status. In the kidney tubule, the enzyme 25 OHD-1-alphahydroxylase causes further hydroxylation to produce the active metabolite 1-alpha, 25(OH) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">{ }_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>, (calcitriol) with biological activity 500-1000 fold higher than that of the precursor 25 OHD . (Fig. 70.2). Its production is regulated by PTH, and serum calcium and phosphorus levels. Both the active products of vitamin D are metabolised by 24-hydroxylase to inactive water soluble products.</p>
<p><img src="assets/images/image-20251214-11a863b1.jpeg" alt="img-56.jpeg"></p>
<p>The plant Solanum malaoxylon contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo>−</mo><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">1,25-(\mathrm{OH})_{2} \mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in water soluble form and is responsible for an endemic disease in grazing animals.</p>
<p>Vitamin D may be looked upon both as a vitamin and as a hormone. As a vitamin, it prevents:</p>
<ul>
<li>Rickets and osteomalacia, by maintaining plasma calcium and inorganic phosphate levels above a certain threshold.</li>
<li>Hypocalcemic tetany, by maintaining plasma calcium above a certain critical level.</li>
<li>Osteoporosis, by promoting GI calcium absorption; and</li>
<li>Muscle weakness.</li>
</ul>
<p>Physiological and pharmacological actions: Vitamin D receptors are widely distributed in many body tissues and cells, many of which can convert circulating 25 OHD into 1<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>. Calcitriol acts by binding to specific nuclear receptor-VDR (vitamin D receptor). Along with PTH and calcitonin, it exerts actions on the classic target tissues: bone, kidney and intestine (Fig. 70.2) and controls plasma calcium and bone mineralisation.
(1)Regulation of calcium metabolism:</p>
<ul>
<li>Bone: Bone tissue undergoes constant remodelling in that the osteoclast-mediated bone</li>
</ul>
<section data-footnotes="true" class="footnotes"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 class="sr-only" level="2" id="footnotes">Footnotes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#footnotes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li id="user-content-fn-0">
<p>I Responsible for superficial fungal infections (skin and mucus membrane)
Surface: Malassezia furfur (tinea versicolor or pityriasis versicolor)
Cutaneous: Dermatophyte species (dermatophytosis or ringworm infection)
II Responsible for invasive fungal infection
(a) Opportunistic:</p>
<ul>
<li>Yeasts: Candida sp. (candidiasis) and Cryptococcus sp. (cryptococcosis)</li>
</ul>
<p>Mycelial or Filamentous Fungi:
(a) Zygomycetes- Mucor sp, Rhizopus sp, Conididiobolus, Basidiobolus (zygomycosis),
(b) Pseudallescheria boydii (mycetoma and maduromycosis) and
(c) Aspergillus spp. (aspergillosis)</p>
<ul>
<li>Protozoan-like fungi: Pneumocystis jiroveci (pneumonia)
(b) True pathogenic:</li>
<li>Common: Histoplasma capsulatum (histoplasmosis), Blastomyces dermatitidis (blastomycosis), Coccidioides immitis (coccidioidomycosis)</li>
<li>Rare: Paracoccidiodies brasiliensis (paracoccidioidomycosis), Cladophialophora carrionii, (chromomycosis chromoblastomycosis), Sporothrix schenckii (sporotrichosis), Trichosporon sp(trichosporonosis)</li>
</ul>
<a href="#user-content-fnref-0" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩</a>
 
<a href="#user-content-fnref-0-2" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>2</sup></a>
 
<a href="#user-content-fnref-0-3" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>3</sup></a>
</li>
</ol>
</section></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>